နိုင်ငံသားစိစစ်ရေးကတ်ပြား



အမှတ် ၁၂/ဗဟန(နိုင်)၁၀၆၃၉၇

ရက်စွဲ ၈.၄.၉၇

အမည် ဦးဝေအောင်ထွန်းကျော်

ဖခင်အမည် ဦးလှမြင့်

မွေးသက္ကရာဇ် ၁၇.၅.၁၉၆၄

လူမျိုး/ဘာသာ ဗမာ/ဗုဒ္ဓဘာသာ

အရပ် ၅'၉" သွေးအုပ်စု ဘီ

ထုတ်ပေးသူလက်မှတ်

အမည်

ရာထူး

ထင်ရှားသည့်အမှတ်အသား [illegible]

အမှတ်စဉ် P 945298

သက်သေခံကတ်ပြားအမှတ် ALE ၀၀၂၁၃၃

အလုပ်အကိုင် ကုန်သည်

နေရပ်လိပ်စာ [illegible]

လက်ဝဲလက်မပုံစံ

ထိုးမြဲလက်မှတ်

၁။ ဤကတ်ပြားကို အမြဲဆောင်ထားရမည်။

၂။ ပျောက်ဆုံး၊ ပျက်စီးသည့်အခါ သက်ဆိုင်ရာ ရဲစခန်း၊ မြို့နယ်လူဝင်မှုကြီးကြပ်ရေးနှင့် အမျိုးသားမှတ်ပုံတင်ရေးဦးစီးဌာနရုံးသို့ သတင်းပို့ရမည်။

၃။ ဤလက်မှတ်ကို အသက်(-)နှစ်ပြည့်လျှင် လဲလှယ်ရမည်။ ဖျက်ကွက်ပါက အရေးယူခြင်းခံရမည်။

Allen&Gledhill

မူကြမ်း ၂၂/၁၂/၂၀၁၅

နေ့ရက် **[•]**

ကျန်းမာရေးဝန်ကြီးဌာန၊ ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်

နှင့်

တည်ဆောက်၊ လည်ပတ်နှင့် လွှဲပြောင်းခြင်းဆိုင်ရာ သဘောတူစာချုပ်

ALLEN & GLEDHILL (MYANMAR) CO., LTD.
NO. 05-03, UNION BUSINESS CENTRE (UBC)
NAT MAUK ROAD, BO CHO QUARTER
BAHAN TOWNSHIP, YANGON
MYANMAR

အကြောင်းအရာ

မာတိကာ .... စာမျက်နှာ

၁။ အဓိပ္ပာယ်ဖွင့်ဆိုချက်များနှင့်ရှင်းလင်းချက်များ 3

၂။ အာမခံချက်များနှင့်ကိုယ်စားပြုမှုများ 5

၃။ တည်ဆောက်၊လည်ပတ်နှင့်လွှဲပြောင်းမှု 6

၄။ မြေအသုံးချမှုပရီမီယံနှင့်နှစ်စဉ်ငှားရမ်းခ 8

၅။ ဆေးရုံတည်ဆောက်ခြင်း 10

၆။ အငှားချထားသူ၏တာဝန်ဝတ္တရားများ 11

၇။ အငှားချထားခံရသူ၏တာဝန်ဝတ္တရားများ 12

၈။ အငှားချထားမြေနှင့်စပ်လျဉ်းသည့်ငွေပေးချေမှုများ 13

၉။ လုပ်ငန်းဆောင်ရွက်မှုအာမခံချက် 13

၁၀။ ပြန်လည်ဝင်ရောက်ပိုင်ခွင့် 13

၁၁။ ပတ်ဝန်းကျင်နှင့်တွင်းထွက်ဓာတ်သတ္တုသယံဇာတများကာကွယ်စောင့်ရှောက်မှု 14

၁၂။ မလွန်ဆန်နိုင်သောဖြစ်ရပ် 14

၁၃။ စာချုပ်ရပ်စဲခြင်း 15

၁၄။ တိုးမြှင့်ငှားရမ်းကာလများ 16

၁၅။ အလုံးစုံသဘောတူညီချက် 18

၁၆။ ဖြည့်စွက်ပြင်ဆင်ချက်များနှင့်ပြန်လည်ညှိနှိုင်းမှု 18

၁၇။ အကြောင်းကြားခြင်း 19

၁၈။ တတိယအဖွဲ့များ၏အခွင့်အရေးများ 20

၁၉။ မူပွားများ 20

၂၀။ ဘာသာစကား 20

၂၁။ လွှမ်းမိုးဥပဒေ 20

၂၂။ အငြင်းပွားမှုဖြေရှင်းခြင်း 21

တည်ဆောက်၊ လည်ပတ်၊ လွှဲပြောင်းခြင်းဆိုင်ရာ သဘောတူစာချုပ်

ဤတည်ဆောက်၊ လည်ပတ်၊ လွှဲပြောင်းခြင်းဆိုင်ရာ သဘောတူစာချုပ်ကို .... ခုနှစ်၊ .... လ (........) ရက်နေ့တွင်

၁။ ကျန်းမာရေးဝန်ကြီးဌာန၊ .... ဌာန၊ .... (ရာထူး) ဦး/ဒေါ် .... ကိုယ်စားပြုသော ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရအဖွဲ့၊ ကျန်းမာရေးဝန်ကြီးဌာန (နောင်တွင် အငှားချထားသူဟု ခေါ်တွင်စေပြီး ယင်းစကားရပ်တွင် ၎င်း၏ဆက်ခံသူများနှင့် ဥပဒေအရ လွှဲအပ်ခြင်းခံရသူများ ပါဝင်သည်ဟု မှတ်ယူရမည်) က တစ်ဖက်နှင့်

၂။ Andaman Alliance Healthcare Limited မှ .... ဌာန၊ .... (ရာထူး) ဦး/ဒေါ် .... နိုင်ငံသားစိစစ်ရေးအမှတ်/နိုင်ငံကူးမှတ်ပုံတင်အမှတ် .... ကိုယ်စားပြုသော Andaman Alliance Healthcare Limited (နောင်တွင် အငှားချထားခံရသူ ဟု ခေါ်တွင်စေပြီး ယင်းစကားရပ်တွင် ၎င်း၏ဆက်ခံသူများနှင့် ဥပဒေအရ လွှဲအပ်ခြင်းခံရသူများ ပါဝင်သည်ဟု မှတ်ယူရမည်) က အခြားတစ်ဖက်တို့က

အောက်ဖော်ပြပါ စည်းကမ်းသတ်မှတ်ချက်များနှင့်အညီ ချုပ်ဆိုကြပါသည်။

ဤသဘောတူစာချုပ်သည် အောက်ပါအချက်များကို ဖော်ညွှန်း၍ သက်သေပြုပါသည်။

(က) ဤစီမံကိန်းကို စီးပွါးရေးအကျိုးအမြတ်တစ်ခုတည်းအတွက် မဟုတ်ဘဲ နိုင်ငံတကာအဆင့်မီဆေးရုံတည်ဆောက်ခြင်းဖြင့် ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်ရှိ ကျန်းမာရေးစောင့်ရှောက်မှု အဆင့်အတန်းကို ပိုမိုတိုးတက်စေရန် ရည်ရွယ်ခြင်းကတစ်ကြောင်း၊

(ခ) အငှားချထားသူသည် ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်ရှိ ကျန်းမာရေးဝန်ကြီးဌာနဖြစ်ပြီး ဤသဘောတူကတိစာချုပ်ပါ သတ်မှတ်ချက်များနှင့်အညီ အငှားချထားမြေကို ဆေးရုံတည်ဆောက်၊ လည်ပတ်ရန်နှင့် ငှားရမ်းခြင်းခံရသူကို ခွင့်ပြုချက်ပေးရန်အတွက် ဥပဒေအရ အခွင့်အာဏာ အပြည့်အဝရှိခြင်းကတစ်ကြောင်း၊

(ဂ) အငှားချထားခံရသူသည် နိုင်ငံတကာအဆင့်ရှိ ဆေးရုံများကို ပိုင်ဆိုင်သည့် ကုမ္ပဏီများအတွင်းရှိ တရားဝင်အဖွဲ့အစည်းတစ်ရပ်ဖြစ်ပြီး အငှားချထားမြေတွင် ဆေးရုံဆောက်လုပ်လည်ပတ်ရန် ဆန္ဒရှိသည်ကတစ်ကြောင်း၊

အောက်ပါအတိုင်း **သဘောတူညီကြပါသည်။**

၁။ အဓိပ္ပာယ်ဖွင့်ဆိုချက်များနှင့် ရှင်းလင်းချက်များ

၁.၁။ အဓိပ္ပာယ်ဖွင့်ဆိုချက်များ

အခြားနည်းဖြင့် ဆန့်ကျင်ကွဲလွဲသည့် ဖော်ပြချက်များ စကားရပ်များ မရှိပါက ဤသဘောတူစာချုပ်နှင့် နောက်ဆက်တွဲဇယားများတွင်

"**သဘောတူစာချုပ်**" ဆိုသည်မှာ ဤသဘောတူစာချုပ်ကို ဆိုလိုခြင်းဖြစ်ပြီး ယင်းတွင် နောက်ဆက်တွဲ ဇယား(၁)ပါဝင်သည်။

"**ပျက်ကွက်စာချုပ်ဝင်**" ဆိုသည်မှာ အပိုဒ် ၁၃.၂.၁ တွင် ဖော်ပြထားသည့်အတိုင်းဖြစ်သည်။

"**စာချုပ်အကျိုးသက်ရောက်သည့်နေ့ရက်**" ဆိုသည်မှာ ဤသဘောတူစာချုပ်ကို လက်မှတ်ရေးထိုး ချုပ်ဆိုသည့်နေ့ရက်ဖြစ်သည်။

"**တိုးမြှင့်ငှားရမ်းကာလ**" ဆိုသည်မှာ ပထမတိုးမြှင့်ငှားရမ်းကာလ သို့မဟုတ် ဒုတိယတိုးမြှင့်ငှားရမ်းကာလကို ဆိုလိုခြင်းဖြစ်ပြီး "**တိုးမြှင့်ငှားရမ်းကာလများ**"ဆိုသည်မှာ ယင်းသက်တမ်းနှစ်ရပ်စလုံးကို ဆိုလိုသည်။

"**ပထမတိုးမြှင့်ငှားရမ်းကာလ**" ဆိုသည်မှာ အပိုဒ် ၃.၂.၂တွင် ဖော်ပြထားသည့်အတိုင်းဖြစ်သည်။

"**မလွန်ဆန်နိုင်သောဖြစ်ရပ်**" ဆိုသည်မှာ စာချုပ်ဝင်တစ်ဖက်ဖက်က လိုအပ်သော သတိ၊ ဝီရိယရှိစေကာမူ မလွန်ဆန်မကျော်လွှားနိုင်သည့် ဖြစ်ရပ်များဖြစ်ပြီး သဘာဝဘေးအန္တရာယ်များ၊ ရေကြီးမှု၊ တိုင်းပြည်၏ အရေးပေါ်အခြေအနေ၊ စစ်မက်ဖြစ်ပွားမှု သို့မဟုတ် သူပုန်ထမှု စသည်တို့ကဲ့သို့ အပါအဝင် စာချုပ်ပါ ဆောင်ရွက်ချက်များကို တိုက်ရိုက်သော်လည်းကောင်း သွယ်ဝိုက်၍သော်လည်းကောင်း တားဆီးခြင်း သို့မဟုတ် နှောင့်နှေးစေခြင်းတို့ဖြစ်ပေါ်စေသည့် ဖြစ်ရပ်များကို ဆိုလိုသည်။

"**ကင်းလွတ်ခွင့်ပြုကာလ**" ဆိုသည်မှာ အပိုဒ် ၃.၁ တွင် ဖော်ပြထားသည့်အတိုင်းဖြစ်သည်။

"**ဆေးရုံ**" ဆိုသည်မှာ အငှားချထားမြေပေါ်တွင် ဆောက်လုပ်လည်ပတ်မည့် ပုဂ္ဂလိကဆေးရုံကို ဆိုလိုသည်။

"**ကနဦးငှားရမ်းကာလ**" ဆိုသည်မှာ အပိုဒ် ၃.၂.၁ တွင် ဖော်ပြထားသည့်အတိုင်းဖြစ်သည်။

"**ကနဦးငှားရမ်းကာလစတင်သည့်နေ့ရက်**" ဆိုသည်မှာ ဖွင့်လှစ်သည့်နေ့ရက် သို့မဟုတ်ကင်းလွတ်ခွင့်ပြုကာလ ပြီးဆုံးပြီးသည့် ကပ်လျက် နေ့ရက်တို့အနက် အစောဆုံးနေ့ရက်ကို ဆိုလိုသည်။

"**ဥပဒေများ**" ဆိုသည်မှာ မြန်မာနိုင်ငံ၏ ဥပဒေများကို ဆိုလိုသည်။

"**မြေအသုံးချမှုပရီမီယံ**" ဆိုသည်မှာ အပိုဒ် ၄.၃ တွင် ဖော်ပြထားသည့်အတိုင်းဖြစ်သည်။

"**ငှားရမ်းမှု**" ဆိုသည်မှာ အပိုဒ် ၃.၂.၁ တွင် ဖော်ပြထားသည့်အတိုင်းဖြစ်သည်။

"**MIC**" ဆိုသည်မှာ နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုအဆိုပြုချက်များကို နိုင်းချင့်သုံးသပ်ရန် မြန်မာနိုင်ငံ၏ နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဥပဒေ ၂၀၁၂ အရ ပြဋ္ဌာန်းဖွဲ့စည်းထားသည့် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်ကို ဆိုလိုသည်။

"**MIC ခွင့်ပြုမိန့်**" ဆိုသည်မှာ ဤသဘောတူစာချုပ်ပါ စည်းကမ်းသတ်မှတ်ချက်များနှင့် ခွင့်ပြုရင်းနှီးမြှုပ်နှံမှုသက်တမ်းကာလတို့ အပါအဝင် စီမံကိန်းအတွက် ရင်းနှီးမြှုပ်နှံမှုဆိုင်ရာ အဓိကအရေးပါသည့် စည်းကမ်းသတ်မှတ်ချက်များကို ခွင့်ပြု၍ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်က ထုတ်ပေးသည့် ကော်မရှင်၏ သဘောတူခွင့်ပြုချက်ကို ဆိုလိုသည်။

"**မြန်မာနိုင်ငံ**" ဆိုသည်မှာ ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်ကို ဆိုလိုသည်။

"**မပျက်ကွက်သည့်စာချုပ်ဝင်**" ဆိုသည်မှာ အပိုဒ် ၁၃.၂.၁ တွင် ဖော်ပြထားသည့်အတိုင်း ဖြစ်သည်။

"**ဖွင့်လှစ်သည့်နေ့ရက်**" ဆိုသည်မှာ ပုဂ္ဂလိက ကျန်းမာရေးလုပ်ငန်းဆိုင်ရာ ဗဟိုအဖွဲ့မှ ဆေးရုံလိုင်စင်ကိုထုတ်ပေး၍ လုပ်ငန်းစတင်ခွင့်ပြုသည့် နေ့ရက်ကို ဆိုလိုသည်။

"**ခွင့်ပြုချက်**" ဆိုသည်မှာ အပိုဒ် ၃.၁ တွင် ဖော်ပြထားသည့်အတိုင်းဖြစ်သည်။

"**စီမံကိန်း**" ဆိုသည်မှာ ဆေးရုံ ဆောက်လုပ်ခြင်း၊ လည်ပတ်ခြင်းနှင့် ပြန်လည်လွှဲပြောင်းခြင်း ကို ဆိုလိုသည်။

"**အငှားချထားမြေ**" ဆိုသည်မှာ ပူးတွဲပါ နောက်ဆက်တွဲဇယား ၁ တွင် သတ်မှတ်ပိုင်းခြား ဖော်ပြထားသည့် မြေကွက်နှင့် ၎င်းမြေပေါ်တွင် ဆောက်လုပ်သည့် အဆောက်အအုံ(များ)၏ တစ်စိတ်တစ်ပိုင်းကိုဖြစ်စေ အပြည့်အဝကိုဖြစ်စေ ဆိုလိုသည်။

"**ဒုတိယတိုးမြှင့်ငှားရမ်းကာလ**" ဆိုသည်မှာ အပိုဒ် ၃.၂.၃ တွင် ဖော်ပြထားသည့်အတိုင်း ဖြစ်သည်။

"**သတ်မှတ်ဘဏ်စာရင်းနံပါတ်**" ဆိုသည်မှာ အပိုဒ် ၄.၃.၂ တွင် ဖော်ပြထားသည့်အတိုင်းဖြစ်သည်။

၁.၂။ အထွေထွေ

အခြားနည်းဖြင့် ကွဲလွဲမှုများမရှိပါက အောက်ပါရှင်းလင်းချက်များအတိုင်း သက်ရောက်မှုရှိပါသည်။

၁.၂.၁။ လူပုဂ္ဂိုလ်တစ်ဦးဟုဆိုရာတွင် တစ်ဦးတစ်ယောက်ချင်းသော်လည်းကောင်း ကော်ပိုရေးရှင်းသော်လည်းကောင်း ပါဝင်ပါသည်။

၁.၂.၂။ အငှားချထားသူဟု ရည်ညွှန်းရာတွင် ၎င်း၏ဆက်ခံသူများနှင့် ဥပဒေအရ လွှဲအပ်ခြင်းခံရသူများ၊ ဤသဘောတူစာချုပ်ပြီးဆုံးပြီးနောက်တွင် အငှားချထားမြေကို ပိုင်ဆိုင်ခွင့်ရှိသူများအားလုံး ပါဝင်သည်။ အငှားချထားခံရသူဟု ရည်ညွှန်းရာတွင် ၎င်း၏ဆက်ခံသူများနှင့် ဥပဒေအရ လွှဲအပ်ခြင်းခံရသူများ ပါဝင်သည်။

၁.၂.၃။ ဤသဘောတူစာချုပ်၏ နောက်ဆက်တွဲဇယားနှင့် နောက်ဆက်တွဲတိုင်းကို စာချုပ်၏တစ်စိတ်တစ်ဒေသဖြစ်သည်။

၁.၂.၄။ အခြားနည်းဖြင့် ဖော်ပြထားခြင်းမရှိပါက စကားလုံးတစ်လုံး သို့မဟုတ် ပြဋ္ဌာန်းချက်တစ်ရပ်သည် အခြားစကားလုံး သို့မဟုတ် ပြဋ္ဌာန်းချက်၏ သက်ရောက်မှုကို ကန့်သတ်မထားပါ။

၁.၂.၅။ တစ်ခုလုံးကို ရည်ညွှန်းချက်သည် တစ်စိတ်တစ်ဒေသလည်း ပါဝင်သည်။

၁.၂.၆။ အကယ်၍ ဤသဘောတူစာချုပ်အရ အငှားချထားသူ၏ သဘောတူညီချက် သို့မဟုတ် ခွင့်ပြုချက်ကို လိုအပ်သောအခြေအနေမျိုးတွင် ယင်းသဘောတူညီချက် သို့မဟုတ် ခွင့်ပြုချက်ကို ခိုင်လုံသောအကြောင်းတစ်စုံတစ်ရာမရှိဘဲ ဆုပ်ကိုင်ထားခြင်းမပြုရ။

၁.၂.၇။ ဥပဒေအရ ပြဋ္ဌာန်းချက်များကို ရည်ညွှန်းချက်တစ်ရပ်ရပ်တွင် စာချုပ်အကျိုးသက်ရောက်သည့်နေ့ရက်တွင် စတင်အာဏာတည်သည့် ယင်းပြဋ္ဌာန်းချက်အောက်တွင် အခါအားလျော်စွာ သတ်မှတ်သည့် အခြားပြဋ္ဌာန်းချက်များလည်း ပါဝင်သည်။

၂။ အာမခံချက်များနှင့် ကိုယ်စားပြုမှုများ

၂.၁။ စာချုပ်ဝင်အသီးသီးသည် အခြားစာချုပ်ဝင်တစ်ဖက်ဖက်၏ အကျိုးအတွက် အောက်ပါအချက်များကို အာမခံ၍ ကိုယ်စားပြုပါသည်။

၂.၁.၁။ အငှားချထားသူသည် –

(၁) မြန်မာနိုင်ငံ၊ ပြည်ထောင်စုအဆင့်ဝန်ကြီးဌာနဖြစ်သည့် ကျန်းမာရေးဝန်ကြီးဌာနသည် အငှားချထားမြေကို ဥပဒေကြောင်းအရ တရားဝင်ပိုင်ဆိုင်ခွင့်ရှိသူနှင့် အကျိုးခံစားခွင့်ရှိသူဖြစ်ပြီး တာဝန်ယူခွင့်နှင့် စီမံခန့်ခွဲခွင့် ရှိပါသည်။

(၂) အငှားချထားမြေသည် မည်သည့်တောင်းဆိုမှု၊ ကြွေးမြီတာဝန်အရှုပ်အရှင်းများနှင့် သတိပေးတားမြစ်ချက်များ မရှိကြောင်း အာမခံပါသည်။

၂.၁.၂။ အငှားချထားခံရသူသည် –

(၁) မြန်မာနိုင်ငံတည်ဆဲဥပဒေများအရ ကုမ္ပဏီဖွဲ့စည်းတည်ထောင်ထားပြီး တရားဝင်တည်ရှိခြင်းဖြစ်ကြောင်း အာမခံပါသည်။

(၂) ဆောင်ရွက်လျက်ရှိသော၊ ဆောင်ရွက်ရန် အဆိုပြုထားသော လုပ်ငန်းများကို ဆောင်ရွက်နိုင်သည့် အခွင့်ရှိကြောင်း အာမခံပါသည်။

၂.၁.၃။ (၁) ဥပဒေနှင့်အညီ သဘောတူစာချုပ်ကို ချုပ်ဆိုရန်၊ ၎င်း၏အခွင့်အရေးများကို ကျင့်သုံးဆောင်ရွက်ရန်၊ ဤသဘောတူစာချုပ်ပါ တာဝန်ဝတ္တရားများကို ဆောင်ရွက်၊ လိုက်နာနိုင်ရန် (၂) ယင်းတာဝန်ဝတ္တရားများသည် တရားဝင်မှု၊ ဥပဒေနှင့်ညီညွတ်မှု၊ အာဏာတည်စေနိုင်မှု ရှိခြင်းတို့ သေချာစေရန်နှင့် (၃) ဤသဘောတူစာချုပ်ကို မြန်မာနိုင်ငံ တရားရုံးများတွင် အထောက်အထားအဖြစ် တင်ပြနိုင်ခွင့်ရှိစေရန် စသည်တို့အတွက် ဆောင်ရွက် ဖြည့်ဆည်း အကောင်အထည်ဖော်ဆောင်ရမည့် လုပ်ငန်းဆောင်ရွက်ချက်များ၊ အခြေအနေများနှင့် ကိစ္စအဝဝကို ဆောင်ရွက် ဖြည့်ဆည်း အကောင်အထည်ဖော်ဆောင်မည်ဖြစ်ကြောင်း အာမခံပါသည်။

၂.၁.၄။ စာချုပ်ချုပ်ဆိုမှု၊ ၎င်း၏အခွင့်အရေးများကို ကျင့်သုံးမှုနှင့်/သို့မဟုတ် စာချုပ်ပါ တာဝန်ဝတ္တရားများကို ဆောင်ရွက်၊ လိုက်နာမှုတို့သည် သက်ဆိုင်ရာ ဥပဒေများက ခွင့်ပြုသည့် သို့မဟုတ် ပြဋ္ဌာန်းသည့် အခွင့်အာဏာများ သို့မဟုတ် ကန့်သတ်ချက်များကို ချိုးဖောက်ခြင်း သို့မဟုတ် ကျော်လွန်ခြင်းတို့မဖြစ်စေရန် အာမခံပါသည်။

၂.၂။ အာမခံချက်များကို စာချုပ်ဝင်တစ်ဖက်ဖက်က အပိုဒ် ၂.၁ နှင့်အညီ တိုးမြှင့်နိုင်ပြီး ယင်းတို့ကို ကနဦးငှားရမ်းကာလနှင့် တိုးမြှင့်ငှားရမ်းကာလတစ်ရပ်ရပ် စတင်သည့်အချိန်တွင် စာချုပ်ဝင်အသီးသီးက ထပ်လောင်းအာမခံရမည်ဖြစ်ကြောင်း မှတ်ယူရမည်။

၃။ တည်ဆောက်၊ လည်ပတ်နှင့် လွှဲပြောင်းမှု

၃.၁။ ဆောက်လုပ်ရန်ခွင့်ပြုချက်

အငှားချထားသူသည် အငှားချထားခံရသူထံ အောက်ပါတို့ကို ခွင့်ပြုပေးပြီး အငှားချထားခံရသူသည် အောက်ပါတို့ကို လက်ခံပါသည်။ အငှားချထားခံရသူနှင့် ၎င်း၏တရားဝင်အခွင့်ရရှိသူများအားလုံးအနေဖြင့် စာချုပ်အကျိုးသက်ရောက်သည့်နေ့ရက်နှင့်ယင်းနေ့ရက်အပြီး ၄၈ လ သို့မဟုတ် အပိုဒ် ၅.၂ နှင့်အညီ

တိုးမြှင့်နိုင်သည့် နေ့ရက်မှစတင်၍("**ကင်းလွတ်ခွင့်ပြုကာလ**") အတွက် တည်ဆောက်ရေးကာလအတွင်း စီမံကိန်းကို ဆောက်လုပ် အကောင်အထည်ဖော်ဆောင်ရန်အတွက် (လုပ်သားများ၊ ပစ္စည်းကိရိယာများ၊ ကုန်ပစ္စည်းများနှင့် တန်ဆာပလာများကို ငှားရမ်းမည့်မြေသို့ ယူဆောင်လာခွင့်ကဲ့သို့သော) ငှားရမ်းမည့်မြေသို့ ခြွင်းချက်မရှိ၊ အတားအဆီး၊ အကန့်အသတ်မရှိ ဝင်ရောက်သုံးစွဲနိုင်သည့် အငှားချထားသူ၏ ခွင့်ပြုချက် ("**ခွင့်ပြုချက်**")

၃.၂။ လည်ပတ်ရန်ငှားရမ်းမှု

အငှားချထားခံရသူသည် ဆေးရုံကို လည်ပတ်ရန်အလို့ငှာ အငှားချထားသူသည် အငှားချထားခံရသူထံ အောက်ပါတို့ကို ခွင့်ပြုပေးပြီး အငှားချထားခံရသူသည် အောက်ပါတို့ကို လက်ခံပါသည်။

၃.၂.၁။ ငှားရမ်းမည့်မြေကို ကနဦးငှားရမ်းကာလစတင်သည့်နေ့ရက်မှစတင်၍ ကနဦး အနှစ် ၅၀ ကာလ ("**ကနဦးငှားရမ်းကာလ**") အတွက် ငှားရမ်းမှု ("**ငှားရမ်းမှု**")

၃.၂.၂။ အပိုဒ် ၁၄.၁ ပါ ပြဋ္ဌာန်းချက်များအရ ကနဦးငှားရမ်းကာလကုန်ဆုံးသည့်နေ့အပြီး နောက်တစ်နေ့တွင် အငှားချထားမြေငှားရမ်းမှု နောက်ထပ်တစ်ဆယ် (၁၀) နှစ် သက်တမ်းအတွက် ချက်ချင်းစတင်အကျုံးဝင်မည်ဖြစ်သည်။ ("**ပထမတိုးမြှင့်ငှားရမ်းကာလ**")

၃.၂.၃။ အပိုဒ် ၁၄.၂ တွင် သတ်မှတ်ပြဋ္ဌာန်းထားမှုများအရ ပထမတိုးမြှင့်ငှားရမ်းကာလ ကုန်ဆုံးပြီး နောက်ထက် ၁၀ နှစ် သက်တမ်းကို ပထမတိုးမြှင့်ငှားရမ်းကာလ ကုန်ဆုံးသည့်နေ့အပြီး နောက်တစ်နေ့တွင် ချက်ချင်းစတင်မည်ဖြစ်သည်။ ("**ဒုတိယတိုးမြှင့်ငှားရမ်းကာလ**")

၃.၃။ အငှားချထားမြေကိုလွှဲပြောင်းခြင်း

၃.၃.၁။ အငှားချထားခံရသူသည် ဤသဘောတူစာချုပ် ရပ်စဲ သို့မဟုတ် ကုန်ဆုံးမှု အကျိုးသက်ရောက်သည့်နေ့မှစတင်၍ သုံးလအတွင်း မည်သည့်ထည့်တွက်စဉ်းစားမှုမဆို မရှိစေရဘဲ အငှားချထားမြေကို "ရှိရင်းစွဲ" အတိုင်း အငှားချထားသူထံ လွှဲပြောင်းပေးရမည်။

(၁) အငှားချထားမြေနှင့်အတူ ယင်းပေါ်တွင် အခိုင်အမာတပ်ဆင်ထားသည့် အသုံးအဆောင်ပစ္စည်းများနှင့် အခြားမရွှေ့ပြောင်းနိုင်သော ပစ္စည်းများ၊

(၂) မီးဆိုင်းများ၊ မီးလုံးမီးချောင်းများ၊ မော်နီတာများနှင့် ခွဲစိတ်ခန်းသုံးစားပွဲများစသည်တို့ကဲ့သို့ ခွဲစိတ်ခန်းများတွင် အခိုင်အမာတပ်ဆင်ထားသည့် အသုံးအဆောင်ပစ္စည်းများအပါအဝင် မရွှေ့ပြောင်းနိုင်သော ဆေးဘက်ဆိုင်ရာ ပစ္စည်းကိရိယာများနှင့်

(၃) ခုတင်များ။

၃.၃.၂။ ထပ်လောင်းရှင်းလင်းအပ်သည်မှာ ရွှေ့ပြောင်းနိုင်သော ဆေးဘက်ဆိုင်ရာမဟုတ်သော ပစ္စည်းကိရိယာများနှင့် ဆေးဘက်ဆိုင်ရာ ပစ္စည်းကိရိယာများအားလုံး (အမ်အာရ်အိုင်အထူးဓာတ်မှန်စက်များ (Magnetic Resonance Imaging)၊ စီ-တီစကင်စက်များ (CT Scanner)၊ အာလ်ထွာဆောင်း (Ultrasound) စသည်တို့ကဲ့သို့အပါအဝင်) ကို အခိုင်အမာတပ်ဆင်ထားသည့် အသုံးအဆောင်ပစ္စည်းများဟု မှတ်ယူရမည်မဟုတ်ဘဲ ယင်းပစ္စည်းများကို အပိုဒ် ၃.၃.၁ အရ အငှားချထားသူထံ လွှဲပြောင်းရမည်မဟုတ်ပါ။ စာချုပ်ဝင်များအကြား နှစ်ဦးနှစ်ဖက် သဘောတူညီမှုများအရလည်းကောင်း၊ အကြောင်းအားလျော်စွာ သဘောတူညီ၍ ထည့်တွက်စဉ်းစားမှုများဖြင့်လည်းကောင်း အငှားချထားခံရသူသည် အဆိုပါပစ္စည်းများကို "ရှိရင်းစွဲ" အတိုင်း အငှားချထားသူထံ လွှဲပြောင်းပေးနိုင်သည်။

၄။ မြေအသုံးချမှုပရီမီယံနှင့် နှစ်စဉ်ငှားရမ်းခ

၄.၁။ စာချုပ်ဝင်များသည် ဖော်ပြပါတို့ကို သဘောတူညီကြပါသည်။

၄.၁.၁။ ကနဦးငှားရမ်းကာလအတွက် ငှားရမ်းမည့်မြေကို ငှားရမ်းမှုကို ထည့်သွင်းစဉ်းစားရာတွင် မြေအသုံးချမှုပရီမီယံနှင့် နှစ်စဉ်ငှားရမ်းခတို့ ပါဝင်ရမည်။

၄.၁.၂။ အငှားချထားခံရသူသည် ကနဦးငှားရမ်းကာလစတင်သက်ရောက်သည့်နေ့ရက်မတိုင်မီတွင် မြေအသုံးချမှုပရီမီယံမှတစ်ပါး အခြားငှားရမ်းခကိုဖြစ်စေ အပိုဒ် ၃.၁ နှင့်အညီ ခွင့်ပြုပေးသည့် ခွင့်ပြုချက်များနှင့်ဆက်နွှယ်သည့် အခြားငွေပမာဏများကိုဖြစ်စေ ပေးချေမှုမရှိစေရပါ။

၄.၂။ အငှားချထားခံရသူသည် မြေအသုံးချမှုပရီမီယံနှင့် နှစ်စဉ်ငှားရမ်းခတို့ကို အပိုဒ် ၄ ပါ စည်းကမ်းချက်များနှင့်အညီ အငှားချထားသူထံ ပေးချေရန် သဘောတူပါသည်။

၄.၃။ "**မြေအသုံးချမှုပရီမီယံ**" ဟု ဆိုရာတွင်

၄.၃.၁။ အငှားချထားသည့်မြေဧရိယာတွင် ပါဝင်သည့် မြေကေအရေအတွက်ကို တစ်ကေလျှင် အမေရိကန်ဒေါ်လာ ၂,၀၀၀,၀၀၀ (အမေရိကန်ဒေါ်လာ နှစ်သန်း တိတိ) ဖြင့် မြှောက်ခြင်းနှင့် ညီမျှသည့် ပမာဏနှင့်

၄.၃.၂။ မြေအသုံးချမှုပရီမီယံကို အငှားချထားခံရသူသည် အောက်ပါအတိုင်း အငှားချထားသူ၏ ဘဏ်စာရင်းသို့ ပေးချေရမည်ဖြစ်ပြီး အသေးစိတ်အချက်အလက်များ (**သတ်မှတ်ဘဏ်စာရင်းနံပါတ်**) ကို အငှားချထားခံရသူထံ စာဖြင့် ရေးသားပေးရမည်။

(၁) ၃၀% ကို ဤသဘောတူစာချုပ်ချုပ်ဆိုသည့်နေ့ရက်မှသုံးလထက်နောက်ကျခြင်းမရှိဘဲ ပေးချေရမည်။

(၂) ၃၀% ကို အထက်ပါအပိုဒ်၄.၃.၂ (၁)ကိုပေးချေပြီး နှင့် ဤသဘောတူစာချုပ်ချုပ်ဆိုပြီး ၆ လထက်နောက်ကျခြင်းမရှိဘဲ ပေးချေရမည်။

(၃) ၄၀% ကို အထက်ပါအပိုဒ်၄.၃.၂ (၂)ကိုပေးချေပြီး နှင့် ဤသဘောတူစာချုပ်ချုပ်ဆိုပြီး ၄၂ လထက်နောက်ကျခြင်းမရှိဘဲ ပေးချေရမည်။

၄.၄။ နှစ်စဉ်ငှားရမ်းခ

၄.၄.၁။ ကနဦးငှားရမ်းကာလဖြစ်သည့် ပထမငါးနှစ်အတွက် ပေးချေရမည့် နှစ်စဉ်ငှားရမ်းခမှာစုစုပေါင်းကြမ်းခင်းဧရိယာ၏ ၇၅% အပေါ် တစ်စတုရန်းမီတာလျှင် အမေရိကန်ဒေါ်လာ ၁၈ နှင့်ညီမျှသည့်ပမာဏ ဖြစ်သည်။

၄.၄.၂။ အငှားချထားခံရသူသည် နှစ်စဉ်ငှားရမ်းခကို

(၁) ကနဦးငှားရမ်းကာလ၏ ပထမသုံးနှစ်တာကာလအတွက် ကနဦးငှားရမ်းကာလ စတင်သက်ရောက်သည့်နေ့ရက်မှစတင်၍ ခြောက်လလျှင်တစ်ကြိမ်ကြိုတင်၍လည်းကောင်း၊

(၂) ကနဦးငှားရမ်းကာလတွင် ကျန်ရှိသည့်ကာလအတွက် ကနဦးငှားရမ်းကာလ စတင်သက်ရောက်သည့်နေ့ရက် သုံးနှစ်ပတ်လည်ပြည့်မြောက်သည့်နေ့မှစတင်၍ နှစ်စဉ်ကြိုတင်၍လည်းကောင်း၊

ပေးချေရမည့်ပမာဏကို သတ်မှတ်ဘဏ်စာရင်းနံပါတ်သို့ ပေးသွင်းရမည်။

၄.၄. ၃။ နှစ်စဉ်ငှားရမ်းခကို ကနဦးငှားရမ်းကာလ စတင်သက်ရောက်သည့်နေ့ရက် ငါးနှစ်ပြည့်သည့် နှစ်ပတ်လည်နေ့မှစ၍ ငါးနှစ်တာကာလ ကုန်ဆုံးချိန်တိုင်းတွင် စာချုပ်ဝင်များက သဘောတူညီခန့်အပ်သော နိုင်ငံတကာ တစ်သီးပုဂ္ဂလရာဖြတ်ကျွမ်းကျင်ပညာရှင်က သတ်မှတ်ပေးသော ကာလပေါက်ဈေးမြေတန်ဖိုးအတိုင်း ပြန်လည်ပြင်ဆင်ရမည်။ ငါးနှစ်တာကာလတိုင်းအတွက် ပေးချေရမည့် နှစ်စဉ်ငှားရမ်းခ မြေတန်ဖိုးကို တိုးမြှင့်ရာတွင် ယခင်ငါးနှစ်ကာလအတွက် ပေးချေရသည့် နှစ်စဉ်ငှားရမ်းခတန်ဖိုး၏ ၅% ထက်မပိုစေရ။ဤအပိုဒ် ၄.၄.၃အရ ရာဖြတ်တစ်ဦးဦးကို ခန့်အပ်ခြင်းအတွက် ကုန်ကျစရိတ်ကို အငှားချထားခံရသူက ကျခံရမည်။

၄.၄.၄။ အငှားချထားခံရသူသည် အပိုဒ် ၄.၄.၂ တွင် သတ်မှတ်ထားသည့် နေ့ရက်မှစတင်၍ ရက်ပေါင်းသုံးဆယ်အတွင်း နှစ်စဉ်ငှားရမ်းခကိုဖြစ်စေ လစဉ်ငှားရမ်းခကိုဖြစ်စေ (သက်ဆိုင်သည်ဆိုပါက) ပေးချေရန် ပျက်ကွက်ပါက လစဉ်မပေးချေရသေးသည့် ငွေပမာဏပေါ်တွင် တစ်နှစ်လျှင် ၅% နှင့်ညီမျှသော ဒဏ်ကြေးငွေကို အငှားချထားသူထံ ပေးဆောင်ရမည်။

၅။ ဆေးရုံတည်ဆောက်ခြင်း

၅.၁။ အငှားချထားခံရသူသည် ဆေးရုံတည်ဆောက်မှုကို ပြီးစီးရန်နှင့် အဆောက်အအုံ ဆောက်လုပ်ပြီးစီးကြောင်းလက်မှတ်ထုတ်ပေးမှုကို ကင်းလွတ်ခွင့်ပြုကာလအတွင်း ရယူနိုင်ရန် ကြိုးပမ်းရမည်။

၅.၂။ အငှားချထားခံရသူ၏ ယူဆချက်အရ ဆေးရုံတည်ဆောက်မှု နှောင့်နှေးနိုင်သည့် အလားအလာ သို့မဟုတ် နှောင့်နှေးနိုင်သည့် အောက်ဖော်ပြပါဖြစ်ရပ်များ ပေါ်ပေါက်ပါက

၅.၂.၁။ အပိုဒ် ၁၂ တွင် ဖော်ပြထားသည့် မလွန်ဆန်နိုင်သောဖြစ်ရပ်။

၅.၂.၂။ အငှားချထားသူကြောင့်ဖြစ်သည့် တားဆီးမှု၊ စာချုပ်ဖောက်ဖျက်မှုနှင့် နှောင့်နှေးကြန့်ကြာမှုစသည့် ဆောင်ရွက်ချက်တစ်ရပ်ရပ်။

၅.၂.၃။ မြန်မာနိုင်ငံရှိ သက်ဆိုင်ရာအာဏာပိုင်များထံမှ လိုအပ်သည့် အစိုးရပိုင်းဆိုင်ရာ၊ စည်းကမ်းထိန်းသိမ်းရေးဆိုင်ရာနှင့်အခြားခွင့်ပြုချက်များနှင့်/သို့မဟုတ် ဆေးရုံတည်ဆောက်ရေးနှင့်ဆက်နွှယ်၍ လိုအပ်သည့် လိုင်စင်များ၊ ခွင့်ပြုမိန့်များနှင့် သဘောတူညီချက်များရရှိရန် ကြန့်ကြာမှု။

၅.၂.၄။ အငှားချထားမြေပေါ်တွင်အဖိုးတန်ကျောက်မျက်များ၊ ဓာတ်သတ္တုများ၊ ရေနံ သို့မဟုတ် ယဉ်ကျေးမှုအမွေအနှစ်များ တွေ့ရှိမှု။

၅.၂.၅။ အငှားချထားခံရသူဘက်မှ ထိုက်သင့်သည့် သတိဝီရိယရှိစေကာမူ အငှားချထားခံရသူက ကိုင်တွယ်ထိန်းချုပ်နိုင်ခြင်းမရှိသည့် ဖြစ်ရပ် သို့မဟုတ် အခြေအနေ။

၅.၂.၆။ စာချုပ်ဝင်များကစာဖြင့်ရေးသားသတ်မှတ်သည့်အခြားအကြောင်းကိစ္စများ။

အငှားချထားခံရသူသည် (မည်သည့်အဖိုးစားနား၊ ထိခိုက်ဆုံးရှုံးမှုများ၊ အခကြေးငွေများ၊ ဒဏ်ကြေးများ ပေးဆောင်ရန်မလိုဘဲ) နှောင့်နှေးကြန့်ကြာသည့် အချိန်ကာလနှင့်ညီမျှသည့် အချိန်ကာလအတိုင်း ကင်းလွတ်ခွင့်ပြုကာလတိုးမြှင့်မှုကို ခံစားခွင့်ရှိသည်။

၆။ အငှားချထားသူ၏တာဝန်ဝတ္တရားများ

၆.၁။ အငှားချထားသူသည် စာချုပ်အကျိုးသက်ရောက်သည့်နေ့ရက်မှစတင်၍ အငှားချထားမြေကို အလွတ်အတိုင်း အငှားချထားခံရသူထံ လက်ရောက်ပေးအပ်ရမည်။ အငှားချထားသည့်မြေပေါ်ရှိ မြေပိုင်ဆိုင်မှုနှင့်ပတ်သက်သည့် တတိယပုဂ္ဂိုလ်မှ တောင်းဆိုလာမည့်အမှုဆိုင်ရာဆောင်ရွက်ချက်များ၊ တောင်းဆိုမှုများ၊ လုပ်ဆောင်ချက်များ စသည် တို့ပေါ်ပေါက်လာပါက အငှားချထားသူက တာဝန်ယူဖြေရှင်းပေးရမည်ဖြစ်သည်။

၆.၂။ အငှားချထားသူသည် ၎င်း၏ အငှားချထားမြေပိုင်ဆိုင်ခွင့်ကို ထိန်းသိမ်းရန်အတွက် အစိုးရထံပေးဆောင်ရမည့် မြေခွန်များနှင့်မြေအခွန်အကောက်များကိုသာ ကျခံရမည်။

၆.၃။ အငှားချထားသူသည် အငှားချထားခံရသူကို ပံ့ပိုးပေးရန်အတွက် အောက်ပါဆောင်ရွက်ချက်များတွင် အကောင်းဆုံးကြိုးစားဆောင်ရွက်ပေးရမည်။

၆.၃.၁။ အငှားချထားမြေထံ အပိုဒ် ၃.၁ နှင့်အညီ ဝင်ထွက်သွားလာခွင့်အတွက်လည်းကောင်း၊ အငှားချထားမြေကို ကနဦးငှားရမ်းကာလနှင့် တိုးမြှင့်ငှားရမ်းကာလတစ်ရပ်ရပ်အတွက် ငှားရမ်းမှုအတွက်လည်းကောင်း မြန်မာနိုင်ငံရှိ သက်ဆိုင်ရာအာဏာပိုင်များ သို့မဟုတ် အဖွဲ့များထံမှ (သက်ဆိုင်သည့်ကိစ္စရပ်များတွင် MIC ခွင့်ပြုချက်များအပါအဝင်) လိုအပ်သည့် ခွင့်ပြုချက်များ၊ လိုင်စင်များနှင့် ခွင့်ပြုမိန့်များအားလုံး ရရှိစေမှု။

၆.၃.၂။ စီမံကိန်းတွင် အသုံးပြုမည့် စက်ပစ္စည်းကိရိယာများ၊ စက်ယန္တရားများနှင့် အပိုပစ္စည်းများ တင်သွင်းလာမှုနှင့်စပ်လျဉ်း၍ နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဥပဒေ (၂၀၁၂) နှင့်အညီ အငှားချထားခံရသူရရှိနိုင်သည့် အခွန်ကင်းလွတ်ခွင့်များ၊ အခွန်လျှော့ပေါ့သက်သာခွင့်များ ရရှိနိုင်မှု။

၆.၄။ အငှားချထားသူသည် အငှားချထားခံရသူထံ အောက်ပါတို့ကိုကတိကဝတ်ပြုပါသည်။

၆.၄.၁။ အငှားချထားသူ သို့မဟုတ် အငှားချထားသူ၏အောက်မှဖြစ်စေ အငှားချထားသူကိုယ်စားဖြစ်စေ ဥပဒေကြောင်းအရ တောင်းဆိုပိုင်ခွင့်ရှိသူ မည်သူမဆိုထံမှ မည်သည့်အနှောင့်အယှက်၊ အတားအဆီးများ မည်သည့်နည်းနှင့်မျှမရှိစေရဘဲ အငှားချထားခံရသူသည် ကင်းလွတ်ခွင့်ပြုကာလတွင်လည်းကောင်း၊ကနဦးငှားရမ်းကာလတစ်လျှောက်လုံးတွင်လည်းေ ကာင်း တိုးမြှင့်ငှားရမ်းကာလတစ်ရပ်ရပ်တွင်လည်းကောင်း အငှားချထားမြေကို ဥပဒေနှင့်အညီ ငြိမ်းချမ်းစွာပိုင်ဆိုင်ထားရှိခွင့်၊ အသုံးပြုခွင့်ရှိသည်။

၆.၄.၂။ အငှားချထားသူသည် မြေနှင့်ပတ်သက်၍ ၎င်း၏ပိုင်ဆိုင်ခွင့်နှင့် အကျိုးစီးပွားများကို အခြားသူထံ လွှဲပြောင်းပေးမည်ဆိုပါက ယင်းလွှဲပြောင်းမှုကို ဤသဘောတူစာချုပ်နှင့်အညီ

ဆောင်ရွက်ရမည်။ အငှားချထားသူသည် လွှဲပြောင်းခံရသူထံမှ စာဖြင့်ရေးသားထားသည့် အာမခံကတိပြုမှုကိုရယူပြီး အငှားချထားခံရသူထံ ပေးရမည်ဖြစ်ပြီး စာချုပ်ပါစည်းကမ်းသတ်မှတ်ချက်များ၊ ကတိကဝတ်များ၊ သတ်မှတ်ချက်များနှင့် အခြေအနေများအားလုံးကို လိုက်နာစေရမည်။ သို့သော် ဤသဘောတူစာချုပ်ကို မလိုက်နာမှု၊ မဆောင်ရွက်မှုများ ပေါ်ပေါက်လာပါက ယင်းဖော်ပြချက်တစ်ရပ်ရပ်သည် အငှားချထားသူထံမှ အငှားချထားခံရသူရရှိထားသည့် အခွင့်အရေးများအပေါ် အကျိုးသက်ရောက်ခြင်း၊ ထိခိုက်နစ်နာခြင်း မဖြစ်စေရ။

၇။ အငှားချထားခံရသူ၏ တာဝန်ဝတ္တရားများ

၇.၁။ အငှားချထားခံရသူသည် ဤသဘောတူစာချုပ်ပါ စည်းကမ်းသတ်မှတ်ချက်များနှင့်အညီ ဆေးရုံတည်ဆောက်မှုကို ဆောင်ရွက် အကောင်အထည်ဖော်ရမည်။

၇.၂။ အငှားချထားခံရသူသည်မြေအသုံးချမှုပရီမီယံ၊ နှစ်စဉ်ငှားရမ်းခနှင့် အခြားပေးချေရမည်များကို ကြန့်ကြာမှုမရှိစေရဘဲ ဤသဘောတူစာချုပ်ပါ စည်းကမ်းသတ်မှတ်ချက်များနှင့်အညီ ပေးရမည်။.

၇.၃။ အငှားချထားခံရသူသည် အငှားချထားမြေကို ဆေးရုံလည်ပတ်မှုနှင့်ဆက်စပ်၍ အသုံးပြုမှုများအပါအဝင် စီမံကိန်းရည်ရွယ်ချက်အတွက်သာ ဝင်ရောက်၊ အသုံးပြုရမည်။ ဆေးရုံလည်ပတ်မှုကို MIC ခွင့်ပြုမိန့်နှင့် ပုဂ္ဂလိကကျန်းမာရေးလုပ်ငန်းဆိုင်ရာဗဟိုအဖွဲ့မှ ထုတ်ပေးသည့် ဆေးရုံလုပ်ငန်းလိုင်စင်နှင့်အညီ ဆောင်ရွက်ရမည်။

၇.၄။ အငှားချထားခံရသူသည် ဘေးအန္တရာယ်ကင်းရှင်းရေးနှင့် ကျန်းမာရေးလိုအပ်ချက်များအတွက် အသုံးပြုခြင်းကဲ့သို့သော အသုံးပြုခြင်းများအပါအဝင် အငှားချထားမြေကိုအသုံးပြုခြင်းနှင့်စပ်လျဉ်း၍ မြန်မာနိုင်ငံပုဂ္ဂလိကကျန်းမာရေးလုပ်ငန်းဆိုင်ရာဥပဒေကို လိုက်နာရမည်။

၇.၅။ အငှားချထားခံရသူသည် ငှားရမ်းထားသည့်အကျိုးခံစားခွင့် တစ်စိတ်တစ်ပိုင်းကို MIC ၏ ခွင့်ပြုချက်ရရှိခြင်းမရှိဘဲ ပေါင်နှံခြင်းမပြုရ။ ထိုသို့ပေါင်နှံခြင်းကို မြန်မာနိုင်ငံ၏ နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဥပဒေ (၂၀၁၂) နှင့်အညီ ဆောင်ရွက်ရမည်။ ထပ်လောင်းရှင်းလင်းအပ်သည်မှာ အငှားချထားခံရသူသည် သက်ဆိုင်သောဥပဒေများနှင့်အညီ ဤသဘောတူစာချုပ်ပါ ၎င်း၏အခွင့်အရေးများကို တစ်ဆင့်ငှားရမ်းခြင်း၊ လွှဲပြောင်းခြင်း၊ ပေးအပ်ခြင်းများ ပြုလုပ်နိုင်မည်ဖြစ်ပြီး အငှားချထားခံရသူသည် အငှားချထားသူ၏ ခွင့်ပြုချက်မရဘဲ မည်သည့်ဆေးရုံအစိတ်အပိုင်းကိုမဆို တစ်ဆင့်ငှားရမ်းခြင်း မပြုရပါ။

၇.၆။ အငှားချထားခံရသူသည် ကင်းလွတ်ခွင့်ပြုကာလ၊ ကနဦးငှားရမ်းကာလနှင့် တိုးမြှင့်ငှားရမ်းကာလများအတွင်း အငှားချထားမြေပေါ်တွင် အဖိုးတန်ကျောက်မျက်များ၊ ဓာတ်သတ္တုများ၊

ရေနံ သို့မဟုတ် ယဉ်ကျေးမှုအမွေအနှစ်များကို တွေ့ရှိပါက အငှားချထားသူထံ တတ်နိုင်သမျှ အမြန်ဆုံးအကြောင်းကြားရမည်။

၈။ အငှားချထားမြေနှင့်စပ်လျဉ်းသည့်ငွေပေးချေမှုများ

ထပ်လောင်းရှင်းလင်းအပ်သည်မှာ အောက်ပါ အငှားချထားမြေနှင့်စပ်လျဉ်းသည့် ငွေပေးချေမှုများကို သက်ဆိုင်ရာစာချုပ်ဝင်က အောက်ဖော်ပြပါအတိုင်း ကျခံရမည်။

၈.၁။ အငှားချထားခံရသူသည်

၈.၁.၁။ မြေအသုံးချမှုပရီမီယံနှင့်

၈.၁.၂။ နှစ်စဉ်ငှားရမ်းခ

အစရှိသည်တို့ကို အပိုဒ် ၄ နှင့်အညီ ပေးချေရန်နှင့်

၈.၁.၃။ ဤစာချုပ်ချုပ်ဆိုခြင်း သို့မဟုတ် အောက်တွင်ဆောင်ရွက်ဖွယ်ရှိသည့် လုပ်ငန်းကိစ္စများအတွက်ကြောင့် ပေးချေရမည့် သက်ဆိုင်သော တံဆိပ်ခေါင်းခွန်၊ နိုတြီကြေးများနှင့် မှတ်ပုံတင်ခွန်များနှင့် အခွန်အကောက်များ။

၈.၂။ အငှားချထားသူသည် အပိုဒ် ၆.၂ နှင့်အညီ ၎င်း၏ အငှားချထားမြေပိုင်ဆိုင်ခွင့်ကို ထိန်းသိမ်းရန်အတွက် အစိုးရထံပေးဆောင်ရမည့် မြေခွန်များနှင့်မြေအခွန်အကောက်များကိုသာ ကျခံရမည်။

၉။ လုပ်ငန်းဆောင်ရွက်မှုအာမခံချက်

အငှားချထားခံရသူသည် စုစုပေါင်းကြမ်းခင်းဧရိယာ၏ ၇၅% ရှိ တစ်စတုရန်းမီတာလျှင် အမေရိကန်ဒေါ်လာ ၄.၅ နှင့်ညီမျှသည့်ပမာဏကို **[ဘဏ်ကိုဖော်ပြပါ]** ဘဏ်အာမခံ အဖြစ်စာချုပ်စတင်အကျိုးသက်ရောက်သည့်နေ့မှစ၍ နှစ်လအတွင်း အငှားချထားသူထံ ပေးအပ်ရမည်။ ("လုပ်ငန်းဆောင်ရွက်မှုအာမခံချက်") လုပ်ငန်းဆောင်ရွက်မှုအာမခံချက်သည် ခြောက်နှစ်တာကာလအထိ အကျုံးဝင်သက်ရောက်မှုရှိစေရမည်ဖြစ်ပြီး အငှားချထားခံရသူ၏ ဆေးရုံတည်ဆောက်ရန် တာဝန်အတွက် အာမခံဖြစ်စေရမည်။

၁၀။ ပြန်လည်ဝင်ရောက်ပိုင်ခွင့်

အငှားချထားခံရသူသည် ဤသဘောတူစာချုပ်ပါ စည်းကမ်းသတ်မှတ်ချက်များကို ဆောင်ရွက်ရန်ပျက်ကွက်ခြင်း၊ ထိုသို့ပျက်ကွက်မှုအတွက် အငှားချထားသူထံမှ စာဖြင့်ရေးသားထားသည့် အကြောင်းကြားစာကို ရရှိအပြီး ခြောက်လ အတွင်း မဆောင်ရွက်မှု သို့မဟုတ် မလိုက်နာမှုကို ပြန်လည်ကုစားခြင်းမရှိလျှင် အငှားချထားသူသည် အငှားချထားမြေပေါ်သို့ ပြန်လည်ဝင်ရောက်၍

ရယူပိုင်ခွင့်ရှိစေရမည်ဖြစ်ပြီး ဤသဘောတူစာချုပ်သည်လည်း ရပ်စဲ၍ဆုံးခန်းတိုင်ရမည်။ ထိုသို့ဝင်ရောက်ရယူရာတွင် (က) စာချုပ်အကျိုးသက်ရောက်သည့်နေ့ရက်မှစ၍ ခြောက်နှစ်အတွင်း ဖွင့်လှစ်သည့်နေ့ရက် မဖြစ်ပေါ်လာပါက ဆေးရုံတည်ဆောက်မှုပြီးဆုံးရန် ကြန့်ကြာမှုသည် ဤသဘောတူစာချုပ်ပါ စည်းကမ်းချက်များကို ဆောင်ရွက်၊ လိုက်နာရန် အငှားချထားခံရသူ၏ ပျက်ကွက်မှုဟု မမှတ်ယူစေရ (ခ) ထိုသို့ပြန်လည်ဝင်ရောက်သည့်ကိစ္စတွင် အငှားချထားခံရသူထံမှ အငှားချထားသူရရှိမည့် ငှားရမ်းခငွေများ၊ ပျက်ဆီးဆုံးရှုံးမှုများအတွက် လျော်ကြေးပေးအပ်မှုများမှ ကင်းလွတ်ခြင်း မရှိစေရ။

၁၁။ ပတ်ဝန်းကျင်နှင့် တွင်းထွက်ဓာတ်သတ္တုသယံဇာတများ ကာကွယ်စောင့်ရှောက်မှု

၁၁.၁။ အငှားချထားခံရသူသည် အငှားချထားသောမြေ၏ ပတ်ဝန်းကျင်ထိန်းသိမ်းရေးအတွက် စီမံကိန်းနှင့်စပ်လျဉ်း၍ အသုံးပြုရမည့် ရေဆိုးစွန့်ပစ်မှုကိုင်တွယ်ထိန်းသိမ်းမှုဆိုင်ရာ ပစ္စည်းပစ္စယများနှင့် အခြားစွန့်ပစ်ပစ္စည်းစီမံခန့်ခွဲမှုဆိုင်ရာ ပစ္စည်းပစ္စယများ တပ်ဆင်ခြင်းစသည့် ထိုက်သင့်သောကြိုးပမ်းမှုများ ဆောင်ရွက်ခြင်းတို့ကဲ့သို့အပါအဝင် မြန်မာနိုင်ငံ တည်ဆဲဥပဒေများနှင့် စည်းမျဉ်းများကို လိုက်နာရမည်။

၁၁.၂။ အငှားချထားသောမြေပေါ်တွင် တည်ရှိသည့် အဖိုးတန်ကျောက်မျက်များ၊ တွင်းထွက်ပစ္စည်းဓာတ်သတ္တုများ၊ ရေနံ သို့မဟုတ် ယဉ်ကျေးမှုအမွေအနှစ်များအားလုံးကို မြန်မာနိုင်ငံအစိုးရက ပိုင်ဆိုင်ပြီး အငှားချထားမြေပေါ်မှ အဆိုပါ ရှာဖွေတွေ့ရှိမှုများကို အငှားချထားခံရသူထံ ရက်ပေါင်း ၆၀ ကြိုတင်အကြောင်းကြားစာ ပေးပို့ခြင်းဖြင့် မြန်မာနိုင်ငံ ဥပဒေ၊ နည်းဥပဒေ၊ စည်းမျဉ်းများနှင့်အညီ တူးဖော်ခွင့်ပေးနိုင်သည်။ အဆိုပါ တူးဖော်ရေးလုပ်ငန်းစဉ်များသည် အငှားချထားခံရသူအနေဖြင့် အငှားချထားမြေကို အသုံးပြုမှုနှင့် ခံစားခွင့်တို့ကို နှောင့်ယှက်ခြင်းမရှိစေရပါ။

၁၁.၃။ အငှားချထားသူသည် အငှားချထားခံရသူ၏ အပိုဒ် ၁၁.၂ ပါ ကိစ္စရပ်များကို ဆောင်ရွက်ခြင်းကြောင့် အငှားချထားခံရသူက တိုက်ရိုက်ဖြစ်စေ သွယ်ဝိုက်၍ဖြစ်စေ ထိခိုက်နစ်နာ ကျသင့်ထားသည့် အမှန်တကယ် ဆုံးရှုံးမှုများ၊ နစ်နာမှုများနှင့် ကုန်ကျစရိတ်များ (ဖွင့်လှစ်သည့်နေ့ရက်ကြန့်ကြာမှုကြောင့် အကျိုးစီးပွား နစ်နာဆုံးရှုံးမှုများ သို့မဟုတ် ဆေးရုံလည်ပတ်မှုများကို ဆိုင်းငံ့ခြင်း သို့မဟုတ် အနှောင့်အယှက်ပေးခြင်း စသည်ကဲ့သို့ ကိစ္စရပ်များအပါအဝင်) ကို ပြန်လည်စိုက်ထုတ်ပေးရမည်။

၁၂။ မလွန်ဆန်နိုင်သောဖြစ်ရပ်

စာချုပ်ဝင်တစ်ဖက်ဖက်သည် ၎င်းတို့၏ တာဝန်ဝတ္တရားများကို ဆောင်ရွက်ရာတွင် မလွန်ဆန်နိုင်သောဖြစ်ရပ်ကြောင့် အတားအဆီးများ ပေါ်ပေါက်ပါက ထိခိုက်ခံရသည့် စာချုပ်ဝင်သည် အခြားစာချုပ်ဝင်ထံ စာဖြင့်ရေးသားအကြောင်းကြားခြင်းဖြင့် မလွန်ဆန်နိုင်သောဖြစ်ရပ်

ဆက်လက်ပေါ်ပေါက်နေသရွေ့ ထိုသို့ဆောင်ရွက်မှုကို တားဆီးထားသည့် အခြေအနေအတိုင်းအတာတစ်ရပ်အထိ ဆိုင်းငံ့ထားရမည်။ သို့ရာတွင် ဤသဘောတူစာချုပ်အရ မလွန်ဆန်နိုင်သောဖြစ်ရပ် သတ်မှတ်ပေးရန် တောင်းဆိုသည့် စာချုပ်ဝင်သည် မလွန်ဆန်နိုင်သောဖြစ်ရပ် ပေါ်ပေါက်ကြောင်း အကြောင်းကြားစာကို အခြားစာချုပ်ဝင်ထံ ပေးပို့ခြင်းမပြုပါက မလွန်ဆန်နိုင်သောဖြစ်ရပ်ကို အသိအမှတ်မပြုစေရ။ အဆိုပါအကြောင်းကြားစာတွင် မလွန်ဆန်နိုင်သောဖြစ်ရပ် သဘောသဘာဝ၏ အသေးစိတ်ဖြစ်ရပ်များ၊ မလွန်ဆန်နိုင်သောဖြစ်ရပ်ကြောင့် သက်ရောက်မှုရှိသည့် တာဝန်ဝတ္တရားများ၊ ယင်းတာဝန်ဝတ္တရားများကို ဆောင်ရွက်ရာတွင် မလွန်ဆန်နိုင်သောဖြစ်ရပ်၏ ထိခိုက်မှုတို့ကို အထိုက်အလျောက် ရေးသားဖော်ပြထားရမည်။

၁၃။ စာချုပ်ရပ်စဲခြင်း

၁၃.၁။ ဤသဘောတူစာချုပ်သည် စာချုပ်ဝင်များ၏ တာဝန်ဝတ္တရားများကို လွှမ်းမိုးထားရမည်ဖြစ်ပြီး စာချုပ်ဝင်များက နှစ်ဦးနှစ်ဖက် စာဖြင့်သဘောတူရပ်စဲပြီး MIC ခွင့်ပြုချက်ကို ရရှိသည့် အချိန်အထိလည်းကောင်း၊ ဤသဘောတူစာချုပ်အရ စာချုပ်ဝင်အသီးသီး၏ တာဝန်ဝတ္တရားများအားလုံးကို အပြည့်အဝ ဆောင်ရွက်ပြီးစီးသည့်အချိန်အထိလည်းကောင်း အပြည့်အဝ ဆက်လက်အကျိုးသက်ရောက်မှုရှိသည်ဟု မှတ်ယူရမည်။

၁၃.၂။ MIC ခွင့်ပြုချက်အရ ဤသဘောတူစာချုပ်ကို စာချုပ်ဝင်တစ်ဖက်ဖက်က အခြားစာချုပ်ဝင်ထံ ရက်ပေါင်း ၃၀ ကြိုတင်အကြောင်းကြားစာ ပေးပို့ခြင်းဖြင့်လည်းကောင်း အောက်ပါဖြစ်ရပ်များ ပေါ်ပေါက်သည့်အခါတွင်လည်းကောင်း ရပ်စဲနိုင်သည်။

၁၃.၂.၁။ ဤသဘောတူစာချုပ်ကို ကြီးကြီးမားမားဖောက်ဖျက်ထားသည့် အခြားစာချုပ်ဝင် ("**ပျက်ကွက်စာချုပ်ဝင်**") ထံ မပျက်ကွက်သည့်စာချုပ်ဝင်က ဖောက်ဖျက်မှုကို စာဖြင့်အကြောင်းကြားပြီးသည့်နောက် ခြောက်လအတွင်း ယင်းဖောက်ဖျက်မှုကို ပြန်လည်ကုစားရန် ပျက်ကွက်လျှင် စာချုပ်ဝင်တစ်ရပ်ရပ် ("**မပျက်ကွက်သည့်စာချုပ်ဝင်**") က ရပ်စဲနိုင်သည်။ ထိုသို့ဆိုရာတွင် အငှားချထားခံရသူ၏ ဆေးရုံတည်ဆောက်ရေးပြီးဆုံးမှု ကြန့်ကြာခြင်းသည် ဤသဘောတူစာချုပ်ကို ကြီးကြီးမားမားဖောက်ဖျက်သည်ဟု မယူဆစေရပါ။

၁၃.၂.၂။ ကျိုးကြောင်းဆီလျော်သည်ဟု အငှားချထားခံရသူက ယူဆသည့် အောက်ပါအချက်များကြောင့် ရပ်စဲနိုင်သည်။

(၁) ၃နှစ်ထက်ကျော်လွန်သော ကာလတစ်လျှောက် ဆက်တိုက်ဆုံးရှုံးမှုအများအပြား ပေါ်ပေါက်ခြင်း သို့မဟုတ်

(၂) စီမံကိန်းကို အကောင်အထည်ဖော်ဆောင်ရန် မစွမ်းဆောင်နိုင်တော့ခြင်း။

၁၃.၂.၃။ မလွန်ဆန်နိုင်သောဖြစ်ရပ်သည် ခြောက်လထက်ပို၍ ဆက်တိုက်ပေါ်ပေါက်ခြင်းကြောင့် စာချုပ်ဝင်တစ်ဖက်ဖက်က ရပ်စဲနိုင်သည်။

၁၃.၃။ (အပိုဒ် ၁၄နှင့်အညီ ငှားရမ်းကာလတိုးမြှင့်မှု အကြောင်းကြားစာတစ်ရပ်ရပ်ကို အငှားချထားခံရသူက မပေးပို့ပါက) ကနဦးငှားရမ်းကာလကုန်ဆုံးအပြီးတွင်ဖြစ်စေ (အပိုဒ် ၁၄နှင့်အညီ ငှားရမ်းကာလတိုးမြှင့်မှု အကြောင်းကြားစာတစ်ရပ်ရပ်ကို အငှားချထားခံရသူက ပေးပို့ပါက) နောက်ဆုံးတိုးမြှင့်ငှားရမ်းကာလအပြီးတွင်ဖြစ်စေ ဤသဘောတူစာချုပ်ကို အပိုဒ် ၁၃နှင့်အညီ အငှားချထားခံရသူက ရပ်စဲလျှင်ဖြစ်စေ အငှားချထားခံရသူသည် အပိုဒ် ၃.၃.၁ ပါ ၎င်း၏ တာဝန်ဝတ္တရားများအရ ၎င်း၏ ပရိဘောဂများ၊ ပစ္စည်းကိရိယာများ၊ ကုန်ပစ္စည်းများ၊ ကုန်စည်များ၊ ရွှေ့ပြောင်းနိုင်သည့်ပစ္စည်းများ၊ ဆိုင်းဘုတ်များ၊ လိုဂိုများနှင့် ကုန်အမှတ်တံဆိပ်များကို အငှားချထားမြေပေါ်မှ မိမိ၏ကုန်ကျစရိတ်ဖြင့် ဖယ်ရှားရမည်ဖြစ်ပြီး ထိုသို့ဆောင်ရွက်ရန်အတွက် အငှားချထားခံရသူသည် သင့်တင်သောအချိန်များတွင် အငှားချထားမြေထံသို့ ထိုက်သင့်သော ဝင်ထွက်သွားလာမှုကို အငှားချထားသူက ခွင့်ပြုပံ့ပိုးပေးရမည်။

၁၄။ တိုးမြှင့်ငှားရမ်းကာလများ

၁၄.၁။ ပထမတိုးမြှင့်ငှားရမ်းကာလ

အငှားချထားခံရသူသည် အငှားချထားသူထံ ကနဦးငှားရမ်းကာလကုန်ဆုံးသည့်နေ့မတိုင်မီ ၁၂ လ ထက် မနည်းစေဘဲ သက်တမ်းတိုးရန် စာဖြင့်ရေးသားအသိပေးပါလျှင် MIC အတည်ပြုချက်ရရှိမှုအပေါ် မူတည်ပြီး စာချုပ်ဂင်များ၏ ကနဦးငှားရမ်းကာလသတ်မှတ်မှုသည် အငှားချထားမြေ ပထမတိုးမြှင့်ငှားရမ်းကာလငှားရမ်းမှုအတွင်းသို့ ဤသဘောတူစာချုပ်တွင် ဖော်ပြထားသည့် စည်းကမ်းသတ်မှတ်ချက်များနှင့်အညီ အကျုံးဂင်သွားပြီဟု မှတ်ယူရမည်ဖြစ်ပြီး ဤတွင် ပထမတိုးမြှင့်ငှားရမ်းကာလဆိုင်ရာ ကျင့်သုံးဆောင်ရွက်မှုကို ချင်းချက်ထားရမည်။

၁၄.၁.၁။ ပထမတိုးမြှင့်ငှားရမ်းကာလနှင့်စပ်လျဉ်း၍ ဆေးရုံတည်ဆောက်ရေးအတွက် ကင်းလွတ်ခွင့်ပြုကာလ မရှိစေရပါ။ "ကနဦးငှားရမ်းကာလ စတင်သက်ရောက်သည့်နေ့ရက်" ဆိုသည်မှာလည်း ပထမတိုးမြှင့်ငှားရမ်းကာလ၏ပထမနေ့ရက်ကို ဆိုလိုရမည်။

၁၄.၁.၂။ ပထမတိုးမြှင့်ငှားရမ်းကာလသည် ပထမတိုးမြှင့်ငှားရမ်းကာလ စတင်သည့်နေ့ရက်မှစ၍ ၁၀ နှစ်တာကာလဖြစ်သည်။

၁၄.၁.၃။ ကနဦးငှားရမ်းကာလအပြီးနှင့် တိုးမြှင့်ငှားရမ်းကာလများနှင့်စပ်လျဉ်းပြီး အငှားချထားခံရသူက အငှားချထားသူထံ မြေအသုံးချမှုပရီမီယံ ပေးချေရန် မရှိစေရ၊

ပထမတိုးမြှင့်ငှားရမ်းကာလအတွက် အငှားချထားမြေကို ငှားရမ်းမှုကို ထည့်သွင်းတွက်ချက်ရာတွင် နှစ်စဉ်ငှားရမ်းခသာလျှင် ပါဝင်စေရမည်။

၁၄.၁.၄။ ပထမတိုးမြှင့်ငှားရမ်းကာလအတွက် အငှားချထားမြေငှားရမ်းမှုနှင့်စပ်လျဉ်းသော နှစ်စဉ်ငှားရမ်းခကို

(၁) အပိုဒ် ၄.၄.၃တွင် ဖော်ပြထားချက်အရ ဆုံးဖြတ်သတ်မှတ်မည့် ကာလပေါက်ဈေး မြေငှားရမ်းတန်ဖိုးနှင့်အညီ တွက်ချက်မည်ဖြစ်ဖြစ်ပြီး ဤနေရာတွင် ပထမတိုးမြှင့်ငှားရမ်းကာလအတွက် နှစ်အလိုက်ငှားရမ်းခသည် ကနဦးငှားရမ်းကာလ နောက်ဆုံးနှစ်တွင် သတ်မှတ်ခဲ့သော နှစ်အလိုက်ငှားရမ်းခ၏ ၁၀ ရာခိုင်နှုန်းထက် ပိုလွန်ခြင်းမရှိစေရ။

(၂) ပထမတိုးမြှင့်ငှားရမ်းကာလ၏ ပထမဆုံးနေ့ရက်မှစတင်၍ ပေးချေရမည့်ပမာဏကို သတ်မှတ်ထားသည့် ဘဏ်စာရင်းနံပါတ်သို့ ထည့်သွင်းခြင်းအားဖြင့် နှစ်စဉ် ကြိုတင်ပေးချေရမည်။

၁၄.၁.၅။ အငှားချထားခံရသူသည် ပထမတိုးမြှင့်ငှားရမ်းကာလကုန်ဆုံးချိန်တွင် အပိုဒ် ၁၄.၂ ပါ သတ်မှတ်ပြဋ္ဌာန်းချက်များနှင့်အညီ နောက်ထပ် ၁၀ နှစ် သက်တမ်း ခွင့်ပြုမှုရရှိခွင့်ရှိသည်။

၁၄.၂။ ဒုတိယတိုးမြှင့်ငှားရမ်းကာလ

အငှားချထားခြင်းခံရသူက အငှားချထားသူထံ ပထမတိုးမြှင့်ငှားရမ်းကာလ ကုန်ဆုံးသည့်နေ့မတိုင်မီ ၁၂ လထက် မနည်းစေဘဲ သက်တမ်းတိုးရန် စာဖြင့်ရေးသားအသိပေးပါလျှင် MIC အတည်ပြုချက်ရရှိမှုအပေါ် မူတည်ပြီး စာချုပ်ဝင်များ၏ ပထမတိုးမြှင့်ငှားရမ်းကာလသတ်မှတ်မှုသည် အငှားချထားမြေကို ဒုတိယတိုးမြှင့်ငှားရမ်းကာလငှားရမ်းမှုအတွင်းသို့ ဤသဘောတူစာချုပ်တွင် ဖော်ပြထားသည့် စည်းကမ်းသတ်မှတ်ချက်များနှင့်အညီ အကျုံးဝင်သွားပြီဟု မှတ်ယူရမည်ဖြစ်ပြီး ဤတွင် ဒုတိယတိုးမြှင့်ငှားရမ်းကာလနှင့်သက်ဆိုင်သော ကျင့်သုံးဆောင်ရွက်မှုကို ချွင်းချက်ထားရမည်။

၁၄.၂.၁။ ဒုတိယတိုးမြှင့်ငှားရမ်းကာလနှင့်စပ်လျဉ်း၍ ဆေးရုံတည်ဆောက်ရေးအတွက် ကင်းလွတ်ခွင့်ပြုကာလ မရှိစေရပါ။ "ကနဦးငှားရမ်းကာလ စတင်သက်ရောက်သည့်နေ့ရက်" ဆိုသည်မှာလည်း ဒုတိယတိုးမြှင့်ငှားရမ်းကာလ၏ပထမနေ့ရက်ကို ဆိုလိုရမည်။

၁၄.၂.၂။ ဒုတိယတိုးမြှင့်ငှားရမ်းကာလသည် ဒုတိယတိုးမြှင့်ငှားရမ်းကာလ စတင်သည့်နေ့ရက်မှစ၍ ၁၀ နှစ်တာကာလဖြစ်သည်။

၁၄.၂.၃။ ကနဦးငှားရမ်းကာလအပြီးနှင့် တိုးမြှင့်ငှားရမ်းကာလများနှင့်စပ်လျဉ်းပြီး အငှားချထားခံရသူက အငှားချထားသူထံ မြေအသုံးချမှုပရီမီယံ ပေးချေရန်မရှိစေရ။

ဒုတိယတိုးမြှင့်ငှားရမ်းကာလအတွက် အငှားချထားမြေငှားရမ်းမှုကို ထည့်သွင်းတွက်ချက်ရာတွင် နှစ်စဉ်ငှားရမ်းခသာလျှင် ပါဝင်စေရမည်။

၁၄.၂.၄။ ဒုတိယတိုးမြှင့်ငှားရမ်းကာလအတွက် အငှားချထားမြေငှားရမ်းမှုနှင့်စပ်လျဉ်းသော နှစ်အလိုက်ပေးဆောင်ရမည့် ငှားရမ်းခကို

(၁) အပိုဒ် ၄.၄.၃တွင် ဖော်ပြထားချက်အရ ဆုံးဖြတ်သတ်မှတ်မည့် ကာလပေါက်ဈေးမြေငှားရမ်းတန်ဖိုးနှင့်အညီ တွက်ချက်မည်ဖြစ်ဖြစ်ပြီး ဤနေရာတွင် ဒုတိယတိုးမြှင့်ငှားရမ်းကာလအတွက် နှစ်အလိုက်ငှားရမ်းခသည် ပထမတိုးမြှင့်ငှားရမ်းကာလ နောက်ဆုံးနှစ်တွင် သတ်မှတ်ခဲ့သော နှစ်အလိုက်ငှားရမ်းခကို ၁၀ ရာခိုင်နှုန်းထက် ပိုလွန်ခြင်း မရှိစေရ။

(၂) ဒုတိယတိုးမြှင့်ငှားရမ်းကာလ၏ ပထမဆုံးနေ့ရက်မှစတင်၍ ပေးချေရမည့်ပမာဏကို သတ်မှတ်ထားသည့် ဘဏ်စာရင်းနံပါတ်သို့ ထည့်သွင်းခြင်းအားဖြင့် နှစ်စဉ် ကြိုတင်ပေးချေရမည်။

၁၄.၂.၅။ အပိုဒ် ၁၄ကို ဖယ်ထုတ်ထားရမည်။

၁၅။ အလုံးစုံသဘောတူညီချက်

ဤသဘောတူစာချုပ်သည် စာချုပ်ဝင်များအကြား အလုံးစုံသဘောတူညီချက်ဖြစ်သည်။ ကိုယ်စားပြုမှုတစ်ရပ်ရပ်အပေါ် အမှီပြုထားမှုမရှိခြင်း၊ ဤသဘောတူစာချုပ်ကို လက်မှတ်ရေးထိုး ချုပ်ဆိုရာတွင် မည်သူတစ်ဦးတစ်ယောက်၏ တိုက်တွန်းဆွဲဆောင်မှုမပါဘဲ ချုပ်ဆိုခြင်းဖြစ်ကြောင်းတို့ကို စာချုပ်ဝင်အသီးသီးက အတည်ပြုပါသည်။

၁၆။ ဖြည့်စွက်ပြင်ဆင်ချက်များနှင့် ပြန်လည်ညှိနှိုင်းမှု

၁၆.၁။ စာချုပ်အကျိုးသက်ရောက်သည့်နေ့ရက်တွင်ဖြစ်စေ ယင်းနေ့ရက်ပြီးနောက်တွင်ဖြစ်စေ နှစ်ဖက်စာချုပ်ဝင်များ၏ တရားဝင်လက်မှတ်ရေးထိုးခြင်းများဖြင့် စာဖြင့်ရေးသား အတည်ပြုခြင်းမှတစ်ပါး စာချုပ်ပါ စည်းကမ်းသတ်မှတ်ချက်များကို အပြောင်းအလဲပြုလုပ်ခြင်းသည် တရားဝင်မှု မဖြစ်စေရ။

၁၆.၂။ ဤသဘောတူစာချုပ်တွင် မြန်မာနိုင်ငံ ဥပဒေများ၊ နည်းဥပဒေများ၊ စည်းမျဉ်းများ၊ အမိန့်ကြော်ငြာစာများ သို့မဟုတ် မူဝါဒအပြောင်းအလဲများစသည်တို့ကဲ့သို့ဖြစ်ရပ်များအပါအဝင် မျှော်မှန်းမထားသည့် အခြေအနေများကြောင့် ကိစ္စတစ်ရပ်ရပ် အနေအထားတစ်ရပ်ရပ် ပေါ်ပေါက်ပါက စာချုပ်ဝင်များသည် ဤသဘောတူစာချုပ်ပါ သတ်မှတ်ချက်များကို သဘောရိုးဖြင့် ပြန်လည်ညှိနှိုင်းဆွေးနွေး၍ လိုအပ်သည့် ဖြည့်စွက်ပြင်ဆင်ချက်များ ပြုလုပ်ရမည်။

၁၇။ အကြောင်းကြားခြင်း

၁၇.၁။ ဤသဘောတူစာချုပ်အရ ပေးပို့မည့် သို့မဟုတ် ပြုလုပ်မည့် အကြောင်းကြားခြင်းများအားလုံးကိုဖြစ်စေ အခြားဆက်သွယ်ဆောင်ရွက်မှုများအားလုံးကိုဖြစ်စေ အင်္ဂလိပ်ဘာသာဖြင့် ရေးသား၍ ဤသဘောတူစာချုပ်ပါ ရည်ရွယ်ချက်များအတွက် စာချုပ်ဝင်တစ်ဖက်က အခြားစာချုပ်ဝင်ထံသို့ ပေးပို့ရန်အတွက် လျာထားသတ်မှတ်သည့် ပေးပို့လိုသူထံ (ရှိပါက) လိပ်မူ၍ လက်ခံမည့်သူ၏ လိပ်စာ သို့မဟုတ် အီးမေးလ်လိပ်စာသို့ လူကိုယ်တိုင်ဖြစ်စေ အပြည်ပြည်ဆိုင်ရာစာပို့စနစ်ဖြင့်ဖြစ်စေ အီးမေးလ်ဖြင့်ဖြစ်စေ ပေးပို့ရမည်။ စာချုပ်ဝင်များက လျာထားသတ်မှတ်ထားသည့် ပေးပို့ရမည့်သူ၏ ကနဦးလိပ်စာနှင့် အမည်တို့ကို အောက်တွင်ဖော်ပြအပ်ပါသည်။

အငှားချထားသူထံသို့

လိပ်စာ : [•]

အီးမေးလ်လိပ်စာ : [•]

လိပ်မူသူ : [•]

အငှားချထားခံရသူထံသို့

လိပ်စာ : [•]

အီးမေးလ်လိပ်စာ : [•]

လိပ်မူသူ : [•]

၁၇.၂။ အောက်ဖော်ပြပါတို့ဖြင့် အဆိုပါအကြောင်းကြားမှု သို့မဟုတ် ဆက်သွယ်ဆောင်ရွက်မှုသည် သင့်တင်လျောက်ပတ်စွာ ဆောင်ရွက်ပြီးစီးပြီဖြစ်ကြောင်း မှတ်ယူရမည်။

၁၇.၂.၁။ စာဖြင့်ပေးပို့ပြီးခြင်းဖြစ်ပါက လူကြုံပေးပို့ခြင်းဖြစ်လျှင် ပေးပို့ပြီးသည်နှင့်တပြိုင်နက် သို့မဟုတ် အပြည်ပြည်ဆိုင်ရာစာပို့စနစ်ဖြင့် ပေးပို့ခြင်းဖြစ်လျှင် ပေးပို့ပြီးနောက် ရုံးဖွင့်ရက် သုံးရက်မြောက်နေ့။ အပြည်ပြည်ဆိုင်ရာစာပို့ဝန်ဆောင်မှုထံမှ ပေးပို့ရမည့် လိပ်စာထံသို့ မည်သည့်နေ့ရက်တွင် ပေးပို့ပြီးဖြစ်ကြောင်း ပြေစာဖြင့် သက်သေအလုံအလောက် ပြနိုင်သည်။

၁၇.၂.၂။ အီးမေးလ်ဖြင့် ပေးပို့ခြင်းဖြစ်ပါက ပေးပို့ပြီးသည်နှင့်တပြိုင်နက်

(၁) ပေးပို့သူသည် အီးမေးလ်ပို့လွှတ်ပြီးစီးကြောင်း အလိုအလျောက်မက်ဆေ့ချ် (Automated Message) ကို ရရှိသောအခါတွင်ဖြစ်စေ

(၂) ပေးပို့သူသည် အီးမေးလ်ပို့လွှတ်မှု မအောင်မြင်ကြောင်း အလိုအလျောက်မက်ဆေ့ချ် (Automated Message) ကို လက်ခံရရှိသည်မှလွဲ၍ ပေးပို့လိုက်သည့်အချိန် (အီးမေးလ်ပို့လွှတ်လိုက်သည့် စက်တွင် မှတ်တမ်းတင်ထားသည့်အချိန်) အပြီး လေးနာရီအကြာတွင်ဖြစ်စေ

အီးမေးလ်ပို့လွှတ်မှုသည် ရုံးဖွင့်ရက်တွင် ညနေ ၅ နာရီနောက်ပိုင်းတွင် ပို့လွှတ်ခြင်း သို့မဟုတ် ရုံးဖွင့်ရက်မဟုတ်သည့်နေ့တွင် ပို့လွှတ်ခြင်းဖြစ်ပါက ထိုသို့ပို့လွှတ်မှုသည် ထိုနေ့ရက်များအပြီး နောက်တစ်နေ့ ရုံးဖွင့်ရက် မနက် ၉ နာရီအချိန်တွင် ပြီးစီးသည်ဟု မှတ်ယူရမည်။ ရုံးဖွင့်ရက်ဟူသည်မှာ စနေ၊ တနင်္ဂနွေ သို့မဟုတ် မြန်မာနိုင်ငံ၏ အများပြည်သူအားလပ်ရက်ကို ရည်ညွှန်းသည်။

၁၈။ တတိယအဖွဲ့များ၏အခွင့်အရေးများ

ဤသဘောတူစာချုပ်တွင် အတိအကျ ဖော်ပြထားသည်နှင့်အညီ ဤသဘောတူစာချုပ်၏ စာချုပ်ဝင်မဟုတ်သူသည် ဤသဘောတူစာချုပ်ပါ စည်းကမ်းသတ်မှတ်ချက်များ၏ အကျိုးခံစားမှုအရပ်ရပ်ကို ခံစားခွင့် သို့မဟုတ် သက်ရောက်မှုရှိခွင့်တို့ မရှိစေရပါ။

၁၉။ မူပွားများ

ဤသဘောတူစာချုပ်ကို မူပွားအရေအတွက်မည်မျှမဆို ပြုလုပ်ချုပ်ဆိုနိုင်ပြီး ယင်းမူပွားများအားလုံးကို အလားတူစာချုပ်တစ်ရပ်တည်းအဖြစ် မှတ်ယူရမည်။ မည်သည့်စာချုပ်ဝင်မဆိုသည် ယင်းမူပွားတစ်စောင်ကို လက်မှတ်ရေးထိုးခြင်းဖြင့် ဤသဘောတူစာချုပ်ကို ချုပ်ဆိုပြီးဖြစ်သည်။

၂၀။ ဘာသာစကား

ဤသဘောတူစာချုပ်ကို အင်္ဂလိပ်ဘာသာဖြင့်လည်းကောင်း မြန်မာဘာသာဖြင့်လည်းကောင်း ပြုလုပ်ရေးသားရမည်။ ကွဲလွဲမှုများရှိပါက မြန်မာဘာသာက လွှမ်းမိုးစေရမည်။

၂၁။ လွှမ်းမိုးဥပဒေ

ဤသဘောတူစာချုပ်ကိုမြန်မာနိုင်ငံဥပဒေများနှင့်အညီ လွှမ်းမိုး၍ အကောင်အထည်ဖော် ဆောင်ရွက်ရမည်။

၂၂။ အငြင်းပွားမှုဖြေရှင်းခြင်း

၂၂.၁။ ဤသဘောတူညီချက် တရားဝင်ဖြစ်မှု၊ ဥပဒေအရ တည်ရှိမှု သို့မဟုတ် ရပ်ဆဲခြင်းဆိုင်ရာ အကြောင်းခြင်းရာများအပါအဝင် ဤသဘောတူညီချက်နှင့်စပ်လျဥ်း၍ စာချုပ်ဝင်များအကြား အငြင်းပွားမှု သို့မဟုတ် ကွဲလွဲမှု တစ်စုံတစ်ရာ ပေါ်ပေါက်လျှင်ဖြစ်စေ စာချုပ်နှင့်ဆက်နွယ်သော ကိစ္စရပ်များ ပေါ်ပေါက်လျှင်ဖြစ်စေ ယင်းအငြင်းပွားမှု သို့မဟုတ် ကွဲလွဲမှုတို့ကို အနုညာတခုံရုံးသို့ တင်ပြရမည်။ အနုညာတစီရင်ဆုံးဖြတ်မည့် ခုံရုံးနှင့် နေရာသည် မြန်မာနိုင်ငံတွင်ဖြစ်ပြီး အနုညာတစီရင်ဆုံးဖြတ်မှုကို အင်္ဂလိပ်ဘာသာဖြင့် ဆောင်ရွက်ရမည်။ အနုညာတခုံရုံးဖြင့် စီရင်ဆုံးဖြတ်ချက်သည် အပြီးသတ်ဖြစ်ပြီး စာချုပ်ဝင်နှစ်ဖက်စလုံးက လိုက်နာရမည်။ အနုညာတခုံရုံးတွင် မြန်မာနိုင်ငံသား သို့မဟုတ် စင်ကာပူသမ္မတနိုင်ငံသားမဟုတ်သည့်ခုံသမာဓိလူကြီး တစ် (၁) ပါး ပါဝင်ရမည်။

၂၂.၂။ ခုံသမာဓိက ဆုံးဖြတ်လိုက်သော အနုညာတစီရင်ဆုံးဖြတ်ချက်ကို အပြီးအပြတ်ဖြစ်ပြီး လိုက်နာရန် တာဝန်ရှိသည်။

၂၂.၃။ ဤသဘောတူစာချုပ်နှင့်စပ်လျဥ်း၍ ထွက်ပေါ်လာသော မည်သည့်အငြင်းပွားမှုအတွက်မဆို ဤအပိုဒ် ၂၂ အရ အနုညာတစီရင်ဆုံးဖြတ်မှုအတည်ဖြစ်အောင် ဆောင်ရွက်ရန်အတွက်မှတစ်ပါး မည်သည့်စာချုပ်ဝင်ကမျှ တရားရုံးတစ်ခုတွင် တရားစွဲဆိုမှုအစပြု သို့မဟုတ် ဆက်လက်တည်မြဲစေခြင်း မပြုစေရဘဲ ဤတွင်အနုညာတစွဲဆိုမှုများ စတင်ဆောင်ရွက်နေစဥ်အတွင်း ကြားဖြတ်သက်သာခွင့်နှင့်စပ်လျဥ်း၍ ချွင်းချက်ထားရမည်။

၂၂.၄။ အနုညာတစီရင်ဆုံးဖြတ်ပေးပါရန် လျှောက်ထားသည့် ကာလအတွင်းနှင့် ယင်းနောက်ကာလတွင် အနုညာတစီရင်ဆုံးဖြတ်မှုခွင့်ပြုခြင်းမတိုင်မီအထိ စာချုပ်ဝင်များသည် စာချုပ်ရပ်ဆဲသည့်ဖြစ်စဥ်မှတစ်ပါး ဆိုခဲ့ပါဆုံးဖြတ်မှုနှင့်အညီ အပြီးသတ်ပြင်ဆင်ညှိနှိုင်းချက်ကို ထိခိုက်နစ်နာမှုမရှိစေရဘဲ ဤသဘောတူစာချုပ်ပါ စည်းကမ်းသတ်မှတ်ချက်များနှင့်အညီ အငြင်းပွားရာတွင်မပါဝင်သည့် ၎င်းတို့၏ဝတ္တရားများကို ဖြစ်နိုင်သမျှအတိုင်းအတာအထိ ဆက်လက်လိုက်နာ ဆောင်ရွက်ရမည်။

နောက်ဆက်တွဲဇယား ၁
အငှားချထားမြေဖော်ပြချက်

လိပ်စာ။ မြေကွက်အမှတ် ၁၈[B] ၊ မြေတိုင်းရပ်ကွက်အမှတ် ၂၈[F] ၊ လမ်းမတော်မြို့နယ် (ပြည်လမ်းနှင့် ဗိုလ်ချုပ်လမ်းထောင့်ရှိ ရန်ကုန်မြို့လယ်ခေါင် စီးပွားရေးအချက်အချာနေရာတွင် တည်ရှိသည်။)

အကျယ်အဝန်း။ ၄.၃ ဧက

[***အငှားချထားမြေ၏ ပန္နက်ပုံကို ထည့်သွင်းပါ။***]

စာချုပ်ဝင်များသည် သက်သေထင်ရှားစိမ့်သောငှာ သဘောတူကြကြောင်း အသိသက်သေများ ရှေ့မှောက်တွင် ဤသဘောတူစာချုပ်ကို အထက်တွင်ဖော်ပြထားသော နေ့ရက်တွင် လက်မှတ်ရေးထိုးကြပါသည်။

အငှားချထားသူ

[**လူပုဂ္ဂိုလ်အမည်ထည့်သွင်းပါ**] ကလက်မှတ်ရေးထိုးပါသည်။

ကျန်းမာရေးဝန်ကြီးဌာန
ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
ကိုယ်စား

အောက်ပါသက်သေရှေ့မှောက်တွင်

____

သက်သေလက်မှတ်

အမည် -

လိပ်စာ -

အငှားချထားခံရသူ

[**လူပုဂ္ဂိုလ်အမည်ထည့်သွင်းပါ**] ကလက်မှတ်ရေးထိုးပါသည်။

ANDAMAN ALLIANCE HEALTHCARE LIMITED

ကိုယ်စား

အောက်ပါသက်သေရှေ့မှောက်တွင်

သက်သေလက်မှတ်

အမည် -

လိပ်စာ -

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ

ကျန်းမာရေးဝန်ကြီးဌာန

ဝန်ကြီးရုံး

ကျန်းမာရေးဝန်ကြီးဌာန
စာအမှတ်---
ရက်စွဲ--သို့--

စာအမှတ်၊ ၅မက(မ)၂၀၁၅/ ၂၁၈၂၀
ရက်စွဲ၊ ၂၀၁၅ခုနှစ်၊ ဒီဇင်ဘာလ(၂၄)ရက်

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

အကြောင်းအရာ။ **သဘောထားမှတ်ချက်ပြန်ကြားခြင်း။**

ရည်ညွှန်းချက်။ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ -

၁။ (၁၁-၁၁-၂၀၁၅)ရက်စွဲပါ စာအမှတ်၊ရက- ၅(အ)/၀၁၂/၂၀၁၅(၃၈၂)။

၂။ (၁၆-၁၁-၂၀၁၅)ရက်စွဲပါ စာအမှတ်၊ရက- ၅(အ)/၀၁၂/၂၀၁၅(၃၉၈)။

၁။ အထက်အကြောင်းအရာနှင့်ပတ်သက်၍ မြန်မာနိုင်ငံ AMMK Medicare Company Limited မှ ၂၁.၅ % ၊ မြန်မာနိုင်ငံ Global Star Company Limited မှ ၁၆%၊ စင်ကာပူနိုင်ငံ Macondray Holdings Pte. Ltd.မှ ၁၀.၅% နှင့် စင်ကာပူနိုင်ငံ Parkway Healthcare Indo-China Pte. Ltd. မှ ၅၂% ထည့်ဝင်၍ ဖက်စပ်နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဖြင့် မြန်မာနိုင်ငံတွင် Andaman Alliance Healthcare Limited တည်ထောင်ကာ ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ ဗိုလ်ချုပ်အောင်ဆန်းလမ်းနှင့် ပြည်လမ်းထောင့်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀^{F})၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမျိုးအစား- ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက်- ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း (၃၇.၅၄၉)ဧကအနက် (၁၁.၁၄၅)ဧက၏ မြေအတိုင်းအတာ (၅)ဧကပေါ်တွင် Parkway Yangon Hospital အမည်ဖြင့် ဆေးရုံတည်ဆောက်ပြီး World Class Multi- Specialty Hospital လုပ်ငန်းအား နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဥပဒေနှင့်အညီ ဆောင်ရွက်ခွင့်ပြုပါရန် တင်ပြချက်ကို ရည်ညွှန်းချက်(၁)ပါစာဖြင့် အဆိုပြုချက်ကို လက်ခံပါကြောင်းပြန်ကြားခဲ့ပြီး နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုနည်းဥပဒေ အခန်း(၆) အပိုဒ်(၄၃)နှင့် အပိုဒ်(၄၅)ပါပြဋ္ဌာန်းချက်နှင့်အညီ ကျန်းမာရေးဝန်ကြီးဌာန၏ သဘောထားမှတ်ချက်ပြန်ကြားပေးပါရန် ရည်ညွှန်းချက်(၂)ပါစာဖြင့် တောင်းခံခဲ့ပါသည်။

၂။ အဆိုပါကိစ္စနှင့်ပတ်သက်၍ ရန်ကုန်တိုင်းဒေသကြီး၊ ရန်ကုန်အနောက်ပိုင်းခရိုင်၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀^{F})၊ မြေကွက်အမှတ်(၁၀^{B})ရှိ ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး) အမည်ပေါက် မြေဧရိယာ(၃၆.၈၅၀)ဧကအနက်မှ မြေဧရိယာ(၁၀.၄၄၆)ဧကအား ပြည်ထဲရေးဝန်ကြီးဌာန၏ (၉-၁၁-၂၀၁၅)ရက်စွဲပါအမိန့်ကြော်ငြာစာ(၁၅၃၇/၂၀၁၅)ဖြင့် ကျန်းမာရေးဝန်ကြီးဌာနသို့ လွှဲပြောင်းပေးခဲ့ပါ၍ (၂၅-၁၁-၂၀၁၅)ရက်နေ့တွင်ကျင်းပပြုလုပ်သော ပြည်ထောင်စုအစိုးရအဖွဲ့အစည်းအဝေး အမှတ်စဉ်(၂၃/၂၀၁၅)မှသဘောတူကြောင်း ပြန်ကြားခဲ့ပါသည်။

၃။ ကျန်းမာရေးဝန်ကြီးဌာနသို့ လွှဲပြောင်းပေးသည့် မြေဧရိယာ(၁၀.၄၄၆)ဧကမှ မြေအတိုင်းအတာ(၄.၃)ဧကအား ဖက်စပ်နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှု Andaman Alliance Healthcare Limited တည်ထောင်၍ Parkway Yangon Hospital အမည်ဖြင့် To contruct, develop, manage and operate a multispecialty hospital of international standard လုပ်ငန်းအနေဖြင့် နိုင်ငံတကာအဆင့်မီဆေးရုံတစ်ရုံကို ခုတင်(၂၅၀)ဆံ့ဆေးရုံအဖြစ် အဆင့်လိုက်တည်ဆောက်လည်ပတ်သွားရန်နှင့် ပထမအဆင့်တွင် ခုတင်(၁၀၀)ဆံ့ ဆေးရုံဖြင့် စတင်လည်ပတ်ပြီး နောက်အဆင့်များကို တစ်ပြိုင်တည်း ဆက်လက်ဆောင်ရွက်သွားမည်ဖြစ်ပါကြောင်း၊ အဆိုပြုတင်ပြချက်အပေါ် ကျန်းမာရေးဝန်ကြီးဌာန၏ ဌာနပိုင်မြေအား ငှားရမ်းရေးအတွက် စိစစ်ရေးအဖွဲ့မှ (၁၅-၁၂-၂၀၁၅)ရက်နေ့တွင် နှစ်ဖက်စာချုပ်ဝင်များ အပြီးသတ်ညှိနှိုင်းဆွေးနွေး၍ (၁၆-၁၂-၂၀၁၅)ရက်နေ့တွင် ကျင်းပပြုလုပ်သော ကျန်းမာရေးဝန်ကြီးဌာန၏ လုပ်ငန်းညှိနှိုင်းအစည်းအဝေး အမှတ်စဉ်(၂၀/၂၀၁၅)သို့တင်ပြ၍ ငှားရမ်းနိုင်ရေးအတွက် ဆုံးဖြတ်ခဲ့ပါသည်။

၄။ ၎င်းအပြင် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ လုပ်ထုံးလုပ်နည်းများနှင့်အညီ ရင်းနှီးမြှုပ်နှံမှု အဆိုပြုလွှာတင်သွင်းနိုင်ရေးအတွက် ငှားရမ်းခြင်းနှင့် လုပ်ငန်းဆိုင်ရာကိစ္စရပ်များ ဆောင်ရွက်ခွင့်ပြုပါရန် (၁၇-၁၂-၂၀၁၅)ရက်နေ့တွင် ကျင်းပပြုလုပ်သော ပြည်ထောင်စုအစိုးရအဖွဲ့အစည်းအဝေး အမှတ်စဉ်(၂၆/၂၀၁၅)သို့တင်ပြ၍ သဘောတူညီကြောင်း ဆုံးဖြတ်ခဲ့ပြီးဖြစ်ပါသည်။

၅။ သို့ဖြစ်ပါ၍ သိရှိနိုင်ပါရန်နှင့် လိုအပ်သလို ဆက်လက်ဆောင်ရွက်ပေးနိုင်ပါရန် ပြန်ကြားအပ်ပါသည်။

ပူးတွဲ- (၁၆)ရွက်နှင့် စာချုပ်(မူကြမ်း) (၁)စုံ

ပြည်ထောင်စုဝန်ကြီး(ကိုယ်စား)

(ပါမောက္ခဒေါက်တာသက်ခိုင်ဝင်း၊ အမြဲတမ်းအတွင်းဝန်)

မိတ္တူကို-

ပြည်ထောင်စုအစိုးရအဖွဲ့ရုံး

ပြည်ထောင်စုရှေ့နေချုပ်ရုံး

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ

ကျန်းမာရေးဝန်ကြီးဌာန

ဝန်ကြီးရုံး

စာအမှတ်၊ ၁မက(က)၂၀၁၅(၁၂၆)

ရက်စွဲ၊ ၂၀၁၅ ခုနှစ်၊ ဒီဇင်ဘာလ (၁၆)ရက်

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော် ပြည်ထောင်စုအစိုးရအဖွဲ့သို့
တင်ပြသည့်အမှာစာ

အကြောင်းအရာ။ **ကျန်းမာရေးဝန်ကြီးဌာနပိုင်မြေအား ငှားရမ်းသုံးစွဲခွင့်ပြုပါရန် တင်ပြသည့်ကိစ္စ**

၁။ အထက်အကြောင်းအရာနှင့်ပတ်သက်၍ ရန်ကုန်တိုင်းဒေသကြီး၊ ရန်ကုန်အနောက်ပိုင်းခရိုင်၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀F)၊ မြေကွက်အမှတ်(၁၀B)ရှိ ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး)အမည်ပေါက် မြေဧရိယာ(၃၆.၈၅၀)ဧကအနက်မှ မြေဧရိယာ(၁၀.၄၄၆)ဧကအား ပြည်ထဲရေးဝန်ကြီးဌာန၏ (၉-၁၁-၂၀၁၅)ရက်စွဲပါ အမိန့်ကြော်ငြာစာ(၁၅၃၇/၂၀၁၅)ဖြင့် ကျန်းမာရေးဝန်ကြီးဌာနသို့ လွှဲပြောင်းပေးခဲ့ပါ၍ (၂၅-၁၁-၂၀၁၅)ရက်နေ့တွင် ကျင်းပပြုလုပ်သော ပြည်ထောင်စုအစိုးရအဖွဲ့ အစည်းအဝေးအမှတ်စဉ်(၂၃/၂၀၁၅)သို့ တင်ပြရာ သဘောတူကြောင်း ပြန်ကြားခဲ့ပါသည်။

(နောက်ဆက်တွဲ-က)

၂။ ကျန်းမာရေးဝန်ကြီးဌာနသို့ လွှဲပြောင်းပေးသည့်မြေဧရိယာ(၁၀.၄၄၆)ဧကမှ မြေအတိုင်းအတာ(၄.၃)ဧကပေါ်တွင် ဖက်စပ်နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှု Andaman Alliance Healthcare Limited တည်ထောင်၍ Parkway Yangon Hospital အမည်ဖြင့် To contruct, develop, manage and operate a multispecialty hospital of international standard လုပ်ငန်းအနေဖြင့် နိုင်ငံတကာအဆင့်မီဆေးရုံတစ်ရုံကို ခုတင်(၂၅၀)ဆံ့ဆေးရုံအဖြစ် အဆင့်လိုက်တည်ဆောက်လည်ပတ်သွားရန်နှင့် ပထမအဆင့်တွင် ခုတင်(၁၀၀)ဆံ့ဆေးရုံဖြင့် စတင်လည်ပတ်ပြီး နောက်အဆင့်များကို တစ်ပြိုင်တည်း ဆက်လက်ဆောင်ရွက်သွားမည်ဖြစ်ပါကြောင်း မြေငှားစာချုပ်၊ လုပ်ငန်းစီမံချက်တို့နှင့်တကွ ပြည်ထောင်စုအစိုးရအဖွဲ့ရုံးသို့တင်ပြခဲ့ရာ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သို့ တင်ပြဆောင်ရွက်နိုင်ပါရန် အကြောင်းပြန်ကြားခဲ့သည်။ **(နောက်ဆက်တွဲ-ခ)**

၃။ ၎င်းအပြင် ပြည်ထောင်စုရှေ့နေချုပ်ရုံးသို့ မြေငှားရမ်းသုံးစွဲခွင့်ကိစ္စအား သဘောထားမှတ်ချက်တောင်းခံခဲ့ပြီး ပြည်ထောင်စုရှေ့နေချုပ်ရုံး၏ သဘောထားမှတ်ချက် ပြန်ကြားချက်နှင့်တကွ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သို့ ညှိနှိုင်းပေးပို့ခဲ့ရာ (၂-၁၁-၂၀၁၅)ရက်နေ့တွင်ကျင်းပပြုလုပ်သည့် မြန်မာနိုင်ငံ

ရင်းနှီးမြှုပ်နှံမှုကော်မရှင် အဆိုပြုချက်စိစစ်ရေးအဖွဲ့၏ (၄၀/၂၀၁၅)ကြိမ်မြောက်အစည်းအဝေးမှ ဖက်စပ်နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှု Andaman Alliance Healthcare Limited တည်ထောင်၍ Parkway Yangon Hospital အမည်ဖြင့် World Class Multi- Specialty Hospital လုပ်ငန်းဆောင်ရွက်ခွင့်အဆိုပြုချက်ကို လက်ခံပါကြောင်းပြန်ကြားခဲ့ပါသည်။ **(နောက်ဆက်တွဲ-ဂ)**

၄။ အဆိုပါကိစ္စအား နိုင်ငံတော်သမ္မတရုံးသို့ တင်ပြခဲ့ရာ ခွင့်ပြုပါသဖြင့် လုပ်ထုံးလုပ်နည်းနှင့်အညီ ဆက်လက်ဆောင်ရွက်သွားရန် အကြောင်းပြန်ကြားခဲ့ပါသည်။ **(နောက်ဆက်တွဲ-ဃ၊င)**

၅။ ၎င်းအပြင် ကျန်းမာရေးဝန်ကြီးဌာန၊ စီမံခန့်ခွဲရေးကော်မတီညှိနှိုင်းအစည်းအဝေး အမှတ်စဉ် (၁၉/၂၀၁၅)မှ အဆိုပါမြေ(၄.၃)ဧကအား Parkway Yangon Hospital သို့ ငှားရမ်းခွင့်ပြုရေးအတွက် ဆက်လက်တင်ပြရန် ဆုံးဖြတ်ခဲ့ပါသည်။

၆။ သို့ဖြစ်ပါ၍ ရန်ကုန်တိုင်းဒေသကြီး၊ ရန်ကုန်အနောက်ပိုင်းခရိုင်၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀^F)၊ မြေကွက်အမှတ်(၁၀^B)ရှိ ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး)အမည်ပေါက် မြေဧရိယာ(၃၆.၈၅၀)ဧကအနက်မှ ကျန်းမာရေးဝန်ကြီးဌာနသို့ လွှဲပြောင်းပေးသည့် မြေဧရိယာ(၁၀.၄၄၆) ဧကမှ မြေအတိုင်းအတာ(၄.၃)ဧကအား မြေငှားရမ်းသုံးစွဲခွင့်ပြုပါရန် ပြည်ထောင်စုအစိုးရအဖွဲ့သို့ တင်ပြအပ်ပါသည်။

၇။ **ဆုံးဖြတ်ရန်အချက်။** ကျန်းမာရေးဝန်ကြီးဌာနပိုင်မြေအား ငှားရမ်းသုံးစွဲခွင့်ပြုပါရန် သဘောတူ-မတူ။

၈။ **ကျန်းမာရေးဝန်ကြီးဌာန၏ ထောက်ခံချက်။** ထောက်ခံတင်ပြအပ်ပါသည်။

(ဒေါက်တာသန်းအောင်)
ပြည်ထောင်စုဝန်ကြီး

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော် ပြည်ထောင်စုအစိုးရအဖွဲ့

(နောက်ဆက်တွဲ -က)

၃

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
ပြည်ထောင်စုအစိုးရအဖွဲ့

စာအမှတ်၊ ၆၈ / ၂၅၇ / အဖရ (၂၃/၂၀၁၅)။
ရက်စွဲ၊ ၂၀၁၅ ခုနှစ်၊ ဒီဇင်ဘာလ ၃ ရက်။

အ မှာ စာ

အကြောင်းအရာ။ ရန်ကုန်တိုင်းဒေသကြီး၊ ရန်ကုန်အနောက်ပိုင်းခရိုင်၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀^{F})၊ မြေကွက်အမှတ်(၁၀^{B})ရှိ ရန်ကုန်နယ်မြေ (ရန်ကုန် ထောင်ကြီး)အမည်ပေါက် မြေဧရိယာ(၃၆.၈၅၀)ဧကအနက်မှ မြေဧရိယာ(၁၀.၄၄၆)ဧကအား ဌာနပိုင်အမည်ပေါက်ရရှိရေး ဆောင်ရွက်ခွင့်ပြုပါရန် တင်ပြသည့်ကိစ္စ။

၁။ ၂၀၁၅ ခုနှစ်၊ နိုဝင်ဘာလ ၂၅ ရက် (ဗုဒ္ဓဟူး)နေ့တွင် ကျင်းပပြုလုပ်သော ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်၊ ပြည်ထောင်စုအစိုးရအဖွဲ့ အစည်းအဝေးအမှတ်စဉ် (၂၃/၂၀၁၅) မှတ်တမ်းကောက်နုတ်ချက်ကို ဆောင်ရွက်နိုင်ပါရန် ပေးပို့အပ်ပါသည်။

၂။ မှတ်တမ်းကောက်နုတ်ချက်ကို ရရှိကြောင်းပြန်ကြားရန်နှင့် ဌာနဆိုင်ရာ အရေးယူဆောင်ရွက်ချက်ကိုလည်း ပြန်လည်အစီရင်ခံတင်ပြရန် ဖြစ်ပါသည်။

ဇော်သန်းသင်း
အတွင်းရေးမှူး

ပြည်ထောင်စုဝန်ကြီး
ကျန်းမာရေးဝန်ကြီးဌာန

၆၈။ ရန်ကုန်တိုင်းဒေသကြီး၊ရန်ကုန်အနောက်ပိုင်းခရိုင်၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀^{F})၊ မြေကွက်အမှတ်(၁၀^{B})ရှိ ရန်ကုန်နယ်မြေ (ရန်ကုန် ထောင်ကြီး)အမည်ပေါက် မြေဧရိယာ(၃၆.၈၅၀)ဧက အနက်မှ မြေဧရိယာ(၁၀.၄၄၆)ဧကအား ဌာနပိုင်အမည်ပေါက်ရရှိရေး ဆောင်ရွက်ခွင့်ပြုပါရန် တင်ပြသည့်ကိစ္စ။

ကျန်းမာရေးဝန်ကြီးဌာန၏ ၂၀၁၅ ခုနှစ်၊ နိုဝင်ဘာလ ၂၃ ရက် နေ့စွဲပါ အမှာစာ အမှတ်၊ ၁ မက (က) ၂၀၁၅ (၉၃)။
အမှာစာကို သဘောတူကြသည်။

ဆောင်ရွက်ရန်၊
ကျန်းမာရေး။

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်

ပြည်ထဲရေးဝန်ကြီးဌာန

အမိန့်ကြော်ငြာစာ (၁၅၃၇ / ၂၀၁၅)

နေပြည်တော်၊ ၁၃၇၇ ခုနှစ်၊ သီတင်းကျွတ်လပြည့်ကျော် ၁၂ ရက်

(၂၀၁၅ ခုနှစ်၊ နိုဝင်ဘာလ ၉ ရက်)

အမှတ်။ ရန်ကုန်တိုင်းဒေသကြီး၊ ရန်ကုန်အနောက်ပိုင်းခရိုင်၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ် (၂၀^{F})၊ မြေကွက်အမှတ် (၁၀^{B})ရှိ၊ ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး) အမည်ပေါက် **မြေဧရိယာ(၃၆.၈၅၀)ဧကအနက်မှ (၁၀.၄၄၆)ဧကအား** မြန်မာ - ဂျပန်ချစ်ကြည်ရေးဆေးရုံမြေနေရာအဖြစ် အသုံးပြုရန်အတွက် မြေနှင့်အခွန်အမိန့်ဆင့်ဆိုချက် ၃၃၂ အရ **ကျန်းမာရေးဝန်ကြီးဌာန** သို့ အခမဲ့လွှဲပြောင်းပေးလိုက်သည်။

အခမဲ့လွှဲပြောင်းပေးသည့်မြေသည် အမှုတွဲပါစစ်ဆေးအတည်ပြုထားသည့် မြေပုံအတိုင်းဖြစ်ပြီး **ကျန်းမာရေးဝန်ကြီးဌာန** က အသုံးမပြုသောနေ့တွင် နိုင်ငံတော်သို့ ပြန်လည်အပ်နှံရမည်။

ဒုတိယဗိုလ်ချုပ်ကြီးကိုကို
ပြည်ထောင်စုဝန်ကြီး

စာအမှတ်၊ ပထရ / ၂-၃ (၁၅၃၇) / ထောက် ၂

ရက် စွဲ၊ ၂၀၁၅ ခုနှစ်၊ နိုဝင်ဘာလ ၉ ရက်

ဖြန့်ဝေခြင်း

၁။ ဝန်ကြီးချုပ်၊ ရန်ကုန်တိုင်းဒေသကြီးအစိုးရအဖွဲ့၊
၂။ ပြည်ထောင်စုဝန်ကြီး၊ ကျန်းမာရေးဝန်ကြီးဌာန၊
၃။ ပြည်ထောင်စုဝန်ကြီး၊ ဆောက်လုပ်ရေးဝန်ကြီးဌာန၊
၄။ ဥက္ကဋ္ဌ၊ ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ၊
၅။ ညွှန်ကြားရေးမှူးချုပ်၊ အထွေထွေအုပ်ချုပ်ရေးဦးစီးဌာန၊
(အမှုတွဲနှင့်အတူ ပူးတွဲပေးပို့ပါသည်)
၆။ ညွှန်ကြားရေးမှူးချုပ်၊ မြို့ပြနှင့် အိမ်ရာဖွံ့ဖြိုးရေးဦးစီးဌာန၊

လျှို့ဝှက်

Com- 4 / Su(2)Land/ (မြေလွှဲ)Nov (မြေလွှဲအမိန့်)

၇။ ဦးဆောင်ညွှန်ကြားရေးမှူး၊ ပုံနှိပ်ရေးနှင့်စာအုပ်ထုတ်ဝေရေးလုပ်ငန်း၊(ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်ပြန်တမ်းတွင် ထည့်သွင်းကြေညာပေးပါရန်)

၈။ အုပ်ချုပ်ရေးမှူး၊ ရန်ကုန်တိုင်းဒေသကြီးအထွေထွေအုပ်ချုပ်ရေးဦးစီးဌာန၊

၉။ ဌာနမှူး၊ မြို့ပြစီမံကိန်းနှင့်မြေစီမံခန့်ခွဲမှုဌာန၊ ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ၊
(မြေအမည်ပေါက် ပြောင်းလဲသတ်မှတ်သွားရန် အကြောင်းကြားချက်ဖြင့် ပေးပို့သည်)

၁၀။ အုပ်ချုပ်ရေးမှူး၊ ရန်ကုန်အနောက်ပိုင်းခရိုင်အထွေထွေအုပ်ချုပ်ရေးဦးစီးဌာန၊

၁၁။ အုပ်ချုပ်ရေးမှူး၊ လမ်းမတော်မြို့နယ်အထွေထွေအုပ်ချုပ်ရေးဦးစီးဌာန၊

၁၂။ လှည့်လည်စာတွဲ၊

၁၃။ ရုံးလက်ခံ။

အမိန့်အရ

ထွန်းလှအောင်
အမြဲတမ်းအတွင်းဝန်

Date:

Chairman
Myanmar Investment Commission
No. 1, Thit Sar Road, Yankin Tonwhip, Yangon.

Subject : Submitting revised Proposal to Commission Meeting for approval of Private Hospital business in the name of "Parkway Yangon Hospital" by "Andaman Healthcare Alliance Limited"

Reference: (1) Proposal Assessment Team, Myanmar Investment Commission's Letter No. YaKa-5 (Ah)/ 012/ 2015 (393) dated 14 November 2015

(2) Myanmar Investment Commission's Letter No. YaKa-5 (Ah)/ 012/ 2015 (442) dated 8 December 2015

(3) Myanmar Investment Commission's Letter No. YaKa-5 (Ah)/ 012/ 2015 (455) dated 16 December 2015

(4) Yangon Region Government' s Letter No. 3/6 -3 (43)/ Agri Livestock dated 3 December 2015

(5) Myanmar Investment Commission's temporary permit no. 1045/2015 (Temporary) dated 10 December 2015

Your Excellency,

Proposal submitted through Ministry of Health for approval of Private Hotel business in the name of "Parkway Yangon Hospital" under Foreign Investment Law at (4.3) acres of (10.446) acres out of (37.549) acres, Plot No. 10, Survey Block No. 20-F, Corner of Bogyoke Aung San Street and Pyay road, Lanmadaw township, Yangon region by forming "Andaman Healthcare Alliance Limited" in joint venture foreign investment by contribution of 21.5% by AMMK Medicare Company Limited from Myanmar, 16% by Global Star Company Limited from Myanmar, 10.5% from Macondray Holdings Pte. Ltd. from Singapore and 52% from Parkway Healthcare Indo – China Pte. Ltd., has been granted with temporary investment permit vide reference no. (5).

As instructed by condition in temporary permit and also in the reference letters no. (1) to (3) above, we have managed to revise proposal [take measurements] as follows and resubmitting herewith for consideration of our proposal in the Commission meeting for issuance of permanent permit.

(1) As per instruction in reference letter no. (1)

(a) Ministry of Health has received approval from the Union Cabinet for land matter is the process to obtain land ownership document is underway.
(b) Based on confirmed land area and site location, conceptual design, engineering drawing of buildings and revised economics projection are submitted.
(c) BOT agreement revised in accordance with the comment from the Attorney General Office is attached.

(2) As per instruction in reference letter no. (2)

We have conducted Initial Environmental Examination (IEE) by ourselves and prepared Environmental Management Plan (EMP) for operational level based on which.

However, in order to get more thorough IEE report, we have engaged following firm and evidence for engagement is also attached herewith. EMP for actual operation will be adjusted based on findings and recommendations by IEE report from this firm also.

(3) As per instruction in reference letter no. (2)

Regarding instruction based on comment from Myanmar Engineering Society (MES), our conceptual design has complied international codes for hospital building. As we will be proceeding according to the master schedule of the project, which we have shared with MES, in the stages of engaging architects, engineers and hospital planners and undertaking designing, we undertake the following comments from MES.

(a) Characteristics of prescribed international standard hospital must be complied and to implement according to standards;

(b) To include exit plan for evacuation of patients who cannot move at the time of fire breaks out and include other plans also such as evacuation plan in case of fire and other emergency and assembly point, etc.

(c) As there is possibility of increased number of patients in the future, to include expansion area plan for car parking and landscaping in accordance with future plan

(d) To follow instruction from respective Fire Brigade

Faithfully yours,

LiawYit Ming
Promoter

Date: 5 | 1 | 16

Chairman
Myanmar Investment Commission
No. 1, Thit Sar Road, Yankin Tonwhip, Yangon.

Subject: Undertaking to deduct withholding tax and pay to Internal Revenue Department by "Andaman Healthcare Alliance Limited" in the operation of Parkway Yangon Hospital"

Your Excellency,

"Andaman Healthcare Alliance Limited" hereby undertakes to deduct following withholding taxes and pay to the Internal Revenue Department:

(a) on the portion of salary of employees at prescribed rates determinate by Union Taw Law whose salaries after allowance fall within the range of taxable income;
(b) payments made under relevant contracts or agreements or any other relevant agreement for procurements and for services;

Faithfully yours,

Liaw Yit Ming
Promoter

GREEN ENVIRONMENTAL, HEALTH, SAFETY & SOCIAL CONSULTANCY CO., LTD.
No-173 (B) Sayar San Road, Bahan Township, Yangon, Myanmar, website: www.greenehss.com
Ph: 01-456782, 09425353553, Email: catherine@greenehss.com, info@greenehss.com

To,
Chairman
Myanmar Investment Commission
Naypyidaw
The Republic of the Union of Myanmar **29th December 2015**

Subject: Initial Environmental Examination (IEE) for Development of Parkway Yangon Hospital

Dear Sir,

We have been engaged by **Andaman Alliance Healthcare Limited** to carry out **Initial Environmental Examination for Development of Parkway Yangon Hospital** in Yangon. The IEE project will be conducted and completed over the next 2-3 months, including initial data collection, initial environmental examination and preparation and delivery of final IEE report.

In this project, we will work in close consultation with the Ministry of Environmental Conservation and Forestry at all times and will conduct the assessments in accordance with the Environmental Conservation Law (2012), the MIC Notification (1/2013) and all applicable Environmental Acts, Rules and Regulations in force in Myanmar.

Yours respectfully,

Catherine Soe Soe Aung
Principal Consultant
Certified Environmental Professional, ECO, CANADA
Member of the Canadian Society of Environmental Biologist
Approved HS Risk Consultant, Ministry of Manpower, Singapore
Green Environmental, Health, Safety and Social Consultancy Co,. Ltd.
Company Registration No: 4289
Website: www.greenehss.com
Email: catherine@greenehss.com

တိုင်းဒေသကြီးအစိုးရအဖွဲ့
စာအမှတ် ၃၁၅၉
ရက်စွဲ ၆.၁၂.၁၅
ရန်ကုန်တိုင်းဒေသကြီး

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
တိုင်းဒေသကြီးအစိုးရအဖွဲ့
ရန်ကုန်တိုင်းဒေသကြီး

စာအမှတ်၊ ၃ / ၆ - ၃ (၄၃) / စိုက်မွေး
ရက်စွဲ၊ ၂၀၁၅ ခုနှစ်၊ ဒီဇင်ဘာ လ ၃ ရက်

သို့

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
အမှတ်(၁)၊ သစ္စာလမ်း၊ ရန်ကင်းမြို့နယ်

အကြောင်းအရာ။ **သဘောထားမှတ်ချက်တောင်းခံခြင်းကိစ္စ**

ရည် ညွှန်း ချက်။ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ ၁၂. ၁၁. ၂၀၁၅ ရက်စွဲပါစာအမှတ်၊ ရက - ၅(အ)/ ၀၁၂ / ၂၀၁၅ (၃၈၉)

၁။ မြန်မာနိုင်ငံ AMMK Medicare Company Limited မှ ၂၀. ၅%၊ မြန်မာနိုင်ငံ Global Star Company Limited မှ ၁၆%၊ စင်္ကာပူနိုင်ငံ Macondray Holdings Pte. Ltd. မှ ၁၀. ၅% နှင့် စင်္ကာပူနိုင်ငံ Parkway Healthcare Indo - China Pte. Ltd. မှ ၅၂% ထည့်ဝင်၍ ဖက်စပ်နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဖြင့် မြန်မာနိုင်ငံတွင် Andaman Alliance Healthcare Limited တည်ထောင်ကာ ကျန်းမာရေးဝန်ကြီးဌာနပိုင် ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ ဗိုလ်ချုပ်အောင်ဆန်းလမ်းနှင့် ပြည်လမ်းထောင့်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀-F)၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမျိုးအစား-ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက်-ရန်ကုန်နယ်မြေ (ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း(၃၇. ၅၄၉)ဧက အနက် (၁၁. ၁၄၅)ဧက၏ မြေအတိုင်းအတာ (၅)ဧက ပေါ်တွင် Parkway Yangon Hospital အမည်ဖြင့် ဆေးရုံတည်ဆောက်ပြီး World Class Multi - Specialty Hospital လုပ်ငန်းအား ဆောင်ရွက်ခွင့်ပြုပါရန် လျှောက်ထားလာမှုအပေါ် သဘောထားမှတ်ချက်ပြန်ကြားပေးပါရန် ရည်ညွှန်းပါစာဖြင့် ညှိနှိုင်းမေတ္တာရပ်ခံလာခြင်းနှင့်စပ်လျဉ်း၍ ကွင်းဆင်းစိစစ်မှုအရ အောက်ပါအတိုင်း သဘောထားမှတ်ချက် တင်ပြအပ်ပါသည်-

(က) ရင်းနှီးမြှုပ်နှံမှု ပြုလုပ်မည့်နေရာသည် နောင်ပြုလုပ်မည့် (သို့မဟုတ်) လက်ရှိမြို့ပြစီမံကိန်းကို ထိခိုက်နိုင်ခြင်းမရှိပါ။

(ခ) အဆိုပြုလုပ်ငန်းလုပ်ကိုင်ပါက အောက်ပါအတိုင်း အလုပ်အကိုင်ရရှိမည် ဖြစ်သောကြောင့် မြို့နယ်ဒေသ အလုပ်အကိုင်အခွင့်အလမ်းနှင့် ဒေသစီးပွားရေး ဖွံ့ဖြိုးတိုးတက်မှု အတွက် အထောက်အကူ ဖြစ်စေပါသည်-

(၁) ပထမနှစ် - ပြည်ပဝန်ထမ်း(၂၈)ဦး၊ ပြည်တွင်းဝန်ထမ်း(၄၃၈)ဦး၊ စုစုပေါင်း(၄၆၆)ဦး

(၂) ဒုတိယနှစ်နှင့် တတိယနှစ် - ပြည်ပဝန်ထမ်း(၃၃)ဦး၊ ပြည်တွင်းဝန်ထမ်း(၅၇၇)ဦး၊ စုစုပေါင်း(၆၁၀)ဦး

(၃) စတုတ္ထနှစ်မှ ဆဋ္ဌမနှစ်အထိ - ပြည်ပဝန်ထမ်း(၆၂)ဦး၊ ပြည်တွင်းဝန်ထမ်း(၁၁၄၄)ဦး၊ စုစုပေါင်း(၁၂၀၆)ဦး

(၄) သတ္တမနှစ်မှ နောက်ပိုင်း - ပြည်ပဝန်ထမ်း(၆၇)ဦး၊ ပြည်တွင်းဝန်ထမ်း(၁၂၂၂)ဦး၊ စုစုပေါင်း(၁၂၈၉)ဦး

(၅) တည်ဆောက်ဆဲကာလ(၃)နှစ်အတွင်း လုပ်သားအင်အား(၂၀၀)ဦးဝန်းကျင်ဖြင့် ဆောင်ရွက်သွားမည်ဖြစ်ပါသည်။

D/2015/Cabinet/54.,(3)

(ဂ) အဆိုပြုလုပ်ငန်းလုပ်ကိုင်ရန် ကျန်းမာရေးဝန်ကြီးဌာနပိုင် ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ ဗိုလ်ချုပ်အောင်ဆန်းလမ်းနှင့် ပြည်လမ်းထောင့်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀-F)၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမျိုးအစား-ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက်-ရန်ကုန်နယ်မြေ (ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း(၃၇. ၅၄၉)ဧက အနက် (၁၁. ၁၄၅)ဧက၏ မြေအတိုင်းအတာ(၅)ဧကအား တစ်နှစ်လျှင် US $ 364217 (1sqft=1.672 $, 1sqm=18 $)နှုန်း၊ တစ်လလျှင် US $ 30351.45 (1sqft=0.1393 $, 1sqm=1.5 $)နှုန်းဖြင့် ကနဦးနှစ်(၅၀)နှင့် သက်တမ်းတိုးတစ်ကြိမ်လျှင် (၁၀)နှစ်စီဖြင့် နှစ်ကြိမ် ငှားရမ်းဆောင်ရွက်ခြင်းအပေါ် ဒေသခံများက လူမှုရေး၊ စီးပွားရေး၊ သဘာဝပတ်ဝန်းကျင် ထိန်းသိမ်းမှုတို့အရ လက်ခံနိုင်ခြင်း ရှိပါသည်။

(ဃ) လုပ်ငန်းဆောင်ရွက်နိုင်သည့် မြေနေရာဖြစ်ပြီး အဆိုပြုလုပ်ငန်းလုပ်ကိုင်ရာတွင် သဘာဝပတ်ဝန်းကျင်အား ထိခိုက်မှုမရှိစေရန် စီမံဆောင်ရွက်မည်ဟု တင်ပြထားပါသည်။

၂။ အထက်ဖော်ပြပါအချက်များကြောင့်(၂၇. ၁၁. ၂၀၁၅)ရက်နေ့တွင် ကျင်းပပြုလုပ်သော ရန်ကုန်တိုင်းဒေသကြီး အစိုးရအဖွဲ့ အစည်းအဝေးအမှတ်စဉ် (၅၄/၂၀၁၅)၏ ဆုံးဖြတ်ချက်အပိုဒ် (၅၄)အရ Andaman Alliance Healthcare Limited ၏ ရင်းနှီးမြှုပ်နှံမှုလုပ်ငန်းသစ်ဆောင်ရွက်မှုအား ခွင့်ပြုသင့်ပါကြောင်း ထောက်ခံတင်ပြအပ်ပါသည်။

(မြင့်ဆွေ)
ဝန်ကြီးချုပ်

မိတ္တူကို

အတွင်းရေးမှူး၊ ရန်ကုန်တိုင်းဒေသကြီးအစိုးရအဖွဲ့
ရန်ကုန်အနောက်ပိုင်းခရိုင်အထွေထွေအုပ်ချုပ်ရေးဦးစီးဌာန
လမ်းမတော်မြို့နယ်အထွေထွေအုပ်ချုပ်ရေးဦးစီးဌာန
Andaman Alliance Healthcare Limited
လက်ခံစာတွဲ
မျှောစာတွဲ

D/2015/Cabinet/54.(4)

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
အမှတ်(၁)၊ သစ္စာလမ်း၊ ရန်ကင်းမြို့နယ်၊ ရန်ကုန်မြို့။

☎ -၀၁-၆၅၈ ၁၃၀
🖷 -၀၁-၆၅၈၁၄၂

စာအမှတ်၊ ရက- ၅(အ)/၀၁၂/ ၂၀၁၅(၄၅၅)
ရက်စွဲ၊ ၂၀၁၅ ခုနှစ် ဒီဇင်ဘာလ ၁၆ ရက်

အကြောင်းအရာ။ **မြန်မာနိုင်ငံ အင်ဂျင်နီယာအသင်း၏ သဘောထားမှတ်ချက်နှင့်အညီ တင်ပြပေးပါရန် အကြောင်းကြားခြင်းကိစ္စ**

ရည် ညွှန်း ချက် ။ (၁) မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှု ကော်မရှင်၏ ၁၆-၁၁-၂၀၁၅ ရက်စွဲပါ စာအမှတ်၊ ရက- ၅(အ)/၀၁၂/၂၀၁၅ (၃၉၇)
(၂) မြန်မာနိုင်ငံ အင်ဂျင်နီယာအသင်း၏ ၁၀-၁၂-၂၀၁၅ ရက်စွဲပါ စာအမှတ် မအသ/ MIC / ၁၆၄၁ / ၂၀၁၅

၁။ မြန်မာနိုင်ငံ AMMK Medicare Company Limitedမှ ၂၁.၅ %၊ မြန်မာနိုင်ငံ Global Star Company Limitedမှ ၁၆%၊ စင်္ကာပူနိုင်ငံ Macondray Holdings Pte. Ltd.မှ ၁၀.၅% နှင့် စင်္ကာပူနိုင်ငံ Parkway Healthcare Indo - China Pte. Ltd.မှ ၅၂% ထည့်ဝင်၍ ဖက်စပ်နိုင်ငံခြား ရင်းနှီးမြှုပ်နှံမှုဖြင့် မြန်မာနိုင်ငံတွင် Andaman Alliance Healthcare Limited တည်ထောင်ကာ ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ ဗိုလ်ချုပ်အောင်ဆန်းလမ်းနှင့် ပြည်လမ်းထောင့်၊ မြေတိုင်းရပ်ကွက် အမှတ်(၂၀-F)၊ မြေကွက် အမှတ် (၁၀)၊ မြေအမျိုးအစား- ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက် - ရန်ကုန်နယ်မြေ (ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း (၃၆.၈၅၀)ဧက အနက် (၁၀.၄၄၆)ဧက၏ မြေအတိုင်းအတာ (၄.၃)ဧက ပေါ်တွင် Parkway Yangon Hospital အမည်ဖြင့် အထပ်(၈)ထပ်ပါ နိုင်ငံတကာအဆင့်မီခုတင် (၂၅၀)ဆံ့ ဆေးရုံတည်ဆောက်ပြီး Private Hospital လုပ်ငန်းကို နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဥပဒေ နှင့်အညီ ဆောင်ရွက်ခွင့်ပြုပါရန် ကျန်းမာရေးဝန်ကြီးဌာနမှ မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှု ကော်မရှင်သို့ အဆိုပြုချက်တင်ပြခြင်းနှင့် စပ်လျဉ်း၍ မြန်မာနိုင်ငံ အင်ဂျင်နီယာအသင်းသို့ ရည်ညွှန်း(၁)ပါစာဖြင့် သဘောထားမှတ်ချက် တောင်းခံခဲ့ရာ ရည်ညွှန်း (၂)ပါ စာဖြင့် အောက်ပါအချက်များကို ထားရှိဆောင်ရွက်ရန် သဘောထားမှတ်ချက် ပြန်ကြားလာပါသည် -

(က) သတ်မှတ်ထားသော နိုင်ငံတကာအဆင့် ဆေးရုံတစ်ရုံ၏ အင်္ဂါရပ်နှင့် ကိုက်ညီပြီး စံချိန်စံညွှန်းနှင့်အညီ လုပ်ဆောင်ရန်၊

(ခ) လူနာအချို့မှ မလှုပ်ရှားနိုင်သဖြင့် မီးဘေးအန္တရာယ်ကြုံတွေ့ရာတွင် အလွယ်တကူ ရွှေ့ပြောင်း ထွက်ပြေးလွတ်မြောက်နိုင်ရန် ထွက်ပေါက် (Exits)များ ထားပေးခြင်း၊ အခြားစီမံချက်များ စီစဉ်ထားရှိရန် (Evacuation plan in case of fire and other emergency situations၊ စုဝေးနေရာ Assembly point သတ်မှတ်ခြင်း)၊

(ဂ) ဆေးကုသမည့်လူနာဦးရေ တိုးလာနိုင်သဖြင့် နောင်အနာဂါတ်တွင် တိုးချဲ့တည်ဆောက်ရန်အတွက် Car parking နှင့် Landscaping ဧရိယာများကို Future planနှင့် ကိုက်ညီစွာ ထည့်သွင်း၍ ပုံစံရေးဆွဲထားရန်၊

(ဃ) သက်ဆိုင်ရာမီးသတ်ဦးစီးဌာနမှ ချမှတ်ထားသော လမ်းညွှန်ချက်များအတိုင်းလိုက်နာဆောင်ရွက်ရန်၊

၂။ သို့ဖြစ်ပါ၍ Andaman Alliance Healthcare Limited အနေဖြင့် အထက်စာပိုဒ်ပါ မြန်မာနိုင်ငံ အင်ဂျင်နီယာအသင်း၏ သဘောထားမှတ်ချက်နှင့်အညီ လိုက်နာဆောင်ရွက်မည့် အစီအစဉ်များအား ကော်မရှင်သို့ ပြန်လည်တင်ပြပါရန် အကြောင်းကြားပါသည်။

ဥက္ကဋ္ဌ (ကိုယ်စား)
(မြသူဇာ၊ တွဲဖက်အတွင်းရေးမှူး)

Andaman Alliance Healthcare Limited
အမှတ်(၃၃)၊ ၆မိုင်ခွဲ၊ ပြည်လမ်း၊ ၁၁ ရပ်ကွက်၊
လှိုင်မြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး။

မိတ္တူကို
ပြည်ထောင်စုဝန်ကြီးရုံး၊ ကျန်းမာရေးဝန်ကြီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ ကုသရေးဦးစီးဌာန
ရုံးလက်ခံ/ မျှောစာတွဲ

Myanmar Engineering Society
Hlaing Universities Campus,
Hlaing Township, Yangon, Myanmar.

Date: 20. 11. 2015

Subject: Informing that we currently do not have list of materials to be imported

Reference : Myanmar Investment Commission's Letter No. YaKa-5 (Ah)/ 012/ 2015 (397) dated 16 November 2015

Regarding **Myanmar Investment Commission's** asking comment from Myanmar Engineering Society on construction work and construction materials to be imported of the proposed business, we would like to inform about our plan for construction and construction materials as follows:

- We have not decided yet which contractor we are using and moreover we have conceptual design only at this stage and not BOQ or import list for now.

- Therefore, we plan to engage contractor on turn-key contract basis and agree that our proposal is processed for investment permit without construction material list to be imported in the proposal.

Faithfully yours,

U Aung Moe Kyaw
Director

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
အမှတ်(၁)၊ သစ္စာလမ်း၊ ရန်ကင်းမြို့နယ်၊ ရန်ကုန်မြို့။

☎ -၀၁-၆၅၈၁၃၀
🖶 -၀၁-၆၅၈၁၄၂

စာအမှတ်၊ ရက- ၅(အ)/ ၀၁၂/ ၂၀၁၅(၄၄၂)
ရက်စွဲ၊ ၂၀၁၅ ခုနှစ် ဒီဇင်ဘာလ ၈ ရက်

အကြောင်းအရာ။ **ပတ်ဝန်းကျင်ထိန်းသိမ်းရေးနှင့် သစ်တောရေးရာဝန်ကြီး၏ သဘောထား မှတ်ချက်နှင့်အညီ တင်ပြပေးပါရန် အကြောင်းကြားခြင်းကိစ္စ**

ရည် ညွှန်း ချက် ။ (၁) မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှု ကော်မရှင်၏ ၁၂-၁၁-၂၀၁၅ ရက်စွဲပါ စာအမှတ်၊ ရက- ၅(အ)/၀၁၂/၂၀၁၅ (၃၉၀)

(၂) ပတ်ဝန်းကျင် ထိန်းသိမ်းရေးနှင့် သစ်တောရေးရာ ဝန်ကြီးဌာန၏ ၂-၁၂-၂၀၁၅ ရက်စွဲပါ စာအမှတ် ၃(၂)/၁၆(ဃ)(၁)/(၃၃၈၄/၂၀၁၅)

၁။ မြန်မာနိုင်ငံ AMMK Medicare Company Limitedမှ ၂၁.၅ %၊ မြန်မာနိုင်ငံ Global Star Company Limitedမှ ၁၆%၊ စင်္ကာပူနိုင်ငံ Macondray Holdings Pte. Ltd.မှ ၁၀.၅% နှင့် စင်္ကာပူနိုင်ငံ Parkway Healthcare Indo - China Pte. Ltd.မှ ၅၂% ထည့်ဝင်၍ ဖက်စပ်နိုင်ငံခြား ရင်းနှီးမြှုပ်နှံမှုဖြင့် မြန်မာနိုင်ငံတွင် Andaman Alliance Healthcare Limited တည်ထောင်ကာ ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ ဗိုလ်ချုပ်အောင်ဆန်းလမ်းနှင့် ပြည်လမ်းထောင့်၊ မြေတိုင်း ရပ်ကွက် အမှတ်(၂၀-F)၊ မြေကွက် အမှတ် (၁၀)၊ မြေအမျိုးအစား- ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက် - ရန်ကုန်နယ်မြေ (ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း (၁၆.၈၅၀)ဧက အနက် (၁၀.၄၄၆)ဧက၏ မြေအတိုင်းအတာ (၄.၄၄၆)ဧက ပေါ်တွင် Parkway Yangon Hospital အမည်ဖြင့် ဆေးရုံတည်ဆောက်ပြီး Private Hospital လုပ်ငန်းကို နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဥပဒေ နှင့်အညီ ဆောင်ရွက်ခွင့်ပြုပါရန် ကျန်းမာရေးဝန်ကြီးဌာနမှ မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှု ကော်မရှင်သို့ အဆိုပြုချက် တင်ပြခြင်းနှင့်စပ်လျဉ်း၍ ပတ်ဝန်းကျင်ထိန်းသိမ်းရေးနှင့် သစ်တောရေးရာ ဝန်ကြီးဌာနသို့ရည်ညွှန်း (၁)ပါ စာဖြင့် သဘောထားမှတ်ချက် တောင်းခံခဲ့ရာ ရည်ညွှန်း(၂)ပါစာဖြင့် အောက်ပါ အချက်များအတိုင်း လိုက်နာဆောင်ရွက်ရန် သဘောထားမှတ်ချက် ပြန်ကြားလာပါသည် -

(က) အဆိုပြုလုပ်ငန်း ဆောင်ရွက်မှုကြောင့် ဖြစ်ပေါ်လာနိုင်သည့် ပတ်ဝန်းကျင်၊ လူမှုရေးနှင့် ကျန်းမာရေး ထိခိုက်ပျက်စီးမှုများကို လျော့နည်းစေရေးအတွက် စီမံကိန်းဆိုင်ရာ အချက်အလက်များကို ပြည့်စုံစွာဖော်ပြပြီး တည်ဆောက်ရေးလုပ်ငန်း ဆောင်ရွက်ရာတွင် ပတ်ဝန်းကျင် ထိခိုက်မှုအနည်းဆုံး ဖြစ်စေမည့် နည်းစနစ်များအား အသုံးပြုရန်နှင့် အဆိုပြုလွှာတွင် ဖော်ပြပါရှိသည့် လူမှုရေးဆိုင်ရာ တာဝန်ခံဆောင်ရွက်မှု(Corporate Social Responsibility – CSR) အတွက် အမြတ်ငွေ၏ (၂%) အား အသုံးပြုရန်

အပါအဝင် ကတိကဝတ်များနှင့် လုပ်ငန်းစီမံချက်များအတိုင်း အကောင်အထည်ဖော် ဆောင်ရွက်သွားရန်၊

(ခ) အဆိုပြုလုပ်ငန်း ဆောင်ရွက်မှုကြောင့် ပတ်ဝန်းကျင်နှင့်လူမှုရေး ထိခိုက်မှုမရှိစေရေး (သို့မဟုတ်) ထိခိုက်မှု အနည်းဆုံး ဖြစ်စေရေးတို့အတွက် ကနဦး ပတ်ဝန်းကျင်ဆန်းစစ်ခြင်း (Initial Environmental Examination-IEE) ဆောင်ရွက်ရန်၊ IEE အစီရင်ခံစာပေါ် မူတည်၍ လိုအပ်ပါက EIA ဆောင်ရွက်ရန်နှင့် IEE အစီရင်ခံစာအား ရေးဆွဲပြုစု တင်ပြရန်၊

(ဂ) အဆိုပါ လေ့လာဆန်းစစ်မှုရလဒ်များကို အခြေခံ၍ လုပ်ငန်းဆောင်ရွက်ရာတွင် ပတ်ဝန်းကျင်နှင့်လူမှုရေး ထိခိုက်မှုအနည်းဆုံးဖြစ်စေမည့် လုပ်ငန်းဆောင်ရွက်မည့် အစီအစဉ်၊ စွန့်ပစ်ပစ္စည်း/ အရည်စီမံခန့်ခွဲမှု အစီအစဉ်များ၊ စောင့်ကြပ်ကြည့်ရှု စစ်ဆေးမည့် အစီအစဉ်၊ ပတ်ဝန်းကျင် ထိခိုက်မှု လျော့ပါးရေး ဆောင်ရွက်မည့် လုပ်ငန်းများအတွက် သုံးစွဲမည့်ရန်ပုံငွေ စသည့်တို့ပါဝင်သည့် ပတ်ဝန်းကျင် စီမံခန့်ခွဲမှု အစီအစဉ် (Environmental Management Plan-EMP)များ ရေးဆွဲတင်ပြရန်နှင့် စီမံချက်ပါအတိုင်း အကောင်အထည်ဖော် ဆောင်ရွက်ရန်၊

၂။ သို့ဖြစ်ပါ၍ Andaman Alliance Healthcare Limited အနေဖြင့် အထက်စာပိုဒ်ပါ ပတ်ဝန်းကျင်ထိန်းသိမ်းရေးနှင့် သစ်တောရေးရာဝန်ကြီးဌာန၏ သဘောထားမှတ်ချက် နှင့်အညီ လိုက်နာဆောင်ရွက်မည့် အစီအစဉ်များအား ကော်မရှင်သို့ ပြန်လည်တင်ပြပါရန် အကြောင်းကြားပါသည်။

ဥက္ကဋ္ဌ(ကိုယ်စား)
(မြသူဇာ၊ တွဲဖက်အတွင်းရေးမှူး)

Andaman Alliance Healthcare Limited
အမှတ်(၃၃)၊ ဗမိုင်ခွဲ၊ ပြည်လမ်း၊ ၁၁ ရပ်ကွက်၊
လှိုင်မြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး။

မိတ္တူကို
- ပြည်ထောင်စုဝန်ကြီးရုံး၊ ကျန်းမာရေးဝန်ကြီးဌာန
- ညွှန်ကြားရေးမှူးချုပ်၊ ကုသရေးဦးစီးဌာန
- ညွှန်ကြားရေးမှူးချုပ်၊ ပတ်ဝန်းကျင်ထိန်းသိမ်းရေးဦးစီးဌာန
- ရုံးလက်ခံ/ မျှောစာတွဲ

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ
ပတ်ဝန်းကျင်ထိန်းသိမ်းရေးနှင့်သစ်တောရေးရာဝန်ကြီးဌာန
ပြည်ထောင်စုဝန်ကြီးရုံး

စာအမှတ် ၃(၂)/၁၆(ဃ)(၁)/(၃၃၈၄ /၂၀၁၅)
ရက်စွဲ ၂၀၁၅ ခုနှစ်၊ ဒီဇင်ဘာလ ၂ ရက်

သို့
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

အကြောင်းအရာ။ <u>သဘောထားမှတ်ချက်ပြန်ကြားခြင်း</u>

ရည်ညွှန်းချက်။ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ ၁၂ - ၁၁ - ၂၀၁၅ ရက်စွဲပါစာအမှတ်၊ ရကာ - ၅(အ) / ၀၁၂ / ၂၀၁၅ (၃၉၀)

၁။ မြန်မာနိုင်ငံ AMMK Medicare Company Limited မှ ၂၀.၅ % ၊ မြန်မာနိုင်ငံ Global Star Company Limited မှ ၁၆ % ၊ စင်္ကာပူနိုင်ငံ Macondray Holdings Pte. Ltd. မှ ၁၀.၅ % နှင့် စင်္ကာပူနိုင်ငံ Parkway Healthcare Indo - China Pte. Ltd. မှ ၅၂ % ထည့်ဝင်၍ ဖက်စပ်နိုင်ငံခြား ရင်းနှီးမြှုပ်နှံမှုဖြင့် မြန်မာနိုင်ငံတွင် Andaman Alliance Healthcare Limited တည်ထောင်ကာ ကျန်းမာရေးဝန်ကြီးဌာနပိုင် ရန်ကုန်တိုင်းဒေသကြီး ၊ လမ်းမတော်မြို့နယ်၊ ဗိုလ်ချုပ် အောင်ဆန်းလမ်း နှင့် ပြည်လမ်းထောင့်၊ မြေတိုင်းရပ်ကွက် အမှတ် (၂၀ - F)၊ မြေကွက်အမှတ် (၁၀)၊ မြေအမျိုးအစား - ပြည်သူ့လုပ်ငန်း ဌာနပိုင်မြေ ၊ မြေအမည်ပေါက် - ရန်ကုန်နယ်မြေ (ရန်ကုန် ထောင်ကြီး)၊ မြေအကျယ်အဝန်း (၃၇.၅၄၉) ဧက အနက် (၁၁.၁၄၅) ဧက၏ မြေအတိုင်းအတာ (၅) ဧကပေါ်တွင် Parkway Yangon Hospital အမည်ဖြင့် ဆေးရုံတည်ဆောက်ပြီး World Class Multi - Specialty Hospital လုပ်ငန်းအား နိုင်ငံခြား ရင်းနှီးမြှုပ်နှံမှု ဥပဒေ နှင့် အညီ ဆောင်ရွက်ခွင့်ပြုပါရန် ကိစ္စ နှင့် ပတ်သက်၍ စိစစ်ပြီး ဌာနဆိုင်ရာ သဘောထားမှတ်ချက် ပြန်ကြားပေးပါရန် ရည်ညွှန်းပါစာဖြင့် အကြောင်းကြားလာပါသည်။

၂။ တည်ဆောက်ရေး လုပ်ငန်းနှင့်ပတ်သက်၍ စိစစ်ရာတွင် မြေသားများ ပြုပြင်ဖော်ထုတ်ခြင်းကြောင့် ထွက်ရှိလာသည့် အမှုန်အမွှားများ ၊ ဖုန်မှုန့်များကြောင့် လေထုညစ်ညမ်းမှုများ ဖြစ်ပေါ်စေနိုင်ခြင်း ၊ တည်ဆောက်ရေးလုပ်ငန်းတွင် အသုံးပြုသည့် စက်ပစ္စည်းများ နှင့် ယာဉ်ယန္တရားများ၏ ဆူညံသံများကြောင့် အသံညစ်ညမ်းမှု ဖြစ်ပေါ်စေနိုင်ခြင်း၊ လုပ်ငန်းခွင်မှ ထွက်ရှိလာမည့် ဘေးအန္တရာယ်ရှိ စွန့်ပစ်ပစ္စည်း နှင့် စွန့်ပစ်အရည်များကြောင့် ပတ်ဝန်းကျင်ရှိ ရေထု ၊ လေထု နှင့် မြေထုညစ်ညမ်းမှုများ ဖြစ်ပေါ်စေနိုင်ပါသည်။ ဆေးရုံလုပ်ငန်းလည်ပတ်ချိန်တွင် ဓါတ်ခွဲခန်း ၊ ခွဲစိတ်ခန်း နှင့် အခြားသွေး နှင့် ဆက်စပ်သော အခန်းများမှ ထွက်ရှိလာမည့် စွန့်ပစ်ပစ္စည်းများ / စွန့်ပစ်အရည် Biomedical Waste များအား စနစ်တကျ စွန့်ပစ်ခြင်း မပြုပါက အနံ့ဆိုးများ ထွက်ရှိနိုင်ခြင်း ၊ ရောဂါများ ပြန့်ပွားကူးစက်နိုင်ခြင်း နှင့် ပတ်ဝန်းကျင် ရှိ မြေထု၊ လေထု၊ရေထုညစ်ညမ်းနိုင်ခြင်း၊ ဓါတ်မှန် နှင့် CT Scan တို့ အသုံးပြုရာမှ ထွက်ပေါ်လာမည့် ဓါတ်ရောင်ခြည်သည် လူကို အန္တရာယ်ဖြစ်စေနိုင်ခြင်း စသည့် ပတ်ဝန်းကျင်ဆိုင်ရာ ထိခိုက်မှုပြဿနာများ ဖြစ်ပေါ် စေနိုင်ကြောင်း စိစစ်တွေ့ရှိရပါသည်။

D:\OD\Andaman Alliance Healthcare Limited(MN).doc1

၃။ သို့ဖြစ်ပါ၍ Andaman Alliance Healthcare Limited မှ Parkway Yangon Hospital အမည်ဖြင့် ဆေးရုံတည်ဆောက်ပြီး World Class Multi-Specilty Hospital လုပ်ငန်း နှင့် ပတ်သက်၍ အောက်ဖော်ပြပါအတိုင်း လိုက်နာဆောင်ရွက်ရန် လိုအပ်မည်ဖြစ်ပါကြောင်း သဘောထားမှတ်ချက် ပြန်ကြားအပ်ပါသည်-

(က) အဆိုပြုလုပ်ငန်းဆောင်ရွက်မှုကြောင့်ဖြစ်ပေါ်လာနိုင်သည့် ပတ်ဝန်းကျင်၊လူမှုရေး နှင့် ကျန်းမာရေး ထိခိုက်ပျက်စီးမှုများကို လျော့နည်းစေရေးအတွက် စီမံကိန်း ဆိုင်ရာ အချက်အလက်များကို ပြည့်စုံစွာ ဖော်ပြပြီး တည်ဆောက်ရေး လုပ်ငန်း ဆောင်ရွက်ရာတွင် ပတ်ဝန်းကျင် ထိခိုက်မှုအနည်းဆုံး ဖြစ်စေမည့် နည်းစနစ်များ အား အသုံးပြုရန် နှင့် အဆိုပြုလွှာတွင် ဖော်ပြပါရှိသည့် လူမှုရေးဆိုင်ရာ တာဝန်ခံ ဆောင်ရွက်မှု (Corporate Social Responsibility - CSR) အတွက် အမြတ်ငွေ၏ (၂ %) အား အသုံးပြုရန် အပါအဝင် ကတိကဝတ်များနှင့် လုပ်ငန်းစီမံချက်များအတိုင်း အကောင်အထည်ဖော် ဆောင်ရွက်သွားရန်၊

(ခ) အဆိုပြုလုပ်ငန်း ဆောင်ရွက်မှုကြောင့် ပတ်ဝန်းကျင် နှင့် လူမှုရေး ထိခိုက်မှု မရှိစေရေး (သို့မဟုတ်) ထိခိုက်မှု အနည်းဆုံး ဖြစ်စေရေးတို့အတွက် ကနဦး ပတ်ဝန်းကျင် ဆန်းစစ်ခြင်း (Initial Environmental Examination - IEE) ဆောင်ရွက်ရန် ၊ IEE အစီရင်ခံစာပေါ် မူတည်၍ လိုအပ်ပါက EIA ဆောင်ရွက်ရန် နှင့် IEE အစီရင်ခံစာအား ရေးဆွဲပြုစုတင်ပြရန်၊

(ဂ) အဆိုပါ လေ့လာဆန်းစစ်မှု ရလဒ်များကို အခြေခံ၍ လုပ်ငန်းဆောင်ရွက်ရာတွင် ပတ်ဝန်းကျင် နှင့် လူမှုရေး ထိခိုက်မှု အနည်းဆုံးဖြစ်စေမည့် လုပ်ငန်းဆောင်ရွက်မည့် အစီအစဉ်၊ စွန့်ပစ်ပစ္စည်း/အရည်စီမံခန့်ခွဲမှု အစီအစဉ်များ ၊ စောင့်ကြပ်ကြည့်ရှု စစ်ဆေးမည့် အစီအစဉ် ၊ ပတ်ဝန်းကျင် ထိခိုက်မှု လျော့ပါးရေး ဆောင်ရွက်မည့် လုပ်ငန်းများအတွက် သုံးစွဲမည့် ရန်ပုံငွေ စသည်တို့ ပါဝင်သည့် ပတ်ဝန်းကျင် စီမံခန့်ခွဲမှု အစီအစဉ် (Environmental Management Plan - EMP) များ ရေးဆွဲတင်ပြရန် နှင့် စီမံချက်ပါအတိုင်း အကောင်အထည်ဖော်ဆောင်ရွက်ရန်၊

(ဃ) ပြဋ္ဌာန်းထားသည့် ပတ်ဝန်းကျင်ထိန်းသိမ်းရေး ဥပဒေ၊ နည်းဥပဒေများ ၊ လုပ်ထုံးလုပ်နည်း၊ စည်းမျဉ်းစည်းကမ်းများနှင့်အညီ လိုက်နာကျင့်သုံး အကောင်အထည်ဖော်ဆောင်ရွက်ရန်၊

(င) သက်ဆိုင်ရာ တိုင်းဒေသကြီး / ပြည်နယ် အစိုးရအဖွဲ့ နှင့် ဒေသခံပြည်သူများ၏ ဆန္ဒ နှင့် သဘောထား ရယူဆောင်ရွက်ရန်။

၂/၂

ပြည်ထောင်စုဝန်ကြီး(ကိုယ်စား)
(မျိုးညွန့် ၊ ဒုတိယအမြဲတမ်းအတွင်းဝန်)

မိတ္တူကို

ညွှန်ကြားရေးမှူးချုပ် ၊ ရင်းနှီးမြှုပ်နှံမှုနှင့်ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ် ၊ ပတ်ဝန်းကျင်ထိန်းသိမ်းရေးဦးစီးဌာန

စာအမှတ် ....
ရက်စွဲ ....

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
ရန်ကုန်တိုင်းဒေသကြီးအစိုးရ
ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ
မြို့တော်ခန်းမ၊ရန်ကုန်မြို့

စာအမှတ်၊ ၁၀၉/၀၁ (၄၇၂၁)/စသက
ရက်စွဲ ၊ ၂၀၁၅ခုနှစ် နိုဝင်ဘာလ ၂၀ ရက်

ဥက္ကဋ္ဌ
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

အကြောင်းအရာ။ **သဘောထားမှတ်ချက်တောင်းခံခြင်းကိစ္စ**

ရည်ညွှန်းချက် ။ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ ၁၆-၁၁-၂၀၁၅ ရက်စွဲပါ စာအမှတ်၊ ရက-၅(အ)/၀၁၂/ ၂၀၁၅(၃၉၆)

၁။ လမ်းမတော်မြို့နယ်၊ ဗိုလ်ချုပ်အောင်ဆန်းလမ်းနှင့်ပြည်လမ်းထောင့်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀-F)၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမျိုးအစား ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက် ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း (၃၇.၅၄၉)ဧကအနက် (၁၁.၁၄၅)ဧက၏ မြေအတိုင်းအတာ(၅)ဧကပေါ်တွင် Parkway Yangon World Class Hospital အမည်ဖြင့် အထပ်(၈)ထပ်ပါ နိုင်ငံတကာအဆင့်မီ ခုတင်(၂၅၀)ဆံ့ဆေးရုံတည်ဆောက်ပြီး Multi-Specialty Hospital လုပ်ငန်းအား နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဥပဒေနှင့်အညီ ဆောင်ရွက်ခွင့်ပြုပါရန် ကျန်းမာရေးဝန်ကြီးဌာနမှ တင်ပြလာခြင်းအပေါ် ရည်ညွှန်းပါစာဖြင့် သဘောထားမှတ်ချက် တောင်းခံလာပါသည်။

၂။ အဆိုပြုတင်ပြလာသောမြေနေရာအား မြေပြင်စစ်ဆေးရာတွင် မြေကွက်အတိုင်းအတာ(၆၀၀'× ၃၂၅')ရှိပြီး မြေကွက်အတွင်း ၂ထပ်တိုက်အဆောက်အဦနှင့် ၁ထပ်သွပ်ကာအဆောက်အဦတို့ရှိ၍ သူနာပြုဝန်ထမ်းများနေထိုင်ကြောင်း၊ ဝဲဘက်တွင် လျှပ်စစ်ဝန်ကြီးဌာနဝင်း(တဘက်တွင် ပြည်လမ်းမကြီး)၊ ယာဘက်တွင် သူနာပြုတက္ကသိုလ်ဝင်း၊ နောက်ဘက်တွင် ဆောက်လုပ်ဆဲ ၇ထပ်တိုက်(ဆေးရုံ)နှင့် ရှေ့မျက်နှာစာ ဗိုလ်ချုပ်အောင်ဆန်းလမ်းမကြီးဖြစ်ကြောင်း၊ ရှေးဟောင်းလက်ရာအဆောက်အဦဖြစ်သော ဆေးတက္ကသိုလ်(၁)နှင့် ပေ(၆၅၀')ခန့်ကွာဝေးကြောင်းနှင့် ကော်မတီသို့ ဆောက်လုပ်ခွင့်လျှောက်ထားလာခြင်း မရှိသေးကြောင်း စိစစ်တွေ့ရှိရပါသည်။

၃။ သို့ဖြစ်ပါ၍ လမ်းမတော်မြို့နယ်၊ ဗိုလ်ချုပ်အောင်ဆန်းလမ်းနှင့်ပြည်လမ်းထောင့်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀-F)၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမည်ပေါက် ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး)၊ မြေကွက်အတိုင်းအတာ(၅)ဧကပေါ်တွင် အထပ်(၈)ထပ်ပါ နိုင်ငံတကာအဆင့်မီ ကုတင်(၂၅၀)ဆံ့ဆေးရုံတည်ဆောက်ပြီး World Class Multi-Specialty Hospital လုပ်ငန်း ဆောင်ရွက်ခွင့်ပြုရန် တင်ပြလာခြင်းနှင့်ပတ်သက်၍ [redacted] ပြန်ကြားအပ်ပါသည်။

ညွှန်ကြားချက်
၂၀.၁၁.၂၀၁၅

ဥက္ကဋ္ဌ (ကိုယ်စား)
(ညဏ်လင်းစိုး၊ ရုံးအဖွဲ့မှူး)

မိတ္တူကို
တွဲဖက်အတွင်းရေးမှူး၊ ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ
ဌာနမှူး၊ အင်ဂျင်နီယာဌာန(အဆောက်အအုံ)၊ ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ
မျှောစာတွဲ
ရုံးလက်ခံ

Form (2)

Sr.No. 449-A
Date 10-12-2015
Republic of the Union of Myanmar ★ Myanmar Investment Commission ★

THE REPUBLIC OF THE UNION OF MYANMAR

The Myanmar Investment Commission

TEMPORARY PERMIT

Permit No. 1045 / 2015(Temporary) Date 10th December, 2015

This Permit is issued by the Myanmar Investment Commission according to the section 13, sub-section (b) of the Republic of the Union of Myanmar Foreign Investment Law-

(a) **Name of Investor/Promoter** MR. LIAW YIT MING

(b) **Citizenship** MALAYSIAN

(c) **Address** 6 KENG CHIN ROAD, #05-05 CYAN, SINGAPORE 258709

(d) **Name and Address of Principal Organization** PARKWAY HEALTHCARE INDO - CHINA PTE. LTD. 111 SOMERSET ROAD #15-01 TRIPLEONE SOMERSET SINGAPORE 238164

(e) **Place of Incorporation** SINGAPORE

(f) **Type of Investment Business** PRIVATE HOSPITAL

(g) **Place(s) at which Investment is** PLOT NO. 10, MYAY TAING BLOCK NO.20- F, CORNER OF PYAY ROAD AND BOGYOKE AUNG SAN ROAD, LANMADAW TOWNSHIP, YANGON

(h) **Amount of Foreign Capital** US$ 53.42 MILLION

(i) **Period for Foreign Capital brought in** WITHIN SEVEN YEARS AFTER THE ISSUANCE OF MIC PERMIT

(j) **Total amount of capital (Kyat)** EQUIVALENT IN KYAT OF US$ 85.47 MILLION (INCLUDING US$ 53.42 MILLION)

(k) **Construction Period** 4 YEARS

(l) **Permitted duration of investment** 50 YEARS

(m) **Form of investment** JOINT VENTURE

(n) **Name of Company incorporated in Myanmar** ANDAMAN ALLIANCE HEALTHCARE LIMITED

Chairman
The Myanmar Investment Commission

Note:

1. This Temporary Permit is issued for the purpose of indication that the Myanmar Investment Commission agreed in principle with Andaman Alliance Healthcare Limited to start its investment on para (f) mentioned above.
2. Andaman Alliance Healthcare Limited. shall complete all processes and formalities within three (3) months started from date of issuance of this temporary permit, the terms of this permit will be expired after three (3) months of the date of issue and the permit shall be null and void after the expiry.

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
ယာယီခွင့်ပြုမိန့်

ခွင့်ပြုမိန့်အမှတ် ၁၀၄၅/၂၀၁၅(ယာယီ) ၂၀၁၅ ခုနှစ် ဒီဇင်ဘာလ ၁၀ ရက်

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှု ဥပဒေပုဒ်မ-၁၃၊ ပုဒ်မခွဲ(ခ) အရ ဤခွင့်ပြုမိန့်ကို မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်က ထုတ်ပေးလိုက်သည် -

(က) ရင်းနှီးမြှုပ်နှံသူ/ကမကထပြုသူ၏အမည် MR. LIAW YIT MING

(ခ) နိုင်ငံသား MALAYSIAN

(ဂ) နေရပ်လိပ်စာ 6 KENG CHIN ROAD, # 05-05 CYAN, SINGAPORE 258709

(ဃ) ပင်မအဖွဲ့အစည်းအမည်နှင့်လိပ်စာ PARKWAY HEALTHCARE INDO-CHINA PTE. LTD 111 SOMERSET ROAD #15-01 TRIPLEONE SOMERSET SINGAPORE 238164

(င) ဖွဲ့စည်းရာအရပ် SINGAPORE

(စ) ရင်းနှီးမြှုပ်နှံသည့်လုပ်ငန်းအမျိုးအစား PRIVATE HOSPITAL

(ဆ) ရင်းနှီးမြှုပ်နှံသည့်အရပ်ဒေသ(များ) မြေတိုင်းရပ်ကွက်အမှတ်(၂၀-F)၊ မြေကွက်အမှတ်(၁၀)၊ ဗိုလ်ချုပ်အောင်ဆန်းလမ်းနှင့် ပြည်လမ်းထောင့်၊ လမ်းမတော်မြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး

(ဇ) နိုင်ငံခြားမတည်ငွေရင်းပမာဏ အမေရိကန်ဒေါ်လာ ၅၃.၄၂ သန်း

(ဈ) နိုင်ငံခြားမတည်ငွေရင်းယူဆောင်လာရမည့်ကာလ ကော်မရှင်ခွင့်ပြုမိန့်ရရှိပြီး ၇ နှစ်အတွင်း

(ည) စုစုပေါင်းမတည်ငွေရင်းပမာဏ(ကျပ်) အမေရိကန်ဒေါ်လာ ၈၅.၄၇ သန်းနှင့် ညီမျှသော မြန်မာကျပ်ငွေ (အမေရိကန်ဒေါ်လာ ၅၃.၄၂ သန်း အပါအဝင်)

(ဋ) တည်ဆောက်မှုကာလ ၄ နှစ်

(ဌ) ရင်းနှီးမြှုပ်နှံခွင့်ပြုသည့် သက်တမ်း ၅၀ နှစ်

(ဍ) ရင်းနှီးမြှုပ်နှံမှုပုံစံ ဖက်စပ်နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှု

(ဎ) မြန်မာနိုင်ငံတွင် ဖွဲ့စည်းမည့် ကုမ္ပဏီအမည် ANDAMAN ALLIANCE HEALTHCARE LIMITED

ဥက္ကဋ္ဌ
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

မှတ်ချက်။

(၁) ဤယာယီခွင့်ပြုမိန့်သည် Andaman Alliance Healthcare Limited. အနေဖြင့် အထက် အပိုဒ်(စ)တွင် ဖော်ပြထားသည့် ရင်းနှီးမြှုပ်နှံမှုလုပ်ငန်းကို စတင်ဆောင်ရွက်နိုင်ရန် မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှု ကော်မရှင်အနေဖြင့် သဘောတူကြောင်း ဖော်ပြချက်သာ ဖြစ်ပါသည်။

(၂) Andaman Alliance Healthcare Limited. သည် ဆောင်ရွက်ရမည့် လုပ်ငန်းစဉ်များ၊ ကိစ္စရပ်များကို ယာယီခွင့်ပြုမိန့်ထုတ်ပေးသည့်နေ့မှစတင်၍ သုံးလအတွင်း ပြီးစီးအောင် ဆောင်ရွက်ရမည်။ ဤယာယီခွင့်ပြုမိန့်၏ သက်တမ်းသည် သုံးလပြည့်မြောက်ပြီးချိန်တွင် ကုန်ဆုံး မည်ဖြစ်ပြီး ထိုကာလမှစတင်ကာ ဤခွင့်ပြုမိန့်သည် ပျက်ပြယ်ပြီးဖြစ်ပါသည်။

လျှို့ဝှက်

၂၅
၃၀/၁၀/၁၅

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ

ကျန်းမာရေးဝန်ကြီးဌာန

ဝန်ကြီးရုံး

စာအမှတ်၊ ၅မက(မ)၂၀၁၅/ ၁၈၃၃၀

ရက်စွဲ၊ ၂၀၁၅ခုနှစ်၊ အောက်တိုဘာလ(၂၀)ရက်

သို့

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

အကြောင်းအရာ။ **မြေငှားရမ်းသုံးစွဲခွင့်ကိစ္စ ညှိနှိုင်းပေးပို့ခြင်း။**

၁။ အထက်အကြောင်းအရာနှင့်ပတ်သက်၍ ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀ F)၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမျိုးအစား-ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက်-ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း(၃၇.၅၄၉)ဧကအနက်(၁၁.၁၄၅)ဧက၏ မြေအတိုင်းအတာ(၅)ဧကပေါ်တွင် AMK Cousortium and Parkway Pantai Limited နှင့်ပူးပေါင်းသည့် ဖက်စပ်လုပ်ငန်းအနေဖြင့် နိုင်ငံတကာအဆင့်မီဆေးရုံတစ်ရုံကို ခုတင်(၂၅၀) ဆံ့ဆေးရုံအဖြစ် အဆင့်လိုက်တည်ဆောက်သွားရန်နှင့် ပထမအဆင့်တွင် ခုတင်(၁၀၀)ဆံ့ ဆေးရုံဖြင့် စတင်လည်ပတ်ပြီး နောက်အဆင့်များကို တစ်ပြိုင်တည်း ဆက်လက်ဆောင်ရွက်သွားမည်ဖြစ်ကြောင်း တင်ပြမှုနှင့်ပတ်သက်၍ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သို့ တင်ပြဆောင်ရွက်သွားရန် ပြည်ထောင်စုအစိုးရအဖွဲ့ရုံး၏ (၁၃-၁၀-၂၀၁၅)ရက်စွဲပါ စာအမှတ်၊ ၂၉၃၁/၃၃၀-မြေ ၂-၄(၃)/အဖရ(၂၀၁၅) ဖြင့် အကြောင်းကြားခဲ့ပါသည်။

၂။ သို့ဖြစ်ပါ၍ လုပ်ငန်းခွင့်ပြုနိုင်ပါရန် အောက်ဖော်ပြပါ နောက်ဆက်တွဲများပူးတွဲလျက် ညှိနှိုင်းပေးပို့အပ်ပါသည်-

(က) AMK Cousortium and Parkway Pantai Limited ၏အကျဉ်းချုပ်တင်ပြချက် (မြန်မာ/အင်္ဂလိပ်)၊

(ခ) LAND LEASE AGREEMENT၊

(ဂ) PROPOSAL FOR MULTITERTIARY HOSPITAL 250 BEDS၊

(ဃ) ပတ်ဝန်းကျင်ထိခိုက်မှုအခြေအနေဖော်ပြချက်၊

လျှို့ဝှက်

(င) Projection Statement ၊

(စ) ပြည်ထောင်စုရှေ့နေချုပ်ရုံးသို့ သဘောထားမှတ်ချက် ညှိနှိုင်းစာ။

(ဒေါက်တာသန်းအောင်)
ပြည်ထောင်စုဝန်ကြီး

မိတ္တူကို-

နိုင်ငံတော်သမ္မတရုံး
ဒုတိယသမ္မတ(၁)ဦးစီးရုံး
ဒုတိယသမ္မတ(၂)ဦးစီးရုံး
ပြည်ထောင်စုအစိုးရအဖွဲ့ရုံး
သမ္မတရုံးဝန်ကြီးဌာန(၃)

လျှို့ဝှက်

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ

ကျန်းမာရေးဝန်ကြီးဌာန

ဝန်ကြီးရုံး

စာအမှတ်၊ ၅မက(မ)၂၀၁၅/၁၈၅၁၄

ရက်စွဲ၊ ၂၀၁၅ခုနှစ်၊ အောက်တိုဘာလ(၂၂)ရက်

သို့

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

အကြောင်းအရာ။ **ကြိုတင်ခွင့်ပြုမိန့်ထုတ်ပေးပါရန် ညှိနှိုင်းခြင်း။**

ရည်ညွှန်းချက်။ ကျန်းမာရေးဝန်ကြီးဌာန၏ (၂၀-၁၀-၂၀၁၅)ရက်စွဲပါ စာအမှတ်၊ ၅မက(မ) ၂၀၁၅/၁၈၃၃။

၁။ အထက်အကြောင်းအရာနှင့်ပတ်သက်၍ ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀ F)၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမျိုးအစား-ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက်-ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း(၃၇.၅၄၉)ဧကအနက် (၁၁.၁၄၅)ဧက၏ မြေအတိုင်းအတာ(၅)ဧကပေါ်တွင် AMK Cousortium and Parkway Pantai Limited နှင့်ပူးပေါင်းသည့် ဖက်စပ်လုပ်ငန်းအနေဖြင့် နိုင်ငံတကာအဆင့်မီဆေးရုံတစ်ရုံကို ခုတင်(၂၅၀)ဆံ့ဆေးရုံအဖြစ် အဆင့်လိုက်တည်ဆောက်သွားရန်နှင့် ပထမအဆင့်တွင် ခုတင်(၁၀၀)ဆံ့ ဆေးရုံဖြင့် စတင်လည်ပတ်ပြီး နောက်အဆင့်များကို တစ်ပြိုင်တည်း ဆက်လက်ဆောင်ရွက်သွားမည်ဖြစ်ကြောင်း တင်ပြမှုနှင့်ပတ်သက်၍ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သို့ တင်ပြဆောင်ရွက်သွားရန် ပြည်ထောင်စုအစိုးရအဖွဲ့ရုံး၏ (၁၃-၁၀-၂၀၁၅)ရက်စွဲပါ စာအမှတ်၊ ၂၉၃၁/၃၃၀-မြေ ၂-၄(၃)/အဖရ(၂၀၁၅) ဖြင့် အကြောင်းကြားချက်အရ လုပ်ငန်းလုပ်ကိုင်ခွင့်ပြုနိုင်ပါရန် ရည်ညွှန်းချက်ပါစာဖြင့် ညှိနှိုင်းပေးပို့ခဲ့ပါသည်။

၂။ သို့ဖြစ်ပါ၍ အဆိုပါလုပ်ငန်းကို ဆောလျင်စွာ ဆောင်ရွက်နိုင်ရေးအတွက် ကြိုတင်ခွင့်ပြုမိန့်ချမှတ်ပေးနိုင်ပါရန် ညှိနှိုင်းအကြောင်းကြားအပ်ပါသည်။

ပြည်ထောင်စုဝန်ကြီး(ကိုယ်စား)

(စိန်ဝင်း၊ ဒုတိယအမြဲတမ်းအတွင်းဝန်)

လျှို့ဝှက်

လျှို့ဝှက်

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ

ကျန်းမာရေးဝန်ကြီးဌာန

ဝန်ကြီးရုံး

စာအမှတ်၊ ၅မက(မ)၂၀၁၅/၁၈၁၇၁

ရက်စွဲ၊ ၂၀၁၅ခုနှစ်၊ အောက်တိုဘာလ(၁၅)ရက်

သို့

ပြည်ထောင်စုရှေ့နေချုပ်ရုံး

အကြောင်းအရာ။ မြေငှားရမ်းသုံးစွဲခွင့်ကိစ္စ သဘောထားမှတ်ချက် ပြန်ကြားပေးပါရန် ညှိနှိုင်းခြင်း။

၁။ အထက်အကြောင်းအရာနှင့်ပတ်သက်၍ ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀ F)၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမျိုးအစား-ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက်-ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း(၃၇.၅၄၉)ဧကအနက် (၁၁.၁၄၅)ဧက၏ မြေအတိုင်းအတာ(၅)ဧကပေါ်တွင် AMK Cousortium and Parkway Pantai Limited နှင့်ပူးပေါင်းသည့် ဖက်စပ်လုပ်ငန်းအနေဖြင့် နိုင်ငံတကာအဆင့်မီဆေးရုံတစ်ရုံကို ခုတင်(၂၅၀)ဆံ့ဆေးရုံအဖြစ် အဆင့်လိုက်တည်ဆောက်သွားရန်နှင့် ပထမအဆင့်တွင် ခုတင်(၁၀၀)ဆံ့ဆေးရုံဖြင့် စတင်လည်ပတ်ပြီး နောက်အဆင့်များကို တစ်ပြိုင်တည်း ဆက်လက်ဆောင်ရွက်သွားမည်ဖြစ်ပါကြောင်း ပြည်ထောင်စုအစိုးရအဖွဲ့ရုံးသို့တင်ပြခဲ့ရာ (၁၃-၁၀-၂၀၁၅)ရက်စွဲပါ စာအမှတ်၊ ၂၉၃၀/၃၃၀-မြေ ၂-၄(၃)/အဖရ(၂၀၁၅) ဖြင့် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သို့ တင်ပြဆောင်ရွက်နိုင်ပါရန် အကြောင်းကြားခဲ့ပါသည်။

၂။ သို့ဖြစ်ပါ၍ မြေငှားရမ်းသုံးစွဲခွင့်ကိစ္စအား သဘောထားမှတ်ချက် ပြန်ကြားပေးနိုင်ပါရန် အောက်ဖော်ပြပါ နောက်ဆက်တွဲများ ပူးတွဲလျက် ပေးပို့ညှိနှိုင်းအပ်ပါသည်-

(က) AMK Cousortium and Parkway Pantai Limited ၏အကျဉ်းချုပ်တင်ပြချက် (မြန်မာ/အင်္ဂလိပ်)၊

(ခ) LAND LEASE AGREEMENT၊

(ဂ) PROPOSAL FOR MULTITERTIARY HOSPITAL 250 BEDS၊

(ဒေါက်တာသန်းအောင်)

ပြည်ထောင်စုဝန်ကြီး

လျှို့ဝှက်

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်

ပြည်ထောင်စုအစိုးရအဖွဲ့ရုံး

စာအမှတ်၊ ၂၉၃၁ /၃၃၀-မြေ ၂-၄(၃)/အဖရ(၂၀၁၅)

ရက်စွဲ ၊ ၂၀၁၅ ခုနှစ်၊ အောက်တိုဘာလ ၁၃ ရက်

ပြည်ထောင်စုဝန်ကြီး

ကျန်းမာရေးဝန်ကြီးဌာန

အကြောင်းအရာ။ **ကျန်းမာရေးဝန်ကြီးဌာနပိုင် မြေငှားရမ်းသုံးစွဲခွင့်တင်ပြသည့်ကိစ္စ**

ရည် ညွှန်း ချက် ။ ကျန်းမာရေးဝန်ကြီးဌာန၏ ၂-၁၀-၂၀၁၅ ရက်စွဲပါ စာအမှတ်၊ ၅မက (မ) ၂၀၁၅/ ၁၇၃၈၅

ရန်ကုန်တိုင်းဒေသကြီး၊လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ်(၂၀ F)၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမျိုးအစား-ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက်-ရန်ကုန်နယ်မြေ (ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း (၃၇.၅၄၉)ကေအနက် (၁၁.၁၄၅)ဧက၏ မြေအတိုင်းအတာ(၅)ဧကပေါ်တွင် AMK Cousortium and Parkway Pantai Limited နှင့် ပူးပေါင်းသည့် ဖက်စပ်လုပ်ငန်းအနေဖြင့် နိုင်ငံတကာအဆင့်မီဆေးရုံတစ်ရုံကို ခုတင်(၂၅၀)ဆံ့ဆေးရုံအဖြစ် အဆင့်လိုက်တည်ဆောက်သွားရန်နှင့် ပထမအဆင့်တွင် ခုတင်(၁၀၀)ဆံ့ဆေးရုံဖြင့် စတင်လည်ပတ်ပြီး နောက်အဆင့်များကို တစ်ပြိုင်တည်း ဆက်လက်ဆောင်ရွက်သွားမည်ဖြစ်ကြောင်း ရည်ညွှန်းစာဖြင့် တင်ပြမှုနှင့်ပတ်သက်၍ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သို့ တင်ပြဆောင်ရွက်နိုင်ပါရန် အကြောင်းကြားပါသည်။

ဇော်သန်းသင်း

ညွှန်ကြားရေးမှူးချုပ်

မိတ္တူ

နိုင်ငံတော်သမ္မတရုံး

ဒုတိယသမ္မတ(၁)ဦးစီးရုံး

ဒုတိယသမ္မတ(၂)ဦးစီးရုံး

သမ္မတရုံးဝန်ကြီးဌာန(၃)

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

ရုံးလက်ခံ

မျှောစာတွဲ

သို့
ဥက္ကဋ္ဌ
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

အကြောင်းအရာ ။ ။ Andaman Alliance Healthcare Limited ၏ နိုင်ငံတကာ အဆင့်မှီ ကဏ္ဍစုံ အထူးကု ပုဂ္ဂလိက ဆေးရုံလုပ်ငန်းဆောင်ရွက် ရန် ရင်းနှီးမြှုပ်နှံမှုခွင့်ပြုမိန့် လျှောက်ထားခြင်းနှင့် စပ်လျဉ်း၍ ရင်းနှီးမြှုပ်နှံမှု ခွင့်ပြုမိန့် (ယာယီ) ထုတ်ပေးပါရန် လျှောက်ထားခြင်း။

ရည်ညွှန်းချက် ။ ။ Andaman Alliance Healthcare Limited ၏နိုင်ငံတကာ အဆင့်မှီ ကဏ္ဍစုံ အထူးကု ပုဂ္ဂလိက ဆေးရုံလုပ်ငန်းကို နိုင်ငံခြားရင်းနှီးမြှုပ်နှံမှုဥပဒေအရ ဆောင်ရွက်ရန် အဆို ပြုလွှာ။

Andaman Alliance Healthcare Limited အမည်ဖြင့် ကျန်းမာရေးဝန်ကြီးဌာနပိုင် ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက် အမှတ် ၂၀ F၊ မြေကွက်အမှတ် ၁၀ ရှိ မြေ (၅) ဧကကို တည်ဆောက်၊ လုပ်ငန်းလုပ်ကိုင်၊ လွှဲပြောင်းစံနစ်ဖြင့် (၅၀+၁၀+၁၀) ငှါးရမ်းကာ နိုင်ငံတကာ အဆင့်မှီ ကဏ္ဍစုံ အထူးကု ပုဂ္ဂလိက ဆေးရုံလုပ်ငန်းဆောင်ရွက်ရန် ကျန်းမာရေးဝန်ကြီးဌာနမှတစ်ဆင့် အဆိုပြုတင်ပြလျှောက်ရှိပါသည်။

၎င်းလုပ်ငန်းအတွက် ပထမအဆင့်တွင် ကုတင် ၁၀၀ နှင့် စတုတ္ထနှစ် မြောက်တွင် စတင်မည့် ဒုတိယ အဆင့် တွင် ကုတင် ၂၀၀ ဖြင့် နိုင်ငံတကာ အဆင့်မှီ ကဏ္ဍစုံ အထူးကု ပုဂ္ဂလိက ဆေးရုံလုပ်ငန်း ဝန်ဆောင် မှုဆောင်ရွက်သွားနိုင်ရန် အတွက် စုစုပေါင်း အမေရိကန် ဒေါ်လာ ၁၅ သန်းခန့်ကို အောက်ပါရင်းနှီးမြှုပ်နှံမှု အချိုးအတိုင်း ဆောင်ရွက်သွားမည်ဖြစ်ပါသည်။

(a) Parkway Healthcare Indo-China Pte. Ltd.	Singapore Company	52.0%
(b) Macondray Holdings Pte. Ltd.	Singapore Company	10.5%
(c) AMMK Medicare Company Limited	100% Myanmar Company	21.5%
(d) Global Star Company Limited	100% Myanmar Company	16.0%

နိုင်ငံတွင်း အထူးလိုအပ်လျှက်ရှိသော နိုင်ငံတကာ အဆင့်မှီကျန်းမာရေးဝန်ဆောင်မှု လုပ်ငန်းပေးနိုင်ရန် အတွက် ခြင်ဆင်၊ တည်ဆောက်မှု လုပ်ငန်းများ အမြန်ဆုံးဆောင်ရွက်နိုင်ရန်အတွက် ရင်းနှီးမြှုပ်နှံမှု ခွင့်ပြုမိန့် (ယာယီ) ထုတ်ပေးပါရန် လျှောက်ထားအပ်ပါသည်။

Parkway
YANGON

 မြေငှားရမ်းခြင်းကိစ္စ အတွက် မူလညှိနှိုင်းခဲ့စဉ် က မြန်မာနိုင်ငံသား ရင်းနှီးမြှုပ်နှံသူ ဘက်မှ AMMK Medicare Company Limited နှင့် နိုင်ငံခြားရင်းနှီးမြှုပ်နှံသူဘက် မှ စင်္ကာပူ အခြေစိုက် Parkway လုပ်ငန်းစုတို့ ပါဝင်မည့် လုပ်ငန်းစုအဖြစ် လုပ်ငန်းစုအမည် AMK Consortium and Parkway Pantai Limited အမည်ဖြင့် ညှိနှိုင်းဆောင်ရွက်ခဲ့ပါသည်။ ယခုအခါ ဤလုပ်ငန်း အကောင်အထည်ဖော်ဆောင်ရွက်ရန် ဖွဲ့စည်းမည့် ဖက်စပ်ကုမ္ပဏီအမည်ကို Andaman Alliance Healthcare Limited အဖြစ်သတ်မှတ်ရွေးချယ်ခဲ့ပြီး ရင်းနှီးမြှုပ်နှံမှု နှင့် ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာနတွင် အမည်စစ် ဆောင်ရွက်ပြီးဖြစ်ပြီး ဖြစ်ပါသဖြင့် ခွင့်ပြုမိန့်နှင့် ခွင့်ပြုမိန့် (ယာယီ) တို့အား Andaman Alliance Healthcare Limited အမည်ဖြင့် လျှောက်ထားအပ်ပါသည်။

လေးစားစွာဖြင့်

Liaw Yit Ming
Promoter

သို့

ကျန်းမာရေးဝန်ကြီးဌာန

ရုံးအမှတ် (၄၇) နေပြည်တော်

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်။

ရက်စွဲ။ ။ ၂၀၁၅ စက်တင်ဘာ (၂၄)ရက်။

ရှိသေလေးစားစွာတင်ပြအပ်ပါသည်။

၁။ ၂၀၁၅ခုနှစ် ဩဂုတ်လ(၁၀)ရက် ရက်စွဲဖြင့် ကျွန်တော်များပေးပို့သော မြေငှားရမ်းခွင့်တောင်းခံခြင်းစာအား လက်ခံပေးသည့်အတွက် အထူးပင်ကျေးဇူးတင်ရှိပါသည်။ AMK Consortium and Parkway Pantai Limited ပူးပေါင်းသည့် ဖက်စပ်လုပ်ငန်းအနေဖြင့် အဆိုပါ မြေငှားရမ်းခြင်းနှင့် စပ်လျဉ်း၍ အသေးစိတ် အချက်အလက်များကို တင်ပြပြီး ညှိနှိုင်းဆွေးနွေးမှုများကို ဆက်လက်ဆောင်ရွက်လိုပါသည်။

<u>ရန်ကုန်မြို့တွင်တည်ဆောက်မည့်ဆေးရုံအတွက် အကျဉ်းချုပ်တင်ပြချက်</u>

၂။ ကျွန်တော်များ ဖက်စပ်ကုမ္ပဏီသည် ရန်ကုန်မြို့လယ်တွင် နိုင်ငံတကာအဆင့်မှီ ဆေးရုံတစ်ရုံ တည်ဆောက်သွားရန် မျှော်မှန်းထားရှိပါသည်။ အဆိုပါဆေးရုံသည် ကုတင် ၂၅၀ ဆန့်ဆေးရုံဖြစ်ပြီး အဆင့်လိုက် တည်ဆောက်လည်ပတ်သွားမည်ဖြစ်ပါသည်။ ပထမအဆင့်တွင် ကုတင် ၁၀၀ အထိ လည်ပတ်နိုင်ရန် ဆောက်လုပ်သွားမည်ဖြစ်ပြီး နောက်အဆင့်များကို ပထမအဆင့် စကင်လည်ပက်ပြီးသည်နှင့် တစ်ပြိုက်နက်ဆက်လက်ဆောင်ရွက်သွားမည်ဖြစ်ပါသည်။

<u>ဆေးရုံ၏ ဝန်ဆောင်မှုများ</u>

၃။ တည်ဆောက်ပြီးစီးသွားသောဆေးရုံတွင် အရေးပေါ်ဌာန ၊ အထူးကြပ်မတ် ကုသဆောင် (ICU, HDU, NICU, Anaesthetic), ခွဲစိတ်မှန်ဌာန၊ ကျန်းမာရေးဆေးစစ်ဌာန၊ ပြန်လည်ထူထောင်ရေးဌာန နှင့် အောက်ဖော်ပြပါ အထူးကု ပြင်ပလူနာဌာနများ ပါရှိမည်ဖြစ်ပါသည်။

(က) အထွေထွေ ခွဲစိတ်ကုသရေး အထူးကု

(ခ) မီးယပ်နှင့်သားဖွား အထူးကု

(ဂ) ကင်ဆာ အထူးကု

(ဃ)နှလုံးရောဂါ အထူးကု

(င) အရိုးအကြောရောဂါ အထူးကု

(စ) ဆေးပညာဌာန

(ဆ)နားနှင့်လည်ချောင်းအထူးကု

(ဇ) ကလေးရောဂါ အထူးကု

၄။ ကင်ဆာရောဂါ၊ နှလုံးရောဂါ၊ အာရုံကြောရောဂါ နှင့် အရိုးအကြောရောဂါစသည့် ရှုပ်ထွေးသော ရောဂါများကို ကောင်းမွန်စွာ ကြပ်မတ်ကုသနိုင်ရန်အတွက် အထူးကုဌာနများကို ထည့်သွင်းထား ရှိသွားမည်ဖြစ်ပါသည်။

၅။ ကျွန်တော်များ၏ ဆေးရုံသည် ပြည်တွင်းသာမက နိုင်ငံတကာ အဆင့်အတန်းသတ်မှတ်ချက်များနှင့် ကိုက်ညီသည့် စံချိန်စံညွှန်းများအတိုင်း လိုက်နာကျင့်သုံးသွားမည်ဖြစ်သည့်အပြင် ခိုင်မာတိကျသော ဆေးပညာ အကြံပေး ဘုတ်အဖွဲ့ မှလည်း ပံ့ပိုးပေးသွားမည်ဖြစ်ပါသည်။

ဆေးရုံ၏ ရည်ရွယ်ချက်

၆။ ကျွန်တော်များ ဖက်စပ်ကုမ္ပဏီသည် မြန်မာနိုင်ငံအတွင်း တည်တံ့ခိုင်မြဲသော ကျန်းမာရေး ဝန်ဆောင်မှု လုပ်ငန်းကို အထောက်အကူဖြစ်စေရန် ရည်ရွယ်၍ ကမ္ဘာ့အဆင့်မှီ ဆေးရုံတည်ဆောက်ကာ ရေရှည် လုပ်ကိုင်ဆောင်ရွက်သွားရန် ရည်ရွယ်ပါသည်။

၇။ မြန်မာနိုင်ငံတွင် အဆင့်အတန်းမြင့်မားသော ကျန်းမာရေး ဝန်ဆောင်မှု အားနည်းခြင်းကြောင့် မြန်မာနိုင်ငံသားများအနေဖြင့် နိုင်ငံခြားသို့ သွားရောက်ဆေးကုသခံယူမှုများ နှစ်စဉ်ပိုမိုများပြားလာခဲ့ပါသည်။ ကျွန်တော်များ တည်ဆောက်မည့်ဆေးရုံသည် မြန်မာနိုင်ငံ၏ ကျန်းမာရေး ဝန်ဆောင်မှု လိုအပ်ချက်များကို ဖြည့်ဆည်းပေးနိုင်မည့်အပြင် ပြည်ပသို့ သွားရောက်ဆေးကုသမှု ခံယူနေသည့် လူနာများ၏ လိုအပ်ချက် များကိုပြည်တွင်းတွင် နိုင်ငံတကာအဆင့်မှီ ဖြည့်ဆည်းပေးနိုင်မည်ဖြစ်ပါသည်။

၈။ နိုင်ငံတကာ စံချိန်စံညွှန်းများကို လိုက်နာကျင့်သုံးခြင်းဖြင့် ဆေးရုံဆေးခန်းအရည်အသွေး နှင့်လူနာ စောင့်ရှောက်မှု ဝန်ဆောင်မှုများကို အဆင့်မြှင့်တင်သွားမည်ဖြစ်ပါသည်။ ကျွန်တော်များဆေးရုံအနေဖြင့် ပြည်ပမှ ဆေးကုသမှုခံယူလိုသူများကိုပါ ဆွဲဆောင်ပြီး အင်ဒိုချိုင်းနားတွင် Health Care hub တစ်ခုအဖြစ် ဖွံ့ဖြိုးလာသည်အထိ ရည်မှန်းချက်ထားရှိ ဆောင်ရွက်သွားမည်ဖြစ်ပါသည်။

၉။ ရန်ကုန်နှင့် အခြားဒေသများမှ လူထု၏ လိုအပ်ချက်များကို နားလည်ပြီး ပိုမိုကောင်းမွန်သော ဝန်ဆောင်မှုများကို ပေးနိုင်ရန်အတွက် ပြည်တွင်းအဖွဲ့အစည်းများနှင့် လက်တွဲဆောင်ရွက်သွားရန် လိုအပ် သည်ကို နားလည်သိရှိထားပါသည်။ ကျွန်တော်တို့ဆေးရုံသည် ပြည်တွင်းမှ ဝန်ထမ်းများကို ခန့်ထား၍ သင်တန်းများပို့ချပေးကာ ကျွန်တော်များ၏ ပတ်သက်ဆက်နွယ်နေသော အခြားနိုင်ငံများမှ ဆေးပညာ ဗဟုသုတများကို ရရှိနိုင်ရန် ဆောင်ရွက်ပေးသွားမည် ဖြစ်ပါသည်။ ပြည်သူလူထု၏ လိုအပ်ချက်ကို နားလည်ပြီး ကောင်းမွန်စွာ ဖြည့်ဆည်းပေးရန်မှာ အချိန်ကြာမြင့်နိုင်သည်ကို ကျွန်တော်တို့နားလည်၍ အစဉ်တစိုက် ကြိုးပမ်းဆောင်ရွက်သွားမည်ဟု ရည်မှန်းထားရှိပါသည်။

ဝန်ထမ်းများခန့်ထားခြင်းနှင့်သင်တန်းပို့ချခြင်းများ

၁၀။ ဆေးရုံ၏ ပထမအဆင့်တွင် သူနာပြု၊ ဆေးဘက်ဆိုင်ရာ ပညာရှင်များ၊ အခြားဝန်ထမ်းများ စသဖြင့် ဝန်ထမ်း (၄၀၀)ခန့် ခန့်အပ်ထားမည်ဖြစ်ပြီး ဆေးရုံကို ကုတင် (၂၅၀)အထိ တိုးမြှင့် တည်ဆောက်ပြီးသည့်အချိန်တွင် ဝန်ထမ်းများ ပိုမိုခန့်ထားနိုင်ရန် ရည်ရွယ်ပါသည်။ ဝန်ထမ်းလိုအပ်ချက် ၏ ၈၅% ကျော်ကို ပြည်တွင်းမှ ဝန်ထမ်းများဖြင့် ဖြည့်ဆည်းသွားမည်ဖြစ်ပါသည်။ ပြည်တွင်းဝန်ထမ်းဖြင့် လုံလောက်မှု မရှိမှသာ ပြည်ပမှ သူနာပြုများ၊ ဆေးဘက်ပညာရှင်များ၊ ဓါတ်မှန်ပညာရှင်များနှင့် ကျန်းမာရေး အတတ်ပညာရှင်များကို ငှားရမ်းသွားမည် ဖြစ်ပါသည်။ အဆင့်အတန်းမြင့်မားသောကျန်းမာရေး ဝန်ဆောင်မှုများကို ပေးနိုင်ရန်အတွက် ရံဖန်ရံခါ ပြည်ပမှ အထူးကုဆရာဝန်ကြီးများ လာရောက်ဆေးကုသမှုပြုပေးမည် ဖြစ်ပါသည်။

၁၁။ ကျွန်တော်တို့၏ ဝန်ထမ်းများကို နိုင်ငံတကာ၏ အကောင်းဆုံး စံချိန်စံညွှန်းများနှင့်အညီ သင်တန်းများ ပို့ချပေးသွားမည်ဖြစ်ပါသည်။ (ဥပမာ-JCI) စင်ကာပူနိုင်ငံနှင့် မလေးရှားနိုင်ငံရှိ Parkway Panti ဆေးရုံများမှာ အတွေ့အကြုံရှိ သူနာပြုဆရာမကြီးများနှင့် ဆရာဝန်ကြီးများ ကိုယ်တိုင် မြန်မာနိုင်ငံသို့ လာရောက်၍ သင်တန်းများပို့ချပေးမည်ဖြစ်သကဲ့သို့ မြန်မာနိုင်ငံမှ ဝန်ထမ်းများကိုလည်း အဆိုပါနိုင်ငံများသို့ စေလွှတ်၍ ပညာသင်ကြားစေမည် ဖြစ်ပါသည်။

၁၂။ ထို့အပြင် ကျွန်တော်တို့၏ ကျယ်ပြန့်သော ကွန်ယက်အတွင်းရှိ အသိအမှတ်ပြု အထူးကု ဆရာဝန်ကြီးများထံမှလည်းဗဟုသုတ ပညာများ မျှဝေလက်ဆင့်ကမ်းပေးမည် ဖြစ်ပါသည်။

မြေငှားစာချုပ်ပါ အဓိက အချက်များ

၁၃။ ကျွန်တော်ဖက်စပ်လုပ်ငန်းသည် မြန်မာနိုင်ငံတွင် ကျန်းမာရေးဝန်ဆောင်မှုလုပ်ငန်းကို အစဉ်တစိုက် အားထုတ်ဆောင်ရွက်လိုပါသောကြောင့် ရန်ကုန်မြို့တွင် ဆေးရုံတစ်ရုံဆောက်လုပ်နိုင်ရန် မြေငှားရမ်းခွင့် ပြုပါရန်အနူးအညွတ်မေတ္တာရပ်ခံ တင်ပြအပ်ပါသည်။ ကျွန်တော်များ ပြင်ဆင်ထားသော အောက်ဖော်ပြပါ အချက်အလက်များပါဝင်သည့် မြေငှားစာချုပ်ကို လေ့လာပြီး အကြံပေးနိုင်ရန် တင်ပြအပ်ပါသည်။

(က) လိပ်စာ	မြေတိုင်းရပ်ကွက်အမှတ် ၂၀/F မြေကွက်အမှတ်(၁၀) လမ်းမတော်မြို့နယ်
(ခ) မြေအတိုင်းအတာ	(၅)ဧကခန့်
(ဂ) ငှားရမ်းလိုသည့်ကာလ	ကနဦးနှစ်(၅၀)နှင့် တဆက်တည်းသက်တမ်းတိုးခွင့်(၁၀)နှစ် (၂)ကြိမ်
(ဃ) မြေငှားရမ်းခ ပရီမီယံ	တစ်ဧကလျှင် အမေရိကန်ဒေါ်လာ(၁.၅)သန်း၊ ငွေပေးချေမှုမှာ MIC ခွင့်ပြုမိန့်ရရှိပြီး မြေငှားရမ်းစာချုပ်ချုပ်ဆိုချိန်တွင် (၂၅%)။ တည်ဆောက်မှုကာလပြီးဆုံးပြီး(၃)နှစ်ကြာတွင် (၂၅%)နှင့် တည်ဆောက်မှုကာလ ပြီးဆုံးပြီး(၆)နှစ်အကြာတွင် (၅၀%)
(င) နှစ်စဉ်မြေငှားရမ်းခ	တည်ဆောက်မှုပြီးစီးချိန်တွင် မြေငှားရမ်းခကို စတင်မည်ဖြစ်ပြီး ငှားရမ်းခမှာ တစ်စတုရန်းမီတာလျှင် အမေရိကန်ဒေါ်လာ (၁၈) ဖြစ်ပါသည်။ ၁၀ နှစ် တစ်ကြိမ် မြေငှားရမ်းခကို ပြန်လည်သုံးသပ်၍ နောက်ဆုံး ငှားရမ်းခ၏ အမြင့်ဆုံး (၁၀%)အထိ တိုးမြှင့်ရန်။

ပူးတွဲပါ ဆေးရုံဆောက်လုပ်ရေး စီမံကိန်းဗိသုကာပုံကို လေ့လာနိုင်ရန် တင်ပြအပ်ပါသည်။

၁၄။ အထက်ပါ အချက်အလက်များအပြင် မြေငှားစာချုပ်ပါ အသေးစိတ်အချက်အလက်များကိုပါ ထည့် သွင်းစဉ်းစားပေးပါရန် မေတ္တာရပ်ခံအပ်ပါသည်။ သဘောတူညီမှု ရရှိခဲ့ပါက မြေငှားစာချုပ်ကို ဆက်လက် ပေးပို့ပေးမည် ဖြစ်ပါသည်။ မေးခွန်းများ နှင့် အခြားလိုအပ်သော အချက်အလက်သိရှိလိုပါက အောက်ဖော်ပြပါ လိပ်စာရှင်များသို့ ဆက်သွယ်မေးမြန်းနိုင်ပါသည်။

AMK Consortium

ဆက်သွယ်ရန်	ဦးအောင်မိုးကျော်
တယ်လီဖုန်း	၀၉ ၈၆၂၂၉၇၁
လိပ်စာ	အမှတ်(၃၃)၊ ဓမ္မိုင်ခွဲ၊ ပြည်လမ်း၊ (၁၁)ရပ်ကွက်၊လှိုင်မြို့နယ်၊ရန်ကုန်။
Email	royalaungmoekyaw@gmail.com

Parkway Panti Limited

Contact Person	Mr Liaw Yit Ming
Telephone	+6597565369
Address	111 Somerset Road#15-01, Singapore 238164
Email	llaw.yitming@ihhhealthcare.com

လေးစားစွာဖြင့်

AMK Consortium	Parkway Panti Limited
(လက်မှတ်)	(လက်မှတ်)
ဦးအောင်မိုးကျော်	Dr Tan See Leng
AMK Consortium ကိုယ်စား	Group CEO and Managing Director

INDEX

- Application for investment permit, exemption and relief
- Form I
- Annex A List of Shareholders and Directors
- Annex B Profile of Parkway
- Annex C Projection statement
- Annex D Draft BOT Agreement
    - Comment from Attorney General Office
    - Draft BOT Agreement amended in accordance with comment from Attorney General Office
    - Drawing of the building (Floor plan, car parking plan)
    - Layout of the utilization of land
- Annex E Draft Joint Venture Agreement
- `Annex F IEE & Environmental Management Plan
- Annex G Fire Protection
- Annex H Electricity, Water Requirement
- Annex I Labor Welfare Plan
- Annex J CSR Plan
- Annex K References for business and financial standing
- Annex L Draft MOA & MOA of the "**Andaman Alliance Healthcare Ltd**."

Parkway YANGON

- **Application for investment permit, exemption and relief**

Parkway
YANGON

Chairman
Myanmar Investment Commission
Yangon

Date: 19 October 2015
Letter No:

Subject: Application for an investment permit from the Myanmar Investment Commission for the construction, development, management and operation of a multi-specialty hospital of international standard in Yangon City.

The Parkway Group would like to submit their application to the Myanmar Investment Commission ("**MIC**") for approval and an investment permit ("**MIC Permit**") for the construction, development, management and operation of a multi-specialty hospital of international standard in Yangon City

The Parkway Group is a leading international provider of premium healthcare services in various markets with strong and rapidly growing demand for quality healthcare services. The holding company of the Parkway Group, IHH Healthcare Berhad, is a public company listed on the main market of Bursa Malaysia Securities Berhad (Bursa Securities) as well as on the main board of the Singapore Exchange Securities Trading Limited (SGX-ST). IHH Healthcare Berhad is the world's second largest listed private healthcare provider, based on market capitalisation and operations & investments in:

- **Home markets**: Singapore, Malaysia and Turkey
- **Key markets**: China (PRC), Hong Kong and India
- **Other markets**: Brunei, Vietnam, United Arab Emirates, Macedonia, and Iraq

The Parkway Group owns and operates a global network of hospitals with over 7,000 licensed beds in 40 hospitals, as well as medical centres, clinics, ancillary healthcare businesses and medical education facilities. We have more than 25,000 employees worldwide. By 2017, the Parkway Group is expected to have an additional 3,000 beds, at least, in 19 hospitals which would either be new developments or an expansion of existing facilities.

The Parkway Group has decided to extend its presence into Myanmar as part of its expansion plan. It is also keen to facilitate the development of the healthcare services industry in Myanmar. As such, the Parkway Group would like to apply for an MIC Permit to construct, develop, manage and operate a multi-specialty hospital of international standard. Such investment would be made by way of a joint venture with AMK Consortium, and the incorporation of a joint venture company by the name of "**Andaman Alliance Healthcare Limited**" ("**JV Company**").

The total investment amount is expected to be approximately US$ 87 million inclusive of approximately US$ 17 million out of cash flow, after 2-5 years of operations, for the purchase of equipment and furniture for the second phase of the project. In addition to the total investment amount, and subject to the approval of the MIC, we further intend to reinvest about US$ 2 million annually out of the profits for the maintenance of the project.

Hospital Objectives

The JV Company will be committed to establishing a long term presence in Myanmar and developing a world-class hospital to contribute to building a robust healthcare industry in Myanmar. Myanmar is faced with a growing need for healthcare services and an increasing demand for quality healthcare. Due to the lack of high quality healthcare in Myanmar today, hundreds of thousands of Myanmar patients seek medical treatment overseas on an annual basis. Our proposed hospital will be of international standards and will help to meet this demand and enable patients who currently seek medical treatment overseas to receive the same level of medical care locally.

We aim to elevate the standards of the healthcare industry by adopting international benchmarks for patient service and clinic quality. The hospital will draw patients from all over Myanmar, and we hope to become a healthcare hub in Indochina.

We recognize that we must work closely together with the community in order to understand the local needs and to better serve the population in Yangon and, subsequently, the rest of Myanmar. The hospital's stakeholders will therefore include our staff. We believe in hiring and training local staff and ensuring that there is adequate knowledge transfer from within our network. Understanding and serving the community well will take time and the JV Company is prepared to commit resources toward developing a long term relationship with the Myanmar community.

Hospital Services

The hospital will have an emergency department, an acute care services department (including ICU, HDU, NICU, Anaesthetic etc), diagnostic imaging services department, health screening department, rehabilitation department, and an extensive range of outpatient specialty clinics, including -

- General Medicine and Surgery
- Obstetrics and Gynaecology
- Oncology
- Cardiology
- Orthopaedic
- Internal Medicine
- Otolaryngology
- Paediatrics

Specialised centres of excellence will be established to enhance the clinical practice for complex diseases, for example in Oncology, Cardiology, Neuroscience, or Orthopaedics.

Salient facts about the proposed project are as follows:

1. <u>Shareholders</u>

	Name	Nationality	Stake
(a)	**Parkway Healthcare Indo-China Pte. Ltd.**	Singapore Company	52.0%
(b)	**Macondray Holdings Pte. Ltd.**	Singapore Company	10.5%
(c)	**AMMK Medicare Company Limited**	100% Myanmar Company	21.5%
(d)	**Global Star Company Limited**	100% Myanmar Company	16.0%

2. <u>Features of the project</u>

Land	
Location	Plot No. 10^{B}, Block No. 20^{F}, Lanmadaw Township, Corner of Pyay Road and Bogyoke Aung San Road
Area	4.3 Acres
Lessor	Ministry of Health
Lease term	50 + 10 + 10 years
Land use premium	US$ 2 Million/ acre
Annual rent	US$ 18/m2/Year
Building	
Number of Floors	**8 storey [excluding ground floor and basement]**
Number of beds	100 beds in the 1st year and 250 bed by the 4th year
Number of Car parking lots	**167 Nos**

3. <u>Technical information</u>

Range of services

The project will commence with 100 beds in the first year of operations. The number of beds is expected to increase to 250 beds by the 4th year of operations. The hospital will provide the comprehensive range of services that other hospitals of the Parkway Group currently render, and at an international standard.

We will maintain our position as a global leader in value-based integrated healthcare services and will pursue excellence in our comprehensive clinical programmes and facilities. We will strive to exceed patients' expectations in all aspects of services rendered.

Our hospital will be supported by a rigorous Medical Advisory Board, to ensure that the standards, processes and practices implemented are aligned with internationally recognised standards.

Human Resources

To meet our objectives, we intend to employ local doctors and nurses to the extent possible. We expect that the number of foreign doctors/ nurses employed will be less than 15% of the total staff count.

Electricity/ Water consumption

While it is anticipated that the hospital will rely on the national grid for its regular electricity supply, the hospital will be equipped with a standby generator.

As for the water supply, it is intended that the hospital will require approximately 212k cubic meters/year. The hospital will rely upon the supply from the Yangon City Development Committee.

Fire protection/ EMP

Fire protection, waste water treatment and solid waste management are a fundamental aspect of our architectural design, which has been tried and tested within hospitals in our networks. Our designs meet the building code standards in all jurisdictions, and we will apply the same standard for our hospital in Yangon, the details of which are set out in Annex G.

Tax benefit to State

The State is expected to receive the following tax benefits;

Income tax (6^{th} year):	US$ 2.3 million
Income tax (10^{th} year):	US$ 4.1 million

Please refer to Annex C for more details.

Other benefits

In addition, the project is expected to bring other benefits including not limited to the following:

- Improving the healthcare standard in Myanmar generally
- Training local healthcare professionals and administrative staff to attain an international standard
- Educating the community on healthcare to prevent disease and injury, and improve health
- Technology and management skills transfer

Our Application

Following documents are attached in support of our application:-

- Application for investment permit
- Application for exemption and relief
- Form I
- Annex A List of Shareholders and Directors
- Annex B Profile of Parkway
- Annex C Projection statement
- Annex D Draft BOT Agreement
  - Comment from Attorney General Office
  - Draft BOT Agreement amended in accordance with comment from Attorney General Office
  - Drawing of the building (Floor plan, car parking plan)
  - Layout of the utilization of land
- Annex E Joint Venture Agreement
- Annex F IEE & Environmental Management Plan
- Annex G Fire Protection
- Annex H Electricity, Water Requirement
- Annex I Labor Welfare Plan
- Annex J CSR Plan
- Annex K References for business and financial standing
- Annex L Draft MOA & MOA of "Andaman Alliance Healthcare Ltd."

Together with our application for the MIC Permit, we are applying for the tax exemptions and relief as specified in Section 27 of the Union of Myanmar Foreign Investment Law as set out below:

a) income tax exemption for a period of five consecutive years including the year of commencement on commercial scale and in case where it is beneficial to the Union, income tax exemption or relief for suitable period depending upon the success of the business;

b) exemptions or reliefs from income tax on profits of the business if they are maintained for re-investment in a reserve fund and re-invested therein within 1 year after the reserve is made;

c) right to deduct depreciation from the profit, after computing as the rate of deducting depreciation stipulated by the Union, in respect of machinery, equipment, building or other capital assets used in the business for the purpose of income tax assessment;

d) right to pay income tax on the income of foreigners at the rates applicable to the citizens residing within the Union;

e) right to deduct expenses from the assessable income, such expenses incurred in respect of research and development relating to the business which are actually required and are carried out within the Union;

f) right to carry forward and set-off the loss up to 3 consecutive years from the year the loss is actually sustained within 2 years following the enjoyment of exemption or relief from income tax as contained in sub-section(a), for each business;

g) exemption or relief from custom duty or other internal taxes or both on machinery, equipment, instruments, machinery components, spare parts and materials used in the business, which are imported as they are actually required for use during the period of construction of business;

h) exemption or relief from customs duty or other internal taxes or both on raw materials imported for production for the first three-years after the completion of the construction of the business;

i) if the volume of investment is increased with the approval of the Commission and the original investment business is expanded during the permitted period, exemption or relief from custom duty or the internal taxes or both on machinery, equipment, instruments, machinery components, spare parts and materials used in the business which are imported as they are actually required for use in the business expanded as such;

We hope our application will be received favorably by the Commission. We look forward to hearing back from you.

Faithfully yours,

Liaw Yit Ming
Promoter

- **Form I**

Parkway
YANGON

Form (I)

PROPOSAL OF THE PROMOTER TO MAKE FOREIGN INVESTMENT IN THE UNION OF MYANMAR

To

Chairman,

Myanmar Investment Commission,

Reference No.

Date 19 October 2015

I wish to make investment in the Union of Myanmar in accordance with the Union of Myanmar Foreign Investment Law, and I herewith apply for permission furnishing the following particulars-

1. Promoter's Particular:

(a)	Name	Liaw Yit Ming
(b)	Father's name	Liaw Kim Tin
(c)	ID No./ National registration Card No./ Passport No.	PP No. 810304085969
(d)	Citizenship	Malaysian
(e)	Address	
	(i) Address in Myanmar	N/A
	(ii) Residence abroad	6 Keng Chin Road, #05-05 Cyan, Singapore 258709
(f)	Name of principal organization	Parkway Healthcare Indo-China Pte. Ltd.
(g)	Type of business	Healthcare service industry
(h)	Principal company's address	111 Somerset Road #15-01 Tripleone Somerset Singapore 238164

2. If investment is to be made by joint-venture, the particulars of the persons wishing to participate in the Joint-Venture with the promoter

- Partner 1

(a)	Name	Mr. Ng How Kiat Charlie
(b)	Father's name	Mr. Ng KeeChiew

(c)	ID No./ National registration Card No./ Passport No.	PP No. E3133254L
(d)	Citizenship	Singapore
(e)	Address	
	(i) Address in Myanmar	N/A
	(ii) Residence abroad	25 Moonstone Lane #19-03 Singapore 328465
(f)	Name of principal organization	Macondray Holdings Pte. Ltd.
(g)	Type of business	Investment Holdings
(h)	Principal company's address	78 Shenton Way #28-01 Singapore 079120

- Partner 2

(a)	Name	U Aung Moe Kyaw
(b)	Father's name	U HlaMyint
(c)	ID No./ National registration Card No./ Passport No.	12/MaYaKa (Naing) 016937
(d)	Citizenship	Myanmar
(e)	Address	
	(i) Address in Myanmar	No. 18, Aung Mingalar Lane, Aung Theikdi Street, (3) ward, Mayangone Township, Yangon.
	(ii) Residence abroad	N/A
(f)	Name of principal organization	AMMK Medicare Company Limited
(g)	Type of business	All kinds of activities permitted to a Myanmar company
(h)	Principal company's address	No. 33, Pyay Road, 6 ½ Miles, Hlaing Township, Yangon.

- Partner 3

(a)	Name	U Thurane Aung @ Christopher Aung
(b)	Father's name	U Win Aung
(c)	ID No./ National registration Card No./ Passport No.	12/ KaMaYa (Naing) 050839
(d)	Citizenship	Myanmar
(e)	Address	
	(i) Address in Myanmar	105, University Avenue Road, (10) Ward, Kamayut Township, Yangon.
	(ii) Residence abroad	N/A
(f)	Name of principal organization	Global Star Company Limited

(g)	Type of business	Property Development & Construction, Logistics and Transport, Commodity Trading, Retail and Distribution, Sea port and storage, Automobiles, Agriculture, Timber & wood based products, Ready mixed concrete and Cement
(h)	Principal company's address	N0. (2) Ba Yint Naung Road, Ywar Mha Gwe (2) Ward, Hlaing Township, Yangon.

Remark: The following documents need to attach according to above paragraph (1) and (2).

(1) Company Registration Certificate (Copy);
(2) National Registration Card (Copy) and Passport (Copy);
(3) Evidence about the business and financial conditions of the participant of the participants of the proposed investment business.

3. Type of business in which investment is to be made-

(a)	Production	
(b)	Services business related with manufacturing	
(c)	Services	**Private Hospital**
(d)	Others	

Remark: Expression about the nature of business with regard to the above paragraph (3).

4. Type of business organization to be formed-

(a) One hundred Percent

(b) Joint venture

(i) Foreigner and Citizen: **"Andaman Alliance Healthcare Limited"**

Parkway Healthcare Indo-China Pte. Ltd. (Singapore)	-	52.0%
Macondray Holdings Pte. Ltd. (Singapore)	-	10.5%
AMMK Medicare Company Limited (Myanmar)	-	21.5%
Global Star Company Limited (Myanmar)	-	16.0%

(ii) Foreigner and Government Department/ Organization:

(c) By contractual basis

(i) Foreigner and Citizen:

(ii) Foreigner and Government Department/ Organization:

Remark: The following information needs to attach for the above paragraph (4):-

(1) ***Share ratio for the authorized capital from abroad and local, names, citizenship, addresses, and occupations of directors;***
(2) ***Joint-Venture Contract (Draft) and recommendation of the Union Attorney General Office if the investment is related with the State.***
(3) ***Contract (Agreement) (draft)***

5. Particulars relating to company incorporation-

(a)	Authorized capital	**US$ 150,000,000**
(b)	Types of shares	**Ordinary shares**
(c)	Number of shares	**150,000,000**

Remark: Memorandum of Association and Articles of Association of the Company shall be submitted with regard to above paragraph 5.

6. Particulars relating to capital of the investment permit-

		Total
(a)	Amount of local capital to be contributed	26,263,706
(b)	Amount of foreign capital to be brought in	43,772,840
(c)	Facilities for expending from 100 to 250 beds out of cash flow	17,066,571
	Total	87,103,117

(d)	Annually or period of proposed capital to be brought in	Within 7years from the date of investment permit
(e)	Last date of capital brought in	31-12-2019
(f)	Proposed duration of investment	Initial 50 years + renewal for another 2 ten years
(g)	Commencement date of construction	As soon as after receiving investment permit and other permits necessary to start construction
(h)	Construction period	4 years

Remark: Describe with annexure if it is required for above Para 6(d).

7. Details of foreign capital to be brought in-

		Equity
(a)	Value of Machineries/ equipment	10,540,690
(b)	Building	25,312,500
(c)	Land use premium	5,536,250
(d)	Furniture and fittings	1,125,000
(e)	Pre-operating	1,252,150
(f)	Others	6,250
	Equity	**43,772,840**
(g)	Facilities for expending from 100 to 250 beds out of cash flow [Machine – U$$ 8,979,107+ Furniture US$ 1,687,500]	**10,666,607**
(h)	Value of rights which can be evaluated, such as license trade mark, patent rights	-
(i)	Value of technical know-how	-
	Total investment	**54,439,447**

Note: Investors will contribute in cash for spending under respective investment headings above.

Remark: The value of permission shall be submitted for the above para (g) and (h).

8. Details of local capital to be contributed --

		Equity
(a)	Value of Machineries/ equipment	6,324,415
(b)	Building	15,187,500
(c)	Land use premium	3,321,750
(d)	Furniture and fittings	675,000
(e)	Pre-operating cost	751,291
(f)	Others	3,750
	Equity	**26,263,706**
(g)	Facilities for expending from 100 to 250 beds out of cash flow [Machine – U$$ 5,387,464+ Furniture US$ 1,012,500]	**6,399,964**
(h)	Value of rights which can be evaluated, such as license trade mark, patent rights	-
(i)	Value of technical know-how	-
	Total	**32,663,670**

Note: Investors will contribute in cash for spending under respective investment headings above.

9. Particulars about the investment business-

(a)	Investment location/ places	Plot No. 10^{B}, Block No. 20^{F}, Corner of Pyay Road and Bogyoke Aung San Road, Lanmadaw Township, Yangon.
(b)	Type and area requirement for land or land and building	
	(i) Location	Plot No. 10^{B}, Block No. 20^{F}, Corner of Pyay Road and Bogyoke Aung San Road, Lanmadaw Township, Yangon.
	(ii) Number of land/ building and area	One vacant plot – 4.3 acres
	(iii) Owner of the land	
	(aa) Name/ Company/ Department	Ministry of Health of the Government of the Union of Myanmar
	(bb) National Registration Card No.	
	(cc) Address	Office No. 4/47, NayPyiTaw
	(iv) Type of land	Ministry owned land
	(v) Period of Grant	Ministry owned land
	(vi) Lease period	50 + 10 + 10 years
	(vii) Lease rate	
	(aa) Land	Rent - US$ 18/m2/year Premium – US$ 2,000,000/acre
	(bb) Building	
	(viii) Ward	N/A
	(ix) Township	Lanmadaw
	(x) State/ region	Yangon region
	(xi) Lessee	
	(aa) Name/ Name of company/Dept	Andaman Alliance Healthcare Limited
	(bb) Father's name	
	(cc) Citizenship	*A company incorporated under the Myanmar Companies Act.*
	(dd) ID No./ Passport No.	*Certificate of Incorporation No. to be advised*
	(ee) Residence address	No. 33, Pyay Road, 6 1/2 miles, (11) Quarter,Hlaing Township, Yangon, Union of Myanmar

Remark : Following particulars have to be enclosed for above Para 9 (b).

(1) to enclose land map, land ownership and ownership evidences;

(2) draft land lease agreement, recommendation from Union Attorney General Office if the land is related to the State

(c)	Requirement of building to be constructed;	
	(i) type/ number, building	Annex C-2
	(ii) area	Annex C-2
(d)	Product to be produced/ Service	

(1) Name of product	
(2) Estimate amount to be produced annually	
(3) Type of service	Healthcare service
(4) Estimate value of service annually	Annex C-9

Remark: Detail list shall be enclosed with regard to the above para 9 (d).

(e)	Annual requirement of material/ raw materials	Annex (C-5) and (C-6)
(f)	Production system	
(g)	Technology	Value-based integrated healthcare services and will pursue excellence in our comprehensive clinical programmes and facilities
(h)	System of sales	Health care services to be rendered to outpatients, inpatients
(i)	Annual fuel requirements (to prescribe type/quantity)	Annex H
(j)	Annual electricity requirement	Annex H
(k)	Annual water requirement (to prescribe daily requirement, if any)	Annex H

10. Detail information about financial standing

(a)	Name/ company name	Parkway Healthcare Indo-China Pte. Ltd.
(b)	ID No./ Registration Card No./ Passport No.	Certificate of Incorporation No - 200723244M
(c)	Bank account number	Deutsche Bank AG (Current Account): 2514347-00-0

Remark: To enclose bank statement from resident country or annual audit report of the principal company with regard to the above para 10.

11. Number of personnel required for the proposed economic activity:-

(a)	Local personnel	**Annex (C-7)**
(b)	Foreign personnel	**Annex (C-7)**

(Engineer, QC, Management, etc. based on the nature of business and required period)

Remark: As per para 11, the following information shall be enclosed:-

(1) Number of personnel, occupation, salary, etc.

(2) Social security and welfare arrangement for personnel

(3) Family accompany with foreign employee

12. Particulars relating to economic justification-

		Foreign Currency	*Estimated Kyat Equivalent*
(a)	Annual income	**Annex (C-9)**	
(b)	Annual expenditure	**Annex (C-11)**	
(c)	Annual net profit	**Annex (C-11)**	
(d)	Yearly investments	**Annex (C-1A&B)**	
(e)	Recoupment period	**Annex (C-12)**	
(f)	Other benefits (to enclose detail calculations)	**Availing international standard healthcare service in the country.** **Training local healthcare workers at international standard hospital**	

13. Evaluation of environmental impact-

(a)	Organization for evaluation of environmental assessment	Parkway Healthcare Indo-China Pte. Ltd.
(b)	Duration for evaluation of environmental assessment	6 months
(c)	Compensation programme for environmental damages	Not applicable
(d)	Water purification system and waste water treatment systems	Attached EMP
(e)	Waste management systems	Attached EMP
(f)	System for storage of chemical	Not applicable

14. Evaluation on social impact assessment-

(a)	Organization for evaluation of social impact assessments;	Parkway Healthcare Indo-China Pte. Ltd.
(b)	Duration of the evaluation for social impact assessments;	6 months

(c)	Corporate social responsibility program	Annex (J)

Signature

Name Liaw Yit Ming

Designation. **Promoter of the Proposal**

- **Annex A   List of Shareholders and Directors**

Parkway
YANGON

Andaman Alliance Healthcare Limited Annex A-1

List of Shareholders

SR	Name of Shareholder	Shareholding Ratio
1	Parkway Healthcare Indo-China Pte. Ltd. Certificate of Incorporation No - 200723244M (Singapore) <u>Represented by</u> Liaw Yit Ming Malaysian Passport: 810304085969	52%
2	AMMK Medicare Company Limited Certificate of Incorporation No - 1397 / 2015 – 2016 (Ya Ka) (Myanmar) No. 18, Aung Mingalar Lane, Aung Theikdi Street, (3) ward, Mayangone Township, Yangon. <u>Represented by</u> U Aung Moe Kyaw Myanmar NRC No: 12/Ma Ya Ka (Naing) 106397	21.5%
3	Global Star Company Limited Certificate of Incorporation No - 1507/2008-2009 (Myanmar) N0. (2) Ba Yint Naung Road, YwarMhaGwe (2) Ward, Hlaing Township, Yangon. <u>Represented by</u> U Thurane Aung @ Christopher Aung Myanmar NRC No: 12/ KaMaYa (Naing) 050839	16%
4	Macondray Holdings Pte. Ltd. Certificate of Incorporation No - 201317874R (Singapore) 78 Shenton Way #28-01 Singapore 079120 <u>Represented by</u> Mr. Ng How Kiat Charlie Singapore PP No: E3133254L	10.5%

Andaman Alliance Healthcare Limited

List of Directors Annex A-2

SR	Name	NRIC or Passport No	Address	Remarks
1	Mr. Tan See Leng	Singapore PP No: E3576314E	16 Siglap Plain, Singapore 456005	Parkway Healthcare Indo-China Pte. Ltd.
2	Ms Tan Hui Ann Sherry	Singapore PP No: E4511856F	28 Leonie Hill, #14-28, Singapore 239227	Parkway Healthcare Indo-China Pte. Ltd.
3	Mr. Lai Kok Peng	Malaysian PP No: A30038099	63 Holland Road, #04-04 Verdure @ Holland Park, Singapore 258887	Parkway Healthcare Indo-China Pte. Ltd.
4	Mr. Liaw Yit Ming	Malaysian PP No: 810304085969	6 Keng Chin Road, #05-05 Cyan, Singapore 258709	Parkway Healthcare Indo-China Pte. Ltd.
5	U Aung Moe Kyaw	Myanmar NRC No: 12/Ma Ka Ya (Naing) 106397	No-18 Aung Mingalar Street, AungTheikdi Road, (3) ward, Mayangone T/S Yangon	AMMK Medicare Company Limited
6	Thurane Aung @ Christopher Aung	Myanmar NRC No: 12/ KaMaYa (Naing) 050839	105, University Avenue Road, (10) Ward, Kamayut Township, Yangon.	Global Star Company Limited
7	Mr. Ng How Kiat Charlie	Singapore PP No: E3133254L	25 Moonstone Lane #19-03 Singapore 328465	Macondray Holdings Pte. Ltd.

3

Pemerhatian/Observation

30038099

3

Tandatangan Pembawa/Signature of Bearer

MALAYSIA

Pasport / Passport

Jenis / Type
P

Kod Negara / Country Code
MYS

No. Pasport / Passport No.
A30038099



1979686

Nama / Name
LAI KOK PENG

Warganegara / Nationality
MALAYSIA

No. Pengenalan / Identity No.
681009075073

Tarikh Lahir / Date of Birth
09 OCT 1968

Tempat Lahir / Place of Birth
PULAU PINANG

Jantina / Sex
L-M

Tinggi / Height
174 cm

Tarikh Dikeluarkan / Date of Issue
06 MAY 2013

Tarikh Tamat / Date of Expiry
06 NOV 2018

Pejabat Pengeluar / Issuing Office
UTC SENTUL



P<MYSLAI<KOK<PENG<<<<<<<<<<<<<<<<<<<<<<<<<<<<<

A300380992MYS6810096M1811065681009075073<<66

3

Pemerhatian/Observation

32825840

Tandatangan Pembawa/Signature of Bearer

MALAYSIA

Pasport / Passport	Jenis / Type	Kod Negara / Country Code	No. Pasport / Passport No.
	P	MYS	A32825840



Nama / Name
LIAW YIT MING

Warganegara / Nationality
MALAYSIA

No. Pengenalan / Identity No.
810304085969

Tarikh Lahir / Date of Birth
04 MAR 1981

Tempat Lahir / Place of Birth
PERAK

Jantina / Sex
L-M

Tinggi / Height
174 cm

Tarikh Dikeluarkan / Date of Issue
30 MAY 2014

Tarikh Tamat / Date of Expiry
30 NOV 2019

Pejabat Pengeluar / Issuing Office
UTC SENTUL

P<MYSLIAW<YIT<MING<<<<<<<<<<<<<<<<<<<<<<<<<<<<

A328258406MYS8103044M1911301810304085969<<38

PASSPORT **REPUBLIC OF SINGAPORE**



Type	Country Code	Passport No
PA	SGP	E4511856F

Name

TAN HUI ANN SHERRY

E4511856F

Sex	Nationality
F	SINGAPORE CITIZEN

Date of birth	**Place of birth**
09 APR 1982	SINGAPORE
Date of issue	**Date of expiry**
27 MAR 2014	10 SEP 2019
Modifications	**Authority**
SEE PAGE 2	MINISTRY OF HOME AFFAIRS

National ID No

S8210419D

```
PASGPTAN<<HUI<ANN<SHERRY<<<<<<<<<<<<<<<<<<<<<<
E4511856F1SGP8204099F1909100S8210419D<<<<<06
```

THIS PASSPORT IS VALID FOR ALL COUNTRIES
EXCEPT THE FOLLOWING:

PASSPORT **REPUBLIC OF SINGAPORE**



Type: PA
Country Code: SGP
Passport No: E3576314E

Name: TAN SEE LENG

Sex: M
Nationality: SINGAPORE CITIZEN

Date of birth: 24 DEC 1964
Place of birth: SINGAPORE

Date of issue: 11 DEC 2012
Date of expiry: 11 DEC 2017

Modifications: SEE PAGE 2
Authority: MINISTRY OF HOME AFFAIRS

National ID No: S1654774C

PASGPTAN<<SEE<LENG<<<<<<<<<<<<<<<<<<<<<<<<<<<<
E3576314E5SGP6412249M1712117S1654774C<<<<<<28

THIS PASSPORT IS VALID FOR ALL COUNTRIES
EXCEPT THE FOLLOWING:

PASSPORT **REPUBLIC OF SINGAPORE**



Type: PA
Country Code: SGP
Passport No: E3133254L

Name

NG HOW KIAT CHARLIE

Sex: M
Nationality: SINGAPORE CITIZEN

Date of birth: 17 OCT 1970
Place of birth: SINGAPORE

Date of issue: 16 APR 2012
Date of expiry: 02 JAN 2018

Modifications: SEE PAGE 2
Authority: MINISTRY OF HOME AFFAIRS

National ID No: S7041731F



PASGPNG<<HOW<KIAT<CHARLIE<<<<<<<<<<<<<<<<<<<<<
E3133254L8SGP7010170M1801020S7041731F<<<<<<44

နိုင်ငံသားစိစစ်ရေးကတ်ပြား



အမှတ် ....

ရက်စွဲ ....

အမည် CHRISTOPHER AUN

ဖခင်အမည် ....

မွေးသက္ကရာဇ် ....

လူမျိုး/ဘာသာ ....

အရပ် .... သွေးအုပ်စု ....

ထင်ရှားသည့်အမှတ်အသား ....

....

ထုတ်ပေးသူလက်မှတ်

အမည် ....

ရာထူး ....

အမှတ်စဉ် G837050

သက်သေခံကတ်ပြားအမှတ် ....

လက်ဝဲလက်မပုံစံ

အလုပ်အကိုင် ....

နေရပ်လိပ်စာ ....

....

ထိုးမြဲလက်မှတ် ....

၁။ ဤကတ်ပြားကို အမြဲဆောင်ထားရမည်။

၂။ ပျောက်ဆုံး၊ ပျက်စီးသည့်အခါ သက်ဆိုင်ရာ ရဲစခန်း၊ မြို့နယ်လူဝင်မှုကြီးကြပ်ရေးနှင့် အမျိုးသားမှတ်ပုံတင်ရေးဦးစီးဌာနမှူးရုံးသို့ သတင်းပို့ရမည်။

၃။ ဤလက်မှတ်ကို အသက်(၁၀)နှစ်ပြည့်လျှင် လဲလှယ်ရမည်။ ပျက်ကွက်ပါက အရေးယူခြင်းခံရမည်။

- **Annex B Profile of Parkway**

Parkway
YANGON

FACTSHEET

PROFILE

- Leading international provider of premium healthcare services in attractive markets with strong and rapidly growing demand for quality healthcare
- Holding Company IHH Healthcare Berhad trades on Main Market of Bursa Malaysia Securities Berhad (Bursa Securities) and on the Main Board of the Singapore Exchange Securities Trading Limited (SGX-ST)
- World's second largest listed private healthcare provider based on market capitalisation
- Operations & investments in:
  - **Home markets**: Singapore, Malaysia and Turkey
  - **Key markets**: China (PRC), Hong Kong and India
  - **Other international markets**: Brunei, Vietnam, United Arab Emirates, Macedonia and Iraq

OVERVIEW

- Owns global network of hospitals with over 7,000 licensed beds in 40 hospitals, as well as medical centres, clinics, ancillary healthcare businesses and medical education
- In the pipeline by 2017: over 3,000 beds in 19 hospitals through new developments and expansion of existing facilities
- More than 25,000 employees worldwide

MARKET PRESENCE

HOME MARKETS		
Singapore [Parkway Pantai]: 900+ beds	***Malaysia: 2,100+ beds***	***Turkey: 2,700+ beds***
• Owns & operates Mount Elizabeth, Mount Elizabeth Novena, Gleneagles and Parkway East Hospitals • Operates Parkway Shenton clinics, ParkwayHealth Radiology, ParkwayHealth Laboratory • Runs Parkway College which comprises School of Nursing and Allied Health and School of Healthcare Management • **Accreditation: All four hospitals are JCI accredited**	• Owns & operates 10 Pantai Hospitals, 3 Gleneagles Hospitals, Pantai Premier Pathology, Pantai Integrated Rehab and 1 ambulatory care centre • Runs International Medical University (Malaysia's leading private healthcare university) and International Medical College (trains nurses and allied health professionals) • **Accreditation: 2 hospitals are JCI accredited and 9 are accredited by the Malaysian Society for Quality in Health (MSQH)**	• Owns & operates 17 hospitals in Turkey, including 1 each in Macedonia and Iraq • Integrated network with 12 outpatient clinics that act as feeders into hospital network • Also integrated across value chain: ancillary services including clinical lab, emergency transport and home health services, and turnkey project management for hospital planning & development • **Accreditation: 3 hospitals are JCI accredited**

KEY MARKETS	
China (PRC and HK)	***India***
• Operates 12 medical centres: 6 clinics in Shanghai, 2 in Suzhou, 2 in Beijing, 1 in Chengdu and a flagship medical centre in Hong Kong • Gleneagles Hong Kong, new 500-bed greenfield JV hospital under development in Hong Kong	• Joint venture with Apollo Hospital Enterprise Limited to operate Apollo Gleneagles Hospital in Kolkata and Apollo Gleneagles PET-CT Centre in Hyderabad • Acquired 51% stake in India's Continental Hospitals in March 2015 • Acquired 73.4% stake in India's Global Hospitals in August 2015

OTHER INTERNATIONAL MARKETS			
Vietnam	***Brunei***	***United Arab Emirates***	***Iraq***
• HMA to manage City International Hospital, a multi-specialty hospital in Ho Chi Minh City with 320 beds	• Owns & operates the 23-bed Gleneagles JPMC Cardiac Centre through 75% joint venture with Brunei Investment Agency	• Consultancy agreement & HMA to manage the 126-bed Danat Al Emarat Hospital, a women and children's specialty hospital in Abu Dhabi	• HMA to manage the 210-bed Faruk Medical City Hospital in Kurdistan, Iraq

AWARDS IN 2015

IHH Healthcare Berhad is pleased to announce that its Managing Director and Chief Executive Officer, Dr Tan See Leng, won Best CEO of the Year at the prestigious 2015 National Award for Management Accounting, or NAfMA. The Best CEO of the Year award recognises the efforts of a business leader who has widely transformed the organisation.

IHH Healthcare Berhad has been named by leading market analysts as the "Overall Best Managed Company in Malaysia" and the "Overall Best Managed Company in Asia for the Pharmaceutical/ Healthcare Sector". IHH was also named one of the top 10 "Overall Best Managed Company in Asia" for Euromoney's Best Managed Companies Survey 2015.

*All facts and figures are accurate as at 18 September 2015

- **Annex C Projection statement**

Parkway
YANGON

Andaman Alliance Healthcare Limited Annex C1-A

Investment Plan

US$

	Item	Total Investment	Equity	Operation Cash Flow*	Equity		Operation Cashflow*	
					Foreign 62.50%	Local 37.50%	Foreign 62.50%	Local 37.50%
1	**Land Premium + Stamp Duty**	8,858,000	8,858,000		**5,536,250**	**3,321,750**	**-**	**-**
					-	**-**	**-**	**-**
2	**Construction**	40,500,000	40,500,000		**25,312,500**	**15,187,500**	**-**	**-**
					-	**-**	**-**	**-**
3	**Furniture and fitting**	4,500,000	1,800,000	2,700,000	**1,125,000**	**675,000**	**1,687,500**	**1,012,500**
					-	**-**	**-**	**-**
3	**Equipment**				**-**	**-**	**-**	**-**
	Medical Equipment	25,014,872	13,508,031	11,506,841	**8,442,519**	**5,065,512**	**7,191,776**	**4,315,065**
	Non-Medical Equipment and IT	6,216,804	3,357,074	2,859,730	**2,098,171**	**1,258,903**	**1,787,331**	**1,072,399**
	Sub-total	31,231,676	16,865,105	14,366,571	**10,540,690**	**6,324,415**	**8,979,107**	**5,387,464**
					-	**-**	**-**	**-**
4	**Others**				**-**	**-**	**-**	**-**
	Vehicles	10,000	10,000		**6,250**	**3,750**	**-**	**-**
	Sub-total	10,000	10,000		**6,250**	**3,750**	**-**	**-**
					-	**-**	**-**	**-**
5	**Pre-Opening Expenses**				**-**	**-**	**-**	**-**
	Working Capital	616,770	616,770		**385,481**	**231,289**	**-**	**-**
	Stamp duty for lease agreement	16,200	16,200		**10,125**	**6,075**	**-**	**-**
	Doctors Fees	360,000	360,000		**225,000**	**135,000**	**-**	**-**
	SWB	681,375	681,375		**425,859**	**255,516**	**-**	**-**
	Fixed Expenses	329,096	329,096		**205,685**	**123,411**	**-**	**-**
	Sub-total	2,003,441	2,003,441		**1,252,150**	**751,291**	**-**	**-**
		87,103,117	**70,036,546**	**17,066,571**	**43,772,840**	**26,263,706**	**10,666,607**	**6,399,964**

Facility expansion from 100 to 250 beds from operation cash flow.

Andaman Alliance Healthcare Limited Annex C1-B

Investment projection patten

I Investment for Setup (Equity and Cashflow)

			Pre-Op Y-0	**Pre-Op Y-1**	**Pre-Op Y-2**	**Pre-Op Y-3**	**Pre-Op Y-4**	**Y-1**	**Y-2**
	Item	**Size**	**USD per unit**	**Total Price**					
1.1	**Phase 1 Investment - Shareholders Equity**								
	Land premium		2,580,000	2,580,000	-	3,440,000	-	-	-
	Land premium stamp duty		258,000						
	Construction and renovation			8,100,000	12,150,000	12,150,000	8,100,000	-	-
	% of total construction and renovation			*20%*	*30%*	*30%*	*20%*	-	-
	Furniture and Fittings			-	-		1,800,000	-	-
	% of F&F			-	-		*40%*	-	-
	Equipment			-	-		16,865,105	-	-
	% of total equipment			-	-		*54%*	-	-
	Pre-operating expenses			-			2,003,441		
	Others (Vehicle)						10,000		
	Sub-total		**2,838,000**	**10,680,000**	**12,150,000**	**15,590,000**	**28,778,546**	**-**	**-**
1.2	**Phase 2 Investment - Expansion of facility from 100-250 beds from cash flow**								
	Furniture and Fittings								-
	% of F&F								-
	Equipment								936,950
	% of total equipment								*3%*
	Sub-total								**936,950**
	Total Investment for Set-Up		**2,838,000**	**10,680,000**	**12,150,000**	**15,590,000**	**28,778,546**	**-**	**936,950**

II Investment from cashflow for repair and maintenance (on continual basis)

Furniture and Fittings	-	-
Equipment	-	-
IT and others	-	-
Total maintenance & replacement capex	**-**	**-**

Andaman Alliance Healthcare Limited Annex C1-B

Investment projection patten

I Investment for Setup (Equity and Cashflov

Item	Y-3	Y-4	Y-5	Y-6	Y-7	Y-8	Y-9	Y-10	Total
1.1 Phase 1 Investment - Shareholders Equity									
Land premium	-								8,600,000
Land premium stamp duty									258,000
Construction and renovation	-								40,500,000
% of total construction and renovation	*-*								
Furniture and Fittings	-								1,800,000
% of F&F	*-*								
Equipment	-								16,865,105
% of total equipment	*-*								
Pre-operating expenses									2,003,441
Others (Vehicle)									10,000
Sub-total	**-**								**70,036,546**
1.2 Phase 2 Investment - Expansion of facility									
Furniture and Fittings	2,700,000	-							2,700,000
% of F&F	*60%*	*-*							
Equipment	-	7,807,919	5,621,702						14,366,571
% of total equipment	*-*	*25%*	*18%*						
Sub-total	**2,700,000**	**7,807,919**	**5,621,702**						**17,066,571**
Total Investment for Set-Up	**2,700,000**	**7,807,919**	**5,621,702**	**-**	**-**	**-**	**-**	**-**	**87,103,117**

II Investment from cashflow for repair and m

Furniture and Fittings	-	96,429	98,495	201,211	209,834	218,827	151,063	157,537
Equipment	-	254,315	738,980	1,381,070	1,920,345	2,030,079	2,216,931	3,138,763
IT and others	-	-	5,714	-	-	-	-	6,531
Total maintenance & replacement capex	**-**	**350,744**	**843,189**	**1,582,281**	**2,130,180**	**2,248,906**	**2,367,994**	**3,302,831**

Annex C-2

Andaman Alliance Healthcare Limited

Land Building Requirement

Land ⇒

■ Location	Plot No. 10B, Block N0. 20F, Corner of Bogyoke Aung San Road and Pyay Road, Lanmadaw Township, Yangon.
■ Type of Land	Land owned by the Ministry of Health
■ Area	4.3 acre
■ Arrangment	BOT Basis
■ Land use premium	US$ 2 M/ acre
■ Annual rent	US$ 18/m2/ year

Building

Phase I		Utilization	Cost
■ Basement	7,158 m2	Kitchen, landaury, water treatment, Technical, electrical, mechanical, staff	40,500,000
■ Ground floor	8,023 m2	OPD/ CONSULTATIONS, IMAGING, ADMIN, Cashier, Pharmacy, Cafetaria/ Gift shops, Mortuary, Emergency, Oncology, Radiotherapy, Hemodialysis, Medical gases, Backup Generation, Laboratory	
■ First floor	7,380 m2	Cardiac, Endoscopy, Obstetrics, Gynaecology, Pediatrics, Internal Medicine, Orthopedics, CSSD (Central Sterilizaation), Staff lounge & Cafeteria, Administration Ofice (Business, Support, Material Management, IT)	
■ Second Floor	2,418 m2	Medical wards (36 Beds), Nurse station	
■ Third Floor	2,418 m2	Medical wards (72 Beds), Nurse station	
■ Fourth Floor	2,418 m2	Medical Wards Suite (2 Beds), Deluxe (5 Beds) Presidential Suite (1 Room), Nurse Station	
Phase-2			
■ Fifth Floor	2,418 m2	Medical wards (36 Beds), Nurse station	
■ Sixth Floor	2,418 m2	Medical wards (36 Beds), Nurse station	
■ Seventh Floor	2,418 m2	Medical Wards Double Room (58 Beds) Single Room 7 Beds, Nurse station	
■ Eight Floor	2,418 m2	Medical Wards Suite (7 Beds), Nurse Station, Medical conference	
	39,482 m2		,

Land area = 4.3 acres

Car parking = 167 cars

Floor area under current drawing = 39,482 m2

Appximate area taken for calculation of rent = 40,000 m2

= (40,000 x 75% x 18)

=US$ 540,000

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
1	Accident & Emergency	Boards, Patient Transfer	337	17	5,732
2	Accident & Emergency	Carts, Emergency (Fully Loaded)	1,869	32	59,794
3	Accident & Emergency	Cast Cutters, Electric, w/ Vacuum	2,318	4	9,273
4	Accident & Emergency	Chest Compressors, Automatic	3,372	1	3,372
5	Accident & Emergency	Electrocardiograph (ECG), Interpretive	5,830	4	23,322
6	Accident & Emergency	Flowmeters, Oxygen	48	339	16,193
7	Accident & Emergency	Infusion Pumps, Syringe	1,863	150	279,450
8	Accident & Emergency	Infusion Pumps, Volumetric, Single	1,350	137	184,950
9	Accident & Emergency	Infusion Stands, Mobile	95	32	3,035
10	Accident & Emergency	Intravenous Poles	105	58	6,111
11	Accident & Emergency	Lights, Exam/ Procedure, Dual, Ceiling	16,588	1	16,588
12	Accident & Emergency	Lights, Exam/ Procedure, Mobile	1,278	14	17,899
13	Accident & Emergency	Lights, Exam/ Procedure, Single, Ceiling	4,206	31	130,372
14	Accident & Emergency	Monitoring Systems, Physiologic, Acute Care (Central Station)	32,598	8	260,784
15	Accident & Emergency	Monitoring Systems, Physiologic, Acute Care I	15,964	21	335,235
16	Accident & Emergency	Monitoring Systems, Physiologic, Basic Care	15,964	22	351,199
17	Accident & Emergency	Oto/Ophthalmoscope Set, w/ Case	320	78	24,985
18	Accident & Emergency	Pumps, Suction/ Aspirator, Electrical	3,161	8	25,289
19	Accident & Emergency	Refrigerators, Pharmacy, Countertop	892	30	26,764
20	Accident & Emergency	Regulators w/ Flowmeters, Oxygen Tank	74	19	1,401
21	Accident & Emergency	Regulators, Suction, Intermittent/ Continuous	365	336	122,735
22	Accident & Emergency	Ring Cutters	140	1	140
23	Accident & Emergency	Sanitisers, Bedpan (with Sluice Function)	12,996	15	194,935
24	Accident & Emergency	Scales, Clinical, Adult, Digital, Floor	1,321	16	21,130
25	Accident & Emergency	Sphygmomanometers, Aneroid	84	84	7,081
26	Accident & Emergency	Step Stools	175	101	17,666
27	Accident & Emergency	Stethoscopes, General Purpose	67	127	8,449
28	Accident & Emergency	Stools, Exam	561	19	10,664
29	Accident & Emergency	Stretchers, Procedure/ Recovery	5,269	47	247,620

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
30	Accident & Emergency	Thermometer, Electronic, Infrared, Ear	153	90	13,782
31	Accident & Emergency	Trolleys, Instrument I	232	27	6,259
32	Accident & Emergency	Trolleys, Plaster	1,180	2	2,360
33	Accident & Emergency	Trolleys, Procedure	639	28	17,899
34	Accident & Emergency	Trolleys, Procedure, With Drawers	773	3	2,318
35	Accident & Emergency	Ventilators, Portable, Transport	16,859	1	16,859
36	Accident & Emergency	Viewboxes, 1 Panel, Surface	485	59	28,597
37	Accident & Emergency	Viewboxes, 2 Panels, Surface	773	50	38,636
38	Accident & Emergency	Wheelchairs, Mechanical, Adult, Large	253	6	1,517
39	Accident & Emergency	Wheelchairs, Mechanical, Adult, Standard	225	28	6,294
40	Cardio Vascular Lab	Anaesthesia Machines, General	37,231	6	223,385
41	Cardio Vascular Lab	Analyzers, Laboratory, Blood Gas, Point-of-Care	20,372	3	61,115
42	Cardio Vascular Lab	Analyzers, Point-of-Care, Whole Blood, Coagulation	20,372	1	20,372
43	Cardio Vascular Lab	Basin Stands (Single)	176	9	1,581
44	Cardio Vascular Lab	Baskets, For Suction Tubing	2,107	7	14,752
45	Cardio Vascular Lab	Carts, Supply, Suture	2,206	1	2,206
46	Cardio Vascular Lab	Computer Information Systems, Cardiac Cath-Lab, Haemodynamic	77,840	1	77,840
47	Cardio Vascular Lab	Electrosurgical Units, Bipolar	45,660	2	91,321
48	Cardio Vascular Lab	Flexible Scales, X-Ray	600	1	600
49	Cardio Vascular Lab	Infusion Pumps, Patient-Controlled Analgesic	1,350	2	2,700
50	Cardio Vascular Lab	Injectors, Contrast Media, Mobile	3,161	1	3,161
51	Cardio Vascular Lab	Kickbuckets	253	9	2,276
52	Cardio Vascular Lab	Laryngoscope Set, with Blades, Neonates	253	1	253
53	Cardio Vascular Lab	Marker Sets, Imaging	686	2	1,371
54	Cardio Vascular Lab	Monitoring Systems, Physiologic, Acute Care II	69,404	17	1,179,864
55	Cardio Vascular Lab	Monitors, Surgical Display, LCD, Flat Panel	4,958	7	34,704
56	Cardio Vascular Lab	Pacemakers, External, Noninvasive Electrodes	5,269	1	5,269
57	Cardio Vascular Lab	Picture Archiving and Communication Systems (PACS) Diagnostic Station, 2 Screens	17,562	7	122,932
58	Cardio Vascular Lab	Printer Machines, Film	13,698	5	68,491

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
59	Cardio Vascular Lab	Pumps, Suction/ Aspirator, General	1,084	3	3,252
60	Cardio Vascular Lab	Radiographic/Fluoroscopic Units, Angiographic, Cardiac Digital Biplane or Similar	964,286	1	964,286
61	Cardio Vascular Lab	Resuscitators, Pulmonary, Manual, Reusable	234	26	6,082
62	Cardio Vascular Lab	Shields, X Ray, Apron, Half	282	24	6,765
63	Cardio Vascular Lab	Shields, X-Ray, Apron, Full	302	12	3,630
64	Cardio Vascular Lab	Shields, X-Ray, Glove	180	1	180
65	Cardio Vascular Lab	Shields, X-Ray, Goggle	381	3	1,142
66	Cardio Vascular Lab	Shields, X-Ray, Goggle (Over The Glasses)	246	2	492
67	Cardio Vascular Lab	Shields, X-Ray, Thyroid	52	21	1,093
68	Cardio Vascular Lab	Stands, Double Holder, Stainless Steel	150	4	601
69	Cardio Vascular Lab	Step Stools, w/ Handrail	105	3	316
70	Cardio Vascular Lab	Timer, Coagulation System	5,163	3	15,489
71	Cardio Vascular Lab	Warming Units, Contrast Media	12,996	3	38,987
72	Cardio Vascular Lab	Warming Units, Patient, Forced Air	1,229	13	15,981
73	Clinical Laboratory	Analyzers, Arterior Blood Gas (ABG)	19,669	1	19,669
74	Clinical Laboratory	Analyzers, Blood Culture, Automated	47,943	1	47,943
75	Clinical Laboratory	Analyzers, Glycoxylated Haemoglobin	165,497	1	165,497
76	Clinical Laboratory	Analyzers, Laboratory, Table Top, Haematology, Automated	83,594	1	83,594
77	Clinical Laboratory	Analyzers, Plasma Coagulation, Automated	28,766	1	28,766
78	Clinical Laboratory	Analyzers, Special Proteins Assay, Automated	59,710	1	59,710
79	Clinical Laboratory	Automated Immunohistochemistry (IHC) Slide Staining Equipment I, Bench Top	7,025	1	7,025
80	Clinical Laboratory	Automated Immunohistochemistry (IHC) Slide Staining Equipment, Floor Standing	7,025	1	7,025
81	Clinical Laboratory	Automated Molecular Diagnostic System	56,651	1	56,651
82	Clinical Laboratory	Automated Slide Processors, Pap Specimen	7,025	1	7,025
83	Clinical Laboratory	Baths, Tissue Floatation	878	2	1,756
84	Clinical Laboratory	Baths, Water, Laboratory	764	2	1,527

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
85	Clinical Laboratory	Baths, Water, Plasma Thawing	7,376	2	14,752
86	Clinical Laboratory	Bilirubinometers	5,620	1	5,620
87	Clinical Laboratory	Bone Saw, Manual	7,025	1	7,025
88	Clinical Laboratory	Cabinets, Biological Safety, Class I, Floor	7,025	2	14,049
89	Clinical Laboratory	Cabinets, Biological Safety, Class II, Type A2, Floor (Vented Out)	11,239	3	33,718
90	Clinical Laboratory	Cassette Printing Station	7,025	2	14,049
91	Clinical Laboratory	Centrifuges, Tabletop, High Speed, Nonrefrigerated I	7,025	1	7,025
92	Clinical Laboratory	Centrifuges, Tabletop, High Speed, Nonrefrigerated II	7,025	1	7,025
93	Clinical Laboratory	Centrifuges, Tabletop, Low Speed, Non-refrigerated, Blood Bank	11,064	3	33,192
94	Clinical Laboratory	Centrifuges, Tabletop, Low Speed, Nonrefrigerated, Cytological	1,180	1	1,180
95	Clinical Laboratory	Clinical Chemistry Analysers, Automated	161,567	1	161,567
96	Clinical Laboratory	Cryocuts	25,286	2	50,571
97	Clinical Laboratory	Dry Baths, Heater Block	746	4	2,983
98	Clinical Laboratory	ELISA Analysers, Automated	33,929	1	33,929
99	Clinical Laboratory	Freezers, Blood Plasma (with Alarm, Temperature Display & Recording)	3,844	2	7,688
100	Clinical Laboratory	Freezers, Laboratory (with Temperature Display, Alarm and Temperature Recording)	5,405	4	21,622
101	Clinical Laboratory	Fume Hoods, Cover Slipping, Countertop	7,025	1	7,025
102	Clinical Laboratory	Fume Hoods, Main Slide Staining, Countertop	7,025	1	7,025
103	Clinical Laboratory	Fume Hoods, Melting Paraffin, Countertop	7,025	1	7,025
104	Clinical Laboratory	Fume Hoods, Vented, 4 ft	7,025	1	7,025
105	Clinical Laboratory	Grossing Station, Floor, Ventilated w/ Water Inlet & Discharge	36,149	1	36,149
106	Clinical Laboratory	Haemaglobin Electrophoresis System	145,130	1	145,130
107	Clinical Laboratory	Immunology Analysers, Automated	119,419	1	119,419
108	Clinical Laboratory	Incubators, Aerobic, Floor, Dual Temperature	7,025	1	7,025
109	Clinical Laboratory	Incubators, Anaerobic, Floor	8,781	1	8,781
110	Clinical Laboratory	Incubators, Clinical, CO2	5,128	3	15,384

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
111	Clinical Laboratory	Incubators, Lab, Platelet, Countertop	8,781	2	17,562
112	Clinical Laboratory	Microbial Identification & Antibiotic Susceptibility Testing System, Automated	317,164	1	317,164
113	Clinical Laboratory	Microscopes, Light, Laboratory, Brightfield	10,533	6	63,197
114	Clinical Laboratory	Microscopes, Light, Laboratory, Brightfield (Pathologist)	17,562	1	17,562
115	Clinical Laboratory	Microscopes, Light, Laboratory, Brightfield, 5 Headed Configuration(Pathologist)	7,025	1	7,025
116	Clinical Laboratory	Microscopes, Light, Laboratory, Fluorescence	14,121	2	28,242
117	Clinical Laboratory	Microscopes, Light, Laboratory, Phase Contrast	217,765	1	217,765
118	Clinical Laboratory	Microtomes, Rotary	8,352	1	8,352
119	Clinical Laboratory	Mixers, Platform, Orbital Shaker	926	2	1,852
120	Clinical Laboratory	Mixers, Roller	955	4	3,821
121	Clinical Laboratory	Mixers, Vortex	436	5	2,178
122	Clinical Laboratory	Osmometers	18,124	1	18,124
123	Clinical Laboratory	Ovens, Drying	1,054	2	2,107
124	Clinical Laboratory	pH Meters	1,082	1	1,082
125	Clinical Laboratory	Photography Station, Pathology, Integrated	7,025	1	7,025
126	Clinical Laboratory	Pre-Treatment Modules (Antigen Retrieval) I, Tissue Specimens, Countertop	7,025	1	7,025
127	Clinical Laboratory	Pre-Treatment Modules (Antigen Retrieval) II, Tissue Specimens, Countertop	7,025	1	7,025
128	Clinical Laboratory	Processors, Tissue	49,173	1	49,173
129	Clinical Laboratory	Refrigerators, Blood Bank, 2 Doors (with Alarm, Temperature Display & Recording)	5,495	1	5,495
130	Clinical Laboratory	Refrigerators, Laboratory, 1 Door (with Alarm, Temperature Display & Recording)	4,338	1	4,338
131	Clinical Laboratory	Refrigerators, Laboratory, 2 Doors (with Alarm, Temperature Display & Recording)	5,405	4	21,622
132	Clinical Laboratory	Slide Printing Station	7,025	2	14,049
133	Clinical Laboratory	Slide Processing Equipment, Automated	7,025	1	7,025
134	Clinical Laboratory	Slide Stainers, Haematology	43,904	1	43,904

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
135	Clinical Laboratory	Sterilising Units, Steam (Autoclave, Floor Standing, Top Loading)	5,377	2	10,754
136	Clinical Laboratory	Tissue Embedding System	7,025	1	7,025
137	Clinical Laboratory	TLA system, Air Compressor	7,025	1	7,025
138	Clinical Laboratory	TLA system, Aptio Automation	7,025	1	7,025
139	Clinical Laboratory	TLA system, Centrifuge Module (CM)	7,025	1	7,025
140	Clinical Laboratory	TLA system, Decapper (DCM)	7,025	1	7,025
141	Clinical Laboratory	TLA system, Desealer	7,025	1	7,025
142	Clinical Laboratory	TLA system, Input/Output Module (IOM)	7,025	1	7,025
143	Clinical Laboratory	TLA system, Sealer	7,025	1	7,025
144	Clinical Laboratory	TLA system, T-Turn Module	7,025	1	7,025
145	Clinical Laboratory	Trolleys, Rectangle, 2 Tiers, w/o Guardrail	948	4	3,793
146	Clinical Laboratory	Urine Analysers, Automated	7,025	1	7,025
147	Clinical Laboratory	Ventilated Station, Bench Top	7,025	1	7,025
148	Clinical Laboratory	Vortexers, Multi-Tube I	7,025	1	7,025
149	Clinical Laboratory	Vortexers, Multi-Tube II	7,025	1	7,025
150	Clinical Laboratory	Warming Units, Microscope Slide	983	1	983
151	Clinical Laboratory	Water Purification Systems, RO, Type 1 Water (60 litres with 02 reservoirs)	4,277	1	4,277
152	Corporate Services	Air Jet	1,020	1	1,020
153	Corporate Services	Basket, Wired	86	12	1,027
154	Corporate Services	Cabinet, Dryer	10,628	1	10,628
155	Corporate Services	Carts, Case	3,286	16	52,572
156	Corporate Services	Carts, Surgical Case	302	22	6,645
157	Corporate Services	Carts, Washer	181,195	1	181,195
158	Corporate Services	CSSD Equipment; Miscellaneous	34,398	1	34,398
159	Corporate Services	Doc Tracking System with Scanner	9,631	6	57,784
160	Corporate Services	Magnifying Glass With Backlight	1,158	2	2,315
161	Corporate Services	Main Steam Sterilizer, with built-in steam generator	134,371	1	134,371
162	Corporate Services	Racks, Basket	906	2	1,813
163	Corporate Services	Racks, Container	906	6	5,438
164	Corporate Services	Spray Gun	4,618	1	4,618
165	Corporate Services	Sterilzers, Low Temperature	145,026	1	145,026
166	Corporate Services	Table, Packing SS	3,789	6	22,735
167	Corporate Services	Table, SS (2mx1m)	2,100	2	4,200

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
168	Corporate Services	Table, with Fluorescent light view box as table top (1.5mx1m)	6,351	1	6,351
169	Corporate Services	Trays, Instrument	79	12	945
170	Corporate Services	Trolleys, Rectangle, 1 Tiers, w/o Guardrail	948	3	2,845
171	Corporate Services	Ultrasonic Cleaner, Floor Standing	30,531	1	30,531
172	Corporate Services	Washer/ Disinfector, Electric	92,918	1	92,918
173	Corporate Services	Washer/ Disinfector, Endoscope	56,197	4	224,790
174	Corporate Services	Water Jet	1,020	3	3,059
175	Corporate Services	Water Purification Systems, Reverse Osmosis w/ Floor Drain (CSSD)	47,148	1	47,148
176	Diagnostic Imaging	Ablation Systems, Radio-Frequency	70,247	1	70,247
177	Diagnostic Imaging	Anaesthesia Machines, MRI Compatible	47,768	1	47,768
178	Diagnostic Imaging	Biopsy System, Breast, Vacuum Assisted	41,094	1	41,094
179	Diagnostic Imaging	CD/ DVD Cutters	42,148	1	42,148
180	Diagnostic Imaging	Chairs, Biopsy	5,339	1	5,339
181	Diagnostic Imaging	Chairs, Phlebotomy	702	10	7,025
182	Diagnostic Imaging	Defibrillator/ Pacemakers, External	29,223	6	175,336
183	Diagnostic Imaging	Densitometers, Bone, Whole Body	89,213	1	89,213
184	Diagnostic Imaging	Digitizers, X-ray Film	878	1	878
185	Diagnostic Imaging	Flowmeters, Air	63	3	190
186	Diagnostic Imaging	Flowmeters, Oxygen, MRI	84	1	84
187	Diagnostic Imaging	Infusion Pumps, Syringe, MRI	1,350	1	1,350
188	Diagnostic Imaging	Infusion Stands, Mobile, MRI	28,099	1	28,099
189	Diagnostic Imaging	Injectors, Contrast Media, CT, Dual Syringe	28,099	1	28,099
190	Diagnostic Imaging	Injectors, Contrast Media, MRI	28,099	1	28,099
191	Diagnostic Imaging	Laryngoscope Set, with Blades, Fiberoptic	667	4	2,669
192	Diagnostic Imaging	Monitoring Systems, Physiologic, Acute Care, MRI	63,882	1	63,882
193	Diagnostic Imaging	Picture Archiving and Communication Systems (PACS), Central System	707,143	1	707,143
194	Diagnostic Imaging	Positioning Aid, Radiographic	372	1	372
195	Diagnostic Imaging	Printer Machines, Colour, Medical Grade	18,967	1	18,967

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
196	Diagnostic Imaging	QA/ QC Tools (Diagnostic Imaging)	85,631	1	85,631
197	Diagnostic Imaging	Radiographic Units, Chest II	299,730	1	299,730
198	Diagnostic Imaging	Radiographic Units, Mobile, Digital	147,857	3	443,571
199	Diagnostic Imaging	Radiographic Units, Stereotactic Biopsy Systems, Mammographic, Digital	282,857	1	282,857
200	Diagnostic Imaging	Regulators w/ Flowmeters, Oxygen Tank , MRI	105	1	105
201	Diagnostic Imaging	Regulators, Suction, Intermittent/Continuous, MRI	492	1	492
202	Diagnostic Imaging	Scales, Clinical, Infant, Digital	632	11	6,954
203	Diagnostic Imaging	Scanning Systems, Computed Tomography, Full Body, With Fluoro	835,714	1	835,714
204	Diagnostic Imaging	Scanning Systems, Magnetic Resonance Imaging, 1.5 Tesla	1,092,857	1	1,092,857
205	Diagnostic Imaging	Scanning Systems, Ultrasonic, Multipurpose I	117,643	1	117,643
206	Diagnostic Imaging	Scoliosis Stand	2,107	1	2,107
207	Diagnostic Imaging	Sharps Containers, Lead Lined	70	1	70
208	Diagnostic Imaging	Shields, X Ray, Apron, Skirt	282	4	1,127
209	Diagnostic Imaging	Shields, X-Ray, CT Breast Shield	228	1	228
210	Diagnostic Imaging	Shields, X-Ray, Half Glass	2,107	4	8,430
211	Diagnostic Imaging	Shields, X-Ray, Lead Blocker	99	6	594
212	Diagnostic Imaging	Shields, X-Ray, Mobile (Half-glass type)	246	3	738
213	Diagnostic Imaging	Shields, X-Ray, Sand Bags	100	9	898
214	Diagnostic Imaging	Stands, Mayo, Foot-Operated	423	2	846
215	Diagnostic Imaging	Stethoscopes, General Purpose, MRI Compatible	46	1	46
216	Diagnostic Imaging	Trolleys, Induction/ Injection, MRI	11	1	11
217	Diagnostic Imaging	Trolleys, Square, 2 Tiers, w/ Guardrail	267	9	2,402
218	Diagnostic Imaging	Ventilators, Portable, Transport, MRI Compatible	11,099	1	11,099
219	Diagnostic Imaging	Viewboxes, 1 Panels, Surface, Mammography (Hi-Lo)	1,967	1	1,967
220	Diagnostic Imaging	Viewboxes, 2 Panels, Surface (Hi-Lo)	1,391	8	11,127

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
221	Diagnostic Imaging	Viewboxes, 2 Panels, Surface, Mammography (Hi-Lo)	1,475	1	1,475
222	Diagnostic Imaging	Warming Units, Gel	12,996	2	25,991
223	Diagnostic Imaging	Waste Can, Lead Lined	2,107	2	4,215
224	Diagnostic Imaging	Workstation, CT System	25,714	3	77,143
225	Diagnostic Imaging	Workstation, Mammography	1,616	1	1,616
226	Diagnostic Imaging	Workstation, Nuclear Med System	1,616	1	1,616
227	Endoscopy	Cabinets, Scope Storage, Ventilated I	42,534	4	170,138
228	Endoscopy	Cabinets, Scope Storage, Ventilated II	5,128	3	15,384
229	Endoscopy	Electrosurgical Units, Monopolar/Bipolar, Argon-Enhanced Coagulation	22,830	2	45,660
230	Endoscopy	Endoscope, Bronchoscope, Video (Normal)	18,334	2	36,669
231	Endoscopy	Endoscope, Bronchoscope, Video (Paed)	18,334	1	18,334
232	Endoscopy	Endoscope, Bronchoscope, Video (Therapeutic)	18,334	1	18,334
233	Endoscopy	Endoscope, Colonoscope, Video (Normal)	28,450	8	227,599
234	Endoscopy	Endoscope, Colonoscope, Video (Paed)	28,450	1	28,450
235	Endoscopy	Endoscope, Cystoscope, Video	17,692	2	35,384
236	Endoscopy	Endoscope, Duodenoscope, Video	32,086	1	32,086
237	Endoscopy	Endoscope, Enteroscope	36,528	1	36,528
238	Endoscopy	Endoscope, Gastroscope (Normal)	24,657	8	197,253
239	Endoscopy	Endoscope, Gastroscope (Therapeutic)	24,657	1	24,657
240	Endoscopy	Heat Probe Unit, General	436	1	436
241	Endoscopy	Monitors, Video, LCD, Flat Panel, Ceiling Mounted	6,259	3	18,777
242	Endoscopy	Radiographic/Fluoroscopy Units, Digital, w/ 90/90 Table Complete w/ C-Arm	205,714	1	205,714
243	Endoscopy	Satelite Arm, Single Monitor	4,448	15	66,722
244	Endoscopy	Scales, Clinical, Adult, Wheelchair	3,161	6	18,967
245	Endoscopy	Scanning Systems, Endoscopic Ultrasound (EUS) Unit	8,078	1	8,078
246	Endoscopy	Trolleys, Injection	551	5	2,757
247	Endoscopy	Ultrasonic Cleaner, Endoscope	4,590	1	4,590
248	Endoscopy	Video Endoscopy Systems	63,766	4	255,063

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
249	Endoscopy	Video Endoscopy Systems (Enteroscopy)	133,328	1	133,328
250	High Dependency Unit	Carts, Supplies	1,784	10	17,843
251	High Dependency Unit	Mattress Systems, Alternating-Pressure	702	10	7,025
252	High Dependency Unit	Pendant, Boom, Ceiling Mtd, Single Arm	17,736	8	141,888
253	Intensive Care Unit	Analyzers, Point-of-Care, Whole Blood, Multianalyte	20,372	1	20,372
254	Intensive Care Unit	Beds, Electric, Critical Care (ICU)	9,058	8	72,465
255	Intensive Care Unit	Beds, Electric, Critical Care,With Scale	9,058	2	18,116
256	Intensive Care Unit	Blood Flow Detectors	1,123	3	3,370
257	Intensive Care Unit	Carts, Emergency, Paed (Fully Loaded)	7,025	1	7,025
258	Intensive Care Unit	Circulatory Assist Units, Cardiac, Intra-Aortic Balloon (IABP)	86,052	2	172,105
259	Intensive Care Unit	Haemodialysis Units (CRRT)	58,656	1	58,656
260	Intensive Care Unit	Humidifiers, Heated	913	2	1,826
261	Intensive Care Unit	Infusion Pumps, Syringe Driver	1,863	2	3,726
262	Intensive Care Unit	Laryngoscope, FlexTip	476	1	476
263	Intensive Care Unit	Monitors, Continuous Cardiac Output	31,611	3	94,833
264	Intensive Care Unit	Monitors, Intracranial Pressure	5,971	2	11,942
265	Intensive Care Unit	Pacemakers, External, Dual Chamber	5,269	3	15,806
266	Intensive Care Unit	Pendant, Boom, Ceiling Mtd, Dual Arm	26,471	17	450,000
267	Intensive Care Unit	Pressure Gauge	211	2	421
268	Intensive Care Unit	Scanning Systems, Ultrasonic, Echo	131,786	3	395,357
269	Intensive Care Unit	Spirometers, Respiratory	1,401	2	2,803
270	Intensive Care Unit	Stimulator, Peripheral Nerve	1,157	3	3,471
271	Intensive Care Unit	Telemetry System (Central Monitoring Station)	64,286	1	64,286
272	Intensive Care Unit	Trolleys, Square, 2 Tiers, w/ 2 Drawers	267	9	2,402
273	Intensive Care Unit	Ventilators, BiPAP	17,716	2	35,432
274	Intensive Care Unit	Ventilators, Intensive Care	12,996	12	155,948
275	Intensive Care Unit	Warming Units, Blood/ Fluid, Massive Transfusion	2,810	1	2,810
276	Intensive Care Unit	Water Purification Systems, Reverse Osmosis w/ Floor Drain	17,562	1	17,562
277	Labour & Delivery Suite	Aspirators, Infant	3,161	3	9,483

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
278	Labour & Delivery Suite	Bassinets	507	14	7,101
279	Labour & Delivery Suite	Beds, Electric, Birthing	12,293	3	36,879
280	Labour & Delivery Suite	Entonox (Premixed)	7,025	3	21,074
281	Labour & Delivery Suite	Monitors, Bedside, Fetal (CTG)	10,537	4	42,148
282	Labour & Delivery Suite	Pressure Infusors	7,025	1	7,025
283	Labour & Delivery Suite	Thermometers, Oral, Digital	153	3	459
284	Labour & Delivery Suite	Thermometers, Rectum, Digital	153	1	153
285	Labour & Delivery Suite	Vacuum Extractor, Obstetrical	3,512	2	7,025
286	Labour & Delivery Suite	Warming Units, Patient, Radiant, Infant, Wall Mtd	2,880	5	14,401
287	Morgue	Freezers, Laboratory, Chest	3,512	1	3,512
288	Morgue	Lifts, Patient, Cadaver, Mobile	7,011	1	7,011
289	Morgue	Refrigerators, Morgue (03 Body)	47,768	1	47,768
290	Morgue	Stretchers, Transport, Cadaver, Covered	3,442	2	6,884
291	Neonatal Intensive Care Unit	Apnea Monitors	1,405	1	1,405
292	Neonatal Intensive Care Unit	Couches, Breast Feeding	1,826	4	7,306
293	Neonatal Intensive Care Unit	Incubators, Infant, Mobile	16,094	1	16,094
294	Neonatal Intensive Care Unit	Incubators, Infant, Transport with Vent Support	16,094	1	16,094
295	Neonatal Intensive Care Unit	Mixers, Air	7,025	1	7,025
296	Neonatal Intensive Care Unit	Pendant, Boom, Ceiling Mtd, Column	10,352	3	31,056
297	Neonatal Intensive Care Unit	Phototheraphy Units, LED	1,995	2	3,991
298	Neonatal Intensive Care Unit	Phototheraphy Units, Ultraviolet	1,995	5	9,977
299	Neonatal Intensive Care Unit	Pumps, Breast	2,336	4	9,343
300	Neonatal Intensive Care Unit	Resuscitaire with Warmer and Phototherapy Light	13,277	5	66,383
301	Neonatal Intensive Care Unit	Stethoscopes, General Purpose, Paeds	76	6	458
302	Neonatal Intensive Care Unit	Trolleys, Baby Nappy Change	551	2	1,103
303	Neonatal Intensive Care Unit	Ventilators, Intensive Care, Neonatal	36,704	1	36,704

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
304	Neonatal Intensive Care Unit	Ventilators, Intensive Care, Neonatal, High Frequency	36,704	1	36,704
305	Neonatal Intensive Care Unit	Warming Units, Infant Formula	2,880	2	5,760
306	Neonatal Intensive Care Unit	Warming Units, Patient, Radiant, Infant, Mobile	2,880	7	20,161
307	Nursery (North Tower)	Analyzers, Otoacoustic OAE Hand Held	7,854	1	7,854
308	Nursery (North Tower)	Stands, Aspiration Collection Canister	150	9	1,353
309	Nursery (North Tower)	Sterilisers, Bottle	7,025	1	7,025
310	Operating Suites	Aspirators, Surgical, Liposuction	89,916	1	89,916
311	Operating Suites	Basin Stands (Double)	246	4	983
312	Operating Suites	Baths, Tissue	878	1	878
313	Operating Suites	Bedpans Utilities	12,996	2	25,991
314	Operating Suites	Blood Shaker	1,932	1	1,932
315	Operating Suites	Boards, Patient Transfer, Large	337	1	337
316	Operating Suites	Camera Systems, OR, In-Light	21,246	4	84,984
317	Operating Suites	Carts, Injector, Anaesthesia	11	5	53
318	Operating Suites	Cataract Extraction Units, Phacoemulsification	70,714	1	70,714
319	Operating Suites	Centrifuges, Floor, Low Speed, Refrigerated	8,781	1	8,781
320	Operating Suites	Colposcopes, General	21,074	1	21,074
321	Operating Suites	Compression Units, Extremity	6,678	4	26,711
322	Operating Suites	Cryosurgical Units, Ophthalmic	27,111	1	27,111
323	Operating Suites	ECMO Units	126,444	1	126,444
324	Operating Suites	Electrosurgical Units, Bipolar/Mono	45,660	5	228,302
325	Operating Suites	Electrosurgical Units, Coblation	11,700	1	11,700
326	Operating Suites	Electrosurgical Units, Transurethral Resection of the Prostate (TURP)	27,818	1	27,818
327	Operating Suites	Endoscope, Bronchoscope, Fiberoscope	18,742	1	18,742
328	Operating Suites	Endoscope, Choledochoscope	16,382	1	16,382
329	Operating Suites	Endoscope, Sigmoidoscope, Video	7,025	1	7,025
330	Operating Suites	Endoscope, Ureteroscope	17,884	1	17,884
331	Operating Suites	Headlight, w/ Light Source	6,701	2	13,401
332	Operating Suites	Heart-Lung Bypass Units	187,910	1	187,910
333	Operating Suites	Laser Indirect Ophthalmoscope	15,472	2	30,944

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
334	Operating Suites	Laser System with Smoke Evacuator Unit	7,025	1	7,025
335	Operating Suites	Lasers, Diode, Ophthalmic	32,313	1	32,313
336	Operating Suites	Lasers, Surgical, Holmium:YAG	56,197	1	56,197
337	Operating Suites	Light Sources, Fiberoptic (Rigid)	5,971	1	5,971
338	Operating Suites	Lights, Surgical, Dual, Ceiling	33,482	7	234,377
339	Operating Suites	Lights, Surgical, Triple, Ceiling I	47,256	1	47,256
340	Operating Suites	Lithotripters, Electrohydraulic	61,817	1	61,817
341	Operating Suites	Microscopes, Light, Operating, Neurosurgery II	205,714	1	205,714
342	Operating Suites	Microscopes, Light, Operating, Ophthalmology	102,560	1	102,560
343	Operating Suites	Microscopes, Light, Operating, Otorhinolaryngology, Floor Mtd	77,271	1	77,271
344	Operating Suites	Monitors, Nerve Integrity	7,025	2	14,049
345	Operating Suites	Ophthalmic Surgical System, Vitreoretinal	128,552	1	128,552
346	Operating Suites	Ophthalmoscopes, Binocular, Indirect	2,896	5	14,478
347	Operating Suites	Pendant, Boom, Anesthesia I	14,655	8	117,237
348	Operating Suites	Pendant, Boom, Equipment	13,838	8	110,702
349	Operating Suites	Pendant, Boom, Equipment (MIS)	13,838	1	13,838
350	Operating Suites	Pendant, Boom, Perfusionist	16,321	1	16,321
351	Operating Suites	Pumps, Irrigation, High Volume	328	2	657
352	Operating Suites	Pumps, Suction/ Aspirator, Ultrasonic	105,019	1	105,019
353	Operating Suites	Pumps, Tracium	1,405	3	4,215
354	Operating Suites	Radiographic/Fluoroscopic Units, Mobile I	166,906	1	166,906
355	Operating Suites	Radiographic/Fluoroscopic Units, Mobile II	51,429	1	51,429
356	Operating Suites	Refrigerators, Blood Bank (1 Door)	6,182	2	12,363
357	Operating Suites	Regulators, Pressure, Fibrinogen Sealant, Tissel Glue	2,136	2	4,271
358	Operating Suites	Saw, Sternal	3,923	1	3,923
359	Operating Suites	Scanning Systems, Ultrasonic, Multipurpose II	117,643	1	117,643
360	Operating Suites	Shields, X Ray, Apron, Half (Drop-Off)	282	6	1,691
361	Operating Suites	Stands, Mayo, Small Size	3,161	3	9,483

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
362	Operating Suites	Step Stools, OR, Double	175	8	1,399
363	Operating Suites	Step Stools, OR, Single	175	8	1,399
364	Operating Suites	Sterilizer, Flash, Countertop	3,983	2	7,966
365	Operating Suites	Stools, Anaesthetist	513	4	2,051
366	Operating Suites	Tables, Surgical, Major, Multipurpose I	38,691	3	116,073
367	Operating Suites	Tables, Surgical, Orthopedic	257,922	1	257,922
368	Operating Suites	Tourniquet System, General	17,562	2	35,123
369	Operating Suites	Trolleys, Gowning	551	4	2,206
370	Operating Suites	Trolleys, Intubation	232	4	927
371	Operating Suites	Trolleys, Square, 2 Tiers, w/o Guardrail, w/ Drawer	190	6	1,138
372	Operating Suites	Ultrasonic Disector	7,025	1	7,025
373	Operating Suites	Video Endoscopy Systems (Endo)	100,779	1	100,779
374	Operating Suites	Video Endoscopy Systems (ENT)	132,626	1	132,626
375	Operating Suites	Video Endoscopy Systems (GS)	147,659	1	147,659
376	Operating Suites	Video Endoscopy Systems (MIS)	160,464	1	160,464
377	Operating Suites	Video Endoscopy Systems (Ortho)	69,615	1	69,615
378	Operating Suites	Warming Units, Patient	2,880	3	8,640
379	Operating Suites	Warming/ Cooling Units, Patient, Heart-Lung Bypass	2,880	2	5,760
380	Pharmacy (In-Patient)	Balances, Electronic, Precision, w/ Counter	478	2	955
381	Pharmacy (In-Patient)	Cabinets, Biological Safety, Class II, Type B2, Floor (5ft)	11,239	2	22,479
382	Pharmacy (In-Patient)	Dispensers, Unit Dose Packaging Machine (BlisPack)	24,586	1	24,586
383	Pharmacy (In-Patient)	Dispensers, Unit Dose Packaging Machine (Tosho)	24,586	1	24,586
384	Pharmacy (In-Patient)	Hoods, Horizontal Laminar Flow (4ft)	3,302	1	3,302
385	Pharmacy (In-Patient)	Hoods, Horizontal Laminar Flow (6ft)	3,302	2	6,603
386	Pharmacy (In-Patient)	Isolators (4 ft)	54,933	1	54,933
387	Pharmacy (In-Patient)	Refrigerators, Pharmacy w/ Freezer, w/ Temperature Display & Alarm (2 Doors)	2,704	3	8,113
388	Pharmacy (In-Patient)	Sealers, Heat	436	2	871
389	Pharmacy (In-Patient)	Step Stools (Mobile with Spring System)	105	3	316
390	Pharmacy (In-Patient)	Trolleys, Rectangle, 3 Tiers, w/ Guardrail	267	3	801
391	Radiotherapy	Scanning Systems, Computed Tomography, w/ Radiotherapy Simulation	642,857	1	642,857

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
392	SOC (Cardiology)	Stress Test Systems, w/ Treadmill	9,483	1	9,483
393	SOC (CHEMO)	Concentrators, Oxygen	1,264	1	1,264
394	SOC (CHEMO)	Monitors, Blood Pressure, Portable	2,269	2	4,538
395	SOC (CHEMO)	Recliners, Chemotherapy, w/ TV Mounted	7,025	6	42,148
396	SOC (Endo/Gastro/Wt Mgmt)	Scales, Clinical, Adult, Digital, Floor, w/ BMI & Fat Analysis Function	1,321	2	2,641
397	SOC (Endo/Gastro/Wt Mgmt)	Scanning Systems, Ultrasonic, Abdominal, Liver Stiffness	99,750	1	99,750
398	SOC (Executive Health)	Analyzers, Body Composition, c/w Printer Stand, Result Sheets & Wet Tissue	20,372	1	20,372
399	SOC (Executive Health)	Audiometers, Diagnostic Pure Tones, Speech Test w Printer	53,066	1	53,066
400	SOC (Executive Health)	Audiometers, Impedance Tympanometry w Printer	53,066	1	53,066
401	SOC (Executive Health)	Camera Systems, Retina	24,586	1	24,586
402	SOC (Executive Health)	Refractometers, Auto	10,537	2	21,074
403	SOC (Executive Health)	Tonometer, Computerised, c/w Screenoscope	7,367	2	14,735
404	SOC (Executive Health)	Visual Acuity Chart Projectors	7,025	2	14,049
405	SOC (EYE/ ENT)	Analyzers, Physiologic, Middle Ear	19,994	1	19,994
406	SOC (EYE/ ENT)	Audiometric Booths	7,025	1	7,025
407	SOC (EYE/ ENT)	Chairs, Patient, Exam/ Treatment, Ophthalmology	7,025	1	7,025
408	SOC (EYE/ ENT)	Chairs, Recliner, Patient, Exam/ Treatment, Otorhinolaryngology	2,515	1	2,515
409	SOC (EYE/ ENT)	Digital Sound Level Meter	112	1	112
410	SOC (EYE/ ENT)	ENT Diagnostic/ Treatment Unit, w/ Integrated ENT Microscope	79,849	1	79,849
411	SOC (EYE/ ENT)	ENT Fiberscope, Portable	11,601	1	11,601
412	SOC (EYE/ ENT)	Keratometers	7,025	3	21,074
413	SOC (EYE/ ENT)	Lasers, Nd:YAG, Frequency-Doubled, Ophthalmic	38,636	1	38,636
414	SOC (EYE/ ENT)	Lenses, Three Mirrors	2,107	3	6,322
415	SOC (EYE/ ENT)	Lenses, Volk	2,107	3	6,322
416	SOC (EYE/ ENT)	Ophthalmoscopes, Direct	2,896	1	2,896
417	SOC (EYE/ ENT)	Recorders, Graphic, Evoked Potential, Auditory	35,510	1	35,510
418	SOC (EYE/ ENT)	Retinoscope/Ophthalmoscope Set, w/ Case	7,025	4	28,099

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
419	SOC (EYE/ ENT)	Slit Lamps	16,393	1	16,393
420	SOC (EYE/ ENT)	Slit Lamps, w/ Integrated Tonometer and Adjustable Table	16,393	2	32,786
421	SOC (EYE/ ENT)	Stools, Patient, w/o Wheels	2,107	11	23,181
422	SOC (EYE/ ENT)	Testers, Hearing Aid	7,025	1	7,025
423	SOC (EYE/ ENT)	Trolleys, Supplies	2,107	3	6,322
424	SOC (EYE/ ENT)	Ultrasound, Pachymeter	128,552	1	128,552
425	SOC (Haematology)	Refrigerators, Pharmacy, Floor Standing	1,777	2	3,554
426	SOC (OBGYN)	Fetal Dopplers	4,215	3	12,644
427	SOC (OBGYN)	Scanning Systems, Ultrasonic, Obstetric/ Gynaecologic, w/ Warming Units, Gel	128,552	2	257,103
428	SOC (OBGYN)	Tables, Exam/ Treatment, Adjustable, Gynaecologic, w/ Paper Roller	913	4	3,653
429	SOC (Rehab)	Bars, Parallel, Motorized	11,169	1	11,169
430	SOC (Rehab)	Bobath Beds, Electrical	2,775	3	8,324
431	SOC (Rehab)	Cogged Scissors	148	1	148
432	SOC (Rehab)	Crutches, Axilliary (Pair)	84	2	169
433	SOC (Rehab)	Crutches, Elbow (Pair)	84	2	169
434	SOC (Rehab)	Deburring Knife	84	1	84
435	SOC (Rehab)	Defibrillators, AED, Wall Mtd	2,968	1	2,968
436	SOC (Rehab)	Diathermy Units, Shortwave Therapy	7,657	3	22,971
437	SOC (Rehab)	Digital Speech Aid Device	1,019	1	1,019
438	SOC (Rehab)	Dynamometers, Hand (Kit)	618	1	618
439	SOC (Rehab)	Eating/ Swallowing Evaluation/Assessment Kit	7,025	1	7,025
440	SOC (Rehab)	Electrolarynx	1,019	1	1,019
441	SOC (Rehab)	Ergometers, Bicycle, Recumbent	7,376	1	7,376
442	SOC (Rehab)	Ergometers, Bicycle, Upright	2,669	1	2,669
443	SOC (Rehab)	Ergometers, Portable Arm	648	2	1,295
444	SOC (Rehab)	Exercisers, Continuous Passive Motion, Elbow	4,617	1	4,617
445	SOC (Rehab)	Exercisers, Continuous Passive Motion, Hand	4,438	1	4,438
446	SOC (Rehab)	Exercisers, Continuous Passive Motion, Shoulder	8,992	1	8,992
447	SOC (Rehab)	Eyelet Setter	70	1	70
448	SOC (Rehab)	Fluido Therapy Machines	8,430	1	8,430
449	SOC (Rehab)	Functional Dexterity Test Kit	210	1	210
450	SOC (Rehab)	Goniometers, Finger/ Wrist/ Elbow (180 degrees and 360 degrees)	98	3	293
451	SOC (Rehab)	Gym Ball (Set)	60	1	60

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
452	SOC (Rehab)	Hydrocollators, Heating Unit, Countertop	1,890	1	1,890
453	SOC (Rehab)	Inclined Boards	450	1	450
454	SOC (Rehab)	Leg Press Machines	7,287	1	7,287
455	SOC (Rehab)	Light Scissors	25	1	25
456	SOC (Rehab)	Manip Beds	2,669	3	8,008
457	SOC (Rehab)	Pans, Splint	2,950	1	2,950
458	SOC (Rehab)	Pen Light Medical	2,107	1	2,107
459	SOC (Rehab)	Pilates Beds	7,025	1	7,025
460	SOC (Rehab)	Platform Attachment, Elbow (Pair)	2,107	1	2,107
461	SOC (Rehab)	Polar Heart Rate Monitors	130	3	390
462	SOC (Rehab)	Pulley Systems, Triplex, Vertical, Dual Column, Wall Mtd	1,888	1	1,888
463	SOC (Rehab)	Quad Sticks	11	2	21
464	SOC (Rehab)	Rainbow Hand Exercisers	18	1	18
465	SOC (Rehab)	Rehab Tools, Aquaplast	239	1	239
466	SOC (Rehab)	Rehab Tools, Hammer	386	1	386
467	SOC (Rehab)	Rehab Tools, Hole Puncher	2,107	1	2,107
468	SOC (Rehab)	Rehab Tools, Hook	88	1	88
469	SOC (Rehab)	Rehab Tools, Plier	32	1	32
470	SOC (Rehab)	Rehab Tools, Polycushion	2,107	1	2,107
471	SOC (Rehab)	Rehab Tools, Splint Cutter	20	1	20
472	SOC (Rehab)	Rehab Tools, Velcro loop	58	1	58
473	SOC (Rehab)	Rehabilitation Bicycles, Motorised	7,025	1	7,025
474	SOC (Rehab)	Revolving Punch	2,107	1	2,107
475	SOC (Rehab)	Shears	34	1	34
476	SOC (Rehab)	Spring Coil Pliers	2,107	1	2,107
477	SOC (Rehab)	Stairs, Training, Wooden	3,302	1	3,302
478	SOC (Rehab)	Step Stools/ Therapy Steps	1,264	6	7,587
479	SOC (Rehab)	Strong Scissors	188	1	188
480	SOC (Rehab)	Tables, Therapy, Clinical Round Hydraulic Lift (Manicure Table Size)	527	1	527
481	SOC (Rehab)	Theraband Hand Exerciser (Set)	20	1	20
482	SOC (Rehab)	Traction Beds	5,514	2	11,029
483	SOC (Rehab)	Traction Units	4,215	1	4,215
484	SOC (Rehab)	Treadmills, Exercise (Rehab/ PT)	9,483	1	9,483
485	SOC (Rehab)	Trolleys, Equipment, Splint Pan	11,984	1	11,984
486	SOC (Rehab)	Ultrasound, Therapeutic, Electrotherapy, Combo	165,080	1	165,080
487	SOC (Rehab)	Volumeters, Hand, Set	421	1	421
488	SOC (Rehab)	Walking Frames	49	2	98
489	SOC (Rehab)	Walking Sticks	16	2	32
490	SOC (Rehab)	Wax Baths	3,161	1	3,161
491	SOC (Rehab)	Workstation, Cardiac Rehab	7,025	1	7,025

Andaman Alliance Healthcare Limited Annex C-3

List of key medical equipment to be imported in the first 9 years of the company's establishment

Sr.	Department	Item Description	Estimated UP	Qty	Estimated Total Cost (USD)
492	SOC (Resp/Derma/Geriatric)	Peak Flow Meters	2,107	3	6,322
493	STAT Laboratory	Stools, Blood Draw	513	3	1,538
494	Wards	Beds, Electric, General	3,316	201	666,495
495	Wards	Carts, Cylinder, Multiple (6 Slots)	235	12	2,824
496	Wards	Carts, Cylinder, Single	119	17	2,030
497	Wards	Carts, Medication	2,803	17	47,648
498	Wards	Carts, Phlebotomy	267	14	3,737
499	Wards	Chairs, Commode	492	22	10,818
500	Wards	Fork Tuning 128 & 512 Hz	1,686	27	45,520
501	Wards	Infusion Pumps, Docking Stations	2,385	34	81,090
502	Wards	Laryngoscope Set, with Blades	414	11	4,559
503	Wards	Lights, Exam/ Procedure, Wall Mtd	1,419	12	17,028
504	Wards	Nebulizers, Heated	913	8	7,306
505	Wards	Oximeters, Pulse	2,536	18	45,646
506	Wards	Pumps, Suction/ Aspirator, Thoracic, Mobile	3,161	10	31,611
507	Wards	Stools, Surgeon	2,318	16	37,090
508	Wards	Tables, Exam/ Treatment, w/ Paper Roller	2,669	53	141,477
509	Wards	Tables, Overbed, General	527	235	123,810
510	Wards	Telemetry System, w/ Viewing Monitor	64,286	1	64,286
511	Wards	Tendon Tapper	20	76	1,527
512	Wards	Trolleys, Dressing	204	21	4,278
513	Wards	Trolleys, Instrument III	232	26	6,027
514	Wards	Trolleys, Rectangle, 2 Tiers, w/ Guardrail	267	14	3,737
515	Wards	Trolleys, Service/ Utility	267	12	3,203
516	Wards	Warming Units, Blood/ Intravenous Solution	2,810	27	75,866
517	Wards	Boxes, Blood Transfer	2,107	4	8,430
518	Wards	Scales, Clinical, Adult, Digital, Sitting	3,161	4	12,644
519	Wards	Beds, Electric, VIP	3,316	10	33,159
520	Wards	Beds, Electric, VIP (Suite)	6,632	4	26,527
		Grand Total		4,143	25,014,872

31,231,676

Andaman Alliance Healthcare Limited Annex C-4

List of non-key medical equipment to be imported in the first 9 years of the company's establishment

US$

Sr.		Decription	Estimated UP	Qty	Cost
1	Accident and Emergency	CRASH CART	2,107	15	31,607
2	Accident and Emergency	LINEN CART	1,748	29	50,688
3	Accident and Emergency	SAFE DEPOSIT BOX FOR BUSINESS UNITS	1,286	5	6,429
4	Admissions	TABLE FOR FINANCIAL COUNSEL ROOMS - PHVC	857	2	1,714
5	Biomedical Engineering	TOOLS CABINET	1,403	2	2,806
6	Building System	VODOKE-IN PATIENT INFO BOARD - BM SYS INTEGRATION	19,643	1	19,643
7	Cath Lab	ANESTHESIA CART	2,074	10	20,743
8	Cath Lab	BOX CATHETER CABINET, MODEL: 3100BC	3,000	1	3,000
9	Cath Lab	CATH CABINET. MODEL: 3100CC	3,000	1	3,000
10	Cath Lab	CATH SUPPLY CART, MODEL: 4290CCS	5,714	1	5,714
11	Cath Lab	LAPTOP WITH PRINTER FOR EP	1,429	1	1,429
12	Corporate Services	PASS BOX WITH MECHANICAL INTERLOCK	1,429	2	2,857
13	Corporate Services	TABLE MOUNTED MAGNIFYING GLASS WITH LIGHT	2,571	1	2,571
14	Endoscopy	ANESTHESIA CART	2,074	4	8,297
15	Endoscopy	ENDOSCOPY CABINET (STORES 16 SCOPES)	4,929	1	4,929
16	Endoscopy	ENDOSCOPY CABINETS (STORES 5 SCOPE)	3,857	1	3,857
17	Endoscopy	ENDOSCOPY WORKSTATION CART	4,571	7	32,000
18	Endoscopy	PASS THRU ENDOSCOPIES CABINET	2,476	5	12,379
19	Endoscopy	PNEUMATICALLY ADJUSTABLE STOOL	871	13	11,329
20	Endoscopy	SCOPE TRANSPORT CART (MDL: 3750DST)	1,429	6	8,571
21	General	HEAVY DUTY VACUUM CLEANER	2,482	6	14,893
22	General	HIGH PRESSURE JET MACHINE	971	3	2,914
23	General	MACHINE, FLOOR SCRUBBER, Auto	3,214	3	9,643
24	General	MACHINE, FLOOR SWEEPER, Auto	2,375	2	4,750
25	General	NILFISK AX410 3-IN-1 CARPET EXTRACTOR MACHINE	3,357	3	10,071
26	General	VIPER DR1500H HIGH SPEED BURNISHER	4,943	4	19,771
27	General	2 x OIL FREE AIR COMPRESSOR + AIR DRYER + STERILE	14,286	1	14,286
28	General	CHAIRS, OFFICE - MANAGER TYPE @PDSMC L4	179	3	536
29	General	CHAIRS, OFFICE- HIGH BACK EXECUTIVE TYPE @PDSMC L4	214	3	643
30	General	LARGE DIRTY LINEN CART	361	10	3,607
31	General	S/STEEL (304) TRANSPORT CART (MDL: TC-5030PW)	1,857	8	14,857
32	General	SCENT DIFFUSION EQUIPMENT	17,143	1	17,143
33	General	ARM CHAIRS FOR VISITORS AT WAITING LOUNGES	357	50	17,857
34	General	LONG COUCH - WAITING LOUNGE	5,429	5	27,143

Andaman Alliance Healthcare Limited Annex C-4

List of non-key medical equipment to be imported in the first 9 years of the company's establishment

US$

Sr.		Decription	Estimated UP	Qty	Cost
35	General	CHANGING RM LOCKERS	1,221	35	42,750
36	General	INSULATION AND CONTINUITY TESTER (MDL: ATI-14FC)	3,857	1	3,857
37	General	SPRAY GUN AIR WITH ADAPTOR (MDL: 610035)	1,500	1	1,500
38	General	STAFF CHAIRS	129	1,070	137,571
39	General	PRINTERS WITH SCANNING, COPYING, FAX	857	25	21,429
40	IT	3M CODEFINDERR TM SOFTWARE-AR-DRG	13,335	1	13,335
41	IT	BAR CODE PRINTER	607	2	1,214
42	IT	DATA PROTECTOR, WIN STARTER PACK & MS OFFICE	1,739	1	1,739
43	IT	DEDICATED LONG CODE CAMPAIGN & SMS WEB SERVICE	7,143	1	7,143
44	IT	DELL POWEREDGE R310	3,282	1	3,282
45	IT	EA CERTIFICATION SETUP/CONFIG TIS & LICENSING	5,714	12	68,571
46	IT	EA-DOCUMENT PROCESSING ROOM	32,143	1	32,143
47	IT	ECRI-AIMS CMMS SYSTEM	26,165	1	26,165
48	IT	ECRI-AIMS HEALTH SOFTWARE SYSTEM (CMMS) MNH 31%	9,919	1	9,919
49	IT	HP DATA PROTECTOR (BACKUP LICENSE)	4,000	1	4,000
50	IT	HP DL380G7 SFF-1*E5645 SERVER	3,571	1	3,571
51	IT	MEDISYS ENDOSCOPY NURSING CARE RECORD	214,286	1	214,286
52	IT	MEDISYS SOFTWARE LICENSE & CUSTOMIZATION	42,857	1	42,857
53	IT	MICROSOFT CLUSTERING	1,714	1	1,714
54	IT	MINDMANAGER 8 & MINDJET CATALYST	1,799	1	1,799
55	IT	ONLINE APPOINTMENT PORTAL	36,743	1	36,743
56	IT	SAN SERVER (IT)	11,429	1	11,429
57	IT	ECC6- PHVC OUT PATIENT BY IBM or equivalent	100,000	1	100,000
58	IT	EMR - HARDWARE (NOTE: EMR = Electronic Medical Records)	259,476	1	259,476
59	IT	EMR - HARDWARE - SERVERS/WEB/CLINICAL/NAS/FACS	405,349	1	405,349
60	IT	EMR - LICENSE 400 PPL PPLESOFT-ORACLE or equivalent	22,450	1	22,450
61	IT	EMR - LICENSE 800 X MS OFFICE LIC - HP - MNH	220,326	1	220,326
62	IT	EMR - LICENSE WIN SVR STD/ENT/FR FRNT TMG	26,801	1	26,801
63	IT	POS SOLUTION	6,024	15	90,357
64	IT	EMR - PROFESSIONAL FEE (ECLIPSYS HEALTHCARE or Equivalent)	1,428,571	1	1,428,571
65	IT	EMR - SUNRISE ACUTE CARE (SCM) LICENSE or equivalent	642,156	1	642,156
66	IT	IT INTEGRATION FOR PATIENT MASTER INTEGRATION	75,000	1	75,000
67	IT	SYNAPSE ENHANCEMENTS	42,214	1	42,214

Andaman Alliance Healthcare Limited Annex C-4

List of non-key medical equipment to be imported in the first 9 years of the company's establishment

US$

Sr.		Decription	Estimated UP	Qty	Cost
68	IT	SYSTEM WORKSTATION	1,671	5	8,357
69	IT	TIS APPLICATION PRODUCTION SERVER	3,571	1	3,571
70	IT	TRUSTED HUB'S (TIS)	9,286	1	9,286
71	Kitchen	BAIN MARIE	5,000	5	25,000
72	Kitchen	BAKER OVEN	5,714	1	5,714
73	Kitchen	BLIXER 3 D BLENDER & MIXER	1,049	3	3,146
74	Kitchen	BLIXER 5 PLUS BLENDER & MIXER	1,826	2	3,651
75	Kitchen	CENTRIFUGAL JUICE EXTRACTOR 25GAL	919	1	919
76	Kitchen	CHILLER	2,857	10	28,571
77	Kitchen	COMBI OVEN	14,286	1	14,286
78	Kitchen	COMMERCIAL BLENDER, 4L	1,122	1	1,122
79	Kitchen	COMMERCIAL NOODLE ELECTRIC MACHINE - PANTRY 4	1,193	1	1,193
80	Kitchen	ELECTRIC DOUGH MIXER W/OVERLOAD SWITCH - PANTRY	1,013	1	1,013
81	Kitchen	FOOD WARMER	2,143	10	21,429
82	Kitchen	FREEZER	5,714	4	22,857
83	Kitchen	ICE CUBE MACHINE	3,714	2	7,429
84	Kitchen	KITCHEN STOVE	2,857	2	5,714
85	Kitchen	MICROWAVE	1,071	1	1,071
86	Kitchen	SALAMANDER	2,143	1	2,143
87	Kitchen	ULTRA FOOD PROCESSOR - 2 X PANTRY 4,	1,137	3	3,410
88	Kitchen	WOK RANGE	4,286	1	4,286
89	Kitchen / Lab	SCOTSMAN FLAKE ICE MACHINE (MDL: AF103AS)	3,254	1	3,254
90	Lab, Pharmacy	FLAMMABLE & CORROSIVE CABINET	686	2	1,371
91	Lab, Pharmacy	FLAMMABLE CABINET 45 GAL, 60 GAL	2,143	4	8,571
92	Lab, Pharmacy	FLAMMABLE SAFETY CABINET	671	1	671
93	Laboratory	5 DRAWERS TROLLEY	1,000	3	3,000
94	Laboratory	LAB CONVEYOR BELT	21,093	1	21,093
95	Laboratory	FRIDGE CAP: 570 LTR	857	1	857
96	Laundry	INDUSTRIAL GRADE DRYERS	5,714	6	34,286
97	Laundry	INDUSTRIAL GRADE WASHERS	5,714	6	34,286
98	Laundry	IRONING	3,571	6	21,429
99	Laundry	PEGASUS INDUSTRIAL SEWING MACHINE (MDL: M852-01)	1,018	1	1,018
100	Lobby	SERVERY COUNTER &TV & MAGAZINE RACK-AUDIOMETRY CTR	1,357	2	2,714
101	Lobby	BIRDCAGE LUGGAGE CART,1.5" DIAMETER	1,429	2	2,857
102	Lobby	VALET COUNTER C/W ROUND EDGE & LOCKABLE CASTERS	1,939	1	1,939
103	Lobby	MASTER-CLOCK HU-TELNU-30	1,907	1	1,907
104	Offices	CUMMINS UNIVERSAL JETSCAN CURRENCY	6,982	2	13,964
105	Offices	SINGLE SIDED PRINTER	2,399	2	4,799
106	Offices	LAPTOPS AND DESKTOP COMPUTERS	857	400	342,857
107	Offices	STAGE ROSTRUM/LACTERN WITH READING LIGHTS	1,071	1	1,071
108	Offices	STAFF ID PRINTER & CLEANING KIT	904	2	1,807
109	Offices	ISS EZY COMPACTOR SHELVES (SETS)	6,964	2	13,929

Andaman Alliance Healthcare Limited Annex C-4

List of non-key medical equipment to be imported in the first 9 years of the company's establishment

US$

Sr.		Decription	Estimated UP	Qty	Cost
110	Offices	LCD PROJECTOR	964	15	14,464
111	Offices	SHREDDER FELLOWES SB99CI,	425	4	1,700
112	OT	STERILIZER, COUNTERTOP	12,500	1	12,500
113	OT	SURGISTOOL WITH ARMREST	2,357	4	9,429
114	OT	SURGISTOOL WITHOUT ARMREST	2,071	4	8,286
115	OT	PLASTER TROLLEY	4,571	3	13,714
116	OT, ICU, A & E, L &D	SLAVE-CLOCK TELNU ROUND 300MM	736	40	29,429
117	OT, ICU, Rooms,	MOBILE RADIATION PROTECTION BARRIERS	10,479	4	41,914
118	Pharmacy	S/STEEL CONTROL DRUG CABINET	2,406	1	2,406
119	Radiology	ENDOSCOPY ERCP CART	3,500	1	3,500
120	Radiology	KODAK SCANNER	5,714	1	5,714
121	Radiology	SOFTWARE FOR BI-VENT OPTION	3,929	1	3,929
122	Rehabilitation	ASSISTANT FREE HIP FRAME-STANDARD	6,000	1	6,000
123	Rehabilitation	CHAIRS	429	38	16,286
124	Rehabilitation	TOY STORAGE: METAL RACKS (AUDIOMETRY CENTRE)	1,018	1	1,018
125	SOC	BLOOD DRAWING CHAIR	914	6	5,486
126	SOC	PAPER TROLLEY INCL. BOTTOM SHELVES (MDL: 610908)	536	50	26,786
127	SOC	SUTURE CART (MDL: 4700SC)	2,243	13	29,157
128	Wards	40" FULL HD LED TV W CABLE & BRACKET	2,179	13	28,321
129	Wards	UNDERCOUNTER PHARMACY (FOOD) REFRIGERATOR FOR PATIENT TO RECORD TEMP	907	110	99,786
130	Wards	VODOKE IPTV SET-UP TOP BOX	4,800	1	4,800
131	Wards	HEAVY DUTY PATIENT LIFT	5,932	3	17,796
132	Wards	OVERBED TABLES	509	239	121,634
133	Wards	HARMONY CART INNERSPACE MDL: 6324W5 (Ward utility carts) or equivalent	1,714	13	22,286
134	Wards	MOBILE COMMODE SHOWER CHAIR	214	170	36,429
135	Wards	SAFE DEPOSIT BOX FOR PATIENT ROOM	357	239	85,357
136	Wards	40 INCHES FULL HD LED TV	571	201	114,857
137	Wards	46 FULL HD SMART LED TV	1,582	15	23,736
138	Wards	SOFA BEDS	1,000	110	110,000
139	Wards	SANITIZER BEDPAN FOR WARDS	13,000	13	169,000
140	Wards	STATIONERY WIRE SHELVES W 4 TIER	1,429	20	28,571
141	Wards	STAINLESS STEEL TROLLEY	1,071	30	32,143
142	Wards	STAINLESS STEEL TROLLEY 4 DRAWER	713	10	7,129
		Grand Total		3,275	6,216,804

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1	2HR OBSERVATION CHART FOR NEONATES
2	30 DEG MICRO TIP STRAIGHT #30 RTS
3	ABDOMINAL BINDER DALE 2410
4	ABDOMINAL BINDER DALE 2411
5	ABDOMINAL BINDER DALE 2810
6	ABDOMINAL BINDER DALE 2811
7	ACCESS SHEATH IN/DIA 9.5FR #FUS-095035
8	ACCUPAK W/ACCURUS 2500 PROBE 8065741012
9	ADAPTOR TUBING 22MMID x 5-9OD #HS70059
10	ADMISSION PACK NORMAL ROOM
11	ADVANCED SOFT CUP FEEDER MEDELA
12	AFO LEAF SPRING
13	AIRWAY DISPOSABLE SIZE 0 2202900
14	AIRWAY DISPOSABLE SIZE 00 2203000
15	AIRWAY DISPOSABLE SIZE 1 2202500
16	AIRWAY DISPOSABLE SIZE 2 2202600
17	AIRWAY DISPOSABLE SIZE 3 2202700
18	AIRWAY DISPOSABLE SIZE 4 2202800
19	AIRWAY GUEDAL 8CM SZ 2 GREEN #1112001
20	AIRWAY GUEDAL 9CM SZ 3 ORANGE #1113001
21	AIRWAY GUEDAL ROMSONS 110MM SZ 4
22	AIRWAY GUEDAL ROMSONS 60MM SZ 0
23	AIRWAY GUEDAL ROMSONS 70MM SZ 1
24	AIRWAY GUEDEL SZ 1.5 (7.0) (1111570)
25	AIRWAY NASOPHARYNGEAL 6MM
26	AIRWAY NASOPHARYNGEAL 7MM
27	AIRWAY NASOPHARYNGEAL 8MM
28	ALCON BLADE RND SHARP TIP 8065-006401
29	ALCON KNIFE CRES ANG BEVELUP 9900-02
30	ALCON KNIFE SLIT 3.2MM ANGLED
31	ALGO VALU PAK #NT040670
32	ANIOS D.D.S.H (1086326)
33	ANIOS PREMIUM WIP'S #SANI-2088655
34	ANIOSYME DD1 #1200095 1L/PER FLASK
35	ANKLE WEIGHT - 1 KG
36	ANKLE WEIGHT - 2KG
37	APPLIER ENDO CLIP LIGAMAX 5MM (EL5ML)
38	APPOINTMENT CARD PARKWAY EYE CENTRE
39	APRON DISPOSABLE (100/BX)
40	APRON DISPOSABLE 59" X 40" (100/PK)
41	AQUAPAK 340 STERILE SHUD-003-40
42	AQUAPAK H20 1070ML W/O ADAPTOR #040-00
43	AQUAPAK H2O 1070ML W/ADAPTOR #041-28
44	ARM SUPPORT ADULT
45	ARM SUPPORT CHILD
46	ARM SUPPORT INFANT
47	ARMSLING CHILD
48	ARMSLING LARGE
49	ARMSLING MEDIUM
50	ARMSLING SMALL
51	ARMSLING X-LARGE
52	ARROW 4 LUMEN 8.5FRX16CM SAR-CS-22854-E
53	ARROW 4 LUMEN 8.5FRX20CM SAR-CS-25854-E
54	ARROW MULTI-LUMEN CATH SET AR-CS-12123E
55	AR'SCP BLADE 4.5MM 7205345
56	AR'SCP BLADE INC 3.5MM #7205312
57	AR'SCP CUTTER 5.5MM #7205327 (6/BX)
58	AR'SCP CUTTER ACROMIONIZER 4MM 7205326
59	AR'SCP CUTTER FULL RAD 3.5MM #7205305
60	AR'SCP CUTTER FULL RAD 4.5MM #7205306
61	AR'SCP CUTTER LINEAR PROXIMATE 75MM

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
62	AR'SCP PROBE E.S.U 7205565 (S&N) 5/BX
63	ATTEST B1 TEST PK-STEAM 4HR READOUT
64	ATTEST BIOLOGICAL INDICATOR 3M #1291
65	AUOTRANSFUSION KIT ELECTA ATS MACH#04170
66	AUTO PBSC COLLECTION SET (777006105)
67	AXILLARY CRUTCHES ADULT
68	AXILLARY CRUTCHES X-LARGE
69	AYRES T-PIECE MAPLESON F
70	BAG BIOHAZARD 9" X 14" KANGAROO
71	BAG BIOHAZARD ZIPLOC 6" X 10"
72	BAG BLOOD CPDA 450ML (8/BOX)
73	BAG CLEAR LDPE 0.04MM X 8" X 12"
74	BAG CLEAR LDPE 0.08MM X 18" X 24"
75	BAG ENDOPOUCH SPECIMEN
76	BAG GARBAGE BLACK 36" X 48" X 0.04MM
77	BAG GARBAGE TRANSPARENT 0.030MMX36"X48"
78	BAG HDPE BLUE 0.04MM X 36" X 48"
79	BAG HDPE CLEAR 0.02MM 8" X 12" (1000/PK)
80	BAG HDPE CLEAR DIRTY RETURN (100/PK)
81	BAG HDPE RED 0.04MM X 36" X 48" (200/PK)
82	BAG HDPE TRANSPARENT 25" X 34" X 0.03"
83	BAG HDPE WHITE 0.03MM X 20" X 28"
84	BAG LDPE TRANSPARENT 20" X 30" X 0.08MM
85	BAG PLASTIC 4" X 6" SEAL TOP (100/PK)
86	BAG PLASTIC CARRIER X-RAY PRINTED
87	BAG POST-OP SENSURA 100MM #19021
88	BAG POST-OP SENSURA 70MM #19020
89	BAG PVC CADAVER
90	BAG RED SOLUBLE 26" X 33" X 22MICRON
91	BAG URINE 2000ML C/W 120CM TUBE
92	BAG URINE 2500ML C/W 120CM TUBE
93	BAG URINE 500ML CONVEEN
94	BAG WHITE W/TAPE 9.5" X 13"
95	BAG YELLOW BIOHAZARD 25" X 36"
96	BAG ZIPLOC 0.04MM X 6" X 8" (100/PK)
97	BALL STAINSTI DISP 5MM DIA E1564 (10/BX)
98	BALLARD TRACH CARE ADULT FAMILY DOUBLE
99	BALLOON COLPO-PNEUMO OCCLUDING #CPO-6
100	BALLOON TTS 10-11-12MM (5841)
101	BALLOON TTS 12-13.5-15MM (5842)
102	BALLOON TTS 15-16.5-18MM (5843)
103	BANDAGE CREPE 5.0CM X 4.0M
104	BANDAGE CREPE 7.5CM X 4.0M
105	BANDAGE CREPE ELASTOLITE 10.0CM X 4.0M
106	BANDAGE CREPE ELASTOLITE 15.0CM X 4.0M
107	BANDAGE ELASTICATED TUBULAR SIZE D
108	BANDAGE ELASTICATED TUBULAR SIZE E
109	BANDAGE ELASTICATED TUBULAR SIZE F
110	BANDAGE ELASTOPLAST 2" 5.0CM X 4.5M
111	BANDAGE ELASTOPLAST 3" 7.5CM X 4.5M
112	BANDAGE ELASTOPLAST 4" 10CM X 4.5M
113	BANDAGE ORTH VELBAND 10.0CM X 2.75M
114	BANDAGE ORTH VELBAND 15.0CM X 2.75M
115	BANDAGE ORTH VELBAND 6.0CM X 2.75M
116	BANDAGE RINKILASTIC 25MM X 4M
117	BANDAGE RINKILASTIC 80MM X 4M
118	BANDAGE TRIANGULAR
119	BANDAGE TUBIGRIP SIZE G 10M
120	BANDAGE WAIST SUSPENSORY SMALL
121	BARD PTFE FELT PLEDGET #007970 (25/PK
122	BARRIER UNDER BUTTOCK DRAPE W/POUCH

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
123	BASKET RETRIEVAL ZEROTIP NITINOL STONE
124	BATH BENCH W/ BACK
125	BATH BENCH W/O BACK
126	BATTERY ALKALINE 1.5V SIZE AA (4/PK)
127	BATTERY ALKALINE 1.5V SIZE AAA (4/PK)
128	BATTERY ALKALINE 1.5V SIZE C (2/PK)
129	BATTERY ALKALINE 1.5V SIZE D (2/PK)
130	BATTERY ALKALINE 9V
131	BEABA THERMOQUICK
132	BED PAN W/ COVER
133	BEDPAN DISPOSABLE 20/4011/D
134	BEDPAN LINER (101AA100)
135	BELLOW MINI-REDON 50ML CH8 #SPH-21636
136	BELT CTG AA95
137	BILATERAL EXTREMITY SET (13560301)
138	BILIARY STENT CLSO-10-11
139	BILIARY STENT CLSO-10-13
140	BILIARY STENT CLSO-10-7
141	BILIARY STENT CLSO-10-8
142	BIN GREY WITH PEDAL AND BAG HOLDER 35L
143	BIOLOGICAL INDICATOR RAPID STEAM #1292
144	BIOTABS 0415E
145	BIPOLAR CABLE FOOT SWITCH (E0509)
146	BIPOLAR PACING 110CM LENGTH #401674
147	BLADE #11 CARBON STEEL (SSM-JDH-11)
148	BLADE 9.5 X 13.5 X 0.6MM #00502312900
149	BLADE 9.5 X 7.5 X 0.6MM #00502312800
150	BLADE AIR DERMATOME #880000010
151	BLADE B.P NO.10 SM-BS-10
152	BLADE B.P NO.11 SM-BS-11
153	BLADE B.P NO.12 SWAN MORTEN
154	BLADE B.P NO.15
155	BLADE B.P NO.20
156	BLADE BEAVER BD-7513
157	BLADE DISP IMA/ENT 3/4" EL #809335W
158	BLADE ELECTRODE E-Z CLEAN 2.5" #0012M
159	BLADE ELECTRODE E-Z CLEAN 4" #0014AM
160	BLADE ELECTRODE E-Z CLEAN 6.5" #0014M
161	BLADE INFERIOR TURBINATE 2MM #1882040
162	BLADE LARYNGOSCOPE HEINE XP DISP MAC 3
163	BLADE LARYNGSCOPE MACINTOSH SZ 2
164	BLADE LARYNGSCOPE MILLER SZ 1
165	BLADE LARYNGSCOPE SZ 3 3940.150.20
166	BLADE LARYNSCOPE SZ 4 (DS.3940.150.25)
167	BLADE MICRO 15O 5.0MM 37-7515
168	BLADE MICROAIRE 0.4MM 15MM X 9.4MM
169	BLADE MICROAIRE 0.5MM 25.5MM X 9.5MM
170	BLADE MINI SHARP BEAVER #6900 (20/BOX)
171	BLADE MORIA 7.0MM #MOR/17171D700
172	BLADE MORIA 7.25MM #MOR/17171D725
173	BLADE MORIA 7.5MM #MOR/17171D750
174	BLADE MORIA 7.75MM #MOR/17171D775
175	BLADE MORIA 8.0MM #MOR/17171D800
176	BLADE MORIA 8.25MM #MOR/17171D825
177	BLADE MORIA 8.5MM #MOR/17171D850
178	BLADE MORIA 8.75MM #MOR/17171D875
179	BLADE MORIA 9.0MM #MOR/17171D900
180	BLADE MORIA 9.5MM #MOR/17171D950
181	BLADE RAD 12 CURVED 5/BOX (1884012)
182	BLADE RAD 40 CURVED SINUS 4MM 1884006
183	BLADE RADENOID 4MM PAED (1884008) 5/BX

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	**Item Description**
184	BLADE RADENOID ZOMED 60 XTREME BLADE 4MM
185	BLADE SLIT 2.65 ANGLED UP #E7551A
186	BLADE STITCH CUTTER SM-SCS
187	BLADE STR TRICUT 4MM 18-84004
188	BLADE TPS/COMMAND2 STYLES 0.4MM THICK
189	BLADE TRICUT 2.9MM #1882904 (5/BX)
190	BLANKET BAIR HUGGER UNDERBODY BH635
191	BLANKET FILTEREDFLO PAED 56"X40" #144
192	BLANKET PEAD 25" X 33" #874 (10/BOX)
193	BLANKET PEDIATRIC LONG #BH530
194	BLOOD CARDIOPLEGIA ADULT CSS
195	BLOOD CARDIOPLEGIA PAED CSS
196	BLOOD TAG IMPORTANT/RECIPIENT
197	BM LACTATE STRIPS (25/PKT)
198	BODY WASH 40ML NOBILITY BOTTLE (200/CTN)
199	BONE WAX 24X2.5G #1029754 (24/BX)
200	BOOK CONTROLLED DRUG (H/C) BK
201	BOOK WARD CONTROLLED DRUGS REG (GHL)
202	BOOKLET PATIENT CARE CHARTER
203	BOTTLE CHEST ATRIUM OCEAN 2002-300
204	BOTTLE DRAINAGE C/W TUBING 400ML
205	BOTTLE DRAINAGE CHEST 2 CHAMBER
206	BOTTLE DRAINAGE W/O TUBING 400ML
207	BOTTLE MALE URINAL (102AA100)
208	BOTTLE MILK 250ML #00942
209	BOTTLE SUCTION C/W TUBING STERILE 200ML
210	BOWL MIXING SMARTSET OPEN #540138000
211	BOX SUGGESTION TO SPECS
212	BOX TISSUES W/LOGO 90'S PT-90
213	BRACELET ADULT GREEN
214	BRACELET ALLERGY ALERT ADULT
215	BRANULA IV-STOPPER STERILE 4238010
216	BRAUNULA MT G12X8CM #04206487
217	BREATHING CIRCUIT ADULT COLLAPSIBLE 3 M
218	BREATHING CIRCUIT HSINER ANAESTHESIA
219	BREATHING CIRCUIT PAED 2606-61-15
220	BRESCO LLETZ LOOP B3-4-1510L
221	BRESCO LLETZ LOOP B3-4-2012L
222	BRIEF DISPOSABLE XL (7/PK)
223	BROCHURE EYE SURGERY
224	BROCHURE INFECTION CONTROL
225	BROCHURE INFECTON CONTROL 4CX4C
226	BROCHURE MANAGING YOUR PAIN - CHINESE
227	BROCHURE MANAGING YOUR PAIN - ENGLISH
228	BROCHURE MANAGING YOUR PAIN - MALAY
229	BROCHURE NICU A4
230	BROCHURE PAIN MANAGEMENT
231	BROCHURE THE BEST START FOR BABY (CHI)
232	BROCHURE THE BEST START FOR BABY (ENG)
233	BRONCHO CATH LEFT 32FR
234	BRUSH BILIARY CYTOLOGY DLB-35-15
235	BRUSH DISPOSABLE DE (WS-1823WA(P))
236	BRUSH HAND STERISSCRUB DRY
237	BRUSH MEDISCRUB CHLORINE (24/BX)
238	BRUSH MEDISCRUB IODINE (24/BX)
239	BRUSH TOOTHBRUSH
240	BULB HANAULUX 22.8V 40W 3000S
241	BULB PHILIP 12V 100W
242	BUR KOMET TCB SURGICAL #KH1LSOS 320 023
243	BUR KOMET TCB SURGICAL #KH33LSOS 320 016
244	BUR MEISINGER SURGICAL #166RF-106-021

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
245	BUR MEISINGER SURGICAL #168RF-105-023
246	BUR ST OSTEON 6.5MM X 38MM #00505612500
247	C RING MILK CAPS
248	C3F8 GAS ALCON
249	CABLE TIES CV150 (100/PK)
250	CAMERA CCTV TO SPECS
251	CANN 7FT NASAL INFANT (HOT-1828)
252	CANN AORTIC PERFUSION #AA0024C
253	CANN AORTIC PERFUSION (ALL SIZES)
254	CANN AORTIC ROOT 2.0MM STOCKERT
255	CANN BALL TIP #ERCP-1-HKB
256	CANN DISP OLYMPUS PR-19A
257	CANN DLP AORTIC 9FR STD TIP #DLP10012
258	CANN DLP SINGLE STAGE VENOUS 28F 66128
259	CANN IV NEOFLON YELLOW 24G 391350
260	CANN IV OPTIVA 20G X 32MM #5066
261	CANN IV OPTIVA 22G X 25MM #5060
262	CANN IV OPTIVA 24G X 19MM 5063
263	CANN IV VENFLON 16G 393209
264	CANN IV VENFLON 18G 393207
265	CANN IV VENFLON 20G 393204
266	CANN IV VENFLON 22G 393202
267	CANN NASAL PAED 7FT (HOT-1826)
268	CANN OPTIVA 2 1018 18G X 45MM
269	CANN OPTIVA 2 1020 20G X 32MM
270	CANN OPTIVA 2 1022 22G X 25MM
271	CANN OPTIVA 2 14G X 45MM #1014 (50/BX)
272	CANN OPTIVA 2 SMDX-1016 16G (50/BOX)
273	CANN PAED ARTERIAL 2.6MM (A900-253)
274	CANN PAED ARTERIAL 3.0MM (A900-252)
275	CANN RETROGRADE CARDIOPLEGIA RC-014
276	CANN TIP 23G DISP SOFT (8065 1495 23)
277	CANN TRIPLE STAGE VENOUS 29/29/29 FR
278	CANN TWIST-IN 6.0MMX7CM (AR-6535)
279	CANN TWIST-IN 8.25MMX7CM (AR-6530)
280	CANN TWO STAGE VENOUS W/3/8"-3/8"
281	CANN VENOUS PAED 90DEG TIP 10FR V132-10
282	CANN VENOUS PAED 90DEG TIP 12FR V132-12
283	CANN VENOUS PAED 90DEG TIP 14FR V132-14
284	CANN VENOUS PAED 90DEG TIP 16FR V132-16
285	CANN VENOUS PAED 90DEG TIP 18FR V132-18
286	CANN VENOUS PAED FEMORAL 12FR #FEMII012V
287	CANN VENOUS PAED FEMORAL 14FR #FEMII014V
288	CANNULA NASAL CO2/O2 ADULT #HP-M2750A
289	CANNULA VEN RT METAL 24FR #69324
290	CAP PATIENT BOUFFANT DISP BLUE (100/PK)
291	CAP PATIENT BOUFFANT DISP PINK
292	CAP PATIENT BOUFFANT DISP WHITE (100/PK)
293	CAP SURGEON BLUE EASY-TIE
294	CAP SURGEON BLUE W/ELASTIC BAND
295	CAP SURGEON PINK W/ELASTIC BAND
296	CAR PARK VALET DOCKET GHL
297	CARD FOR ENVIRONMENTAL SERVICES
298	CARD RADIATION TREATMENT (CANCER CTR)
299	CARDI PERF CANNULA STOCKERT AORT 6.5
300	CARDIAC HEMO CON SET DIDECO 077117
301	CARDIAC HEMOCONCENTRATOR INFANT 076285
302	CARTRIDGE I-STAT CG8+ ABBOTT 3M86-02
303	CARTRIDGE I-STAT EG7+ (220300) 25/BX
304	CASENOTES 2 RING 1" D/SHAPE (Beige)
305	CASENOTES 2 RING 1" D/SHAPE (ORANGE)

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
306	CASTING TAPE BLUE 2" X 4YD #82002B
307	CASTING TAPE BLUE 4" X 4YD #82004B
308	CATH 100% SILICONE #12
309	CATH 100% SILICONE #16
310	CATH ANGLED INTERCOSTAL 24FG
311	CATH CHEST TROCAR ARGYLE FR16
312	CATH CHEST TROCAR FR10 PTX
313	CATH CHEST TROCAR PTX FR12
314	CATH CHEST TROCAR PTX FR16
315	CATH CHEST TROCAR PTX FR20
316	CATH CHEST TROCAR PTX FR24
317	CATH CHEST TROCAR PTX FR28
318	CATH CV 3 LUMEN 5.5FR X 5 CM CS-12553-J
319	CATH ES 700 THERMACHOICE
320	CATH FEMALE STRAIGHT 12FG 0201618
321	CATH FOGARTHY EMB 3FG 40CM
322	CATH FOGARTHY EMB 3FG 80CM
323	CATH FOGARTHY EMB 4FG 40CM
324	CATH FOGARTHY EMB 4FG 80CM
325	CATH FOGARTHY EMB 5FG 80CM
326	CATH FOGARTHY EMB 6FG 80CM
327	CATH FOLEY 2WAY 30CC CH12
328	CATH FOLEY 2WAY 30CC CH14
329	CATH FOLEY 2WAY 30CC CH16
330	CATH FOLEY 2WAY 30CC CH18
331	CATH FOLEY 2WAY 30CC CH20
332	CATH FOLEY 2WAY 30CC CH22
333	CATH FOLEY 2WAY 30CC CH24
334	CATH FOLEY 2WAY 30CC CH26
335	CATH FOLEY 2WAY 5CC CH10
336	CATH FOLEY 2WAY 5CC CH8
337	CATH FOLEY 2WAY CH06 5CC ALLEGIANCE
338	CATH FOLEY 2WAY CH30
339	CATH FOLEY 2WAY SILICO 5CC 12FR
340	CATH FOLEY 2WAY SILICO 5CC 14FR
341	CATH FOLEY 2WAY SILICO 5CC 16FR
342	CATH FOLEY 3WAY 30CC CH16
343	CATH FOLEY 3WAY 30CC CH18
344	CATH FOLEY 3WAY 30CC CH20
345	CATH FOLEY 3WAY 30CC CH22
346	CATH FOLEY 3WAY 30CC CH24
347	CATH FOLEY 3WAY 30CC CH26
348	CATH HAEMATURIA 3WAY 22FX30ML 2551H22
349	CATH HAEMATURIA 3WAY 24FX30ML 2551H24
350	CATH INTERCOSTAL ANGLE 20FG
351	CATH INTERCOSTAL ANGLE 28FG
352	CATH IV ANGIO 20G X 1.88" #381137
353	CATH IV INSYTE 20G X 1.88"
354	CATH MOUNT WITH DOUBLE SWIVEL 331-5389
355	CATH NELATON 08FG RH-402100
356	CATH NELATON 10FG RH-402100
357	CATH NELATON 12FG RH-402100
358	CATH NELATON 14FG RH-402100
359	CATH NELATON 16FG RH-402100
360	CATH NELATON 18FG RH-402100
361	CATH NELATON 20FG RH-402100
362	CATH NELATON 22FG RH-402100
363	CATH NELATON 24FG RH-402100
364	CATH NELATON 28FG RH-402100
365	CATH NELATON UNO-08 0100418
366	CATH NELATON UNO-10 0100718

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
367	CATH NELATON UNO-12 01008182
368	CATH NELATON UNO-16 0101318
369	CATH OPEN END URETERAL 6FR 70CM
370	CATH PAED TRILUMEN 5.5F X 8CM CS15553E
371	CATH QUAD-LUMEN 8.5FR X 16CM
372	CATH RADIAL ARTERY ARROW 20G X 1 3/4"
373	CATH RECTAL DISP 28CH
374	CATH REPLACEMENT THO'CIC STR 20
375	CATH REPLACEMENT THO'CIC STR 24
376	CATH REPLACEMENT THO'CIC STR 32
377	CATH SINGLE USE SPRAY ENDOGATOR #100131
378	CATH SPIGOT 84001182
379	CATH STENT FLX DBL J 6FRX16CM #039616-FS
380	CATH STOKE ON TRENT- CATH CHOLANGIOGRAM
381	CATH SUCTION CONTROL VALVE 12FG 0703118
382	CATH SUCTION CONTROL VALVE 14FG 0703318
383	CATH SUCTION CONTROL VALVE 16FG 0703518
384	CATH SUCTION CONTROL VALVE 6FG 0702918
385	CATH SUCTION CONTROL VALVE 8FG 0702418
386	CATH SUCTION FEMALE STRAIGHT 10FG
387	CATH SUCTION FEMALE STRAIGHT 14FG
388	CATH SUCTION FEMALE STRAIGHT 16FG
389	CATH SUCTION FUNNEL STR CH14
390	CATH SURFLO IV 22GX1" (TMSR+OX2225C)
391	CATH SYRINGE TIP 60CC BD (309620) 40/BX
392	CATH THORACIC 28F #200/810/280
393	CATH THORACIC ST 10F #SPL-200-810-100
394	CATH THORACIC ST 12F #SPL-200-810-120
395	CATH THORACIC ST 16F #SPL-200-810-160
396	CATH TRI-LUM C.VEN ADULT 7F L15CM
397	CATH UMBILICAL 2.5FR 30CM #1270-02
398	CATH UMBILICAL PVC 3.5FR 30CM #270-03
399	CATH UMBILICAL PVC 5.0FR 30CM #270-05
400	CATH URETERAL OPEN-END 4FR #G15945
401	CATH URETERAL OPEN END 5FR 70CM
402	CATH URETERAL OPEN-END 3FR #G14818
403	CATH VENT #E061
404	CATH VYGON 2FR 30CM SILICONE #2484.302
405	CATH VYGON SINGLE LUMEN #115-11 STAR MED
406	CEMENT BONE CMW TYPE 1 40G #3312040
407	CERVICAL COLLAR SOFT LARGE
408	CERVICAL COLLAR SOFT MEDIUM
409	CERVICAL COLLAR SOFT SMALL
410	CHAIR OFFICE W/O ARM REST TO SPECS
411	CHAIR SHOULDER PACK BEACH (13560003)
412	CHAIR WITH PVC FABRIC
413	CHART MAMMOGRAPHY RADIOLOGIC CLINIC
414	CHART NEONATAL APNOEA (PHS)
415	CHEMO DISPENSING PIN (412003) (50/CTN)
416	CIRCLING BAND 0.6MM X 2.5MM X 125MM #240
417	CIRCUIT BREATHING PAED #WI/6883
418	CIRCUIT INVASIVE BIPAP VISION 652002
419	CITRATE DEXTROSE CS SOLUTION USP (ACD)
420	CLAMP CORD
421	CLAMP INSERT FOGARTY EVERGRIP 61MM
422	CLAMP INSERT FOGARTY EVERGRIP 86MM
423	CLAMP URINARY CATHETER PLASTIC G CLAMP
424	CLEANER BATHROOM HEAVY DUTY ACID 2L
425	CLEANER DIATHERMY TIP 31142717
426	CLEANER GENERAL PURPOSE BLUE SHINE 5L
427	CLEANER GLASS 2L

Annex C-5

Sr.	Item Description
428	CLEANING SERVICE (FNB GHL)
429	CLEAR TRAC 5.5MM X 72MM #72200907
430	CLEAR TRAC 8.5MM X 72MM #72200903
431	CLINICIAN'S COLLABORATIVE PROG NOTE(PHS)
432	CLIP HEMOLOK LARGE POLYMER #544240
433	CLIP HEMOLOK ML GREEN #544230
434	CLIP RANEY SCALP #20-1037
435	CLIP TITANIUM HORIZON MEDIUM BLUE 2200
436	CLIPPER BODY SURGICAL 3M #9661
437	CLIPPER CHARGER SURGICAL 3M #9668
438	CLIPPER DISP. BLADE #9660 (50/BX)
439	CODMAN EXTERNAL DRAINAGE SYSTEM 82-1720
440	COLLECTOR SHARPS YELLOW BD NESTABLE
441	COLLECTOR URINE PAED
442	COLOSTOMY DRAINAGE POUCH 22771
443	COLOSTOMY TAIL CLOSURE
444	COMBINE PROCEDURE TOTAL PLUS PAK 23GA
445	COMMODE SHOWER CHAIR
446	COMMODE W/ BACKREST, HT ADJ, STATIONARY
447	COMPRESSION STOCKING LARGE
448	COMPRESSION STOCKING MEDIUM
449	COMPRESSION STOCKING SMALL
450	COMPRESSION STOCKING X-LARGE
451	CONDITION OF SERVICE 3PLY(MEH/GHL/ESH)
452	CONDITIONER 40ML NOBILITY BOTTLE
453	CONNECTOR 4MM X 10MM
454	CONNECTOR 4MM X 4MM 8605100
455	CONNECTOR 4MM X 7MM 8605400
456	CONNECTOR 7MM X 7MM 8605200
457	CONNECTOR NEEDLELESS #011-C3300
458	CONNECTOR STERILE 7 X 7
459	CONNECTOR STRAIGHT 22F #T3325666
460	CONNECTOR VENOUS 1/4" #080099
461	CONNECTOR VENOUS 3/8" #05172 (20/BX)
462	CONNECTOR WATERPORT #100115
463	CONNECTOR Y SP-S660C GAMBRO (105745)
464	CONSENT FOR BED UPGRADE (PHS)
465	CONTAINER BLUE SEMI-OPEN FRONTED #LF322
466	CONTAINER BLUE SEMI-OPEN FRONTED #LF543
467	CONTAINER SEMI OPEN FRONTED #LF110
468	CONTAINER SEMI OPEN FRONTED #LF211
469	CONTAINER SHARPS 1.4L 300491
470	CONTAINER SHARPS 7.6L
471	CONTAINER URINE STERILE 60ML (150/BX)
472	CONTAMINATION GUARD FOR CUSA #C0005
473	CONTIANER BLUE SEMI-OPEN FRONTED #LF533
474	CONTIANER HINGED CHEMO YELLOW 18GA 8989
475	CONTIANER SHARPS 7.6L
476	CONTINENCE URISHEATH 25MM
477	CONTINENCE URISHEATH 30MM
478	CONTINENCE URISHEATH 35MM
479	CONTRAST OMNIPAQUE 350 X 50 MLS
480	COOLER & TUBE ASSEMBLY
481	COTTON BUD (200/PK)
482	COTTON LEUNG BILARY STENT #CLBS-10-10
483	COTTON LEUNG BILARY STENT #CLBS-10-11
484	COTTON LEUNG BILARY STENT #CLBS-10-12
485	COTTON LEUNG BILARY STENT #CLBS-10-9
486	COTTON LEUNG BILARY STENT #CLSO-10-5
487	COTTON TAPE STERILE 1.5CM X 180CM 827106
488	COUCH ROLL H 52CMX150M #2025100

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
489	COVER BEDPAN (100/PK)
490	COVER LINEN TROLLEY
491	COVER MICROSCOPE NEURO #4838CL
492	COVER PROBE BEAR/DUCK-SHAPE PROBE
493	COVER PROBE THERMOSCAN BRAUN #GTPC80
494	COVER PROBE THERMOSCAN BRAUN PC20
495	COVER RECTANGLE SHAPE
496	COVER SHOE DISPOSABLE (100/PK)
497	COVER URINAL (100/PK)
498	CREAM ULTRASONIC CONTACT #SIE-1022754
499	CSF-SHUNT KIT BURR HOLE MEDIUM PRESSURE
500	CSF-VENTRICULAR RESERVOIR 12MM
501	CSSD REQUISITION VOUCHER (PHS)
502	CUFF BP ADULT 40401C
503	CUFF NEONATAL BP DISP SIZE B
504	CUP FOAM 8OZ
505	CUP KIWI OMNI C/W PALM PUMP #VAC-6000M
506	CUP MEDICINE DISPOSABLE 30ML (100/PK)
507	CUP PLASTIC DENTURE 8OZ
508	CUP PLASTIC DISPOSABLE 7OZ (50/PK)
509	CURETTE BERKELEY CURVED 8MM
510	CURETTE BERKELEY STRAIGHT 10MM
511	CURETTE BERKELEY STRAIGHT 8MM
512	CURETTE BERKELEY STRAIGHT 9MM
513	CURETTE GYNAE BERKERLEY CURV 9MM
514	CURETTE KARMAN FLEXIBLE 8MM
515	CURETTE KARMAN FLEXIBLE 9MM
516	CURETTE RIGID CURVED 6MM PLASLINE
517	CURETTE RIGID CURVED 7MM (MCR07)
518	CURETTE RIGID STRAIGHT 11MM (27.33.89)
519	CURETTE RIGID STRAIGHT 6MM EUROPLAST
520	CURETTE RIGID STRAIGHT 7MM
521	CUSA 36KHZ EXCEL CEM NOSECONE #C6636
522	CUSA STRAIGH STD TIP/BLU PAK #C4613S
523	CUSHION - WATER (SQUARE)
524	DEPRESSOR TONGUE WOODEN 5.5" X 5/8"
525	DERMACARRIER 8 INCH #00-7708-000-10
526	DETERGENT ANIOSYME FIRST #SANI-1410544UZ
527	DETERGENT BLEACH
528	DETERGENT JIFF LEMON 16 X 500ML
529	DETERGENT TRI-ENZYME 5L #SANI-1920038
530	DETERGENT ZIP DISHWASHING LIQUID 1000ML
531	DGRI PERFORATOR 11/7MM (PAED)
532	DGRI PERFORATOR 14/11MM (ADULT)
533	DIAPER ADULT LARGE TENA SLIP (28/PK)
534	DIAPER GREEN ADULT LARGE
535	DIAPER GREEN ADULT MEDIUM
536	DIAPER HUGGIES EXTRA-LARGE (30/PK)
537	DIAPER HUGGIES NEWBORN (24/PK)
538	DIAPER HUGGIES SMALL (22/PK)
539	DIATHERMY LETROCHUCK DISP E2504 VLB
540	DIATHERMY ROCKER DISP E2515 VLB
541	DIDECO ADV CARDIOTOMY RESERVIOR 5263
542	DISINFECT TABLET 0.5GM IN FOIL (72/BOX)
543	DISINFECT TABLET 2.5GM PRESEPT (100/BOX)
544	DISINFECTANT ACECIDE 750ML
545	DISINFECTANT ACECIDE 875ML
546	DISINFECTANT ANIOSYME DD1 5L #1200036
547	DISK COMPACT RECORDABLE W/PRINTING
548	DIVIDER COLOUR WITH PRINTING PLASTIC
549	DORC MEMBRANEBLUE DUAL STER #MBD-05-S

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
550	DORNIA BASKET - 4 WIRES AGM-4227-1060
551	DRAIN 10FR 10FT JACKSON PRATT SU130-0521
552	DRAIN BLAKE 10FR RD HUBLES 1/8" TRO
553	DRAIN BLAKE 19FR R/F #2231 (10/BOX)
554	DRAIN BLAKE ROUND 15FR #2229 (10/BX)
555	DRAIN BLAKE ROUND 24F HUBLESS SILICONE
556	DRAIN FLAT10X4MM JACKSON PRAT SU130-1311
557	DRAIN JACKSON PRAT FLAT 7X4MM SU130-1310
558	DRAINAGE CORRUGATED 2.5CM X 25CM
559	DRAINAGE RADIVAC STERITEX #10
560	DRAINAGE RADIVAC STERITEX #12
561	DRAINAGE RADIVAC STERITEX #14
562	DRAINAGE SET D BAG (DBAG600)
563	DRAINAGE U/WATER CHEST 2000CC
564	DRAINAGE YEATE'S 2.5X25CM PL300/240/090
565	DRAPE BARRIER BACK TABLECOVER #13580215
566	DRAPE BARRIER MAYO STAND COVER (1244)
567	DRAPE BARRIER SET UP PACK 0282 (32/BOX)
568	DRAPE BARRIER UNDER BUTTOCK DRAPE
569	DRAPE BARRIER UNIVERSAL SET #13566100-00
570	DRAPE CARDIOVASCULAR SET #1356946401
571	DRAPE EXTREMITY SET (13560207) 8/BX
572	DRAPE FULLBODY NON-WOVEN 8065-1031-20
573	DRAPE HAND SET #13560307 (10/BOX)
574	DRAPE IOBAN 35CM X 35CM 6640
575	DRAPE IOBAN 60CM X 45CM 6650
576	DRAPE LAPAROSCOPIC SET #135903020
577	DRAPE LAPAROSCOPY PELVISCOPY PACK #76263
578	DRAPE LITHOTOMY PACK II 0251/1250 CS/12
579	DRAPE MINI C-ARM OEC 6800 54X84 C9-1
580	DRAPE MSC 79CM X 145CM #135610601I
581	DRAPE STERIDRAPE 120 X 130CM 1015
582	DRAPE SURGICAL 75.75 #DOR100108
583	DRAPE TRIDENT SUPPORT
584	DRAPE UTILITY DISP 75X90CM 135800530I
585	DRAWSHEET HYGIENE 85CM X 210CM
586	DRESSING ADH DERMABOND TOPICAL (AHV12)
587	DRESSING AIRSTRIP 7290 3.8CM X 2.2CM
588	DRESSING AIRSTRIP 7292 6.3CM X 2.2CM
589	DRESSING AIRSTRIP 7295 7.5CM X 2.2CM
590	DRESSING COTTON TWILL 1/2"
591	DRESSING COTTONWOOL BALL 0.5GM STERILE
592	DRESSING COTTONWOOL BALL N/STERILE 2GM
593	DRESSING COTTONWOOL ROLL BUNNY 400GM
594	DRESSING DUODERM EXTRA THIN 4 X 4"
595	DRESSING DUODERM EXTRA THIN CGF 3" X 3"
596	DRESSING GAUZE ROLL 12PLY X 3" X 1.5M
597	DRESSING IV3000 10CM X 12CM 4008
598	DRESSING JELONET STERILE 10CM X 10CM
599	DRESSING LEUKOPLAST 1.25CM X 5.0M
600	DRESSING LEUKOPLAST 2.5CM X 5M
601	DRESSING MEFIX 10M X 30CM
602	DRESSING MEFIX ADH FABRIC 10CM X 10M
603	DRESSING MELOLIN STERILE 10CM X 10CM
604	DRESSING MELOLIN STERILE 5CM X 5CM
605	DRESSING MEROCEL KENNEDY PAK 12MM
606	DRESSING OMNIPLAST/LEUKOPLAST 7.5CM X 5M
607	DRESSING OPSITE POST-OP 15.5 X 8.5CM
608	DRESSING OPSITE POST-OP 20CM X 10CM
609	DRESSING OPSITE POST-OP 6.5 X 5.0CM
610	DRESSING OPSITE POST-OP 9.5 X 8.5CM

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
611	DRESSING POST-OP 25CM X 10CM
612	DRESSING PRIMAPORE 15 X 8CM 66000318
613	DRESSING PRIMAPORE 20 X 10CM 66000319
614	DRESSING PRIMAPORE 25 X 10CM 66000320
615	DRESSING PRIMAPORE 6 X 8.30CM 7135
616	DRESSING SPRAY OPSITE 4980 250ML
617	DRESSING STERISTRIP 1/2 X 4"
618	DRESSING STERISTRIP 1/4 X 4"
619	DRESSING STERISTRIP 1/4" X 1 1/2"
620	DRESSING TEGADERM 10CM X 12CM 1626W
621	DRESSING TEGADERM 10CM X 25CM 1627
622	DRESSING TEGADERM 15CM X 20CM 1628W
623	DRESSING TEGADERM 6CM X 7CM 1623W
624	DRESSING TEGADERM 6CM X 7CM 1624W
625	DRESSING TEGADERM 9CM X 15CM 3589
626	DRESSING TEGADERM 9CM X 25CM 3591
627	DRESSING TEGADERM W/PAD 6CM X 10CM
628	DRESSING TEGASORB 10CM X 10CM
629	DRESSING TRANSPORE 1527-1 1" X 10YDS
630	DRESSING TRANSPORE TAPE 1/2" X 10YDS
631	DRILL BIT 2 L67/55 2FLUTE #513.14
632	DRILL BIT AO 2.0MM 310.19
633	DRILL BIT AO 2.5MM 310.25
634	DR'S ADMISSION ASSESSMENT NS11A (PHS)
635	DUET DRAINAGE SYSTEM #46916
636	DUODERM EXTRA THIN 4"X4" #187955 (BX/10)
637	DUOTRAV 2.5ML
638	DUPLOJECT SPRAY CATHETER
639	DVD DVD+RW SONY 5.25" 4.7GB
640	EARPIECE SZ 3 AUROSCOPE REUSEABLE
641	EARTIPS 3.7MM PASTEL YELLOW #8-68-32100
642	EARTIPS 4.0MM PASTEL GREEN #8-68-32101
643	ELBOW CRUTCHES (PAIR)
644	ELECTRODE BLADE COATED #E1450X
645	ELECTRODE BLADE PTFE 4" #E1455
646	ELECTRODE BLUE SENSOR TOO-S (25/PK)
647	ELECTRODE CASED 4" EDGE BLADE #TE14504
648	ELECTRODE CASED EXT #TE14506
649	ELECTRODE DISP PAED SP-OO-S/50
650	ELECTRODE DISPOSABLE ITT
651	ELECTRODE ECG #BR-50-K
652	ELECTRODE ECG SOLID GEL T716
653	ELECTRODE GEL SOLID HP13943B (100/PK)
654	ELECTRODE INSULATED COATED #809337W
655	ELECTRODE PAT RTN PAED E7510-25
656	ELECTRODE PATIENT RTN REM E7507 VLB
657	EMPTY CARTON BOX WITH COVER
658	ENDOLOOP PDS II (EZ10G) 12/BX
659	ENDOSCOPY NURSING CARE RECORD D/SIDED
660	END'SCP CUTTER 35MM RELOAD BLUE (TR35B)
661	END'SCP SCISSOR CORIDOPATH 5MM #5DCS
662	END'SCP THORACOPORT 10.5MM TROCAR 179301
663	END'SCP THORACOPORT 11.5MM TROCAR
664	END'SCP TROCAR APPLE P/TIP 5MM
665	END'SCP TROCAR ENDOPATH THORACIC 12MM
666	ENVELOPE A4 229X324MM (GHL)
667	ENVELOPE A5 162X229MM (GHL)
668	ENVELOPE A5 162X229MM (PANTAI)
669	ENVELOPE DESPATCH LARGE
670	ENVELOPE DESPATCH LARGE (MED REC FOLDER)
671	ENVELOPE DESPATCH SMALL

Sr.	Item Description
672	ENVELOPE DL W/O WINDOW 110X220MM (GHL)
673	ENVELOPE DL W/WINDOW 110X220MM (GHL)
674	ENVELOPE WHITE PARKWAY EYE CENTRE
675	ENVELOPE X-RAY LARGE 390X460MM
676	ENVELOPE X-RAY SMALL 280X330MM
677	EPIDURAL W/SPINAL NEEDLE 16G
678	EPIDURAL W/SPINAL NEEDLE 18G
679	ETT ARMD SAFETY FLEX 118-80 R.CUFF 8MM
680	ETT ARMD SAFETY FLEX 118-85 R.CUFF 8.5MM
681	ETT BRONCH 2-LUMEN CH28 LT #125-28
682	ETT BRONCH 2-LUMEN CH35 LT #125-35
683	ETT BRONCH 2-LUMEN CH37 LT #125-37
684	ETT BRONCH 2-LUMEN CH39 LT #125-39
685	ETT BRONCH 2-LUMEN CH41 LT
686	ETT CUFF 7.5MM #SPL100-189-075 (10/BOX)
687	ETT CUFF 8.0MM #SPL100-189-080 (10/BOX)
688	ETT CUFFED SAFETY FLEX 5.5MM (11855)
689	ETT INTRODUCER SZ 4.3MM #503000
690	ETT LASER FC 5.0MM #160-50
691	ETT NASAL CUFF NTH 6.0MM #PL100-133-060
692	ETT NASAL CUFF NTH 7.0MM #PL100-133-070
693	ETT ORAL NORTH CUFF 7.0MM
694	ETT ORAL NORTH CUFF 7.5MM
695	ETT ORAL NORTH CUFF 8.0MM
696	ETT RAE NASAL CUFF 7.0MM #119-70A
697	ETT RAE ORAL CUFF 5.0MM #115-50A
698	ETT RAE ORAL CUFF 5.5MM #115-55
699	ETT RAE ORAL CUFF 6.5MM #115-65A
700	ETT RAE ORAL CUFF 7.0MM #115-70
701	ETT RAE ORAL CUFF 7.5MM #115-75
702	ETT RAE ORAL CUFF 8.0MM #115-80
703	ETT RAE ORAL CUFF 8.5MM #115-85
704	ETT RAE ORAL UNCUFF 3.5MM #113-35
705	ETT RAE ORAL UNCUFF 4.0MM #113-40
706	ETT RAE ORAL UNCUFF 4.5MM #113-45
707	ETT RAE ORAL UNCUFF 5.0MM #113-50
708	ETT RAE ORAL UNCUFF 5.5MM 113-55
709	ETT RAE ORAL UNCUFF 6.0MM #113-60
710	ETT REINFORCED 6.5MM #118-65 (10/BX)
711	ETT REINFORCED 7.5MM #118-75
712	ETT REINFORCED CUFFED MURPHY 7MM
713	ETT TUBE MICROLARYNGEAL 6.0MM #121-60
714	EURO BATH HAIR & BODY SHAMPOO
715	EVAC 70 WAND WITH CABLE (EIC5872-01)
716	EXT TUBING 200CM PERFUSOR #872286/2
717	EXTRACTOR MUCUS W/LUER CONNECTOR 40CM
718	EXTRACTOR RETRIEVAL BALLON MICROVASIVE
719	EXTRACTOR XL TRIPLE LUMEN BALLONS 5047
720	EYE PAK BLWW APDR W/P #8065-1043-20
721	EYEDROP ANTI INFLAMMATORY NEVANAC 5ML
722	EYEDROP PROTECTIVE BLINK #100264707
723	EYEGARD ADULT #S2020
724	EYETEC PVA SPEARS (180/BOX) #ETC/40-405
725	FALL RISK ASSESSMENT TOOL (100/PAD)
726	FD-22 FORM VARIABLE ALLOWANCE
727	FELT TEFLON PTFE 15X15CM #UIM-007837
728	FIBRILLAR ABS HEMOSTAT 1"X2"#1961(10/BX)
729	FILE CASENOTE
730	FILM DRYVIEW DVB 20X25CM 125SH #6549711
731	FILM DRYVIEW DVB 25X30CM 125SH #6549737
732	FILTER AIR FOR OER-A OR OER-AW

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
733	FILTER BACTERIAL W/O2 INLET
734	FILTER BACTERIAL/VIRAL VITAL SIGNS #5096
735	FILTER BARRIERBAC T3505422
736	FILTER GAS FOR OER-A OR OER-AW
737	FILTER HYDROPHOBIC DISP 300MM LONG
738	FILTER HYGROBAC 'S' COMBINE HME #3525877
739	FILTER LEUKOCYTE FOR BLOOD PALL #RC1VAE
740	FILTER SET FOR XPLUME #LVPF750
741	FILTER STERIFIX 0.2 MICRO INJE
742	FILTER THERMAL #SPL-100-570-015
743	FILTER WATER FOR OER-A OR OER-AW
744	FLARE MINI 45DEG KELMAN ABS #8065750853
745	FLEXIFLO (12F / 14F)
746	FLEXON 3/0 (STEEL) 24" T 31 (8886259243)
747	FLU. BIVALVE INTRANASAL SPLINT
748	FOAM WALKER
749	FOLDER CASE PARKWAY EYE CENTRE
750	FOLDER MEDICAL RECORDS 340MM X 255MM
751	FOLDER PARKWAYHEALTH
752	FOLDING FRAME
753	FOLIODRAPE PROTECT 90X150CM (277506)
754	FOOT - MELLEOTRAIN
755	FOOT CUFF SCD EXPRESS (73032) 10/BX
756	FORCEP GRASPING OLYMPUS (FG-301Q)
757	FORCEP HOT BX RJ3 2.2MM JAW O.D 240CM
758	FORCEP OGD BX 2.2MM JAW O.D 160CM
759	FORCEP STRAIGHT IRIS W/O CABLE 10/BX
760	FORM ADM HISTORY/NURSING ASSESSMENT
761	FORM ADMISSION ASSESSMENT (MATERNITY)
762	FORM ANAESTHETIC RECORD (PHS) (100/PK)
763	FORM ANALGESIA CHART (PHS)
764	FORM CARE PATHWAY - EXTRA CARE DAY
765	FORM CARE PATHWAY (NEWBORN)
766	FORM CARE PATHWAY CAESAREAN SECTION
767	FORM CARE PATHWAY VAGINAL DELIVERY
768	FORM CONSENT CONTRAST MEDIA
769	FORM CONSENT ELE.TRAN.BLOOD PRODUCT(PHS)
770	FORM CONSENT FOR OPERATION (PHS)
771	FORM CONTINUATION SHEET (REHAB & HCS)
772	FORM CORNOR CASE TAG (GHL)
773	FORM CT CORONARY ANGIOGRAM A5 70GSM
774	FORM DAYWARD ADMISSION & NURSING
775	FORM DIABETIC CHART (PHSPL)
776	FORM DIETARY CONSULTATION REQUEST (PHS)
777	FORM ENTERAL FEEDS ORDERS SCHEDULING
778	FORM ESTIMATION OF HOSP CHARGE (GHL)
779	FORM EYE SURGURY ADMISSION ASSESSMENT
780	FORM FLUID BALANCE CHART (PHS)
781	FORM FOUR HOUR CLINICAL CHART (PHS)
782	FORM INFANT FEEDING CHART (PHS)
783	FORM INPATIENT PHARMACY CHARGE FORM
784	FORM IV SITE CHECK (PHS)
785	FORM LABORATORY SVCS LB60 YELLOW (GHL)
786	FORM LAUNDRY SERVICES (GHL)
787	FORM LEAFLETS METABOLIC SCREENING TEST
788	FORM LEAFLETS NEWBORN HEARING SCREENING
789	FORM MAT-REGISTER REC-OF OP (GHL)
790	FORM MEDICAL CERTIFICATE CHIT (GHL)
791	FORM MEDICATION /MAT WARD A4 (GHL)
792	FORM MEDICATION ADMINISTERED
793	FORM MEDICATION USED IN THEATRE (GHL)

Sr.	**Item Description**
794	FORM NEONATAL ADMISSION HISTORY &
795	FORM NEONATAL INTAKE & OUTPUT (PHS)
796	FORM NEONATAL OBSERVN CHART (PHS)
797	FORM NEONATAL RESPIRATORY CHART (PHS)
798	FORM NEURO OBSERVATION CHART (PHS)
799	FORM NICU PLAN OF CARE
800	FORM NON CORNOR CASE TAG (GHL)
801	FORM NURSERY ADMISSION & NURSING
802	FORM NURSERY PLAN OF CARE
803	FORM NURSING APPOINTMENT CARD (GHL)
804	FORM NURSING CARE PLAN (CON'T SHEET)
805	FORM NURSING SER 24 HRS REPORT (GHL)
806	FORM NUTRITION ASSESSMENT (PHS)
807	FORM OBSERVATION CHART (PHS)
808	FORM OPERATION RECORD (H/C) (GHL)
809	FORM OUTPATIENT RECORD (REHAB & HCS)
810	FORM PAED ADMISSION HISTORY & NURSING
811	FORM PARENTERAL INFUSION/TRANSFUSION
812	FORM PARTOGRAM A3 (PHS)
813	FORM PATIENT DISCHARGE (GHL)
814	FORM PATIENT EDU & DISCHARGE PLAN (PHS)
815	FORM PATIENT NAME TAG" (GHL)
816	FORM PATIENT'S EXTRAS (GHL)
817	FORM PATIENT'S OWN MEDICATION
818	FORM PERI-OPERATIVE NURSING RECORD (PHS)
819	FORM PHARMACY BILLING SH A5 (GHL)
820	FORM PLAN OF CARE
821	FORM POST OPERATION REFRACTION (PEC)
822	FORM PRECAUTION OF FALLS (ENGLISH)-PGH
823	FORM PRE-OPERATIVE PHOROMETRY A4
824	FORM PRESCRIPTION A5 (PHS) 4C/0C
825	FORM PREVENTION OF FALL (MALAY)-PGH
826	FORM RADIOLOGY PROCEDURE CHECKLIST A4
827	FORM RECOVERY ROOM NURSING RECORD (PHS)
828	FORM REFRACTION REPORT (PEC)
829	FORM SWAB/NDLE/BLADE/INSTR COUNT RECORD
830	FORM TIME-OUT CHECKLIST A4 LOOSE SHEETS
831	FORM TRANSFER CHECKLIST (GENERAL)
832	FORM TRANSFER CHECKLIST (MATERNITY)
833	FORM ULTRASOUND WORKSHEET FOR
834	FORM WARD BILLING SHEET A5 (GHL)
835	FORM X-RAY REQUEST (GHL) A5 3C/1C
836	FORM X-RAY REQUEST RD-10 (MEH)
837	FORM,NICU ACTIVITY FLOWSHEET 2C/1C(GHL)
838	FRACTURE BANDING #DO870R
839	FRIDGE 197 LITRES
840	FUNNEL BREAST-SHIELD W/CONNECTOR
841	GAMCATH DOLPHIN PROTECT #109710
842	GAMCATH TRI-LUM 15CM 12F #GTK-1215
843	GAMCATH TRI-LUM 20CM 12F #GTK-1220
844	GAUSSETTED VIEW PACK 300MM X100M
845	GAUZE GREEN N/STERILE 8PLY X 10CM X 10CM
846	GAUZE PARAFIN JELONET 10CM X 7M 7477
847	GAUZE PLAIN N/STER 16PLY 7.5CM X 7.5CM
848	GAUZE PLAIN N/STER 32PLY 4" X 4"
849	GAUZE PLAIN STERILE 16PLY 10CM X 10CM
850	GAUZE RAYTEX TAIWAN 32PLY X 10CM
851	GAUZE RIBBON 1 PLY 1.25CM X 180CM
852	GAUZE RIBBON 1 PLY 2.5CM X 180CM
853	GAUZE SPONGES N/STER 16PLY 4" X 4"
854	GAUZE STERILE XRAY 16PLY 10CM X 10CM

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
855	GAUZE STERILE XRAY 32PLY 7.5CM X 7.5CM
856	GAUZE SWABS STERILE 16PLY 3" X 3"
857	GEL - 4OZ
858	GEL AQUASONIC 3 LITRE (2/BOX)
859	GEL FOAM 12.7 20*60*7MM
860	GEL INTRASITE 25F 10'S #7313
861	GERM KILLER GK CONCENTRATE 5L
862	GLOVE EXAM COPOLYMER STERILE MEDIUM
863	GLOVE EXAM COPOLYMER STERILE SMALL
864	GLOVE FOR RECTAL PROBE 503190
865	GLOVE LATEX LONG POWDER FREE SMALL
866	GLOVE LATEX POWDER FREE LONG 530MM LARGE
867	GLOVE LATEX POWDER FREE LONG 530MM SMALL
868	GLOVE SURGEON ANSELL NON POWDERED SZ 5.5
869	GLOVE SURGEON ANSELL NON POWDERED SZ 6.0
870	GLOVE SURGEON ANSELL NON POWDERED SZ 6.5
871	GLOVE SURGEON ANSELL NON POWDERED SZ 7.0
872	GLOVE SURGEON ANSELL NON POWDERED SZ 7.5
873	GLOVE SURGEON ANSELL NON POWDERED SZ 8.0
874	GLOVE SURGEON ANSELL POWDERED SZ 5.5
875	GLOVE SURGEON ANSELL POWDERED SZ 6.0
876	GLOVE SURGEON ANSELL POWDERED SZ 6.5
877	GLOVE SURGEON ANSELL POWDERED SZ 7.0
878	GLOVE SURGEON ANSELL POWDERED SZ 7.5
879	GLOVE SURGEON ANSELL POWDERED SZ 8.0
880	GLOVE SURGEON ANSELL POWDERED SZ 8.5
881	GLOVE WASH ABSBOND 16.5X25CM (175/BX)
882	GLOVES ANSELL GAMMEX PF SZ 8.5
883	GLOVES DERMAPRENE SURGICAL PF SZ 5.5
884	GLOVES DERMAPRENE SURGICAL PF SZ 6.0
885	GLOVES DERMAPRENE SURGICAL PF SZ 6.5
886	GLOVES DERMAPRENE SURGICAL PF SZ 7.0
887	GLOVES DERMAPRENE SURGICAL PF SZ 8.0
888	GLOVES EXAM LATEX N/STERILE EX-SMALL
889	GLOVES EXAM LATEX N/STERILE LARGE
890	GLOVES EXAM LATEX N/STERILE MEDIUM
891	GLOVES EXAM LATEX N/STERILE SMALL
892	GLOVES LARGE PURPLE NITRILE-XTRA PF
893	GLOVES LATEX POWDERFREE SIZE "M"
894	GLOVES NITRILE N/STER N/POWDERED (L)
895	GLOVES NITRILE N/STER N/POWDERED (M)
896	GLOVES NITRILE N/STER N/POWDERED (S)
897	GLOVES PURPLE NITRILE-XTRA EXAM MEDIUM
898	GLOVES PVC N/STERILE MEDIUM (100/PK)
899	GLOVES RADIATION FLUROSHIELD 8.0
900	GLOVES SURGICAL DERMAPRENE PF SZ 7.5
901	GOWN CPE WITH SLEEVES #PPEPM-02121
902	GOWN IMPERVIOUS MICROCOOL #92043 X-LARGE
903	GOWN ISOLATION GREEN L #1351903
904	GOWN ISOLATION HB505
905	GOWN OPERATING DISP LARGE 13597000519
906	GOWN SURGEON BARRIER X-LARGE (36/BX)
907	GOWN SURGICAL REINFORCED XLL (135660106)
908	GRAFT DURA TUTOPLAST 4 X 10CM #68352
909	GRAFT DURA TUTOPLAST 4 X 5CM #68351
910	GRAFT DURA TUTOPLAST 6 X 8CM
911	GROMMET TUBE MINI SHAH XOM (14311) 5/BX
912	GUIDEWIRE ANGLED 0.035 150CM
913	GUIDEWIRE M 0.035" 150CM #RFPA35153M
914	GUIDEWIRE TEFLON #TSF-25-145
915	GUIDEWIRE TEFLON #TSF-35-145

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	**Item Description**
916	GUIDEWIRE ZEBRA 0.025 HYDROPHILLIC TIP
917	GUT CHROMIC 1 75CM BP-27 #TCG48
918	GYM BALL - 55CM
919	GYM BALL - 65CM
920	HAIR WASH 40ML NOBILITY BOTTLE (200/CTN)
921	HAMPER STEP-ON LINEN #6300-BLA
922	HANA BABY WRAP
923	HANAULUX LIGHT BULB 22.8V 50W
924	HAND RESTRAINER
925	HANDLE SUCTION YANKAUER
926	HANDTOWEL PAPER SENSORCUT 186MX20CM
927	HEAD POSITIONER DISPOSA-VIEW (FOAM)
928	HEALTH BOOKLET (PARKWAY HEALTH)
929	HEAT PAD - BACK
930	HEAT PAD - NECK
931	HEEL & ANKLE PROTECTOR
932	HEMOCLIP OGD & COLONO 235CM ADJUSTABLE
933	HEMOCLIP WECK T1 MEDIUM 533802
934	HEMOSTASIS QUICKCLIPS OLYMPUS
935	HIGH VACCUM SYS MEDINORM 150 #JVS5022312
936	HIP SET (13560606) 8/BX
937	HME CUM FILTER HYGROBABY #355/5427
938	HME CUM FILTER HYGROBOY #355/5430
939	HOLDER ETT TUBE DALE STABILOCK #270
940	HOLDER TRACHESTOMY TUBE DALE #240
941	HOOD SURGEON PROTECTIVE 13542072I
942	HOOD T4 (36/BOX)
943	HOOK AMNI 10" STERILE CURVE
944	HOOK ELASTIC STAY 5MM SHARP #3311-8G
945	HOT FILE II
946	HOT PACK BACK E'CENEL
947	HOT PACK NECK E'CENEL
948	HOT/COLD PACK 12"X14" (THERAPIST SIZE)
949	HOT/COLD PACK 6" X 9" (REGULAR)
950	HUMIDIFICATION CHAMBER HC 150 HUMIDIFIER
951	HUMIDIFIER DISP AUTO-FLOW MR290 (10/BOX)
952	HUMIDIFIER W/NEONATAL CIRCUIT RT225
953	I.V. SOLUMED'S SWABSTICKS (10203)
954	ILLUMINATOR FIBRE OPTIC 20G
955	IMEX TIRE EYE #S5-2000
956	IMMOBILIZER KNEE 20" SMALL (4030-S)
957	IMP CLOVERLEAF PLATE 3.5MM THIN BLADE
958	IMP DCS 95 DEG 14 HOLE L242 #281.93
959	IMP DRILL BIT 1.3 L46/34 2FLUTE #513.035
960	IMP DRILL BIT 1.5 L96/82 2FLUTE #310.507
961	IMP DRILL BIT 2.4 L80/66 2FLUTE #317.871
962	IMP DRILL BIT 2.8 L165 2FLUTE #310.284
963	IMP DRILL BIT 4.3 L280 F/324.007 310.423
964	IMP L-BUTTRESS PLATE LT SUPP 4H #240.540
965	IMP L-BUTTRESS PLATE RT SUPP 4H #240.440
966	IMP LC-DCP 3.5MM PLATE 10H #223.600
967	IMP PIN GUIDE DIA 25MM L230 #338.000
968	IMP PLATE 1/3 TUBULAR 5 HOLES #241.350
969	IMP PLATE 1/3 TUBULAR 6 HOLES #241.360
970	IMP PLATE 1/3 TUBULAR 7 HOLES #241.370
971	IMP PLATE 1/4 TUBULAR 4 HOLES #242.040
972	IMP PLATE 1/4 TUBULAR 6 HOLES #242.060
973	IMP PLATE 135DEG 4 HOLES L78MM #281.140
974	IMP PLATE 135DEG 5 HOLES L94MM #281.150
975	IMP PLATE 135DEG 6 HOLES L110MM #281.160
976	IMP PLATE 150DEG 4 HOLES L78MM #281.440

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	**Item Description**
977	IMP PLATE 3.5MM RECON 9 HOLES
978	IMP PLATE 3.5MM 'T' 3 HOLES #241.130
979	IMP PLATE LC-DCP 3.5MM 6 HOLES #223.560
980	IMP PLATE LC-DCP 3.5MM 7 HOLES #223.570
981	IMP PLATE LC-DCP 3.5MM 8 HOLES #223.580
982	IMP PLATE LC-DCP 4.5MM 10H #224.600
983	IMP PLATE LC-DCP 4.5MM 10H #226.600
984	IMP PLATE LC-DCP 4.5MM L160 SST #226.590
985	IMP PLATE LC-DCP 4.5MM NARROW 7H
986	IMP PLATE LC-DCP BROAD 8 HOLES #226.580
987	IMP PLATE RECON 4.5MM 8HOLE #229.380
988	IMP PLATE RECON PELV 3.5MM 8H #245.180
989	IMP PLATE RECONSTN 3.5MM 7H #245.170
990	IMP PLATE SEMI-TUBULAR 5 H
991	IMP SCREW 1.5MM CORTICAL 14MM #210.014
992	IMP SCREW 1.5MM CORTICAL 16MM #210.016
993	IMP SCREW 2.0MM CORTICAL 16MM #211.016
994	IMP SCREW 2.7MM CORTEX L12MM #202.012
995	IMP SCREW 2.7MM CORTEX L16MM #202.016
996	IMP SCREW 2.7MM CORTICAL 10MM #202.010
997	IMP SCREW 2.7MM CORTICAL 14MM #202.014
998	IMP SCREW 2.7MM CORTICAL 18MM #202.018
999	IMP SCREW 2.7MM CORTICAL 20MM #202.020
1000	IMP SCREW 2.7MM CORTICAL 8MM #202.008
1001	IMP SCREW 3.5MM CORTICAL 10MM #204.010
1002	IMP SCREW 3.5MM CORTICAL 12MM #204.012
1003	IMP SCREW 3.5MM CORTICAL 14MM #204.014
1004	IMP SCREW 3.5MM CORTICAL 16MM #204.016
1005	IMP SCREW 3.5MM CORTICAL 18MM #204.018
1006	IMP SCREW 3.5MM CORTICAL 20MM #204.020
1007	IMP SCREW 3.5MM CORTICAL 22MM #204.022
1008	IMP SCREW 3.5MM CORTICAL 24MM #204.024
1009	IMP SCREW 3.5MM CORTICAL 26MM #204.026
1010	IMP SCREW 3.5MM CORTICAL 28MM #204.028
1011	IMP SCREW 3.5MM CORTICAL 32MM #204.032
1012	IMP SCREW 3.5MM CORTICAL 36MM #204.036
1013	IMP SCREW 3.5MM CORTICAL 40MM #204.040
1014	IMP SCREW 4.0MM CANCELLOUS F/T 35MM
1015	IMP SCREW 4.5MM CORTICAL 18MM #214.018
1016	IMP SCREW 4.5MM CORTICAL 20MM #214.020
1017	IMP SCREW 4.5MM CORTICAL 22MM #214.022
1018	IMP SCREW 4.5MM CORTICAL 24MM #214.024
1019	IMP SCREW 4.5MM CORTICAL 26MM #214.026
1020	IMP SCREW 4.5MM CORTICAL 28MM #214.028
1021	IMP SCREW 4.5MM CORTICAL 30MM #214.030
1022	IMP SCREW 4.5MM CORTICAL 32MM #214.032
1023	IMP SCREW 4.5MM CORTICAL 34MM #214.034
1024	IMP SCREW 4.5MM CORTICAL 36MM #214.036
1025	IMP SCREW 4.5MM CORTICAL 38MM #214.038
1026	IMP SCREW 4.5MM CORTICAL 40MM #214.040
1027	IMP SCREW 4.5MM CORTICAL 42MM #214.042
1028	IMP SCREW 4.5MM CORTICAL 44MM #214.044
1029	IMP SCREW 4.5MM CORTICAL 46MM #214.046
1030	IMP SCREW 4.5MM CORTICAL 48MM #214.048
1031	IMP SCREW 4.5MM CORTICAL 52MM #214.052
1032	IMP SCREW 4.5MM CORTICAL 56MM #214.056
1033	IMP SCREW 4.5MM CORTICAL 58MM #214.058
1034	IMP SCREW 4MM CANCELLOUS 16MM ST#207.016
1035	IMP SCREW 4MM CANCELLOUS 40MM ST#207.040
1036	IMP SCREW 4MM CANCELLOUS FT 12MM 206.012
1037	IMP SCREW 4MM CANCELLOUS FT 16MM 206.016

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1038	IMP SCREW 4MM CANCELLOUS FT 18MM 206.018
1039	IMP SCREW 4MM CANCELLOUS FT 20MM 206.020
1040	IMP SCREW 4MM CANCELLOUS FT 22MM 206.022
1041	IMP SCREW 4MM CANCELLOUS FT 26MM 206.026
1042	IMP SCREW 4MM CANCELLOUS FT 28MM 206.028
1043	IMP SCREW 4MM CANCELLOUS FT 40MM 206.040
1044	IMP SCREW 4MM CANCELLOUS FT 45MM 206.045
1045	IMP SCREW 4MM CANCELLOUS FT 50MM 206.050
1046	IMP SCREW 4MM CANCELLOUS FT 60MM 206.060
1047	IMP SCREW 4MM CANCELLOUS PT 14MM 206.014
1048	IMP SCREW 6.5MM CAN FT 25MM 218.025
1049	IMP SCREW 6.5MM CANCELLOUS 16T 30MM
1050	IMP SCREW 6.5MM CANCELLOUS 16T 35MM
1051	IMP SCREW 6.5MM CANCELLOUS 16T 40MM
1052	IMP SCREW 6.5MM CANCELLOUS 16T 45MM
1053	IMP SCREW 6.5MM CANCELLOUS 16T 50MM
1054	IMP SCREW 6.5MM CANCELLOUS 16T 55MM
1055	IMP SCREW 6.5MM CANCELLOUS 16T 90MM
1056	IMP SCREW 6.5MM CANCELLOUS 32T 45MM
1057	IMP SCREW 6.5MM CANCELLOUS 32T 50MM
1058	IMP SCREW 6.5MM CANCELLOUS 32T 55MM
1059	IMP SCREW 6.5MM CANCELLOUS 32T 60MM
1060	IMP SCREW 6.5MM CANCELLOUS 32T 70MM
1061	IMP SCREW 6.5MM CANCELLOUS 32T 80MM
1062	IMP SCREW 6.5MM CANCELLOUS FT 35MM
1063	IMP SCREW 6.5MM CANCELLOUS FT 40MM
1064	IMP SCREW 6.5MM CANCELLOUS FT 70MM
1065	IMP SCREW CANCELLOUS PT 4MM*50MM 207.050
1066	IMP SCREW CANCELLOUS ST 4MM*30MM 207.030
1067	IMP SCREW CANCELLOUS ST 4MM*35MM 207.035
1068	IMP SCREW CANCELLOUS ST 4MM*45MM 207.045
1069	IMP SCREW DHS COUPPLING # 280.990
1070	IMP SCREW DHS/DCS 12.5 L55 SST #280.55
1071	IMP SCREW DHS/DCS LAG L85MM #280.850
1072	IMP SCREW DHS/DCS SCREW L65MM #280.650
1073	IMP SCREW LAG DHS 105MM
1074	IMP SCREW LAG DHS 60MM #280.600
1075	IMP SCREW LAG DHS 75MM #280.750
1076	IMP SCREW LAG DHS 80MM #280.800
1077	IMP TUBULAR 1/3 PLATE 3 HOLES #241.330
1078	IMP WASHER 7MM FOR SMALL SCREWS #219.980
1079	IMP WIRE 1.00MM KIRSCHNER 150MM #292.100
1080	IMP WIRE 1.25X150 W/TRO TIP #292.120
1081	IMP WIRE 1.40X150 W/TRO TIP #292.140
1082	IMP WIRE 1.6MM KIRSCHNER 285MM #292.180
1083	IMP WIRE 1.6X150MM KIRSCHNER #292.160
1084	IMP WIRE 2.00MM KIRSCHNER 150MM #292.200
1085	IMP WIRE 2.00MM KIRSCHNER 285MM #292.210
1086	IMP WIRE ARTH 0.8MMX100MM #292.000.502
1087	IMP WIRE ARTH 1.25MMX100MM #292.000.618
1088	IMP WIRE ARTH 1MMX100MM #292.000.604
1089	IMR ADULT REGULAR MEDICATIONS A3-OPEN
1090	INCENTIVE SPIROMETER (VOLDYNE)
1091	INCISOR 4.5MM CURVED CONCAVE #7205332
1092	INCONTINENCE MOLINEA PLUS
1093	INCONTINENCE PAD 43CM X 60CM
1094	INCONTINENCE PAD 5PLY 76CM X 76CM
1095	INDICATOR CYCLESURE BIOLOGICAL 14324
1096	INDICATOR SOIL TEST FORMULA #SBL-2315
1097	INDICATOR SPECIAL PH3.8-5.4(1.09555.0003
1098	INFANT RECORD (PHS)

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1099	INFINITI ANT VITRECTOMY PAK 8065750157
1100	INFINITI INTREPID FMS + 2.2MM
1101	INFINITI ULTRASOUND PAK + 2.75MM
1102	INFUSOR BAG 3L
1103	INJECTOR HEMOSTASIS (18351) 5/BX
1104	INJECTOR Ø2.4X2300MM 23G NL- 4MM
1105	INSTRU-STAIN RUST/STAIN REMOVER 5L
1106	INTERCEED ADHESION BARRIER 3"X4" #4350
1107	INTERSORB PLUS SODA LIME 5LTRS #2179
1108	INTRALASE PATIENT INTERFACE (CONE)PI-20U
1109	INTRODUCER BOUGIE 15CH SPL-100-123-515
1110	INTUBATION STYLET 2.2MM SMALL
1111	INTUBATION STYLET 4.2MM MEDIUM
1112	IRIS FLUTED ENDO PROBE 11473
1113	IRRIGATION SET MALIS BIPOLAR 80-1165
1114	IRRIGATION ST ORTHO SURGILAV #5150-47500
1115	JACKSON REES MODIFIED (VS5104BVWE) 20/CS
1116	JAGWIRE SU GUIDEWIRE 0.025/450CM
1117	JAGWIRE SU GUIDEWIRE 0.035/450CM
1118	JUG MEASURING PLASTIC 1000ML
1119	J-VAC RESV 100CC #2160 (10/BX)
1120	KALTOSTAT ROPE 2 G (BX/5)
1121	KALTOSTAT SHEET 7.5 X 12 CM (10/BX)
1122	KELMAN MICRO TIP 30 DEG #30KTS
1123	KIDNEY DISH PLASTIC 12" #SWAR-KD250
1124	KINESIO TAPE - 5CM X 5M
1125	KIT 100% OXYGEN W/OXYGEN TUBE TPIECE
1126	KIT DENTAL
1127	KIT ESPOCAN WITH PENCAN #4050176 (1/BX)
1128	KIT GAS CHANGE SP69003000
1129	KIT GLEN ART-1 TRANSDUCER
1130	KIT GLEN VEN-1 TRANSDUCER
1131	KIT MONITORING GLEN ART-2
1132	KIT SENSOR FLOTRAC X 84" #MHD8
1133	KIT SHOULDER STABLIZATION #7210573 12'S
1134	KLARITY WHITE 460X610X2.4MM NON PERF
1135	KLINWIPE DOR10 60 00 500/CTN
1136	KNEE - GENUTRAIN
1137	KNEE - GENUTRAIN P3
1138	KNEE BRACE
1139	KNEE CRYOCUFF
1140	KNIFE CRESCENT 2.25 ANGLED (581118) 5/BX
1141	KNIFE SLIT 2.75MM SATIN FINISH (9927-45)
1142	LABEL 2HB EXPIRY DATE & STERILIZED DATE
1143	LABEL 5FU RED (500/BX)
1144	LABEL ADRENALINE 45MMX15MM RED T1036/161
1145	LABEL ATROPINE
1146	LABEL BLACK BUPIVACAINE WITH ADRENALINE
1147	LABEL BLACK CO-PHENYLCAINE
1148	LABEL BLACK STERILE WATER
1149	LABEL BLACK VERAPAMIL
1150	LABEL BLANK 40MMX15MM T1036/119
1151	LABEL BLANK MRO 100MM X 40MM
1152	LABEL BLUE CETRIMIDE
1153	LABEL BLUE CHLORHEXIDE AQUEOUS
1154	LABEL BLUE HEXODANE 2%
1155	LABEL BLUE POVIDONE IODINE
1156	LABEL BLUE POVIDONE WITH SPIRIT
1157	LABEL BROWN ACETIC ACID 40MM X 15MM
1158	LABEL BROWN BONNIE BROWNING 40MM X 15MM
1159	LABEL BROWN LUGOL'S IODINE 40MM X 15MM

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1160	LABEL BSS 40X15MM MIRRORKOTE
1161	LABEL CALCIUM CHLORIDE GREEN (500/BX)
1162	LABEL DATE CHANGE 8.1MMX12.7 MM
1163	LABEL DEXAMETHASONE 40X15MM MIRRORKOTE
1164	LABEL DOPAMINE 45MMX15MM RED T1036/139
1165	LABEL DORMICUM 40MMX15MM GREEN T1036/160
1166	LABEL DRUG DILUTION 70MMX65MM (A105WF)
1167	LABEL EPIDURAL/IV 100MMX40MM (1000/PK)
1168	LABEL ETOMIDATE
1169	LABEL EXPIRY DATE TAG 23MMX16MM
1170	LABEL FENTANYL 0.05MG/ML 20MMX10MM
1171	LABEL FENTANYL 40MMX15MM BLUE T1036/109
1172	LABEL G6PD DEFICIENT
1173	LABEL GENTAMYCIN 40X15MM MIRRORKOTE
1174	LABEL HEPARIN BLACK (500/BX)
1175	LABEL HYDROGEN PEROXIDE 40X15MM
1176	LABEL INFECTION RISKS (MASK ETC)(GHL)
1177	LABEL LASER AVERY #5960 (250/BOX)^^
1178	LABEL LASER AVERY WHITE #BBDC07793UP
1179	LABEL LIGNOCAINE 40X15MM MIRRORKOTE
1180	LABEL MARCAINE 40X15MM MIRRORKOTE
1181	LABEL METHYLENE BLUE (500/BX)
1182	LABEL MIOSTAT 40X15MM MIRRORKOTE
1183	LABEL MITOMYCIN RED (500/BX)
1184	LABEL MORPHINE RED 40MM X 15MM (500/BX)
1185	LABEL NACL 20MMX5MM (MIN 1K)
1186	LABEL NAROPIN ORANGE (500/BX)
1187	LABEL NORMAL SALINE 40X15MM MIRRORKOTE
1188	LABEL ORANGE ACRIFLAVINE 40MM X 15MM
1189	LABEL ORANGE COMPOUND BENZOIN TINCTURE
1190	LABEL ORANGE PROFLAVINE EMULSION
1191	LABEL PETHIDINE 40MMX15MM BLUE T1036/117
1192	LABEL PETHIDINE 50MG/ML 20MMX10MM
1193	LABEL PILOCARPINE 2% YELLOW (500/BX)
1194	LABEL PINK STICKER (AVERY)
1195	LABEL POVIDONE 40X15MM MIRRORKOTE
1196	LABEL PURPLE BIPP PASTE
1197	LABEL PURPLE MONSEL PASTE
1198	LABEL SCOLINE 40MMX15MM GREEN T1036/118
1199	LABEL SHINCORT 40X15MM MIRRORKOTE
1200	LABEL TRACRIUM 40MMX15MM PINK T1036/089
1201	LABEL VASOPRESSIN 40X15MM MIRRORKOTE
1202	LABEL XYLOCAINE WITH ADRENALINE (500/BX)
1203	LABEL YELLOW EUSOL MAX SOLUTION
1204	LABEL YELLOW EUSOL PARAFFIN
1205	LABELER HAND 2HGB
1206	LABTICIAN TIRE 7.0MM 2.5MM #277
1207	LABTICIAN TIRE 9.0MM 2.5MM #279
1208	LARGE WASHER 13.0MM #219.990
1209	LAUNDRY SERVICES
1210	LDPE BAGS 0.04MM X 10" X 16"
1211	LEAD ELECTRICAL ADAPTOR #5603
1212	LEGBAG CONTOURED 600ML 45CM TUBE (5171)
1213	LEGEND 10CM 3MM BALL FLUTED (10BA30)
1214	LEGEND 10CM 3MM MATCH (10MH30)
1215	LEGEND 10CM 3MM MATCH DIAMOND
1216	LEGEND 10CM 4MM BALL DIAMOND 10BA40D
1217	LEGEND 10CM 4MM BALL FLUTED (10BA40)
1218	LEGEND 14CM 3MM BALL FLUTED (14BA30)
1219	LEGEND 14CM 3MM MATCH (14MH30)
1220	LEGEND 14CM 3MM MATCH DIAMOND (14MH30D)

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1221	LEGEND 14CM 5MM BALL FLUTED (14BA50)
1222	LEGEND 26CM 6MM BALL FLUTED (26BA60)
1223	LEGEND 3MM METAL CUTTER (MC30)
1224	LEGEND 7CM 2MM BALL DIAMOND (7BA20D)
1225	LEGEND 7CM 2MM BALL FLUTED (7BA20)
1226	LEGEND 7CM 4MM BALL FLUTED (7BA40)
1227	LEGEND 7CM 7MM BALL FLUTED 7BA70-MN
1228	LEGEND 8CM 2.3MM TAPERED (F2/8TA23)
1229	LEGEND 9CM 3MM MATCH (9MH30)
1230	LEGEND 9CM 3MM MATCH DIAMOND 9MH30D
1231	LEGEND 9CM 3MM TAPERED (F3/9TA30)
1232	LEGEND 9CM 6MM ACORN 9AC60
1233	LEGEND T12 TUBE 2.5MM MATCH (T12MH25)
1234	LEGGING LITHOTOMY XL #135255P
1235	LENSX PATIENT INTERFACE #8065998163
1236	LETTER OF CERTIFICATION (PHS)
1237	LETTERHEAD GHL
1238	LETTERHEAD PARKWAY EYE CENTRE A4
1239	LETTERHEAD PHS
1240	LEVEL 1 AQEOUS CONTROL 131000 (10/BX)
1241	LIGATOR KILROID HAEMORRHOID (KIL-067252)
1242	LIGATOR VARICES (6 SHOOTER) MBL-6
1243	LIMB CIRCULATION CHART (100/PAD)
1244	LINEAR CUTTER 100M BLU (TLC10)
1245	LINEAR CUTTER 100M RELOAD BLU (TCR10)
1246	LINER BAXTER THIN WALL 1500CC
1247	LINER CRD FLEX 1500CC DISP *65651-920C
1248	LINER RECEPTAL W/LID 2 LITRE
1249	LINERS PEDAL BIN 18" X 18"
1250	LITHOTRIPTOR MECHANICAL #BML-V442QR-30
1251	LLETZ/LEEP RD LOOP 12MM #B3-4-1208L
1252	LLETZ/LEEP RD LOOP 20MM #B3-4-2515L
1253	LMA FLEXIBLE SINGLE USE SIZE 5 (115050)
1254	LMA SUPREME SIZE 3 SINGLE USE #175030
1255	LMA SUPREME SIZE 4 SINGLE USE #175040
1256	LMA SUPREME SIZE 5 SINGLE USE #175050
1257	LMA UNIQUE SIZE 1.5 (125015) 10/BX
1258	LOOP PDS II 1.5M 50MM ETHIGD (W9967T)
1259	LOTION 40ML NOBILITY BOTTLE (200/CTN)
1260	LOTION EYE SYRINGE 0.5ML (VBL-10-S)
1261	LOTION SKIN CLEASER GENTLE 500ML 18/CTN
1262	LOW LEVEL SENSOR STOCKERT 232741
1263	LSCS SECTIO SET 8'S (135694135) 8/BX
1264	LUCENTIS INJECTION VIAL 10MG/ML #51334
1265	LYOSTYPT FELT 5X30CM (1069306) 4/BX
1266	MANOMETER LINE W/MALE-MALE LURE LOCK
1267	MARKER SKIN STERILE FINETIP 1000-01
1268	MARKER SPOT ENDOSCOPIC LESION #GIS-44
1269	MASIMO SET LNOP ADT OXIMETRY SENSOR B/20
1270	MASK CPAP SMALL
1271	MASK FACE ADULT RESUSCITATION SZ4 REUSE
1272	MASK FACE ADULT SMALL DISPOSABLE SZ 4
1273	MASK FACE DISPOSABLE FOAM 7429 7210559
1274	MASK HIGH CONCENTRATION HOT-1007
1275	MASK LARYNGEAL ARMOURED SIZE 4 110040
1276	MASK LARYNGEAL ARMOURED SZ 3 110030
1277	MASK LARYNGEAL DISPOSABLE SZ 3.0
1278	MASK LARYNGEAL DISPOSABLE SZ 4.0
1279	MASK LARYNGEAL PROSEAL SZ 3 150030
1280	MASK LARYNGEAL PROSEAL SZ 4 150040
1281	MASK LARYNGEAL UNIQUE DISP SZ 2.0 125020

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	**Item Description**
1282	MASK LARYNGEAL UNIQUE DISP SZ 2.5 125025
1283	MASK LARYNGEAL UNIQUE DISP SZ 3.0 125030
1284	MASK LARYNGEAL UNIQUE DISP SZ 4.0 125040
1285	MASK LARYNGEAL UNIQUE DISP SZ 5.0 125050
1286	MASK MICRO MIST NEBULIZER PAED HOT-1886
1287	MASK MULTIVENT 7' OXYGEN ADULT HOT-1088
1288	MASK MULTI-VENT CHILD HOT-1089
1289	MASK NON-REBREATHING ADULT HOT-1060
1290	MASK O2 MED CONC ADULT 7FT HOT-1041
1291	MASK OXYGEN ADULT NBLZ HOT-1885
1292	MASK OXYGEN CHILD ELONGATED HOT-1042
1293	MASK PARTICULATE RESPIRATOR N95 8210
1294	MASK PASTURE N95 F550G
1295	MASK PROCEDURE LITE ONE LOOP 62356
1296	MASK RESPIRATOR N95 #8110S
1297	MASK SURGICAL CLASSIC 3PLY W/O LOOP
1298	MASK SURGICAL FACE DISP ANTIFOG 4231
1299	MASK SURGICAL FLUIDSHIELD LOOP 47147
1300	MASK SURGICAL FLUIDSHIELD TIE-ON 48247
1301	MASK TIE-ON ANTI-FOG #49214
1302	MASK TRACHEOSTOMY ADULT W/O TUBE
1303	MATERNITY RESERVATION FORM (PHS) 100/PD
1304	MAXIPANTS TENAFIX LARGE
1305	MAYFIELD DISPOSABLE SKULL PINS A-1072
1306	MEDELA BREASTSHELL
1307	MEDELA CALMA SOLITAIRE
1308	MEDELA CALMA W 150ML BOTTLE
1309	MEDELA CONTACT NIPPLE SHIELD S/M/L
1310	MEDI CRD FLEX LINER 1L 6561-910C
1311	MEDIQUIC #ACS222
1312	MEDISAVE FORM A4 80GSM LASER (2K/CTN)
1313	MEDIVAC CRD FLEX LINER 3000CC 65651-930C
1314	MEFIX 10MX15CM (1/BX)
1315	MEMBRANE MEDELA LACTINA
1316	MEROCEL EPISTAXI 10CM 400406
1317	MEROCEL NASAL (LONG STRING) #440406
1318	METAL CUTTER LEGEND 25.4MM (MC254)
1319	MICROFLOW PHACO TIP NEEDLE 30" DP8230
1320	MICROSHIELD 2% 500ML #61354
1321	MILK INFANT - ABBOTT (48 BTL/CTN)
1322	MILK INFANT - DANONE DUMEX (24 BTL/CTN)
1323	MILK INFANT - FRIESLAND (24 BTL/CTN)
1324	MILK INFANT - MEADJOHNSON (48 BTL/CTN)
1325	MILK INFANT - NESTLE (32 BTL/CTN)
1326	MILK INFANT - NESTLE NAN-HA (32 BTL/CTN)
1327	MLT ENDO 5MM #T12150 (10/BOX)
1328	MODIFIED BRADEN SCALE (100/PAD)
1329	MODIFIED GOODE T-TUBE XOMED #24771
1330	MOP REFILL
1331	MOUTHPIECE FOR SPIROMETRY (30MM)
1332	MQA K-SPONGES SPEARS K20-5000 (20/BX)
1333	MQA STRIP
1334	MULTI-LENGTH STENT SET 6FR #USH-600
1335	MULTI-LENGTH STENT SET 8.2FR
1336	MVI STEAM STERILIZER INDICATOR 2551
1337	MY BREST FRIEND NURSING PILLOW
1338	NAPKIN PS' LUNCHEON 30 X 30
1339	NASAL PACKING W/AIRWAY 8CM (400410)
1340	NASOPORE FORTE 8CM (8/BX)
1341	NASOPORE STANDARD 8CM (8/BX)
1342	NEBULIZER T-PIECE FOR SERVO 2505

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1343	NEEDLE & DRAIN MEDINORM CH10 #JVS3310520
1344	NEEDLE & DRAIN MEDINORM CH12#JVS3312520
1345	NEEDLE & DRAIN MEDINORM CH8 #JVS3308520
1346	NEEDLE 20G SOFT TIP NEEDLE (8065149520)
1347	NEEDLE 25"X1 NN2525R
1348	NEEDLE BIOPSY TRU-CUT 4.5"
1349	NEEDLE BIOPSY TRU-CUT 6.0"
1350	NEEDLE DENTAL LONG 27G 1 5/8"
1351	NEEDLE EPIDURAL TUOHY SIZE 16G X 80MM
1352	NEEDLE INITIAL PUNCTURE #DWOAV-18-12.0
1353	NEEDLE INJECT DISP 18G X 1 1/2" (100/BX)
1354	NEEDLE INJECT DISP 19G X 1 1/2" (100/BX)
1355	NEEDLE INJECT DISP 20G X 1 1/2" (100/BX)
1356	NEEDLE INJECT DISP 21G X 1 1/2" (100/BX)
1357	NEEDLE INJECT DISP 22G X 1 1/2" (100/BX)
1358	NEEDLE INJECT DISP 23G X 1" (100/BX)
1359	NEEDLE INJECT DISP 24G X 1" (100/BX)
1360	NEEDLE INJECT DISP 25G X 5/8" (100/BX)
1361	NEEDLE INJECT DISP 26G X 1/2" (100/BX)
1362	NEEDLE INJECT DISP 27G X 1/2" (100/BX)
1363	NEEDLE INJECT.DISP.23G X 1 1/4"
1364	NEEDLE INTROCAN-W 14G
1365	NEEDLE INTROCAN-W 16G 2 1.7 X 50MM
1366	NEEDLE INTROCAN-W 18G 1.3 X 32MM
1367	NEEDLE INTROCAN-W 20G 1.1 X 32MM
1368	NEEDLE INTROCAN-W 22G 1 0.9 X 25MM
1369	NEEDLE JAMSHIDI 11G X 4" #TJC4011
1370	NEEDLE JAMSHIDI 15G X 3/8" DIN1515X
1371	NEEDLE JAMSHIDI 18G X 3/8" DIN1518X
1372	NEEDLE NON-BEVELLED 18G X 1 1/2"
1373	NEEDLE PERICAN EPIDURAL 18G #4512200
1374	NEEDLE PLEXUFIX G24 X 2" #04891562 BX/50
1375	NEEDLE RETROBULAR 26G X 2" X/LONG
1376	NEEDLE SPINAL 18G X 3 1/2"
1377	NEEDLE SPINAL 19G X 2 3/4"
1378	NEEDLE SPINAL 19G X 3 1/2"
1379	NEEDLE SPINAL 20G X 2 3/4"
1380	NEEDLE SPINAL 20G X 3 1/2"
1381	NEEDLE SPINAL 21G X 2 3/4"
1382	NEEDLE SPINAL 21G X 3 1/2"
1383	NEEDLE SPINAL 22G X 3 1/2"
1384	NEEDLE SPINAL 23G X 3 1/2"
1385	NEEDLE SPINAL 25G X 3 1/2"
1386	NEEDLE STERICAN G23 X 1 1/2" #4666410
1387	NEEDLE STIMUPLEX A 22GX2" (4894502)
1388	NEEDLE STIMUPLEX A100 30DEG 21G X 4"
1389	NEEDLE SZ.18G TUOHY (4512383)
1390	NEEDLE ULTRA FAST FIX CURVED #72201491
1391	NEONATAL NASAL CPAP SET SLE#4427/09 SZ 9
1392	NEONATAL NASAL CPAP SIZE 10.5FG
1393	NEONATAL REM POLYHESIVE II #E7512
1394	NIGHT SPLINT
1395	NON-ADHESIVE SKIN TRACTION ADULT 075613
1396	NOTE PAD FOR WARDS (GHL)
1397	NOTES OPHTHALMOLOGY CONSULTATION
1398	NS-70 NURSES' WEEKLY ROSTER(MEH)
1399	NURSERY ACTIVITY FLOWSHEET (PHS)
1400	NUT/TAIL PIECE 2555
1401	NUTRITIONAL SCREENING TOOL 100/PAD
1402	O2 NIPPLE (NUT/TAIL PIECE)
1403	O2 RESERVOIR BAG 2.6 LTR #531901

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1404	OBSTETRIC EPIDURAL/COMBINED SPINAL
1405	OIL DISPENSER W/SYNTHES-OIL 50ML
1406	OIL OXANE SILICON 1300 (VRL500)
1407	OKTA LINE 5ML VIAL #VRL200
1408	OPERATION RECORD (PHS)
1409	OPMIDRAPE #2962CL (5/BX)
1410	OXYGENATOR CAPIOX NEONATAL CX*RX05RW
1411	OXYGENATOR FIBER TERUMO CAPIOX "RX" HOLL
1412	OXYGENATOR HOLLOW FIBRE #2400LT
1413	OXYGENATOR MID-FLOW CAPIO TERUMO
1414	OXYGENATOR SMALL ADULT D905 EOS DIDECO
1415	PACK HOT/COLD (2/BOX)
1416	PACK MINI EPIDURAL W/16G NDL 100-391-116
1417	PACK MINI EPIDURAL W/18G NDL 100-391-118
1418	PACK ORAL HYGIENE STERILE
1419	PACK STERIL WARDLINE RADIOLOGY PREP
1420	PAD DEFIB 3M 2346N
1421	PAD EPI KOOL FOR PERINEAL PAIN (3/BX)
1422	PAD EYE STERILE
1423	PAD GAMGEE 20CM X 20CM #05-040-0055
1424	PAD HEARTSTART PAED HP-M3717A
1425	PAD KOTEX FREEDOM MAXI 10X48 513316
1426	PAD KOTEX FREEDOM SLIM LONG
1427	PAD RADIOLUCENT ADULT HP-M3716A (10/BX)
1428	PAD SANITARY MATERNITY LOOP #5018103
1429	PAD SCOURING WHITE 6 X 9
1430	PAK COMBINED #8065751468
1431	PAK PROCEDURE #8065751077
1432	PAK TOTAL PLUS 23GA W/ENTRY (8065750828)
1433	PANTY XXL
1434	PAPER CREPE GREEN 90 X 90 CM
1435	PAPER CREPE STERILISATION 90X90CMX60GSM
1436	PAPER CREPE WHITE 100CM X 100CM
1437	PAPER CREPE WHITE 30CM X 30CM
1438	PAPER CREPE WHITE 75CM X 75CM
1439	PAPER CTG RECORDING HPM1911A
1440	PAPER ECG RECORDING HP M1709A
1441	PAPER FOR DEFIB 50X30MM #40457C
1442	PAPER PHOTO CANON 4R (KP108IN) 108/PK
1443	PAPER PRINTER OCUSCAN RXP #806570128
1444	PAPER PRINTER-HEMOCHRON RESPONSE(5ROLLS)
1445	PAPER PRINTING SONY A5 #UPC55
1446	PAPER ROLL NETS 57MM(W) X 40MM(OD)
1447	PAPER SONY PRINTING UP21L
1448	PAPER STERISHEET 60 X 60CM WM-CREPE-60W
1449	PAPER THERMAL ARRAY RECORDER
1450	PAPER THERMAL B/W PRINT #SACL-UPP-110HG
1451	PAPER THERMAL DATASCOPE 57MM X 25M
1452	PATSLIDE 1525MM X 635MM
1453	PATTIES SURGICAL 1/2" X 1" #80-1402
1454	PATTIES SURGICAL 1/2" X 1/2" #80-1400
1455	PATTIES SURGICAL 1/2" X 2" #80-1406
1456	PATTIES SURGICAL STERILE 1/4" X 1/4"
1457	PEDAL EXERCISER -FOLDABLE W/ FOOT LOOP
1458	PEN BALLPOINT WITH PARKWAY LOGO
1459	PENCIL BIPOLAR DISPOSABLE 23G#E7923
1460	PEST CONTROL SERVICE (GHL)
1461	PHACO PACK STELLARIS 1.8MM PREMIUM
1462	PILLCAM SB2 (20451/10)
1463	PIN SAFETY N/STERILE LARGE
1464	PLASTIBELL 1.1CM

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1465	PLASTIBELL 1.2CM
1466	PLASTIBELL 1.5CM
1467	PLASTIBELL 1.7CM
1468	PLASTIC BAG BLACK 0.023X 33"X39"
1469	PLASTIC BAGS GREEN 0.03MM X 36" X48"
1470	PLASTRONA (P.O.P) 8CMX2.75M (#332391/1)
1471	PLATE DHS-TSP LOCKING SST (281.871)
1472	PLATE ELECTROSURGICAL STD NON CORD
1473	PM FIRE ALARM SYSTEM
1474	POC TUBING WITH SWIVEL HANDLE #KHS-3030
1475	POSEY BELT
1476	POSEY SA02 PROBE-WRAP CAT#6554 (BX/12)
1477	POST OP SHOE - MEN
1478	POST OP SHOE - WOMEN
1479	POUCH FLUID COLLECTION #5218
1480	POUCH IRRIGATION 50X50CM (135831200I)
1481	POUCH ROLL 100X70M TYVEK #12410 (6RL/CS)
1482	POUCH ROLL 150X70M TYVEK #12415 (4RL/CS)
1483	POUCH TELEMETRY DISP HP9300-0768-050
1484	PREFERBRAND HYGIENIC PILLOWCASE
1485	PREP-DRAPE TOWEL 18"X12" N/STER #D1000RL
1486	PROBE 1 SKIN TEMP DUAL DISPOSABLE(10/BX)
1487	PROBE FINGER 23G
1488	PROBE IRIS 20 GAUGE ADJ AND INTUITIVE
1489	PROBE IRIS 23G STRAIGHT 14390 MAND OPTO
1490	PROBE IRIS G (IRS/11256) (6/BOX)
1491	PROBE RECTAL 30" 12FR #21090A
1492	PROBE TEMP 9FR #4918 (20/BOX)
1493	PROTECTOR EYE POSEY
1494	PROTOSCOPE
1495	PROXIMATE HAEM CIRCULAR STAPLER #PPH03
1496	PULLEY - OVERHEAD, SINGLE
1497	PULSE OXIMETER - FINGER-TIP
1498	PUMP EASY LT270-54=270ML (4438043)
1499	PUNCH AORTA/VEIN 3.5MM SCANLAN #1001-621
1500	PUNCH AORTIC 4MM (PILLING) #353440
1501	PUREVISION BANDAGE LENS
1502	QUAD STICK
1503	QUAD STICK NARROW BASED
1504	QUESTO CALYPSO DUAL ELECTRIC BUNDLE
1505	QUESTO GOLD CREAM
1506	QUESTO SINGLE ELECTRIC PUMP
1507	QUESTO TULIPS (M / L)
1508	RAISED TOILET SEAT - 2"
1509	RAISED TOILET SEAT - 4"
1510	RAPID INFUSION SET #35-000393-00REV.C
1511	RAZOR DISPOSABLE FORAZE 0617003/0
1512	RECEIPT BOOK OFFICIAL (GHL) 3C/0C
1513	RECORD OF DEVICES (100/PAD)
1514	REFILL URINAL I-GENE 4IN1
1515	REFLEX PTR 45 (EIC4835-01)
1516	REFLEX ULTRA SP W/INTEGRATED CABLE
1517	RENTAL SERVICE CONTRACT (GHL)
1518	RENTAL/SERVICE/SUPPLY LANDSCAPING
1519	REQUISITION VOUCHER BY COST CENTRE (PHS)
1520	RESTRAINER BODY POSEY #3311 SMALL
1521	RESUSCITATOR INFANT W/BAG #845031
1522	RESUSCITATOR MANUAL SINGLE USE
1523	RETRACTOR DORC IRIS #4020 (5/BOX)
1524	RIBBON THERMAL TRANSFER 110MM X 74M
1525	RIBBON THERMAL TRANSFER RBOWA4711074

Sr.	Item Description
1526	ROD MEASURING SECA 233
1527	ROD OSTOMY SUR-FIT LOOP 65MM #S22355
1528	ROD OSTOMY SUR-FIT LOOP 90MM #S22356
1529	ROLL COTTONELLE BT EMB (2PLY) #0515101
1530	ROLL JRT ROLL 2PLY 12X300M (OR-300)
1531	ROLLATOR
1532	ROLLER INK 2HS
1533	ROTH RETRIEVAL NET 2.5/230CM 711050
1534	RUBBER BUNG #60/10
1535	RUBBER BUNG 50/4.0
1536	RUBBER NIPPLE W/O PERPORATN #27550D
1537	RUBER AIR RING CUSHION - 18"
1538	SALT
1539	SANDBAG DARK GREEN 3" X 8.5"
1540	SANDBAG DARK GREEN 5" X 11.5"
1541	SANDBAG DARK GREEN 6" X 8.5"
1542	SARNS L-ATRIAL VENT CATH 18FR #4333
1543	SCALE WEIGHING DIGITAL #SECA703
1544	SCANLAN SURGI-LOOP BLUE MAXI (1001-78)
1545	SCANLAN SURGI-LOOP BLUE MINI (1001-77)
1546	SCANLAN SURGI-LOOP RED MAXI (1001-76)
1547	SCANLAN SURG-I-LOOP RED MINI (1001-75)
1548	SCD EXPRESS SLEEVES KNEE MEDIUM (73022)
1549	SCISSOR SHAFT METZENBAUM 310MM DISP
1550	SCOTCHCAST ONE STEP SPLINT (W) 2X10" 3M
1551	SCOTCHCAST TAPE (Y) 2"X4 #82002 (10/CS)
1552	SEAL BONNET (50/3.6) #6127490
1553	SEAL SECURITY W/SERIAL NO.
1554	SEDATION RECORD (100PCS/PAD)
1555	SELF RETAINING ACM 20G 9/64”(585061)
1556	SENSOR FLOW #1503-3856-000
1557	SENSOR OXIMAX NELLCOR DISP ADULT MAX-A1
1558	SENSOR OXIMAX NEONATAL DISP MAX-NI
1559	SENSOR QUATRO #T1860106
1560	SENSOR SP02 NEONATAL MASIMO LNOP
1561	SERVICE FLOWER ARRANGEMENT
1562	SERVICE STORAGE AND MANAGEMENT (MRO)
1563	SERVIETTE PS' ECONOMY 30 X 16
1564	SERVO DUO GUARD #SSIE-661775 (60/PK)
1565	SET AIR VENT 35CM 4190114
1566	SET BLOOD SANGOFIX 200CM 4039130
1567	SET COLLECTN ASSEMBLY W RESERVOIR(04051)
1568	SET EYE DRESSING DRE10 00 12 100/CTN
1569	SET INTRAFIX AIR #4054520
1570	SET IRRIGATION CYSTO STR #2C4040
1571	SET IRRIGATION Y-TYPE TUR BLADDER
1572	SET IV C/W BURETTE TS*PM 370L42
1573	SET IV FLUID WARMING W/INJ PORT SL1-L70
1574	SET IV W/O BURETTE TS*PA 300L
1575	SET MANIFOLD TUBING CUSA 36KHZ #C3601
1576	SET MINI REDOVAC 6CH 13001182
1577	SET NEEDLE DISP LIVER BIOPSY 17G
1578	SET OXYGEN NASAL CANNULA 150CM HOT-1103
1579	SET PERFUSION MULTIPLE DLP
1580	SET PNEUMO CARDIOCENTESIS
1581	SET SANGOFIX ES 180CM G18 4034228
1582	SET SHAVING WD
1583	SET STENT MULTI-LENGTH 7FR
1584	SET STENT MULTI-LENGTH D/B J 4.7FR
1585	SET SWABBING
1586	SET T-CONNECTOR LUER SLIP

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1587	SET TRANSOFIX TRANSER 4090500
1588	SET TUBING SCD EXPRESS #T9528
1589	SET TUOHY CONTIPLEX 18GX38MM (331695)
1590	SET WD CATHETERISATION
1591	SET WD DRESSING DISP
1592	SET WD EYE CARE TRAY
1593	SET WINGED INFUSION 21G SV*21CLK
1594	SET WINGED INFUSION 23G SV*23CLK
1595	SET WINGED INFUSION 25G X 3/4"
1596	SET Y EXTENSION #011-C33022
1597	SHAMPOO CAP
1598	SHARP DISCARD-A-PAD MAGNETIC
1599	SHARPOINT KNIFE 15DEG 5.7MM 72-1502
1600	SHARPOINT MINI CRESCENT ANGLED 1.25MM
1601	SHEATH URETERAL ACCESS FLEXOR SZ12 L35CM
1602	SHEPARD VT.FLPL W/WIRE 1.02M #1016301
1603	SHIELD EYE UNIVERSAL CLEAR
1604	SHOULDER SET W/POUCH BTC MSC STOCKINETTE
1605	SHOWER CHAIR W/ ARMREST, BACKREST
1606	SHROUD PLASTIC LARGE
1607	SILICONE SLEEVE 0.76MM I.D X 1.65MM #270
1608	SILICONE SPONGE 2.5MM X 4.0MM X 80MM
1609	SITZ BATH DISPOSABLE
1610	SKIN PREP SINGLE WIPE (50/BX)
1611	SKIN STAPLER VISITAT 35W #528235 (BOX/6)
1612	SLEEVE CAMERA 9900
1613	SLEEVE DIGITAL THERMOMETER (1000/BX)
1614	SLIDE CLOTEST DIAGNOSTIC #60480
1615	SLIPPER PLASTIC MALE X-L
1616	SLIPPERS TERRY COTTON W/O LOGO
1617	SNARE POLYPECTOMY SHORT THROW (62652)
1618	SOCK WHITE COTTON ANKLE LENGTH SZ 5-8
1619	SOLN ANTI-FOG FRED II #220-50
1620	SOLN WATER IRRIGATION 1L-BOT #6431
1621	SP WALKER
1622	SPEAKING VALVE W/ O2 PORT
1623	SPECIAL ACTIVITY CHART (100/PAD)
1624	SPECIAL ANAESTHESIA CIRCUIT ASSEMBLY
1625	SPECULUM VAGINAL STERILE DISP LARGE
1626	SPECULUM VAGINAL STERILE DISP MEDIUM
1627	SPECULUM VAGINAL STERILE DISP SMALL
1628	SPILL KIT BIG CUSTOMIZED 5.5 GAL #930NPC
1629	SPINAL COLUMN - LUMBOLOC
1630	SPINAL NEEDLE WHITACRE BD 22G X 3 1/2
1631	SPINAL NEEDLE WHITACRE BD 25G X 3 1/2"
1632	SPINAL NEEDLE WHITACRE BD 27G X 3 1/2
1633	SPLINT FINGER ALUMINIUM 1/2" 00054800500
1634	SPLINT FINGER ALUMINIUM 3/4" 00054800100
1635	SPLINT ONE-STEP SCOTCHCAST 3"X12" 76312A
1636	SPLINT ONE-STEP SCOTCHCAST 4"X15" 76415A
1637	SPLINT ONE-STEP SCOTCHCAST 5"X30" 76530
1638	SPONGE LAP 30CM X 30CM
1639	SPONGE LAP STERILE 8PLY 9" X 9"
1640	SPONGOSTAN ANAL (MS0004) 20/BX
1641	SPRAY AIR FRESHENER HAZE LAVENDER 300ML
1642	SPRAY OIL STERILIT I 300ML #JG600
1643	STAPLER SKIN REMOVER DG8039-12
1644	STAR-TEM 10X10 #503-01
1645	STEEL 5 2X75CM BGS-26X12 #T8886249789
1646	STELLARIS 2.65MM PREMIUM PHACO PACK
1647	STELLARIS PREMIUM PHACO CASSETTE 2.2MM

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1648	STENT NASAL DRESS & SINUS 4 X 4CM
1649	STENT WALL (BOSTON)
1650	STER.FLAT REEL 200MMX200M (422R)
1651	STERI-DRAPE APERTURE POUCH (1072) 10/BX
1652	STERILE SWAB STICK 5'S #83349
1653	STERITITE FILTER PAPER 9.7" X 4" #13908
1654	STERITITE SEAL TAMPER EVIDENT #13909
1655	STERRAD100NX CASSETTES (10144) (2/CS)
1656	STETHOSCOPE CODE 2113
1657	STETHOSCOPE LITMANN CLASSIC II 28" #2203
1658	STICKER ALLERGY TO (RED) 1000/PK
1659	STICKER NO KNOWN ALLERGY 1000/PK
1660	STICKER SPECIMEN FOR HISTOLOGY (GHL)
1661	STOCKINET 3"X25YDS #MS03
1662	STOCKINET 4"X25YDS #MS04
1663	STOCKINET JERSEY COTTON 7CM X 25M
1664	STOCKING THROMBEXIN THIGH EXTRA SMALL
1665	STOOL S/S SINGLE STEP 400X260X260MM
1666	STOPCOCK 3 WAY 25CM TUBING 4098218
1667	STOPCOCK 3 WAY BLUE STERILE 04095111
1668	STOPCOCK 3 WAY I/C EXTN-1OCM 4098102
1669	STOPPER COMBI RED #4495101 (100/BOX)
1670	STRAINER MICRO SIEVE PHILIP
1671	STRAP VELCO CONVEEN
1672	STRAW DRINKING FLEXIBLE WHITE
1673	STRIP INDICATOR CHEMICAL #14100 (1000'S)
1674	STRIP SHEER (BAND AID) (100/BOX)
1675	SUCTION TUBE SOFT TIP 6.5" DLP-1005247
1676	SUPER C-ARM DISP KIT
1677	SURFANIOS CITRON 5L 4BTL/CTN #347036
1678	SURFA'SAFE SANI-1568544 12/CTN
1679	SURGIBAND 1/4" BLACK (1001-71)
1680	SURGIBAND 1/4" BLUE (1001-67)
1681	SURGIBAND 1/4" GREEN (1001-68)
1682	SURGIBAND 1/4" ORANGE (1001-66)
1683	SURGIBAND 1/4" PURPLE (1001-95)
1684	SURGIBAND 1/4" RED (1001-64)
1685	SURGIBAND 1/4" WHITE (1001-70)
1686	SURGIBAND 1/4" YELLOW (1001-65)
1687	SURGICAL PENS AND RULER (431030) (36/CS)
1688	SURGICLIP M-11.5" #US-134053
1689	SURGITIE LIGATING LOOP #SGL-1
1690	SUT ALCON NYLON 10.0 AU-5 692101
1691	SUT ALCON NYLON 10.0 C3 193001
1692	SUT ALCON NYLON 5.0 R5 215501
1693	SUT ALCON NYLON 8.0 C4 194101
1694	SUT ALCON SILK 8.0 C3 203801
1695	SUT BIOSYN 0 75CM GU-46 (UM877) 36/CTN
1696	SUT C VICRYL 1 70CM VIOLET CT-1 J341H
1697	SUT C VICRYL 5/0 45CM PS-3 W9782/J500G
1698	SUT C VICRYL UNDYED 6/0 45CM #W9981
1699	SUT COATED VICRYL 6/0 #W9500T (24/BOX)
1700	SUT COATED VICRYL 8/0(J548) W9560
1701	SUT COATED VICRYL J NEEDLE RB 35MM
1702	SUT ETHIBOND 0 75CM GRN 1/2CIR RB #W975
1703	SUT ETHIBOND 2 1/2C TC (W4843) 12/BX
1704	SUT ETHIBOND 2 OS 75CM 4-1/2 CIR #X519H
1705	SUT ETHIBOND 2/0 90CM GRN TCX2 #W6937
1706	SUT ETHIBOND 2/0 90CM WHT TCX2 #W6917
1707	SUT ETHIBOND 2/0 GRN 25MM TCX2 #W6977
1708	SUT ETHIBOND 2/0 TAPERCUT W6987 (12/BX)

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	**Item Description**
1709	SUT ETHIBOND 2/0 V-5 PXX52
1710	SUT ETHIBOND 3/0 GRN 17MM TCX2 #W6936
1711	SUT ETHIBOND 3/0 RBX2 25MM #W6552
1712	SUT ETHIBOND 4/0 90CM GRN 17MM TC W6935
1713	SUT ETHIBOND 4/0 X204H (36/BX)
1714	SUT ETHIBOND 5 55MM #W4846 (12/BX)
1715	SUT ETHIBOND 5/0 W88345CM 1/2C X 2
1716	SUT ETHILON 1 CUTTING W2797 (12/BX)
1717	SUT ETHILON 10/0 R.B. W2814 (12/BX)
1718	SUT ETHILON 10/0 R.B. W2870 (12/BX)
1719	SUT ETHILON 2/0 1M 30MM W568
1720	SUT ETHILON 2/0 75CM W1626T BX/24EA
1721	SUT ETHILON 3/0 35CM BL 26MM RC #W320
1722	SUT ETHILON 4/0 45CM BL 19MM RC #W319
1723	SUT ETHILON 4/0 PS-1 (1667G) 12/BX
1724	SUT ETHILON 5/0 BL 15MM SLIM BLADE #W526
1725	SUT ETHILON 6/0 12MM P CT #W1610T BX/24
1726	SUT ETHILON 6/0 CUTTING W507 (12/BX)
1727	SUT ETHILON 7/0 BLK 31647G
1728	SUT ETHILON 8/0 13CM W2808 (12/BX)
1729	SUT ETHILON 9/0 R.B. W2813 (12/BX)
1730	SUT FIBER WIRE #2 38" BLUE (AR7200)
1731	SUT FIBREWIRE 20" 17.9MM (AR-7229-20)
1732	SUT HERNIA PROLENE SYSTEM MED.#PHSM
1733	SUT HERNIA STAPLER PROTACK 174006
1734	SUT HORIZON CLIP #1205 P WECK (25/BX)
1735	SUT LIGACLIP (MED-LAR) LT-300
1736	SUT LIGACLIP MEDIUM #LT-200
1737	SUT LIGACLIP TITANIUM LT400
1738	SUT LIGACLIP TITANIUM SMALL #LT100
1739	SUT MAXON 5-0 PRE1 4CM 11MM 8886653221
1740	SUT MERSILENE STRIP 30CM WHITE RS22
1741	SUT MERSILK 2 W196 (12/BX)
1742	SUT MERSILK 2/0 30MM RB #W333H BX/36
1743	SUT MERSILK 2/0 45CM #W321H (BOX/36)
1744	SUT MERSILK 3/0 CUTTING W622H BX/36
1745	SUT MERSILK 4/0 13MM REV CUT #W811
1746	SUT MERSILK 4/0 45CM BLK 19MM W329H
1747	SUT MERSILK 5/0 75CM BLACK #W595 (12/BX)
1748	SUT MERSILK 6/0 R.C. W812 (12/BX)
1749	SUT MERSILK 7/0 30CM BLK 6MM W1814
1750	SUT MERSILK BLACK 1 13X60CM #W21501
1751	SUT MERSILK BLACK 2.0 20MM W587H BX/36
1752	SUT MERSILK BLACK 2/0 25MM W327H (36/BX)
1753	SUT MERSILK BLACK 3.5 W214/W204
1754	SUT MERSILK BLACK 3/0 W570H 36/BX
1755	SUT MERSILK BLACK 4/0 13X60CM #W21101
1756	SUT MERSILK BLACK 4/0 20MM W586H 36/BX
1757	SUT MERSILK BLACK 5/0 12MM W580 (12/BX)
1758	SUT MERSILK BLK 0 30MM W334H (36/BX)
1759	SUT MERSILK BLK 1 35MM #W338H BX/36
1760	SUT MERSILK O 45MM RC #W782H BX/36
1761	SUT MERSILK W328H 3/0 45CM BLK 26MM RC
1762	SUT MONOCRYL 3/0 ON PS-2 #Y427H (BX/36)
1763	SUT MONOCRYL 3/0 Y523H ON KS NEEDLE
1764	SUT MONOCRYL 36IN (90CM) 1 UND #Y947H
1765	SUT MONOCRYL 4/0 ON PS-2 #Y426H (BX/36)
1766	SUT MONOCRYL 4/0 P-3 45CM #Y494G (12/BX)
1767	SUT MONOCRYL 5/0 CUTTING 16MM CC #W3221
1768	SUT MONOCRYL 5/0 P-3 Y493G
1769	SUT MONOCRYL 5/0 PS-2 #Y495G (12/BOX)

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1770	SUT MONOCRYL 6/0 P-1 Y489G
1771	SUT MONOSYN UNDYED 2/0 70CM DS30 3/8
1772	SUT NYLON BLK MONO 9000G
1773	SUT NYLON TAPE 6MM X 70CM #W277
1774	SUT NYLON TAPE 70CM X 3MM #W275
1775	SUT PDS 1 40MM 1/2C TC HEAVY LOOP W9394
1776	SUT PDS 2/0 CT-1 W9151T 24/BX
1777	SUT PDS 3/0 70CM PURPLE W9124H (36/BX)
1778	SUT PDS 4/0 70CM VIOLET W9115H (36/BX)
1779	SUT PDS 5/0 VIOLET 70CM #W9201H 36/BX
1780	SUT PDS 6/0 45CM VIOLET CRBX2 (W9093T)
1781	SUT PDS II 1 40MM 1/2C RB W9234T
1782	SUT PDS II 1 VIOLET 50MM #W9254T BX/24
1783	SUT PDS II 150CM M4 LOOP W9237T (24/BX)
1784	SUT PDS II 2/0 SH Z317H
1785	SUT PDS II 4/0 RBX2 W9109H
1786	SUT PDS II 40MM 0.5C 0 #W9233T (BX/24)
1787	SUT PDS II 5/0 RBX2 W9108H
1788	SUT PDS II 6/0 Z123H
1789	SUT PDSII 3/0 70CM 30MM 1/2C W9132H
1790	SUT POLYSORB* 0 75CM GS-21 (CL812)
1791	SUT POLYSORB* 0 75CM GU-46 (UL877) 36/BX
1792	SUT POLYSORB* 1 90CM 37MM (CL925) 36/BX
1793	SUT POLYSORB* 2-0 12X60CM (L33) 24/BX
1794	SUT POLYSORB* 2-0 75CM GU-46 (UL878)
1795	SUT POLYSORB* 2-0 75CM V-20 (GL123)
1796	SUT POLYSORB* 2-0 75CM V-30 (GL223)
1797	SUT POLYSORB* 2-0 90CM 37MM (CL923)
1798	SUT POLYSORB* 3 90CM 37MM (CL922)
1799	SUT POLYSORB* 3/0 75CM 30MM (GL222)
1800	SUT POLYSORB* 3-0 12X60CM (L32) 24/BX
1801	SUT POLYSORB* 3-0 75CM 24MM SL693
1802	SUT POLYSORB* 3-0 75CM CV-25 (GL182)
1803	SUT POLYSORB* 3-0 75CM GS-21 (CL810)
1804	SUT POLYSORB* 3-0 75CM P-12 (SL5638)
1805	SUT POLYSORB* 3-0 75CM V-20 (GL122)
1806	SUT POLYSORB* 4-0 75CM CV-25 (GL181)
1807	SUT POLYSORB* 4-0 75CM P-12 (SL5637)
1808	SUT POLYSORB* O 75MM 30MM (GL224) 36/BX
1809	SUT POLYSORB*0 12X60CM TIES (L34) 24/BX
1810	SUT POLYSORB*0 90CM 40MM (CL914) 36/BX
1811	SUT POLYSORB*1 90CM 40MM (CL915) 36/BX
1812	SUT PROLENE 0 BLUE HEAVYRB W8430 (12/BX)
1813	SUT PROLENE 1 BLUE RB 1/2CIR #W742
1814	SUT PROLENE 2/0 75CM BLUE SRBX2 #W8400
1815	SUT PROLENE 2/0 X-CUT C W8689
1816	SUT PROLENE 3.0 BLUE 60MM SC #W621
1817	SUT PROLENE 3/0 25MM W8976 (12/BX)
1818	SUT PROLENE 3/0 CRBXZ W8630
1819	SUT PROLENE 3/0 VISIBLC RB W8354
1820	SUT PROLENE 3/0 W538 (12/BX)
1821	SUT PROLENE 4/0 20MM 1/2C RBXZ W8340
1822	SUT PROLENE 4/0 45CM BLUE W525 (12/BX)
1823	SUT PROLENE 4/0 90CM BLUE 1/2CIR #W8761
1824	SUT PROLENE 4/0 SLIM BLADE CC W539
1825	SUT PROLENE 5/0 45CM BLUE #W527 (12/BX)
1826	SUT PROLENE 5/0 BLUE 8720H
1827	SUT PROLENE 5/0 CC-N W8803
1828	SUT PROLENE 5/0 VISIBLC RB W8330
1829	SUT PROLENE 6/0 BLUE 13MM CRBX2 #W8706
1830	SUT PROLENE 6/0 BLUE 8805H

Sr.	**Item Description**
1831	SUT PROLENE 60CM NO.7 6/0 (W8802) 12/BX
1832	SUT PROLENE 7/0 318C BV-1X2 BLUE #M8304
1833	SUT PROLENE 7/0 BL 60CM CRBX2 #W8304
1834	SUT PROLENE 7/0 BV-1 M8702
1835	SUT PROLENE 7/0 W8702
1836	SUT PROLENE 8/0 BLUE 8730H
1837	SUT PROLENE BLU 5/0 60CM 1/2 13 (8205H)
1838	SUT PROLENE BLUE 2/O 75CM #W295 (12/BX)
1839	SUT PROLENE BLUE 25MM 2/O W8977 (12/BX)
1840	SUT PROLENE BLUE 3/0 25MM RBX2 #W8522
1841	SUT PROLENE BLUE 3/0 W8558 BOX/12EA
1842	SUT PROLENE BLUE 4/0 16MM W8557 (12/BX)
1843	SUT PROLENE BLUE 5/0 13MM W8710 (12/BX)
1844	SUT PROLENE BLUE 5/0 16MM 1/2CIR #W8556
1845	SUT PROLENE BLUE 6/0 W8697 (12/BX)
1846	SUT PROLENE MESH 15CMX15CM (PMM1)
1847	SUT PROLENE MESH 30CM X 30CM PML(1PC/BX)
1848	SUT PROLENE MESH 6CMX11CM SMALL PMS3
1849	SUT RUMI U/M 8MM #UMB678 (BOX/5)
1850	SUT SILK 2/0 13X60CM BLK #W213 (#W1313)
1851	SUT SILK 3/0 13X60CM BLK #W21201 (12/BX)
1852	SUT SOFSILK TIE 2 S318
1853	SUT STEEL 5 MONOFILAMENT 45CM #M653G
1854	SUT STEEL FLEXON 0 2597-63 (12/BOX)
1855	SUT SURGICEL 10CM X 20CM #W1912 (12/BX)
1856	SUT SURGICEL AB.HAEM 5X7CM #1913T BX/24
1857	SUT SURGIPRO 3-0 45CM P-12 (SP5687)
1858	SUT VCRL 3/0(9511T/J398) W9571T 24/BX
1859	SUT VICRYL 0 75MM VIOLET RB #W9138
1860	SUT VICRYL 0 TIE (W9046) V906E 24/BX
1861	SUT VICRYL 10/0 CS90-6 V980G
1862	SUT VICRYL 2 RCH W9287
1863	SUT VICRYL 2/0 25MM VIOLET TC #W9350
1864	SUT VICRYL 2/0 75CM VIOLET 30MM #W9136
1865	SUT VICRYL 2/0 FSL (J589H) 36/BX
1866	SUT VICRYL 2/0 TIES(W9045)#V905E BX/24
1867	SUT VICRYL 2/0 UR-6 5/8CIR (J602H) 36/BX
1868	SUT VICRYL 2/0 VIOLET CT-1 J339H
1869	SUT VICRYL 2/0(J317H) VIOLET 25MM #W9121
1870	SUT VICRYL 3/0 70CM SH J316H (36/BX)
1871	SUT VICRYL 3/0 70CM VIOLET J338H
1872	SUT VICRYL 3/0 TIES (W9044) V904H BX/36
1873	SUT VICRYL 3/0 UNDYED VIOLET W9114
1874	SUT VICRYL 3/O VIOLET 1/2CIR RB #W9120
1875	SUT VICRYL 4/0 J315H
1876	SUT VICRYL 4/0 VIOLET (J214H) #W9106
1877	SUT VICRYL 4/0(J397H) P-NDLE CC #W9570T
1878	SUT VICRYL 5/0 45CM UNDYED 12MM #W9501T
1879	SUT VICRYL 5/0 75CM VIOLET 18MM #W9105
1880	SUT VICRYL 5/0 UNDYED CUT 11MM J490G
1881	SUT VICRYL 6/0 45CM J670G (12/BX)
1882	SUT VICRYL 6/0 45CM VIOLET W9552 (12/BX)
1883	SUT VICRYL 6/0 SPATULA W9566 (12/BX)
1884	SUT VICRYL 7/0 VIOLET W9561 (12/BX)
1885	SUT VICRYL CTD+ANTIBACT 4/0 45 VCP494G
1886	SUT VICRYL O 75CM VIOLET 1/2CIR #W9230
1887	SUT VICRYL RAPID 2/0 35MM W9962 (12/BX)
1888	SUT VICRYL RAPIDE M1.5 4/0 75CM #W9971
1889	SUT VICRYL S-29 X 2 6/0 #J556G
1890	SUT VICRYL S-29 X 2 6/0 J555G
1891	SUT VICRYL VIO 2/0 10X50CM #V9050H

Sr.	**Item Description**
1892	SUT VICRYL+CTD ANTIBACT VI 1 90 #VCP486H
1893	SUT V-LOC 180 DEVICE 2-0 GS21 30CM
1894	SUT,ETHILON 9/0 BLK 30CM (W1769) (12/BX)
1895	SUT/A ENDOCATCH GOLD 10MM #T173050G
1896	SUT/A ENDOCUTTER 35MM BLUE TSB35
1897	SUT/A PROXIMATE #TLC 55
1898	SUT/A RELOAD UNIT 55MM TCR55
1899	SUT/A RELOAD UNIT 75MM TCR75
1900	SUT/A RELOADING UNIT LINR TRH30
1901	SUT/A STAPLER ENDO INTRA'LUM CUR 29MM
1902	SUT/A STAPLER INTRA'LUM CUR 33MM CDH33
1903	SUT/A STAPLER PROXIMATE CUR 25MM CDH25
1904	SUT/A STAPLER PROXIMATE TLH30
1905	SUT/A STAPLER PROXIMATE TLH60
1906	SUT/A STAPLER PROXIMATE TLH90
1907	SUT/A STAPLER RELOAD UNIT TRH60
1908	SUT/A STAPLER RELOAD UNIT TRH90
1909	SUTURE BOOT INSTR COVERS YELLOW 1001-514
1910	SUTURE ETHILON 18" 3/0 BLK #1663H
1911	SUTURE SUPRAMID II (LHR-40W)
1912	SWAB ALCOHOL 30MM X 60MM
1913	SWAB STERILE SKIN CLEANSER KD5110
1914	SWAB THROAT ADULT 90X10CM 24-6809-900
1915	SYRINGE 20CC LUER LOCK SS+20L (50/BX)
1916	SYRINGE 3CC LUER LOCK SS+03L (100/BX)
1917	SYRINGE 5CC LUER LOCK SS+05L (100/BX)
1918	SYRINGE BULB IRRIGATION 50CC 67000
1919	SYRINGE CATHETER TIP 50CC SS*50CE
1920	SYRINGE ECCENTRIC TIP 20ML SS+20ES
1921	SYRINGE ECCENTRIC TIP 30ML SS*30ESZ1
1922	SYRINGE INSULIN 1CC W/NDLE 27G X 1/2"
1923	SYRINGE INSULIN W/NDLE 29G 1/2CC
1924	SYRINGE LUER LOCK 10ML SS+10L (100/BX)
1925	SYRINGE LUER LOCK 30ML #TC-SS-30L
1926	SYRINGE LUER LOCK TIP 50CC SS*50LE
1927	SYRINGE MEDRAD CVL 150FT
1928	SYRINGE SLIP-TIP DISP 10ML SS+10S
1929	SYRINGE SLIP-TIP DISP 3ML SS+03S
1930	SYRINGE SLIP-TIP DISP 5ML SS+05S
1931	SYRINGE TUBERCULIN 1CC W/NDLE SS*01T2516
1932	SYRINGE TUBERCULIN 1CC W/O NDLE SS+01T
1933	SYRINGE W/NEEDLE TIP 50CC SS*50ESE
1934	SYSTANE ULTRA
1935	SYSTEM ODOURGUARD C/W REFILL
1936	TAG BAGGAGE 74MMX129MM
1937	TAMPER EVIDENT ARROWS DOUBLE #AS2-3
1938	TAN ENDOGLIDE #NTW/51-820
1939	TAPE COMPLY 18MM #1322
1940	TAPE DURAPORE 1"
1941	TAPE DURAPORE 1" X 10YD #1538-1
1942	TAPE DURAPORE CLOTH 3" X 10YDS
1943	TAPE MEASURING DISP
1944	TAPE MICROPORE 1" X 10YDS
1945	TAPE MICROPORE 1/2" X 10YDS
1946	TAPE MICROPORE 2" X 10 YDS
1947	TAPE MICROPORE 3"X10YDS (BOX/4)
1948	TAPE SCOTCHCAST PLUS 10.1CM X 3.6M
1949	TAPE SCOTCHCAST PLUS 12.7CM X 3.6M
1950	TAPE SCOTCHCAST PLUS 7.6CM X 3.6M
1951	TAPE SEALSURE (14202) (6/CS)
1952	TAPE SURGIBAND BLUE 1/8" 1001-633

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
1953	TAPE SURGIBAND GREEN 1/8" 1001-640
1954	TAPE SURGIBAND PURPLE 1/8" 1001-639
1955	TAPE SURGIBAND RED 1/8" 1001-630
1956	TAPE SURGIBAND WHITE 1/8" 1001-636
1957	TAPE SURGIBAND YELLOW 1/8" 1001-631
1958	TAX INVOICE (GHL) A4 3C/0C
1959	TENS MACHINE
1960	THERMOMETER DIGITAL ORAL TERUMO ET*C402S
1961	THERMOMETER DIGITALAXILLARY ET*C202S
1962	THERMOSCAN PRO 3000 BRAUN
1963	TICRON 2/0 75CM 2XSC-250 #8886294753
1964	TIP GREEN DISP 6.7MM X 10CM #UMG670
1965	TISSUE BATHROOM (HBT) PLAIN 2PLY
1966	TONSIL SQUARE 3CM X 3CM 24-PLY (5/PK)
1967	TONSIL STRIP 2.5CM X 14.5CM 16-PLY
1968	TOOTHBRUSH - ADULT
1969	TOOTHETTE ORAL SWAB SAGE 6075
1970	TOURNIQUET MEDIUM 27CM
1971	TOWEL HAND 2'S #DRE500012
1972	TOWEL HAND C-FOLD 1PLY 20 X 200S AP-MF8
1973	TOWEL HAND ROLL HRT210M 1PLY RF (AP-210)
1974	TOWEL M-FOLD 16X250S (230MMX220MM)
1975	TPE SET SPECTRA (70500)
1976	TRACHEOSTOMY DRESSING ALLEVYN
1977	TRACHEOSTOMY TUBE -FEN CUFFLESS
1978	TRACHEOSTOMY TUBE-FEN, LOW PRESSURE CUFF
1979	TRANSPORTATION CHARGES TO SPECS
1980	TRAY 4 COMPARTMENT 270X180X41MM(CIT2718)
1981	TRAY BLUE 4 COMPARTMENT #SWAR-CIT2718
1982	TRAY FOUR COMPARTMENTS STERILE
1983	TRAY PH MANOMETER #4330
1984	TRAY PROCEDURAL #38-000001-00 REV B
1985	TRAY SPINAL WHITACRE 27G BD 401479
1986	TREPHINE SIZE 7.0 #NTW/51-835-7.0
1987	TREPHINE SIZE 7.25 #NTW/51-835-7.25
1988	TREPHINE SIZE 7.5 #NTW/51-835-7.5
1989	TREPHINE SIZE 7.75 #NTW/51-835-7.75
1990	TREPHINE SIZE 8.0 #NTW/51-835-8.0
1991	TREPHINE SIZE 8.25 #NTW/51-835-8.25
1992	TREPHINE SIZE 8.5 #NTW/51-835-8.5
1993	TREPHINE SIZE 8.75 #NTW/51-835-8.75
1994	TREPHINE SIZE 9.0 #NTW/51-835-9.0
1995	TRILUMEN 12F/24CM STRAIGHT 8888340637
1996	TROCAR EXCEL BLADLESS 11X100 (B11LT)
1997	TROCAR XCEL BLADELESS 12X100 (B12LT)
1998	TROCAR XCEL BLADELESS 5X100 (B5LT)
1999	TST BROWNE BOWIE DICK TEST PACK BL-2352
2000	TUBE CONNECTING 10FT 6MM N610
2001	TUBE CONNECTING STERILE 6 FT
2002	TUBE ETT ORAL PROFILE CUFFED 5.0MM
2003	TUBE ETT ORAL/NASAL PROFILE 5.5MM
2004	TUBE ETT ORAL/NASAL PROFILE 6.0MM
2005	TUBE ETT ORAL/NASAL PROFILE 6.5MM
2006	TUBE ETT ORAL/NASAL PROFILE 7.0MM
2007	TUBE ETT ORAL/NASAL PROFILE 7.5MM
2008	TUBE ETT ORAL/NASAL PROFILE 8.0MM
2009	TUBE ETT ORAL/NASAL PROFILE 8.5MM
2010	TUBE ETT ORAL/NASAL PROFILE 9.0MM
2011	TUBE ETT ORAL/NASAL SOFT CUFF 6.0MM
2012	TUBE ETT ORAL/NASAL SOFT CUFF 6.5MM
2013	TUBE ETT ORAL/NASAL SOFT CUFF 7.0MM

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
2014	TUBE ETT ORAL/NASAL SOFT CUFF 7.5MM
2015	TUBE ETT ORAL/NASAL SOFT CUFF 8.0MM
2016	TUBE ETT ORAL/NASAL SOFT CUFF 8.5MM
2017	TUBE ETT ORAL/NASAL UNCUFFED 2.5MM
2018	TUBE ETT ORAL/NASAL UNCUFFED 3.0MM
2019	TUBE ETT ORAL/NASAL UNCUFFED 3.5MM
2020	TUBE ETT ORAL/NASAL UNCUFFED 4.0MM
2021	TUBE ETT ORAL/NASAL UNCUFFED 4.5MM
2022	TUBE ETT ORAL/NASAL UNCUFFED 5.0MM
2023	TUBE ETT ORAL/NASAL UNCUFFED 5.5MM
2024	TUBE ETT ORAL/NASAL UNCUFFED 6.0MM
2025	TUBE FREKA FEEDING 8F 120CM LL 7981691
2026	TUBE HEMOCHRON BLACK (95/BOX)
2027	TUBE INFANT FEEDING 10FG
2028	TUBE INFANT FEEDING 6FG
2029	TUBE INFANT FEEDING 8FG
2030	TUBE IRRIGATION SURGIC XT/PLUS #Z263-001
2031	TUBE NASAL FEEDING JEJUNAL (NJFT-10)
2032	TUBE PEG REPLACEMENT #PEG-24-BRT-S
2033	TUBE PERCUTANEOUS ENDO GASTROSTOMY PEG
2034	TUBE RECTAL 50CM CH32
2035	TUBE RYLE'S 10FG 1100218
2036	TUBE RYLE'S 12FG 1100318
2037	TUBE RYLE'S 14FG 1100418
2038	TUBE RYLE'S 16FG 1100518
2039	TUBE RYLE'S 18FG 1100618
2040	TUBE SENGSTAKEN 18G #204803-18 (2/BOX)
2041	TUBE SET DYONICS 25 INFLOW (7211004) 3
2042	TUBE SHILEY TRACHEOSTOMY LP CUFF 6FEN
2043	TUBE SHILEY TRACHEOSTOMY LP CUFF 8LPC
2044	TUBE SMOOTH FLOW-CORRA 6FT 1518
2045	TUBE SPLINTING SINGLE USE #ST-SB1
2046	TUBE SUCTION FUNNEL 90"1/4"2
2047	TUBE TRACH CUFFLESS FEN 4CFN
2048	TUBE TRACH CUFFLESS FEN 6CFN
2049	TUBE TRACH PORTEX 8.5MM PL100-800-085
2050	TUBE TRACH PORTEX CUFF 9MM PL100-523-090
2051	TUBE TRACH PORTEX CUFF S8 PL-100-523-080
2052	TUBE TRACH PROFILE CUFF SZ 7.0
2053	TUBE TRACH PROFILE CUFF SZ 7.5
2054	TUBE TRACH PROFILE CUFF SZ 8.0
2055	TUBE TRACH PROFILE CUFF SZ 9.0
2056	TUBE TRACH PROFILE CUFF SZ.6.0
2057	TUBE YANKEUR SUCKER RIGID END DISP
2058	TUBING COMBIDYN 1 X 2MM X 200CM 5215035
2059	TUBING EXTENSION 140CM 4097408
2060	TUBING EXTENSION 75CM #4097173 (100/BOX)
2061	TUBING FLUID GAS EXCHANGE ALCON
2062	TUBING MINIMUM VOLUME W/T-CONNECTOR 10CM
2063	TUBING ONE PIECE MAIN FOR AR 6450
2064	TUBING OXYGEN 7FT HOT-1115
2065	TUBING PERFUSOR 150CM L/LOCK #8255504
2066	TUBING PRESSURE PT36
2067	TUBING PRESSURE PT60
2068	TUBING SET ADULT CSS
2069	TUBING SET CHILD CSS
2070	TUBING SET NEONATE CSS
2071	TUBING SINGLE USE 1.8M FISHER & PAYKEL
2072	TUBING SMARTCAP #100145S
2073	TUBING STR.SHOT IRRIGATION #1895522
2074	TUBING SUCTION 120" ID 1/4"

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
2075	TUBING SUCTION FOR LIPOPLAASTY PAL-900
2076	TURQUOISE HEAD/NECK SET 135696940
2077	TUTA TUBING #80.601
2078	TYCO ADULT DISP SIMPLIFIED B/CIRCUIT
2079	TYVEK ROLL WITH CI 200MM X 70M (12420)
2080	TYVEK ROLL WITH CI 250MMX70M (12425)
2081	TYVEK ROLL WITH CI 350MM X 70M #12435
2082	ULTEM KOH CUP 3.0CM N/STERILE COOPER
2083	ULTEM KOH CUP 3.5CM N/STERILE COOPER
2084	ULTEM KOH-CUP 4.0MM N/STERILE COOPER
2085	ULTRA KNOT PUSHER W/SUT CUTTER
2086	UNIFORM BLOUSE LONG SLEEVE STD
2087	UNIFORM APRON STD
2088	UNIFORM BLOUSE SHORT SLEEVE MTM
2089	UNIFORM BLOUSE SHORT SLEEVE STD
2090	UNIFORM CARDIGAN FEMALE STD
2091	UNIFORM DRESS MTM
2092	UNIFORM DRESS STD
2093	UNIFORM JACKET FEMALE MTM
2094	UNIFORM JACKET FEMALE STD
2095	UNIFORM JACKET MALE MTM
2096	UNIFORM LAB COAT MTM
2097	UNIFORM LAB COAT STD
2098	UNIFORM PANTS FEMALE MTM
2099	UNIFORM PANTS FEMALE STD
2100	UNIFORM PANTS MALE MTM
2101	UNIFORM PANTS MALE STD
2102	UNIFORM PANTS X-RAY (FREE SIZE)
2103	UNIFORM SHIRT LONG SLEEVE MALE MTM
2104	UNIFORM SHIRT LONG SLEEVE MALE STD
2105	UNIFORM SHIRT SHORT SLEEVE MALE MTM
2106	UNIFORM SHIRT SHORT SLEEVE MALE STD
2107	UNIFORM SHOE MALE
2108	UNIFORM SKIRT MTM
2109	UNIFORM VEST MTM
2110	UNIFORM VEST STD
2111	UNIVERSAL ADHESIVE REMOVER WIPE (B/50)
2112	UNIVERSAL PH PAPER (100/BX)
2113	URGOTUL 10X10CM (691800) 10/BX
2114	URIMETER
2115	URINAL MALE C/W COVER GF-3201
2116	UROSTOMY BAG ALTERNA PAED #8009 (20/BX)
2117	UROSTOMY BAG(25MM) CONVATEC 20917 BX/15
2118	UTERINE INJECTOR 4MM
2119	UTERINE MANIPULATOR 4.5MM #1151 (12/BX)
2120	UTRATOME X L3 LUMEN(PAPILLOTOME)
2121	VACUUM GARD FILTER #60119
2122	VAL INFUVALVE BACK CHECK #4094000N
2123	VALUE HEAD MEDELA LACTINA
2124	VALVE DEFENDO BIOPSY #100301
2125	VALVE PEEP 10.0CM H2O
2126	VALVE PEEP 15CM H2O (VS-9015)
2127	VALVE Y-OPSY #100303
2128	VANITY BOX (500/CTN)
2129	VENTURI PHACO PACK DP4305 W/E7551A
2130	VERSAPORT T179095
2131	VERSAPORT V2 5-12MM #T179096P (BX/3EA)
2132	VEST MEDICATION
2133	VIEW PACK FLAT 250MMX200MM (425R)
2134	VIEW PACK FLAT 405R 50MM X 200M
2135	VIEW PACK FLAT 410R 75MM X 200M

Andaman Alliance Healthcare Limited
List of Key Consumables to be imported

Annex C-5

Sr.	Item Description
2136	VIEW PACK FLAT 415R 100MM X 200M
2137	VIEW PACK FLAT 420R 150MM X 200M
2138	VISITING CARD (GHL) 3C/1C
2139	VISOR CLEAR FULL LENGTH #41204
2140	VITRECTOMY KNIFE SHARPOINT 20G 71-2001
2141	VLOC 180 DEVICE 0 GS-21 30CM #TVLOCL0316
2142	VLOC 180 DEVICE 3-0 V-20 15CM #TLOCL0604
2143	VYGON ART LEADERCATH CATH SZ 20G 115-090
2144	VYGON PREMICATH 1FR 20CM #1261.20
2145	W/CHAIR SEAT - 2"
2146	WALKING STICK
2147	WARMAIR FILTEREDFLO PACU (B/10)
2148	WATER OXYGENATED 5 GAL
2149	WATERTRAP (HP-M1657B)
2150	WECK-LUBE CONCENTRATE #850150W
2151	WEIGHING SCALE BABY ELECTRONIC SECA 374
2152	WIPE BABY SOFTCARE JOHNSON
2153	WIPE DISINFECTANT
2154	WIPE WET DISPOSABLE #003911
2155	WIPES INSTR SZ 1MM 8.25CM #Q604201
2156	WOOMBIE (CONVERTIBLE)
2157	WOOMBIE (ORIGINAL/SUMMER)
2158	WORKSAFE COVERALL WHITE
2159	WRAP STERILIZATION KC200 101CM X 101CM
2160	WRAP STERILIZATION KC200 121CM X 121CM
2161	WRAP STERILIZATION KC200 91CM X 91CM
2162	WRAPPER ENVIRONMENTAL SERVICES
2163	WRISTBAND INFANT CLEAR W/CARD #110
2164	WYPALL X70 MANUFACTURED RAGS QUARTER
2165	XOMED EXTERNAL SPLT SINGLE L #1528121
2166	XOMED EXTERNAL SPLT SINGLE LGE #1528138

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1	ABILIFY 10MG TABLETS
2	ABILIFY 10MG TABLETS (ARIPIPRAZOLE)
3	ABILIFY 15MG TABLETS (ARIPIPRAZOLE)
4	ACD-A 500ML SOLUTION (CITRATE DEXTROSE)
5	ACEBUTOLOL 100MG TABLETS
6	ACETAZOLAMIDE 250MG TABLETS
7	ACETIC ACID 3% (in alcohol) 100ML EAR DROPS (ACETIC ACID 3%)
8	ACETIC ACID 3% 100ML SOLUTION
9	ACETIC ACID 5% 100ML SOLUTION (ACETIC ACID)
10	ACETIC ACID 5% SOLUTION
11	ACETYLCYSTEINE 5G/25ML INJECTION
12	ACLASTA 5MG/100ML INJECTION (ZOLENDRONIC ACID)
13	ACRIFLAVINE 0.1% SOLUTION
14	ACTAL TABLET (ALUMINIUM HYDROXIDE)
15	ACTAL TABLET
16	ACTICOAT 10CMX10CM DRESSING
17	ACTIFED CO LINCTUS (TRIPOLIDINE-PSEUDOEPHEDRINE-CODEINE)
18	ACTIFED CO LINCTUS
19	ACTIFED DM LINCTUS
20	ACTIFED EXPECTORANT SYRUP (TRIPROLIDINE-PSEUDOEPHEDRINE-GUAIPHENESIN)
21	ACTIFED SYRUP (PSEUDOEPHEDRINE-TRIPROLIDINE)
22	ACTIFED TABLETS (TRIPROLIDINE-PSEUDOEPHEDRINE)
23	ACTILYSE 50MG INJECTION
24	ACTILYSE 50MG INJECTION (ALTEPLASE)
25	ACTIVELLE TAB 28'S TABLETS (OESTRADIOL-NORETHISTERONE)
26	ACTONEL 35MG TABLETS (RISEDRONATE)
27	ACTOS 15MG TABLETS (PIOGLITAZONE)
28	ACTOS 30MG TABLETS (PIOGLITAZONE)
29	ACTRAPID 100 unit/ml 10ML INJECTION (INSULIN NEUTRAL MC)
30	ACULAR 0.5% 5ML EYE DROPS (KETOROLAC)
31	ACUVAIL 0.45% 0.4ML 30'S MINIMS-EYEDROPS (KETOROLAC)
32	ACYCLOVIR 10G CREAM
33	ACYCLOVIR 250MG INJECTION
34	ACYCLOVIR 400mg TABLETS
35	ACYCLOVIR 800MG TABLETS
36	ADALAT LA 30MG TABLETS
37	ADALAT LA 30MG TABLETS (NIFEDIPINE LA)
38	ADENOCOR 6 MG/2 ML INJECTION
39	ADENOCOR 6 MG/2 ML INJECTION (ADENOSINE)
40	ADRENALINE 1:1000 1ML INJECTION (ADRENALINE)
41	ADRENALINE 1:1000 1ML INJECTION
42	ADRIAMYCIN 10 MG INJECTION (DOXORUBICIN)
43	ADRIAMYCIN 50 MG INJECTION (DOXORUBICIN)
44	ADVAGRAF 0.5mg CAPSULES (TACROLIMUS SR)
45	ADVAGRAF 1mg CAPSULES (TACROLIMUS SR)
46	ADVAGRAF 5mg CAPSULES (TACROLIMUS SR)
47	AERIUS 0.5MG/ML SYRUP (DESLORATADINE)
48	AERIUS 5MG TABLETS
49	AERIUS 5MG TABLETS (DESLORATADINE)
50	AFRIN 0.05% (15ML) NASAL SPRAY
51	AFRIN 0.05% (15ML) NASAL SPRAY (OXYMETAZOLINE)
52	AGGRASTAT 12.5MG/50ML INJECTION (TIROFIBAN)
53	AGNESIA 100GM POWDER (TALCUM POWDER BP)
54	AGRYLIN 0.5MG CAPSULES (ANAGRELIDE)
55	ALBENDAZOLE 400MG TABLETS
56	ALBOTHYL 90MG VAGINAL TABLETS (POLICRESULEN)
57	ALBUMIN (LOW SALT) 20% 50ML INFUSION
58	ALBUMIN (LOW SALT) 20% 50ML INFUSION (ALBUMIN (HUMAN))

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
59	ALBUMIN 25% 100ML INFUSION (ALBUMIN)
60	ALBUMIN 25% 50ML INFUSION
61	ALBUMIN 25% 50ML INFUSION (ALBUMIN (HUMAN))
62	ALBUMIN 5% 250ML INFUSION
63	ALBUMIN 5% 250ML INFUSION (ALBUMIN (HUMAN))
64	ALCAINE 0.5% 15ml EYE DROPS (POPARACAINE HCL)
65	ALCOHOL WIPE 20'S (ALCOHOL SWABS)
66	ALDACTONE 25MG TABLETS
67	ALDACTONE 25MG TABLETS (SPIRONOLACTONE)
68	ALDARA 5% CREAM (IMIQUIMOD)
69	ALKERAN 2MG TABLETS (MELPHALAN)
70	ALKERAN 50MG INJECTION (MELPHALAN)
71	ALLEVYN ADHESIVE 3!X3! (66000043) DRESSING (HYDROCELLULAR WOUND DRESSING A
72	ALLEVYN ADHESIVE 5!x5!(66000044) DRESSING (HYDROCELLULAR WOUND DRESSING AD
73	ALLEVYN GENTLE 10X10CM DRESSING
74	ALLEVYN NON-ADHESIVE 2!x2!(66007643) DRESSING (HYDROCELLULAR WOUND DRESSIN
75	ALLEVYN NON-ADHESIVE 4!x4!(66007637) DRESSING (HYDROCELLULAR WOUND DRESSIN
76	ALLOPURINOL 100MG TABLETS
77	ALLOPURINOL 300MG TABLETS
78	ALOE VERA 6 OZ GEL
79	ALOXI 250MCG/5ML INJECTION (PALONOSETRON)
80	ALOXI 75MCG/1.5ML INJECTION (PALONOSETRON)
81	ALPHAGAN P 0.15% 5ML EYE DROPS (BRIMONIDINE)
82	ALPHANATE 250 int.unit INJECTION (FACTOR 8+VWF)
83	ALTARGO 1% 5G OINTMENT (RETAPAMULIN)
84	AMARYL 1MG TABLETS
85	AMARYL 1MG TABLETS (GLIMEPIRIDE)
86	AMARYL 2MG TABLETS (GLIMEPIRIDE)
87	AMARYL 3MG TABLETS (GLIMEPIRIDE)
88	AMBISOME 50MG INJECTION (AMPHOTERICIN B LIPOSOME)
89	AMIKACIN 500mg/2mL INJECTION
90	AMINOCAPROIC ACID 5GM/20ML INJECTION
91	AMINOPHYLLINE 250 MG/10 ML INJECTION
92	AMINOPLASMAL 10% 500ML INFUSION
93	AMINOPLASMAL 10% 500ML INFUSION (AMINO ACIDS WITH ELECTROLYTES)
94	AMINOPLASMAL 5% 500ML INFUSION
95	AMINOPLASMAL 5% 500ML INFUSION (AMINO ACID)
96	AMINOVEN 10% 500ML INFUSION (AMINO ACID)
97	AMITRIPTYLINE 10MG TABLETS
98	AMITRIPTYLINE 25mg TABLETS
99	AMOXIL 500MG CAPSULES (AMOXYCILLIN)
100	AMOXYCILLIN 125mg/5mL 60ML SYRUP
101	AMOXYCILLIN 250mg CAPSULES
102	AMOXYCILLIN 250mg/5mL 60ML SYRUP
103	AMPHOTERICIN 50MG INJECTION
104	AMPICILLIN 250mg CAPSULES
105	AMPICILLIN 500mg INJECTION
106	AMVISC PLUS 0.8ML INJECTION (HYALURONATE SOD)
107	ANAFRANIL SR 75MG TABLETS (CLOMIPRAMINE)
108	ANDRIOL TESTOCAPS 40MG CAPSULES (TESTOSTERONE UNDECANOATE)
109	ANDROCUR 50 MG TABLETS (CYPROTERONE)
110	ANEXATE 0.5 MG/5 ML INJECTION
111	ANEXATE 0.5 MG/5 ML INJECTION (FLUMAZENIL)
112	ANIOXYDE 1000 5L SOLUTION (PERACETIC ACID)
113	ANTI-EMBOLIC STOCKING
114	APIDRA SoloSTAR 100 unit/ml 3ML INJECTION (INSULIN GLULISINE)
115	APO-AMILZIDE 5/50MG TABLETS (HYDROCHLOROTHIAZIDE-AMILORIDE)
116	APO-CHLORAX 5/2.5MG CAPSULES (CHLORDIAZEPOXIDE-CLIDINIUM BR)
117	APO-CHLORAX 5/2.5MG CAPSULES

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
118	APO-TRIAZIDE 50-25MG TABLETS (HYDROCHLOROTHIAZIDE-TRIAMTERENE)
119	APPELIN-B12 150ML SYRUP
120	APPELIN-B12 SYRUP (LYSINE VITAMINS)
121	APPETON MV PLUS INFANT 30ML DROPS (MULTIVITAMINS-INFANT)
122	APRESOLINE 10 MG TABLETS (HYDRALAZINE)
123	APRESOLINE 20 MG/ML INJECTION
124	APRESOLINE 20 MG/ML INJECTION (HYDRALAZINE)
125	APROVEL 150MG TABLETS
126	APROVEL 150MG TABLETS (IRBESARTAN)
127	APROVEL 300MG TABLETS
128	APROVEL 300MG TABLETS (IRBESARTAN)
129	AQUA 30G CREAM (AQUEOUS)
130	AQUACEL 10CMX10CM DRESSING
131	AQUACEL AG 10CMX10CM DRESSING
132	AQUACEL AG 15CMX15CM DRESSING
133	AQUACEL AG ROPE 2CM X 45CM DRESSING
134	AQUACEL FOAM 10CMX10CM DRESSING
135	AQUACEL ROPE 2CMX45CM DRESSING
136	AQUEOUS 15G CREAM (AQUEOUS)
137	AQUEOUS 30G CREAM
138	AQUEOUS BP 100G CREAM (AQUEOUS)
139	ARANESP 40MCG SYRINGE (DARBEPOETIN ALFA)
140	ARAVA 20MG TABLETS (LEFLUNOMIDE)
141	ARCALION 200MG TABLETS (SULBUTIAMINE)
142	ARCOXIA 120MG TABLETS
143	ARCOXIA 120MG TABLETS (ETORICOXIB)
144	ARCOXIA 60MG TABLETS
145	ARCOXIA 60MG TABLETS (ETORICOXIB)
146	ARCOXIA 90MG TABLETS
147	ARCOXIA 90MG TABLETS (ETORICOXIB)
148	ARICEPT 5MG TABLETS
149	ARICEPT 5MG TABLETS (DONEPEZIL)
150	ARICEPT EVESS 5MG TABLETS (DONEPEZIL)
151	ARIMIDEX 1MG TABLETS (ANASTROZOLE)
152	ARTESUNATE 50MG TABLETS
153	ARTESUNATE 60MG INJECTION
154	ARTREX CAPSULES (WINTER CHERRY-INDIAN FRANKINCENSE-TURMERIC-GINGER)
155	ASACOL 400MG TABLETS (MESALAZINE)
156	ASIGYN 500 MG TABLETS (TINIDAZOLE)
157	ASPIRIN 500mg TABLETS
158	ASPIRIN CARDIO 100MG CAPSULES (ASPIRIN)
159	ATACAND 16MG TABLETS (CANDESARTAN CILEXETIL)
160	ATACAND 4MG TABLETS
161	ATACAND 4MG TABLETS (CANDESARTAN CILEXETIL)
162	ATACAND 8MG TABLETS (CANDESARTAN CILEXETIL)
163	ATACAND PLUS 16/12.5MG TABLETS (CANDESARTAN-HYDROCHLOROTHIAZIDE)
164	ATARAX 10MG TABLETS
165	ATARAX 10MG TABLETS (HYDROXYZINE)
166	ATARAX 25MG TABLETS
167	ATARAX 25MG TABLETS (HYDROXYZINE)
168	ATARAX 2MG/ML SYRUP (HYDROXYZINE)
169	ATENOLOL 100MG TABLETS (ATENOLOL)
170	ATENOLOL 50MG TABLETS (ATENOLOL)
171	ATGAM 250MG/5ML INJECTION (ANTITHYMOCYTE GLOBULIN (EQUINE))
172	ATOPICLAIR 100ML CREAM
173	ATOPICLAIR 120ML LOTION
174	ATOPICLAIR 40ML CREAM
175	ATRACURIUM 50mg/5mL INJECTION
176	ATROPINE 0.5% 10ML EYE DROPS

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
177	ATROPINE 0.6 MG/ML INJECTION
178	ATROPINE 1% 5ML EYE DROPS
179	ATROVENT 0.025% 20ML RESPIRATOR SOLUTION (IPRATROPIUM)
180	ATROVENT 20MCG INHALER (IPRATROPIUM)
181	AUGMENTIN 1.2 GM INJECTION
182	AUGMENTIN 1.2 GM INJECTION (AMOXYCILLIN-CLAVULANIC ACID)
183	AUGMENTIN 1GM TABLETS (AMOXYCILLIN-CLAVULANIC ACID)
184	AUGMENTIN 228MG/5ML 70ML SYRUP
185	AUGMENTIN 228MG/5ML 70ML SYRUP (AMOXYCILLIN-CLAVULANIC ACID)
186	AUGMENTIN 600 MG INJECTION (AMOXYCILLIN-CLAVULANIC ACID)
187	AUGMENTIN 625 MG TABLETS
188	AUGMENTIN 625 MG TABLETS (AMOXYCILLIN-CLAVULANIC ACID)
189	AUGMENTIN ES 643MG/5ML 100ML SUSPENSION (AMOXYCILLIN-CLAVULANIC ACID)
190	AVAMYS 27.5MCG/SPRAY (120D) NASAL SPRAY (FLUTICASONE)
191	AVASTIN 100MG/4ML INJECTION (BEVACIZUMAB)
192	AVELOX 400MG TABLETS
193	AVELOX 400MG TABLETS (MOXIFLOXACIN)
194	AVELOX 400MG/250ML INJECTION
195	AVELOX 400MG/250ML INJECTION (MOXIFLOXACIN)
196	AVODART 0.5MG CAPSULES (DUTASTERIDE)
197	AZACITIDINE 100 MG INJECTION
198	AZACTAM 1 GM INJECTION
199	AZARGA 5ml EYE DROPS (BRINZOLAMIDE-TIMOLOL)
200	AZATHIOPRINE 50MG TABLETS
201	AZOPT 1% 5ML EYE DROPS (BRINZOLAMIDE)
202	AZOREN 20MG/5MG TABLETS (OLMESARTAN-AMLODIPINE)
203	BACLOFEN 10MG TABLETS
204	BACTIDOL 250ML MOUTHWASH (HEXETIDINE)
205	BACTIGRAS 10CMx10CM DRESSING
206	BACTIGRAS 10CMx10CM DRESSING (CHLORHEXIDINE ACETATE)
207	BACTIGRAS 5CM X 5CM DRESSING (CHLORHEXIDINE ACETATE)
208	BACTROBAN 2% 15GM CREAM
209	BACTROBAN 2% 15GM CREAM (MUPIROCIN)
210	BACTROBAN 2% 15GM OINTMENT (MUPIROCIN)
211	BACTROBAN 2% 3GM NASAL OINTMENT (MUPIROCIN)
212	BACTROBAN 2% 5GM OINTMENT (MUPIROCIN)
213	BACTROBAN 2% 3GM NASAL OINTMENT
214	BAMBEC 10MG TABLETS (BAMBUTEROL)
215	BAMBEC 1MG/ML SOLUTION (BAMBUTEROL)
216	BANEOCIN 10G POWDER
217	BANEOCIN 10G POWDER (BACITRACIN-NEOMYCIN SULPHATE)
218	BARACLUDE 0.5MG TABLETS (ENTECAVIR)
219	BARIUM EZ CAT 225ML
220	BARIUM EZ HD WITH STRAW
221	BAYHEP B 0.5ML INJECTION (HEPATITIS B (IMMUNOGLOBULIN))
222	BAYHEP B 5ML INJECTION (HEPATITIS B IMMUNOGLOBULIN)
223	BCG. VACCINE (BCG)
224	BECLOMETHASONE 50MCG INHALER
225	BECOZYME 2ML INJECTION (VITAMIN B COMPLEX)
226	BENGAY GREASELESS 57G CREAM (METHYL SALICYLATE-MENTHOL)
227	BENGAY ULTRA STRENGTH 4OZ (113G) CREAM (METHYL SALICYLATE-MENTHOL)
228	BENZATHINE PENICILLIN 2.4 megaunit INJECTION
229	BENZHEXOL 2MG TABLETS
230	BENZOIN COMPOUND 50ML TINCTURE (BENZOIN COMPOUND)
231	BENZOIN COMPOUND 50ML TINCTURE (BENZOIN COMPOUND TINCTURE)
232	BENZTROPINE 2MG TABLETS
233	BENZYL BENZOATE 25% 100ML APPLICATION
234	BENZYLPENICILLIN 3000MG (5megaunit) INJECTION
235	BENZYLPENICILLIN 600MG (1megaunit) INJECTION

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
236	BEROCCA EFFERVESCENT 15'S TABLETS (MULTIVITAMINS AND MINERALS)
237	BERODUAL 20ML RESPIRATOR SOLUTION (IPRATROPIUM-FENOTEROL)
238	BERODUAL INHALER (IPRATROPIUM-FENOTEROL)
239	BEROTEC N 100MCG INHALER (FENOTEROL)
240	BETADINE 10 GM OINTMENT (POVIDONE IODINE)
241	BETADINE VAGINAL DOUCHE KIT 100ML DOUCHE
242	BETAMETHASONE 0.1% 15G OINTMENT (BETAMETHASONE VALERATE)
243	BETAMETHASONE C 0.1%-3% 15G CREAM (BETAMETHASONE VALERATE-CLIQUINOL)
244	BETASERC 16MG TABLETS (BETAHISTINE)
245	BETASERC 24MG TABLETS (BETAHISTINE)
246	BETNOVATE 0.1% 15GM CREAM (BETAMETHASONE VALERATE)
247	BETNOVATE 0.1% 30ML SCALP APPLICATION (BETAMETHASONE VALERATE)
248	BETNOVATE RD 0.025% 15GM CREAM (BETAMETHASONE VALERATE)
249	BETOPTIC 0.5% 5ML EYE DROPS (BETAXOLOL)
250	BETOPTIC S 0.25% 5ML EYE DROPS (BETAXOLOL)
251	BICNU 100MG INJECTION (CARMUSTINE)
252	BIOGAIA ORS+ZINC SACHETS
253	BIOGAIA PROBIOTIC 5ML DROPS
254	BIOGAIA STICK 1G SACHETS
255	BIOGESIC 500MG TABLETS
256	BIOGESIC 500MG TABLETS (PARACETAMOL)
257	BION TEARS 0.4ML 28'S EYE DROPS (DEXTRAN METHYLCELLULOSE)
258	BIOTENE (BOT) MOUTHWASH (ENZYME ANTIBACTERIAL)
259	BIOTENE ORAL BALANCE 42G GEL (SALIVA SUBSTITUTE)
260	BIPP (GAUZE) 12.5MMX1M PASTE (BISMUTH SUBNITRATE-IODOFORM-LIQUID PARAFFIN)
261	BIPP PASTE (BISMUTH SUBNITRATE-IODOFORM-LIQUID PARAFFIN)
262	BISACODYL 10MG SUPPOSITORIES
263	BISMUTH SUBGALLATE CO 200MG SUPPOSITORIES
264	BLEOMYCIN 15MG INJECTION
265	BLEPHAGEL EYE 40G GEL (POLYGLYCOL CO)
266	BONDRONAT 6MG/6ML INJECTION (IBANDRONIC ACID)
267	BONJELA 15G GEL (CHOLINE SALICYLATE-CETALKONIUM CHLORIDE)
268	BONNIE & BROWNING 25ML SOLUTION (BRILLIANT GREEN-GENTIAN VIOLET-M.SPITIT 70%
269	BONNIE & BROWNING 50ML SOLUTION (BRILLIANT GREEN-GENTIAN VIOLET-M.SPITIT 70%
270	BONVIVA 150MG TABLETS (IBANDRONIC ACID)
271	BOOST WITH BENEFIBER 237ML LIQUID (MILK SUBSTITUE)
272	BOOSTRIX 0.5ML VACCINE (DIPHTHERIA-TETANUS-PERTUSSIS)
273	BOTOX (OCULINUM) 100 int.unit INJECTION (CLOSTRIDIUM BOTULINUM TOXIN TYPE A)
274	BOUND 24G SACHETS
275	BREVIBLOC 100MG/10ML INJECTION
276	BREVIBLOC 100MG/10ML INJECTION (ESMOLOL)
277	BRICANYL 500MCG/ML INJECTION (TERBUTALINE)
278	BRILINTA 90MG TABLETS
279	BRILINTA 90MG TABLETS (TICAGRELOR)
280	BROMHEXINE 4MG/2ML INJECTION
281	BROMHEXINE 4MG/5ML SYRUP
282	BROMHEXINE 8MG TABLETS
283	BROMOCRIPTINE 2.5MG TABLETS
284	BSS. 15ML EYE IRRIGATION (BALANCED SALT SOLUTION)
285	BSS. 250 ML EYE IRRIGATION (BALANCED SALT SOLUTION)
286	BSS. 500 ML EYE IRRIGATION (BALANCED SALT SOLN)
287	BUDENOFALK 3MG CAPSULES
288	BUDENOFALK 3MG CAPSULES (BUDESONIDE)
289	BUPIVACAINE ADRENALINE 0.5% 20mL INJECTION (BUPIVACAINE-ADRENALINE T PK)
290	BURINEX 1 MG TABLETS
291	BURINEX 1 MG TABLETS (BUMETANIDE)
292	BURINEX 2 MG/4 ML INJECTION
293	BURINEX 2 MG/4 ML INJECTION (BUMETANIDE)
294	BUSCOPAN 10 MG TABLETS

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
295	BUSCOPAN 10 MG TABLETS (HYOSCINE-N-BUTYLBROMIDE)
296	BUSCOPAN 20 MG/ML INJECTION (HYOSCINE ButylBr)
297	BUSULPHAN 60MG/10ML INJECTION
298	CAELYX 20MG/10ML INJECTION (DOXORUBICIN (Liposomal))
299	CAFERGOT TABLETS (ERGOTAMINE-CAFFEINE)
300	CAFFEINE CITRATE 10MG/ML INJECTION
301	CAFFEINE CITRATE 10MG/ML SYRUP
302	CAFFEINE CITRATE 1GM POWDER
303	CAFFEINE CITRATE 20MG/ML SOLUTION (CAFFEINE CITRATE)
304	CAFFEINE CITRATE 40MG/2ML INJECTION
305	CAFFOX 1MG/100MG TABLETS (ERGOTAMINE-CAFFEINE)
306	CALAMINE 100 ML LOTION (CALAMINE APF)
307	CALAMINE WITH MENTHOL 100 ML LOTION
308	CALCIJEX 1MCG/ML INJECTION (CALCITRIOL)
309	CALCIUM 115mg/5ml SYRUP
310	CALCIUM ACETATE 667MG TABLETS
311	CALCIUM C 1000 SANDOZ EFF 1GM (10'S) TABLETS (CALCIUM LACTATE-GLUCONATE-CAR
312	CALCIUM CALCIONATE elemental Ca 115mg/5ml SYRUP (CALCIUM CALCIONATE)
313	CALCIUM CARBONATE (TUMS) 1000MG TABLETS
314	CALCIUM CARBONATE 1250 MG TABLETS (CALCIUM CARBONATE)
315	CALCIUM CHLORIDE 1 GM/10 ML INJECTION
316	CALCIUM D REDOXON EFF 1 GM (10'S) TABLETS (CALCIUM-VIT.C-VIT.D-VIT.B6)
317	CALCIUM GLUCONATE 1g/10mL INJECTION
318	CALCIUM LACTATE 300MG TABLETS
319	CALCIUM SANDOZ 108MG/5ML SYRUP (CALCIUM)
320	CALCIUM SANDOZ FORTE 500MG (10'S) TABLETS (CALCIUM)
321	CALPOL 120MG/5ML SUSPENSION
322	CALPOL 120MG/5ML SUSPENSION (PARACETAMOL)
323	CALTRATE 600MG TABLETS (CALCIUM)
324	CALTRATE D 600MG TABLETS (CALCIUM VIT D)
325	CALTRATE PLUS TABLETS (CALCIUM-VIT.D-MINERALS)
326	CAMCOLIT CR 400MG TABLETS (LITHIUM CARBONATE)
327	CANCIDAS 50MG INJECTION (CASPOFUNGIN ACETATE)
328	CANCIDAS 70MG INJECTION (CASPOFUNGIN ACETATE)
329	CANESTAN 1% 10GM CREAM (CLOTRIMAZOLE)
330	CANESTEN 1% 20GM CREAM (CLOTRIMAZOLE)
331	CANESTEN 100MG PESSARIES (CLOTRIMAZOLE)
332	CANESTEN 500MG PESSARIES (CLOTRIMAZOLE)
333	CANESTEN HC 1% 15G CREAM (CLOTRIMAZOLE-HYDROCORTISONE)
334	CAPTOPRIL 12.5MG TABLETS
335	CAPTOPRIL 25mg TABLETS
336	CARBIMAZOLE 5MG TABLETS
337	CARBOPLATIN 150MG INJECTION (CARBOPLATIN)
338	CARDIBLOC SR 40MG CAPSULES (NICARDIPINE SR)
339	CARDIOPLEGIA 20 ML SOLUTION (MAGNESIUM CHLORIDE-POTASSIUM CHLORIDE-PROCA
340	CARDIPRIN 100MG TABLETS
341	CARDIPRIN 100MG TABLETS (ASPIRIN- GLYCINE)
342	CARDOPAR 25/100MG TABLETS (LEVODOPA-CARBIDOPA)
343	CARDURA 2MG TABLETS (DOXAZOSIN)
344	CARMINATIVE MIXTURE (MAGNESIUM CARBONATE-SODIUM BICARBONATE)
345	CARMINATIVE MIXTURE
346	CASODEX 150MG TABLETS (BICALUTAMIDE)
347	CASODEX 50MG TABLETS (BICALUTAMIDE)
348	CATAFLAM 15MG/ML 15ml DROPS (DICLOFENAC SODIUM)
349	CATAFLAM 50MG TABLETS
350	CATAFLAM 50MG TABLETS (DICLOFENAC POTASSIUM)
351	CATHETER SILICONE (PHARMACY)
352	CAUSTIC APPLICATORS APPLICATION (SILVER NITRATE APPLICATORS)
353	CAVERJECT 20MCG INJECTION (ALPROSTADIL)

Sr	Item Description
354	CAVERJET 10MCG INJECTION (ALPROSTADIL)
355	CAVILON BARRIER 92G CREAM (DIMETHICONE)
356	CAVILON NO-STING BARRIER 28ML SPRAY (DIMETHICONE)
357	CAVINTON 5 MG TABLETS (VINPOCETINE)
358	CEDAX 180MG/5ML 30ML SYRUP (CEFTIBUTEN)
359	CEDAX 400 MG CAPSULES (CEFTIBUTEN)
360	CEELIN 100MG/5ML SYRUP (ASCORBIC ACID)
361	CEENU 40MG CAPSULES (LOMUSTINE)
362	CEFACLOR 125MG/5ML 60ML SUSPENSION
363	CEFACLOR 250MG CAPSULES
364	CEFACLOR MR 375MG TABLETS
365	CEFADROXIL 250MG/5ML 60ML SYRUP
366	CEFADROXIL 500MG CAPSULES
367	CEFOXITIN 1G INJECTION
368	CEFTRIAXONE 1G IV/IM INJECTION
369	CEFTRIAXONE 500MG IV/IM INJECTION
370	CELEBREX 200MG CAPSULES
371	CELEBREX 200MG CAPSULES (CELECOXIB)
372	CELLCEPT 250MG CAPSULES (MYCOPHENOLATE)
373	CELLCEPT 500MG INJECTION (MYCOPHENOLATE)
374	CELLCEPT 500mg TABLETS (MYCOPHENOLATE)
375	CENTELLASE 10 GM OINTMENT
376	CENTRUM SILVER TABLETS (MULTIVITAMINS &MINERALS)
377	CENTRUM TABLETS (MULTIVITAMINS &MINERALS)
378	CENTRUM TABLETS
379	CEPHALEXIN 250mg CAPSULES
380	CEPHALEXIN 250MG/5ML 60ML SYRUP
381	CEPHAZOLIN (CEFAZOLIN) 1g INJECTION
382	CEPHAZOLIN (CEFAZOLIN) 1g INJECTION (CEPHAZOLIN)
383	CERTICAN 0.75MG TABLETS (EVEROLIMUS)
384	CERVAGEM 1 MG PESSARIES (GEMEPROST)
385	CERVARIX VACCINE (PAPILLOMAVIRUS HUMAN)
386	CETAPHIL CLEANSER 8OZ BATH (PROPYLENE GLYCOL,CETY ALCOHOL, SOD LAURYL SUI
387	CETAPHIL INTENSIVE MOISTURISING 85G CREAM
388	CETAPHIL MOISTURIZING 200ML LOTION (GLYCERIN,NUT OIL, HYDROGENATED POLYISOE
389	CETAPHIL RESTORADERM MOISTURISER 295ML LOTION
390	CETAPHIL RESTORADERM WASH 295ML
391	CETOMACROGOL CREAM (CETOMACROGOL)
392	CETRIMIDE 5% SHAMPOO
393	CHAMPIX 1MG TABLET (VARENICLINE)
394	CHAMPIX STARTER PACK 25'S TABLET (VARENICLINE)
395	CHARCODOTE AQUEOUS 250ML SUSPENSION (CHARCOAL ACTIVATED)
396	CHIROCAINE 5OMG/10ML INJECTION (LEVOBUPIVACAINE)
397	CHLORAL HYDRATE 500MG/5ML SYRUP
398	CHLORAMPHENICOL 0.25% 5ML EYE DROPS (CHLORAMPHENICOL)
399	CHLORAMPHENICOL 0.5% 0.5ML MINIMS-EYEDROPS (CHLORAMPHENICOL)
400	CHLORAMPHENICOL 0.5% 5ML EYE DROPS (CHLORAMPHENICOL)
401	CHLORAMPHENICOL 0.5% EYE DROPS
402	CHLORAMPHENICOL 1% 3GM EYE OINTMENT
403	CHLORAPREP 2%/70% 3ML APPLICATION (CHLORHEXIDINE WITH IPA)
404	CHLORHEX 0.015% CET 0.15% 100ML SOLUTION (CHLORHEXIDINE-CETRIMIDE)
405	CHLORHEX 0.015% CET 0.15% 500ML SOLUTION (CHLORHEXIDINE-CETRIMIDE)
406	CHLORHEX 0.5% IN ALC 70% 100 ML SOLUTION (CHLORHEXIDINE ALCOHOLIC)
407	CHLORHEX 0.5% IN ALC 70% 500ML SOLUTION (CHLORHEXIDINE ALCOHOLIC)
408	CHLORHEX 2% IN SPIRIT 70% 100ML SOLUTION (CHLORHEXIDINE ALCOHOLIC)
409	CHLORHEXIDINE 0.05% 100ML SOLUTION (CHLORHEXIDINE ACETATE)
410	CHLORHEXIDINE 0.05% 500ML SOLUTION (CHLORHEXIDINE ACETATE)
411	CHLORHEXIDINE 0.2% MOUTHWASH
412	CHLORHEXIDINE 1% 15G CREAM

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
413	CHLORHEXIDINE 2% SWABS
414	CHLORHEXIDINE 4% 500ML SOLUTION
415	CHLORHEXIDINE OBSTETRIC 1% (200G) LOTION (CHLORHEXIDINE GLUCONATE)
416	CHLORHEXIDINE PRE-OP WASH 50 ML SOLUTION (CHLORHEXIDINE)
417	CHLORHEXIDINE WITH IPA 2%/70% SWABS
418	CHLOROQUINE PHOSPHATE 250MG TABLETS (CHLOROQUINE PHOSPH.)
419	CHLORPHENIRAMINE 10MG/ML INJECTION
420	CHLORPHENIRAMINE 10MG/ML INJECTION
421	CHLORPHENIRAMINE 4MG TABLETS
422	CHLORPHENIRAMINE 4MG/5ML SYRUP
423	CHLORPROMAZINE 25MG TABLETS
424	CHLORPROMAZINE 50 MG/2 ML INJECTION
425	CHLORTETRACYCLINE 1% 3.5G EYE OINTMENT
426	CHOLESTYRAMINE 4G SACHETS
427	CIALIS 20MG TABLETS (TADALAFIL)
428	CIALIS 5MG TABLETS (TADALAFIL)
429	CICA-CARE 12CMx6CM DRESSING
430	CIDOFOVIR 375MG/5ML INJECTION
431	CILOXAN 0.3% 3.5G EYE OINTMENT (CIPROFLOXACIN)
432	CILOXAN EYE/EAR 0.3% 5ML EYE DROPS (CIPROFLOXACIN)
433	CIMETIDINE 200MG TABLETS
434	CIPRAM 20MG TABLETS (CITALOPRAM)
435	CIPROBAY 100MG/50ML INJECTION
436	CIPROBAY 100MG/50ML INJECTION (CIPROFLOXACIN)
437	CIPROBAY 200mg/100mL INJECTION
438	CIPROBAY 200mg/100mL INJECTION (CIPROFLOXACIN)
439	CIPROBAY 250MG TABLETS
440	CIPROBAY 250MG TABLETS (CIPROFLOXACIN)
441	CIPROBAY 500MG TABLETS
442	CIPROBAY 500MG TABLETS (CIPROFLOXACIN)
443	CIPROBAY HC 10ML EAR DROPS (CIPROFLOXACIN HYDROCORTISONE)
444	CIRCADIN PR 2MG TABLETS (MELATONIN)
445	CISPLATIN 50MG INJECTION
446	CITRAVESCENT 4 GM SACHETS
447	CITRAVESCENT 4 GM SACHETS (SODIUM BICARBONATE COMPOUND)
448	CLAFORAN 0.5 GM INJECTION (CEFOTAXIME)
449	CLARINASE 24HR TABLETS (LORATADINE-PSEUDOPHEDRINE)
450	CLARINASE 24HR TABLETS
451	CLARINASE REPETABS TABLETS (LORATADINE-PSEUDOEPHEDINE)
452	CLARINASE SYRUP (LORATADINE-PSEUDOEPHEDRINE)
453	CLARITYNE 10MG TABLETS
454	CLARITYNE 10MG TABLETS (LORATADINE)
455	CLARITYNE 1MG/ML SYRUP (LORATADINE)
456	CLEXANE 20 MG/0.2 ML SYRINGE (ENOXAPARIN SODIUM)
457	CLEXANE 40 MG/0.4 ML SYRINGE
458	CLEXANE 40 MG/0.4 ML SYRINGE (ENOXAPARIN SODIUM)
459	CLEXANE 60 MG/0.6 ML SYRINGE
460	CLEXANE 60 MG/0.6 ML SYRINGE (ENOXAPARIN SODIUM)
461	CLEXANE 80MG/0.8ML SYRINGE
462	CLEXANE 80MG/0.8ML SYRINGE (ENOXAPARIN SODIUM)
463	CLOMIPHENE 50MG TABLETS
464	CLOMIPRAMINE 25MG TABLETS
465	CLONAZEPAM 0.5MG TABLETS
466	CLOPIXOL DEPOT 200MG/ML INJECTION (ZUCLOPENTHIXOL DECANOATE)
467	CLOTRIMAZOLE 1% 10ML LOTION
468	CLOXACILLIN 125MG/5ML 60ML SYRUP
469	CLOXACILLIN 250 MG CAPSULES
470	CLOXACILLIN 500mg INJECTION
471	CLOZARIL 100MG TABLETS (CLOZAPINE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
472	CLOZARIL 25 MG TABLETS (CLOZAPINE)
473	COAPROVEL 150/12.5MG TABLETS
474	COAPROVEL 150/12.5MG TABLETS (IRBESARTAN/HCTZ)
475	COAPROVEL 300/12.5MG TABLETS
476	COAPROVEL 300/12.5MG TABLETS (IRBESARTAN/HCTZ)
477	COAPROVEL 300/25MG TABLETS (IRBESARTAN/HCTZ)
478	COCAINE 10% SOLUTION
479	CODEINE PHOSPHATE 30MG TABLETS
480	CODEINE PHOSPHATE 60mg/ml INJECTION
481	CO-DIOVAN 12.5/160MG TABLETS (HYDROCHLOROTHIAZIDE-VALSARTAN)
482	CO-DIOVAN 12.5/80MG TABLETS
483	CO-DIOVAN 12.5/80MG TABLETS (HYDROCHLOROTHIAZIDE-VALSARTAN)
484	CO-DIOVAN 25/160MG TABLETS (HYDROCHLOROTHIAZIDE-VALSARTAN)
485	CODIPRONT CAPSULES (CODEINE-PHENYLTOLOXAMINE)
486	CO-ENZYME Q10 50MG CAPSULES
487	COGENTIN 2MG/2ML INJECTION (BENZTROPINE)
488	COLCHICINE 500MCG TABLETS
489	COLIFOAM 10% RECTAL FOAM (HYDROCORTISONE)
490	COLIMIX SYRUP (DICYCLOMINE/SIMETHICONE)
491	COLIMIX SYRUP
492	COLLOMACK 10 ML SOLUTION (SALICYLIC-LACTIC-POLIDOCANOL)
493	COLPERMIN 187MG CAPSULES (PEPPERMINT OIL)
494	COMBIDERM 15G CREAM (BETAMETHASONE-CLOTRIMAZOLE-GENTAMICIN)
495	COMBIGAN 0.2%-0.5% EYE DROPS (BRIMONIDINE-TIMOLOL)
496	COMBIVENT 2.5ML RESPULES
497	COMBIVENT 2.5ML RESPULES (IPRATROPIUM-SALBUTAMOL)
498	COMTAN 200MG TABLETS (ENTACAPONE)
499	CONCERTA 18MG TABLETS (METHYLPHENIDATE SR)
500	CONCERTA 27MG TABLETS (METHYLPHENIDATE SR)
501	CONCERTA 36MG TABLETS (METHYLPHENIDATE SR)
502	CONCERTA 54MG TABLETS (METHYLPHENIDATE SR)
503	CONCOR 2.5MG TABLETS
504	CONCOR 2.5MG TABLETS (BISOPROLOL)
505	CONCOR 5MG TABLETS
506	CONCOR 5MG TABLETS (BISOPROLOL)
507	CONTROLOC 20MG TABLETS
508	CONTROLOC 20MG TABLETS (PANTOPRAZOLE)
509	CONTROLOC 40MG INJECTION
510	CONTROLOC 40MG INJECTION (PANTOPRAZOLE)
511	CONTROLOC 40MG TABLETS
512	CONTROLOC 40MG TABLETS (PANTOPRAZOLE)
513	CO-PHENYLCAINE F (PER ML) NASAL SPRAY (LIGNOCAINE-PHENYLEPHRINE)
514	CO-PHENYLCAINE F 50ML NASAL SPRAY (LIGNOCAINE-PHENYLEPHRINE)
515	CO-PLAVIX 75MG/100MG TABLETS (CLOPIDOGREL-ASPIRIN)
516	CORALAN 5MG TABLETS
517	CORDARONE 150MG/3ML INJECTION
518	CORDARONE 150MG/3ML INJECTION (AMIODARONE)
519	CORDARONE 200MG TABLETS
520	CORDARONE 200MG TABLETS (AMIODARONE)
521	CORTISONE ACETATE 25MG TABLETS
522	COSMEGEN 500mcg INJECTION (DACTINOMYCIN)
523	COSOPT 5ML EYE DROPS (DORZOLAMIDE-TIMOLOL)
524	CO-TRIMOXAZOLE 200-40mg/5ml SUSPENSION
525	CO-TRIMOXAZOLE 200-40mg/5ml SUSPENSION (TRIMETHOPRIM-SULFAMETHOXAZOLE)
526	CO-TRIMOXAZOLE 480MG/5ML INJECTION
527	CO-TRIMOXAZOLE 480MG/5ML INJECTION (TRIMETHOPRIM-SULFAMETHOXAZOLE)
528	CO-TRIMOXAZOLE 80mg-400mg TABLETS
529	CO-TRIMOXAZOLE 80mg-400mg TABLETS (TRIMETHOPRIM-SULFAMETHOXAZOLE)
530	COTTON BALL (PHARMACY) 10'S DRESSING (COTTON BALL)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
531	COUNTERPAIN 30 GM CREAM (METHYL SALICYLATE-EUGENOL-MENTHOL)
532	COVERAM 5MG/5MG TABLETS (PERINDOPRIL-AMLODIPINE)
533	COVERSYL 5MG TABLETS
534	COVERSYL 5MG TABLETS (PERINDOPRIL)
535	COVERSYL PLUS 5/1.25MG TABLETS (PERINDOPRIL-INDAPAMIDE)
536	COZAAR 100MG TABLETS (LOSARTAN POTASSIUM)
537	COZAAR 50MG TABLETS
538	COZAAR 50MG TABLETS (LOSARTAN POTASSIUM)
539	CRAVIT 0.5% 5ML EYE DROPS (LEVOFLOXACIN)
540	CRAVIT 250MG/50ML INJECTION (LEVOFLOXACIN)
541	CRAVIT 500MG TABLETS
542	CRAVIT 500MG TABLETS (LEVOFLOXACIN)
543	CRAVIT 500MG/100ML INJECTION
544	CRAVIT 500MG/100ML INJECTION (LEVOFLOXACIN)
545	CREON 10000 150MG CAPSULES (PANCREATIN)
546	CRESTOR 10MG TABLETS
547	CRESTOR 10MG TABLETS (ROSUVASTATIN)
548	CRESTOR 20MG TABLETS (ROSUVASTATIN)
549	CRINONE 8% VAGINAL GEL (PROGESTERONE)
550	CURACAO 2 OZ SPRAY
551	CURAM (AMOXYCILLIN-CLAVULANIC ACID) 500mg-125mg TABLETS (AMOXYCILLIN-CLAVUL
552	CUTIVATE 0.05% 15GM CREAM (FLUTICASONE PROPIONATE)
553	CYCLOGEST 400MG PESSARIES (PROGESTERONE)
554	CYCLOGYL 1% EYE DROPS (CYCLOPENTOLATE)
555	CYCLOMYDRIL 5ML EYE DROPS (CYCLOPENTOLATE-PHENYLEPHRINE)
556	CYCLOPENTOLATE 1% 0.5ML MINIMS-EYEDROPS
557	CYCLOSERINE 250MG CAPSULES
558	CYKLOKAPRON 500MG TABLETS
559	CYKLOKAPRON 500MG TABLETS (TRANEXAMIC ACID)
560	CYKLOKAPRON 500MG/5ML INJECTION
561	CYKLOKAPRON 500MG/5ML INJECTION (TRANEXAMIC ACID)
562	CYMBALTA 30MG CAPSULES (DULOXETINE)
563	CYMBALTA 60MG CAPSULES (DULOXETINE)
564	CYMEVENE 500MG INJECTION (GANCICLOVIR)
565	CYPROHEPTADINE 4MG TABLETS
566	CYTARABINE 100MG INJECTION (CYTARABINE)
567	CYTARABINE 1GM INJECTION (CYTARABINE)
568	CYTOTEC 200MCG TABLETS (MISOPROSTOL)
569	DACARBAZINE 200MG INJECTION
570	DAFLON 500MG TABLETS
571	DAFLON 500MG TABLETS (FLAVONOIDIC ACID)
572	DAIVOBET 30G OINTMENT (CALCIPOTRIOL-BETAMETHASONE)
573	DAIVONEX 30G CREAM (CALCIPOTRIOL)
574	DAIVONEX 30GM OINTMENT (CALCIPOTRIOL)
575	DAKTACORT 15 GM CREAM (MICONAZOLE-HYDROCORTISONE)
576	DAKTARIN 2% 15G CREAM
577	DAKTARIN 2% 15G CREAM (MICONAZOLE)
578	DAKTARIN 2% 20G POWDER (MICONAZOLE)
579	DAKTARIN ORAL 2% 15G GEL (MICONAZOLE)
580	DALACIN C 150MG CAPSULES
581	DALACIN T 1% 30g GEL (CLINDAMYCIN)
582	DALACIN T 1% SOLUTION (CLINDAMYCIN)
583	DANAZOL 200MG CAPSULES
584	DANTRIUM 20 MG INJECTION (DANTROLENE)
585	DANZEN 5MG TABLETS
586	DANZEN 5MG TABLETS (SERRAPEPTASE)
587	DAONIL 5MG TABLETS
588	DAONIL 5MG TABLETS (GLIBENCLAMIDE)
589	DARAPRIM 25MG TABLETS (PYRIMETHAMINE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
590	DAUNOBLASTINE 20MG INJECTION (DAUNORUBICIN)
591	DEANXIT TABLETS (FLUPENTHIXOL-MELITRACEN)
592	DEBRIDAT 100MG TABLETS
593	DEBRIDAT 100MG TABLETS (TRIMEBUTINE MALEATE)
594	DEBRIDAT 24MG/5ML 250ML SUSPENSION (TRIMEBUTINE MALEATE)
595	DEBRIDAT 24MG/5ML SUSPENSION (TRIMEBUTINE MALEATE)
596	DECADURABOLIN 25 MG/ML INJECTION (NANDROLONE DECANOATE)
597	DECAPEPTYL CR 3.75MG INJECTION (TRIPTORELIN)
598	DECITABINE 50MG INJECTION
599	DEEP HEAT RUB 94.4G (METHYL SALICYLATE-MENTHOL)
600	DEFERASIROX 500MG TABLETS
601	DEFIBROTIDE 200MG/2.5ML INJECTION
602	DEHYDRATED ALCOHOL 5ML INJECTION (ETHANOL)
603	DE-NOL 120 MG TABLETS (BISMUTH SUBCITRATE)
604	DENTINOX COLIC DROPS 100ML SYRUP (DIMETHICONE-DIL OIL)
605	DENTINOX TEETHING 15G GEL (LIGNOCAINE-CETYLPYRIDIUM)
606	DEPONIT 10MG PATCHES
607	DEPONIT 10MG PATCHES (GLYCERYL TRINITRATE)
608	DEPONIT 5mg PATCHES
609	DEPONIT 5mg PATCHES (GLYCERYL TRINITRATE)
610	DEPO-PROVERA 150 MG/3 ML INJECTION (MEDROXYPROGESTERONE)
611	DEPO-TESTOSTERONE 1000MG/10ML INJECTION (TESTOSTERONE ESTERS)
612	DEQUADIN 25's LOZ LOZENGES
613	DEQUADIN 25's LOZ LOZENGES (DEQUALINIUM)
614	DERM-AID 0.5% 15GM CREAM (HYDROCORTISONE)
615	DERMATIX ULTRA 15G GEL (POLYSILOXANE-SILICON DIOXIDE)
616	DERMOVATE 0.05% 25G CREAM (CLOBETASOL)
617	DERMOVATE 0.05% 25G OINTMENT (CLOBETASOL)
618	DERMOVATE 0.05% 30ml SCALP APPLICATION (CLOBETASOL)
619	DESFERRIOXAMINE 500mg INJECTION
620	DESITIN 56GM PASTE (ZINC OXIDE)
621	DESITIN CREAMY 56GM CREAM (ZINC OXIDE)
622	DESOWEN 0.05% 15G CREAM (DESONIDE)
623	DESOWEN 0.05% 60ML LOTION (DESONIDE)
624	DETRUSITOL 2MG TABLETS
625	DETRUSITOL 2MG TABLETS (TOLTERODINE)
626	DETRUSITOL SR 4MG CAPSULES (TOLTERODINE SR)
627	DEXAMETHASONE 0.1% 0.5ML EYE DROPS
628	DEXAMETHASONE 0.5 MG TABLETS
629	DEXAMETHASONE 4 MG TABLETS
630	DEXAMETHASONE 4MG/ML INJECTION
631	DEXAMETHASONE Preservative Free 4mg/mL INJECTION (DEXAMETHASONE)
632	DEXILANT 30MG CAPSULES (DEXLANSOPRAZOLE)
633	DEXILANT 60MG CAPSULES (DEXLANSOPRAZOLE)
634	DEXTROMETHORPHAN 15MG TABLETS
635	DEXTROMETHORPHAN 15MG/5ML SYRUP
636	DEXTROSE 10% 500ML INFUSION
637	DEXTROSE 20% 500ML INFUSION (DEXTROSE)
638	DEXTROSE 5% 100ML INFUSION
639	DEXTROSE 5% 100ML INFUSION (GLUCOSE)
640	DEXTROSE 5% 250ML INFUSION (GLUCOSE)
641	DEXTROSE 5% 500ML (BAG) INFUSION (GLUCOSE)
642	DEXTROSE 5% 50ML INFUSION (GLUCOSE)
643	DEXTROSE 5% NACL 0.2% 500 ML(BAG) INFUSION (DEXTROSE / SODIUM CHLORIDE)
644	DEXTROSE 5% NACL 0.45% 500 ML (BAG) INFUSION (DEXTROSE / SODIUM CHLORIDE)
645	DEXTROSE 5% NACL 0.45% 500ML (BOTT) INFUSION (DEXTROSE / SODIUM CHLORIDE)
646	DEXTROSE 5% NACL 0.9% 500 ML (BAG) INFUSION (DEXTROSE-SODIUM CHLORIDE)
647	DEXTROSE 5% NACL 0.9% 500 ML (BOT) INFUSION (DEXTROSE-SODIUM CHLORIDE)
648	DEXTROSE 50% 20ML INJECTION (DEXTROSE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
649	DEXTROSE 50% 500ML INFUSION (DEXTROSE)
650	DEXTROSE 20% 500ML INFUSION
651	DEXTROSE 5% 50ML INFUSION
652	DEXTROSE 50% 20ML INJECTION
653	DEXTROSE 50% 500ML INFUSION
654	DHACOPAN 5MG/5ML SYRUP (HYOSINE-N-BUTYLBROMIDE)
655	DHAMOTIL 2.5mg-25mcg TABLETS
656	DHAMOTIL 2.5mg-25mcg TABLETS (DIPHENOXYLATE-ATROPINE)
657	DHASEDYL SYRUP (PSEUDOEPHEDRINE-PHOLCODINE-PROMETHAZINE)
658	DIAMICRON 80MG TABLETS
659	DIAMICRON 80MG TABLETS (GLICLAZIDE)
660	DIAMICRON MR 60MG TABLETS
661	DIAMICRON MR 60MG TABLETS (GLICLAZIDE MR)
662	DIAMOX 500 MG INJECTION
663	DIAMOX 500 MG INJECTION (ACETAZOLAMIDE)
664	DIANE-35 21'S TABLETS (ETHINYLESTRADIOL-CYPROTERONE)
665	DIAZEPAM 10MG TABLETS
666	DIAZEPAM 10MG/2ML INJECTION
667	DIAZEPAM 2MG TABLETS
668	DIAZEPAM 5MG TABLETS
669	DIBETASOL 1ML INJECTION
670	DIBETASOL 1ML INJECTION (BETAMETHASONE)
671	DICITRATE SOLUTION (SODIUM CITRATE-CITRIC ACID MONO)
672	DICLOFENAC SODIUM 1% 20G GEL (DICLOFENAC)
673	DICLOFENAC SODIUM 25MG TABLETS (DICLOFENAC)
674	DICLOFENAC SODIUM 50MG SUPPOSITORIES (DICLOFENAC)
675	DICLOFENAC SODIUM 50MG TABLETS (DICLOFENAC)
676	DICLOFENAC SODIUM 50MG TABLETS
677	DICYNONE 250 MG/2 ML INJECTION
678	DICYNONE 250 MG/2 ML INJECTION (ETHAMSYLATE)
679	DICYNONE 500 MG TABLETS
680	DICYNONE 500 MG TABLETS (ETHAMSYLATE)
681	DIETHYLCARBAMAZINE 50MG TABLETS
682	DIFFERIN 0.1% 30G GEL (ADAPALENE)
683	DIFFLAM 100ML MOUTHWASH (BENZYDAMINE)
684	DIFFLAM 200ML MOUTHWASH
685	DIFFLAM 200ML MOUTHWASH (BENZYDAMINE)
686	DIFFLAM 3MG (8'S) LOZENGES (BENZYDAMINE)
687	DIFFLAM 3MG LOZENGES
688	DIFFLAM 3MG LOZENGES (BENZYDAMINE)
689	DIFFLAM C 200ML MOUTHWASH (BENZYDAMINE-CHLORHEXIDINE)
690	DIFFLAM FORTE THROAT 15ML MOUTH SPRAY (BENZYDAMINE)
691	DIFLUCAN 100 MG CAPSULES
692	DIFLUCAN 100 MG CAPSULES (FLUCONAZOLE)
693	DIFLUCAN 100 MG/50 ML INJECTION
694	DIFLUCAN 100 MG/50 ML INJECTION (FLUCONAZOLE)
695	DIFLUCAN 150MG CAPSULES (FLUCONAZOLE)
696	DIFLUCAN 50MG CAPSULES (FLUCONAZOLE)
697	DIGIFAB 40MG INJECTION (DIGOXIN SPECIFIC ANTIBODIES)
698	DILANTIN 100MG CAPSULES
699	DILANTIN 100MG CAPSULES (PHENYTOIN SODIUM)
700	DILANTIN 125MG/5ML SUSPENSION
701	DILANTIN 125MG/5ML SUSPENSION (PHENYTOIN)
702	DILANTIN 250 MG/5 ML INJECTION (PHENYTOIN)
703	DILANTIN 30MG CAPSULES (PHENYTOIN SODIUM)
704	DILATREND 12.5MG TABLETS (CARVEDILOL)
705	DILATREND 25 MG TABLETS
706	DILATREND 25 MG TABLETS (CARVEDILOL)
707	DILATREND 6.25MG TABLETS

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
708	DILATREND 6.25MG TABLETS (CARVEDILOL)
709	DILTIAZEM 30MG TABLETS
710	DIMENHYDRINATE 15MG/5ML SYRUP
711	DIMENHYDRINATE 50MG TABLETS
712	DIMETAPP ELIXIR (BROMPHENIRAMINE-PHENYLEPHRINE)
713	DIOVAN 160MG TABLETS
714	DIOVAN 160MG TABLETS (VALSARTAN)
715	DIOVAN 80MG TABLETS
716	DIOVAN 80MG TABLETS (VALSARTAN)
717	DIPEPTIVEN 20G/100ML INFUSION (GLUTAMINE)
718	DIPHENHYDRAMINE 25MG TABLETS
719	DIPHENHYDRAMINE 50MG/ML INJECTION
720	DIPHENOXYLATE-ATROPINE 2.5mg-25mcg TABLETS
721	DIPROCEL 0.05% 15GM OINTMENT (BETAMETHASONE DIPROPIONATE)
722	DIPROGENTA 15 GM CREAM (BETAMETHASONE-GENTAMYCIN)
723	DIPROSALIC 15G OINTMENT (BETAMETHASONE-SALICYLIC ACID)
724	DIPROSONE 0.05% 15GM CREAM (BETAMETHASONE DIPROPIONATE)
725	DIPYRIDAMOLE 25MG TABLETS
726	DIPYRIDAMOLE 75MG TABLETS
727	DISCOVISC 1ML INJECTION
728	DISFLATYL 40MG TABLETS (DIMETHICONE-SILICON DIOXIDE)
729	DISTACLOR MR 375MG TABLETS
730	DIXARIT 25MCG TABLETS (CLONIDINE)
731	DK-LINE 5ML SOLUTION
732	DOBUJECT 250MG/5ML INJECTION
733	DOBUJECT 250MG/5ML INJECTION (DOBUTAMINE)
734	DOGMATIL 50 MG CAPSULES (SULPIRIDE)
735	DOMPER 10MG SUPPOSITORIES (DOMPERIDONE)
736	DOPAMINE 200 MG/5 ML INJECTION
737	DORIBAX 500MG INJECTION
738	DORITHRICIN LOZENGES (TYROTHRICIN-BENZALKONIUM-BENZOCAINE)
739	DORMICUM 15 MG TABLETS
740	DORMICUM 15 MG TABLETS (MIDAZOLAM)
741	DORMICUM 15 MG/3 ML INJECTION
742	DORMICUM 15 MG/3 ML INJECTION (MIDAZOLAM)
743	DORMICUM 5 MG/5 ML INJECTION
744	DORMICUM 5 MG/5 ML INJECTION (MIDAZOLAM)
745	DOSTINEX 0.5MG TABLETS
746	DOSTINEX 0.5MG TABLETS (CABERGOLINE)
747	DOTHIEPIN 25MG CAPSULES
748	DOXYCYCLINE 100mg CAPSULES
749	DOXYCYCLINE 100mg CAPSULES
750	DOXYCYCLINE 100MG/5ML INJECTION
751	DRAINA S MINI
752	DRAPOLENE 55 GM CREAM (BENZALKONIUM-CETRIMIDE)
753	DROPERIDOL 2.5MG/ML INJECTION
754	DROPERIDOL 5MG/2ML INJECTION
755	DUKORAL 3ML ORAL VACCINE (CHOLERA)
756	DULCOLAX 5MG SUPPOSITORIES (BISACODYL)
757	DULCOLAX 5MG TABLETS (BISACODYL)
758	DUODERM 30GM GEL
759	DUODERM 30GM PASTE
760	DUODERM CGF 4!x4! DRESSING
761	DUODERM CGF BORDER 4!x5! DRESSING (DUODERM CFG BORDER)
762	DUODERM THIN 2!x8! DRESSING
763	DUODERM THIN 4"x4" DRESSING
764	DUOVENT 4ML SOLUTION (IPRATROPIUM-FENOTEROL)
765	DUOVISC 0.4ML SOLUTION (DUOVISC)
766	DUPHALAC SYRUP (LACTULOSE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
767	DUPHALAC SYRUP
768	DUPHASTON 10MG TABLETS (DYDROGESTERONE)
769	DURATEARS 3.5 GM EYE OINTMENT
770	DURATOCIN 100MCG/ML INJECTION (CARBETOCIN)
771	DUROGESIC 12MCG/HR PATCHES (FENTANYL)
772	DUROGESIC 25MCG/HR PATCHES (FENTANYL)
773	DUROGESIC 50MCG/HR PATCHES (FENTANYL)
774	DUROMINE 15MG CAPSULES (PHENTERMINE)
775	DUROMINE 30MG CAPSULES (PHENTERMINE)
776	DUROTUSS COUGH LOZENGES (PHOLCODINE-CETYLPYRIDINIUM)
777	DUROTUSS EXPECTORANT (PHOLCODINE-BROMHEXINE)
778	DUROTUSS FORTE 15MG/5ML LINCTUS (PHOLCODINE)
779	DUROTUSS REGULAR 5MG/5ML LINCTUS
780	DUROTUSS REGULAR 5MG/5ML LINCTUS (PHOLCODINE)
781	DUROTUSS EXPECTORANT
782	DUSPATALIN RETARD 200MG CAPSULES (MEBEVERINE SR)
783	DUSPATALIN RETARD 200MG CAPSULES
784	DYNASTAT 40MG INJECTION (PARECOXIB)
785	EBIXA 10MG TABLETS (MEMANTINE)
786	EDROPHONIUM 10MG/ML 15ML INJECTION
787	EFEMOLINE 5 ML EYE DROPS (FLUOROMETHOLONE-TETRAZOLINE)
788	EFEXOR XR 150MG CAPSULES (VENLAFAXINE SR)
789	EFEXOR XR 75MG CAPSULES (VENLAFAXINE SR)
790	EFFICORT 0.127% 30G CREAM (HYDROCORTISONE ACEPONATE)
791	EFFIENT 10MG TABLETS (PRASUGREL)
792	EGOZITE 50 GM CREAM (ZINC OXIDE-DIMETHICONE)
793	ELIDEL 1% 15G CREAM (PIMECROLIMUS)
794	ELIQUIS 2.5MG TABLETS (APIXABAN)
795	ELOMET 0.1% 15GM CREAM (MOMETASONE FUROATE)
796	ELOMET 0.1% 15GM OINTMENT (MOMETASONE)
797	ELOMET 0.1% 30ML LOTION (MOMETASONE FUROATE)
798	ELTROXIN 100 MCG TABLETS
799	ELTROXIN 100 MCG TABLETS (THYROXINE SOD.)
800	ELTROXIN 50MCG TABLETS (THYROXINE SOD.)
801	ELUDRIL 90ML MOUTHWASH (CHLORHEXIDINE-CHLOROBUTANOL)
802	EMEND 125MG CAPSULES (APREPILANT)
803	EMEND 150MG INJECTION (FOSAPREPITANT)
804	EMEND 80MG CAPSULES (APREPITANT)
805	EMEND TRI-PACK CAPSULES (APREPITANT)
806	EMLA 5% 5G CREAM (LIGNOCAINE-PRILOCAINE)
807	EMULSIFYING (per g) OINTMENT
808	ENBREL 25MG INJECTION (ETANERCEPT)
809	ENDOSOL BSS 500ML SOLUTION (BALANCED SALT SOLN)
810	ENDOXAN 1GM INJECTION (CYCLOPHOSPHAMIDE)
811	ENDOXAN 50 MG TABLETS (CYCLOPHOSPHAMIDE)
812	ENERVON-C KIDS SYRUP (MULTIVITAMINS)
813	ENERVON-C TABLETS (VITAMIN B CO & VITAMIN C)
814	ENGERIX-B 10MCG VACCINE (HEPATITIS B (Recombinant))
815	ENGERIX-B 20MCG VACCINE (HEPATITIS B (Recombinant))
816	ENSURE 250ML LIQUID
817	ENSURE 250ML LIQUID (ENSURE LIQUID (Vanilla))
818	ENSURE LIFE 400G POWDER
819	ENSURE PLUS 200ML LIQUID (ENSURE PLUS LIQUID Vanilla)
820	ENSURE WITH FIBER 237ML LIQUID (ENSURE WITH FIBER)
821	ENZYPLEX TABLETS (PANCREATIN + VITAMIN B COMPLEX)
822	EPHEDRINE 30 MG/ML INJECTION
823	EPILIM 200MG/5ML SYRUP
824	EPILIM 200MG/5ML SYRUP (VALPROATE SOD)
825	EPILIM 400MG/4ML INJECTION

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
826	EPILIM 400MG/4ML INJECTION (VALPROATE SOD.)
827	EPILIM CHRONO 200MG TABLETS (VALPROATE SODIUM CR)
828	EPILIM CHRONO 300MG TABLETS (VALPROATE SODIUM CR)
829	EPILIM CHRONO 500MG TABLETS
830	EPILIM CHRONO 500MG TABLETS (VALPROATE SODIUM CR)
831	EPILIM EC 200 MG TABLETS
832	EPILIM EC 200 MG TABLETS (VALPROATE SODIUM EC)
833	EPINEPHRINE AUTOINJECTOR 0.15MG INJECTION (ADRENALINE)
834	EPINEPHRINE AUTOINJECTOR 0.3MG INJECTION (ADRENALINE)
835	EPIVIR 10MG/ML 240ML SOLUTION (LAMIVUDINE)
836	EPIVIR 150MG TABLETS (LAMIVUDINE)
837	EPREX 10,000 unit/ml INJECTION (ERYTHROPOIETIN (Recombinant Human))
838	EPREX 2000 unit/0.5ML SYRINGE (ERYTHROPOIETIN (Recombinant Human))
839	EPREX 40,000 unit/ml INJECTION (ERYTHROPOIETIN (Recombinant Hum)
840	EPREX 4000 unit/0.4ml SYRINGE (ERYTHROPOIETIN (Recombinant Human))
841	EPREX* 10,000 unit/ml INJECTION (ERYTHROPOIETIN (Recombinant Human))
842	EPREX* 40,000 unit/ml SYRINGE (ERYTHROPOIETIN (Recombinant Hum)
843	ERAXIS 100MG/30ML INJECTION (ANIDULAFUNGIN)
844	ERGOCALCIFEROL 50000IU TABLETS
845	ERGOMETRINE 500MCG/ML INJECTION (ERGOMETRINE MALEATE)
846	ERYACNE 4% 30G GEL (ERYTHROMYCIN)
847	ERYPED 400 MG/5 ML SUSPENSION (ERYTHROMYCIN)
848	ERYTHROMYCIN 200MG/5ML 60ML SYRUP
849	ERYTHROMYCIN 250MG TABLETS
850	ERYTHROMYCIN 500MG INJECTION
851	ESMERON 50MG/5ML INJECTION (ROCURONIUM)
852	ESSENTIALE FORTE N CAPSULES (PHOSPHOLIPIDS + VITAMINS)
853	ESTRACYT 140MG CAPSULES (ESTRAMUSTINE)
854	ESTRADERM MX 25 PATCHES (OESTRADIOL)
855	ESTRADERM MX 50 PATCHES (OESTRADIOL)
856	ESTROFEM 1MG 28'S TABLETS (ESTRADIOL)
857	ESTROFEM 2MG 28'S TABLETS (ESTRADIOL)
858	ETHAMBUTOL 100MG TABLETS
859	ETHAMBUTOL 400MG TABLETS
860	ETHICHOLINE 100 MG/2 ML INJECTION (SUXAMETHONIUM)
861	ETHYL CHLORIDE 100 ML SPRAY (ETHYL CHLORIDE)
862	ETOMIDATE 20MG/10ML INJECTION
863	ETOPOSIDE 100MG/5ML INJECTION
864	ETOPOSIDE 25MG CAPSULES
865	ETOPOSIDE 50MG CAPSULES
866	EURAX 10% 20GM CREAM (CROTAMITON)
867	EUSOL MAX 120ML SOLUTION (SODIUM HYPOCHLORITE)
868	EUSOL PARAFFIN 30G CREAM
869	EUTHYROX 100MCG TABLETS (THYROXINE SOD.)
870	EUTHYROX 25MCG TABLETS (THYROXINE SOD.)
871	EUTHYROX 50MCG TABLETS (THYROXINE SOD.)
872	EVISTA 60MG TABLETS (RALOXIFENE HCL)
873	EVRA PATCHES (ETHINYLESTRADIOL-NORELGESTROMIN)
874	EXELON 1.5MG CAPSULES (RIVASTIGMINE)
875	EXELON 10 (9.5MG/24HR) PATCHES (RIVASTIGMIN)
876	EXELON 3MG CAPSULES (RIVASTIGMIN)
877	EXELON 5 (4.6MG/24HR) PATCHES (RIVASTIGMIN)
878	EXELON 6MG CAPSULES (RIVASTIGMINE)
879	EXFORGE 10MG/160MG TABLETS (AMLODIPINE-VALSARTAN)
880	EXFORGE 5MG/160MG TABLETS (AMLODIPINE-VALSARTAN)
881	EXFORGE 5MG/80MG TABLETS (AMLODIPINE-VALSARTAN)
882	EXFORGE HCT 160/10/12.5MG TABLETS (VALSARTAN/AMLODIPINE/HCTZ)
883	EXFORGE HCT 160/5/12.5MG TABLETS (VALSARTAN/AMLODIPINE/HCTZ)
884	EYE. STREAM 120ML EYE IRRIGATION (BALANCED SALT SOLN)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
885	EZETROL 10MG TABLETS
886	EZETROL 10MG TABLETS (EZETIMIBE)
887	FACTOR IX 500 int units/5ml INJECTION
888	FACTOR VIII (Haemoctin) 250 unit INJECTION
889	FAKTU SUPPOSITORIES
890	FAMOTIDINE 20MG TABLETS
891	FASIGYN 500 MG TABLETS
892	FASTUM 2.5% 30G GEL (KETOPROFEN)
893	FAVERIN 50 MG TABLETS (FLUVOXAMINE)
894	FEDAC SYRUP (PSEUDOEPHEDRINE-TRIPOLIDINE) 30mg-1.25mg/5mL MIXTURE (PSEUDOE
895	FEDAC TABLETS (PSEUDOEPHEDRINE-TRIPROLIDINE)
896	FELDENE 20MG TABLETS (PIROXICAM)
897	FEMARA 2.5MG TABLETS (LETROZOLE)
898	FENTANYL 0.1 MG/2 ML INJECTION
899	FENTANYL 0.5 MG/10 ML INJECTION
900	FERINJECT 100MG/2ML INJECTION (FERRIC CARBOXYMALTOSE)
901	FERINJECT 500MG/10ML INJECTION (FERRIC CARBOXYMALTOSE)
902	FERRIPROX 500MG TABLETS (DEFERIPRONE)
903	FERROCYTE 50MG TABLETS (FERROUS SODIUM CITRATE)
904	FERROUS FUMARATE 200MG TABLETS
905	FERRUM 100 MG/2 ML INJECTION (IRON POLYMALTOSE)
906	FERRUM 50MG/1ML DROPS (IRON POLYMALTOSE)
907	FERRUM 50MG/5ML SYRUP (IRON POLYMALTOSE)
908	FIBROSOL 5G SACHETS (FIBRE DIETARY)
909	FIBRO-VEIN 1% 2ML INJECTION (SODIUM TETRADECYL SULPHATE)
910	FIBRO-VEIN 3% 2ML INJECTION (SODIUM TETRADECYL SULPHATE)
911	FLAGYL 200MG TABLETS
912	FLAGYL 400MG TABLETS
913	FLAGYL 500MG/100ML INJECTION
914	FLAGYSTATIN PESSARIES (METRONIDAZOLE-NYSTATIN)
915	FLEBOGAMMA 10G/200ML INJECTION (IMMUNOGLOBULIN)
916	FLEBOGAMMA 2.5G/50ML INJECTION (IMMUNOGLOBULIN)
917	FLEBOGAMMA 5G/100ML INJECTION (IMMUNOGLOBULIN)
918	FLEET (PAED) 66.6ML ENEMA (PHOSPHATE ENEMA)
919	FLEET ADULT 133ML ENEMA
920	FLEET ADULT 133ML ENEMA (PHOSPHATE ENEMA)
921	FLEXIFLO NG TUBE
922	FLIXONASE 0.05% 150D NASAL SPRAY (FLUTICASONE)
923	FLIXOTIDE 0.5MG/2ML NEBULES (FLUTICASONE)
924	FLIXOTIDE EVO 125MCG/DOSE INHALER (FLUTICASONE)
925	FLIXOTIDE EVO 50MCG/DOSE INHALER (FLUTICASONE)
926	FLIXOTIDE 0.5MG/2ML NEBULES
927	FLOLAN 500mcg INJECTION (EPOPROSTENOL)
928	FLORINEF 0.1 MG TABLETS (FLUDROCORTISONE)
929	FLO-SINUS CARE (SACHET) POWDER
930	FLO-SINUS CARE STARTER KIT
931	FLOXIA DISCO 40ML CREAM
932	FLUANXOL 0.5 MG TABLETS (FLUPENTHIXOL)
933	FLUANXOL DEPOT 20MG/ML INJECTION (FLUPENTHIXOL)
934	FLUARIX 0.5ML INJECTION (INFLUENZA)
935	FLUCONAZOLE 50mg CAPSULES
936	FLUDARA 10MG TABLETS (FLUDARABINE)
937	FLUDARA 50MG INJECTION (FLUDARABINE)
938	FLUIMICIL** 600MG TABLETS (ACETYLCYSTEINE)
939	FLUIMUCIL 100MG SACHETS
940	FLUIMUCIL 100MG SACHETS (ACETYLCYSTEINE)
941	FLUIMUCIL 600MG TABLETS
942	FLUIMUCIL 600MG TABLETS (ACETYLCYSTEINE)
943	FLUNARIZINE 5MG CAPSULES

Sr	Item Description
944	FLUOCINOLONE 0.025% CREAM
945	FLUORESCIEN SODIUM 2% 0.5ML MINIMS-EYEDROPS (FLUORESCIEN)
946	FLUORETS 1MG OPHTHALMIC STRIPS (FLUORESCIEN)
947	FLUOROURACIL 500MG/10ML INJECTION
948	FLUOXETINE 10MG CAPSULES
949	FLURAZEPAM 30MG CAPSULES
950	FML. 0.1% 5ML EYE DROPS (FLUOROMETHOLONE)
951	FOLIC ACID 400MCG TABLETS (FOLIC ACID)
952	FOLIC ACID 5MG TABLETS
953	FORADIL (30'S) 12MCG inhalation CAPSULES (FORMOTEROL)
954	FORANE (per ml) SOLUTION (ISOFLURANE)
955	FORLAX 10G SACHETS (MACROGOL 4000)
956	FORTEO 20MCG/80uL INJECTION (TERIPARATIDE)
957	FORTRANS 74G SACHETS
958	FORTRANS 74G SACHETS (ELECTROLYTE COLONIC LAVAGE)
959	FORTUM 1 GM INJECTION
960	FORTUM 1 GM INJECTION (CEFTAZIDIME)
961	FORTUM 2 GM INJECTION
962	FORTUM 2 GM INJECTION (CEFTAZIDIME)
963	FORXIGA 10MG TABLETS (DAPAGLIFLOZIN)
964	FOSAMAX 10MG TABLETS (ALENDRONATE)
965	FOSAMAX 70MG TABLETS (ALENDRONATE)
966	FOSAMAX PLUS 70mg/5600 unit TABLETS (ALENDRONATE-COLECALCIFEROL)
967	FOSCAVIR 6G/250ML INJECTION (FOSCARNET)
968	FRAGMIN 10000IU/4ML INJECTION
969	FRAGMIN 10000IU/4ML INJECTION (DALTEPARIN)
970	FRAMYCETIN 0.5% 5ML EYE DROPS
971	FRAXIPARINE 2850IU/0.3ML INJECTION
972	FRAXIPARINE 2850IU/0.3ML INJECTION (NADROPARIN CALCIUM)
973	FRAXIPARINE 3800IU/0.4ML INJECTION
974	FRAXIPARINE 3800IU/0.4ML INJECTION (NADROPARIN CALCIUM)
975	FRAXIPARINE 5700IU/0.6ML INJECTION (NADROPARIN CALCIUM)
976	FREKA FEEDING TUBE SIZE12 120CM
977	FRESUBIN HEPA 200ML LIQUID
978	FRISIUM 10MG TABLETS (CLOBAZAM)
979	FRUSEMIDE 20MG/2ML INJECTION
980	FUCICORT 15G CREAM (FUSIDIC-BETAMETHASONE)
981	FUCICORT 5 GM CREAM (FUSIDIC-BETAMETHASONE)
982	FUCIDIN 2% 15GM CREAM (FUSIDIC ACID)
983	FUCIDIN 2% 15GM OINTMENT (FUSIDIC ACID)
984	FUCIDIN 2% 5GM CREAM (FUSIDIC ACID)
985	FUCIDIN 2% 5GM OINTMENT (FUSIDIC ACID)
986	FUCIDIN H 5G CREAM (FUSIDIC-HYDROCORTISONE)
987	FUCITHALMIC 5 GM EYE DROPS (FUSIDIC ACID)
988	FYBOGEL SACHETS (FYBOGEL ORANGE)
989	GABAPENTIN 100MG CAPSULES
990	GALVUS 50MG TABLETS (VILDAGLIPTIN)
991	GALVUS-MET 50/1000MG TABLETS (VILDAGLIPTIN-MET)
992	GALVUS-MET 50/500MG TABLETS (VILDAGLIPTIN-MET)
993	GALVUS-MET 50/850MG TABLETS (VILDAGLIPTIN-MET)
994	GANFORT 3ML EYE DROPS (BIMATOPROST-TIMOLOL)
995	GARDASIL VACCINE (PAPILLOMAVIRUS HUMAN)
996	GAUZE SWAB (PHARMACY) 3!X3!(PACK) DRESSING (GAUZE)
997	GAVISCON ADVANCE SUSPENSION
998	GAVISCON SUSPENSION (GAVISCON)
999	GAVISCON TABLET
1000	GAVISCON SUSPENSION
1001	GELAFUSIN 4% 500ML INFUSION
1002	GELFOAM 12X7MM (GELFOAM)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1003	GEMFIBROZIL 300MG CAPSULES
1004	GEMZAR 1G INJECTION (GEMCITABINE)
1005	GEMZAR 200MG INJECTION (GEMCITABINE)
1006	GENTAMICIN 0.1% 15G CREAM
1007	GENTAMICIN 0.3% 5GM EYE OINTMENT
1008	GENTAMICIN 0.3% EYE DROPS
1009	GENTAMICIN 80MG/2ML INJECTION
1010	GENTEAL EYE 0.3% 10G GEL (CARBOMER-HYPROMELLOSE)
1011	GENTIAN VIOLET 0.5% 50ML SOLUTION
1012	GENTIAN VIOLET Galenicals
1013	GENURIN 200MG TABLETS
1014	GENURIN 200MG TABLETS (FLAVOXATE)
1015	GLAMIN 500ML INFUSION (GLYCYL-L-GLUTAMINE)
1016	GLIBENCLAMIDE 5MG TABLETS
1017	GLIVEC 100MG CAPSULES (IMATINIB)
1018	GLIVEC* 100MG TABLETS (IMATINIB)
1019	GLIVEC* 400MG TABLETS (IMATINIB)
1020	GLUCAGON 1 MG INJECTION (GLUCAGON VIAL)
1021	GLUCERNA 250ML LIQUID
1022	GLUCOBAY 50MG TABLETS
1023	GLUCOBAY 50MG TABLETS (ACARBOSE)
1024	GLUCOPHAGE 500 MG TABLETS
1025	GLUCOPHAGE 500 MG TABLETS (METFORMIN)
1026	GLUCOPHAGE 850MG TABLETS (METFORMIN)
1027	GLUCOPHAGE XR 500MG TABLETS
1028	GLUCOPHAGE XR 500MG TABLETS (METFORMIN XR)
1029	GLUCOPHAGE XR 750MG TABLETS (METFORMIN XR)
1030	GLUCOPHAGE 850MG TABLETS
1031	GLUCOSE 5% (500mL) IV FLUID
1032	GLUCOVANCE 500MG/2.5MG TABLETS (METFORMIN-GLIBENCLAMIDE)
1033	GLUCOVANCE 500MG/5MG TABLETS (METFORMIN-GLIBENCLAMIDE)
1034	GLUTAMINE PLUS (ORANGE) POWDER (GLUTAMINE)
1035	GLUTAMINE PLUS SACHETS (GLUTAMINE)
1036	GLYCERIN (CHILDREN) 2G SUPPOSITORIES (GLYCEROL)
1037	GLYCERINE PURE SOLUTION (GLYCEROL)
1038	GLYCERYL TRINITRATE 0.5MG TABLETS
1039	GLYCINE 1.5% 3L IRRIGATION
1040	GLYPRESSIN 1MG INJECTION
1041	GLYPRESSIN 1MG INJECTION (TERLIPRESSIN)
1042	GLYPRESSIN 1mg/8.5ml INJECTION (TERLIPRESSIN)
1043	GLYTRIN MOUTH SPRAY (GLYCERIN TRINITRATE)
1044	GLYTRIN MOUTH SPRAY
1045	GRAN 300MCG INJECTION (FILGRASTIM GCSF)
1046	GRANOCYTE 263MCG INJECTION (LENOGRASTIM)
1047	GUTRON 5MG TABLETS (MIDODRINE)
1048	GYNERA 21'S TABLETS (GESTODENE-ETHINYLOESTRADIOL)
1049	GYNO-PEVARYL 150 MG PESSARIES (ECONAZOLE)
1050	GYNO-PEVARYL DEPOT 150MG PESSARIES (ECONAZOLE)
1051	GYNO-TRAVOGEN 600MG PESSARIES (ISOCONAZOLE)
1052	GYNO-TROSYD 100MG VAGINAL TABLETS (TICONAZOLE)
1053	HALOPERIDOL 0.5mg TABLETS
1054	HALOPERIDOL 1.5MG TABLETS
1055	HALOPERIDOL 5MG TABLETS
1056	HALOPERIDOL 5MG/ML INJECTION
1057	HARNAL OCAS 0.4MG TABLETS
1058	HARNAL OCAS 0.4MG TABLETS (TAMSULOSIN)
1059	HARTMANN'S (BAG) 1 L INFUSION (SODIUM LACTATE COMPOUND)
1060	HARTMANN'S (BAG) 500ML INFUSION (LACTATED RINGERS)
1061	HARTMANN'S (BOT) 500ML INFUSION (SODIUM LACTATE COMPOUND)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1062	HAVRIX 1440 unit/ml VACCINE (HEPATITIS A)
1063	HAVRIX JUNIOR 720 unit/0.5ml VACCINE (HEPATITIS A (inactivated)-HEPATITIS B (recombinan
1064	HEALON 5 23MG/ML 0.6ML SOLUTION (HYALURONATE)
1065	HEALON 5.5MG/0.55ML SOLUTION (HYALURONATE)
1066	HEALON GV 0.85ML SOLUTION (HYALURONATE)
1067	HEMABATE 250MCG/ML INJECTION (CARBOPROST)
1068	HEPARIN 1000 UNIT/ML INJECTION
1069	HEPARIN 1000 UNIT/ML INJECTION (HEPARIN SODIUM)
1070	HEPARIN 25000UNIT/5ML INJECTION (HEPARIN SODIUM)
1071	HEPARIN 5000 UNIT/ML INJECTION
1072	HEPARIN 5000 UNIT/ML INJECTION (HEPARIN SODIUM)
1073	HEPATIC-AID II 88.7G SACHETS
1074	HEPAVITE CAPSULES (SILYMARIN, VIT B)
1075	HEPSAL 50 UNIT/5 ML INJECTION (HEPARINISED SALINE)
1076	HEPSERA 10MG TABLETS (ADEFOVIR DIPIVOXIL)
1077	HEPTRAL 200MG TABLETS (METHIONINE)
1078	HERBESSER 10 MG INJECTION
1079	HERBESSER 10 MG INJECTION (DILTIAZEM)
1080	HERBESSER R 100MG CAPSULES
1081	HERBESSER R 100MG CAPSULES (DILTIAZEM SR)
1082	HERBESSER R 200MG CAPSULES (DILTIAZEM SR)
1083	HEXOSCRUB 4% 120ML SOLUTION
1084	HEXOSCRUB 4% 120ML SOLUTION (CHLORHEXIDINE)
1085	HIALID 0.1% 5ML EYE DROPS (HYALURONATE)
1086	HIBERIX 0.5ML VACCINE (HAEMOPHILUS INFLUENZAE TYPE B)
1087	HIRUDOID 14G CREAM
1088	HIRUDOID 14G CREAM (MUCOPOLYSACCHARIDE POLYSULFATE)
1089	HISTOACRYL 0.5 GM/0.5 ML SOLUTION (ENBUCRILATE)
1090	HOLOXAN 1GM INJECTION (IFOSFAMIDE)
1091	HOMATROPINE 2% 15ML EYE DROPS (HOMATROPINE)
1092	HUMALOG (PER DOSE) 100 unit/ml INJECTION (INSULIN LISPRO)
1093	HUMALOG 100 unit/ml 10ML INJECTION (INSULIN LISPRO (Human))
1094	HUMALOG MIX 25 100 unit/ml 3ML INJECTION (INSULIN LISPRO-PROTAMINE)
1095	HUMALOG PENFILL 100 unit/ml 3ML INJECTION (INSULIN LISPRO (Human))
1096	HUMULIN 30/70 (PER DOSE) 100 unit/ml INJECTION (INSULIN NEUTRAL ISOPHANE)
1097	HUMULIN 30/70 100 unit/ml 10ML INJECTION (INSULIN NEUTRAL-ISOPHANE 30/70 (Human))
1098	HUMULIN N 100 unit/ml 10ML INJECTION (INSULIN ISOPHANE)
1099	HUMULIN R 100 unit/ml 10ML INJECTION (INSULIN SOLUBLE)
1100	HYALASE 1500 int.unit INJECTION (HYALURONIDASE)
1101	HYCAMTIN 4MG INJECTION (TOPOTECAN HYDROCHLORIDE)
1102	HYDERGINE 1 MG TABLETS (DIHYDROERGOCRISTINE)
1103	HYDRALAZINE 10MG TABLETS
1104	HYDRALAZINE 50MG TABLETS
1105	HYDRALYTE 62.5 ML SACHETS (ELECTROLYTES)
1106	HYDROCHLOROTHIAZIDE 25MG TABLETS
1107	HYDROCORTISONE 1% 15G CREAM
1108	HYDROCORTISONE 10 MG TABLETS
1109	HYDROCORTISONE 100 MG INJECTION
1110	HYDROCORTISONE 100 MG INJECTION (HYDROCORTISONE SODIUM SUCCINATE)
1111	HYDROGEN PEROXIDE 3% 100ML SOLUTION
1112	HYDROGEN PEROXIDE 3% 500ML SOLUTION
1113	HYDROGEN PEROXIDE 6% 100ML SOLUTION
1114	HYDROXYUREA 500MG CAPSULES
1115	HYOSCINE 0.4 MG/ML INJECTION
1116	HYOSCINE 0.4 MG/ML INJECTION (HYOSCINE HYDROBROMIDE)
1117	HYOSCINE ButylBr (COPAN) 20mg/mL INJECTION
1118	HYOSCINE ButylBr 20mg/mL INJECTION (HYOSCINE ButylBr)
1119	HYPER RHO 1500IU/300mcg INJECTION (IMMUNOGLOBULIN RHO(D))
1120	HYPROMELLOSE 0.3% 10ML EYE DROPS

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1121	HYTRIN 1MG TABLETS
1122	HYTRIN 1MG TABLETS (TERAZOSIN)
1123	HYTRIN 2MG TABLETS (TERAZOSIN)
1124	HYTRIN 5MG TABLETS (TERAZOSIN)
1125	HYZAAR 50MG/12.5MG TABLETS
1126	HYZAAR 50MG/12.5MG TABLETS (HYDROCHLOROTHIAZIDE -LOSARTAN)
1127	HYZAAR FORTE 100MG/25MG TABLETS (LOSARTAN-HCTZ)
1128	IBERET-FOLIC TABLETS (MULTI-VITAMIN)
1129	IBERET-FOLIC TABLETS
1130	IBUPROFEN 100MG/5ML SYRUP
1131	IBUPROFEN 10MG/2ML INJECTION
1132	IBUPROFEN 200MG TABLETS
1133	IBUPROFEN 20MG/2ML INJECTION
1134	ILIADIN (DROP) 0.05% (ADULT) 10ML NASAL DROPS (OXYMETAZOLINE)
1135	ILIADIN (DROP) 0.05% (ADULT) 10ML NASAL DROPS
1136	ILIADIN (SPRAY) 0.05% (ADULT)10ML NASAL SPRAY (OXYMETAZOLINE)
1137	ILIADIN 0.01% (INFANT) 5ML NASAL DROPS (OXYMETAZOLINE)
1138	ILIADIN 0.025% (SMALL CHILD) 10ML NASAL DROPS (OXYMETAZOLINE)
1139	ILIADIN 0.01% (INFANT) 5ML NASAL DROPS
1140	ILIADIN 0.025% (SMALL CHILD) 10ML NASAL DROPS
1141	ILOPROST 20MCG/ML INJECTION
1142	IMDUR DURULES (ISMN) 60MG TABLETS
1143	IMDUR DURULES (ISMN) 60MG TABLETS (ISOSORBIDE MONONITRATE SR)
1144	IMIGRAN 2x6MG & INJECTOR INJECTION (SUMATRIPTAN)
1145	IMIGRAN 50MG TABLETS (SUMATRIPTAN)
1146	IMIPRAMINE 10MG TABLETS
1147	IMIPRAMINE 25MG TABLETS (IMIPRAMINE)
1148	IMODIUM 2 MG CAPSULES
1149	IMODIUM 2 MG CAPSULES (LOPERAMIDE)
1150	IMOVANE 7.5 MG TABLETS
1151	IMOVANE 7.5 MG TABLETS (ZOPICLONE)
1152	IMOVAX POLIO 0.5ML INJECTION (POLIOMYELITIS INACTIVATED)
1153	IMPACT 74G SACHETS
1154	IMURAN 50MG TABLETS (AZATHIOPRINE)
1155	INDAPAMIDE 2.5MG TABLETS
1156	INDERAL 1 MG/ML INJECTION (PROPRANOLOL)
1157	INDERAL 40 MG TABLETS (PROPRANOLOL)
1158	INDIGO CARMINE 20MG/5ML INJECTION (INDIGO CARMINE)
1159	INDIGO CARMINE 40MG/5ML INJECTION
1160	INDOCID 1 MG INJECTION
1161	INDOMETHACIN 25mg CAPSULES
1162	INDOMETHACIN 5MG/ML SYRUP
1163	INFANRIX DTPA 0.5ML INJECTION (DIPHTHERIA-TETANUS-PERTUSSIS)
1164	INFANRIX IPV/HIB 0.5ML INJECTION (DIPHTHERIA TETANUS PERTUSSIS POLIO HAEMOPHI
1165	INNOHEP 0.35ML/3,500 ANTI-XA IUL SYRINGE (TINZAPARIN SODIUM)
1166	INNOHEP 0.5ML/10,000 ANTI-XA IU SYRINGE (TINZAPARIN SODIUM C)
1167	INNOHEP 2ML/20,000 ANTI-XA IU INJECTION (TINZAPARIN SODIUM)
1168	INSPRA 50MG TABLETS (EPLERENONE)
1169	INTEGRILIN 20MG/10ML INJECTION (EPTIFIBATIDE)
1170	INTEGRILIN 75MG/100ML INJECTION (EPTIFIBATIDE)
1171	INTRAGLOBIN F 2.5G/50ML INJECTION
1172	INTRASITE 25GM GEL (CARBOXYMETHYLCELLULOSE)
1173	INTRATECT 2.5G/50ML INJECTION
1174	INTRATECT 5G/100ML INJECTION
1175	INVANZ 1 GM INJECTION
1176	INVEGA 3MG TABLETS (PALIPERIDONE SR)
1177	INVEGA 6MG TABLETS (PALIPERIDONE SR)
1178	INVEGA 9MG TABLETS (PALIPERIDONE SR)
1179	INVOKANA 100MG TABLETS (CANAGLIFLOZIN)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1180	IODINE TINCTURE 1% 500ML SOLUTION
1181	IODOSORB 10G OINTMENT (IODINE CADEXOMER)
1182	IODOSORB 3G POWDER (IODINE CADEXOMER)
1183	IONIL T 200ML SHAMPOO (COAL TAR - SALICYLIC ACID)
1184	IRESSA 250MG TABLETS (GEFITINIB)
1185	ISOCAL 237ML LIQUID
1186	ISOCAL 237ML LIQUID (ISOCAL HCN)
1187	ISOCAL 425GM POWDER
1188	ISOKET 1.25MG/0.05ML 15ML SPRAY (ISOSORBIDE DINITRATE)
1189	ISOKET 10MG/10ML INJECTION
1190	ISONIAZID 100 MG TABLETS
1191	ISONIAZID 300MG TABLETS
1192	ISONIAZID 500MG INJECTION (ISONIAZID)
1193	ISOPRINOSINE 250 MG/5 ML SYRUP (METHISOPRINOL)
1194	ISOPRINOSINE 500 MG TABLETS (METHISOPRINOL)
1195	ISOPROPYL ALCOHOL 70%/ML Galenicals
1196	ISOPROPYL ALCOHOL SOLUTION
1197	ISOPTIN SR 240MG TABLETS
1198	ISOPTIN SR 240MG TABLETS (VERAPAMIL SR)
1199	ISOPTO CARPINE 2% 15ML EYE DROPS (PILOCARPINE)
1200	ISOPTO CARPINE 4% 15ML EYE DROPS (PILOCARPINE)
1201	ISOPTO-HOMATROPINE 2% 15ML EYE DROPS (HOMATROPINE)
1202	ISOSORBIDE DINITRATE 10MG TABLETS
1203	ISOSORBIDE DINITRATE 10MG TABLETS (ISOSORBIDE DINITRATE)
1204	ISOSORBIDE DINITRATE S/L 5MG TABLETS
1205	ISOSORBIDE DINITRATE S/L 5MG TABLETS (ISOSORBIDE DINITRATE)
1206	ISUPREL 0.2 MG/ML INJECTION (ISOPRENALINE)
1207	JANUMET 50/1000MG TABLETS (SITAGLIPTIN-METFORMIN)
1208	JANUMET 50/500MG TABLETS
1209	JANUMET 50/500MG TABLETS (SITAGLIPTIN-METFORMIN)
1210	JANUMET 50/850MG TABLETS (SITAGLIPTIN-METFORMIN)
1211	JANUVIA 100MG TABLETS (SITAGLIPTIN PHOSPHATE)
1212	JANUVIA 25MG TABLETS (SITAGLIPTIN PHOSPHATE)
1213	JANUVIA 50MG TABLETS
1214	JANUVIA 50MG TABLETS (SITAGLIPTIN PHOSPHATE)
1215	JAPANESE ENCEPHALITIS VACCINE (JAPANESE ENCEPHALITIS VACCINE)
1216	JELONET (PHARMACY) 4!x4! DRESSING (PARAFFIN GAUZE)
1217	JELONET (PHARMACY) 4"x4" DRESSING
1218	JELONET 10CMX7M DRESSING (PARAFFIN GAUZE)
1219	JETEPAR CAPSULES (BETAINE, DIETHANOLAMIN, NICOTINAMIDE)
1220	JETEPAR CAPSULES
1221	JEVITY 240ML LIQUID
1222	JEVITY 240ML LIQUID (MILK SUBSTITUE)
1223	JEVITY 946ml LIQUID (MILK SUBSTITUTE)
1224	JOHNSON BABY 1000ML BATH (BABY BATH)
1225	JOHNSON BABY 100GM POWDER (BABY POWDER)
1226	JOHNSON BABY 200ML BATH (BABY BATH)
1227	JOHNSON BABY 300ML OIL (BABY OIL)
1228	JOHNSON BABY 500GM POWDER (BABY POWDER)
1229	JOHNSON BABY 500ML LOTION (BABY LOTION)
1230	JOHNSON BABY COLOGNE 200ML SOLUTION (BABY COLOGNE)
1231	JUMEX 5 MG TABLETS (SELEGILINE)
1232	JURNISTA PR 8MG TABLETS (HYDROMORPHONE)
1233	K.Y. 100GM JELLY (LUBRICATING)
1234	KALETRA 200/50MG TABLETS (IOPINAVIR-RITONAVIR)
1235	KALTOSTAT 10x20CM DRESSING (ALGINATE)
1236	KALTOSTAT 5x5 CM DRESSING
1237	KALTOSTAT 7.5x12CM DRESSING
1238	KALTOSTAT WOUND PACK 2GM (KALTOSTAT)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1239	KANAMYCIN 1 GM INJECTION
1240	KAOLIN MIXTURE (KAOLIN BPC 1968)
1241	KAOLIN PECTIN SUSPENSION
1242	KAOLIN MIXTURE
1243	KEPPRA 100MG/ML SOLUTION (LEVITIRACETAM)
1244	KEPPRA 250MG TABLETS
1245	KEPPRA 250MG TABLETS (LEVETIRACETAM)
1246	KEPPRA 500MG TABLETS (LEVETIRACETAM)
1247	KEPPRA 500MG/5ML INJECTION
1248	KEPPRA 500MG/5ML INJECTION (LEVETIRACETAM)
1249	KESTINE 10MG TABLETS (EBASTINE)
1250	KETAMINE (PER DOSE/ML) 50MG/ML INJECTION (KETAMINE)
1251	KETAMINE 50MG/ML 10ML INJECTION
1252	KETOROLAC 30MG/ML INJECTION
1253	KETOSTERIL TABLETS (ESSENTIAL KETOACIDS)
1254	KETOTOP 30MG (EACH PC) PATCHES
1255	KETOTOP 30MG (EACH PC) PATCHES (KETOPROFEN)
1256	KIDNEY COCKTAIL SOLUTION
1257	KIVEXA 600-300MG TABLETS (ABACAVIR-LAMIVUDINE)
1258	KLACID 125MG/5ML 60ML SUSPENSION (CLARITHROMYCIN)
1259	KLACID 250MG TABLETS
1260	KLACID 250MG TABLETS (CLARITHROMYCIN)
1261	KLACID 250MG/5ML 60ML SUSPENSION (CLARITHROMYCIN)
1262	KLACID FORTE 500mg TABLETS (CLARITHROMYCIN)
1263	KLACID MR 500MG TABLETS
1264	KLACID MR 500MG TABLETS (CLARITHROMYCIN MR)
1265	KONAKION 10MG/ML INJECTION
1266	KONAKION 10MG/ML INJECTION (PHYTOMENADIONE)
1267	KONAKION 2MG/0.2ML INJECTION (PHYTOMENADIONE)
1268	KYTRIL 1 MG TABLETS (GRANISETRON)
1269	KYTRIL 1MG/ML INJECTION
1270	KYTRIL 1MG/ML INJECTION (GRANISETRON)
1271	KYTRIL 3 MG/3 ML INJECTION (GRANISETRON)
1272	KYTRIL* 1MG TABLETS
1273	KYTRIL* 1MG TABLETS (GRANISETRON)
1274	KYTRIL* 3MG/3ML INJECTION
1275	KYTRIL* 3MG/3ML INJECTION (GRANISETRON)
1276	LABETALOL 100MG TABLETS
1277	LACIPIL 4MG TABLETS (LACIDIPINE)
1278	LACRYVISC EYE 0.3% 10g GEL (CARBOMER)
1279	LACTACYD & APPARATUS 250ML SOLUTION (LACTIC ACID-LACTOSERUM-PHOSPHORIC A(
1280	LACTACYD pH3.5 250 ML SOLUTION (LACTIC ACID-LACTOSERUM-PHOSPHORIC ACID)
1281	LACTEOL FORTE CAPSULES (LACTOBACILLUS ACIDOPHILUS (METABOLIC PRODUCT))
1282	LACTEOL FORTE SACHETS (LACTOBACILLUS ACIDOPHILUS (METABOLIC PRODUCT))
1283	LACTEOL FORTE CAPSULES
1284	LACTEOL FORTE SACHETS
1285	LACTO-GG 20 BILLION CFU CAPSULES (LACTOBACILLUS GG)
1286	LADOGAL 200MG CAPSULES (DANAZOL)
1287	LAMICTAL 100MG TABLETS (LAMOTRIGINE)
1288	LAMICTAL 50 MG TABLETS (LAMOTRIGINE)
1289	LAMISIL 1% 15G CREAM (TERBINAFINE)
1290	LAMISIL 250MG TABLETS (TERBINAFINE)
1291	LAMISIL DERMGEL 1% 15G GEL (TERBINAFINE)
1292	LANOXIN 0.25MG TABLETS
1293	LANOXIN 0.25MG TABLETS (DIGOXIN)
1294	LANOXIN 100MCG/ML INJECTION (DIGOXIN)
1295	LANOXIN 50 MCG/ML 60ML ELIXIR (DIGOXIN)
1296	LANOXIN 500MCG/2ML INJECTION
1297	LANOXIN 500MCG/2ML INJECTION (DIGOXIN)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1298	LANOXIN PG 0.0625 MG TABLETS
1299	LANOXIN PG 0.0625 MG TABLETS (DIGOXIN)
1300	LANTUS INSULIN 100 unit/ml 10ML INJECTION (INSULIN GLARGINE)
1301	LANTUS SoloSTAR 100 unit/ml 3ML SYRINGE (INSULIN GLARGINE)
1302	LARIAM 250MG TABLETS (MEFLOQUINE)
1303	LASIX 40MG TABLETS (FRUSEMIDE)
1304	LASIX 40MG TABLETS
1305	LAXAROL SUSPENSION (PARAFFIN LIQUID-BENZOIC ACID)
1306	LEFTOSE 5MG/ML SYRUP (LYSOZYME)
1307	LENALIDOMIDE 10MG CAPSULES
1308	LENALIDOMIDE 15MG CAPSULES
1309	LENALIDOMIDE 25MG CAPSULES
1310	LENALIDOMIDE 5MG CAPSULES
1311	LESCOL XL 80MG TABLETS (FLUVASTATIN XL)
1312	LEUCOVORIN CALCIUM 15MG TABLETS (FOLINIC ACID)
1313	LEUCOVORIN CALCIUM 300MG/30ML INJECTION (FOLINIC ACID CALCIUM)
1314	LEUCOVORIN CALCIUM 50MG/5ML INJECTION (FOLINIC ACID CALCIUM)
1315	LEUKERAN 2 MG TABLETS (CHLORAMBUCIL)
1316	LEUNASE 10000KU INJECTION (ASPARAGINASE)
1317	LEVEMIR FLEXPEN 100 unit/ml 3ML INJECTION (INSULIN DETEMIR)
1318	LEVITRA 10MG TABLETS (VARDENAFIL)
1319	LEVITRA 20MG TABLETS (VARDENAFIL)
1320	LEVOPHED 4MG/4ML INJECTION
1321	LEVOPHED 4MG/4ML INJECTION (NORADRENALINE ACID TARTRATE)
1322	LEVOTHYROXINE 500MCG INJECTION (THYROXINE SODIUM)
1323	LEXAPRO 10MG TABLETS (ESCITALOPRAM)
1324	LEXOTAN 1.5MG TABLETS
1325	LEXOTAN 1.5MG TABLETS (BROMAZEPAM)
1326	LEXOTAN 3MG TABLETS (BROMAZEPAM)
1327	LICE CARE 0.5% 50ML LOTION (MALATHION)
1328	LID-CARE STERILE WIPES 20'S (LID-CARE)
1329	LIGNOCAINE 1% 200mg/20ML INJECTION
1330	LIGNOCAINE 2% 10ML SYRINGE
1331	LIGNOCAINE 2% 20G GEL
1332	LIGNOCAINE 2% 20ML INJECTION
1333	LIGNOCAINE 2% 400mg/20ML INJECTION
1334	LIGNOCAINE 5% (2's) PATCHES
1335	LIGNOCAINE ADRENALINE 2%/1:80000 INJECTION (LIGNOCAINE-ADRENALIN)
1336	LIGNOPAD 5% (5'S) PATCHES (LIGNOCAINE)
1337	LIORESAL 10 MG TABLETS (BACLOFEN)
1338	LIPANTHYL PENTA 145MG TABLETS
1339	LIPANTHYL PENTA 145MG TABLETS (FENOFIBRATE)
1340	LIPITOR 10MG TABLETS
1341	LIPITOR 10MG TABLETS (ATORVASTATIN)
1342	LIPITOR 20MG TABLETS (ATORVASTATIN)
1343	LIPOFUNDIN 20% 500ML INFUSION
1344	LIPOFUNDIN 20% 500ML INFUSION (FAT EMULSION)
1345	LIP-THERAPY OINTMENT (PARAFFIN WHITE SOFT)
1346	LIVIAL 2.5MG TABLETS (TIBOLONE)
1347	LOCERYL NAIL LACQUER 5% 2.5ml SOLUTION (AMOROLFINE)
1348	LOPERAMIDE 1MG/5ML SYRUP (LOPERAMIDE)
1349	LORAZEPAM 1MG TABLETS
1350	LORAZEPAM 4MG/ML INJECTION
1351	LOSEC 40MG INJECTION
1352	LOSEC 40MG INJECTION (OMEPRAZOLE)
1353	LOSEC MUPS 10MG TABLETS (OMEPRAZOLE)
1354	LOSEC MUPS 20MG TABLETS
1355	LOSEC MUPS 20MG TABLETS (OMEPRAZOLE)
1356	LOTEMAX 0.5% EYE DROPS (LOTEPREDNOL ETABONATE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1357	LOVASTATIN 20MG TABLETS
1358	LTR. 10MG/5ML SYRUP (CODEINE PHOSPHATE)
1359	LUBRICATING (STERILE) 56.7G JELLY (LUBRICATING)
1360	LUBRICATING 5GM JELLY (LUBRICATING)
1361	LUCRIN DEPOT 11.25MG INJECTION (LEUPRORELIN)
1362	LUCRIN DEPOT 3.75MG INJECTION (LEUPRORELIN)
1363	LUGOL'S IODINE SOLUTION (IODINE AQUEOUS (LUGOL'S))
1364	LUMIGAN 0.03% 3ML EYE DROPS (BIMATOPROST)
1365	LYRICA 25MG CAPSULES
1366	LYRICA 25MG CAPSULES (PREGABALIN)
1367	LYRICA 75MG CAPSULES
1368	LYRICA 75MG CAPSULES (PREGABALIN)
1369	MABCAMPATH 30MG/3ML INJECTION (ALEMTUZUMAB)
1370	MABTHERA 100MG/10ML INJECTION (RITUXIMAB)
1371	MABTHERA* 500MG/50ML INJECTION (RITUXIMAB)
1372	MADOPAR 125MG CAPSULES (LEVODOPA-BENSERAZIDE)
1373	MADOPAR 250MG TABLETS (LEVODOPA-BENSERAZIDE)
1374	MADOPAR DISPERSIBLE 125MG TABLETS (LEVODOPA-BENSERAZIDE)
1375	MADOPAR HBS 125MG CAPSULES (LEVODOPA-BENSERAZIDE CR)
1376	MAGNESIUM 250MG TABLETS
1377	MAGNESIUM SULPHATE 15G POWDER
1378	MAGNESIUM SULPHATE 25G PASTE (MAGNESIUM SULPHATE-GLYCEROL)
1379	MAGNESIUM SULPHATE 49.3% 5ML INJECTION
1380	MAGNESIUM TRISILICATE CO MIXTURE (MAGNESIUM TRISILICATE AND BELLADONNA BPC
1381	MAGNESIUM TRISILICATE CO MIXTURE
1382	MAGNESIUM TRISILICATE MIXTURE (MAGNESIUM TRISILICATE BPC)
1383	MAGRILAN 20MG CAPSULES (FLUOXETINE)
1384	MALARONE TABLETS (ATOVAQUONE-PROGUANIL)
1385	MANNITOL 20% 250ML INFUSION (MANNITOL)
1386	MANNITOL 20% 250ML INFUSION
1387	MARCAINE 0.5% 10ML INJECTION
1388	MARCAINE 0.5% 10ML INJECTION (BUPIVACAINE T PK)
1389	MARCAINE 0.5% 20ML INJECTION
1390	MARCAINE 0.5% 20ML INJECTION (BUPIVACAINE T PK)
1391	MARCAINE 0.5% 4ML INJECTION (BUPIVACAINE (Isobaric))
1392	MARCAINE ADRENALINE 0.5% 20mL INJECTION (BUPIVACAINE-ADRENALINE T PK)
1393	MARCAINE HEAVY 0.5% 4ML INJECTION
1394	MARCAINE HEAVY 0.5% 4ML INJECTION (BUPIVACAINE HEAVY)
1395	MAREVAN 1MG TABLETS
1396	MAREVAN 1MG TABLETS (WARFARIN)
1397	MAREVAN 3MG TABLETS
1398	MAREVAN 3MG TABLETS (WARFARIN)
1399	MAREVAN 5MG TABLETS
1400	MAREVAN 5MG TABLETS (WARFARIN)
1401	MAXIDEX 0.1% 3.5G EYE OINTMENT (DEXAMETHASONE)
1402	MAXIDEX 0.1% 5ML EYE DROPS (DEXAMETHASONE)
1403	MAXIPIME 2G INJECTION (CEFEPIME)
1404	MAXITROL 3.5 GM EYE OINTMENT (NEOMYCIN-POLYMYXIN-DEXAMETHASONE)
1405	MAXITROL 5 ML EYE DROPS (NEOMYCIN-POLYMYXIN-DEXAMETHASONE)
1406	MCT. per ml OIL (MEDIUM CHAIN TRIGLYCERIDE)
1407	MEASLE MUMP RUBELLA 0.5ML VACCINE (MEASLES-MUMPS-RUBELLA)
1408	MEBEVERINE 135MG TABLETS
1409	MEDELA PURELAN 7G OINTMENT (LANOLIN)
1410	MEFENAMIC ACID 125MG/5ML SUSPENSION
1411	MEFENAMIC ACID 250MG CAPSULES
1412	MEGACE 160MG TABLETS
1413	MEGACE 160MG TABLETS (MEGESTROL ACETATE)
1414	MEGALOTECT CP 5000int unit/50ml INJECTION (CETOMEGALOVIRUS GLOBULIN)
1415	MEGESTROL 40MG TABLETS (MEGESTROL ACETATE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1416	MELATONIN 3MG TABLETS
1417	MELIANE 21'S TABLETS (GESTODENE-ETHINYLESTRADIOL)
1418	MENINGOCOCCAL VACCINE (MENINGOCOCCAL ACWY)
1419	MEPILEX 10X10CM DRESSING
1420	MEPILEX 15X15CM DRESSING
1421	MEPILEX AG 12.5X12.5CM DRESSING
1422	MEPILEX BORDER 10X10CM DRESSING
1423	MERCAPTOPURINE 50MG TABLETS
1424	MERCILON 21'S TABLETS (ETHINYLESTRADIOL-DESOGESTREL)
1425	MERCURIC CHLORIDE 0.1 % SOLUTION
1426	MERISLON 6 MG TABLETS
1427	MERISLON 6 MG TABLETS (BETAHISTINE)
1428	MERONEM 1GM INJECTION
1429	MERONEM 500 MG INJECTION
1430	MESNA 20% 3ML RESPIRATOR SOLUTION
1431	MESTINON 60MG TABLETS (PYRIDOSTIGMINE)
1432	METALLINE 8X9CM DRESSING
1433	METALYSE (TNK-tPA) 50MG (10000IU) INJECTION (TENECTEPLASE)
1434	METENIX 5MG TABLETS
1435	METENIX 5MG TABLETS (METOLAZONE)
1436	METEOSPASMYL CAPSULES (ALVERINE-SIMETHICONE)
1437	METEOSPASMYL CAPSULES
1438	METFORMIN 250MG TABLETS
1439	METFORMIN 500MG TABLETS
1440	METHOTREXATE (DBL) 1000mg/10mL INJECTION (METHOTREXATE)
1441	METHOTREXATE 2.5MG TABLETS
1442	METHOTREXATE 500MG/20ML INJECTION
1443	METHOTREXATE 50MG/2ML INJECTION
1444	METHYCOBAL 0.5 MG/ML INJECTION (MECOBALAMIN)
1445	METHYCOBAL 500MCG TABLETS
1446	METHYCOBAL 500MCG TABLETS (MECOBALAMINE)
1447	METHYLATED SPIRIT 70% 100ML SOLUTION
1448	METHYLATED SPIRIT 70% 500ML SOLUTION
1449	METHYLDOPA 125mg TABLETS
1450	METHYLDOPA 250mg TABLETS
1451	METHYLENE BLUE 1% 5ML INJECTION
1452	METOCLOPRAMIDE 10mg TABLETS
1453	METOCLOPRAMIDE 10MG/2ML INJECTION
1454	METOCLOPRAMIDE 5MG/5ML SYRUP (METOCLOPRAMIDE)
1455	METOLAZONE 5MG TABLETS
1456	METOPROLOL 50MG TABLETS
1457	METRONIDAZOLE 500MG/100ML INJECTION
1458	MIACALCIC 100 I.Unit./ML INJECTION (CALCITONIN)
1459	MIACALCIC 200 int.unit NASAL SPRAY (CALCITONIN)
1460	MIACALCIC 50 I.Unit./ML INJECTION (CALCITONIN)
1461	MICARDIS 40MG TABLETS
1462	MICARDIS 40MG TABLETS (TELMISARTAN)
1463	MICARDIS 80MG TABLET (TELMISARTAN)
1464	MICARDIS PLUS 40/12.5MG TABLETS (TELMISARTAN HYDROCHLOROTHIAZIDE)
1465	MICARDIS PLUS 80/12.5MG TABLETS (TELMISARTAN HYDROCHLOROTHIAZIDE)
1466	MICROGYNON 30 21'S TABLETS (LEVONORGESTREL-ETHINYLOESTRADIOL)
1467	MICROSHIELD 2% 500ML SOLUTION (CHLORHEXIDINE)
1468	MICROSHIELD HANDRUB 500ML SOLUTION (CHLORHEXIDINE GLUCONATE 0.5% ETHANOL
1469	MIDAZOLAM 5MG/5ML INJECTION
1470	MINICA S 8ML ENEMA
1471	MINIDIAB 5MG TABLETS
1472	MINIDIAB 5MG TABLETS (GLIPIZIDE)
1473	MINIPRESS 1 MG TABLETS
1474	MINIPRESS 1 MG TABLETS (PRAZOSIN)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1475	MINIPRESS 2MG TABLETS (PRAZOSIN)
1476	MINIRIN 0.1MG TABLETS (DESMOPRESSIN)
1477	MINIRIN 0.2MG TABLETS (DESMOPRESSIN)
1478	MINIRIN 4 MCG/ML INJECTION (DESMOPRESSIN)
1479	MINOCYCLINE 100MG CAPSULES
1480	MINOCYCLINE 50MG CAPSULES
1481	MIOSTAT 0.01% 1.5ML VIAL (CARBACHOL)
1482	MIRENA 52MG IMPLANTS (LEVONORGESTREL)
1483	MISTABRON 20 % 3ml SOLUTION (MESNA)
1484	MITOMYCIN C 10MG INJECTION
1485	MITOMYCIN C 2MG INJECTION
1486	MITOXANTRONE 20MG/10ML INJECTION
1487	MITRIPTYLINE 10MG TABLETS
1488	MIVACRON 20 MG/10 ML INJECTION (MIVACURIUM)
1489	MIXTARD 30 HM (PER DOSE) 100 unit/ml INJECTION (INSULIN NEUTRAL ISOPHANE)
1490	MIXTARD 30 HM 100 unit/ml 10ML INJECTION (INSULIN NEUTRAL-ISOPHANE 30/70 (Human))
1491	MOBIC 7.5MG TABLETS (MELOXICAM)
1492	MOCLOBEMIDE 150MG TABLETS
1493	MODALIM 100MG TABLETS (CIPROFIBRATE)
1494	MONSEL'S (per ml) SOLUTION (IRON)
1495	MONSEL'S THICKENED 8ML SOLUTION (FERRIC SUBSULFATE)
1496	MORPHINE (MST CONTINUS) 30MG TABLETS (MORPHINE SULFATE SR)
1497	MORPHINE (STATEX) 5MG/5ML SYRUP
1498	MORPHINE (STATEX) 5MG/5ML SYRUP (MORPHINE HYDROCHLORIDE APF)
1499	MORPHINE 10MG/ML INJECTION (MORPHINE SULFATE)
1500	MORPHINE 15MG/ML INJECTION (MORPHINE SULFATE)
1501	MOTILIUM 10MG TABLETS
1502	MOTILIUM 10MG TABLETS (DOMPERIDONE)
1503	MOTILIUM 5MG/5ML SUSPENSION (DOMPERIDONE)
1504	MOTILIUM IN WATER 1MG/ML SUSPENSION (DOMPERIDONE)
1505	MOVICOL SACHETS (PEG-SOD POT CHLORIDE SOD BICARB)
1506	MUCILIN 5GM SACHETS (ISPAGHULA)
1507	MUCOFLUX 100MG CAPSULES (CYCLIDROL)
1508	MUCOSOLVAN 30MG TABLETS
1509	MUCOSOLVAN 30MG TABLETS (AMBROXOL)
1510	MUCOSOLVAN 30MG/5ML SYRUP
1511	MUCOSOLVAN 30MG/5ML SYRUP (AMBROXOL)
1512	MULTAQ 400MG TABLETS (DRONEDARONE)
1513	MULTIVITAMIN + MINERALS TABLETS (MULTIVITAMINS &MINERALS)
1514	MULTIVITAMIN INJECTION (MULTIVITAMIN)
1515	MULTIVITAMIN TABLETS
1516	MULTIVITAMIN INJECTION
1517	MYCAMINE 50MG INJECTION (MICAFUNGIN)
1518	MYDFRIN 2.5% 5ML EYE DROPS (PHENYLEPHRINE)
1519	MYDRIACYL 1% 15ML EYE DROPS (TROPICAMIDE)
1520	MYFORTIC 180MG TABLETS (MYCOPHENOLATE)
1521	MYFORTIC 360MG TABLETS (MYCOPHENOLATE)
1522	MYLOTARG 5MG INJECTION (GEMTUZUMAB OZOGAMICIN)
1523	MYONAL 50 MG TABLETS (EPERISONE)
1524	MYOTEIN 300G POWDER
1525	MYSOLINE 250MG TABLETS (PRIMIDONE)
1526	NALOXONE 0.04 MG/2 ML INJECTION
1527	NALOXONE 0.4 MG/ML INJECTION
1528	NALTREXONE 50MG TABLETS
1529	NAPHCON-A 15 ML EYE DROPS (NAPHAZOLINE-PHENIRAMINE MALEATE)
1530	NARAMIG 2.5MG TABLETS (NARATRIPTAN)
1531	NARCARICIN MITE 50MG TABLETS (BENZBROMARONE)
1532	NAROPIN 10MG/ML 10ML INJECTION
1533	NAROPIN 10MG/ML 10ML INJECTION (ROPIVACAINE HYDROCHLORIDE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1534	NAROPIN 10MG/ML 20ML INJECTION (ROPIVACAINE HYDROCHLORIDE)
1535	NAROPIN 2MG/ML 200ML INFUSION (ROPIVACAINE HYDROCHLORIDE)
1536	NASACORT AQ 55MCG/DOSE (120D) NASAL SPRAY (TRIAMCINOLONE)
1537	NASONEX 0.05% (140D) NASAL SPRAY (MOMETASONE FUROATE)
1538	NATACYN 5% 15ML EYE DROPS (NATAMYCIN)
1539	NATOPHEROL 400 int.unit CAPSULES (TOCOPHEROL)
1540	NATOPHEROL SURBEX 400 int units CAPSULES (TOCOPHEROL)
1541	NATRILIX SR 1.5MG TABLETS (INDAPAMIDE SR)
1542	NAVELBINE 10MG INJECTION (VINORELBINE)
1543	NAVELBINE 50MG INJECTION (VINORELBINE)
1544	NEBIDO 1G/4ML INJECTION (TESTOSTERONE UNDECANOATE)
1545	NEBILET 5MG TABLETS
1546	NEBILET 5MG TABLETS (NEBIVOLOL)
1547	NEILMED SINUS RINSE (STARTER KIT) NASAL SOLUTION
1548	NEODERM 15G CREAM (BETAMETHASONE, GENTAMYCIN,CLOTRIMAZOLE)
1549	NEOGOBION CAPSULES (FERROUS GLUCONATE)
1550	NEOMYCIN 500MG TABLETS
1551	NEOMYCIN 500MG TABLETS (NEOMYCIN SULPHATE)
1552	NEOMYCIN SULPHATE POWDER (NEOMYCIN)
1553	NEOSTIGMINE 2.5MG/ML INJECTION
1554	NEOTIGASON 10MG CAPSULES (ACITRETIN)
1555	NEOTIGASON 25MG CAPSULES (ACITRETIN)
1556	NEOVITA CAPSULES (MULTIVITAMINS &MINERALS)
1557	NEPRO 237ML LIQUID
1558	NEPRO 237ML LIQUID (MILK SUBSTITUTE)
1559	NEPRO HP 220ml LIQUID (MILK SUBSITUTE)
1560	NEUPOGEN 300 MCG INJECTION (FILGRASTIM GCSF)
1561	NEUPOGEN* 300 MCG INJECTION (FILGRASTIM GCSF)
1562	NEUPRO 2MG/24HR PATCHES (ROTIGOTINE)
1563	NEUROBION 3ML INJECTION (VITAMIN B COMPLEX)
1564	NEUROBION TABLETS (VITAMIN B COMPLEX)
1565	NEUROBION TABLETS
1566	NEUROFORTE TABLETS (VITAMIN B COMPLEX)
1567	NEUROGEN E TABLETS (VITAMIN B & E)
1568	NEURONTIN 300MG CAPSULES
1569	NEURONTIN 300MG CAPSULES (GABAPENTIN)
1570	NEURONTIN 400MG CAPSULES (GABAPENTIN)
1571	NEVANAC 0.1% 5ML EYE DROPS (NEPAFENAC)
1572	NEVRAMIN 2ML INJECTION (VITAMIN B COMPLEX)
1573	NEVRAMIN TABLETS (VITAMIN B COMPLEX)
1574	NEXAVAR 200MG TABLETS (SORAFENIB TOSYLATE)
1575	NEXIUM 20MG TABLETS
1576	NEXIUM 20MG TABLETS (ESOMEPRAZOLE)
1577	NEXIUM 40MG INJECTION
1578	NEXIUM 40MG INJECTION (ESOMEPRAZOLE)
1579	NEXIUM 40MG TABLETS
1580	NEXIUM 40MG TABLETS (ESOMEPRAZOLE)
1581	NIASPAN 500MG TABLETS (NICOTINIC ACID SR)
1582	NICORETTE 10MG INHALER (NICOTINE)
1583	NICORETTE 10MG/16HR PATCHES (NICOTINE)
1584	NICORETTE 15MG/16HR PATCHES (NICOTINE)
1585	NICORETTE 5MG/16HR PATCHES (NICOTINE)
1586	NICORETTE CHEWING GUM 2MG (NICOTINE)
1587	NICORETTE CHEWING GUM 4MG (NICOTINE)
1588	NICOTINELL TTS 10 PATCHES (NICOTINE)
1589	NICOTINELL TTS 20 PATCHES (NICOTINE)
1590	NICOTINELL TTS 30 PATCHES (NICOTINE)
1591	NIFEDIPINE 10mg TABLETS
1592	NIFEDIPINE 5MG CAPSULES

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1593	NIFEDIPINE RETARD 20MG TABLETS (NIFEDIPINE)
1594	NIFETEX TR CAPSULES (NIFEDIPINE-ATENOLOL SR)
1595	NIFTEN CAPSULES (NIFEDIPINE-ATENOLOL SR)
1596	NIFTEN CAPSULES
1597	NIMENRIX 0.5ML INJECTION (MENINGOCOCCAL)
1598	NIMOTOP 10MG/50ML INJECTION
1599	NIMOTOP 10MG/50ML INJECTION (NIMODIPINE)
1600	NIMOTOP 30MG TABLETS
1601	NIMOTOP 30MG TABLETS (NIMODIPINE)
1602	NITRAZEPAM 5mg TABLETS
1603	NITROCINE 10 MG/10 ML INJECTION
1604	NITROCINE 10 MG/10 ML INJECTION (GLYCERYL TRINITRATE)
1605	NITROFURANTOIN 100MG TABLETS
1606	NITROPRESS 50MG/2ML INJECTION
1607	NITROPRESS 50MG/2ML INJECTION (NITROPRUSSIDE SODIUM)
1608	NIZORAL 2% 100ML SHAMPOO (KETOCONAZOLE)
1609	NIZORAL 2% 15G CREAM (KETOCONAZOLE)
1610	NIZORAL 200MG TABLETS (KETOCONAZOLE)
1611	NOOTROPIL 1200MG TABLETS
1612	NOOTROPIL 1200MG TABLETS (PIRACETAM)
1613	NOOTROPIL 1GM/5ML 20% SYRUP (PIRACETAM)
1614	NOOTROPIL 3GM/15ML INJECTION
1615	NOOTROPIL 3GM/15ML INJECTION (PIRACETAM)
1616	NOOTROPIL 800MG TABLETS
1617	NOOTROPIL 800MG TABLETS (PIRACETAM)
1618	NORDAZ 15MG TABLETS (NORDAZEPAM)
1619	NORETHISTERONE 5MG TABLETS
1620	NORFLOXACIN 400MG TABLETS
1621	NORGESIC TABLETS (ORPHENADRINE-PARACETAMOL)
1622	NORGESIC TABLETS
1623	NORTRIPTYLINE 10MG CAPSULES
1624	NORTRIPTYLINE 25MG CAPSULES
1625	NORVASC 10MG TABLETS (AMLODIPINE)
1626	NORVASC 5MG TABLETS
1627	NORVASC 5MG TABLETS (AMLODIPINE)
1628	NOVANTRONE 20MG INJECTION (MITOXANTRONE)
1629	NOVASOURCE RENAL 237ML SOLUTION (MILK SUBSTITUE)
1630	NOVOMIX 30 FLEXPEN 100 unit/ml 3ML INJECTION (INSULIN ASPART SOLUBLE-PROTAMINE
1631	NOVONORM 0.5MG TABLETS (REPAGLINIDE)
1632	NOVONORM 1MG TABLETS
1633	NOVONORM 1MG TABLETS (REPAGLINIDE)
1634	NOVONORM 2MG TABLETS (REPAGLINIDE)
1635	NOVONORM 0.5MG TABLETS
1636	NOVONORM 2MG TABLETS
1637	NOVORAPID FLEXPEN 100 unit/ml 3ML INJECTION (INSULIN ASPART)
1638	NOVORAPID PENFILL 100 unit/ml 3ML INJECTION (INSULIN ASPART)
1639	NOVOSEVEN 1MG INJECTION (FACTOR 7a)
1640	NOVOSEVEN 2MG INJECTION (FACTOR 7a)
1641	NUELIN 80MG/15ML SYRUP (THEOPHYLLINE)
1642	NUELIN SR 250MG TABLETS
1643	NUELIN SR 250MG TABLETS (THEOPHYLLINE SR)
1644	NUROFEN 100MG/5ML SYRUP
1645	NUROFEN 100MG/5ML SYRUP (IBUPROFEN)
1646	NUROFEN 200mg TABLETS (IBUPROFEN)
1647	NUTREN DIABETES 237ML LIQUID (MILK SUBSTITUE)
1648	NUTRICOMP 450G POWDER (MALTODEXTRIN)
1649	NUTROPLEX WITH LYSINE SYRUP (MULTIVITAMIN WITH LYSINE)
1650	NUTROPLEX WITH LYSINE SYRUP
1651	NYSTATIN 100000 unit/ml 100ML SUSPENSION

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1652	OBIMIN (NEW) TABLETS (MULTIVITAMINS &MINERALS)
1653	OCUVITE with LUTEIN TABLETS (MULTIVITAMIN)
1654	OESTROGEL 0.06% 80G GEL (ESTRADIOL)
1655	OFLOXACIN 200MG TABLETS
1656	OILATUM 100GM SOAP (MINERAL OIL)
1657	OILATUM 40GM CREAM (ARACHIS OIL)
1658	OILATUM EMOLLIENT 150ML LIQUID (MINERAL OIL)
1659	OKTA-LINE 5ML SOLUTION
1660	OLBETAM 250MG CAPSULES (ACIPIMOX)
1661	OLICLINOMEL 1.5L CENTRAL (N7-1000E) INFUSION (TPN)
1662	OLICLINOMEL 1.5L PERIPHERAL (N4-550E) INFUSION (TPN)
1663	OLICLINOMEL 1L CENTRAL (N7-1000) INFUSION (TPN)
1664	OLICLINOMEL 2L CENTRAL (N7-1000E) INFUSION (TPN)
1665	OLIVE OIL (OLIVE OIL)
1666	OLMETEC 20MG TABLETS (OLMESARTAN)
1667	OLMETEC 40MG TABLETS (OLMESARTAN)
1668	OLMETEC PLUS 20/12.5MG TABLETS (OLMESARTAN-HCTZ)
1669	OMEPRAZOLE 20MG CAPSULES (OMEPRAZOLE)
1670	OMEPRAZOLE 2MG/ML SUSPENSION
1671	OMEPRAZOLE 20MG CAPSULES
1672	ONBREZ BREEZHALER 150MCG 30'S INHALATION (INDACATEROL)
1673	ONBREZ BREEZHALER 300MCG 30'S INHALATION (INDACATEROL)
1674	ONE-ALPHA 0.25MCG CAPSULES (ALFACALCIDOL)
1675	ONE-ALPHA 1MCG CAPSULES (ALFACALCIDOL)
1676	ONE-ALPHA 1MCG/0.5ml INJECTION (ALFACALCIDOL)
1677	ONE-ALPHA 2 MCG/ML DROPS (ALFACALCIDOL)
1678	ONGLYZA 5MG TABLETS (SAXAGLIPTIN)
1679	ONKOVERTIN 40 IN DEXTROSE 5% 500 ML INFUSION (DEXTRAN 40-GLUCOSE)
1680	ONKOVERTIN 40 IN NaCL 0.9% 500 ML INFUSION (DEXTRAN 40-N/SALINE)
1681	ONKOVERTIN 70 IN NaCL 0.9% 500 ML INFUSION (DEXTRAN 70-N/SALINE)
1682	OPSITE 240ML SPRAY
1683	OPTICROM 2% 10ML EYE DROPS (SODIUM CROMOGLYCATE)
1684	OPTODEXINE 5ML EYE DROPS (CHLORAMPHENICOL-DEXAMETHASONE-TETRAHYDROZO
1685	ORABASE 5g PASTE (CARMELLOSE-PECTIN)
1686	ORACORT E 5G PASTE (TRIAMCINOLONE-LIDOCAINE)
1687	ORAL AID LOTION (TRIAMCINOLONE-CHLORHEXIDINE-LIGNOCAINE)
1688	ORAL FLEET SOLUTION (SODIUM PHOSPHATE MONOBASIC-SOD.PHOSPHATE DIBASIC)
1689	ORAL FLEET SOLUTION
1690	ORA-SED JELLY (CHOLINE SALICYLATE)
1691	ORUVAIL 100MG CAPSULES (KETOPROFEN SR)
1692	OSCAL+D 500 MG TABLETS
1693	OSCAL+D 500 MG TABLETS (CAL CARB + VIT D)
1694	OSTEOMED 20MCG TABLETS
1695	OSTEOMED 20MCG TABLETS (CHOLECALCIFEROL-D3)
1696	OTRIVIN (drop) 0.05% 10ML CHILD NASAL DROPS (XYLOMETAZOLINE)
1697	OTRIVIN (DROP) 0.1% 10ML ADULT NASAL DROPS (OXYMETAZOLINE)
1698	OXYBUTININ 5MG TABLETS (OXYBUTYNIN)
1699	OXYCONTIN 10MG TABLETS (OXYCODONE SR)
1700	OXYCONTIN 20MG TABLETS (OXYCODONE SR)
1701	OXYLIM 100 MG/2 ML INJECTION (OXYTETRACYCLINE WITH LIDOCAINE)
1702	OXYMETHOLONE 50MG TABLETS (OXYMETHOLONE)
1703	OXY-NASE 0.05% 15mL NASAL SPRAY (OXYMETAZOLINE)
1704	OXYNORM 10MG CAPSULES (OXYCODONE)
1705	OXYNORM 10MG/ML INJECTION (OXYCODONE)
1706	OXYNORM 5MG CAPSULES (OXYCODONE)
1707	PAMIDRONATE 30MG/10ML INJECTION
1708	PAMIDRONATE 90MG/10ML INJECTION
1709	PANADEINE TABLETS (PARACETAMOL-CODEINE)
1710	PANADEINE TABLETS

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1711	PANADOL 120MG TABLETS (PARACETAMOL)
1712	PANADOL 500mg TABLETS
1713	PANADOL 500mg TABLETS (PARACETAMOL)
1714	PANADOL EXTRA 500MG-65MG CAPSULES (PARACETAMOL-CAFFEINE)
1715	PANBESY 30MG CAPSULES (PHENTERMINE)
1716	PAPAVERINE 120 MG/10 ML INJECTION
1717	PARA-AMINOSALICYLIC ACID 4G SACHETS
1718	PARACETAMOL 125MG SUPPOSITORIES
1719	PARACETAMOL 250 MG/5 ML SUSPENSION
1720	PARACETAMOL 325MG SUPPOSITORIES
1721	PARACETAMOL 650MG SUPPOSITORIES
1722	PARAFFIN (STERILE) 5G LIQUID (PARAFFIN STERILE)
1723	PARAFFIN LIQUID (PARAFFIN LIQUID)
1724	PARAFFIN LIQUID EMULSION EMULSION (PARAFFIN LIQUID-BENZOIC ACID)
1725	PAREMANOL 30G OINTMENT (BISMUTH SUBNITRATE)
1726	PARIET 10MG TABLETS (RABEPRAZOLE SODIUM)
1727	PARIET 20MG TABLETS
1728	PARIET 20MG TABLETS (RABEPRAZOLE SODIUM)
1729	PARLODEL 2.5 MG TABLETS (BROMOCRIPTINE)
1730	PAROMOMYCIN 250MG TABLETS
1731	PATANOL 0.1% 5ml EYE DROPS (OLOPATADINE HCL)
1732	PAVULON 4 MG/2 ML INJECTION (PANCURONIUM)
1733	PAXIDORM 25MG TABLETS (DIPHENHYDRAMINE)
1734	PEDIASURE COMPLETE 400G POWDER (PROTEIN-CARBOHYDRATE-FAT)
1735	PEDIASURE COMPLETE triplesure 237ML LIQUID (PROTEIN-CARBOHYD-FAT(PEDIASURE))
1736	PEDITRACE 10ML INJECTION (TRACE ELEMENT)
1737	PEGASYS 180MCG INJECTION (PEGINTERFERON ALPHA 2A)
1738	PEGLASTA 6MG INJECTION (PEGFILGRASTIM PEG-GCSF)
1739	PEGLASTA* 6MG INJECTION (PEGFILGRASTIM PEG-GCSF)
1740	PENICILLAMINE 250MG CAPSULES
1741	PENICILLIN V 250 MG TABLETS (PHENOXYMETHYLPENICILLIN)
1742	PENTAGLOBIN 2.5G/50ML INJECTION (IMMUNOGLOBULIN)
1743	PENTAMIDINE 300MG INJECTION (PENTAMIDINE)
1744	PENTASA 500MG TABLETS (MESALAZINE)
1745	PERITONEAL DIALYSIS LOW CA 1.5% 2.5L (PD-4) SOLUTION (PERITONEAL DIALYSIS)
1746	PERITONEAL DIALYSIS LOW CA 1.5% 2L(U-BAG) SOLUTION (PERITONEAL DIALYSIS)
1747	PERITONEAL DIALYSIS LOW CA 2.5% 2.5L SOLUTION (PERITONEAL DIALYSIS)
1748	PERITONEAL DIALYSIS LOW CA 4.25% 2.5L SOLUTION (PERITONEAL DIALYSIS)
1749	PERSANTIN 10MG/2ML INJECTION (DIPYRIDAMOLE)
1750	PERSANTIN 75MG TABLETS
1751	PETHIDINE 100MG/2ML INJECTION
1752	PETHIDINE 50MG/ML INJECTION
1753	PHARMATON CAPSULES (MULTIVITAMINS &MINERALS)
1754	PHARMATON KIDDI SYRUP (MULTIVITAMIN LYSINE)
1755	PHARMORUBICIN 10MG INJECTION (EPIRUBICIN)
1756	PHARMORUBICIN 50MG INJECTION (EPIRUBICIN)
1757	PHENEXPECT CD SYRUP (DIPHENHYDRAMINE-CODEINE PHOSPHATE-AMMON.CHLORIDE)
1758	PHENEXPECT CD SYRUP
1759	PHENEXPECT SYRUP (DIPHENHYDRAMINE-AMMONIUM CHLORIDE)
1760	PHENOBARBITONE 15 MG/5 ML ELIXIR (PHENOBARBITONE APF)
1761	PHENOBARBITONE 200MG/ML INJECTION
1762	PHENOBARBITONE 30MG/ML INJECTION
1763	PHENOBARBITONE 60MG TABLETS
1764	PHENOL IN OIL 5% 5ML INJECTION (PHENOL IN ALMOND OIL)
1765	PHENOXYBENZAMINE 10MG CAPSULES
1766	PHENTOLAMINE 10MG/ML INJECTION
1767	PHENYLEPHRINE 10% 0.5ML MINIMS-EYEDROPS
1768	PHENYLEPHRINE 10MG/ML INJECTION
1769	PHENYLEPHRINE 2.5% 0.5ML MINIMS-EYEDROPS

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1770	PHENYTOIN 250MG/5ML INJECTION
1771	PHOSPHATE 1G(10.54mmol)/15ML MIXTURE
1772	PHYSEPTONE 5 MG TABLETS (METHADONE)
1773	PHYSIOGEL 75ML CREAM
1774	PHYSIOGEL INTENSIVE CARE 50ML CREAM
1775	PHYSOSTIGMINE 2MG/2ML INJECTION
1776	PILOCARPINE 2% 0.5ML MINIMS-EYEDROPS (PILOCARPINE)
1777	PIRITON 4MG TABLETS
1778	PIRITON 4MG TABLETS (CHLORPHENIRAMINE)
1779	PLAQUENIL 200MG TABLETS (HYDROXYCHLOROQUINE)
1780	PLASMA-LYTE A 1L IV FLUID (MULTIPLE ELECTROLYTES)
1781	PLASMA-LYTE A 500ML IV FLUID (MULTIPLE ELECTROLYTES)
1782	PLAVIX 75 MG TABLETS
1783	PLAVIX 75 MG TABLETS (CLOPIDOGREL)
1784	PLENDIL 10MG TABLETS (FELODIPINE)
1785	PLENDIL 5MG TABLETS (FELODIPINE SR)
1786	PNEUMOVAX 23 0.5ML VACCINE (PNEUMOCOCCAL POLYVALENT)
1787	PODOFILM WART TREATMENT 25% SOLUTION (PODOPHYLLIN)
1788	POLARAX (DEXCHLORPHENIRAMINE) 2mg TABLETS (DEXCHLORPHENIRAMINE)
1789	POLIO (10 DOSES) ORAL VACCINE (POLIOMYELITIS LIVE VACCINE)
1790	POLYDEXA EAR DROPS (DEXAMETHASONE-NEOMYCIN-POLYMIXIN)
1791	POLYMIXIN 500000 unit INJECTION
1792	POLYSILIC III SUSPENSION
1793	POLYSILIC III SUSPENSION
1794	POLYVISOL(WITH IRON) 50 ML DROPS (MULTIVITAMIN + IRON)
1795	POSACONAZOLE 40MG/ML 105ML SUSPENSION
1796	POSTINOR 750MCG TABLETS (LEVONORGESTREL)
1797	POTASSIUM ACETATE 49% (25mEq/5ml) INJECTION
1798	POTASSIUM CHLORIDE 500MG(6.7mmol)/5ML MIXTURE
1799	POTASSIUM CHLORIDE 7.45% 10ML INJECTION (POTASSIUM CHLORIDE)
1800	POTASSIUM CHLORIDE BP Galenicals
1801	POTASSIUM CHLORIDE SR 600MG TABLETS
1802	POTASSIUM CHLORIDE 7.45% 10ML INJECTION
1803	POTASSIUM CITRATE ALKALINE MIXTURE (POTASSIUM CITRATE)
1804	POTASSIUM CITRATE ALKALINE MIXTURE
1805	POTASSIUM DIHYD PHOSPHATE 1.361G/10ML INJECTION
1806	POTASSIUM DIHYD PHOSPHATE 1.361G/10ML INJECTION (POTASSIUM DIHYROGEN PHOSI
1807	POTASSIUM in D5%/NaCL0.33% 10mmol/500ml INFUSION
1808	POTASSIUM in D5%/NaCL0.45% 20mmol/1L INFUSION
1809	POTASSIUM PERMANGANATE 0.1% 100ML SOLUTION
1810	POTASSIUM PHOSPHATE 10ML INJECTION (POT. PHOSPHATE)
1811	POTASSIUM(KCL) in D5% 10mmol/500ml INFUSION
1812	POTASSIUM(KCL) in D5/NS0.9% 20mmol/1000ml INFUSION (POTASSIUM(KCL) in D5/NS0.9%)
1813	POTASSIUM(KCL) in NS0.9% 10mmol/500ml INFUSION (POTASSIUM(KCL) in NS0.9%)
1814	POVIDONE IODINE 10% 100ML SOLUTION (POVIDONE-IODINE)
1815	POVIDONE IODINE 10% 30ML SOLUTION (POVIDONE IODINE)
1816	POVIDONE IODINE 10% 500ml SOLUTION (POVIDONE-IODINE AQUEOUS)
1817	POVIDONE IODINE 10% IN SPIRIT 100ML SOLUTION (POVIDONE-IODINE ALCOHOLIC)
1818	POVIDONE IODINE 15G OINTMENT
1819	POVIDONE IODINE SCRUB 7.5% 500ML SOLUTION (POVIDONE-IODINE)
1820	POVIDONE IODINE SWAB STICK 3'S (POVIDONE IODINE)
1821	PRADAXA 110MG CAPSULES (DABIGATRAN ETEXILATE)
1822	PRADAXA 150MG CAPSULES (DABIGATRAN ETEXILATE)
1823	PRADAXA 75MG CAPSULES (DABIGATRAN ETEXILATE)
1824	PRAVASTATIN 20MG TABLETS
1825	PRAXILENE 200MG TABLETS (NAFTIDROFURYL)
1826	PRAZIQUANTEL 600 MG TABLETS
1827	PRECEDEX 200MCG/2ML INJECTION
1828	PRECEDEX 200MCG/2ML INJECTION (DEXMEDETOMIDINE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1829	PRED FORTE 1% 5ml EYE DROPS (PREDNISOLONE ACETATE)
1830	PRED MILD 0.12% 5ml EYE DROPS (PREDNISOLONE ACETATE)
1831	PREDNISOLONE 1 MG TABLETS
1832	PREDNISOLONE 10 MG/5 ML SYRUP
1833	PREDNISOLONE 10 MG/5 ML SYRUP (PREDNISOLONE)
1834	PREDNISOLONE 20MG TABLETS
1835	PREDNISOLONE 25MG/ML 10ML INJECTION
1836	PREDNISOLONE 5MG TABLETS
1837	PREGNYL 5000 int.unit INJECTION (CHORIONIC GONADOTROPHIN (H))
1838	PREMARIN 0.625MG TABLETS (OESTROGENS CONJUGATED)
1839	PREMARIN 14G VAGINAL CREAM (OESTROGENS CONJUGATED)
1840	PRESEPT 500MG TABLET (DICHLOROISOCYANURATE)
1841	PRESEPT GRANULES (DICHLOROISOCYANURATE)
1842	PRETERAX TABLETS (PERINDOPRIL-INDAPAMIDE)
1843	PREVACID 30MG CAPSULES (LANSOPRAZOLE)
1844	PRIMACOR 10 MG/10 ML INJECTION
1845	PRIMACOR 10 MG/10 ML INJECTION (MILRINONE)
1846	PRIMAQUINE 15MG (base) TABLETS
1847	PRIMAX 0.5% EYE DROPS (POPARACAINE HCL)
1848	PRIMOLUT-N 5MG TABLETS (NORETHISTERONE)
1849	PRIMPERAN 10 MG SUPPOSITORIES (METOCLOPRAMIDE)
1850	PRIMPERAN 10mg TABLETS (METOCLOPRAMIDE)
1851	PRIMPERAN 20MG SUPPOSITORIES (METOCLOPRAMIDE)
1852	PRINCI-B FORTE TABLETS (VIT B1-B12-B6)
1853	PRISMASOL 5L SOLUTION
1854	PRISMOCAL 5L PERITONEAL DIALYSIS FLUID
1855	PRISMOCITRATE 10/2 5L SOLUTION (PRIMOCITRATE 10/2)
1856	PRISTIQ ER 50MG TABLETS (DESVENLAFAXINE SR)
1857	PROBENECID 500MG TABLETS
1858	PROCAINAMIDE 1G/10ML INJECTION
1859	PROCAINAMIDE 1G/2ML INJECTION
1860	PROCAINE SPIRIT 2% SOLUTION
1861	PROCHLORPERAZINE 5MG TABLETS
1862	PROCODIN 100ML SYRUP (PROMETHAZINE-CODEINE PHOSPHATE)
1863	PROCODIN SYRUP (PROMETHAZINE-CODEINE PHOSPHATE)
1864	PROCTOLOG 20 GM CREAM (RUSCOGENINS-TRIMEBUTINE)
1865	PROCTOLOG SUPPOSITORIES (RUSCOGENINS-TRIMEBUTINE)
1866	PROCTOSEDYL 15G OINTMENT (HYDROCORTSIONE-CINCHOCAINE)
1867	PROCTOSEDYL SUPPOSITORIES (HYDROCORTISONE-CINCHOCAINE-FRAMYCETIN-AESCU
1868	PROFLAVINE 0.1% 120ML LOTION (PROFLAVINE)
1869	PROFLAVINE EMULSION 0.1% (per ml) APPLICATION
1870	PROGESTERONE 50 MG/ML INJECTION
1871	PROGRAF 0.5MG CAPSULES (TACROLIMUS)
1872	PROGRAF 1MG CAPSULES (TACROLIMUS)
1873	PROGRAF 5MG CAPSULES (TACROLIMUS)
1874	PROGRAF 5MG CAPSULES
1875	PROGRAF 5mg/mL INJECTION (TACROLIMUS)
1876	PROGRAF 1MG CAPSULES
1877	PROGUT CAPSULES (PROBIOTICS)
1878	PROGYLUTON 21'S TABLETS (OESTRADIOL-NORGESTREL)
1879	PROGYNOVA 2MG TABLETS (OESTRADIOL VALERATE)
1880	PROLIA 60MG/ML SYRINGE (DENOSUMAB)
1881	PROLUTON DEPOT 250 MG/ML INJECTION (HYDROXYPROGESTERONE)
1882	PROMETHAZINE 50MG/2ML INJECTION
1883	PROMETHAZINE 5MG/5ML ELIXIR
1884	PROMETHAZINE THEOCLATE 25MG TABLETS
1885	PROMETHAZINE-CODEINE SYRUP (PROMETHAZINE-CODEINE PHOSPHATE)
1886	PROMETHAZINE-CODEINE SYRUP
1887	PROPECIA 1MG TABLETS (FINASTERIDE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
1888	PROPOFOL 1% 200MG/20ML INJECTION
1889	PROPOFOL 1% 500MG/50ML INJECTION
1890	PROPOFOL 2% 1G/50ML INJECTION
1891	PROPRANOLOL 10MG TABLETS
1892	PROPRANOLOL 1MG/ML INJECTION
1893	PROPRANOLOL 40MG TABLETS
1894	PROPYLTHIOURACIL 50MG TABLETS
1895	PROSCAR 5MG TABLETS (FINASTERIDE)
1896	PROSPAN COUGH 100ML SYRUP
1897	PROSTIN E2 3 MG PESSARIES (DINOPROSTONE)
1898	PROSTIN VR 0.5 MG/ML INJECTION (ALPROSTADIL)
1899	PROSURE 240ML LIQUID
1900	PROSURE 380G POWDER
1901	PROTAMINE SULPHATE 50 MG/5 ML INJECTION
1902	PROTOPIC 0.03% 10G OINTMENT (TACROLIMUS)
1903	PROTOPIC 0.1% 10G OINTMENT (TACROLIMUS)
1904	PROTOS 2G SACHETS (STRONTIUM RANELATE)
1905	PROVERA 5MG TABLETS (MEDROXYPROGESTERONE)
1906	PROVIGIL 100MG TABLETS (MODAFINIL)
1907	PROVIRONUM 25MG TABLETS (MESTEROLONE)
1908	PROZAC 20mg CAPSULES
1909	PROZAC 20mg CAPSULES (FLUOXETINE)
1910	PSEUDOEPHEDRINE 60MG TABLETS
1911	PULMICORT 1MG/2ML RESPULES
1912	PULMICORT 1MG/2ML RESPULES (BUDESONIDE)
1913	PULMICORT 200MCG/DOSE TURBUHALER (BUDESONIDE)
1914	PULMICORT 500mcg/2mL RESPULES
1915	PULMICORT 500mcg/2mL RESPULES (BUDESONIDE)
1916	PULMOCARE 237ML LIQUID
1917	PULMOCARE 237ML LIQUID (MILK SUBSTITUTE)
1918	PYRAZINAMIDE 500MG TABLETS
1919	Q.V. 100G CREAM
1920	Q.V. 100G CREAM (PARAFFIN LIQUID,GLYCEROL, DIMETHICONE)
1921	Q.V. 250ML LOTION (PARAFFIN WHITE SOFT)
1922	Q.V. LIP BALM 15G
1923	Q.V. WASH 250ML SOLUTION (GLYCEROL)
1924	QUINAX 15ML EYE DROPS (SODIUM DIHYDROAZAPENTACENE)
1925	QUININE DI-HCL 600 MG/2 ML INJECTION (QUININE DIHYDROCHLORIDE)
1926	QUININE SULPHATE 300 MG TABLETS
1927	RABIES VACCINE (RABIES VACCINE)
1928	RANITIDINE 150MG TABLETS
1929	RAPAMUNE 1MG TABLETS (SIROLIMUS)
1930	RAPIFEN 1MG/2 ML INJECTION (ALFENTANYL)
1931	REBETOL 200MG CAPSULES (RIBAVIRIN)
1932	RECORMON 10000 int.unit INJECTION (EPOETIN BETA)
1933	RECORMON 2000 int.unit INJECTION (EPOETIN BETA)
1934	RECORMON 30000 int.unit INJECTION (EPOETIN BETA)
1935	RECORMON 4000 int.unit INJECTION (EPOETIN BETA)
1936	RECORMON 5000 int.unit INJECTION (EPOETIN BETA)
1937	RECTOGESIC 0.2% 30G OINTMENT (GLYCERYL TRINITRATE)
1938	REDOXON DOUBLE ACTION EFF 1G 15'S TABLETS (ASCORBIC ACID-ZINC)
1939	REFOBACIN PALACOS 40G POWDER (GENTAMICIN BONE CEMENT)
1940	REFRESH 0.4ML (EACH) MINIMS-EYEDROPS (POLYVINYL ALCOHOL-POVIDONE)
1941	REFRESH LIQUIGEL 1% EYE DROPS (CARBOXYMETHYLCELLULOSE)
1942	REFRESH PLUS 0.4ML (EACH) MINIMS-EYEDROPS (CARBOXYMETHYLCELLULOSE)
1943	REFRESH PLUS 0.4ML 30'S MINIMS-EYEDROPS (CARBOXYMETHYCELLULOSE)
1944	REGAINE 2% SOLUTION (MINOXIDIL)
1945	REGAINE 5% SOLUTION (MINOXIDIL)
1946	RELENZA 5MG 20'S ROTADISKS (ZANAMIVIR)

Sr	Item Description
1947	RELPAX 40MG TABLETS (ELETRIPTAN)
1948	REMERON 30MG TABLETS (MIRTAZAPINE)
1949	REMERON SOL 30MG TABLETS (MIRTAZAPINE)
1950	REMICADE 100MG INJECTION (INFLIXIMAB)
1951	REMIFEMIN 20MG TABLETS (CIMICIFUGAE RACEMOSA EXTRACT)
1952	RENALVITE TABLETS (VITAMIN B CO & VITAMIN C)
1953	RENITEC 10MG TABLETS (ENALAPRIL)
1954	RENITEC 20MG TABLETS (ENALAPRIL)
1955	RENITEC 5MG TABLETS
1956	RENITEC 5MG TABLETS (ENALAPRIL)
1957	REOPRO 10mg/5mL INJECTION (ABCIXIMAB)
1958	REPALYTE SACHETS (ELECTROLYTES-MIXED FOR ORAL REPLACEMENT)
1959	REPALYTE SACHETS
1960	REQUIP 0.25MG TABLETS (ROPINIROLE)
1961	REQUIP 1MG TABLETS (ROPINIROLE)
1962	REQUIP PD-24HR 2MG TABLETS (ROPINIROLE PD)
1963	RESOLOR 1MG TABLETS (PRUCALOPRIDE)
1964	RESOLOR 2MG TABLETS (PRUCALOPRIDE)
1965	RESONIUM 30G/120ML ENEMA (SODIUM POLYSTYRENE SULFONATE)
1966	RESOURCE 2.0 237ML SOLUTION (MILK SUBSTITUE)
1967	RESOURCE BREEZE/FRUIT BEVERAGE 237ML LIQUID (MILK SUBSTITUE)
1968	RESOURCE DIABETIC 237ML LIQUID (MILK SUBSTITUE)
1969	RESOURCE PLUS 237ML LIQUID (MILK SUBSTITUTE)
1970	RESOURCE STANDARD 237ML LIQUID (MILK SUBSTITUE)
1971	RESTORE 1 BILLION CFU SACHETS (FRUCTOOLIGOSACCHARIDE-PROBIOTIC)
1972	RETIN A 0.025% 15GM GEL (TRETINOIN)
1973	RETIN A 0.025% 20GM CREAM (TRETINOIN)
1974	RETIN A 0.05% 20GM CREAM (TRETINOIN)
1975	RETIN A 0.1% 20GM CREAM (TRETINOIN)
1976	RETROVIR 100MG CAPSULES (ZIDOVUDINE)
1977	REVICON FORTE TABLETS (MULTIVITAMINS &MINERALS)
1978	RHINATHIOL ADULT 250MG/5ML SYRUP (CARBOCYSTEINE)
1979	RHINATHIOL INFANT 100MG/5ML SYRUP
1980	RHINATHIOL INFANT 100MG/5ML SYRUP (CARBOCYSTEINE)
1981	RHINATHIOL-PROMETHAZINE SYRUP (CARBOCYSTEINE-PROMETHAZINE)
1982	RHINATHIOL-PROMETHAZINE SYRUP
1983	RHINIRAMINE 2mg/5mL SYRUP (DEXCHLORPHENIRAMINE)
1984	RHINOCORT AQUA 32MCG/DOSE (120d) NASAL SPRAY (BUDESONIDE AQUEOUS)
1985	RHINOCORT AQUA 64MCG/DOSE (120d) NASAL SPRAY (BUDESONIDE AQUEOUS)
1986	RHINOCORT NASAL TURBUHALER 100MCG/DOSE 200D (BUDESONIDE)
1987	RIDWIND BABY 100mg/mL DROPS (SIMETHICONE)
1988	RID-WIND BABY DROP 30ML DROPS (SIMETHICONE)
1989	RIFAMPICIN 150MG CAPSULES
1990	RIFAMPICIN 600MG INJECTION
1991	RIFAXIMIN 200MG TABLETS
1992	RINGER (BAG) 1000ML INFUSION (RINGER'S INJECTION BP)
1993	RINGER (BAG) 500 ML INFUSION (RINGERS)
1994	RISPERDAL 1MG TABLETS
1995	RISPERDAL 1MG TABLETS (RISPERIDONE)
1996	RISPERDAL 1MG/ML 30ML SOLUTION (RISPERIDONE)
1997	RISPERDAL 2MG TABLETS (RISPERIDONE)
1998	RISPERDAL CONSTA 25MG INJECTION (RISPERIDONE)
1999	RISPERDAL CONSTA 37.5MG INJECTION (RISPERIDONE)
2000	RITALIN 10MG TABLETS (METHYLPHENIDATE)
2001	RITALIN LA 20MG CAPSULES (METHYLPHENIDATE SR)
2002	RITALIN SR 20MG TABLETS (METHYLPHENIDATE SR)
2003	ROACCUTANE 10MG CAPSULES (ISOTRETINOIN)
2004	ROACCUTANE 20MG CAPSULES (ISOTRETINOIN)
2005	ROBITUSSIN DM SYRUP (DEXTROMETHORPHAN-GUAIPHENESIN)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
2006	ROBITUSSIN EX 100 MG/5 ML SYRUP (GUAIPHENESIN)
2007	ROBITUSSIN PS SYRUP (PSEUDOEPHRINE-GUIFENESIN)
2008	ROCALTROL 0.25 MCG CAPSULES
2009	ROCALTROL 0.25 MCG CAPSULES (CALCITRIOL)
2010	ROCEPHINE IM 1G INJECTION (CEFTRIAXONE)
2011	ROCEPHINE IM 250MG INJECTION (CEFTRIAXONE)
2012	ROCEPHINE IM 500MG INJECTION (CEFTRIAXONE)
2013	ROCEPHINE IV 1G INJECTION (CEFTRIAXONE)
2014	ROCEPHINE IV 250MG INJECTION (CEFTRIAXONE)
2015	ROCEPHINE IV 500MG INJECTION (CEFTRIAXONE)
2016	ROMITEXAN 400MG/4ML INJECTION (MESNA)
2017	ROSIDEN 0.5% 60GM GEL (PIROXICAM)
2018	ROVACOR 20MG TABLETS (LOVASTATIN)
2019	ROVAMYCINE 500MG/1.5MIU TABLETS (SPIRAMYCIN)
2020	ROZEX 0.75% 15G GEL (METRONIDAZOLE)
2021	RYTMONORM 150MG TABLETS (PROPAFENONE)
2022	SALAGEN 5MG TABLETS (PILOCARPINE)
2023	SALAZOPYRIN EN 500 MG TABLETS (SULPHASALAZINE)
2024	SALBUTAMOL (PER ML) 0.5% SOLUTION (SALBUTAMOL)
2025	SALBUTAMOL 0.5% (10ml) RESPIRATOR SOLUTION (SALBUTAMOL)
2026	SALBUTAMOL 0.5% (BOT) RESPIRATOR SOLUTION
2027	SALICYLIC ACID 1% (in alcohol) 100ML EAR DROPS
2028	SALICYLIC ACID 10% OINTMENT (SALICYLIC ACID)
2029	SALICYLIC ACID 2% (in alcohol) 100ML EAR DROPS
2030	SALOFALK 250MG SUPPOSITORIES (MESALAZINE)
2031	SALOFALK 2G/30ML ENEMA (MESALAZINE)
2032	SALOFALK 500MG SUPPOSITORIES (MESALAZINE)
2033	SALOFALK 500MG TABLETS (MESALAZINE)
2034	SALT 300MG TABLETS
2035	SALT 300MG TABLETS (SODIUM CHLORIDE)
2036	SALT FOR SITZ BATH (50g) POWDER (SODIUM CHLORIDE)
2037	SANDIMMUM 500MG/5ML (50ML) SYRUP (CYCLOSPORIN)
2038	SANDIMMUN 100MG CAPSULES (CYCLOSPORIN)
2039	SANDIMMUN 10MG CAPSULES (CYCLOSPORIN)
2040	SANDIMMUN 25MG CAPSULES (CYCLOSPORIN)
2041	SANDIMMUN 50 MG/ML INJECTION (CYCLOSPORIN)
2042	SANDOSTATIN 0.1MG/ML INJECTION (OCTREOTIDE)
2043	SANGOBION CAPSULES (FERROUS GLUCONATE)
2044	SANGOBION CAPSULES
2045	SAPHRIS 10MG S/L TABLETS (ASENAPINE)
2046	SAPHRIS 5MG S/L TABLETS (ASENAPINE)
2047	SARGRAMOSTIM 500MCG INJECTION
2048	SARNA 222ML LOTION (CAMPHOR-MENTHOL-PHENOL)
2049	SCHILLERS IODINE SOLUTION
2050	SEBAMED MOISTURIZING BODY 200ML LOTION
2051	SEBIVO 600MG TABLETS (TELBIVUDINE)
2052	SECURA MOISTURISING CLEANSER SOLUTION
2053	SECURA PROTECTIVE 78G CREAM
2054	SECURA PROTECTIVE 78G CREAM (ZINC OXIDE)
2055	SELEGILINE 5MG TABLETS
2056	SELSUN 125ML SHAMPOO (SELENIUM SULPHIDE)
2057	SENOKOT TABLETS (SENNOSIDE B)
2058	SENOKOT TABLETS
2059	SEPTOPAL CHAIN BEADS (30 beads) (GENTAMICIN BEADS)
2060	SERETIDE 50MCG/100MCG ACCUHALER (SALMETEROL, FLUTICASONE)
2061	SERETIDE 50MCG/250MCG ACCUHALER (SALMETEROL, FLUTICASONE)
2062	SERETIDE 50MCG/500MCG ACCUHALER (SALMETEROL,FLUTICASONE)
2063	SERETIDE EVO 25MCG/125MCG INHALER (SALMETEROL, FLUTICASONE)
2064	SERETIDE EVO 25MCG/250MCG INHALER (SALMETEROL, FLUTICASONE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
2065	SERETIDE EVO 25MCG/50MCG INHALER (SALMETEROL, FLUTICASONE)
2066	SEROQUEL 100MG TABLETS (QUETIAPINE)
2067	SEROQUEL 25MG TABLETS
2068	SEROQUEL 25MG TABLETS (QUETIAPINE)
2069	SEROQUEL XR 200MG TABLETS (QUETIAPINE SR)
2070	SEROQUEL XR 300MG TABLETS (QUETIAPINE SR)
2071	SEROQUEL XR 50MG TABLETS (QUETIAPINE SR)
2072	SEROXAT CR 12.5MG TABLETS (PAROXETINE CR)
2073	SEROXAT CR 25MG TABLETS (PAROXETINE CR)
2074	SERRATIOPEPTIDASE 5MG TABLETS (SERRAPEPTASE)
2075	SERTRALINE 50MG CAPSULES
2076	SEVORANE (per ml) SOLUTION (SEVOFLURANE)
2077	SEVORANE 250mL SOLUTION (SEVOFLURANE)
2078	SHINCORT 40MG/ML (IM) INJECTION (TRIAMCINOLONE)
2079	SHINCORT 50MG/5ML (IA) INJECTION (TRIAMCINOLONE)
2080	SIFROL 0.125MG TABLETS (PRAMIPEXOLE)
2081	SIFROL ER 0.375MG TABLETS (PRAMIPEXOLE)
2082	SILESSE SKIN BARRIER WIPES
2083	SILICON 50GM CREAM (SILICONE)
2084	SILICONE OIL FOR EYE (1300) (SILICONE OIL)
2085	SILICONE OIL FOR EYE (5700) (SILICONE OIL)
2086	SILVIN 50GM CREAM (SILVER SULPHADIAZINE)
2087	SIMEPAR CAPSULES (SILYMARIN, VIT B)
2088	SIMULECT 20MG INJECTION (BASILIXIMAB)
2089	SIMVASTATIN 10MG TABLETS
2090	SIMVASTATIN 20MG TABLETS
2091	SINEMET CR 50MG/200MG TABLETS (LEVODOPA-CARBIDOPA CR)
2092	SINGULAIR 10MG TABLETS
2093	SINGULAIR 10MG TABLETS (MONTELUKAST)
2094	SINGULAIR 4MG TABLETS
2095	SINGULAIR 4MG TABLETS (MONTELUKAST)
2096	SINGULAIR 5MG TABLETS (MONTELUKAST)
2097	SINGULAIR GRANULES 4MG SACHETS (MONTELUKAST)
2098	SINUPRET SYRUP
2099	SINUPRET TABLETS (HERBAL REMEDY)
2100	SKINOREN 20% CREAM (AZELAIC ACID)
2101	SMECTA SACHETS (DIOCTAHEDRAL SMECTITE)
2102	SMECTA SACHETS
2103	SODIUM ACETATE 20 MMOL INJECTION
2104	SODIUM BICARBONATE (per g) POWDER
2105	SODIUM BICARBONATE 500MG CAPSULES
2106	SODIUM BICARBONATE 8.4% 20ML INJECTION (SODIUM BICARBONATE)
2107	SODIUM BICARBONATE 8.4% 250ML INFUSION (SODIUM BICARBONATE)
2108	SODIUM BICARBONATE 8.4% 20ML INJECTION
2109	SODIUM BICARBONATE 8.4% 250ML INFUSION
2110	SODIUM CHLORIDE 0.45% 500ML INFUSION (SODIUM CHLORIDE)
2111	SODIUM CHLORIDE 0.9% 1000ML (BOTT) INFUSION (SODIUM CHLORIDE)
2112	SODIUM CHLORIDE 0.9% 100ML (GLASS) INFUSION (SODIUM CHLORIDE Glass)
2113	SODIUM CHLORIDE 0.9% 100ML INFUSION
2114	SODIUM CHLORIDE 0.9% 100ML SOLUTION
2115	SODIUM CHLORIDE 0.9% 10ML INJECTION (SODIUM CHLORIDE (Plastic))
2116	SODIUM CHLORIDE 0.9% 1L (BRAUN) IRRIGATION
2117	SODIUM CHLORIDE 0.9% 1L IV (BAXTER) INFUSION
2118	SODIUM CHLORIDE 0.9% 20mL INJECTION (SODIUM CHLORIDE (Plastic))
2119	SODIUM CHLORIDE 0.9% 250ML INFUSION
2120	SODIUM CHLORIDE 0.9% 3L IRRIGATION
2121	SODIUM CHLORIDE 0.9% 500ML (BAG) INFUSION (SODIUM CHLORIDE (BAG))
2122	SODIUM CHLORIDE 0.9% 500ML (BOT) INFUSION (SODIUM CHLORIDE (BOTT))
2123	SODIUM CHLORIDE 0.9% 500ML (BRAUN) IRRIGATION (SODIUM CHLORIDE)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
2124	SODIUM CHLORIDE 0.9% 50ML INFUSION
2125	SODIUM CHLORIDE 0.9% 50ML INFUSION (SODIUM CHLORIDE)
2126	SODIUM CHLORIDE 0.9% EYE DROPS (SODIUM CHLORIDE)
2127	SODIUM CHLORIDE 20% 10ML INJECTION
2128	SODIUM CHLORIDE 3% 500ML INFUSION (SODIUM CHLORIDE)
2129	SODIUM CHLORIDE 5% 5G EYE OINTMENT
2130	SODIUM CHLORIDE 0.45% 500ML INFUSION
2131	SODIUM CHLORIDE 0.9% 10ML INJECTION
2132	SODIUM CHLORIDE 0.9% 20mL INJECTION
2133	SODIUM CHLORIDE 3% 500ML INFUSION
2134	SODIUM GLYCEROL PHOSPHATE 20MMOL/20ML INJECTION
2135	SODIUM IODIDE 1 GM/10 ML INJECTION
2136	SODIUM POLYSTYRENE 15G / 60ML SOLUTION
2137	SODIUM POLYSTYRENE 15G / 60ML SOLUTION (SODIUM POLYSYTRENE SULFONATE)
2138	SODIUM THIOSULPHATE 25% 100ML INJECTION
2139	SODIUM THIOSULPHATE 25% 50ml INJECTION
2140	SOFRADEX 8 ML EYE DROPS
2141	SOLCOSERYL 10% 20GM JELLY
2142	SOLCOSERYL 5% 20GM OINTMENT (SOLCOSERYL)
2143	SOLCOSERYL DENTAL 5G PASTE (SOLCOSERYL-POLIDOCANOL)
2144	SOLCOSERYL EYE 5 GM GEL (SOLCOSERYL)
2145	SOLIAN 200MG TABLETS (AMISULPRIDE)
2146	SOLU-MEDROL 500 MG INJECTION
2147	SOLU-MEDROL 500 MG INJECTION (METHYLPREDNISOLONE SODIUM SUCCINATE)
2148	SOLUVIT N 10 ML INJECTION (MULTIVITAMIN)
2149	SOLUWAX 10ML EAR DROPS (DOCUSATE SODIUM)
2150	SOTALOL 80MG TABLETS
2151	SPERSALLERG 10 ML EYE DROPS (ANTAZOLINE-TETRAHYDROZOLINE)
2152	SPIRIVA COMBOPACK 18MCG CAPSULES (TIOTROPIUM)
2153	SPIRIVA INHALATION 18MCG CAPSULES (TIOTROPIUM)
2154	SPIRIVA RESPIMAT 2.5MCG INHALER (TIOTROPIUM)
2155	SPONGOSTAN 1 PIECE DRESSING (GELATIN SPONGE)
2156	SPORANOX 100 MG CAPSULES (ITRACONAZOLE)
2157	SPORANOX 10MG/ML SOLUTION (ITRACONAZOLE)
2158	STABLON 12.5MG TABLETS (TIANEPTINE)
2159	STALEVO 100/25/200MG TABLETS (LEVODOPA-CARBIDOPA-ENTACAPONE)
2160	STARLIX 120MG TABLETS (NATEGLINIDE)
2161	STEMETIL 12.5MG/ML INJECTION
2162	STEMETIL 12.5MG/ML INJECTION (PROCHLORPERAZINE)
2163	STEMETIL 5 MG TABLETS (PROCHLORPERAZINE)
2164	STERIMAR 50ML NASAL SPRAY (SEA WATER)
2165	STERIMAR BABY (0-3YRS) MICROSPRAY NASAL SPRAY (SEA WATER)
2166	STESOLID 5MG RECTAL TUBE (DIAZEPAM)
2167	STIEMYCIN 2% 25ML SOLUTION (ERYTHROMYCIN)
2168	STIEPROX 1.5% 150ML SHAMPOO (CICLOPIROX OLAMINE)
2169	STILAMIN 3000 MCG INJECTION (SOMATOSTATIN)
2170	STILNOX CR 12.5MG TABLETS
2171	STILNOX CR 12.5MG TABLETS (ZOLPIDEM CR)
2172	STILNOX CR 6.25MG TABLETS
2173	STILNOX CR 6.25MG TABLETS (ZOLPIDEM CR)
2174	STOCRIN 600MG TABLETS (EFAVIRENZ)
2175	STRATTERA 10MG CAPSULES (ATOMOXETINE)
2176	STRATTERA 40MG CAPSULES (ATOMOXETINE)
2177	STREPSIL 6'S LOZENGES (DICHLOROBENZYL ALCOHOL CPD)
2178	STREPTASE 1500000 int.unit INJECTION (STREPTOKINASE)
2179	STREPTOMYCIN 1 GM INJECTION
2180	STROCAIN TABLETS (OXETACAINE-POLYMIGEL)
2181	STROMECTOL 3MG TABLETS (IVERMECTIN)
2182	STRUCTOKABIVEN CENTRAL 1477ml INFUSION (TPN)

Sr	Item Description
2183	STRUCTOKABIVEN CENTRAL 1970ML INFUSION (TPN)
2184	STUGERON 25MG TABLETS
2185	STUGERON 25MG TABLETS (CINNARIZINE)
2186	SUCRALFATE 1G TABLETS
2187	SUFENTA FORTE 0.25MG/5ML INJECTION (SUFENTANYL)
2188	SULINDAC 200MG TABLETS
2189	SULPHADIAZINE 500MG TABLETS
2190	SUPLENA 237ML LIQUID
2191	SUPLENA 237ML LIQUID (MILK SUBSTITUTE)
2192	SURBEX 750 WITH ZINC TABLETS (MULTI-VITAMIN)
2193	SURVANTA 25MG/ML (8ML) SUSPENSION (BERACTANT)
2194	SUSTANON 1ML INJECTION (TESTOSTERONE ESTERS)
2195	SYMBICORT 160/4.5MCG (60doses) TURBUHALER (BUDESONIDE-FORMOTEROL)
2196	SYMMETREL 100MG CAPSULES (AMANTADINE)
2197	SYNACTHEN 0.25MG/ML INJECTION (TETRACOSACTRIN)
2198	SYNFLEX 275MG TABLETS
2199	SYNFLEX 275MG TABLETS (NAPROXEN SODIUM)
2200	SYNTOCINON 10 int.Unit/ML INJECTION (OXYTOCIN)
2201	SYNTOMETRINE 1 ML INJECTION (OXYTOCIN-ERGOMETRINE)
2202	TACHOCOMB 2.5x3CM DRESSING (FIBRINOGEN,THROMBIN, APROTININ)
2203	TACHOSIL 2.5x3CM DRESSING
2204	TACHOSIL 9.5x4.8CM DRESSING
2205	TAFLOTAN 0.0015% 2.5ml EYE DROPS (TAFLUPROST)
2206	TALCUM 4G POWDER (TALC STERILE)
2207	TAMBOCOR 100MG TABLETS (FLECAINIDE)
2208	TAMIFLU 30MG CAPSULES (OSELTAMIVIR)
2209	TAMIFLU 45MG CAPSULES (OSELTAMIVIR)
2210	TAMIFLU 75MG CAPSULES (OSELTAMIVIR)
2211	TAMOXIFEN 10MG TABLETS
2212	TAMOXIFEN 20MG TABLETS
2213	TANAKAN 40 MG TABLETS
2214	TANAKAN 40 MG TABLETS (GINKGO BILOBA)
2215	TANATRIL 5MG TABLETS (IMIDAPRIL)
2216	TARGIN 10MG/5MG TABLETS (OXYCODONE-NALOXONE)
2217	TARGIN 20MG/10MG TABLETS (OXYCODONE-NALOXONE)
2218	TARGIN 5MG/2.5MG TABLETS (OXYCODONE-NALOXONE)
2219	TARGOCID 200 MG INJECTION
2220	TARGOCID 200 MG INJECTION (TEICOPLANIN)
2221	TARIVID 100MG TABLETS (OFLOXACIN)
2222	TARIVID 3MG/ML 5ML EAR DROPS
2223	TARIVID 3MG/ML 5ML EAR DROPS (OFLOXACIN)
2224	TAZOBACTAM-PIPERACILLIN 4.5G INJECTION
2225	TAZOCIN 4.5 GM INJECTION
2226	TAZOCIN 4.5 GM INJECTION (PIPERACILLIN-TAZOBACTAM)
2227	TEARS NATURALE EYE FREE 32'S EYE DROPS (DUASORB)
2228	TEARS NATURALE FREE 0.8ML (EACH) EYE DROPS (DUASORB)
2229	TEARS NATURALE II 15ML EYE DROPS
2230	TEARS NATURALE II 15ML EYE DROPS (DUASORB)
2231	TEBONIN FORTE 120MG TABLETS (GINGKO BILOBA)
2232	TEGADERM (PHARMACY) 10CMX12CM DRESSING (POLYURETHANE)
2233	TEGADERM (PHARMACY) 6CMx7CM DRESSING (POLYURETHANE)
2234	TEGADERM 15CMX20CM DRESSING (POLYURETHANE)
2235	TEGADERM CHG 8.5X11.5CM DRESSING
2236	TEGRETOL 100MG/5ML SYRUP (CARBAMAZEPINE)
2237	TEGRETOL 200MG TABLETS
2238	TEGRETOL 200MG TABLETS (CARBAMAZEPINE)
2239	TEGRETOL CR 200MG TABLETS (CARBAMAZEPINE CR)
2240	TEGRETOL CR 400MG TABLETS (CARBAMAZEPINE CR)
2241	TELFAST 180MG TABLETS

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
2242	TELFAST 180MG TABLETS (FEXOFENADINE)
2243	TELFAST D TABLETS (FEXOFENADINE-PSEUDOEPHEDRINE)
2244	TEMODAL 100MG TABLETS (TEMOZOLAMIDE)
2245	TEMODAL 20MG TABLETS (TEMOZOLAMIDE)
2246	TENORMIN 100 MG TABLETS (ATENOLOL)
2247	TENORMIN 25MG TABLETS
2248	TENORMIN 25MG TABLETS (ATENOLOL)
2249	TENORMIN 50MG TABLETS
2250	TENORMIN 50MG TABLETS (ATENOLOL)
2251	TERBUTALINE 1.5MG/5ML ELIXIR
2252	TERBUTALINE 2.5MG TABLETS
2253	TERRAMYCIN 3.5 GM EYE OINTMENT (OXYTETRACYCLINE-POLYMIXIN)
2254	TERTROXIN 20MCG TABLETS (LIOTHYRONINE)
2255	TETANUS (single dose) VACCINE
2256	TETANUS IMMUNOGLOBULIN 250 int.unit INJECTION
2257	TETRABENAZINE 25MG TABLETS
2258	TETRACAINE 0.5% MINIMS-EYEDROPS (AMETHOCAINE)
2259	TETRACAINE 1% MINIMS-EYEDROPS (AMETHOCAINE)
2260	TETRACYCLINE 250MG CAPSULES
2261	TETRACYCLINE 3% 15G OINTMENT
2262	THALIDOMIDE 50MG CAPSULES
2263	THEOPHYLLINE 100MG TABLETS
2264	THEOPHYLLINE LA 200MG TABLETS (THEOPHYLLINE SR)
2265	THIAMINE 100MG/ML INJECTION
2266	THICK & EASY 227 GM POWDER (MODIFE FOOD STARCH, MALTODEXTRIN)
2267	THIOGUANINE 40MG TABLETS
2268	THIOPENTONE 0.5 GM INJECTION (THIOPENTONE SODIUM)
2269	THIOPENTONE 1G INJECTION
2270	THROMBOSTAT 5000 UNIT POWDER
2271	THROMBOSTAT 5000 UNIT POWDER (THROMBIN)
2272	THYMOGLOBULIN 25MG/5ML INJECTION (ANTITHYMOCYTE IMMUNOGLOBULIN (Rabbit)10)
2273	THYMOL (per bottle) MOUTHWASH (THYMOL CPD GLYCERIN)
2274	THYMOL 30 ML MOUTHWASH
2275	THYROZOL 10MG TABLETS (THIAMAZOLE)
2276	THYROZOL 5MG TABLETS (THIAMAZOLE)
2277	TICLID 250MG TABLETS
2278	TICLID 250MG TABLETS (TICLOPIDINE)
2279	TIENAM IV 0.5G INJECTION
2280	TIENAM IV 0.5G INJECTION (IMIPENEM-CILASTATIN)
2281	TIMOLOL 0.5% EYE DROPS
2282	TIMOPTOL 0.5% 5ML EYE DROPS (TIMOLOL)
2283	TIMOPTOL XE 0.5% 2.5ML EYE DROPS (TIMOLOL MALEATE IN GELLAN SOLUTION)
2284	TISEPT 100ML SOLUTION (CHLORHEXIDINE-CETRIMIDE)
2285	TISSEEL 1 ML SOLUTION (FIBRINOGEN)
2286	TISSEEL 2 ML SOLUTION (FIBRINOGEN)
2287	TISSEEL 5 ML SOLUTION (FIBRINOGEN)
2288	TOBRADEX 3.5 GM EYE OINTMENT (TOBRAMYCIN-DEXAMETHASONE)
2289	TOBRADEX 5 ML EYE DROPS (TOBRAMYCIN-DEXAMETHASONE)
2290	TOBREX 0.3% 3.5G EYE OINTMENT (TOBRAMYCIN)
2291	TOBREX 0.3% 5ML EYE DROPS
2292	TOBREX 0.3% 5ML EYE DROPS (TOBRAMYCIN)
2293	TOLBUTAMIDE 500MG TABLETS
2294	TOMIDATE 20MG/10ML INJECTION
2295	TOPAMAX 100MG TABLETS (TOPIRAMATE)
2296	TOPAMAX 25MG TABLETS (TOPIRAMATE)
2297	TOPAMAX 50MG TABLETS (TOPIRAMATE)
2298	TPN-NEONATAL NO LIPID (TPN)
2299	TPN-NEONATAL WITH LIPID (TPN)
2300	TPN-PAED NO LIPID (TPN)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
2301	TPN-PAED WITH LIPID (TPN)
2302	TPN-WITH FAT (MEH) OUT-PT INFUSION (TPN)
2303	TPN-WITH FAT (TPN)
2304	TPN-WITH GLUTAMINE (TPN)
2305	TPN-WITHOUT FAT (TPN)
2306	TRACE ELEMENT 10 ML INJECTION
2307	TRACE ELEMENT 10 ML INJECTION (TRACE ELEMENTS Cu,Mn,Cr,Zn (BL))
2308	TRACHISAN LOZENGES (TYROTHRICIN, CHLORHEX, LIGNOCAINE)
2309	TRACHISAN LOZENGES
2310	TRACRIUM 50mg/5mL INJECTION (ATRACURIUM)
2311	TRAJENTA 5MG TABLETS (LINAGLIPTIN)
2312	TRAMADOL 50MG CAPSULES
2313	TRAMADOL 50MG/ML INJECTION
2314	TRANDATE 25 MG/5 ML INJECTION
2315	TRANDATE 25 MG/5 ML INJECTION (LABETOLOL)
2316	TRANXENE 5MG CAPSULES
2317	TRANXENE 5MG CAPSULES (CLORAZEPATE)
2318	TRAVATAN 0.004% 2.5ML EYE DROPS (TRAVOPROST)
2319	TRAVOCORT 10G CREAM (ISOCONAZOLE, DIFLUCOTOLONE)
2320	TRAVOGEN 20G CREAM (ISOCONAZOLE)
2321	TREDAPTIVE 1G/20MG TABLETS (NICOTINIC ACID-LAROPIPRANT)
2322	TRENTAL 400 MG TABLETS (PENTOXIFYLLINE SR)
2323	TRIAMCINOLONE 0.1% 15G CREAM
2324	TRIAMCINOLONE ORAL 0.1% PASTE (TRIAMCINOLONE in ORABASE)
2325	TRIAMCINOLONE ORAL 0.1% PASTE
2326	TRIDERM 15G CREAM (BETAMETHASONE, GENTAMYCIN,CLOTRIMAZOLE)
2327	TRIFLUOPERAZINE 1MG TABLETS (TRIFLUOPERAZINE)
2328	TRIFLUOPERAZINE 5MG TABLETS
2329	TRIMETHOPRIM 50MG/5ML SUSPENSION
2330	TRISEQUENS 28's/pack TABLETS (ESTRADIOL-NORETHISTERONE)
2331	TRITACE 2.5MG TABLETS
2332	TRITACE 2.5MG TABLETS (RAMIPRIL)
2333	TRITACE 5MG TABLETS (RAMIPRIL)
2334	TRITTICO 50MG TABLETS (TRAZODONE)
2335	TROPICAMIDE 1% 0.5ML MINIMS-EYEDROPS (TROPICAMIDE)
2336	TRUSOPT 2% 5ML EYE DROPS (DORZOLAMIDE HYDROCHLORIDE)
2337	TRYPTANOL 10 MG TABLETS
2338	TUBERCULIN PPD 2TU/0.1ML INJECTION
2339	TUSSIL 24'S LOZENGES (DEXTROMETHORPHAN)
2340	TUSSIL 5 6'S LOZENGES (DEXTROMETHORPHAN)
2341	TWINRIX 1ML INJECTION (HEPATITIS A & B)
2342	TWYNSTA 40MG/10MG TABLETS (TELMISARTAN-AMLODIPINE)
2343	TWYNSTA 40MG/5MG TABLETS (TELMISARTAN-AMLODIPINE)
2344	TWYNSTA 80MG/10MG TABLETS (TELMISARTAN-AMLODIPINE)
2345	TWYNSTA 80MG/5MG TABLETS (TELMISARTAN-AMLODIPINE)
2346	TYGACIL 50MG INJECTION
2347	TYGACIL 50MG INJECTION (TIGECYCLINE)
2348	TYPHIM VI 0.025MG/0.5ML VACCINE (TYPHOID VI)
2349	UBRETID 5MG TABLETS
2350	UBRETID 5MG TABLETS (DISTIGMINE)
2351	ULTIVA 1MG INJECTION (REMIFENTANIL)
2352	ULTRACARBON 250MG TABLETS
2353	ULTRACARBON 250MG TABLETS (CHARCOAL ACTIVATED)
2354	ULTRACET TABLETS (PARACETAMOL-TRAMADOL)
2355	ULTRACET TABLETS
2356	UNASYN 1.5 GM INJECTION
2357	UNASYN 1.5 GM INJECTION (AMPICILLIN - SULBACTAM)
2358	UNASYN 250MG/5ML 30ML SUSPENSION (AMPICILLIN - SULBACTAM)
2359	UNASYN 375MG TABLETS

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
2360	UNASYN 375MG TABLETS (AMPICILLIN-SULBACTAM)
2361	UNASYN 750 MG INJECTION (AMPICILLIN - SULBACTAM)
2362	UNIFIBER 4G SACHETS (CELLULOSE, CORN SYR, XANTHAN)
2363	UNISEPT 100ML SOLUTION (CHLORHEXIDINE GLUCONATE)
2364	UNISEPT 25ML SOLUTION (CHLORHEXIDINE GLUCONATE)
2365	UREA 100G CREAM
2366	URGOTUL 10CM X 10CM DRESSING (LIPIDO-COLLOID CONTACT LAYER)
2367	URGOTUL S.S.D 10CM X 12CM DRESSING (LIPIDO-COLLOID CONTACT LAYER-SULFADIAZI
2368	URISPAS 200MG TABLETS
2369	URISPAS 200MG TABLETS (FLAVOXATE)
2370	UROCIT K 1080MG (10MEQ) TABLETS (POT CITRATE)
2371	UROGESIC 100 MG TABLETS
2372	UROGESIC 100 MG TABLETS (PHENAZOPYRIDINE)
2373	UROKINASE 60,000 int.unit INJECTION
2374	UROTRACTIN 400MG CAPSULES (PIPEMIDIC ACID)
2375	URSOFALK 250 MG CAPSULES
2376	URSOFALK 250 MG CAPSULES (URSODEOXYCHOLIC ACID)
2377	UTROGESTAN 100MG CAPSULES (PROGESTERONE)
2378	VAGIFEM 25MCG VAGINAL TABLETS (OESTRADIOL)
2379	VALCYTE 450MG TABLETS (VALGANCICLOVIR)
2380	VALDOXAN 25MG TABLETS (AGOMELATINE)
2381	VALENS CARBORIE 350G POWDER (GLUCOSE POLYMER)
2382	VALTREX 500MG TABLETS (VALACICLOVIR)
2383	VAMINOLACT 100ML INFUSION (AMINOACIDS, NITROGEN)
2384	VAMINOLACT 500ML INFUSION (AMINO ACID)
2385	VANCOMYCIN 500 MG INJECTION
2386	VANCOMYCIN 500 MG INJECTION (VANCOMYCIN)
2387	VARICELLA ZOSTER 125IU (IVIG) INJECTION
2388	VARILRIX 0.5ML VACCINE (VARICELLA VIRUS VACCINE)
2389	VASELINE 3.75OZ OINTMENT (PARAFFIN WHITE SOFT)
2390	VASOPRESSIN 20 unit/ml INJECTION
2391	VASTAREL 20MG TABLETS
2392	VASTAREL 20MG TABLETS (TRIMETAZIDINE)
2393	VASTAREL MR 35MG TABLETS
2394	VASTAREL MR 35MG TABLETS (TRIMETAZIDINE SR)
2395	VAXIGRIP 0.5ML INJECTION (INFLUENZA (TEX,GUAN,HARB))
2396	VENOFER 100MG/5ML INJECTION (IRON SUCROSE)
2397	VENTOLIN 2 MG/5 ML SYRUP (SALBUTAMOL)
2398	VENTOLIN 2.5MG/2.5ML NEBULES (SALBUTAMOL)
2399	VENTOLIN 200MCG ACCUHALER (SALBUTAMOL)
2400	VENTOLIN 2MG TABLETS
2401	VENTOLIN 2MG TABLETS (SALBUTAMOL)
2402	VENTOLIN 5 MG/5 ML INJECTION
2403	VENTOLIN 5 MG/5 ML INJECTION (SALBUTAMOL)
2404	VENTOLIN 5MG/ML (10ML) RESPIRATOR SOLUTION
2405	VENTOLIN 5MG/ML (10ML) RESPIRATOR SOLUTION (SALBUTAMOL)
2406	VENTOLIN EVO 100 MCG/DOSE INHALER
2407	VENTOLIN EVO 100 MCG/DOSE INHALER (SALBUTAMOL)
2408	VENTOLIN 2.5MG/2.5ML NEBULES
2409	VERAGEL TABLETS (SIMETHICONE,DICYCLOMINE, ALUMINIUM, MAG)
2410	VERAGEL TABLETS
2411	VERAPAMIL 40MG TABLETS
2412	VERAPAMIL 5MG/2ML INJECTION
2413	VERRUMAL 13ML SOLUTION (DIMETHYLSULPHOXIDE,FU,SALICYCLIC ACID)
2414	VFEND 200MG INJECTION (VORICONAZOLE)
2415	VFEND 200MG TABLETS (VORICONAZOLE)
2416	VFEND 40MG/ML 70ML SUSPENSION (VORICONAZOLE)
2417	VFEND* 200MG INJECTION (VORICONAZOLE)
2418	VFEND* 200MG TABLETS

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
2419	VFEND* 200MG TABLETS (VORICONAZOLE)
2420	VIAGRA 100MG TABLETS (SILDENAFIL)
2421	VIAGRA 50MG TABLETS (SILDENAFIL)
2422	VIARTRIL-S 1500MG SACHETS (GLUCOSAMINE)
2423	VIARTRIL-S 250MG CAPSULES (GLUCOSAMINE)
2424	VIARTRIL-S 500MG CAPSULES (GLUCOSAMINE)
2425	VIDISIC 10 GM GEL (CARBOMER 940)
2426	VIGAMOX 0.5% 5ML EYE DROPS (MOXIFLOXACIN)
2427	VISCOAT 0.75ML INJECTION (CHONDROITIN - HYALURONATE)
2428	VITA EPA 1000MG CAPSULES (OMEGA TRIGLYCERIDES)
2429	VITACAL+D 250MG TABLETS
2430	VITACAL+D 250MG TABLETS (CAL CARB/VIT D)
2431	VITALIPID N ADULT INJECTION (MULTIVITE(VIT A,D2,E,K))
2432	VITALIPID N INFANT INJECTION (MULTI-VITAMIN PAEDIATRIC)
2433	VITAMIN A 10000 int.unit CAPSULES
2434	VITAMIN B COMPLEX TABLETS
2435	VITAMIN B COMPLEX TABLETS
2436	VITAMIN B1 100 MG TABLETS (THIAMINE)
2437	VITAMIN B1 10MG TABLETS (THIAMINE)
2438	VITAMIN B12 10 MG/10 ML INJECTION (CYANOCOBALAMIN)
2439	VITAMIN B12 100MCG TABLETS (CYANOCOBALAMIN)
2440	VITAMIN B2 5MG TABLETS (RIBOFLAVINE)
2441	VITAMIN B6 10MG TABLETS (PYRIDOXINE)
2442	VITAMIN B6 50MG TABLETS (PYRIDOXINE)
2443	VITAMIN C 100MG TABLETS (ASCORBIC ACID)
2444	VITAMIN C 250MG TABLETS (ASCORBIC ACID)
2445	VITAMIN C 500 MG/5 ML INJECTION (ASCORBIC ACID)
2446	VITAMIN C 500MG TABLETS
2447	VITAMIN C 500MG TABLETS (ASCORBIC ACID)
2448	VITAMIN C SR 1G TABLETS (ASCORBIC ACID)
2449	VITAMIN D3 25MCG (1000IU) TABLETS (CHOLECALCIFEROL)
2450	VITAMIN E 100G CREAM
2451	VITAMIN E 200 I.U. CAPSULES
2452	VITAMIN E 400IU CAPSULES
2453	VOLTAREN 12.5MG SUPPOSITORIES
2454	VOLTAREN 12.5MG SUPPOSITORIES (DICLOFENAC)
2455	VOLTAREN 20G GEL (DICLOFENAC)
2456	VOLTAREN 20G GEL
2457	VOLTAREN 25MG SUPPOSITORIES
2458	VOLTAREN 25MG SUPPOSITORIES (DICLOFENAC)
2459	VOLTAREN 50MG SUPPOSITORIES
2460	VOLTAREN 50MG SUPPOSITORIES (DICLOFENAC)
2461	VOLTAREN 50MG TABLETS (DICLOFENAC)
2462	VOLTAREN 75 MG/3 ML INJECTION
2463	VOLTAREN 75 MG/3 ML INJECTION (DICLOFENAC)
2464	VOLTAREN OPHTHA 0.1% 5ML EYE DROPS (DICLOFENAC SODIUM)
2465	VOLTAREN SR 100MG TABLETS (DICLOFENAC SODIUM)
2466	VOLTAREN SR 75MG TABLETS
2467	VOLTAREN SR 75MG TABLETS (DICLOFENAC SODIUM)
2468	VOLULYTE 6% 500ML INFUSION (HYDROXYETHYL STARCH)
2469	VOLUVEN 6% 500ML INFUSION (HYDROXYETHYL STARCH)
2470	VOLUVEN 6% 500ML INFUSION
2471	VSL-3 CAPSULES
2472	VYTORIN 10MG/10MG TABLETS (EZETIMIBE-SIMVASTATIN)
2473	VYTORIN 10MG/20MG TABLETS (EZETIMIBE-SIMVASTATIN)
2474	WATER FOR INJECTION 10 ML * (WATER FOR INJECTION (Plastic))
2475	WATER FOR INJECTION 20 ML * (WATER FOR INJECTION (Plastic))
2476	WATER FOR INJECTION 500 ML (WATER FOR INJECTION)
2477	WATER FOR IRRIGATION (PHARMACY) 1000ML (BOT) BOTTLE (WATER FOR IRRIGATION)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
2478	WATER FOR IRRIGATION 2000 ML *
2479	WATER FOR IRRIGATION 500ML BOTTLE (WATER FOR IRRIGATION)
2480	WEAK IODINE 2.5% 50ML SOLUTION (IODINE-POTASSIUM IODINE)
2481	WELLBUTRIN SR 150MG TABLETS (BUPROPION SR)
2482	WHITE SOFT PARAFFIN 10g (sterile) OINTMENT (PARAFFIN WHIT SOFT)
2483	WHITE SOFT PARAFFIN 50G (non-sterile) OINTMENT (PARAFFIN WHITE SOFT)
2484	XALACOM 2.5ML EYE DROPS (LATANOPROST-TIMOLOL)
2485	XALATAN 0.005% 2.5ML EYE DROPS (LATANOPROST)
2486	XANAX 0.25MG TABLETS (ALPRAZOLAM)
2487	XANAX 0.5MG TABLETS
2488	XANAX 0.5MG TABLETS (ALPRAZOLAM)
2489	XANAX XR 1MG TABLETS (ALPRAZOLAM)
2490	XARELTO 10MG TABLETS (RIVAROXABAN)
2491	XARELTO 15MG TABLETS (RIVAROXABAN)
2492	XARELTO 2.5MG TABLETS (RIVAROXABAN)
2493	XARELTO 20MG TABLETS (RIVAROXABAN)
2494	XATRAL SR 5MG TABLETS (ALFUZOSIN SR)
2495	XATRAL XL 10MG TABLETS
2496	XATRAL XL 10MG TABLETS (ALFUZOSIN SR)
2497	XENICAL 120MG CAPSULES (ORLISTAT)
2498	XYLOCAINE (per dose) 10% SPRAY (LIGNOCAINE (per dose))
2499	XYLOCAINE 1% 5ML INJECTION
2500	XYLOCAINE 1% 5ML INJECTION (LIGNOCAINE)
2501	XYLOCAINE 1.5% 20ML INJECTION (LIGNOCAINE)
2502	XYLOCAINE 10% 50ML SPRAY (LIGNOCAINE)
2503	XYLOCAINE 2% 30GM GEL (LIGNOCAINE)
2504	XYLOCAINE 4% 50ML SOLUTION (LIGNOCAINE)
2505	XYLOCAINE 5% 35GM OINTMENT (LIGNOCAINE)
2506	XYLOCAINE ADRENALINE 2% 20ML INJECTION (LIGNOCAINE-ADRENALINE)
2507	XYLOCAINE VISCOUS 2% SOLUTION (LIGNOCAINE (VISCOUS))
2508	XYZAL 5MG TABLETS
2509	XYZAL 5MG TABLETS (LEVOCETIRIZINE)
2510	YASMIN 21'S TABLETS (ETHINYLESTRADIOL-DROSPIRENONE)
2511	YAZ. 28's TABLETS (DROSPIRENONE-ETHINYLESTRADIOL)
2512	YELLOW FEVER VACCINE (YELLOW FEVER VACCINE)
2513	ZADITEN 1 MG/5 ML SYRUP (KETOTIFEN)
2514	ZADITEN 1MG TABLETS (KETOTIFEN)
2515	ZANTAC 150 MG/10 ML SYRUP
2516	ZANTAC 150 MG/10 ML SYRUP (RANITIDINE)
2517	ZANTAC 150MG TABLETS
2518	ZANTAC 150MG TABLETS (RANITIDINE)
2519	ZANTAC 50 MG/2 ML INJECTION
2520	ZANTAC 50 MG/2 ML INJECTION (RANITIDINE)
2521	ZAVEDOS 10MG INJECTION (IDARUBICIN)
2522	ZAVEDOS 5MG INJECTION (IDARUBICIN)
2523	ZEFFIX 100MG TABLETS (LAMIVUDINE)
2524	ZELDOX 40MG CAPSULES (ZIPRASIDONE)
2525	ZELMAC 6MG TABLETS (TEGASEROD)
2526	ZEMPLAR 5MCG/ML INJECTION (PARICALCITOL)
2527	ZENTEL 400 MG/10 ML SUSPENSION (ALBENDAZOLE)
2528	ZESTRIL 10MG TABLETS (LISINOPRIL)
2529	ZESTRIL 20MG TABLETS (LISINOPRIL)
2530	ZESTRIL 5MG TABLETS
2531	ZESTRIL 5MG TABLETS (LISINOPRIL)
2532	ZIDOVUDINE 100MG CAPSULES
2533	ZINACEF 750 MG INJECTION
2534	ZINACEF 750 MG INJECTION (CEFUROXIME)
2535	ZINC & CASTOR OIL 100GM CREAM
2536	ZINC & CASTOR OIL 20 GM CREAM (ZINC & CASTOR OIL BP)

Andaman Alliance Healthcare Limited
LIST OF KEY DRUGS TO BE IMPORTED

Annex C-6

Sr	Item Description
2537	ZINC 20G CREAM (ZINC BP)
2538	ZINC SULPHATE 220mg (Zinc50mg) CAPSULES
2539	ZINFORO 600MG INJECTION (CEFTAROLINE FOSAMIL)
2540	ZINNAT 125MG/5ML 50ML SUSPENSION (CEFUROXIME)
2541	ZINNAT 250MG TABLETS
2542	ZINNAT 250MG TABLETS (CEFUROXIME)
2543	ZINNAT 500MG TABLETS
2544	ZINNAT 500MG TABLETS (CEFUROXIME)
2545	ZITHROMAX 200MG/5ML 15ML SUSPENSION (AZITHROMYCIN)
2546	ZITHROMAX 250MG TABLETS
2547	ZITHROMAX 250MG TABLETS (AZITHROMYCIN)
2548	ZITHROMAX 500MG INJECTION (AZITHROMYCIN)
2549	ZITHROMYCIN 500MG INJECTION
2550	ZMAX 2G SUSPENSION (AZITHROMYCIN)
2551	ZOCOR 10MG TABLETS
2552	ZOCOR 10MG TABLETS (SIMVASTATIN)
2553	ZOCOR 20MG TABLETS (SIMVASTATIN)
2554	ZOFRAN 4 MG/2 ML INJECTION
2555	ZOFRAN 4 MG/2 ML INJECTION (ONDANSETRON)
2556	ZOFRAN 8 MG/4 ML INJECTION
2557	ZOFRAN 8 MG/4 ML INJECTION (ONDANSETRON)
2558	ZOFRAN 8MG TABLETS
2559	ZOFRAN 8MG TABLETS (ONDANSETRON)
2560	ZOLADEX DEPOT 10.8MG INJECTION (GOSERELIN ACETATE)
2561	ZOLOFT 50MG TABLETS
2562	ZOLOFT 50MG TABLETS (SERTRALINE)
2563	ZOMETA 4MG INJECTION (ZOLENDRONIC ACID)
2564	ZOMIG RAPIMELT 2.5MG TABLETS (ZOLMITRIPTAN)
2565	ZOVIRAX 10G CREAM (ACYCLOVIR)
2566	ZOVIRAX 200 MG/5 ML SUSPENSION (ACYCLOVIR)
2567	ZOVIRAX 200MG TABLETS (ACYCLOVIR)
2568	ZOVIRAX 2G CREAM (ACYCLOVIR)
2569	ZOVIRAX 4.5 GM EYE OINTMENT (ACYCLOVIR)
2570	ZOVIRAX DISPERSIBLE 800MG TABLETS (ACYCLOVIR)
2571	ZYLORIC 100MG TABLETS
2572	ZYLORIC 100MG TABLETS (ALLOPURINOL)
2573	ZYLORIC 300MG TABLETS (ALLOPURINOL)
2574	ZYMAR 0.3% 5ML EYE DROPS (GATIFLOXACIN)
2575	ZYPREXA 5MG TABLETS (OLANZAPINE)
2576	ZYPREXA ZYDIS 10MG DISP. TABLETS (OLANZAPINE)
2577	ZYRTEC 10MG TABLETS
2578	ZYRTEC 10MG TABLETS (CETIRIZINE)
2579	ZYRTEC 10MG/ML DROPS (CETIRIZINE)
2580	ZYRTEC 1MG/ML SOLUTION (CETIRIZINE)
2581	ZYRTEC-D TABLETS (CETIRIZINE-PSEUDOEPHEDRINE)
2582	ZYVOX 100MG/5ML 150ML SUSPENSION (LINEZOLID)
2583	ZYVOX 600MG TABLETS
2584	ZYVOX 600MG TABLETS (LINEZOLID)
2585	ZYVOX 600MG/300ML INJECTION
2586	ZYVOX 600MG/300ML INJECTION (LINEZOLID)

Andaman Alliance Healthcare Limited Annex C-7 Annex C-

DETAILS OF PROJECTED EMPLOYMENT AT THE HOSPITAL

	Position	Basic Salary USD/month [3]	Year 1			Year 2-3		
			Total	Foreign	Local	Total	Foreign	Local
1	CEO (foreign)[1]	5,000 - 9,000	1	1		1	1	
2	CFO (foreign)[1]	3,000 - 5,000	1	1		1	1	
3	Head of Nursing (foreign)[1]	1,000 - 3,000	1	1		1	1	
4	Corporate Office	300 - 2,000	12		12	20		20
5	Nursing Staff [2]	300 - 800	179	27	152	231	35	196
6	Healthcare Assistants	250 - 400	30		30	40		40
7	Radiographer	300 - 800	4		4	4		4
8	Resident Specialists (Anesthetists, Intensivists, Cardiologists, Perfusionists, Phlebotomists, Medical Officer, Sonographer) [2]	600 - 1,500	8	2	6	14	3	11
9	Clinical Technicians	300 - 800	4		4	4		4
10	Administrative/Service	250 - 800	30		30	40		40
11	Laboratory Specialists	500 - 1,200	8		8	10		10
12	Laboratory Support	300 - 700	5		5	8		8
13	Pharmacists and Support	300 - 800	10		10	12		12
14	Radiology Imaging Specialists [2]	600 - 1,800	5	1	4	10	2	8
15	Radiology Imaging Support	300 - 700	4		4	9		9
16	Radiology Oncology Specialists and Support [2]	600 - 1,800	0	0	0	0	0	0
17	Rehabilitation Therapists	500 - 1,200	6		6	8		8
18	Rehabilitation Support	300 - 700	4		4	6		6
19	IT Engineers and Support	250 - 800	5		5	8		8
20	Biomedical Engineers and Support	250 - 800	4		4	8		8
21	Procurement/Purchasing Officers	250 - 800	5		5	8		8
22	Plant Operations	250 - 700	4		4	9		9
	Subtotal of Basic Salary							
	Total, excluding Doctors		**330**	**33**	**297**	**452**	**43**	**409**
23	Doctors (Salary, bonus and benefits)	7,000 - 11,000	20	3	17	35	6	29
	Total, including Doctors		**350**	**36**	**314**	**487**	**49**	**438**

DETAILS OF PROJECTED EMPLOYMENT AT THE HOSI

	Position	Basic Salary USD/month [3]	Year 4-6			Year 7-10		
			Total	Foreign	Local	Total	Foreign	Local
1	CEO (foreign)[1]	5,000 - 9,000	1	1		1		1
2	CFO (foreign)[1]	3,000 - 5,000	1	1		1		1
3	Head of Nursing (foreign)[1]	1,000 - 3,000	1	1		1		1
4	Corporate Office	300 - 2,000	30		30	30		30
5	Nursing Staff [2]	300 - 800	410	61	349	443	68	375
6	Healthcare Assistants	250 - 400	100		100	100		100
7	Radiographer	300 - 800	10		10	10		10
8	Resident Specialists (Anesthetists, Intensivists, Cardiologists, Perfusionists, Phlebotomists, Medical Officer, Sonographer) [2]	600 - 1,500	20	3	17	25	4	21
9	Clinical Technicians	300 - 800	7		7	7		7
10	Administrative/Service	250 - 800	50		50	60		60
11	Laboratory Specialists	500 - 1,200	12		12	12		12
12	Laboratory Support	300 - 700	10		10	10		10
13	Pharmacists and Support	300 - 800	15		15	15		15
14	Radiology Imaging Specialists [2]	600 - 1,800	12	2	10	12	2	10
15	Radiology Imaging Support	300 - 700	10		10	10		10
16	Radiology Oncology Specialists and Support [2]	600 - 1,800	10	2	8	10	2	8
17	Rehabilitation Therapists	500 - 1,200	10		10	10		10
18	Rehabilitation Support	300 - 700	8		8	8		8
19	IT Engineers and Support	250 - 800	10		10	10		10
20	Biomedical Engineers and Support	250 - 800	10		10	10		10
21	Procurement/Purchasing Officers	250 - 800	10		10	10		10
22	Plant Operations	250 - 700	12		12	12		12
	Subtotal of Basic Salary							
	Total, excluding Doctors		**759**	**71**	**688**	**807**	**76**	**731**
23	Doctors (Salary, bonus and benefits)	7,000 - 11,000	50	8	42	60	9	51
	Total, including Doctors		**809**	**79**	**730**	**867**	**85**	**782**

Andaman Alliance Healthcare Limited Annex C-7

DETAILS OF PROJECTED EMPLOYMENT AT THE HOS

	Position	Basic Salary USD/month [3]	Median/mth (before bonus)	Median/mth (after bonus)	Y1 Annual Salary Cost (before bonus)
1	CEO (foreign)[1]	5,000 - 9,000	**7,000**	**8,750**	84,000
2	CFO (foreign)[1]	3,000 - 5,000	**4,000**	**5,000**	48,000
3	Head of Nursing (foreign)[1]	1,000 - 3,000	**2,000**	**2,500**	24,000
4	Corporate Office	300 - 2,000	**800**	**1,000**	115,200
5	Nursing Staff [2]	300 - 800			
6	Healthcare Assistants	250 - 400	**300**	**375**	108,000
7	Radiographer	300 - 800	**550**	**688**	26,400
8	Resident Specialists (Anesthetists, Intensivists, Cardiologists, Perfusionists, Phlebotomists, Medical Officer, Sonographer) [2]	600 - 1,500	**900**	**1,125**	86,400
9	Clinical Technicians	300 - 800	**400**	**500**	19,200
10	Administrative/Service	250 - 800	**350**	**438**	126,000
11	Laboratory Specialists	500 - 1,200	**650**	**813**	62,400
12	Laboratory Support	300 - 700	**350**	**438**	21,000
13	Pharmacists and Support	300 - 800	**425**	**531**	51,000
14	Radiology Imaging Specialists [2]	600 - 1,800	**850**	**1,063**	51,000
15	Radiology Imaging Support	300 - 700	**400**	**500**	19,200
16	Radiology Oncology Specialists and Support [2]	600 - 1,800	**1,000**	**1,250**	0
17	Rehabilitation Therapists	500 - 1,200	**800**	**1,000**	57,600
18	Rehabilitation Support	300 - 700	**350**	**438**	16,800
19	IT Engineers and Support	250 - 800	**450**	**563**	27,000
20	Biomedical Engineers and Support	250 - 800	**450**	**563**	21,600
21	Procurement/Purchasing Officers	250 - 800	**450**	**563**	27,000
22	Plant Operations	250 - 700	**350**	**438**	16,800
	Subtotal of Basic Salary				**1,820,400**
	Total, excluding Doctors				**2,725,500**
23	Doctors (Salary, bonus and benefits)	7,000 - 11,000	8,716		2,091,800
	Total, including Doctors				**4,817,300**

Andaman Alliance Healthcare Limited Annex C-8
Estimated prices range for services

Prices of non-complicated package priced procedures	**Proposed Prices in USD**		
Appendectomy (no complications)	2,500	-	3,000
Breast Lump Removal (Biopsy)	1,100	-	1,400
Carpal Tunnel Release	1,100	-	1,300
Cataract Surgery	1,700	-	2,100
Colonoscopy	700	-	900
Delivery (C-Section)	1,600	-	2,000
Delivery (Normal)	800	-	1,000
Eye (Laser Treatment for retinal disorders)	1,000	-	1,200
Laparascopic Cholecystectomy (Gall bladder removal)	2,200	-	2,600
Gastroscopy	400	-	600
Gastroscopy with lower GI Scope	1,100	-	1,300
Glaucoma Surgery	600	-	800
Hemorrhoidectomy	1,100	-	1,400
Hand, wrist or finger surgery	1,600	-	2,000
Coronary Angiography (same day)	1,000	-	1,200
Coronary Angioplasty with 1 stent	8,600	-	10,000
Heart Attack with Angioplasty	8,600	-	10,000
Coronary Artery Bypass Graft	16,600	-	19,300
Pacemaker implant	2,000	-	2,400
Hernia Repair	2,000	-	2,400
Hip Replacement Surgery	12,000	-	13,900
Hysterectomy	5,000	-	5,800
Knee Arthroscopic Surgery	2,300	-	2,700
Knee Replacement Surgery	8,600	-	10,000
Myopia Lasik (one eye)	600	-	800
Myopia Lasik (both eyes)	2,300	-	2,700
Tonsillectomy	2,000	-	2,400
Lithotripsy for urinary stones	1,600	-	2,000

Andaman Alliance Healthcare Limited Annex C-9

OPERATING STATISTICS FOR INCOME

		Phase 1------->		Phase 2------->					
		Y-1	**Y-3**	**Y-4**	**Y-6**	**Y-7**	**Y-8**	**Y-9**	**Y-10**
Operating Statistics									
No. of beds		100	100	250	250	250	250	250	250
Number of outpatients		28,000	98,000	151,200	184,800	201,600	201,600	201,600	201,600
OPD Charge per visit	US$	80	90	95	107	113	120	128	135
Number of inpatients		3,080	7,300	16,632	20,328	20,857	20,857	20,857	20,857
Inpatient Bill Size	US$	1,700	2,057	2,222	2,543	2,696	2,858	3,029	3,211
Revenue	US$	7,476,000	23,825,124	51,355,515	71,483,348	79,105,321	83,851,640	88,882,739	94,215,703

Andaman Alliance Healthcare Limited Annex C-10

Depreciation and Amortization

			Pre-Op Y-0	Pre-Op Y-1	Pre-Op Y-2
Depreciation	**Capex**	**Amortisation years**			
Land premium	8,600,000	50			
Construction and renovation	40,500,000	50			
Furniture and Fittings	4,500,000	7			
Equipment	31,231,676	7			
IT and others (vehicle)	10,000	7			
Total depreciation					
Depreciation waterfall					
Land premium					
Pre-Op					
Inc. capex year 1					
Inc. capex year 2					
Inc. capex year 3					
Inc. capex year 4					
Inc. capex year 5					
Total					
Construction and renovation					
Pre-Op					
Inc. capex year 1					
Inc. capex year 2					
Inc. capex year 3					
Inc. capex year 4					
Inc. capex year 5					
Total					
Furniture and Fittings					
Pre-Op					
Phase 2 Y-3					
Inc. capex year 1					-
Inc. capex year 2					-
Inc. capex year 3					-
Inc. capex year 4					15%
Inc. capex year 5					15%
Inc. capex year 6					30%
Inc. capex year 7					30%
Inc. capex year 8					30%
Inc. capex year 9					30%
Inc. capex year 10					30%
Total					
Equipment					
Pre-Op					
Y-1					
Y-2 (Phase 2)					
Y-3 (Phase 2)					
Y-4 (Phase 2)					
Y-5 (Phase 2)					
					Reinvest rate
Inc. capex year 1					-
Inc. capex year 2					-
Inc. capex year 3					-
Inc. capex year 4					10%
Inc. capex year 5					20%
Inc. capex year 6					30%
Inc. capex year 7					40%
Inc. capex year 8					40%
Inc. capex year 9					75%
Inc. capex year 10					100%
Total					
Others					
Pre-Op					
Inc. capex year 1					-
Inc. capex year 2					-
Inc. capex year 3					-
Inc. capex year 4					-
Inc. capex year 5					400%
Inc. capex year 6					-
Inc. capex year 7					-
Inc. capex year 8					-
Inc. capex year 9					-
Inc. capex year 10					800%
Total					

Andaman Alliance Healthcare Limited Annex C-10

Depreciation and Amortization

		Pre-Op Y-3	Pre-Op Y-4	Y-1	Y-2
Depreciation	**Capex**				
Land premium	8,600,000			172,000	172,000
Construction and renovation	40,500,000			810,000	810,000
Furniture and Fittings	4,500,000			257,143	257,143
Equipment	31,231,676			2,409,301	2,543,151
IT and others (vehicle)	10,000			1,429	1,429
Total depreciation				3,649,872	3,783,722
Depreciation waterfall					

Land premium	**Capex**		
Pre-Op	8,600,000	172,000	172,000
Inc. capex year 1	-	-	-
Inc. capex year 2	-		-
Inc. capex year 3	-		
Inc. capex year 4			
Inc. capex year 5			
Total	8,600,000	172,000	172,000

Construction and renovation	**Capex**		
Pre-Op	40,500,000	810,000	810,000
Inc. capex year 1	-	-	-
Inc. capex year 2	-		-
Inc. capex year 3	-		
Inc. capex year 4	-		
Inc. capex year 5			
Total	40,500,000	810,000	810,000

Furniture and Fittings	**Capex**		
Pre-Op	1,800,000	257,143	257,143
Phase 2 Y-3	2,700,000		
Inc. capex year 1	-	-	-
Inc. capex year 2	-		-
Inc. capex year 3	-		
Inc. capex year 4	96,429		
Inc. capex year 5	98,495		
Inc. capex year 6	201,211		
Inc. capex year 7	209,834		
Inc. capex year 8	218,827		
Inc. capex year 9	151,063		
Inc. capex year 10	157,537		
Total	5,633,396	257,143	257,143

Equipment	**Capex**		
Pre-Op	16,865,105	2,409,301	2,409,301
Y-1	-	-	-
Y-2 (Phase 2)	936,950		133,850
Y-3 (Phase 2)	-		
Y-4 (Phase 2)	7,807,919		
Y-5 (Phase 2)	5,621,702		
	Additional capex		
Inc. capex year 1	-	-	-
Inc. capex year 2	-		-
Inc. capex year 3	-		
Inc. capex year 4	254,315		
Inc. capex year 5	738,980		
Inc. capex year 6	1,381,070		
Inc. capex year 7	1,920,345		
Inc. capex year 8	2,030,079		
Inc. capex year 9	2,216,931		
Inc. capex year 10	3,138,763		
Total	42,912,160	2,409,301	2,543,151

Others	**Capex**		
Pre-Op	10,000	1,429	1,429
Inc. capex year 1	-	-	-
Inc. capex year 2	-		-
Inc. capex year 3	-		
Inc. capex year 4	-		
Inc. capex year 5	5,714		
Inc. capex year 6	-		
Inc. capex year 7	-		
Inc. capex year 8	-		
Inc. capex year 9	-		
Inc. capex year 10	6,531		
Total	22,245	1,429	1,429

Andaman Alliance Healthcare Limited Annex C-10

Depreciation and Amortization

		Y-3	Y-4	Y-5	Y-6
Depreciation	**Capex**				
Land premium	8,600,000	172,000	172,000	172,000	172,000
Construction and renovation	40,500,000	810,000	810,000	810,000	810,000
Furniture and Fittings	4,500,000	642,857	656,633	670,703	699,448
Equipment	31,231,676	2,543,151	3,694,899	4,603,567	4,800,863
IT and others (vehicle)	10,000	1,429	1,429	2,245	2,245
Total depreciation		4,169,436	5,334,960	6,258,516	6,484,556
Depreciation waterfall					
Land premium				**Depreciation**	
Pre-Op		172,000	172,000	172,000	172,000
Inc. capex year 1		-	-	-	-
Inc. capex year 2		-	-	-	-
Inc. capex year 3		-	-	-	-
Inc. capex year 4			-	-	-
Inc. capex year 5				-	-
Total		172,000	172,000	172,000	172,000
Construction and renovation				**Depreciation**	
Pre-Op		810,000	810,000	810,000	810,000
Inc. capex year 1		-	-	-	-
Inc. capex year 2		-	-	-	-
Inc. capex year 3		-	-	-	-
Inc. capex year 4			-	-	-
Inc. capex year 5					
Total		810,000	810,000	810,000	810,000
Furniture and Fittings				**Depreciation**	
Pre-Op		257,143	257,143	257,143	257,143
Phase 2 Y-3		385,714	385,714	385,714	385,714
Inc. capex year 1		-	-	-	-
Inc. capex year 2		-	-	-	-
Inc. capex year 3		-	-	-	-
Inc. capex year 4			13,776	13,776	13,776
Inc. capex year 5				14,071	14,071
Inc. capex year 6					28,744
Inc. capex year 7					
Inc. capex year 8					
Inc. capex year 9					
Inc. capex year 10					
Total		642,857	656,633	670,703	699,448
Equipment				**Depreciation**	
Pre-Op		2,409,301	2,409,301	2,409,301	2,409,301
Y-1		-	-	-	-
Y-2 (Phase 2)		133,850	133,850	133,850	133,850
Y-3 (Phase 2)		-	-	-	-
Y-4 (Phase 2)			1,115,417	1,115,417	1,115,417
Y-5 (Phase 2)				803,100	803,100
Inc. capex year 1		-	-	-	-
Inc. capex year 2		-	-	-	-
Inc. capex year 3		-	-	-	-
Inc. capex year 4			36,331	36,331	36,331
Inc. capex year 5				105,569	105,569
Inc. capex year 6					197,296
Inc. capex year 7					
Inc. capex year 8					
Inc. capex year 9					
Inc. capex year 10					
Total		2,543,151	3,694,899	4,603,567	4,800,863
Others				**Depreciation**	
Pre-Op		1,429	1,429	1,429	1,429
Inc. capex year 1		-	-	-	-
Inc. capex year 2		-	-	-	-
Inc. capex year 3		-	-	-	-
Inc. capex year 4			-	-	-
Inc. capex year 5				816	816
Inc. capex year 6					-
Inc. capex year 7					
Inc. capex year 8					
Inc. capex year 9					
Inc. capex year 10					
Total		1,429	1,429	2,245	2,245

Andaman Alliance Healthcare Limited Annex C-10

Depreciation and Amortization

		Y-7	Y-8	Y-9	Y-10
Depreciation	**Capex**				
Land premium	8,600,000	172,000	172,000	172,000	172,000
Construction and renovation	40,500,000	810,000	810,000	810,000	810,000
Furniture and Fittings	4,500,000	729,424	503,542	525,123	547,628
Equipment	31,231,676	5,075,198	2,955,909	3,138,763	3,587,158
IT and others (vehicle)	10,000	2,245	816	816	1,749
Total depreciation		6,788,867	4,442,267	4,646,702	5,118,535
Depreciation waterfall					
Land premium					
Pre-Op		172,000	172,000	172,000	172,000
Inc. capex year 1		-	-	-	-
Inc. capex year 2		-	-	-	-
Inc. capex year 3		-	-	-	-
Inc. capex year 4		-	-	-	-
Inc. capex year 5		-	-	-	-
Total		172,000	172,000	172,000	172,000
Construction and renovation					
Pre-Op		810,000	810,000	810,000	810,000
Inc. capex year 1		-	-	-	-
Inc. capex year 2		-	-	-	-
Inc. capex year 3		-	-	-	-
Inc. capex year 4		-	-	-	-
Inc. capex year 5					
Total		810,000	810,000	810,000	810,000
Furniture and Fittings					
Pre-Op		257,143			
Phase 2 Y-3		385,714	385,714	385,714	385,714
Inc. capex year 1		-			
Inc. capex year 2		-	-		
Inc. capex year 3		-	-	-	
Inc. capex year 4		13,776	13,776	13,776	13,776
Inc. capex year 5		14,071	14,071	14,071	14,071
Inc. capex year 6		28,744	28,744	28,744	28,744
Inc. capex year 7		29,976	29,976	29,976	29,976
Inc. capex year 8			31,261	31,261	31,261
Inc. capex year 9				21,580	21,580
Inc. capex year 10					22,505
Total		729,424	503,542	525,123	547,628
Equipment					
Pre-Op		2,409,301			
Y-1		-			
Y-2 (Phase 2)		133,850	133,850		
Y-3 (Phase 2)		-	-	-	
Y-4 (Phase 2)		1,115,417	1,115,417	1,115,417	1,115,417
Y-5 (Phase 2)		803,100	803,100	803,100	803,100
Inc. capex year 1		-			
Inc. capex year 2		-	-		
Inc. capex year 3		-	-	-	
Inc. capex year 4		36,331	36,331	36,331	36,331
Inc. capex year 5		105,569	105,569	105,569	105,569
Inc. capex year 6		197,296	197,296	197,296	197,296
Inc. capex year 7		274,335	274,335	274,335	274,335
Inc. capex year 8			290,011	290,011	290,011
Inc. capex year 9				316,704	316,704
Inc. capex year 10					448,395
Total		5,075,198	2,955,909	3,138,763	3,587,158
Others					
Pre-Op		1,429			
Inc. capex year 1		-			
Inc. capex year 2		-	-		
Inc. capex year 3		-	-	-	
Inc. capex year 4		-	-	-	-
Inc. capex year 5		816	816	816	816
Inc. capex year 6		-	-	-	-
Inc. capex year 7		-	-	-	-
Inc. capex year 8			-	-	-
Inc. capex year 9				-	-
Inc. capex year 10					933
Total		2,245	816	816	1,749

Andaman Alliance Healthcare Limited **Annex C-11**

Profit and Loss Statemet

	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6	Year 7	Year 8	Year 9	Year 10
Revenue	7,476,000	17,832,782	23,825,124	51,355,515	61,306,473	71,483,348	79,105,321	83,851,640	88,882,739	94,215,703
Consumables and Drugs	(2,467,080)	(5,884,818)	(7,862,291)	(16,433,765)	(19,618,072)	(22,159,838)	(24,522,650)	(25,994,009)	(27,553,649)	(29,206,868)
% of hospital revenue	*33%*	*33%*	*33%*	*32%*	*32%*	*31%*	*31%*	*31%*	*31%*	*31%*
Doctors Fees	(2,091,800)	(4,472,220)	(5,887,276)	(11,605,279)	(13,776,267)	(16,009,331)	(17,749,683)	(18,814,664)	(19,943,544)	(21,140,156)
% of hospital revenue	*28%*	*25%*	*25%*	*23%*	*22%*	*22%*	*22%*	*22%*	*22%*	*22%*
Salaries, Training and Benefits	(2,725,500)	(3,296,923)	(3,521,177)	(7,773,137)	(9,239,575)	(10,136,793)	(10,834,923)	(11,582,135)	(12,381,949)	(13,238,143)
% of hospital revenue	*36%*	*18%*	*15%*	*15%*	*15%*	*14%*	*14%*	*14%*	*14%*	*14%*
Adminstration and Operations	(676,990)	(1,346,209)	(1,772,289)	(3,651,708)	(4,328,067)	(5,107,338)	(5,662,469)	(5,995,717)	(6,348,242)	(6,721,154)
% of hospital revenue	*9%*	*8%*	*7%*	*7%*	*7%*	*7%*	*7%*	*7%*	*7%*	*7%*
Electricity and Fuel	(348,000)	(724,000)	(1,068,000)	(1,388,000)	(1,560,000)	(1,560,000)	(1,560,000)	(1,560,000)	(1,560,000)	(1,560,000)
Water	(4,012)	(8,576)	(9,545)	(21,994)	(24,484)	(24,484)	(24,484)	(24,484)	(24,484)	(24,484)
Land rental	(540,000)	(540,000)	(540,000)	(540,000)	(540,000)	(567,000)	(567,000)	(567,000)	(567,000)	(567,000)
Stamp duty on land rental	(16,200)									
% of land rental	*3%*									
Depreciation	(3,649,872)	(3,783,722)	(4,169,436)	(5,334,960)	(6,258,516)	(6,484,556)	(6,788,867)	(4,442,267)	(4,646,702)	(5,118,535)
Profit before Tax	(5,043,453)	(2,223,687)	(1,004,891)	4,606,672	5,961,493	9,434,009	11,395,246	14,871,364	15,857,169	16,639,362
% of hospital revenue	*-67%*	*-12%*	*-4%*	*9%*	*10%*	*13%*	*14%*	*18%*	*18%*	*18%*
Income-tax (25%)						2,358,502	2,848,811	3,717,841	3,964,292	4,159,841
Profit after tax	(5,043,453)	(2,223,687)	(1,004,891)	4,606,672	5,961,493	7,075,506	8,546,434	11,153,523	11,892,877	12,479,522
CSR	-	-	-	92,133	119,230	141,510	170,929	223,070	237,858	249,590
Profit after tax and CSR	(5,043,453)	(2,223,687)	(1,004,891)	4,514,538	5,842,264	6,933,996	8,375,505	10,930,453	11,655,019	12,229,931

Andaman Alliance Healthcare Limited Annex C-12

Recoupment period

	Pre-Op Y-0	Pre-Op Y-1	Pre-Op Y-2	Pre-Op Y-3	Pre-Op Y-4	Y-1	Y-2	Y-3
Cash inflow						**(1,393,581)**	**1,560,035**	**3,164,546**
Profit						(5,043,453)	(2,223,687)	(1,004,891)
Depreciation						3,649,872	3,783,722	4,169,436
Terminal value								
Cash outflow	(2,838,000)	(10,680,000)	(12,150,000)	(15,590,000)	(28,778,546)	(413,740)	(1,510,120)	(3,031,631)
Land premium	(2,838,000)	(2,580,000)	-	(3,440,000)	-	-	-	-
Facilities expansion from cash flow							-	-
Furniture and Fittings		-	-	-	(1,800,000)	-	-	(2,700,000)
Equipment and IT		-	-	-	(16,865,105)	-	(936,950)	-
Others		-	-	-	(10,000)	-	-	-
Pre-Opening		-	-	-	(2,003,441)	-	-	-
Construction and Renovation		(8,100,000)	(12,150,000)	(12,150,000)	(8,100,000)	-	-	-
Replacement						-	-	-
Change in Net Working Capital						(413,740)	(573,170)	(331,631)
Tax						-	-	-
Net Cash Flow	(2,838,000)	(10,680,000)	(12,150,000)	(15,590,000)	(28,778,546)	(1,807,321)	49,915	132,915
Accumulated Cash Flow	(2,838,000)	(13,518,000)	(25,668,000)	(41,258,000)	(70,036,546)	(71,843,867)	(71,793,952)	(71,661,038)

Recoupment period =
10th year of operation

Andaman Alliance Healthcare Limi Annex C-12

Recoupment period

	Y-4	Y-5	Y-6	Y-7	Y-8	Y-9	Y-10
Cash inflow	**9,941,632**	**12,220,009**	**15,918,564**	**18,184,113**	**19,313,631**	**20,503,871**	**141,402,610**
Profit	4,606,672	5,961,493	9,434,009	11,395,246	14,871,364	15,857,169	16,639,362
Depreciation	5,334,960	6,258,516	6,484,556	6,788,867	4,442,267	4,646,702	5,118,535
Terminal value							119,644,713
Cash outflow	(9,766,682)	(7,031,959)	(4,638,233)	(5,425,868)	(6,245,025)	(6,627,260)	(7,775,343)
Land premium							
Facilities expansion from cash flow	-	-	-	-	-	-	-
Furniture and Fittings	-	-					
Equipment and IT	(7,807,919)	(5,621,702)					
Others							
Pre-Opening							
Construction and Renovation	-						
Replacement	(350,744)	(843,189)	(1,582,281)	(2,130,180)	(2,248,906)	(2,367,994)	(3,302,831)
Change in Net Working Capital	(1,608,020)	(567,068)	(697,449)	(446,877)	(278,277)	(294,974)	(312,672)
Tax	-	-	(2,358,502)	(2,848,811)	(3,717,841)	(3,964,292)	(4,159,841)
Net Cash Flow	174,949	5,188,050	11,280,332	12,758,244	13,068,607	13,876,610	133,627,267
Accumulated Cash Flow	(71,486,089)	(66,298,039)	(55,017,707)	(42,259,463)	(29,190,856)	(15,314,246)	118,313,021

Recoupment period =
10th year of operation

Andaman Alliance Healthcare Limited Annex C-13

IRR

Year	Net Cash Flow	5%		15%	
		DF	DCF	DF	DCF
Preparation 0	(2,838,000)	1.00000	(2,838,000)	1.00000	(2,838,000)
Preparation 1	(10,680,000)	0.95238	(10,171,429)	0.86957	(9,286,957)
Preparation 2	(12,150,000)	0.90703	(11,020,408)	0.75614	(9,187,146)
Preparation 3	(15,590,000)	0.86384	(13,467,228)	0.65752	(10,250,678)
Preparation 4	(28,778,546)	0.82270	(23,676,181)	0.57175	(16,454,227)
Operation 1	(1,807,321)	0.78353	(1,416,084)	0.49718	(898,558)
Operation 2	49,915	0.74622	37,247	0.43233	21,580
Operation 3	132,915	0.71068	94,460	0.37594	49,968
Operation 4	174,949	0.67684	118,412	0.32690	57,191
Operation 5	5,188,050	0.64461	3,344,263	0.28426	1,474,768
Operation 6	11,280,332	0.61391	6,925,145	0.24718	2,788,325
Operation 7	12,758,244	0.58468	7,459,481	0.21494	2,742,298
Operation 8	13,068,607	0.55684	7,277,089	0.18691	2,442,616
Operation 9	13,876,610	0.53032	7,359,063	0.16253	2,255,337
Operation 10	133,627,267	0.50507	67,490,850	0.14133	18,885,362
			37,516,682		(18,198,120)

IRR Rate 11.73 %

- **Annex D   Draft BOT Agreement**
    - **Comment from Attorney General Office**
    - **Draft BOT Agreement amended in accordance with comment from Attorney General Office**
    - **Drawing of the building (Floor plan, car parking plan)**
    - **Layout of the utilization of land**

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ
ပြည်ထောင်စုရှေ့နေချုပ်ရုံး
နေပြည်တော်

စာအမှတ်၊ ၂ (၅) ၃- ၁၈၈ / နပတ (၁၀၆၆)

ရက်စွဲ၊ ၂၀၁၅ ခုနှစ်၊ အောက်တိုဘာလ ၂၀ ရက်

အကြောင်းအရာ။ မြေငှားရမ်းသုံးစွဲခွင့်ကိစ္စအား သဘောထားမှတ်ချက်ပြန်ကြားပေးပါရန် ညှိနှိုင်းခြင်းကိစ္စ

ရည်ညွှန်းချက်။ ကျန်းမာရေးဝန်ကြီးဌာန၊ဝန်ကြီးရုံး၏ ၁၅-၁၀-၂၀၁၅ ရက်စွဲပါစာအမှတ်၊ ၅ မက (မ) ၂၀၁၅/ ၁၈၁၇၁

၁။ ရန်ကုန်တိုင်းဒေသကြီး၊ လမ်းမတော်မြို့နယ်၊ မြေတိုင်းရပ်ကွက်အမှတ် (၂၀F)၊ မြေကွက်အမှတ်(၁၀)၊ မြေအမျိုးအစား ပြည်သူ့လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက် ရန်ကုန်နယ်မြေ(ရန်ကုန်ထောင်ကြီး)၊ မြေအကျယ်အဝန်း (၃၇.၅၄၉)ကေအနက် (၁၁.၁၄၅)ကေ၏ မြေ(၅)ကေပေါ်တွင် AMK Cousortium and Parkway Pantai Limited နှင့်ပူးပေါင်းသည့် ဖက်စပ်လုပ်ငန်းအနေဖြင့် နိုင်ငံတကာအဆင့်မီဆေးရုံတစ်ရုံကို ခုတင်(၂၅၀)ဆံ့ ဆေးရုံအဖြစ် အဆင့်လိုက်တည်သွားမည်ဖြစ်ပါ၍ မြေငှားရမ်းသုံးစွဲခွင့်ကိစ္စအား သဘောထားမှတ်ချက်ပြန်ကြားပေးပါရန် ရည်ညွှန်းချက်ပါစာဖြင့် ပေးပို့ညှိနှိုင်းလာသောကိစ္စဖြစ်ပါသည်။

၂။ ရည်ညွှန်းချက်ပါစာနှင့်အတူ အောက်ပါစာရွက်စာတမ်းများ ပူးတွဲပေးပို့လာပါသည် -

(က) AMK Cousortium နှင့် Parkway Pantai Limited တို့၏ အကျဉ်းချုပ်တင်ပြချက်(မြန်မာ/ အင်္ဂလိပ်)၊

(ခ) Land Lease Agreemet (မူကြမ်း)နှင့်

(ဂ) Proposal for Multitertiary Hospital 250 Beds ။

၃။ ရည်ညွှန်းချက်ပါစာနှင့်အတူ ပေးပို့လာသော Land Lease Agreemet (မူကြမ်း) အား ဥပဒေရှုထောင့်မှ လေ့လာစိစစ်ပြီး အောက်ပါအတိုင်း သုံးသပ်အကြံပြုပြန်ကြားအပ်ပါသည် -

(က) စာချုပ်(မူကြမ်း)အား လေ့လာရာတွင် စာချုပ်(မူကြမ်း)သည် ဌာနနှင့် ချုပ်ဆိုမည့် ကုမ္ပဏီတို့အကြား နှစ်ဖက်ညှိနှိုင်းထားသော စာချုပ်(မူကြမ်း)မဟုတ်ဘဲ Allen & Gledhill (Myanmar) Co., Ltd က ပြုစုပေးပို့လာသော စာချုပ်(မူကြမ်း) ဖြစ်ကြောင်း တွေ့ရှိရပါသည်။ ပြည်ထောင်စုရှေ့နေချုပ်ရုံးအနေဖြင့် နှစ်ဖက် စာချုပ်ဝင်များအပြီးသတ်ညှိနှိုင်းထားသော စာချုပ်(မူကြမ်း) (Final Draft) ကို စိစစ်အကြံပြုပါကြောင်း ဤရုံး၏ ၁၀-၂-၂၀၁၄ ရက်စွဲပါစာအမှတ်၊ ၂(၅) ၁၆-၁၀/ နပတ (၁၄၆)ဖြင့် အကြောင်းကြားစာပေးပို့ခဲ့ပြီးဖြစ်ပါကြောင်း ဦးစွာပြန်ကြား အပ်ပါသည်၊

(ခ) စာချုပ်(မူကြမ်း)၏ မျက်နှာဖုံးနှင့် စာချုပ်ဝင်စာပိုဒ်၌ ချုပ်ဆိုမည့် တစ်ဖက်စာချုပ် ဝင်အား JVCo ဟုသာဖော်ပြထားပြီး JVCo ၏အမည်အား ဖော်ပြထားခြင်းမရှိ သဖြင့် မည်သည့်ဖက်စပ်ကုမ္ပဏီနှင့် ချုပ်ဆိုမည်ဖြစ်ကြောင်း ဖော်ပြရန်လိုအပ် ပါသည်။ စာချုပ်ချုပ်ဆိုချိန်၌ အဆိုပါ JVCo အား တည်ထောင်ပြီးဖြစ်ရန် လိုအပ်ပါသည်၊

(ဂ) စာချုပ်(မူကြမ်း)၌ စာချုပ်ဝင်စာပိုဒ်မပါရှိသဖြင့် မင်နီဖြင့်ရေးသားပေးလိုက်ပါ သည်၊

(ဃ) စာချုပ်(မူကြမ်း) အပိုဒ် 1.1 Definitions ခေါင်းစဉ်အောက်တွင် Force Majeure ၏ အဓိပ္ပာယ်၌ a change in the relevant laws, rules, regulations, notifications or polices in Myanmar အား ထည့်သွင်းဖွင့် ဆိုထားရာ ယင်းတို့အား Force Majeure ဟု သတ်မှတ်ရန်မသင့်ပါ။ ဥပဒေ၊ နည်းဥပဒေ၊ လုပ်ထုံးလုပ်နည်း၊ အမိန့်ညွှန်ကြားချက်များ သို့မဟုတ် မူဝါဒ

များပြောင်းလဲပါက စာချုပ်ပါ Renegotiation နှင့် Amendment အပိုဒ်ဖြင့် ဖြေရှင်းသင့်သည်ဟု သဘောရရှိပါသည်။ ဌာနမှပြန်လည်စိစစ်သင့်ပါသည်၊

(င) စာချုပ်(မူကြမ်း) အပိုဒ် 1.1 Definitions ခေါင်းစဉ်အောက်တွင် Property အား **Property** means the whole of [.] plots of land along (**address**), measuring approximately [.] acres,---------ဟုအဓိပ္ပါယ်ဖွင့်ဆိုထား သည်ကိုတွေ့ရှိရပါသည်။မြေငှားရမ်းမည့်စာချုပ်၌ ငှားရမ်းမည့်မြေသည်အဓိက ဖြစ်သောကြောင့် စာချုပ်(မူကြမ်း)ပါ Property ၏ အဓိပ္ပါယ်ဖွင့်ဆိုချက် နှင့် စပ်လျဉ်း၍ ပြည့်စုံစွာဖော်ပြထားရန် လိုအပ်ပါသည်။ ထို့အပြင် ငှားရမ်းမည့်မြေအား သီးခြားခေါင်းစဉ်ဖြင့် တည်နေရာ၊ အကျယ်အဝန်းတို့ကို ဖော်ပြပြီး စည်းကမ်းချက်တစ်ရပ် အနေဖြင့် ဖော်ပြသင့်ပါသည်။ယင်းအပိုဒ်၌ Annexure 1 အားပူးတွဲထားသည်ဟု ရည်ညွှန်း ထားသော်လည်း စာချုပ်(မူကြမ်း)၌ အဆိုပါ Annexure 1 သည် ပူးတွဲပါရှိ လာခြင်းမရှိသဖြင့်ပြန်လည်စိစစ်သင့်ပါသည်။ နောက်ဆက်တွဲများသည် စာချုပ် ၏ တစ်စိတ်တစ်ဒေသဖြစ်သောကြောင့် စာချုပ်ချုပ်ဆိုချိန်၌ နောက်ဆက်တွဲများ ပြည့်စုံစွာ ပူးတွဲဖော်ပြရန် လိုအပ်ပါသည်၊

(စ) စာချုပ်(မူကြမ်း) အပိုဒ် 2 Warranties and Representations ၊ အပိုဒ်ခွဲ 2.1.1 ၌ Lessor ဖြစ်သော ကျန်းမာရေးဝန်ကြီးဌာနသည် ငှားရမ်းမည့်မြေ (Property) ကို စီမံခန့်ခွဲပိုင်ခွင့်ရှိကြောင်း ဖော်ပြထားပြီး အဆိုပါမြေအား တရားဝင်ပိုင်ဆိုင်ကြောင်း ဖော်ပြထားခြင်းမရှိသည်ကို တွေ့ရှိရပါသည်။ ရည်ညွှန်းချက်ပါစာ၌ မြေအမျိုးအစား-ပြည်လုပ်ငန်းဌာနပိုင်မြေ၊ မြေအမည်ပေါက်-ရန်ကုန်နယ်မြေ (ရန်ကုန်ထောင်ကြီး)ဟုဖော်ပြထားရာ ငှားရမ်းမည့်မြေအား ကျန်းမာရေးဝန်ကြီးဌာနအနေဖြင့် တရားဝင်ပိုင်ဆိုင်ခြင်းမရှိပါက တရားဝင်ပိုင်ဆိုင်သောသက်ဆိုင်ရာ ဝန်ကြီးဌာနမှ ကျန်းမာရေးဝန်ကြီးဌာနသို့ တရားဝင်စာဖြင့် လွှဲပြောင်းပေး

အပ်ရန်လိုအပ်ပါသည်။ ထိုသို့သက်ဆိုင်ရာဝန်ကြီးဌာနမှ ကျန်းမာရေးဝန်ကြီးဌာနသို့ တရားဝင်စာဖြင့် လွှဲပြောင်းပေးအပ်သည့်စာရွက်စာတမ်းအထောက်အထားများကို စာချုပ်(မူကြမ်း)၌ နောက်ဆက်တွဲအဖြစ် ပူးတွဲဖော်ပြရန် လိုအပ်ပါသည်၊

(ဆ) စာချုပ်(မူကြမ်း) အပိုဒ်ခွဲ 2.1.4 ၌ဖော်ပြထားသော 'any Laws' သည် မည်သည့်နိုင်ငံ၏ဥပဒေများကိုဆိုလိုကြောင်း ပြည့်စုံစွာဖော်ပြရန် လိုအပ်ပါသည်၊

(ဇ) စာချုပ်(မူကြမ်း) အပိုဒ် 3.2 ၌ Initial Term ဟုလည်းကောင်း၊ အပိုဒ် 12 ၌ Extended Terms ဟုလည်းကောင်း၊ အပိုဒ်ခွဲ 12.2 ၌ First Extended Term ၊ အပိုဒ်ခွဲ 12.3 ၌ Second Extended Term ၊ အပိုဒ်ခွဲ 12.4 ၌ Further Term ဟုလည်းကောင်းဖော်ပြထားသည်ကိုတွေ့ရှိရပါသည်။ အဆိုပါ စည်းကမ်းချက်များသည် ငှားရမ်းကာလ သို့မဟုတ် စာချုပ်သက်တမ်းကို ဆိုလိုခြင်းဟုတ်မဟုတ် ရှင်းလင်းမှုမရှိပါ။ ငှားရမ်းကာလနှင့် စာချုပ် သက်တမ်းတို့မှာ တူညီခြင်းမရှိပါသဖြင့် ငှားရမ်းကာလနှင့် စာချုပ်သက်တမ်းတို့အား သီးခြားခေါင်းစဉ် များဖြင့် ဖော်ပြရန်လိုအပ်ပါသည်၊

(ဈ) စာချုပ်(မူကြမ်း) အပိုဒ် 4.1 တွင် Lessee အနေဖြင့် မြေအသုံးချမှုပရီမီယံကြေးနှင့် နှစ်စဉ်ကြေးကိုသာ ပေးဆောင်မည်ဖြစ်ကြောင်းနှင့် လိုင်စင်ခွင့်ပြုမိန့်အတွက် မည်သည့်အခကြေးငွေမျှ ပေးမည်မဟုတ်ကြောင်း ဖော်ပြထားရာ လိုင်စင်ကြေး ပေးဆောင်မှုမပြုခြင်းကို ဌာနအနေဖြင့် လက်ခံရန်သင့်မသင့် ပြန်လည် စိစစ်သင့်ပါသည်၊

(ည) စာချုပ်(မူကြမ်း) အပိုဒ် 4.3.2 ၌ Lessee မှ Land Use Premium ပေးရန်အတွက် Lessor ဖြစ်သော ဌာနက Lessee သို့ ဌာန၏ဘဏ်စာရင်းနံပါတ်အား စာဖြင့် ပေးပို့ဆောင်ရွက်ရမည်ဖြစ်ကြောင်းဖော်ပြထားရာ ထိုသို့အကြောင်း ကြား

ခြင်းထက် ပေးပို့ရမည့် ဘဏ်စာရင်းနံပါတ်အား စာချုပ်(မူကြမ်း) တွင် ထည့်သွင်း ရန် သင့်မသင့် ဌာနမှ ပြန်လည်စိစစ် သင့်ပါသည်၊

(ဍ) စာချုပ်(မူကြမ်း) အပိုဒ်ခွဲ 4.3.2 (i)(ii)(iii) တို့၌ Land Use Premium အား (၃) ကြိမ်ခွဲ၍ ပေးချေမည့်နေ့တို့အား ဖော်ပြထားသည်ကို တွေ့ရှိရပါသည်။ အဆိုပါ သတ်မှတ်ထားသည့်နေ့တို့တွင် ပေးချေခြင်းမရှိပါက ဌာနအနေဖြင့် ဒဏ်ကြေးမည်သို့ကောက်ခံမည် သို့မဟုတ် မည်သို့ဆောင်ရွက်မည်ဆိုသော စည်းကမ်း ချက်အား ထည့်သွင်းဖော်ပြရန် လိုအပ်ပါသည်၊

(ဎ) စာချုပ်(မူကြမ်း) အပိုဒ် 4.4 Annual Rent ၊ အပိုဒ်ခွဲ 4.4.1 ၌ Commencement Date မှ ပထမ(၁၀)နှစ်အတွက် နှစ်စဉ်ငှားရမ်းခအား ၁ စတုရန်းမီတာလျှင် အမေရိကန်ဒေါ်လာ(၁၈)ဒေါ်လာနှုန်းဖြင့် တွက်ချက်၍ ပေးရမည်ဖြစ်ကြောင်းဖော်ပြထားရာ နောင်အငြင်းပွားမှုမဖြစ်စေရေးအတွက် စတုရန်းမီတာမည်မျှအတွက် နှစ်စဉ်မြေငှားရမ်းခမှာ မည်မျှဖြစ်ကြောင်း ဖော်ပြသင့်ပါသည်။ ထို့အပြင် စာချုပ်(မူကြမ်း) အပိုဒ်ခွဲ 4.4.3 ၌ သတ်မှတ်ဖော်ပြထားသောနေ့တွင် နှစ်စဉ်ငှားရမ်းခကို ပေးချေနိုင်ခြင်းမရှိပါက ဒဏ်ကြေးမည်မျှပေးဆောင်ရမည်ဖြစ်ကြောင်းကို ဌာနအနေဖြင့်ဖော်ပြရန်သင့် မသင့် စဉ်းစားသင့်ပါသည်၊

(ဏ) စာချုပ်(မူကြမ်း) ၌ အချိန်ကာလများအား တွက်ချက်ဖော်ပြရာတွင် စတင်သည့်နေ့အား the date of execution of this Agreement ဟု လည်းကောင်း၊ the date of the Agreement ဟုလည်းကောင်း အမျိုးမျိုး ဖော်ပြထား၍ နောင်အငြင်းပွားမှုပေါ်ပေါက်လာနိုင်သဖြင့်တစ်မျိုးတည်းကိုသာ သုံးနှုန်းဖော်ပြရန် လိုအပ်ပါသည်၊

(ဃ) စာချုပ်(မူကြမ်း) ၌ ငှားရမ်းမည့်မြေ၏ မြေပုံအားနောက်ဆက်တွဲဖြင့်ဖော်ပြသင့်ပြီး အဆိုပါမြေပုံသည် သက်ဆိုင်ရာဌာနက တရားဝင်ရေးဆွဲထားသော မြေပုံဖြစ်ရန်လိုအပ်ပါသည်၊

(ဏ) စာချုပ်(မူကြမ်း) အပိုဒ် 5.3 ၌ Project တည်ဆောက်ရာတွင် Project သို့မဟုတ် တည်ဆောက်ရေးစတင်ရာ၌ နှောင့်နှေးကြန့်ကြာသည်ဟု Lessee ဖက်မှ တင်ပြထားသည့်အဖြစ်အပျက်(events)များကို ဖော်ပြထားရာ ဌာနအနေဖြင့် အဆိုပါ အဖြစ်အပျက်ဖော်ပြချက်များကို သတိပြုသင့်ပါသည်။ ထို့အပြင် အဆိုပါ အဖြစ်အပျက်များဖြစ်ပေါ်မှုကြောင့် နှောင့်နှေးခဲ့ပါက အခကြေးငွေတစ်စုံတစ်ရာ၊ နစ်နာမှုများ သို့မဟုတ် ဒဏ်ကြေးများပေးရန်ပါဝင်ခြင်းမရှိဘဲ (without having to pay any fees, damages, charges or penalities) တည်ဆောက်ရေးကာလအား မျှတ၍သင့်တော်စွာတိုးမြှင့်ရန် အခွင့်အရေး Lessee ၌ ရှိ ကြောင်း ဖော်ပြထားရာ (without having to pay any fees, damages, charges or penalities) ဟူသောဖော်ပြချက်အား လက်ခံနိုင်ခြင်းရှိ မရှိ ပြန်လည်စိစစ်သင့်ပါသည်၊

(တ) စာချုပ်(မူကြမ်း) အပိုဒ် 6 Obligations of the Lessor ၊အပိုဒ်ခွဲ 6.1 တွင် Lessor အနေဖြင့် Lessee မှ အငှားချထားမည့်မြေကို ရယူခြင်းမပြုမီ အငှားချထားသည့်မြေ အတွင်းကျူးကျော်သူများ နှင့် နေထိုင်သူများအား ပြန်လည်နေရာချထားပေးရန် တာဝန်ရှိကြောင်း ဖော်ပြထားရာ ဌာနအနေဖြင့် ကြိုတင် ဆောင်ရွက်ထားရန်လိုအပ်မည်ဖြစ်ပါသည်၊

(ထ) စာချုပ်(မူကြမ်း) အပိုဒ် 6 Obligations of the Lessor ၊အပိုဒ်ခွဲ 6.1 တွင် Lessor မှ အာမခံသည့်ကိစ္စရပ်များ၊ အပိုဒ်ခွဲ 6.2 တွင် Lessor မှ ပြင်ဆင်

ဆောင်ရွက်ပေးရမည့်ကိစ္စရပ်များကို ဖော်ပြထားရာ ဌာနအနေဖြင့် ဆောင်ရွက် ပေးနိုင်ခြင်းရှိ မရှိ ပြန်လည်စိစစ်သင့်ပါသည်၊

(ဒ) စာချုပ်(မူကြမ်း) အပိုဒ် 6 Obligations of the Lessor အပိုဒ်ခွဲ 6.3 ၌ Lessor မှ Lessee သို့ ကူညီဆောင်ရွက်ပေးမည့် ကိစ္စရပ်များတွင် အခြားဝန်ကြီးဌာနများနှင့် သက်ဆိုင်သောကိစ္စရပ်များပါဝင်နေကြောင်းတွေ့ရှိရပါသည်။ သို့ပါ၍ ဌာနအနေဖြင့် သက်ဆိုင်ရာဝန်ကြီးဌာနများနှင့် ညှိနှိုင်းဆောင်ရွက် သင့်ပါသည်၊

(ဓ) စာချုပ်(မူကြမ်း) အပိုဒ်ခွဲ 6.4.2 ၌ The Lessor hereby covenants with Lessee that in the event of any transfer by the Lessor of its title and interests in the Land, such transfer shall be made subject to this Agreement. ဟု ဖော်ပြထားရာ အဆိုပါ ဖော်ပြချက်နှင့်စပ်လျဉ်း၍အစိုးရပိုင် မြေဖြစ်၍ ပိုင်ဆိုင်ခွင့်(title)ကို လွှဲပြောင်းခွင့်မရှိဘဲ အသုံးပြုခွင့် (Right to use) ကိုသာခွင့်ပြုနိုင်မည်ဖြစ်သောကြောင့် ဌာန အနေဖြင့် ပြန်လည် စိစစ်သင့်ပါသည်၊

(န) စာချုပ်(မူကြမ်း) အပိုဒ်ခွဲ 6.4.2 ၌ The Lessor shall procure the transferee to undertake in writing to the Lessee that it shall be bound by all the terms, covenants ---------- of this Agreement. ဟု ဖော်ပြထားရာ အဆိုပါ ဖော်ပြချက်နှင့်စပ်လျဉ်း၍ ဌာနအနေဖြင့် လက်ခံနိုင်ခြင်းရှိမရှိ ပြန်လည် စိစစ်သင့်ပါသည်၊

(ပ) စာချုပ်(မူကြမ်း) ၌ ငှားရမ်းသည့် မြေ၏ မြေခွန်ကို မည်သူက ပေးဆောင်မည် ဖြစ်ကြောင်း၊ မြေခွန်မှအပ ကျန်အခွန်အခများကို မည်သူက ပေးဆောင်မည်ဖြစ်ကြောင်း ဖော်ပြထားခြင်းမရှိသဖြင့် ဖော်ပြရန်လိုအပ်ပါသည်၊

(ဖ) စာချုပ်(မူကြမ်း) အပိုဒ် 7 Obligations of the Lessee အပိုဒ်ခွဲ 7.4 ၌ Lessee မှ လိုက်နာဆောင်ရွက်ရမည့် applicable laws သည်လည်းကောင်း၊ အပိုဒ်ခွဲ 7.5

နှင့်အပိုဒ်ခွဲ12.4 တို့၌ ဖော်ပြထားသော applicable law သည်လည်းကောင်း မည်သည့်နိုင်ငံ၏ ဥပဒေများကိုဆိုလိုကြောင်း ဖော်ပြထားခြင်းမရှိသဖြင့် ဖော်ပြရန် လိုအပ်ပါသည်၊

(ဗ) စာချုပ်(မူကြမ်း) အပိုဒ် 7 Obligations of the Lessee အပိုဒ်ခွဲ 7.5 ၌ Lessee သည် ငှားရမ်းထားသည့်အကျိုးခံစားခွင့်တစ်စိတ်တစ်ပိုင်းကို MIC ၏အတည်ပြုချက်မရရှိဘဲ ပေါင်နှံခြင်းမပြုလုပ်ရဟုဖော်ပြထားရာ ပေါင်နှံခြင်းနှင့် စပ်လျဉ်း၍ MIC ၏အတည်ပြုချက်အပြင် Lessor ၏ တရားဝင်စာဖြင့် ခွင့်ပြုချက်ရရှိရန်လိုအပ်ကြောင်း ဖော်ပြရန်သင့် မသင့် စဉ်းစားသင့်ပါသည်၊

(ဘ) စာချုပ်(မူကြမ်း) အပိုဒ် 7 Obligations of the Lessee အပိုဒ်ခွဲ 7.5 ၌ Lessee သည် သက်ဆိုင်ရာဥပဒေနှင့်အညီ ယခုစာချုပ်အရ ၎င်း၏အခွင့်အရေးများကို တဆင့်ငှားရမ်း၊ လွှဲပြောင်း သို့မဟုတ် ပေးအပ်နိုင်ကြောင်းဖော်ပြထားရာ ထိုသို့ ၎င်း၏အခွင့်အရေးများကို တဆင့်ငှားရမ်း၊ လွှဲပြောင်း သို့မဟုတ် ပေးအပ်မည်ဆိုပါ က Lessor ၏ တရားဝင်စာဖြင့် ခွင့်ပြုချက်ရရှိရန်လိုအပ်ကြောင်း ဖော်ပြရန်သင့် မသင့် စဉ်းစားသင့်ပါသည်၊

(မ) စာချုပ်(မူကြမ်း)အပိုဒ် 8 Right of Re-entry ၌ ဖော်ပြထားသော material breach သည် မည်သည့်ကိစ္စရပ်များကိုဆိုလိုခြင်းဖြစ်ကြောင်း ရှင်းလင်းစွာ ဖော်ပြရန်လိုအပ်ပါသည်။ Right of Re-entry နှင့်စပ်လျဉ်း၍ အလားတူ စာချုပ်များတွင် ဖော်ပြလေ့ရှိသော စည်းကမ်းချက်အား Slip ကပ်ပေးလိုက်ပါသည်။ ဌာန၏လိုအပ်ချက်နှင့် ကိုက်ညီခြင်းရှိ မရှိ စိစစ်သင့်ပါသည်၊

(ယ) စာချုပ်(မူကြမ်း) အပိုဒ် 9 Protection of Environment and Mineral Resources ၊ အပိုဒ်ခွဲ 9.3 ၌ အငှားချထားသည့်မြေမှ သဘာဝသယံဇာတပစ္စည်းများတွေ့ရှိ၍ တူးဖော်ဆောင်ရွက်မှုကြောင့် Lessee ၏အမှန်တကယ်ဆုံးရှုံးမှုများ၊

နစ်နာမှုများ၊ ကုန်ကျစရိတ်များကို Lessor အနေဖြင့် Lessee သို့ ပြန်လည်ပေးဆပ်ရန်သဘောတူကြောင်း ဖော်ပြထားသည်ကိုတွေ့ရှိရပါသည်။ ဌာနအနေဖြင့် အဆိုပါဖော်ပြချက်အား လက်ခံနိုင်ခြင်းရှိ မရှိ ပြန်လည်စိစစ်သင့်ပါသည်၊

(ရ) စာချုပ်(မူကြမ်း) အပိုဒ် 10 Force Majeure ၌ Force Majeure ဖြစ်ပွားကြောင်း အကြောင်းကြားသည့် အကြောင်းကြားစာကို ချက်ချင်းပေးပို့ရာတွင် Force Majeure ဖြစ်ပွားသည့်နေ့မှ ရက်ပေါင်းမည်မျှအတွင်းပေးပို့ရမည်ဆိုသည့် အချက်နှင့် တစ်ဖက်စာချုပ်ဝင်မှ ထိုသို့ပေးပို့သည်ကို လက်ခံအတည်ပြုမှသာလျှင် Force Majeure မြောက်သည်ဆိုသောအချက်တို့ ဖော်ပြထားခြင်းမရှိသဖြင့် ထည့်သွင်းဖော်ပြရန်လိုအပ်ပါသည်၊

(လ) စာချုပ်(မူကြမ်း) အပိုဒ် 11.4 ၌ ဖော်ပြထားသော initial term or the last extended term သည် ငှားရမ်းကာလနှင့် စာချုပ်သက်တမ်းအနက် မည်သည်ကိုဆိုလိုကြောင်းရှင်းလင်းမှုမရှိပါ။ ဌာနမှပြန်လည်စိစစ်ပြီး ရှင်းလင်းစွာဖော်ပြရန်လိုအပ်ပါသည်၊

(ဝ) စာချုပ်(မူကြမ်း) အပိုဒ် 14 Notice ၌ စာချုပ်ဝင်အချင်းချင်းဆက်သွယ်ရာ၌ မည်သည့်ဘာသာစကားဖြင့် ဆက်သွယ်ဆောင်ရွက်မည်ဆိုသောအချက်မပါရှိ၍ ထည့်သွင်းဖော်ပြရန် လိုအပ်ပါသည်၊

(သ) စာချုပ်(မူကြမ်း) အပိုဒ် 18 Governing Law ၌ " save for Clause 19 below, which shall be governed by and construed solely in accordance with Singapore law."ဟု ဖော်ပြထားရာ Dispute Resolution အား အပိုဒ် 19 တွင် ဖော်ပြထားပြီးဖြစ်၍ Governing Law အပိုဒ်တွင် " save for Clause 19 ------with Singapore law." စည်းကမ်းချက် အား

ထည့်သွင်းရန်မသင့်သောကြောင့်ပယ်ဖျက်သင့်ပါသည်။ ဌာနမှ ပြန်လည်စိစစ်သင့်ပါသည်၊

(ဟ) စာချုပ်(မူကြမ်း) အပိုဒ် 19 Dispute Resolution၊ အပိုဒ် 19.1 ၌ အငြင်းပွား မှုသို့မဟုတ် ကွဲလွဲမှုများကို Singapore International Arbitration Centre ၌ ထိုအချိန်တွင် အာဏာသက်ရောက်မည့် arbitration rules နှင့်အညီ ဖြေရှင်းမည်ဖြစ်ကြောင်း၊ the seat of arbitration မှာ Singapore ဖြစ်ကြောင်းဖော်ပြထားပါသည်။the seat အစား venue ဟုပြောင်းလဲသုံးစွဲသင့်ပါသည်။ မြန်မာနိုင်ငံသည် ကုလသမဂ္ဂကြီးမှူးရေးဆွဲထားသော New York Convention ၏ အဖွဲ့ဝင်နိုင်ငံတစ်နိုင်ငံဖြစ်သော UNCITRAL Rules ဖြင့် ရန်ကုန်မြို့၌ ဖြေရှင်းရန်နှင့် ရန်ကုန်မြို့၌ ဖြေရှင်းရန်လက်မခံပါက UNCITRAL Rules ဖြင့် စင်္ကာပူ၌ဖြေရှင်းရန် တစ်ဖက်စာချုပ်ဝင်နှင့် ညှိနှိုင်းသင့်ပါသည်။ တစ်ဖက်စာချုပ်ဝင်ကလက်မခံပါက ဌာနအနေဖြင့် မိမိ၏စီမံခန့်ခွဲရေးနှင့် လုပ်ငန်းပိုင်းဆိုင်ရာဘောင်အတွင်းမှ စဉ်းစားသုံးသပ်ဆုံးဖြတ်ရန် ဖြစ်ကြောင်း ပြန်ကြားအပ်ပါသည်၊

(ဠ) စာချုပ်(မူကြမ်း) အပိုဒ် 19.2 သည် "The arbitral award made and --------- and may be used as a basis for Judgement thereon in Singapore, Myanmar or elwsewhere."ဟူသော ဖော်ပြချက်အား ဌာနအနေဖြင့် သတိပြုသင့်ပါသည်၊

(အ) စာချုပ်(မူကြမ်း) အပိုဒ် 19.4 ၌ arbitration သို့ တင်ပြစဉ်ကာလအတွင်း သို့မဟုတ် abitration award ၏ ခွင့်ပြုချက်မရမချင်း စာချုပ်ဝင်များသည် ရပ်စဲခြင်းကိစ္စရပ်များမှလွဲ၍ စာချုပ်ပါစည်းကမ်းချက်များအရ ၄င်းတို့၏ဝတ္တရားများကို ဆက်လက်ဆောင်ရွက်မည်ဖြစ်ကြောင်းဖော်ပြထားရာ ဌာနအနေဖြင့် သိရှိထားသင့်ပါသည်၊

(ကက) စာချုပ်(မူကြမ်း) ၌ အရေးကြီးသောဥပဒေရေးရာစည်းကမ်းချက်တစ်ခုဖြစ်သည့် စာချုပ်စတင်အကျိုးသက်ရောက်မည့်နေ့မပါရှိ၍ ဖော်ပြရန်လိုအပ်ပါသည်၊

(ခခ) စာချုပ်(မူကြမ်း) ၌ ဥပဒေရေးရာစည်းကမ်းချက်တစ်ဖြစ်သော Renegotiation စာပိုဒ်မပါရှိ၍ Slip ကပ်ပေးလိုက်ပါသည်၊

(ဂဂ) စာချုပ်(မူကြမ်း) ၌ လုပ်ငန်းဆောင်ရွက်မှုအတွက် အာမခံ (Performance Bank Guarantee) နှင့်စပ်လျဉ်း၍ ဖော်ပြထားခြင်းမရှိသဖြင့် လုပ်ငန်းဆောင်ရွက်မှုအတွက် အာမခံရယူရန်သင့် မသင့် ဌာနအနေဖြင့် စဉ်းစားသင့်ပါသည်၊

(ဃဃ) စာချုပ်(မူကြမ်း) ပါ ကွက်လပ်များကို စာချုပ်ချုပ်ဆိုချိန်၌ ပြည့်စုံစွာဖော်ပြထားပြီးဖြစ်ရန်လိုအပ် ပါသည်၊

(ငင) လိုအပ်သောနေရာများ၌ မင်နီဖြင့် ပြင်ဆင်ပေးလိုက်ပါသည်။

၄။ စာချုပ်(မူကြမ်း)ခေါင်းစဉ်အားမြေငှားစာချုပ်(မူကြမ်း)ဟုဖော်ပြထားသည်ကိုတွေ့ရှိရပါသည်။ သို့ရာတွင် စာချုပ်(မူကြမ်း)ပါ စည်းကမ်းချက်များ၌ မြေငှား၍ဆေးရုံတည်ဆောက်မည်ဖြစ်ကြောင်း ဖော်ပြထားသည်ကိုတွေ့ရှိရပါသည်။ ယင်းကိစ္စနှင့်စပ်လျဉ်း၍ အစိုးရပိုင်မြေဖြစ်သောကြောင့် Lessee အနေဖြင့် အကောင်အထည်ဖော်မည့် စီမံကိန်းလုပ်ငန်းအတွက် ခွင့်ပြုသက်တမ်းအတွင်း လုပ်ကိုင်ခွင့်အား ပိုင်ဆိုင်ခွင့်ရှိမည်ဖြစ်ပြီး ငှားရမ်းသက်တမ်းကုန်ဆုံးပါက အဆိုပါမြေနှင့်မြေပေါ်ရှိ ဆေးရုံအဆောက်အဦးများကို ဌာနသို့ပြန်လည်လွှဲပြောင်းပေးအပ်ရမည်ဖြစ်ပါသည်။ သို့ပါ၍ စာချုပ်ခေါင်းစဉ်အား မြေငှားစာချုပ် (Land Lease Agreement) အစား တည်ဆောက်၊ ပိုင်ဆိုင်၊ လုပ်ကိုင်၊ လွှဲပြောင်းရေးစာချုပ် (Build, Own, Operate and Transfer Agreement) (B.O.O.T) ဟု ရေးသားသင့်ပါ သည်။

၅။ တိုင်းဒေသကြီး (သို့မဟုတ်) ပြည်နယ်အစိုးရအဖွဲ့ဥပဒေပုဒ်မ ၃၃ ၌ တိုင်းဒေသကြီး (သို့မဟုတ်) ပြည်နယ်အစိုးရသည် ပြည်ထောင်စုအစိုးရကချမှတ်ထားသည့် မူဝါဒများနှင့် သော်လည်းကောင်း၊ ပြည်ထောင်စုဥပဒေများနှင့်သော်လည်းကောင်း မဆန့်ကျင်စေဘဲ တိုင်းဒေသကြီး (သို့မဟုတ်) ပြည်နယ်အတွင်းအကောင်အထည်ဖော် ဆောင်ရွက်မည့်လုပ်ငန်းများနှင့် စပ်လျဉ်းသည့် စီမံကိန်းများကိုလွှတ်တော်၏အတည်ပြုချက်ဖြင့် အကောင်အထည်ဖော်ဆောင်ရွက်ရမည်ဟု ပြဋ္ဌာန်းထားရာ စာချုပ်(မူကြမ်း)ပါ လုပ်ငန်းကိုလည်း ယင်းဥပဒေနှင့်အညီ ဆောင်ရွက်ရန်လိုအပ်ပါသည်။

၆။ စာချုပ်(မူကြမ်း)ပါ အဆင့်မီ ဆေးရုံဆောက်လုပ်ခြင်းနှင့် စပ်လျဉ်း၍ ၁၄-၈-၂၀၁၄ ရက်စွဲဖြင့် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်က ထုတ်ပြန်သော အမိန့်ကြော်ငြာစာအမှတ်(၅၀/၂၀၁၄)၏အပိုဒ်(က)သက်ဆိုင်ရာဝန်ကြီးဌာန၏သဘောထားမှတ်ချက်ဖြင့်နိုင်ငံသားနှင့်ဖက်စပ်စနစ်ဖြင့်သာဆောင်ရွက်ခွင့်ပြုသည့် စီးပွားရေးလုပ်ငန်းအမျိုးအစားများစာရင်း၊ အမှတ်စဉ် ၆ ၌ ကျန်းမာရေးဝန်ကြီးဌာန၏ လုပ်ငန်းများတွင် ပုဂ္ဂလိကဆေးရုံလုပ်ငန်းပါဝင်ကြောင်း ဖော်ပြထား သည်ကို သိရှိနိုင်ရန်အတွက် ဖော်ပြအပ်ပါသည်။

၇။ စာချုပ်ချုပ်ဆိုမည့် ဖက်စပ်ကုမ္ပဏီသည် ဥပဒေအရ တရားဝင်ဖွဲ့စည်းထားသော ကုမ္ပဏီဟုတ် မဟုတ်၊ စာချုပ်ပါလုပ်ငန်းကို လုပ်ကိုင်နိုင်ခွင့်နှင့် လုပ်ကိုင်နိုင်စွမ်းရှိ မရှိ၊ ငွေကြေးအင်အားပြည့်စုံမှုရှိ မရှိ၊ စာချုပ်တွင်လက်မှတ်ရေးထိုးမည့်သူသည် တရားဝင်လွှဲအပ်ထားခြင်းခံရသူဟုတ် မဟုတ် စသည်တို့အတွက် သက်ဆိုင်ရာ စာရွက်စာတမ်းများ တောင်းယူစိစစ်သင့် ပါသည်။

၈။ ဤစာချုပ်(မူကြမ်း)ကို ပြည်ထောင်စုရှေ့နေချုပ် ဥပဒေနှင့်အညီ ဥပဒေကြောင်း အရသာ ဥပဒေအကြံဉာဏ်ပေးခြင်းဖြစ်ပါသည်။ ဥပဒေရေးရာမဟုတ်သည့် စီမံရေးရာ၊ ဘဏ္ဍာရေးရာ၊ ကျွမ်းကျင်မှုဆိုင်ရာကိစ္စရပ်များကို ဤရုံးအနေဖြင့် မှတ်ချက်ပေးရန်မရှိပါကြောင်းနှင့် ယင်းကိစ္စရပ်များနှင့်စပ်လျဉ်း၍ သက်ဆိုင်ရာကျွမ်းကျင်သူများနှင့် ဆွေးနွေးညှိနှိုင်းဆောင်ရွက်ရန် အကြံပြုပါသည်။

၉။ ဤစာချုပ်(မူကြမ်း)ကို လက်မှတ်ရေးထိုးချုပ်ဆိုပြီးပါက မှတ်တမ်းတင် ထားနိုင်ရန် အတွက် ဤရုံးသို့ မိတ္တူ(၃)စောင်ပေးပို့ပါရန် မေတ္တာရပ်ခံအပ်ပါသည်။

၁၀။ ဤအကြံပြုချက်ကို လျှို့ဝှက်အဆင့် သတ်မှတ်ဆောင်ရွက်ရန်ဖြစ်ပါသည်။

၂၀.၁၀.၂၀၁၅

(ကျော်ဆန်း)

ညွှန်ကြားရေးမှူးချုပ်(တာဝန်)

ကျန်းမာရေးဝန်ကြီးဌာန

ဝန်ကြီးရုံး

မိတ္တူ - ရုံးလက်ခံ / မျှောစာတွဲ

Allen&Gledhill

Draft 22/12/2015

Dated [•]

MINISTRY OF HEALTH, THE REPUBLIC OF THE UNION OF MYANMAR

And

ANDAMAN ALLIANCE HEALTHCARE LIMITED

BUILD, OPERATE, AND TRANSFER AGREEMENT

ALLEN & GLEDHILL (MYANMAR) CO., LTD.
NO. 05-03, UNION BUSINESS CENTRE (UBC)
NAT MAUK ROAD, BO CHO QUARTER
BAHAN TOWNSHIP, YANGON
MYANMAR

TABLE OF CONTENTS

အကြောင်းအရာ

Contents Page

1. Definitions and Interpretation 2
2. Warranties and Representations 5
3. Build Operate and Transfer 5
4. Land Use Premium and Annual Rent 7
5. Construction of the Hospital 9
6. Obligations of the Lessor 9
7. Obligations of the Lessee 10
8. Payments relating to the Property 11
9. Performance Guarantee 12
10. Right of Re-entry 12
11. Protection of Environment and Mineral Resources 12
12. Force Majeure 13
13. Termination 13
14. Extended Lease Terms 14
15. Entire Agreement 16
16. Amendments and Renegotiation 16
17. Notice 17
18. Rights of Third Parties 18
19. Counterparts 18
20. Language 18
21. Governing Law 18
22. Dispute Resolution 18

Annexure 1 Description of Property 20

BUILD, OPERATE, AND TRANSFER AGREEMENT

This Build, Operate, and Transfer Agreement is mutually entered into in ...., on the day of ...., by and between

(1) U/Daw ...., [Designation] ...., [Department] ...., Ministry of Health representing the Ministry of Health, Government of the Republic of the Union of Myanmar (hereinafter referred to as "Lessor" which expression shall include its successors and permitted assigns) of the one part, and

(2) Mr./Ms. ...., Passport No./NRC No. ...., [Designation] ...., Andaman Alliance Healthcare Limited representing Andaman Alliance Healthcare Limited (hereinafter referred to as "Lessee" which expression shall include its successors and permitted assigns) of the other part,

under the following terms and conditions.

Whereas:

(A) The objective of the Project is to improve thehealthcare standards of the Republic of the Union of Myanmar through the establishment of a hospital of international standard, and not solely for commercial gain.

(B) The Lessor is the Ministry of Health of the Republic of the Union of Myanmar and has full power and capacity to grant the Lessee permission and a lease over the Property to buildand operate the Hospital in accordance with the terms of this Agreement.

(C) The Lessee is an entity within a group of companies which owns an international hospital brand, and the Lessee is desirous of building and operating the Hospital at the Property.

It is agreed as follows:

1. Definitions and Interpretation

1.1 Definitions:

In this Agreement and the Annexes, unless there is something in the subject or context inconsistent therewith:

“**Agreement**” means this Agreement and includesAnnexure 1.

“**Defaulting Party**” shall have the meaning ascribed to it in Clause13.2.1.

“**Effective Date**” means the date of this Agreement;

“**Extended Lease Terms**” means the First Extended Lease Term and the Second Extended Lease Term, and “**Extended Lease Term**” means either of them.

“**First Extended Lease Term**” shall have the meaning ascribed to it in Clause 3.2.2.

“**Force Majeure**” means any circumstances beyond the reasonable control of either the Lessor or the Lessee which directly or indirectly prevents or impedes the due performance of the Agreement, including but without limitation to, an act of God, flooding, national emergency, war, or insurgency

"**Grace Period**” shall have the meaning ascribed to it in Clause 3.1.

“**Hospital**” means the private hospital to be developed and operated at the Property.

“**Initial Lease Term**” shall have the meaning ascribed to it in Clause 3.2.1

“**Initial Lease TermCommencement Date**” means the Opening Date or the day immediately following the date of expiry of the Grace Period, whichever is earlier;

“**Laws**” shall mean the laws of Myanmar;

“**Land Use Premium**” shall have the meaning ascribed to it in Clause 4.3.

“**Lease**” shall have the meaning ascribed to it in Clause 3.2.1

“**MIC**” means the Myanmar Investment Commission, a statutory body formed under the Myanmar Foreign Investment Law of 2012 to appraise foreign investment proposals.

“**MIC Permit**” means the permit issued by the MIC approving the material terms of the investment for the Project, including the terms of this Agreement and the permitted duration of the investment.

“**Myanmar**” means the Republic of the Union of Myanmar.

“**Non-Defaulting Party**” shall have the meaning ascribed to it in Clause 13.2.1.

"**Opening Date**" means the date of the issuance of the private hospital Licenceby the Central Body relating to private health care services.

“**Permission**” shall have the meaning ascribed to it in Clause 3.1.

“**Project**” means the building, operation and transferof the Hospital.

“**Property**” means the whole of the plot of land as described and demarcated in the plan attached hereto as **Annexure 1**together with any building(s) to be erected thereon.

“**Second Extended Lease Term**” shall have the meaning ascribed to it in Clause3.2.3.

“**Stipulated Bank Account**” shall have the meaning ascribed to it in Clause 4.3.2

1.2 General

The following rules of interpretation apply unless the context requires otherwise:

1.2.1 A person includes an individual and a corporation.

1.2.2 A reference to the Lessor includes its successors and assigns and all persons entitled to possession of the Property at the end of this Agreement. A reference to the Lessee includes its successors and permitted assigns.

1.2.3 Each schedule of and annexure to this Agreement forms part of it.

1.2.4 Unless stated otherwise, one word or provision does not limit the effect of another.

1.2.5 Reference to the whole includes part.

1.2.6 If under this Agreement, the consent or approval of the Lessor is required, the consent and approval of the Lessor shall not be unreasonably withheld.

1.2.7 Any reference to a statutory provision shall include any subsidiary legislation made from time to time under that provision which is in force at the Effective Date.

2. Warranties and Representations

2.1 Each Party hereby represents and warrants to and for the benefit of the other as follows:

2.1.1 in the case of the Lessor,

(i) it is the Ministry of Health, a Union-Level Ministryof Healthandis the legal and beneficial owner of the Property duly empowered to manage and administer the Property;

(ii) the Property is free of all claims, encumbrances and caveats of any nature;

2.1.2 in the case of the Lessee,

(i) it is a company duly incorporated and validly existing under the Laws of Myanmar;

(ii) ithas the power and authority to conduct the business which it conducts and/or proposes to conduct;

2.1.3 all actions, conditions and things required to be taken, fulfilled and done by it in order (i) to enable it lawfully to enter into, exercise its rights and perform and comply with its obligations under this Agreement, (ii) to ensure that those obligations are valid, legally binding and enforceable, and (iii) to make this Agreementadmissible in evidence in the courts of Myanmar, have been taken, fulfilled and done; and

2.1.4 its entry into, exercise of its rights and/or performance of or compliance with its obligations under this Agreementdo not and will not violate, or exceed any power or restriction granted or imposed byany Laws to which it is subject.

2.2 The warranties extended by each Party pursuant to Clause 2.1 are deemed to be repeated by the respective Parties at the commencement of the Initial Lease Term andany Extended Lease Term.

3. Build Operate and Transfer

3.1 Permission to Build

The Lessor hereby grants unto the Lessee, and the Lessee hereby accepts, the Lessor's permission ("**Permission**") for the exclusive, unrestricted and uninterrupted access by the Lessee and all persons authorised by the Lessee to the Property (including, but without limitation to, the right to bring workmen, equipment, materials and appliances onto the Property) for the purposes ofbuilding and completing the Hospital,commencing from the Effective Date and ending 48 months thereafter or as may be extended pursuant to Clause 5.2("**Grace Period**").

3.2 Lease to Operate

The Lessor hereby grants unto the Lessee and the Lessee hereby accepts:

3.2.1 a lease ("**Lease**") of the Property for an initial term of 50 years commencing from the Initial Lease Term Commencement Date ("**Initial Lease Term**");

3.2.2 subject to the provisions of Clause 14.1, a lease of the Property for a further term of ten (10) years commencing on the day immediately following the date of expiry of the Initial Lease Term (the "**First Extended Lease Term**"); and

3.2.3 subject to the provisions of Clause 14.2, a lease of the Property for a further term of ten (10) years upon expiry of the First Extended Lease Term, commencing on the day immediately following the date of expiry of the First Extended Lease Term (the "**Second Extended Lease Term**")

for the Lessee to operate the Hospital.

3.3 Transfer of Property

3.3.1 The Lessee shall, within three months from the effective date of termination or the expiration of this Agreement, transferto the Lessor on an "as is where is" basis and without any consideration:

(i) the Property together with any fixtures and other immovable property thereon;

(ii) immovable medical equipment which includes fixtures in the operating theatre such as pendants, lights, monitors and the operating theatre tables; and

(iii) beds

3.3.2 For the avoidance of doubt, all movable non-medical and medical equipment (including but not limited to the Magnetic Resonance Imaging machine, CT Scanner, Ultrasound machines etc) shall not be considered to be fixtures and shall not be transferred to the Lessor for the purposes of Clause 3.3.1. The Lessee may transfer such assets to the Lessor on an "as is where is" basis subject to the mutual agreement of the Parties and on such consideration as may be agreed.

4. Land Use Premium and Annual Rent

4.1 The Parties agree that:

4.1.1 the consideration for the lease of the Property for the Initial Lease Term shall comprise of the Land Use Premium and the annual rent only;

4.1.2 the Lessee shall not, except for the Land Use Premium, pay any rent or any other sums in connection with the Permission granted in accordance with Clause 3.1before the Initial Lease Term Commencement Date.

4.2 The Lessee agrees to pay the Land Use Premium and the annual rent to the Lessorin accordance with the terms of this Clause 4.

4.3 The "**Land Use Premium**" shall be:

4.3.1 an amount equal toUS$2,000,000 (United States Dollars Two Million Only) per acre multiplied by the number of acres comprising the land area only of the Property;and

4.3.2 paidin the following manner to the bank account of the Lessor, details of which the Lessor shall furnish in writing to the Lessee ("**Stipulated Bank Account**"):

(i) 30% shall be so paid no later than 3 months fromthe date of execution of this Agreement;

(ii) 30% shall be so paid after the payment in Clause 4.3.2 (i) is made and no later than 6 monthsfrom the execution of this Agreement; and

(iii) 40% shall be so paid after the payment in Clause 4.3.2 (ii) is made and no later than 42 monthsfrom the execution of this Agreement;

4.4 Annual Rent

4.4.1 The annual rent payable in respect of the first fiveyears of the Initial Lease Term shall be US$18 per square metre of 75% of the gross or total floor area of the Hospital.

4.4.2 The Lessee must pay the annual rent:

(i) for the first three years of the Initial Lease Term, every six months in advance commencing on the Initial Lease Term Commencement Date; and

(ii) for the remainder of the Initial Lease Term, annually in advance commencing on the third anniversary of the Initial Lease Term Commencement Date;

by depositing the amount payable into the Stipulated Bank Account.

4.4.3 The annual rent shall be revisedto the prevailing land rental value of the Propertyat the end of every five-year period commencing from the fifthanniversary of the Initial Lease Term Commencement Date, as may be determined by an independentinternational professional valuer as may be agreed by the Parties provided that any increase in annual rent payable for every five-year period shall not exceed 5% of the annual rent applicable to the immediate preceding five-year period. The Lessee shall bear the cost of the appointment of any valuer made pursuant to this Clause 4.4.3.

4.4.4 If the Lessee fails to pay the annual rent or the monthly rent (where applicable) within thirty days from the dates stipulated in Clauses 4.4.2, the Lessee shall pay

to the Lessor, a penalty equal to 5% per annum on the unpaid amount accruing on a monthly basis.

5. Construction of the Hospital

5.1 The Lessee shall endeavour to complete construction of the Hospitaland procure issuance of the Building Completion Certificatewithin the Grace Period.

5.2 If the construction of the Hospital is, in the Lessee's reasonable opinion, likely to be delayed or has been delayed due to any of the following events:

5.2.1 a Force Majeure event as provided in Clause 12;

5.2.2 any act of prevention, breach of contract, delay or impediment caused by the Lessor;

5.2.3 any delay in the issuance of any necessary governmental, regulatory and other approvals from relevant authorities in Myanmar,and/or licenses, permits and consents which may be required in connection with the construction of the Hospital;

5.2.4 the discovery of precious stones, minerals, oil or cultural artefacts on the Property;

5.2.5 any event or circumstance beyond the reasonable control of the Lessee despite the exercise of reasonable diligence on the Lessee's part; and

5.2.6 such other cause as the Parties may agree in writing,

the Lessee shall (without having to pay any fees, damages, charges or penalties) be entitled to an extension of the Grace Period for a duration equal to the duration of the delay.

6. Obligations of the Lessor

6.1 The Lessor shall put the Lessee in vacant possession of the Property from the EffectiveDate. The Lessor shall be responsible for resolving any proceedings, claims, actions or demands by any third parties relating to or in connection with ownership of the Property.

6.2 The Lessor shall be responsible for payment of all land tax and land revenue only payable to the government to maintain the Lessor's title to the Property.

6.3 The Lessor shall use its best endeavours to assist the Lessee in:

6.3.1 obtaining all requisite approvals, licences and permits from the relevant authorities or agencies in Myanmar (including such approval of MIC, where applicable) for the grant of the rights of access to the Property in accordance with Clause 3.1 and the lease of the Property for the Initial Lease Term and any Extended Lease Term; and

6.3.2 obtaining all tax exemptions and tax relief as may be available to the Lessee pursuant to the Foreign Investment Law (2012) in connection with the import of all plant and equipment, machinery and spare parts to be used in connection with the Project.

6.4 The Lessor hereby covenants with the Lessee that:

6.4.1 the Lessee may lawfully and peaceably hold and enjoy the Property throughout the Grace Period, Initial Lease Term and any Extended Lease Term without any interruption, disruption or disturbance of whatsoever nature by the Lessor or by any person lawfully claiming through, under or in trust for the Lessor; and

6.4.2 in the event of any transfer by the Lessor of its title and interests in the Land, such transfer shall be made subject to this Agreement. The Lessor shall procure the transferee to undertake in writing to the Lessee that it shall be bound by all the terms, covenants, stipulations and conditions of the Agreement but nothing herein shall be construed to affect or prejudice the Lessee's rights against the Lessor in the event of any non-performance, non-observance or non-compliance of this Agreement.

7. Obligations of the Lessee

7.1 The Lessee shall carry out and complete the construction of the Hospitalin accordance with the terms and conditions of this Agreement.

7.2 The Lessee shall pay the Land Use Premium, annual rent and all other sums payable without delay and in accordance with the terms and conditions of this Agreement

7.3 The Lessee shall occupy the Property and use the Property only for purposes of theProject, including all uses which are ancillary to or associated with the operation of a Hospital. The operation of the Hospital shall be conducted in accordance with the MIC Permit and the private hospital license issued by theby the Central Body relating to private health care services.

7.4 The Lessee shall comply with the Law Relating to Private Health Care Services in Myanmar in connection with the use of the Property including but not limited to safety and health requirements.

7.5 The Lessee shall not mortgage any part of the leasehold interest hereby created without the approval of the MIC, provided always that any such mortgage shall be conducted in accordance with Myanmar Foreign Investment Law (2012). For the avoidance of doubt, the Lessee may sub-lease, transfer or assign its rights under this Agreement in accordance with applicable Law provided that the Lessee shall not sub-lease any material portion of the Hospital without the Lessor's approval.

7.6 The Lessee shall inform the Lessor as soon as practicable if precious stones, minerals, oil or cultural artefacts are discovered on the Property at any time during the Grace Period, the Initial Lease Term and any Extended Lease Term.

8. Payments relating to the Property

For the avoidance of doubt, the following payments relating to the Property shall be borne by the relevant Party as set out below:

8.1 The Lessee shall pay for;

8.1.1 the Land Use Premium; and

8.1.2 the annual rent,

in accordance with Clause 4; and

8.1.3 the applicable stamp duty, notarial fees and registration taxes and duties payable as a result of the execution of this Agreement or any transaction contemplated hereunder.

8.2 The Lessor shall be responsible for payment of all land tax and land revenue only payable to the government to maintain the Lessor's title to the Propertyin accordance with Clause 6.2

9. Performance Guarantee

The Lessee shall, within twomonths from the Effective Date, provide the Lessor with a banker's guarantee issued by [indicate bank]for an amount equal to US$4.50 per square metre of 75% of the gross or total floor areaof the Hospital ("**Performance Guarantee**"). The Performance Guarantee shall be valid for six years and shall constitute security for the Lessee's obligation to construct the Hospital.

10. Right of Re-entry

If the Lessee, in any substantial respect, fails to perform or observe the terms and conditions of this Agreement and fails to rectify such non-performance or non-observance within six months after receiving written notice in writing from the Lessor of such default, the Lessor shall be at liberty to re-enter upon and take possession of the Property and thisAgreement shall, thereupon, determine and terminate, provided that (a) a delay in the completion of the construction of the Hospital shall not constitute a substantial failure by the Lessee to perform or observe the terms and conditions of this Agreement unless the Opening Date does not occur within six years from the Effective Date; and (b) such right of re-entry shall not prejudice any right of action of the Lessor for recovery of money from the Lessee by way rent or compensation for damages;

11. Protection of Environment and Mineral Resources

11.1 The Lessee shall comply with the prevailing laws and regulations of Myanmar in respect of the conservation of the environment at the Property including but not limited to using reasonable efforts to install waste water treatment facilities and other waste management facilities to be used in connection with the Project.

11.2 All precious stones, minerals, oil or cultural artefacts located on the Property belong to the Government of Myanmarwhich shall be at liberty to excavate the aforesaid finds from the Property upon granting the Lessee60 days' notice in writing, in accordance with laws, rules and regulations of Myanmar provided that such excavation activities do not disturb the Lessee's use and enjoyment of the Property.

11.3 The Lessor hereby agrees to reimburse the Lessee all of its actual losses, damages costs and expenses (including,but without limitation, loss of profit due to any delay in the Opening Date or the suspension of, or any interruption in, the operations of the Hospital) which the Lessee may suffer or incur, directly or indirectly, as a result of the Lessor exercising its under or pursuant to Clause 11.2.

12. Force Majeure

In the event that the performance of any obligation hereunder of either Party is prevented by an event of Force Majeure then the Party so affected shall, upon prompt written notice to the other Party, be excused from performance to the extent of such preventing circumstance for so long as the Force Majeure condition continues to subsist, provided, however, that an event of Force Majeure shall not be recognised under this Agreement unless the Party seeking to assert such an event gives notice of the existence of such event to the other Party, which notice shall explain in reasonable detail the nature of the Force Majeure Event, the obligations that have been affected by the Force Majeure Event and how such Force Majeure Event has impaired the performance of such obligations.

13. Termination

13.1 This Agreementshall govern the Parties' obligations and shall be deemed to continue in full force and effect until such time that, the Parties have obtained MIC approval and agree mutually to its termination in writing,or all obligations of the respective Parties under this Agreement have been performed and discharged in full.

13.2 Subject to MIC approval, this Agreement may be terminated by the Party described below by 30 days' written notice to the other Party and on the occurrence of any of the following:

13.2.1 by any Party ("**Non-Defaulting Party**"), where the other Party ("**Defaulting Party**") is in material breach of this Agreement, and fails to rectify such material breach

within six months of the Non-Defaulting Party notifying the Defaulting Party in writing of the breach provided that a delay in the completion of the construction of Hospital shall not constitute a material breach by the Lessee for purposes of this Agreement;

13.2.2 by the Lesseeif, in the Lessee's reasonable opinion, the Lessee:

(i) has suffered substantial losses for a duration exceeding 3years; or

(ii) is no longer able to implement the Project; and

13.2.3 byeither party,in the event of the continuation of a Force Majeure condition for more than six months.

13.3 Upon the expiration of the Initial Lease Term (in the event that the Lessee does not serve any written notice of extension in accordance with Clause 14) or the last of the Extended Lease Term (where the Lessee has served a written notice of extension in accordance with Clause 14) or if this Agreement is terminated in accordance with Clause 13, the Lessee shall, subject to its obligations under Clause 3.3.1,be entitled to remove all of its furniture, equipment, stock in trade, goods, movable property, signage, logos and trademarks from the Property at its own cost and expense and the Lessor must provide the Lessee with reasonable access to the Property for this purpose at reasonable times.

14. Extended Lease Terms

14.1 First Extended Lease Term

If the Lessee serves a written notice of extension on the Lessor not less than 12 months before the date of expiry of the Initial Lease Term, and subject to MIC approval having been obtained, the Parties shall, upon determination of the Initial Lease Term be deemed to have entered into a lease of the Property for the First Extended Lease Term and on the same terms and conditions as set out in this Agreement save and except that in their application to the First Extended Lease Term:

14.1.1 there shall be no Grace Period for construction of the Hospital in respect of the First Extended Lease Term and the "Initial Lease Term Commencement Date" shall mean the first day of the First Extended Lease Term;

14.1.2 the duration of the First Extended Lease Term shall be 10 years commencing on the date of commencement of the First Extended Lease Term;

14.1.3 there shall be no land use premium to be paid by the Lessee to the Lessor after the Initial Lease Term and in respect of the Extended Lease Terms and the consideration for the lease of the Property for the First Extended Lease Term shall comprise of the annual rent only;

14.1.4 the annual rent payable in respect of the lease of the Property for the First Extended Lease Term shall be:

(i) calculated in accordance with the prevailing land rental value to be determined in the manner provided under Clause 4.4.3, provided that the annual rent for the First Extended Lease Term shall not exceed 10% of the annual rent applicable to the last year of the Initial Lease Term; and

(ii) payable annually in advance commencing on the first day of the First Extended Lease Term by depositing the amount payable into the Stipulated Bank Account; and

14.1.5 the Lessee shall have the right to the grant of a further 10 year term in accordance with the provisions of Clause 14.2upon expiry of the First Extended Lease Term.

14.2 Second Renewal Lease Term

If the Lessee serves a written notice of extension on the Lessor not less than 12 months before the date of expiry of the First Extended Lease Term, and subject to MIC approval having been obtained the Parties shall, upon determination of the First Extended Lease Term be deemed to have entered into a lease of the Property for the Second Extended Lease Term and on the same terms and conditions as set out in this Agreement save and except that in their application to the Second Extended Lease Term:

14.2.1 there shall be no Grace Period for construction of the Hospital in respect of the Second Extended Lease Term and the "Initial Lease Term Commencement Date" shall be mean the first day of the Second Extended Lease Term;

14.2.2 the duration of the Second Extended Lease Term shall be 10 years commencing on the date of commencement of the Second Extended Lease Term;

14.2.3 there shall be no land use premium to be paid by the Lessee to the Lessor after the Initial Lease Term and in respect of the Extended Lease Terms and the consideration for the lease of the Property for the Second Extended Lease Term shall comprise of the annual rent only.

14.2.4 the annual rent payable in respect of the lease of the Property for the Second Extended Lease Term shall be

(i) calculated in accordance with the prevailing land rental value to be determined in the manner provided under Clause 4.4.3, provided that the annual rent for the Second Extended Lease Term shall not exceed 10% of the annual rent applicable to the last year of the First Extended Lease Term; and

(ii) payable annually in advance commencing on the first day of the Second Extended Lease Term by depositing the amount payable into the Stipulated Bank Account; and

14.2.5 Clause14shall be excluded.

15. Entire Agreement

This Agreement constitutes the entire agreement between the parties. Each party confirms that it has not relied upon any representation not recorded in this document inducing it to enter into this Agreement.

16. Amendments and Renegotiation

16.1 No variation of these terms and conditions will be valid unless confirmed in writing by authorised signatories of both parties on or after the Effective Date.

16.2 In the event that any situation or condition arises due to circumstances not envisaged in this Agreement, including but not limited to any change in Laws, rules regulations, notification or policies of Myanmar, the Parties shall renegotiate the terms of this Agreement in good faith and make the necessary amendments.

17. Notice

17.1 All notices or other communications required or permitted to be given or made under this Agreement shall be in writing in the English language and delivered personally or sent by international courier or by e-mail addressed to the intended recipient thereof at its address or email address, and marked for the attention of such person (if any), designated by each Party to the other Party for the purposes of this Agreement. The initial address and person (if any) so designated by the Parties are set out below:

To the Lessor

Address : **[•]**
E-mail Address : **[•]**
Attention : **[•]**

To the Lessee

Address : **[•]**
E-mail Address : **[•]**
Attention : **[•]**

17.2 Any such notice or communication shall be deemed to have been duly served:

17.2.1 if given or made by letter, immediately if hand delivered or three business days after sending by international courier and in proving the same it shall be sufficient to show the receipt from the international courier showing that the package was duly addressed and the date on which it was sent; and

17.2.2 if sent by email, the earlier of:

(i) when the sender receives an automated message confirming delivery; or

(ii) four hours after the time sent (as recorded on the device from which the sender sent the email) unless the sender receives an automated message that the email has not been delivered,

provided that where such delivery or transmission occurs after 5 p.m. on a business day or on a day which is not a business day, service shall be deemed to occur at 9 a.m. on the next following business day. Reference to "business day" means a day that is not a Saturday, Sunday or public holiday in Myanmar.

18. Rights of Third Parties

Save as expressly provided in this Agreement, a person who is not a party to this Agreement has no rights to enforce or enjoy the benefit of any terms of this Agreement.

19. Counterparts

This Agreement may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument. Any Party may enter into this Agreement by signing any such counterpart.

20. Language

This Agreement is prepared in both the English and the Myanmar language. In the event of an inconsistency, the Myanmar language shall prevail.

21. Governing Law

This Agreement shall be governed by, performed and construed in accordance with, the laws of the Myanmar.

22. Dispute Resolution

22.1 In case any dispute or difference shall arise between the Parties as to the construction of this Agreement or as to any matter of whatsoever nature arising hereunder or in connection therewith, including any question regarding its existence, validity or

termination, such dispute or difference shall be submitted to arbitration. The seat and thevenue of the arbitration shall be Myanmar and the arbitration shall be conducted in English. The award of the arbitration tribunal shall be final and binding on the Parties. The arbitration tribunal shall consist of one (1) arbitrator who shall not be a citizen of Myanmar or a citizen of the Republic of Singapore.

22.2 The arbitral award made and granted by the arbitrator shall be final and binding.

22.3 Neither of the Parties shall be entitled to commence or maintain any action in a court of law upon any matter in dispute arising from or in relation to this Agreement except for the enforcement of an arbitral award granted pursuant to this Clause 22, and save and except in connection with interim relief, pursuant to the commencement of arbitration proceedings.

22.4 During the period of submission to arbitration and thereafter until the granting of the arbitral award, the Parties shall, except in the event of termination, continue to perform their obligation under and the terms and conditions of this Agreement that are not in dispute, to the extent possible, without prejudice to a final adjustment in accordance with the said award.

Annexure 1

Description of Property

Address: Plot number 10^B, Block number 20^F, Lanmadaw Township (located in the Yangon CBD at the corner of Pyay Road and Bo Gyoke Road)

Size: 4.3 Acres

[*Insert plan of Property*]

In witness whereof this Agreement has been entered into on the date stated at the beginning.

The Lessor

SIGNED by **[Click here and type individual name]**
for and on behalf of

MINISTRY OF HEALTH,
THE REPUBLIC OF THE UNION OF MYANMAR

in the presence of:

____
Witness' signature

Name:

Address:

The Lessee

SIGNED by **[Click here and type individual name]**
for and on behalf of

ANDAMAN ALLIANCE HEALTHCARE LIMITED

in the presence of:

Witness' signature

Name:

Address:

- **Annex E Draft Joint Venture Agreement**

Parkway
YANGON

(A&GM Comments 12 November 2015)

Dated this day of 2015

Among

AMMK MEDICARE COMPANY LTD

GLOBAL STAR COMPANY, LTD

MACONDRAY HOLDINGS PTE. LTD.

and

PARKWAY HEALTHCARE INDO-CHINA PTE. LTD.

JOINT VENTURE AGREEMENT

WONG PARTNERSHIP

WONGPARTNERSHIP LLP
12 Marina Boulevard Level 28
Marina Bay Financial Centre Tower 3
Singapore 018982
Tel: +65 6416 8000
Fax: +65 6532 5711/+65 6532 5722
Email: contactus@wongpartnership.com
Website: www.wongpartnership.com

TABLE OF CONTENTS

CLAUSE	*HEADING*	*PAGE*
1.	DEFINITIONS AND INTERPRETATION	2
2.	OBJECTIVES OF THE PARTIES	10
3.	CAPITAL STRUCTURE OF THE COMPANY	10
4.	EFFECTIVE DATE, WARRANTIES AND COVENANTS	11
5.	EXERCISE OF RIGHTS	13
6.	APPOINTMENT OF LOCAL PARTNER REPRESENTATIVE	13
7.	BOARD OF DIRECTORS	14
8.	SHAREHOLDERS' MEETINGS	17
9.	REGISTERED OFFICE ETC	17
10.	FINANCE FOR THE COMPANY	18
11.	DIVIDEND POLICY	19
12.	ADMINISTRATION	20
13.	CONFLICT OF INTERESTS	21
14.	RESERVED MATTERS	21
15.	INFORMATION RIGHTS	21
16.	PREEMPTIVE RIGHTS: ISSUE OF NEW SHARES	23
17.	TRANSFER OF SHARES	23
18.	TRANSFER OF SHARES: CHANGE IN CONTROL	27
19.	TAG-ALONG RIGHTS	29
20.	TERMINATION	31
21.	DEADLOCK	31
22.	DEFAULT	34
23.	NON-COMPETITION	40
24.	CONFIDENTIALITY	40
25.	ANNOUNCEMENTS	41
26.	COSTS	42
27.	GENERAL	42
28.	ILLEGALITY	43
29.	NOTICES	43
30.	FURTHER ASSURANCE	44
31.	ENTIRE AGREEMENT	44
32.	ASSIGNMENT	44
33.	VARIATIONS	44
34.	REMEDIES AND WAIVERS	45
35.	SEVERAL OBLIGATIONS	45
36.	NO PARTNERSHIP	45
37.	SPIRIT OF AGREEMENT AND INTENTION	45

38.	TIME OF ESSENCE	45
39.	FORCE MAJEURE	45
40.	COUNTERPARTS	46
41.	JOINT AND SEVERAL LIABILITY	46
42.	RIGHTS OF THIRD PARTIES	46
43.	GOVERNING LAW	46
44.	DISPUTE RESOLUTION	46
SCHEDULE 1	FORM OF EQUITY DRAWDOWN NOTICE	47
SCHEDULE 2	FORM OF LOAN DRAWDOWN NOTICE	48
SCHEDULE 3	RESERVED MATTERS	49
SCHEDULE 4	DEFAULT CALL OPTION NOTICE	51
SCHEDULE 5	DEFAULT PUT OPTION NOTICE	52
SCHEDULE 6	DEED OF RATIFICATION AND ACCESSION	53
APPENDIX A	TRADE MARK LICENCE AGREEMENT	55
APPENDIX B	HOSPITAL MANAGEMENT AGREEMENT	56
APPENDIX C	CONSULTANCY SERVICES AGREEMENT	57
APPENDIX D	MANAGEMENT SERVICES AGREEMENT	58

THIS JOINT VENTURE AGREEMENT is made on ___________________.

AMONG:

(1) **AMMK MEDICARE COMPANY LTD,** (Company Registration Number: 1397 of 2015-2016), a company incorporated in the Republic of the Union of Myanmar and having its registered office at 33, Pyay Road, 6 ½ Miles, (11) Quarter, Hlaing Township, Yangon, the Republic of the Union of Myanmar ("**AMMK**");

(2) **GLOBAL STAR COMPANY, LTD,** (Company Registration Number: 1507 of 2008-2009), a company incorporated in the Republic of the Union of Myanmar and having its registered office at No. 2, Bayint Nuang Main Road, Ywama Curve, Ward No. (2), Hlaing Township, Yangon, the Republic of the Union of Myanmar ("**GSC**");

(3) **MACONDRAY HOLDINGS PTE. LTD.,** (Company Registration Number: 201317874R), a company incorporated in Singapore and having its registered office at 78 Shenton Way, #28-01, Singapore (079120) ("**MHPL**"); and

(4) **PARKWAY HEALTHCARE INDO-CHINA PTE LTD** (Company Registration Number: 200723244M), a company incorporated in Singapore and having its registered office at 111 Somerset Road #15-01 Tripleone Somerset Singapore (238164) ("**PHIC**"),

(collectively, the "**Parties**" and each, a "**Party**").

WHEREAS:

(A) The Parties are desirous of forming a company incorporated in Myanmar (the "**Company**") as a joint venture company in Myanmar, with such name as may be agreed by the Parties, to construct, develop, manage and operate a multi-specialty hospital of international standard which shall have 250 beds (the "**Hospital**") at the Property (the "**Project**").

(B) The Parties agree that the Hospital shall be branded under the "**Parkway**" brand ("**Brand**") and the Company shall be obliged to use such Brand on terms and conditions as may be determined by the relevant Parkway Group Entity (as defined below) licensing the Brand. In this connection, the Parties agree that the Company will enter into the Trade Mark Licence Agreement with the relevant Parkway Group Entity in the form set out in Appendix A of this Agreement (the "**Trade Mark Licence Agreement**").

(C) The Parties further agree that the Company will enter into:

(i) a hospital management agreement with Gleneagles Management Services Pte Ltd ("**GMS**") for the management and operation of the Hospital by GMS in the form set out in Appendix B of this Agreement (the "**Hospital Management Agreement**");

(ii) a consultancy services agreement with GMS for the provision of consultancy services by GMS in the form set out in Appendix C of this Agreement (the "**Consultancy Services Agreement**"); and

(iii) a management services agreement with AMMK pursuant to which AMMK will assist the Company in certain local management and administrative matters in Myanmar based on its local knowledge and expertise in the form set out in Appendix D of this Agreement (the "**Management Services Agreement**").

(D) The Parties intend that the Business (as defined below) and affairs of the Company shall be properly and efficiently managed and shall operate in accordance with sound commercial principles and in accordance with all applicable laws and all rules and regulations of all governmental and self-regulatory entities.

(E) To regulate the relationship of the Shareholders *inter se* as shareholders of the Company and in the conduct of the business and affairs of the Company in the spirit of mutual confidence and co-operation, the Parties have agreed to enter into this Agreement on the terms and conditions hereinafter set out.

NOW IT IS HEREBY AGREED as follows:

1. DEFINITIONS AND INTERPRETATION

1.1 In this Agreement and in the Schedules unless the context requires otherwise:

"**Affiliates**" means in relation to a company, any parent, subsidiary or holding company or related corporation of the company, any subsidiary of such holding company, and any company in which the company or any such holding company holds or controls directly or indirectly not less than 20% of the issued share capital;

"**Agreed Portion**" shall have the meaning ascribed to it in Clause 10.2;

"**AMMK**" shall have the meaning ascribed to it in the Preamble;

"**Allocation Notice**" shall have the meaning ascribed to it in Clause 17.6(c)(a) ;

"**Approved Accounting Firm**" means any of:

(a) Deloitte & Touche LLP;

(b) PricewaterhouseCoopers, LLP;

(c) Ernst & Young LLP; and

(d) KPMG LLP,

or any of their successor firms. In the event Myanmar law prohibits the firms listed above from acting as an Approved Accounting Firm for the purposes as set out in this Agreement, the Approved Accounting Firm shall be such certified public accountant which is authorised to operate in Myanmar, as may be selected by mutual agreement between the Shareholders;

"**Articles**" means the articles of association, for the time being, of the Company and references to "**Article**" shall be construed accordingly;

"**Available Profits**" shall have the meaning ascribed to it in Clause 11.3;

"**Board**" means the board of Directors, for the time being, of the Company;

"**Brand**" shall have the meaning ascribed to it in Recital (B);

"**Business**" means the proposed businesses of the Company as set out in Clause 2;

"**Business Day**" means a day (other than a Saturday, Sunday or gazetted public holiday) on which commercial banks are open for business in Singapore and Myanmar;

"**Buyer**" shall have the meaning ascribed to it in Clause 17.3;

"**Chairman**" means the chairman of the Board at any given time;

"**Change in Control**" means:

(a) with respect to the Local Partner Shareholders, U Aung Moe Kyaw and his immediate family, U Thurane Aung @ Christopher Aung and his immediate family or Mr. Chew Leong Chee and his immediate family ceasing to control or hold, directly or indirectly, at least 50% of the issued share capital in AMMK, GSC and MHPL respectively; and

(b) with respect to PHIC, Parkway Pantai Limited ceasing to hold, directly or indirectly, at least 50% of the issued share capital in PHIC;

"**Companies Act**" means the Myanmar Companies Act (1914);

"**Company**" shall have the meaning ascribed to it in Recital (A);

"**Confidential Information**" means any information which is proprietary and confidential to the Company including but not limited to information concerning or relating in any way whatsoever to the negotiation and preparation of this Agreement, the Trade Mark Licence Agreement, the Hospital Management Agreement, the Consultancy Services Agreement, and the Management Services Agreement, the Company's distributorship, franchise or other arrangements, principals, any of the trade secrets or confidential operations, processes or inventions carried on or used by the Company, any information concerning the organisation, business, finances, transactions or affairs of the Company, its dealings, secret or confidential information which relates to its business or any of its principals', clients' or customers' transactions or affairs, its technology, designs, documentation, manuals, budgets, financial statements or information, accounts, dealers' lists, customer lists, marketing studies, drawings, notes, memoranda and the information contained therein, any information therein in respect of trade secrets, technology and technical or other information relating to the development, analysis, marketing, sale or supply or proposed development, analysis, marketing, sale or supply of any products or services by the Company, and plans for the development or marketing of such products or services and information and material which is either marked confidential or is by its nature intended to be exclusively for the knowledge of the recipient alone;

"**Consultancy Services Agreement**" shall have the meaning ascribed to it in Recital (C)(ii);

"**Control**" means the authority, whether exercised or not, to direct or indirectly control a person's business and affairs, which authority shall conclusively be presumed to exist upon possession of beneficial ownership or power to direct the vote of more than 50% of the votes entitled to be cast or to control the composition of the board of directors and references to "**is Controlled by**" and "**is under the Control of**" shall be construed accordingly;

"**Deadlock**" shall have the meaning ascribed to it in Clause 20;

"**Deadlock Consideration**" shall have the meaning ascribed to it in Clause 21.7;

"**Deadlock Shares**" shall have the meaning ascribed to it in Clause 21.7;

"**Deed of Ratification and Accession**" means the deed to be executed by a purchaser or transferee of shares in the capital of the Company under which he agrees to be bound by, and shall be entitled to the benefit of, this Agreement, as if an original party hereto in place of the Transferring Shareholder, substantially in the form set out in Schedule 6;

"**Deemed Offer**" shall have the meaning ascribed to it in Clause 18.2 (b)(i);

"**Default Call Option**" shall have the meaning ascribed to it in Clause 22.2(b)(ii);

"**Default Call Option Notice**" shall have the meaning ascribed to it in Clause 22.3;

"**Default Event**" shall have the meaning ascribed to it in Clause 22.1;

"**Default Option Completion**" shall have the meaning ascribed to it in Clause 22.11;

"**Default Option Shares**" means the Defaulting Party's Shares (in the event the Default Call Option is exercised) or the Non-Defaulting Party's Shares (in the event the Default Put Option is exercised);

"**Default Put Option**" shall have the meaning ascribed to it in Clause 22.2(b)(ii);

"**Default Put Option Notice**" shall have the meaning ascribed to it in Clause 22.5;

"**Default Transferee(s)**" means the Non-Defaulting Party(ies) (in the event the Default Call Option is exercised) or the Defaulting Party (in the event the Default Put Option is exercised);

"**Default Transferor(s)**" means the Defaulting Party (in the event the Default Call Option is exercised) or the Non-Defaulting Party(ies) (in the event the Default Put Option is exercised);

"**Defaulting Party**" shall have the meaning ascribed to it in Clause 22.2;

"**Defaulting Party's Shares**" shall have the meaning ascribed to it in Clause 22.2(b)(i);

"**Deputy Chairman**" means the deputy chairman of the Board at any given time;

"**DICA**" shall have the meaning ascribed to it in Clause 4.1(a);

"**Director**" means a director at any given time of the Company;

"**Encumbrance**" means any mortgage, assignment of receivables, debenture, lien, hypothecation, charge, pledge, title retention, right to acquire, security interest, option, pre-emptive or other similar right, right of first refusal, restriction, third-party right or interest, any other encumbrance, condition or security interest whatsoever or any other type of preferential arrangement (including without limitation, a title transfer or retention arrangement) having similar effect;

"**Equity Drawdown Notice**" shall have the meaning ascribed to it in Clause 10.3;

"**Fair Market Value**" means the price as determined by a Valuer to be the market value of each Share;

"**First Adjourned Board Meeting**" shall have the meaning ascribed to it in Clause 7.12;

"**First Adjourned Shareholders Meeting**" shall have the meaning ascribed to it in Clause 8.3;

"**<u>Funding Shareholder</u>**" shall have the meaning ascribed to it in Clause 10.5;

"**<u>GMS</u>**" shall have the meaning ascribed to it in Recital (C)(i);

"**<u>GSC</u>**" shall have the meaning ascribed to it in the Preamble;

"**<u>Highest Bidder</u>**" shall have the meaning ascribed to it in Clause 21.7;

"**<u>Hospital</u>**" shall have the meaning ascribed to it in Recital (A);

"**<u>Hospital Management Agreement</u>**" shall have the meaning ascribed to it in Recital (C)(i);

"**<u>Hospital Management Services</u>**" shall have the meaning ascribed to it in the Hospital Management Agreement;

"**<u>IFRS</u>**" means the International Financial Reporting Standards;

"**<u>immediate family</u>**" means parents, siblings, spouse and children;

"**<u>Initial Capital Requirement</u>**" shall have the meaning ascribed to it in Clause 10.1;

"**<u>Initial Investment Amount</u>**" shall have the meaning ascribed to it in Clause 3.2;

"**<u>Insolvency Event</u>**" means:

(a) an event of default is declared by any licensed financial institution lending to the Company or its subsidiaries (if any) and the Company would be unable to remediate the event of default and continue its business as a going concern;

(b) commencement of winding-up of the Company; or

(c) a petition is presented or an order is made for the appointment of an administrator in relation to the Company or if a receiver, administrative receiver, judicial manager or manager shall be appointed over any part of the assets or undertaking of the Company or if any event analogous to any of the foregoing shall occur in any jurisdiction.

"**<u>Intellectual Property Rights</u>**" means:

(a) patents, trade marks, service marks, logos, get-up, trade names, internet domain names, rights in designs, copyright (including rights in computer software) and moral rights, database rights, rights in know-how and other intellectual property rights, in each case whether registered or unregistered and including applications for registration, and all rights or forms of protection having equivalent or similar effect anywhere in the world;

(b) rights under licences, consents, orders, statutes or otherwise in relation to a right under sub-paragraph (a) above;

(c) rights of the same or similar effect or nature as or to those in sub-paragraphs (a) and (b) which now or in the future may subsist;

(d) the right to sue for past infringements of any of the foregoing rights; and

(e) in respect of PHIC, the Know-How and the Improvements (each as may be defined in the Hospital Management Agreement or the Consultancy Services Agreement).

"**Legal Requirements**" shall have the meaning ascribed to it in the Hospital Management Agreement;

"**Lease Agreement**" shall have the meaning ascribed to it in Clause 4.1(b);

"**Loan Drawdown Notice**" shall have the meaning ascribed to it in Clause 10.4;

"**Local Partner Shareholder Director**" shall have the meaning ascribed to it in Clause 7.1;

"**Local Partner Representative**" shall have the meaning ascribed to it in Clause 6.1;

"**Local Partner Shareholders**" means AMMK, GSC and MHPL and "**Local Partner Shareholder**" means any one of them;

"**Management Services Agreement**" shall have the meaning ascribed to it in Recital (C)(iii);

"**MFRS**" means Myanmar Financial Reporting Standards;

"**MHPL**" shall have the meaning ascribed to it in the Preamble;

"**MIC**" shall have the meaning ascribed to it in Clause 4.1(b);

"**MIC Permit**" shall have the meaning ascribed to it in Clause 4.1(b);

"**MOA**" means the memorandum of association of the Company, as may be amended from time to time;

"**net asset value of each Share**" means the total assets of the Company on a fully revalued basis at their current market value less the total liabilities of the Company (including without limitation, the principal amount of any outstanding Shareholders' Loans and all interest accrued thereon) divided by the total number of issued Shares;

"**Non-Allocation Notice**" shall have the meaning ascribed to it in Clause 17.6(b);

"**Non-Funding Shareholder**" shall have the meaning ascribed to it in Clause 10.5;

"**Non-Defaulting Party**" shall have the meaning ascribed to it in Clause 22.2;

"**Non-Defaulting Party's Shares**" shall have the meaning ascribed to it in Clause 22.2(b)(ii);

"**Non-Transferring Shareholders**" shall have the meaning ascribed to it in Clause 19.1;

"**Notice of Participation**" shall have the meaning ascribed to it in Clause 19.2;

"**Officers**" shall have the meaning ascribed to it in Clause 21.2;

"**Opening Date**" means the date of the soft opening of the Hospital whereby the Hospital is open to the general public for the provision of medical services;

"**Other Bidder**" shall have the meaning ascribed to it in Clause 21.7;

"**Other Shareholders**" shall have the meaning ascribed to it in Clause 17.3;

"**Outstanding Amount**" means the principal amount of all outstanding Shareholders' Loans made by the relevant transferor and/or its related corporations to the Company, together with interest accrued thereon, Provided Always that if the net asset value of the Company (based on the latest available consolidated audited accounts of the Company) shall be negative, the Outstanding Amount shall be the principal amount of all outstanding Shareholders' Loans made by the relevant transferor and/or its related corporations to the Company, together with interest accrued thereon, deducting therefrom an amount which is equal to the product obtained by multiplying (A) the (negative) net asset value of the Company by (B) the relevant transferor's Shareholding Proportion at the time of the transfer.

"**Parkway Group**" means Parkway Group Healthcare Pte Ltd and its related corporations;

"**Parkway Group Entity**" means a company belonging to the Parkway Group;

"**Permitted Transferee**" means:

(a) in relation to PHIC, any other corporation which is the holding company, ultimate holding company or subsidiary of PHIC or which is a subsidiary of the holding company or ultimate holding company of PHIC;

(b) in relation to a Local Partner Shareholder:

(i) any other corporation which is the holding company, ultimate holding company or subsidiary of such Local Partner Shareholder or which is a subsidiary of the holding company or ultimate holding company of such Local Partner Shareholder; or

(ii) any other Local Partner Shareholder;

"**PHIC**" shall have the meaning ascribed to it in the Preamble;

"**PHIC Director**" shall have the meaning ascribed to it in Clause 7.1;

"**Prescribed Entities**" means:

(a) any entity controlled by any Shareholder; and

(b) in respect of:

(i) PHIC, any wholly owned subsidiaries of Parkway Pantai Limited; and

(ii) a Local Partner Shareholder:

(A) the other Local Partner Shareholders;

(B) the ultimate shareholders of any of the Local Partner Shareholders; and

(C) any entity controlled by any of the ultimate shareholders of any of the Local Partner Shareholders.

"**Prescribed Terms**" shall have the meaning ascribed to it in Clause 17.3(iii);

"**Project**" shall have the meaning ascribed to it in Recital (A);

"**Property**" means the plot of land located at Plot No. 10, Block number 20F, Lanmadaw Township in Yangon, the Republic of the Union of Myanmar;

"**Purchase Price**" shall have the meaning ascribed to it in Clause 21.6;

"**Purchaser Bid**" shall have the meaning ascribed to it in Clause 21.6;

"**related corporation**" means a corporation which is:

(a) the holding company of another corporation;

(b) a subsidiary of another corporation; or

(c) a subsidiary of the holding company of another corporation;

"**Relevant Approvals**" means the approvals referred to in Clauses 4.1(a), (b) and (c);

"**Sale Shares**" shall have the meaning ascribed to it in Clause 17.3(i);

"**Second Adjourned Board Meeting**" shall have the meaning ascribed to it in Clause 7.12;

"**Second Adjourned Shareholders Meeting**" shall have the meaning ascribed to it in Clause 8.3;

"**Shareholders**" means the Parties and any other person holding Shares who shall have executed a Deed of Ratification and Accession pursuant to the provisions of this Agreement;

"**Shareholders' Loans**" means loans by the Shareholders or their respective related corporations to the Company;

"**Shareholding Proportion**" means in relation to any Shareholder at any given time, the proportion in which the Shares for which that Shareholder is registered in the Company's register of members bears to the total number of Shares issued in the capital of the Company;

"**Shares**" means the shares in the capital of the Company;

"**Shortfall**" shall have the meaning ascribed to it in Clause 10.5;

"**SIAC**" means the Singapore International Arbitration Centre;

"**Singapore Dollar**" or "**S$**" means the lawful currency of Singapore;

"**Subscription Offer**" shall have the meaning ascribed to it in Clause 16.1;

"**subsidiary**" means, in relation to a corporation, such corporation shall be deemed to be a subsidiary of another corporation, if:

(a) that other corporation:

   (i) controls the composition of the board of directors of the first-mentioned corporation;

   (ii) controls more than half of the voting power of the first-mentioned corporation; or

(iii) holds more than half of the issued share capital of the first-mentioned corporation (excluding any part thereof which consists of preference shares and treasury shares); or

(b) the first-mentioned corporation is a subsidiary of any corporation which is that other corporation's subsidiary;

"**Tag-Along Notice**" shall have the meaning ascribed to it in Clause 19.1;

"**Tag-Along Participant**" shall have the meaning ascribed to it in Clause 19.2;

"**Target Shareholder**" shall have the meaning ascribed to it in Clause 18.2;

"**Third Party Confidential Information**" means any information which is proprietary and confidential to a Party including but not limited to the terms and conditions of this Agreement;

"**Trade Mark Licence Agreement**" shall have the meaning ascribed to it in Recital (B);

"**Transaction**" includes any transaction, act, event or omission of whatever nature;

"**Transfer**" means any voluntary or involuntary sale, assignment, conveyance, pledge, encumbrance, hypothecation, gift, distribution or other disposition or transfer;

"**Transfer Loans**" shall have the meaning ascribed to it in Clause 17.2(c);

"**Transfer Notice**" shall have the meaning ascribed to it in Clause 17.3;

"**Transfer Price**" shall have the meaning ascribed to it in Clause 17.3(ii);

"**Transferring Shareholder**" shall have the meaning ascribed to it in Clause 17.3;

"**Valuer**" means any Approved Accounting Firm; and

"**US$**" or "**US Dollars**" means the lawful currency of the United States of America.

1.2 In this Agreement, a reference to:

(a) a statutory provision shall include that provision and any regulations made in pursuance thereof as from time to time modified or re-enacted, whether before or after the date of this Agreement and shall include also any past statutory provision or regulation (as from time to time modified or re-enacted) which such provision or regulation has directly or indirectly replaced;

(b) "**this Agreement**" includes all amendments, additions, and variations thereto agreed between the Parties;

(c) "**person**" shall include an individual, corporation, company, partnership, firm, trustee, trust, executor, administrator or other legal personal representative, unincorporated association, joint venture, syndicate or other business enterprise, any governmental, administrative or regulatory authority or agency (notwithstanding that "**person**" may be sometimes used herein in conjunction with some of such words), and their respective successors, legal personal representatives and assigns, as the case may be, and pronouns shall have a similarly extended meaning;

(d) "**financial year**" means a period in respect of which an audited profit and loss account of the Company has or is to be prepared for the purpose of laying before the Company at its annual general meeting, whether that period is a year or not;

(e) "**month**" is a reference to a period starting on one day in a calendar month and ending on the numerically corresponding day in the next succeeding calendar month;

(f) "**written**" and "**in writing**" include any means of visible reproduction;

(g) "**Recitals**", "**Clauses**", "**Schedules**" and "**Appendices**" are to the recitals, clauses of, and the schedules and appendices to, this Agreement (unless the context otherwise requires); and

(h) "**paragraph**" is a reference to a paragraph of the Clause in which such reference appears.

1.3 Unless the context otherwise requires, words importing the singular shall include the plural and *vice versa* and words importing a specific gender shall include the other genders (male, female or neuter).

1.4 The Schedules and Appendices form part of this Agreement and have the same force and effect as if expressly set out in the body of this Agreement.

1.5 The headings in this Agreement are inserted for convenience only and shall not affect the construction of this Agreement.

1.6 Any thing or obligation to be done under this Agreement which requires or falls to be done on a stipulated day, shall be done on the next succeeding Business Day, if the day upon which that thing or obligation is required or falls to be done falls on a day which is not a Business Day.

2. OBJECTIVES OF THE PARTIES

The Business of the Company shall unless and until the Shareholders otherwise agree be confined to the following:

(a) the Project;

(b) the entering of the Company into the Trade Mark Licence Agreement, the Hospital Management Agreement, the Consultancy Services Agreement, and the Management Services Agreement; and

(c) generally, to perform all acts, matters and things as may be consistent with, necessary for and incidental to the attainment of any and all of the foregoing objects.

3. CAPITAL STRUCTURE OF THE COMPANY

3.1 The authorised share capital of the Company shall be US$150,000,000.

3.2 The initial paid-up share capital of the Company shall be the minimum initial capital contribution by the Parties as stipulated by DICA (the "**Initial Investment Amount**").

3.3 The Parties agree that, immediately after the contribution of the Initial Investment Amount in Clause 3.2, their Shareholding Proportion shall be as follows:

Party	Percentage of share capital
AMMK	21.5%
GSC	16%
MHPL	10.5%
PHIC	52%
Total	100%

3.4 The Parties shall forthwith, within 30 days after the execution of this Agreement, jointly commence the applications for the incorporation of the Company (with such name as may be mutually agreed between the Parties and approved by the relevant authorities in Myanmar) pursuant to which each of the Parties shall become the registered holder of such number of Shares representing *inter se*, the Shareholding Proportion set out opposite its name in the second column of Clause 3.3, in consideration of the payment of such amount of the Initial Investment Amount in proportion to its Shareholding Proportion.

3.5 Subject to Clause 32, no Shareholder shall without the prior written consent of the other Shareholder create or permit to subsist any Encumbrance of any nature whatsoever over its Shares or any part of its interest in any Shares.

4. EFFECTIVE DATE, WARRANTIES AND COVENANTS

4.1 Save for Clauses 1, 3.1, 3.2, 3.3, 3.4, 4, 6, 7.1, 20 and 23 to 44, which shall take effect immediately, the remaining provisions of this Agreement shall take effect only upon the following conditions having been fulfilled to the satisfaction of both Parties (or waived by agreement of both Parties):

(a) the incorporation of the Company with the Directorate of the Investment and Company Administration ("**DICA**");

(b) the Myanmar Investment Commission ("**MIC**") permit and decision approving this Agreement, the incorporation of the Company for the Project, and the lease agreement between the Company and the relevant government authorities in relation to the Property (the "**Lease Agreement**") having been obtained on terms acceptable to both Parties and not having been withdrawn or modified (save on terms acceptable to both Parties) ("**MIC Permit**");

(c) all other necessary governmental, regulatory and other approvals from relevant authorities in Myanmar (including but not limited to the Ministry of Health and the Yangon City Development Committee) and/or consents which may be required in connection with the establishment of the Company and the commencement of the Project;

(d) execution of the Trade Mark Licence Agreement, Hospital Management Agreement, Consultancy Services Agreement, and Management Services Agreement;

(e) completion of land due diligence on the Property and execution of the Lease

Agreement upon receipt of approval from MIC; and

(f) the issuance by the Company to each of the Parties of such number of Shares representing *inter se*, the Shareholding Proportion set out opposite its name in the second column of Clause 3.3.

4.2 Each Party warrants to the other Party that:

(a) all action will have been taken so that the execution and delivery of, and the performance by it of its obligations under, this Agreement shall not (i) conflict with or result in a breach of its memorandum (if applicable) and articles of association or other constitutive documents, (ii) infringe, or constitute a default under, any instrument, contract, document or agreement to which it is a party or by which its assets are bound and (iii) result in a breach of any law, rule, regulation, ordinance, order, judgment or decree of or undertaking to any court, government body, statutory authority or regulatory, administrative or supervisory body (including without limitation, any relevant stock exchange or securities council) to which it is a party or by which it or its assets are bound, whether in Myanmar, Singapore or elsewhere;

(b) all relevant statutory, governmental or other approvals necessary for the Parties to enter into this Agreement have been obtained; and

(c) it has full power and authority to execute and deliver this Agreement and the agreements contemplated herein and, subject to the Relevant Approvals having been obtained, to consummate the Transactions contemplated hereby and thereby and that this Agreement and all such other agreements and obligations entered into and undertaken in connection with the Transactions contemplated hereby constitute its valid and legally binding obligations, enforceable against it in accordance with their respective terms.

4.3 The Parties acknowledge and agree that the Company shall be responsible for the following:

(a) construction, development and renovation of the Hospital;

(b) growth and expansion of the business of the Hospital within the Property;

(c) sales and marketing activities in relation to the promotion of the Hospital;

(d) purchasing and maintaining assets such as the movable medical and non-medical equipment required by the Hospital;

(e) all costs and expenses in connection with obtaining the Relevant Approvals;

(f) rental payments to the government of the Republic of the Union of Myanmar for the lease of the Property;

(g) operating the Hospital under the Brand and entering into the Trade Mark Licence Agreement with the relevant member of the Parkway Group;

(h) appointing GMS to provide hospital management services relating to the management and operation of the Hospital and entering into the Hospital Management Agreement and any renewals thereof;

(i) appointing GMS to provide consultancy services relating to the construction, development, establishment, furnishing and equipping of the Hospital and entering into

the Consultancy Services Agreement; and

(j) appointing AMMK to provide advisory services in respect of local management and administration matters of the Company and entering into the Management Services Agreement.

4.4 The Local Partner Shareholders jointly undertake that they shall use reasonable endeavours to assist the Company in the following:

(a) obtaining the Relevant Approvals;

(b) sourcing for suitable land for the Hospital;

(c) negotiating contracts in connection with the construction and development of the Hospital;

(d) recruitment of local personnel;

(e) procurement of goods and services locally; and

(f) negotiating equipment capital expenditure and consumables procurement.

Notwithstanding the foregoing, AMMK shall enter into the Management Services Agreement with the Company.

4.5 PHIC undertakes that it shall use reasonable endeavours to assist and advise the Company in the following:

(a) obtaining the Relevant Approvals; and

(b) tapping into PHIC's network of doctors to encourage them to do sessional visits to the Hospital.

5. EXERCISE OF RIGHTS

Each of the Shareholders shall exercise its rights as a shareholder in the Company in a manner consistent with the provisions of this Agreement. Where a resolution of the shareholders of the Company in general meeting is required under the laws of the Republic of the Union of Myanmar or under the Articles to give effect to all or any of the provisions of this Agreement, each of the Shareholders shall exercise its voting rights for the time being in the Company and take all such actions, things and steps as lie within their powers as are necessary to give effect thereto.

6. APPOINTMENT OF LOCAL PARTNER REPRESENTATIVE

6.1 The Local Partner Shareholders shall unconditionally and jointly appoint one of the Local Partner Shareholders, acting singly, as each of their attorney (the "**Local Partner Representative**") with powers to:

(a) exercise all of such Local Partner Shareholder’s rights under this Agreement;

(b) give any consents or approvals on behalf of such Local Partner Shareholder for the purposes of this Agreement;

(c) execute all authorisations, documents and instruments pursuant to or in connection with this Agreement (including any supplemental agreement thereto); and

(d) perform any other deed, matter or act which in the opinion of the Local Partner Representative ought to be done, executed or performed by or on behalf of such Local Partner Shareholder under this Agreement.

6.2 Further to Clause 6.1, the Local Partner Shareholders jointly appoint AMMK as the first Local Partner Representative. The Local Partner Shareholders may at any time jointly appoint another Local Partner Shareholder to be the Local Partner Representative and shall, as soon as practicable, give notice in writing to PHIC of the identity of such Local Partner Representative. The replacement of the existing Local Partner Representative by the Local Partner Shareholders shall take effect from PHIC's receipt of such written notice.

6.3 For the purposes of this Agreement, any action, consent, approval, appointment, vote or nomination to be taken, given or made by each of the Local Partner Shareholders pursuant to this Agreement shall be deemed to have been duly taken, given or made by and on behalf of, and be binding upon, such Local Partner Shareholder if taken, given or made by the Local Partner Representative acting singly.

6.4 Each of the Local Partner Shareholders hereby undertakes to and with the other Part(ies) that he shall not exercise his rights under this Agreement in any manner which will or may conflict with the terms of this Agreement.

7. BOARD OF DIRECTORS

7.1 Unless otherwise agreed by the Shareholders in writing, the Board shall comprise seven (7) Directors, among which four (4) Directors will be appointed by PHIC (each, a "**PHIC Director**") and three (3) Directors will be appointed by the Local Partner Shareholders (each, a "**Local Partner Shareholder Director**").

7.2 Clause 7.1 shall cease to apply:

(a) if at any time the aggregate Shareholding Proportion of the Local Partner Shareholders shall vary from the total of that set out against the Local Partner Shareholders' names in the second column of Clause 3.3; or

(b) if at any time the Shareholding Proportion of PHIC shall vary from that set out against PHIC's name in the second column of Clause 3.3,

and the number of Directors that PHIC, on one hand, and the Local Partner Shareholders jointly, on the other hand, shall be pro-rated to their respective Shareholding Proportion, Provided Always that if PHIC holds a majority of the Shares, PHIC may appoint a majority of the Directors.

7.3 In the event of any reduction in the aggregate Shareholding Proportion of the Local Partner Shareholders or the Shareholding Proportion of PHIC such that the number of directors appointed by the Local Partner Shareholders jointly and PHIC exceeds their/its respective entitlement under Clauses 7.1 and 7.2, the Local Partner Shareholders or PHIC, as the case may be, shall remove, or procure the resignation of, the relevant number of its appointee(s) as Director(s).

7.4 Each of the Shareholders shall exercise its rights as a shareholder in the Company to procure the appointment or removal, as the case may be, of any Director whose appointment or

removal, as the case may be, is required or requested by a Shareholder under Clause 7.1. The right of appointment of Directors conferred on a Shareholder under Clause 7.1 shall include the right of such Shareholder to remove from office at any time and from time to time such person(s) appointed by such Shareholder as a Director and the right of such Shareholder at any time and from time to time to determine the period during which such person shall hold the office of Director. Notwithstanding anything in the foregoing, the Board may remove a Director or refuse to accept the appointment of a new nominee director to fill any vacancy if the Board reasonably deems such Director or new nominee director unfit as a Director by reason of such individual having committed any fraudulent, unlawful or criminal acts. For the avoidance of doubt, where the Board removes a Director or refuses to accept the appointment of a new nominee director to fill any vacancy, his appointor has the right to appoint or nominate a replacement Director.

7.5 Every request for the appointment or removal of a Director by a Shareholder shall be in writing and signed by or on behalf of the Shareholder appointing or removing, as the case may be, such Director and shall be delivered to the registered office for the time being of the Company. Whenever for any reason a person appointed by a Shareholder ceases to be a Director, that Shareholder shall be entitled to appoint forthwith another Director.

7.6 The Chairman shall be a PHIC Director. The Deputy Chairman shall be a Local Partner Shareholder Director. In the event of equality of votes, neither the Chairman nor the Deputy Chairman shall be entitled to a second or casting vote at any meeting of the Board or at any general meeting of the Company.

7.7 Subject to Clause 14, all decisions of the Board shall be taken by a simple majority of the Board.

7.8 The Board shall meet as required in Singapore or Yangon, Myanmar or any other place as the Board may decide for purposes of discussing reports and other matters (including reviewing the progress of the Project).

7.9 Each Director shall be entitled at any time and from time to time to appoint any person to act as his alternate and to terminate the appointment of such person and in that connection the provisions of the Articles shall be complied with. Such alternate director shall be entitled while holding office as such to receive notices of all meetings of the Board and to attend and vote as a Director at any such meetings at which the Director appointing him is not present and generally to exercise all the powers, duties and authorities and to perform all functions of the Director appointing him. A Director or any other person may act as an alternate director to represent more than one (1) Director and an alternate Director shall be entitled at meetings of the Board to one (1) vote for every Director whom he represents in addition to his own vote (if any) as a Director.

7.10 At least seven (7) days' notice (or such shorter period of notice in respect of any particular meeting as may be unanimously agreed in writing by all the Directors) of meetings of the Board (including, but not limited to, details of the date, place and time of the Board meeting, the agenda and any relevant papers or documents to be discussed at such Board meeting) shall be given to each Director at such address as he shall from time to time notify to the Company for this purpose. In the case of urgent business the right to receive notice may be waived by any Director by cable, telex, facsimile or otherwise in writing. Each notice of meeting of the Board shall contain an agenda of the business to be discussed at such meeting and unless agreed by all Directors present, no Board meeting shall vote on or resolve any matter not specified or referred to in the agenda. The Company shall bear the travelling and out-of-pocket expenses incurred by the Directors attending the Board meetings.

7.11 Each Director present personally or by his alternate shall have one (1) vote at all meetings of the Board.

7.12 The quorum of all meetings of the Board shall be four (4) Directors, of whom one (1) shall be a PHIC Director and one (1) shall be a Local Partner Shareholder Director, present in person at the time when the relevant business is transacted; Provided That where no quorum is present at any duly convened meeting within half an hour from the time appointed for the holding of the Board meeting, the Board meeting shall be adjourned to seven (7) days thereafter with the same agenda and at the same time and place, or to such other date, time and place as the Directors may agree (the "**First Adjourned Board Meeting**") and at least three (3) days' notice shall be given to the Directors in relation to the First Adjourned Board Meeting. The quorum at the First Adjourned Board Meeting shall be any four (4) Directors. In the event that no quorum is present at the First Adjourned Board Meeting within half an hour from the time appointed for the holding of the First Adjourned Board Meeting, the First Adjourned Board Meeting shall be adjourned to three (3) days thereafter with the same agenda and at the same time and place, or to such other date, time and place as the Directors may agree ("**Second Adjourned Board Meeting**") and at least two (2) days' notice shall be given to the Directors in relation to the Second Adjourned Board Meeting. The quorum at the Second Board Adjourned Meeting shall be any three (3) Directors. An alternate Director shall not constitute a quorum if he is the only person present at a Board meeting, a First Adjourned Board Meeting or a Second Adjourned Board Meeting, notwithstanding that he may be the alternate director to more than one Director.

7.13 Subject always to Clause 14, a resolution in writing signed by a simple majority of the Directors for the time being or their alternates shall be valid and effectual as if it had been passed at a meeting of the Board duly convened and held. Any such resolution may consist of several documents in like form, each signed by one or more of the Directors. For the purpose of this Clause 7.13, "in writing" and "signed" shall include approval by electronic mail, fax and/or telex. Such resolution in writing shall be effective as of the date of the resolution or, if the resolution is signed in two or more counterparts, as of the last date appearing on the counterparts.

7.14 Discussion at all meetings of the Board shall be duly recorded by such person as the Board may direct and minutes of such meetings shall be drawn up and circulated to all the Directors at least two (2) days prior to the next meeting of the Board.

7.15 A Director shall not be prohibited from voting or being counted in a quorum at any meeting of the Board in respect of any contract or arrangement in which he is or may be interested provided he has disclosed the nature of his interest.

7.16 The Shareholders acknowledge that where any Director is appointed by any Shareholder under a right conferred by this Agreement, that Director, in performing any of his duties or exercising any power, right or discretion as a Director, shall be entitled to have regard to and represent the interests of his appointor, to report all matters concerning the Company, including but not limited to, matters discussed at any meeting of the Board to and to act on the wishes of his appointor except in any particular case where no honest and reasonable director may hold the view that in so doing the Director was acting *bona fide* in the best interests of the Company.

7.17 The meetings of the Board may be conducted by means of telephone or audio-visual conferencing or other methods of simultaneous communication by electronic, telegraphic or other means by which all persons participating in the meeting are able to hear and be heard at all times by all other participants without the need for a Director to be in the physical presence of the other Directors and participation in the meeting in this manner shall be deemed to constitute presence in person at such meeting. The Directors participating in any such meeting shall be counted in the quorum for such meeting and subject to there being a requisite quorum at all times during such meeting, all resolutions agreed by the Directors in such meeting shall be deemed to be as effective as a resolution passed at a meeting in person of the Directors duly convened and held. A Director may disconnect or cease to participate in the meeting if he makes known to all other Directors participating that he is ceasing to participate in the meeting and such Director shall, notwithstanding such disconnections but provided that such Director

was present at all material times at such meeting by way of telephone or audio-visual conferencing or other methods of simultaneous communication, be counted in the quorum for such part of the meeting. The minutes of such a meeting shall be circulated to all Directors who attended such a meeting for comments not later than 14 days after the conclusion of such meeting, and subject as aforesaid, the minutes of such meeting after incorporating the comments (if any) from the Directors, signed by the Chairman shall be conclusive evidence of any resolution of any meeting conducted in the manner as aforesaid. A meeting conducted by the aforesaid means is deemed to be held at the place agreed upon by the Directors attending the meeting Provided That at least one (1) of the Directors participating in the meeting was at that place for the duration of the meeting.

8. SHAREHOLDERS' MEETINGS

8.1 The number of Shareholders necessary to form a quorum for the transaction of business at a meeting of the Shareholders shall be two (2) Shareholders, of whom one (1) shall be PHIC and one (1) shall be a Local Partner Shareholder, present personally or by representative, attorney or proxy, and such representative, attorney or proxy need not be a member of the Company. All matters raised at a meeting of the Shareholders shall, unless otherwise required by the Companies Act or the Articles or Clause 14, be decided by a simple majority vote of the Shareholders present and voting at the meeting and on the basis that each Share will carry one vote.

8.2 Subject always to Clause 14, a resolution in writing signed by or on behalf of the Shareholders holding a majority of the voting rights in the Company for the time being shall be as valid and effectual as if it had been passed at a general meeting of the Company duly convened and held. Any such resolution may consist of several documents in like form each signed by a Shareholder. For the purpose of this Clause 8.2, "in writing" and "signed" shall include approval by electronic mail, fax and/or telex. Such resolution in writing shall be effective as of the date of the resolution or, if the resolution is signed in counterparts, as of the last date appearing on the counterparts.

8.3 If within half an hour from the time appointed for holding the meeting a quorum is not present, the meeting (the "**First Adjourned Shareholders Meeting**") shall be adjourned to seven (7) days thereafter at the same time and place and no notice needs to be given to the Shareholders in relation to such adjourned meeting. The quorum at the First Adjourned Shareholders Meeting shall be any two (2) Shareholders, including PHIC and the one Local Partner Shareholder. In the event that no quorum is present at the First Adjourned Shareholders Meeting within half an hour from the time appointed for the holding of the First Adjourned Shareholders Meeting, the First Adjourned Shareholders Meeting shall be adjourned to three (3) days thereafter with the same agenda and at the same time and place, or to such other date, time and place as the Shareholders may agree (the "**Second Adjourned Shareholders Meeting**") and at least two (2) days' notice shall be given to the Shareholders in relation to the Second Adjourned Shareholders Meeting. The Shareholder(s) holding at least 30% of the voting rights in the Company for the time being present at such adjourned meeting shall be the quorum for the Second Adjourned Shareholders Meeting.

9. REGISTERED OFFICE ETC.

Unless and until the Board shall otherwise determine, the following particulars shall remain unchanged:

(a) the registered office of the Company shall be at No. 33, Pyay Road, 6 1/2 miles, (11) Quarter, Hlaing Township, Yangon, The Republic of the Union of Myanmar;

(b) the Company's financial year shall end on 31 March in each year; and

(c) the Company's audited balance sheet and profit and loss account shall be prepared on a consistent basis and in accordance with MFRS and IFRS.

10. FINANCE FOR THE COMPANY

10.1 Prior to the date of this Agreement, the Shareholders have reviewed an estimate budget for the total funding requirements for the Business of the Company (the "**Initial Capital Requirement**") and have agreed that the Initial Capital Requirement shall be S$95,000,000. For the avoidance of doubt, the Initial Capital Requirement shall include the Initial Investment Amount.

10.2 PHIC undertakes that it shall use reasonable endeavours to assist the Company to secure external financing for such part of the Initial Capital Requirement as may be agreed by the Parties (the "**Agreed Portion**"). In the event that one of the following occurs:

(a) the Company is unable to secure any external financing for the Agreed Portion; or

(b) the Company is able to secure only a part of the Agreed Portion through external financing,

each Shareholder undertakes to contribute to the entire portion or remaining portion of the Initial Capital Requirement not funded by external financing in proportion to its Shareholding Proportion, in such amounts and at such times as shall be determined by the Board (save for the payment of the Initial Investment Amount in accordance with Clause 3.3) by way of such Shareholder subscribing for new Shares in the capital of the Company in accordance with Clause 10.3 or by way of Shareholders' Loans in accordance with Clause 10.4, as shall be determined by the Board.

10.3 Upon receipt of a notice in substantially the form set out in Schedule 1 (an "**Equity Drawdown Notice**") from the Board, each Shareholder shall be obliged to subscribe for the number of Shares specified in the Equity Drawdown Notice within a period of 14 days from the date of such Equity Drawdown Notice. Each Shareholder shall pay into the Company's bank account, within such time, the sum specified in the Equity Drawdown Notice from the Board, representing such Shareholder’s respective payment for the subscription of further Shares. The Company shall issue such further Shares in the capital of the Company to the Shareholders and shall register the names of the Shareholders as the registered holders of such Shares in the Company's register of members.

10.4 Upon receipt of a notice in substantially the form set out in Schedule 2 (a "**Loan Drawdown Notice**") from the Board, each Shareholder shall be obliged to extend the amount specified in the Loan Drawdown Notice within 14 days from the date of such Loan Drawdown Notice. Each Shareholder shall pay into the Company's bank account, within such time, the sum specified in the Loan Drawdown Notice from the Board, representing the Shareholders' Loan extended by such Shareholder to the Company.

10.5 In the event that a Shareholder ("**Non-Funding Shareholder**") fails or refuses to subscribe and pay in full for the Shares pursuant to an Equity Drawdown Notice or extend in full the Shareholders' Loan pursuant to a Loan Drawdown Notice (such subscription amount or Shareholders' Loan amount shall be referred to as the "**Shortfall**"), the other Shareholders who have subscribed and paid in full for the Shares pursuant to the Equity Drawdown Notice issued to them or have extended in full a Shareholders' Loan pursuant to the Loan Drawdown Notice (as the case may be) (each a "**Funding Shareholder**"), shall have the right (but not the obligation) to fund the Shortfall:

(a) on the same terms as the relevant Equity Drawdown Notice save that the date referred to in paragraph 5 of the Equity Drawdown Notice shall be extended by a period of 14 days and the Shareholding Proportion of the Non-Funding Shareholder shall be diluted accordingly; or

(b) on the same terms as the relevant Loan Drawdown Notice save that the date referred to in paragraph 5 of the Loan Drawdown Notice shall be extended by a period of 14 days and that any Shareholders' Loan extended by a Funding Shareholder in accordance with this Clause 10.5(b) shall be convertible at the sole option of the Funding Shareholder into Shares at par value as stated in the memorandum and articles of association of the Company and such Shares shall, upon conversion, be vested in the Funding Shareholder or its Permitted Transferee as the Funding Shareholder may direct, and the Shareholding Proportion of the Non-Funding Shareholder shall be diluted accordingly.

10.6 In addition to the rights and remedies of the Funding Shareholders, any failure or refusal by a Non-Funding Shareholder to subscribe and pay for the Shares pursuant to an Equity Drawdown Notice or extend the Shareholders' Loan pursuant to a Loan Drawdown Notice shall constitute a material breach of the Non-Funding Shareholder's obligations under this Agreement.

10.7 Subject to Clause 14, the Shareholders agree that any additional funding requirement for the Business of the Company in excess of the Initial Capital Requirement shall be provided by way of:

(a) the Shareholders subscribing for new Shares in the Company in accordance with Clause 10.3 or by way of Shareholders' Loans in accordance with Clause 10.4 in accordance with their respective Shareholding Proportion, unless otherwise agreed by the Parties; or

(b) loans and other credit facilities from the Company's bankers and other parties on such terms as the Shareholders may agree.

10.8 It is hereby agreed that none of the Shareholders shall be required to provide any form of security or comfort in respect of any banking or credit facility granted to the Company or in relation to it or its Business. Notwithstanding the foregoing, in the event that undertakings, guarantees or any other securities are provided by the Shareholders or any of their respective related corporations to any third party or parties in connection with any credit or banking facilities to the Company, the Shareholders shall, unless otherwise unanimously agreed, provide the same in proportion to their Shareholding Proportion (or such other proportion as may be agreed by all the Shareholders) and on a several basis.

11. <u>DIVIDEND POLICY</u>

11.1 Subject to any applicable laws and regulations, the MOA and Articles and the completion of the construction of the Hospital, the Shareholders hereby agree that:

(a) unless otherwise agreed, 50% of all Available Profits (after taking into account any repayment of principal of external financing and Shareholders' Loans, if any) in respect of each financial year of the Company shall be applied by the Company in payment of dividends to the Shareholders within such timeframe as may be agreed to by the Shareholders; and

(b) the Board may declare and pay interim dividends out of any Available Profits if it thinks

fit.

11.2 All payments of dividends are to be paid to the Shareholders pro-rata to their respective Shareholding Proportions at the relevant time.

11.3 For the purpose of this Clause 11, "**Available Profits**" in respect of any financial year means all profits and retained earnings available to the Company for distribution as dividends pursuant to applicable laws, less any accumulated losses incurred in the past by the Company, subject to any applicable laws and regulations, the requirements of the Company, cash availability and to the appropriation of such reasonable and proper reserves for working capital or otherwise as the Board may think appropriate.

12. ADMINISTRATION

12.1 The Board will be responsible for the management and supervision of the Business.

12.2 In consideration of the mutual obligations of the Shareholders herein contained, and except as the Shareholders may otherwise agree in writing or save as otherwise provided or contemplated in this Agreement, each of the Shareholders shall (so far as it is able) exercise its voting rights and powers and control available to it in a manner consistent with the provisions of this Agreement and in relation to the Company so as to ensure that:

(a) the accounting policies, practice or procedures adopted by the Company shall comply with the requirements of all relevant laws and with all applicable statements of standard accounting practices and MFRS and IFRS;

(b) the Company shall keep each Director fully informed as to all material developments regarding its financial and Business affairs and shall notify the Directors forthwith in writing upon becoming aware of any event affecting or likely to affect the Company in a materially adverse manner; and

(c) all Intellectual Property Rights owned by the Company shall be adequately protected.

12.3 The Parties acknowledge and agree that as at the date hereof, neither the Company nor the Local Partner Shareholders own, use, has been granted a licence in respect of, or has any interests, in any Intellectual Property Rights belonging to PHIC or any Parkway Group Entity except as may be provided for under the Trade Mark Licence Agreement, the Consultancy Services Agreement, and the Hospital Management Agreement (to the extent such agreements have been duly executed). For the avoidance of doubt, neither the Company nor the Local Partner Shareholders shall have, at any time, any rights except as may be provided for under the Trade Mark Licence Agreement, Consultancy Services Agreement, and the Hospital Management Agreement in and to any Intellectual Property Rights licensed from, or otherwise made available to the Company for use by, PHIC or any Parkway Group Entity (including not limited to pursuant to the Trade Mark Licence Agreement, Consultancy Services Agreement, and the Hospital Management Agreement) which Intellectual Property Rights shall all continue at all times to remain vested in, owned and held by PHIC or the relevant Parkway Group Entity.

12.4 The Shareholders agree that pending the approval of the Company's annual and supplementary budgets and if the revised budget is not approved, the Company shall have the authority to continue to operate on an interim budget based on the previous year's budget, as adjusted by the Myanmar Consumer Price Index.

12.5 Subject to Clause 14, the Shareholders acknowledge and agree that:

(a) PHIC shall be entitled to appoint, replace and/or remove from time to time any person as the Chief Executive Officer and the Chief Financial Officer respectively of the Company;

(b) The Local Partner Shareholders shall be entitled to jointly appoint, replace and/or remove from time to time any person as the Deputy Chief Executive Officer of the Company;

(c) the Board shall determine the remuneration (including benefits) of the Chief Executive Officer, Chief Financial Officer and Deputy Chief Executive Officer of the Company; and

(d) the Company shall appoint, replace and/or remove from time to time:

(i) the Chief Medical Officer of the Company (to be appointed only when the Hospital commences operations); and

(ii) all other staff, including but not limited to the Director of Nursing.

13. CONFLICT OF INTERESTS

Each Shareholder who is in any way at any time and from time to time, whether directly or indirectly, interested in a contract or a proposed contract with the Company, shall as soon as practicable declare the nature of its interest to the other Shareholder and to the Board. Every Shareholder shall further ensure that if such Shareholder holds any office or possesses any property whereby, whether directly or indirectly, duties or interests might be created in conflict with its duties or interests as a Shareholder or as set out in this Agreement, it shall forthwith declare to the other Shareholder the fact, nature, character and extent of the conflict.

14. RESERVED MATTERS

Where questions arise or resolutions are proposed at any general meeting of the Company or any meeting of the Board (as the case may be) in respect of the matters set out in Schedule 3, the affirmative votes of PHIC and at least one (1) Local Partner Shareholder at such general meeting or the affirmative votes of at least one (1) PHIC Director and one (1) Local Partner Shareholder Director at meetings of the Board shall be required to decide on such questions or pass any such resolutions.

15. INFORMATION RIGHTS

15.1 For so long as this Agreement is in effect, the Shareholders will exercise their rights as shareholders in relation to the Company so as to ensure that the Company will deliver to each of the Directors:

(a) on or before 1 February in each year:

(i) a detailed draft annual operating budget for the Company (including estimated major items of revenue and capital expenditure) for the following financial year, broken down on a monthly basis; and

(ii) an accompanying cash-flow forecast prepared on an annual basis together with a balance sheet showing the projected position of the Company, as at the

end of the following financial year;

(b) within 20 days after the end of each calendar month, unaudited management accounts, such accounts to include a detailed profit and loss account, balance sheet and cash-flow statement, an analysis of sales and other revenue, with revenue and capital budgets for the corresponding month, and (if so required by the Board) a statement of the source and application of funds for such month;

(c) as soon as available, but in any event within five (5) months of the financial year end of the Company (or when furnished to the Board, if earlier) a copy of the balance sheet of the Company as at the end of each fiscal year and the related statements of operations, shareholders equity and cash flows of the Company for each fiscal year, all in reasonable detail and stating in comparative form the figures as at the end of and for the previous fiscal year accompanied by an opinion of an Approved Accounting Firm, which opinion shall state that such audit was conducted in accordance with MFRS and IFRS auditing standards and which opinion shall not be subject to any qualifications resulting from a limit on the scope of the examination of the financial statement or the underlying data or a departure from generally accepted accounting principles. All such financial statements shall be complete and correct in all material respects and prepared in reasonable detail and in accordance with MFRS and IFRS accounting principles applied consistently throughout the period reflected therein except as stated therein; and

(d) from time to time such additional information regarding results of the business, affairs, operations, assets, financial condition or prospects of the Company and/or any of its subsidiaries, including annual budgets, cash flow analyses and projects of the Board, as any Director may require in writing.

15.2 The Parties further agree that in addition to the preparation of audited accounts as may be required under the laws of the Republic of the Union of Myanmar, the Company shall prepare annual accounts in respect of each calendar year in accordance with generally accepted accounting practices and in compliance with all applicable legislation in Singapore, and in each case at the Company's own cost and expense.

15.3 The Local Partner Shareholders acknowledge that PHIC may from time to time reasonably request for amendments to the terms of this Agreement so as to ensure that PHIC is able to have the Company consolidated in its accounts for the purposes of financial reporting provided that PHIC shall have in the first instance, used best endeavours by working with its auditors, to achieve such consolidation based on the existing terms of this Agreement. The Local Partner Shareholders shall consent to such requests if it is satisfied (in its discretion, which shall be exercised reasonably), that such amendments do not prejudice the rights of the Local Partner Shareholders under this Agreement. In the event the Local Partner Shareholders are of the reasonable view that such amendments will prejudice its rights under this Agreement, the Local Partner Shareholders shall enter into good faith discussions with PHIC to come to an appropriate solution so as to enable PHIC to consolidate the Company in its accounts for the purposes of financial reporting. For the avoidance of doubt, the Shareholders shall not propose and/or permit amendments that will cause the Company and/or the Local Partner Shareholders to contravene the terms of the MIC Permit, any other any applicable law or regulation or any contract to which either is party or which is binding on any of them or their assets.

15.4 Upon reasonable notice, the Company shall not refuse any reasonable requests from any Shareholder to inspect and examine, during normal business hours, any of the assets or properties, books or accounts, records and reports of the Company, and to discuss the affairs, finances and accounts of the Company with the Directors.

16. PREEMPTIVE RIGHTS: ISSUE OF NEW SHARES

16.1 Subject to Clause 14 and without prejudice to Clause 10, any unissued shares or issuance of new or additional shares in the capital of the Company shall before issue be offered for subscription in the first instance to each of the Shareholders in (as nearly as may be) their respective Shareholding Proportion and in accordance with the Articles (each offer to a Shareholder being a "**Subscription Offer**" and all such offers being the "**Subscription Offers**").

16.2 A Subscription Offer shall be accepted by the relevant Shareholder as to all but not some only of the Shares comprised in such Subscription Offer within 14 days from the date of the Subscription Offer. Any failure by a Shareholder to accept such Subscription Offer shall constitute a breach of such Shareholder's obligations under this Agreement.

16.3 An acceptance of a Subscription Offer by a Shareholder shall be irrevocable except with the written consent of the other Shareholders.

16.4 The obligation of each Shareholder to subscribe for new Shares pursuant to this Clause 16 may be assigned by such Shareholder to any Permitted Transferee thereof, provided that such Permitted Transferee shall execute the Deed of Ratification and Accession pursuant to which such Permitted Transferee agrees that the Shares which it acquires are subject to the provisions of this Agreement to the same extent as such provisions apply or applied to the Shareholder assigning such rights and that such Permitted Transferee is bound hereby as if an original party hereto. By subscribing for the new Shares, such Permitted Transferee shall become and be considered to come within the definition of "**Shareholder**" as used in this Agreement. In the event that such company ceases to be a Permitted Transferee of that Shareholder, that Shareholder shall procure that such company shall before such cessation re-Transfer such Shares to that Shareholder.

17. TRANSFER OF SHARES

17.1 A Shareholder shall not, at any time before the Opening Date or 48 months from the date of execution of this Agreement, whichever is earlier, Transfer its Shares to any third party without first obtaining the prior written consent of the other Shareholders.

17.2 Notwithstanding anything to the contrary in this Agreement, and unless otherwise agreed amongst the Shareholders, a Shareholder shall not Transfer all or any portion of its Shares under this Clause 17:

(a) to:

(i) any person; or

(ii) any person who is controlled by or otherwise connected or related to a person,

that is:

(A) sanctioned pursuant to any United Nations Security Council resolution issued under the Charter of the United Nations, or any sanctions programme administered by the United States of America or the European Union; or

(B) has been convicted, indicted, or subjected to any similar criminal

sanction, or by any court or governmental body of competent jurisdiction, for engaging in money laundering or financing of terrorism or any other sanctionable practice; or

(b) where the Transferring Shareholder is any of the Local Partner Shareholders, to any hospital operators who operates (whether wholly or partially) in Southeast Asia or their Affiliates; and

(c) unless such Transfer is accompanied by an assignment, by such Shareholder, of a proportionate value of the Shareholders' Loans made to the Company by such Shareholder and/or its related corporations for the time being outstanding ("**Transfer Loans**") to the relevant transferee.

17.3 Subject to Clause 17.1 and 17.2 and except as hereinafter provided, if a Shareholder (hereinafter referred to as the "**Transferring Shareholder**") wishes to Transfer any of its Shares and provided that the Transferring Shareholder has received from a prospective buyer ("**Buyer**") a binding offer in respect of such Shares, the Transferring Shareholder shall give to the Company and:

(a) PHIC (in the case where the Transferring Shareholder is any of the Local Partner Shareholders); or

(b) the Local Partner Shareholders (in the case where the Transferring Shareholder is PHIC),

(the "**Other Shareholders**") notice in writing of such desire (a "**Transfer Notice**"), which notice shall specify:

(i) the number of its Shares that is proposed to be sold and transferred (the "**Sale Shares**");

(ii) the binding price fixed by the Buyer and the Transferring Shareholder for the sale of each such Sale Shares (the "**Transfer Price**");

(iii) the other terms and conditions of such sale (if any) (the "**Prescribed Terms**"); and

(iv) the identity of the Buyer.

17.4 Subject as hereinafter mentioned, a Transfer Notice shall constitute an offer by the Transferring Shareholder for the sale of the Sale Shares to the Other Shareholders at the Transfer Price and on the Prescribed Terms (if any). A Transfer Notice shall not be revocable except with the sanction of the Other Shareholders.

17.5 The Company shall forthwith by notice in writing inform the Other Shareholders of the number of the Sale Shares and the Transfer Price and to invite the Other Shareholders to apply in writing to the Company within 60 days of the date of despatch of the notice (which date shall be specified therein) for all (and not part only) of the Sale Shares.

17.6 If the Other Shareholders shall within the said period of 60 days apply for the Sale Shares, the Board shall allocate the Sale Shares to or amongst the Other Shareholders and in case of competition pro-rata (as nearly as possible) according to the respective Shareholding Proportion *inter se* of the applicants and the Company shall forthwith:

(a) give notice of such allocations (an "**Allocation Notice**") to the Transferring Shareholder and to the Other Shareholders to whom the Sale Shares have been

allocated; or

(b) if none of the Other Shareholders have applied for the Sale Shares, give notice of the same (a "**<u>Non-Allocation Notice</u>**").

17.7 Subject to Clause 17.2:

(a) if an Allocation Notice is given by the Company to PHIC as the Other Shareholder, PHIC shall be entitled to direct that the Sale Shares be transferred to such person as it may direct; or

(b) if an Allocation Notice is given by the Company to the Local Partner Shareholders as the Other Shareholder, the Local Partner Shareholder shall be entitled to jointly direct that the Sale Shares be transferred to such person as they may direct.

17.8 If a Non-Allocation Notice is given by the Company, the Transferring Shareholder may, subject to Clause 19, and during a period of not more than 30 days from the date the MIC extends its approval for the sale and purchase of the Sale Shares to the Buyer, Transfer the Sale Shares to the Buyer and no other party and at any price (not being less than the Transfer Price) and on terms not more favourable than the Prescribed Terms (if any) except that the Transferring Shareholder may provide representations, warranties, covenants and indemnities customary for such transfer to the Buyer.

17.9 Completion of the sale and purchase of any Shares under this Clause 17 shall take place at the registered office of the Company and on the date falling no later than 30 days from the date the MIC extends its approval for such sale and purchase of Shares On completion, in accordance with the rules and procedures prescribed by the Companies Act and subject to the requirements of the MIC:

(a) the Transferring Shareholder shall deliver to the relevant transferee or such person as it may direct:

(i) a duly executed transfer form in favour of the relevant transferee or such person as it or they may direct;

(ii) the share certificate(s) in respect of the Shares to be sold;

(iii) a working sheet signed by a Director or the secretary of the Company computing the net asset value per share of the Company;

(iv) duly executed assignment(s) (in such form and substance as may be acceptable to the relevant transferee) of the Transfer Loans; and

(v) any other document which may be required to enable the relevant transferee or such person as it or they may direct to obtain the effective (A) transfer of the Shares to it and to be registered as the holder thereof; and (B) assignment of the Transfer Loans to be assigned to it,

and the Transferring Shareholder shall procure the resignation(s) of such number of Director(s) which were appointed pursuant to its nominations as may be commensurate with the change in the Transferring Shareholder's Shareholding Proportion, which said resignations shall take effect on the date of the completion of the sale and purchase of any Shares under this Clause 17; and

(b) the relevant transferee shall deliver to the Transferring Shareholder a cashier's order or

banker's draft or such other mode of payment agreed between the Transferring Shareholder and the relevant transferee for the full amount of the consideration payable for the Shares to be purchased, and the Transfer Loans to be assigned, which shall be expressed in US Dollars.

17.10 Any Shareholder (being a corporation) shall be entitled at any time to Transfer any Shares registered in its name to a Permitted Transferee of that Shareholder provided that:

(a) that Shareholder shall not be relieved of any of its obligations hereunder and shall remain responsible for ensuring the due performance of all its obligations hereunder, either by itself or by the registered holder for the time being of such Shares; and

(b) in the event that the other company ceases to be a Permitted Transferee of that Shareholder, it shall, and that company shall procure that it shall, re-Transfer such Shares to that Shareholder before such cessation.

17.11 The Transferring Shareholder and the relevant transferee shall use their best endeavours to promptly obtain the approval of the MIC, as well as all necessary consents and approvals required by applicable law and regulations or any other person, to effect any Transfer of Shares and assignment of Transfer Loans in accordance with the terms of this Agreement, and the other Shareholders (other than the Transferring Shareholder) shall extend their full co-operation and assistance, as may be reasonably requested by the Transferring Shareholder and the relevant transferee, in respect of the same.

17.12 It shall be a condition precedent to the right of any Transferring Shareholder to transfer Shares that:

(a) the MIC has extended its approval for the Transfer of Shares to the relevant transferee (including the Permitted Transferees, Buyer or the Other Shareholders, as the case may be) on the terms and conditions upon which the Transfer is to take place;

(b) the relevant transferee, if not already bound by the provisions of this Agreement, executes the Deed of Ratification and Accession under which it agrees to be bound by and be entitled to the benefit of this Agreement as if it were an original party hereto in place of the Transferring Shareholder;

(c) the Transferring Shareholder assigns, and the relevant transferee accepts the assignment of, the Transfer Loans, and any guarantees or other financial undertakings of the Transferring Shareholder made in connection with or for the benefit of the Company (on such terms as may be agreed between the Transferring Shareholder and the transferee), and the Transferring Shareholder shall obtain where necessary the consent of the beneficiary of such guarantees or undertakings to the said Transfer;

(d) the Transferring Shareholder shall remain liable and be responsible for the due discharge, performance and observance of all its liabilities and obligations whether actual or contingent arising out of or on or in respect of or in connection with this Agreement and in respect of the Shares and/or the Transfer Loans being transferred and/or assigned at any time up to the date of the Transfer, and shall remain entitled to all rights and benefits arising out of or in connection with the Shares and/or the Transfer Loans made to the Company for the time being outstanding being Transferred at any time up to and including the date of Transfer;

(e) the Transferring Shareholder indemnifies the Company or, as the case may be, the Other Shareholders, against any increase in financing costs which the Company or, as the case may be, such Shareholder, may incur or suffer in connection with or arising

from the assignment referred to in Clause 17.12(c); and

(f) the stamp duty payable on the transfer of Shares under this Clause 17 shall be borne wholly by the relevant transferee (including the Permitted Transferees, Buyer or the Other Shareholders, as the case may be).

17.13 The provisions of Clauses 17.2(a) and 17.2(c) and this 17.13 shall apply to any Transfer of Shares including, for the avoidance of doubt, any Transfer made pursuant to Clauses 18, 21 and 22. In addition, in respect of any transfer of Shares by a Shareholder, it shall be the obligation of the transferring Shareholder to ensure that such Transfer of Shares shall be effected in compliance with Myanmar laws. In particular, the transferring Shareholder shall ensure that such Transfer of Shares shall be effected in such manner and to such person(s) so that, Myanmar Companies (within the definition of the Companies Act) or Myanmar citizens (within the definition of the Myanmar Citizenship Law (1982)) shall continue to hold at least 20%, or such other minimum percentage imposed by Myanmar in connection with local ownership requirements, of the issued share capital of the Company, immediately after the completion of such Transfer of Shares.

18. TRANSFER OF SHARES: CHANGE IN CONTROL

18.1 A Shareholder shall not:

(a) at any time before the Opening Date or 48 months from the date of execution of this Agreement, whichever is earlier, undergo or permit or procure to be undergone, in a single transaction or a series of related transactions relating to itself or its holding companies which will result in:

(i) with respect to the Local Partner Shareholders, U Aung Moe Kyaw and his immediate family, U Thurane Aung @ Christopher Aung and his immediate family or Mr. Chew Leong Chee and his immediate family ceasing to directly or indirectly collectively hold all of the issued share capital in AMMK, GSC and MHPL respectively; and

(ii) with respect to PHIC, Parkway Pantai Limited ceasing to hold, directly or indirectly, all of the issued share capital in PHIC; and

(b) at any time after the Opening Date or 48 months from the date of execution of this Agreement, whichever is earlier, undergo or permit or procure to be undergone a Change in Control.

18.2 If any Shareholder (the "**Target Shareholder**") undergoes or permits or procures to be undergone a Change in Control at any time after the Opening Date or 48 months from the date of execution of this Agreement, whichever is earlier, then, unless otherwise waived by the other Shareholders:

(a) the Target Shareholder shall promptly give written notice to the other Shareholders of the Transfer or Change of Control, and such written notice shall describe in reasonable detail the terms and conditions of the Transfer or the Change in Control, including without limitation, the number of shares of the Target Shareholder transferred, the nature of such Transfer or Change in Control, the consideration paid, and the name and address of each purchaser or transferee;

(b) (i) where the Target Shareholder is any of the Local Partner Shareholders, such Transfer or Change in Control will be deemed to be an offer (a "**Deemed Offer**")

by all of the Local Partner Shareholders to PHIC of all of their Shares and Transfer Loans to PHIC at a price which shall be the sum of (a) the Fair Market Value of the Target Shareholder's Shares; and (b) the Outstanding Amount, each as at the date of such Transfer or Change in Control; and

(ii) where the Target Shareholder is PHIC, such Transfer or Change in Control will be a Deemed Offer by PHIC to the Local Partner Shareholders by PHIC of all of its Shares and Transfer Loans to the Local Partner Shareholders jointly in (as nearly as may be) their respective Shareholding Proportion and at a price which shall be the sum of (a) the Fair Market Value of the Target Shareholder's Shares; and (b) the Outstanding Amount, each as at the date of such Transfer or Change in Control.

18.3 At any time after the receipt of the Deemed Offer by:

(a) PHIC, where the Target Shareholder is any of the Local Partner Shareholders, PHIC may; or

(b) the Local Partner Representative, where the Target Shareholder is PHIC, the Local Partner Shareholders jointly may,

procure that the Company appoint the Valuer in writing and at the expense of the Target Shareholder.

The Valuer shall act as an expert and not as an arbitrator and shall deliver to the Shareholders a written determination of the Fair Market Value of each Share within 30 days (or such other date as may be agreed by the Shareholders) from the date of his appointment. His written determination of the Fair Market Value of each Share shall (in the absence of clerical or manifest error) be final and binding on the Shareholders. In determining the Fair Market Value, the Valuer shall take into consideration the following assumptions:

(i) that the relevant Shares are the subject of an arm's length sale between a willing vendor and a willing purchaser;

(ii) that the Company would continue to carry on its business as a going concern; and

(iii) that there shall be no discount or enhancement in the value of the relevant Shares by reference to the number of the relevant Shares as a rateable proportion of the issued share capital of the Company.

18.4 Within 60 days from the Shareholders receiving the Valuer’s written determination of the Fair Market Value of each Share, any Shareholder (other than the Target Shareholder) may accept the Deemed Offer by notice in writing to the Company and the Target Shareholder. The Target Shareholder and the relevant transferee shall use their best endeavours to promptly obtain the approval of the MIC as well as all necessary consents and approvals required by applicable law and regulations or any other person, to effect any Transfer of the Target Shareholder’s Shares and the assignment of the relevant Transfer Loans in accordance with this Clause 18, and the other Shareholders (other than the Target Shareholder) shall extend their full co-operation and assistance, as may be reasonably requested by the Target Shareholder and the relevant transferee, in respect of the same.

18.5 Any sale or purchase of Shares under the provisions of this Clause 18 shall take place at the registered office of the Company and on the date falling no later than 30 days from the date the MIC extends its approval for such sale and purchase of Shares and the assignment of the Transfer Loans. On completion, in accordance with the rules and procedures prescribed by the

Companies Act and subject to the requirements of the MIC:

(a) the Target Shareholder shall deliver to PHIC (where any of the Local Partner Shareholders is the Target Shareholder) or to the Local Partner Representative (where PHIC is the Target Shareholder):

(i) a duly executed transfer form in favour of the transferee(s) or such person as it or they may direct;

(ii) the share certificate(s) in respect of the Target Shareholder’s Shares to be sold; and

(iii) a working sheet signed by a Director or the secretary of the Company computing the net asset value per share of the Company;

(iv) duly executed assignment(s) (in such form and substance as may be acceptable to the transferee(s)) of the Transfer Loans; and

(v) any other document which may be required to enable the transferee(s) or such persons as it may direct to obtain the effective (A) transfer of the Target Shareholder’s Shares to it and to be registered as the holder thereof; and (B) assignment of the Transfer Loans to be assigned to it,

and the Target Shareholder shall procure the resignation(s) of all Director(s) which were appointed pursuant to its nominations and which said resignations shall take effect on the date of the completion of the sale and purchase of any Shares under this Clause 18; and

(b) the transferee(s) shall deliver to the Target Shareholder a cashier's order or banker's draft or such other mode of payment agreed between the Target Shareholder and the transferee(s) for the full amount of the consideration payable for the Target Shareholders’ Shares, which amount shall be Fair Market Value of the Shares and the Outstanding Amount, each which shall be expressed in US Dollars.

18.6 Subject to Clauses 17.2(a) and 17.2(c) which shall apply *mutatis mutandis*:

(a) if the Target Shareholder is any of the Local Partner Shareholders, PHIC shall be entitled to direct that the Target Shareholder’s Shares be transferred to such person as it may direct; or

(b) if the Target Shareholder is PHIC, the Local Partner Shareholders shall be entitled to jointly direct that the Target Shareholder’s Shares be transferred to such person as they may direct.

18.7 The Shareholder who has accepted the Deemed Offer in accordance with the provisions of Clause 18 shall be entitled to deduct from the aggregate purchase price for its proportion of the Target Shareholder's Shares any cost and expenses incurred or to be incurred by such Shareholder (including the cost and expenses of the appointment of the Valuer and all legal and accounting costs) in connection with the Transfer of the Target Shareholder's Shares.

19. <u>TAG-ALONG RIGHTS</u>

19.1 Subject always to Clause 14 and after compliance with the procedures set out in Clause 17, if any Transferring Shareholder desires to Transfer, in a single transaction or a series of related

transaction, any of the Shares held by it in a bona fide sale, then the Transferring Shareholder shall promptly give written notice (the "**Tag-Along Notice**") simultaneously to the Company and to the other Shareholders (the "**Non-Transferring Shareholders**"). The Tag-Along Notice shall describe in reasonable detail the terms and conditions of the proposed Transfer, including without limitation, the number of Shares to be transferred, the nature of such transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee.

19.2 Each Non-Transferring Shareholder shall have the right, exercisable upon written notice (the "**Notice of Participation**") to the Company within 60 days after the receipt of the Tag-Along Notice, to inform the Company in writing whether any of them elect to participate in the Transfer by the Transferring Shareholder on the same terms and conditions as set forth in the Tag-Along Notice. The Notice of Participation shall indicate the number of Shares the Non-Transferring Shareholder elects to Transfer pursuant to this Clause 19.2, up to that number of Shares equal to the product obtained by multiplying (a) the aggregate number of Shares set forth in the Tag-Along Notice by (b) that Non-Transferring Shareholder's Shareholding Proportion at the time of the Transfer. Each Non-Transferring Shareholder who elects to participate in the Transfer by the Transferring Shareholder pursuant to this Clause 19.2 (the "**Tag-Along Participant**") shall promptly deliver to the Company (who shall be deemed to be constituted the agent of the Transferring Shareholder and the Tag-Along Participant for the transfer in accordance with the Articles) for transfer to the prospective purchaser one or more share transfer forms, properly executed for transfer, which represent the number of Shares which the Tag-Along Participant elects to Transfer, together with the relevant share certificate(s) and a working sheet signed by a Director or the secretary of the Company computing the net asset value per share of the Company, for the purposes of stamping the said Transfer. To the extent one or more of the Non-Transferring Shareholders exercise such right of participation in accordance with the terms and conditions set forth above, the number of Shares that the Transferring Shareholder may Transfer in the transaction shall be correspondingly reduced.

19.3 To the extent any Non-Transferring Shareholder fails to elect to participate in the Transfer by the Transferring Shareholder, such Shareholder shall be deemed to have consented to the Transfer by the Transferring Shareholder on the terms and conditions and to the proposed transferee set forth in the Tag-Along Notice. The Company shall (as agent for the Tag-Along Participants) Transfer the number of Shares which the Tag-Along Participants have elected to Transfer to the proposed transferee on the terms set out in the Tag-Along Notice. Any proposed Transfer on terms and conditions more favourable than those described in the Tag-Along Notice or to a transferee not identified in such notice, as well as any subsequent proposed Transfer of any of the Shares held by the Transferring Shareholder, shall again be subject to the tag-along rights of the Non-Transferring Shareholders and shall require compliance by the Transferring Shareholder with the procedures described in this Clause 19. The exercise or non-exercise of the rights of a Shareholder hereunder to participate in one or more sales by the other Shareholders shall not adversely affect the first-mentioned Shareholder's rights to participate in subsequent sales of Shares by any Shareholder pursuant to this Clause 19.

19.4 Upon consummation of the Transfer of the Shares pursuant to the terms and conditions specified in the Tag-Along Notice, the Transferring Shareholder or the Company, as the case maybe, shall remit to each Tag-Along Participant that portion of the proceeds to which such Tag-Along Participant is entitled by reason of its participation in such Transfer. To the extent that any prospective purchaser or purchasers prohibits such assignment or otherwise refuses to purchase Shares from a Tag-Along Participant exercising its tag-along rights hereunder, the Transferring Shareholder shall not transfer to such prospective purchaser or purchasers any of its Shares unless and until, simultaneously with such transfer, the Transferring Shareholder shall purchase the Shares from such Tag-Along Participant on the same terms and conditions specified in the Tag-Along Notice.

19.5 Notwithstanding the foregoing, tag-along rights shall not apply to any Transfer or Transfers by a Shareholder to a Permitted Transferee of such Shareholder or made pursuant to a *bona fide* loan transaction with a financial institution that creates a mere security interest, and the provisions of Clauses 17.2, 17.10 and 17.12 shall apply *mutatis mutandis*.

19.6 Any purported Transfer by a Shareholder in violation of this Agreement shall be null and void and of no force and effect and the purported transferees shall have no rights or privileges in or with respect to the Company or the Shares purported to have been so transferred. The Company shall refuse to recognise any such transfer and shall not reflect in its records any change in ownership of such Shares purported to have been so transferred.

20. TERMINATION

20.1 This Agreement shall continue in force without limit in point of time until terminated in accordance with the provisions of this Clause 20 or by unanimous agreement of all Shareholders in writing. Further, this Agreement shall be deemed to be terminated in the event either PHIC or the Local Partner Shareholders jointly holds all the issued share capital of the Company.

20.2 This Agreement shall terminate in respect of any Party if at any time as a result of a Transfer of Shares made in accordance with this Agreement and the Articles, that Party holds no Shares but without prejudice to any rights which any other Party may have against that Party prior to such termination.

20.3 This Agreement shall terminate forthwith if the Company is put into liquidation, whether voluntary or compulsory.

20.4 Upon any of the Shareholders ceasing to be a Shareholder or a Party to this Agreement for any reason, the provisions of this Agreement will cease to be applicable to such Shareholder as if it were not a party to this Agreement, save for Clauses 17.10, 20.2, 23 and 24 and save for such rights, benefits and obligations as have accrued to it at the date of its ceasing to be a Shareholder or a party to this Agreement and save further that the right of any Shareholder to claim damages or any other remedies by reason of any breach of this Agreement by any other Shareholder which has accrued prior to any Shareholder so ceasing shall not be affected.

21. DEADLOCK

21.1 For the purposes of this Clause 21, a "**Deadlock**" is deemed to have occurred when:

(a) the Shareholders are unable, within thirty (30) days from the date PHIC requests for amendments to the terms of this Agreement, to agree on such amendments and an appropriate solution under Clause 15.3 so as to enable PHIC to consolidate the Company in its accounts for the purposes of financial reporting;

(b) a resolution of the Directors for the transaction of any business of the Directors cannot be passed after two (2) successive attempts;

(c) a resolution of the Shareholders for the transaction of any Business of the Company cannot be passed after two (2) successive attempts; or

(d) a general meeting of Shareholders or a meeting of the Board cannot be convened because of the absence of the requisite quorum, after three (3) successive attempts.

21.2 In the event of a Deadlock occurring, the Board shall immediately upon the occurrence of any such Deadlock, refer the matter which is the subject of the approval under Clause 21.1(a) and/or Clause 21.1(b) or the matter(s) which was to have been discussed at the general meeting or the meeting of the Shareholders or the meeting of the Board under Clause 21.1(c) (as the case may be) to:

(a) in respect of PHIC, the chief executive officer or the most senior officer of PHIC; and

(b) in respect of the Local Partner Shareholders, a senior representative nominated by the Local Partner Shareholders,

(collectively, the "**Officers**"). PHIC and the Local Partner Shareholders jointly shall procure that its/their Officer shall negotiate in good faith with the other Officer with a view to a resolution of such matter.

21.3 Upon the resolution of such matter in accordance with Clause 21.2, the Board shall be bound to give effect to the agreement reached between the Officers in respect of such matter.

21.4 If no resolution of the subject matter in accordance with Clause 21.2 is reached within 30 days after the date of the Board's referral to the Officers, either PHIC or the Local Partner Shareholders jointly, may issue a notice to the other Shareholder(s) for the Shareholders to jointly procure that the Company appoint a Valuer to determine the Fair Market Value.

21.5 The said Valuer shall be such person as shall be appointed in writing by the Company and at the direction of the Shareholders jointly or, failing such joint direction, at the direction of the Company's auditors (in the latter case, upon the application at any time of any Shareholder) at the expense, equally of each Shareholder that has submitted a Purchase Bid. The Valuer shall act as an expert and not as an arbitrator and shall deliver to the Shareholders a written determination of the Fair Market Value of each Share within 30 days (or such other date as may be agreed by the Shareholders) from the date of his appointment. His written determination of the Fair Market Value of each Share shall (in the absence of clerical or manifest error) be final and binding on the Shareholders. In determining the Fair Market Value, the Valuer shall take into consideration the following assumptions:

(a) that the Shares are the subject of an arm's length sale between a willing vendor and a willing purchaser;

(b) that the Company would continue to carry on its business as a going concern; and

(c) that there shall be no discount or enhancement in the value of the Shares by reference to the number of the Shares as a rateable proportion of the issued share capital of the Company.

21.6 Within 60 days after the delivery of the written determination of the Fair Market Value of each Share by the Valuer, PHIC or the Local Partner Shareholders jointly shall (without prejudice to such other rights and remedies it/they may have) be entitled to submit a bid (a "**Purchase Bid**") to the Company's auditors offering to purchase all, but not some only, of the Shares held by the Local Partner Shareholders jointly or PHIC at a price per Share specified in the notice (the "**Purchase Price**"). Once submitted, a Purchase Bid cannot be withdrawn without the written consent of the other Shareholder(s). Any bid at a price less than the Fair Market Value shall be rejected by the Company's auditors. The Company's auditors shall notify in writing the Shareholders of the outcome of the bids within 14 days after the close of the bids.

21.7 In the event that any Purchase Bid is above the Fair Market Value, the Shareholder(s) submitting the highest Purchase Bid (the "**Highest Bidder**") shall be entitled to purchase all the

Shares (the "**Deadlock Shares**") held by:

(a) PHIC (in the case where the Highest Bidder is the Local Partner Shareholders jointly); or

(b) the Local Partner Shareholders (in the case where the Highest Bidder is PHIC),

(the "**Other Bidder**") at an amount equal to the sum of the highest Purchase Price and the Outstanding Amount ("**Deadlock Consideration**"), and shall make payment for the same not later than 30 days from the date of receipt of written notification by the Company's auditors.

21.8 The Shareholders shall use their best endeavours to promptly obtain the approval of the MIC as well as all necessary consents and approvals required by applicable law and regulations or any other person, to effect any Transfer of the Deadlock Shares and the assignment of the relevant Transfer Loans in accordance with this Clause 21.

21.9 Any sale or purchase of Shares under the provisions of this Clause 21 shall take place at the registered office of the Company and on the date falling no later than 30 days from the date the MIC extends its approval for such sale and purchase of Shares. On completion, in accordance with the rules and procedures prescribed by the Companies Act and subject to the requirements of the MIC:

(a) the Other Bidder shall deliver to the Highest Bidder or such person as it may direct:

(i) a duly executed transfer form in favour of the Highest Bidder or such person as it may direct;

(ii) the share certificate(s) in respect of the Deadlock Shares to be sold;

(iii) a working sheet signed by a Director or the secretary of the Company computing the net asset value per share of the Company;

(iv) duly executed assignment(s) (in such form and substance as may be acceptable to the Highest Bidder) of the Transfer Loans; and

(v) any other document which may be required to enable the Highest Bidder or such person as it may direct to obtain the effective (A) transfer of the Shares to it and to be registered as the holder thereof; and (B) assignment of the Transfer Loans to be assigned to it,

and the Other Bidder shall procure the resignation(s) of all Director(s) which were appointed pursuant to its nominations and which said resignations shall take effect on the date of the completion of the sale and purchase of the Deadlock Shares under this Clause 21; and

(b) the Highest Bidder shall deliver to the Other Bidder a cashier's order or banker's draft or such other mode of payment agreed between the Other Bidder and the Highest Bidder for the full amount of the Deadlock Consideration which shall be expressed in US Dollars.

21.10 Subject to Clauses 17.2(a) and 17.2(c) which shall apply *mutatis mutandis*:

(a) in the event that PHIC is the Highest Bidder, PHIC shall be entitled to direct that the Deadlock Shares be transferred to such person as it may direct; or

(b) in the event that the Local Partner Shareholders are the Highest Bidder, the Local Partner Shareholders shall be entitled to jointly direct that the Deadlock Shares be transferred to such person as they may direct.

21.11 If the Other Bidder fails to transfer the Deadlock Shares to the Highest Bidder, or such person as it may direct, in accordance with this Clause 21 or is in breach of Clause 21.8, any Director appointed by the Highest Bidder shall be deemed to have been appointed attorney of the Other Bidder with full power to execute, complete and deliver, in the name and on behalf of the Other Bidder all documents necessary to give effect to the provisions of this Clause 21, including but not limited to all application forms and information to be submitted to the MIC in order to obtain MIC's approval for the sale and transfer of the Deadlock Shares and duly executed share transfer form(s) so as to effect the Transfer of the Deadlock Shares to the Highest Bidder against payment of the Deadlock Consideration for the Deadlock Shares to the Company.

21.12 On payment of the Deadlock Consideration to the Company, the Highest Bidder shall be deemed to have obtained a good quittance for such payment and the Company shall cancel the share certificate(s) representing the Deadlock Shares issued in favour of the Other Bidder and issue and deliver new share certificate(s) for the Deadlock Shares to the Highest Bidder. On execution and delivery of the transfer of Deadlock Shares, the Highest Bidder shall be entitled to require that its name or the name of such person(s) as it may direct be entered in the Company's register of members as the holder of the Deadlock Shares and the Company shall so enter the name of the Highest Bidder or the name of such person(s) as it may direct as the holder of the Deadlock Shares. Where the Local Partner Shareholders jointly constitute the Highest Bidder, the Local Partner Shareholders shall pro-rate the number of Deadlock Shares to be registered in the name of each Local Partner Shareholder (in as nearly as may be) according to their respective Shareholding Proportion *inter se*.

The Highest Bidder shall procure that the Company shall forthwith pay the Deadlock Consideration into a separate bank account in the Company's name and shall hold such price for the account of the Other Bidder.

21.13 Without prejudice to the provisions of Clause 21.11, the Other Bidder hereby irrevocably and unconditionally appoints the Director appointed by the Highest Bidder to be its attorney and on its behalf and in its name or otherwise to execute and do all such assurances, acts and things which it ought to do under the undertakings and provisions contained in this Clause 21 and generally in its name or otherwise and on its behalf to seal and deliver and otherwise perfect any deed, assurance, agreement, instrument or act which the Highest Bidder may deem proper in or for the purpose of fulfilling the obligations of the Other Bidder hereunder. The Other Bidder hereby ratify(ies) and confirm(s) and agree(s) to ratify and confirm whatever any such attorney as is mentioned in this Clause 21.13 shall do or purport to do in the exercise or purported exercise of all or any of the powers, authorities and discretions referred to in this Clause 21.

21.14 The stamp duty payable on the transfer of the Deadlock Shares shall be borne wholly by the Highest Bidder.

21.15 The restrictions on Transfer of shares contained in Clauses 17 (except for Clauses 17.2(a), 17.2(c) and 17.13) and 19 and in the Articles shall not apply to the sale and transfer of shares under this Clause 21.

22. <u>DEFAULT</u>

22.1 "**<u>Default Event</u>**" in relation to any Shareholder means any of the following:

(a) if the Defaulting Party is in breach of, or fails to comply with, Clauses 17.1, 18.1(a) or

23.1;

(b) if the Non-Defaulting Party has obtained an award of the arbitral tribunal, convened in accordance with Clause 44, that the Defaulting Party is in material breach of any of its obligations under this Agreement other than Clauses 17.1, 18.1(a) and 23.1, and where an Insolvency Event in respect of the Company will occur or is likely to occur as a result of such breach;

(c) if the Defaulting Party shall go into liquidation whether compulsory or voluntary (except for the purposes of a bona fide reconstruction or amalgamation with the consent of the other Shareholder, such consent not to be unreasonably withheld) or if a petition shall be presented or an order made from the appointment of an administrator in relation to the Defaulting Party or if a receiver, administrative receiver, judicial manager or manager shall be appointed over any part of the assets or undertaking of the Defaulting Party and such appointment is not revoked within 30 days from the date of such appointment or if any event analogous to any of the foregoing shall occur in any jurisdiction;

(d) if the Defaulting Party shall make a general assignment or any composition or arrangement with or for the benefit of its creditors; or

(e) if the Defaulting Party shall sell, transfer, lease or otherwise dispose of the whole or substantially the whole of its assets, rights and undertaking.

22.2 Where any Default Event occurs in relation to any Party (the "**Defaulting Party**"):

(a) PHIC (in the case where the Defaulting Party is any of the Local Partner Shareholders); and

(b) the Local Partner Shareholders jointly (in the case where the Defaulting Party is PHIC),

(the "**Non-Defaulting Party**") shall, without prejudice to any other rights and remedies which the Non-Defaulting Party may have at law or otherwise, be entitled to:

(i) a call option (the "**Default Call Option**"), being the right of any or all of the Non-Defaulting Parties to require the Defaulting Party to sell to such Non-Defaulting Party free from all Encumbrances and with all rights and benefits attaching thereto, all (and not some only) of the Shares held by the Defaulting Party for the time being in the capital of the Company (the "**Defaulting Party's Shares**") on the terms and conditions contained herein; or

(ii) a put option (the "**Default Put Option**"), being the rights of any or all of the Non-Defaulting Parties to require the Defaulting Party to purchase from such Non-Defaulting Party free from all Encumbrances and with all rights and benefits attaching thereto, all (and not some only) of the Shares held by the Non-Defaulting Party for the time being in the capital of the Company (the "**Non-Defaulting Party's Shares**") on the terms and subject to the conditions contained herein.

For the avoidance of doubt, the Default Call Option shall lapse upon the exercise of the Default Put Option and *vice versa.*

22.3 The Default Call Option may be exercised by the Non-Defaulting Party by serving a notice in substantially the form set out in Schedule 4 (the "**Default Call Option Notice**") on the Defaulting Party within a period of 60 days from the date of the notice specifying the breach or default referred to in Clause 22.1, failing which it will lapse.

22.4 Upon receiving a Default Call Option Notice from the Non-Defaulting Party, the Defaulting Party shall sell to the Non-Defaulting Party, and the Non-Defaulting Party shall purchase or procure the purchase of, all of the Defaulting Party's Shares.

The Defaulting Party's Shares shall be sold free from all Encumbrances and with all rights and benefits attaching thereto Provided That all relevant approvals, consents and permits have been obtained from the governmental, regulatory, supervisory or administrative bodies or agencies (including without limitation, any stock exchange and securities council, whether in Myanmar, Singapore or elsewhere). The Defaulting Party shall procure that all such approvals, consents and permits shall have been obtained.

22.4A Subject to Clauses 17.2(a) and 17.2(c) which shall apply *mutatis mutandis*:

(a) in the event that PHIC exercises the Default Call Option as the Non-Defaulting Party, PHIC shall be entitled to direct that the Defaulting Party's Shares be transferred to such person as it may direct; and

(b) inn the event that the Local Partner Shareholder jointly exercise the Default Call Option as the Non-Defaulting Parties, the Local Partner Shareholders shall be entitled to jointly direct that the Defaulting Party's Shares be transferred to such person as they may direct.

22.5 The Default Put Option may be exercised by a Non-Defaulting Party by serving notice in substantially the form set out in Schedule 5 (the "**<u>Default Put Option Notice</u>**") on the Defaulting Party within a period of 60 days from the date of the notice specifying the beach or default referred to in Clause 22.1, failing which it will lapse.

22.6 Upon receiving a Default Put Option Notice from a Non-Defaulting Party, the Defaulting Party shall purchase from the Non-Defaulting Party and the Non-Defaulting Party shall sell all of the Non-Defaulting Party's shares.

The Non-Defaulting Party's Shares shall be sold free from all Encumbrances and with all rights and benefits attaching thereto Provided That all relevant approvals, consents and permits have been obtained from the governmental, regulatory, supervisory or administrative bodies or agencies (including without limitation, any stock exchange and securities council, whether in Myanmar, Singapore or elsewhere). The Defaulting Party shall procure that all such approvals, consents and permits shall have been obtained.

22.6A Subject to Clauses 17.2(a) and 17.2(c) which shall apply *mutatis mutandis*:

(a) in the event that the Local Partner Shareholders jointly exercise the Default Put Option as the Non-Defaulting Party, PHIC shall be entitled to direct that the Non-Defaulting Party's Shares be transferred to such person as it may direct; or

(b) in the event that PHIC exercise the Default Put Option as the Non-Defaulting Party, the Local Partner Shareholders shall be entitled to jointly direct that the Non-Defaulting Party's Shares be transferred to such person as they may direct.

22.7 The purchase price of each of the Defaulting Party's Shares shall be:

(a) where the Default Event occurs at any time before the Opening Date or 48 months from the date of execution of this Agreement, whichever is earlier:

(i) the sum equal to 90% of the amount actually paid up as share capital for the Default Option Shares in the event of an exercise of the Default Call Option; or

(ii) the sum equal to 110% of the amount actually paid up as the share capital for the Default Option Shares in the event of an exercise of the Default Put Option; or

(b) in all other cases,

(i) the sum equal to 90% of their Fair Market Value of the Default Option Shares in the event of an exercise of the Default Call Option; or

(ii) the sum equal to 110% of the Fair Market Value of the Default Option Shares in the event of an exercise of the Default Put Option,

Provided Always that if the Fair Market Value as determined under Clause 22.9 is in the negative, the aggregate purchase price for all the Default Option Shares shall be US$1.

22.8 In this Clause, the expressions "**Non-Defaulting Party**" and "**Defaulting Party**" include the Shareholders and the registered holders for the time being of the Shares originally held by any of the Shareholders but subsequently transferred by them pursuant to this Agreement.

22.9 For the purposes of determining the Fair Market Value and if the Default Event occurs after the Opening Date or 48 months from the date of execution of this Agreement, whichever is earlier, the Valuer shall be such person as shall be appointed in writing by the Company at the direction of the Non-Defaulting Party and at the expense of the Defaulting Party. The Valuer shall act as an expert and not as an arbitrator and shall deliver to the Non-Defaulting Party a written determination of the Fair Market Value of each Default Option Share within 30 days (or such other date as may be agreed by the Non-Defaulting Party) from the date of his appointment. His written determination of the Fair Market Value of each Default Option Share shall (in the absence of clerical or manifest error) be final and binding on the Shareholders.

22.10 In determining the Fair Market Value, the Valuer shall take into consideration the following assumptions:

(a) that the Default Option Shares are the subject of an arm's length sale between a willing vendor and a willing purchaser;

(b) that the Company would continue to carry on its business as a going concern; and

(c) that there shall be no discount or enhancement in the value of the Default Option Shares by reference to the number of the Default Option Shares as a rateable proportion of the issued share capital of the Company.

22.11 The Shareholders shall use their best endeavours to promptly obtain the approval of the MIC as well as all necessary consents and approvals required by applicable law and regulations or any other person, to effect any Transfer of the Default Option Shares and the assignment of the relevant Transfer Loans in accordance with this Clause 22.

22.12 Completion of the sale and purchase of the Default Option Shares (the "**Default Option Completion**") shall take place at the registered office of the Company on the date falling no later than 30 days from the date the MIC extends its approval for such sale and purchase of Shares. On the Default Option Completion, in accordance with the rules and procedures prescribed by the Companies Act and subject to the requirements of the MIC:

(a) the Default Transferor shall deliver to the Default Transferee or such person as it may direct:

(i) a duly executed transfer form in favour of the Default Transferee or such person as it may direct;

(ii) the share certificate(s) in respect of the Default Option Shares to be sold;

(iii) a working sheet signed by a Director or the secretary of the Company computing the net asset value per share of the Company;

(iv) duly executed assignment(s) (in such form and substance as may be acceptable to the Default Transferee) of any Transfer Loans; and

(v) any other document which may be required to enable the Default Transferee to obtain the effective (A) transfer of the Shares to it and to be registered as the holder thereof; and (B) assignment of the Transfer Loans to be assigned to it,

and the Default Transferee shall procure the resignation(s) of all Director(s) which were appointed pursuant to its nominations and which said resignations shall take effect on the date of the completion of the sale and purchase of the Default Option Shares under this Clause 22; and

(b) the Default Transferee shall:

(i) deliver to the Default Transferor a cashier's order or banker's draft or such other mode of payment agreed between the Default Transferor and Default Transferee for the full amount of the consideration payable for the Default Option Shares to be purchased which shall be expressed in US Dollars; and

(ii) pay the consideration for the assignment of the Transfer Loans and in the manner contemplated in Clause 22.12(b)(i), which shall be:

(A) the sum of 110% of the Outstanding Amount in the event that the Non-Defaulting Party is the Default Transferor; or

(B) the sum of 90% of the Outstanding Amount in the event that the Defaulting Party is the Default Transferor.

22.13 In the case of the Default Call Option, in the event that the Defaulting Party fails to complete the sale and purchase of the Default Option Shares on the Default Option Completion or is in breach of Clause 22.11, any Director shall be deemed to have been appointed attorney of the Defaulting Party with full power to execute, complete and deliver, in the name and on behalf of the Defaulting Party, transfers of the Default Option Shares to the Non-Defaulting Party and/or its nominees against payment of the purchase price for the Default Option Shares to the Company.

On payment of the purchase price to the Company, the Non-Defaulting Party shall be deemed to have obtained a good quittance for such payment and the Company shall cancel the share certificate(s) representing the Default Option Shares issued in favour of the Defaulting Party and issue and deliver new share certificate(s) for the Default Option Shares to the Non-Defaulting Party and/or its nominee. On execution and delivery of the transfer of the Default Option Shares, the Non-Defaulting Party shall be entitled to require that its name and/or its nominee' names be entered in the Company's register of members as the holder of the Default Option Shares and the Company shall so enter the name of the Non-Defaulting Party

and/or its nominee as the holder of the Default Option Shares.

The Non-Defaulting Party shall procure that the Company shall forthwith pay the purchase price into a separate bank account in the Company's name and shall hold such price for the account of the Defaulting Party.

22.14 In the case of the Default Put Option, the Defaulting Party shall upon or immediately prior to the Default Option Completion, procure the immediate release of all undertakings, guarantees, indemnities, covenants, assurances, security, comfort or similar obligations (if any) given by the Non-Defaulting Party and/or its related corporations for the benefit of the Company or in relation to it or its Businesses as at the date of the Default Put Option Notice and pending such release shall indemnify and keep the Non-Defaulting Party and its related corporations fully and effectively indemnified from and against all claims arising thereunder.

22.15 Where the Local Partner Shareholders jointly are the Default Transferee, the Local Partner Shareholders shall pro-rate the number of Default Option Shares to be registered in the name of each Local Partner Shareholder (in as nearly as may be) according to their respective Shareholding Proportion *inter se.*

22.16 The stamp duty payable on the transfer of the Default Option Shares shall be borne wholly by the Defaulting Party. In the case of the Default Call Option, the Defaulting Party shall at least two (2) days prior to the Default Option Completion deliver to each of the Non-Defaulting Party(ies) the stamp duty payable on the transfer of the relevant Default Option Shares in US Dollars by way of a cashier's order, bank draft or cheque drawn on a licensed bank in Myanmar and made out in favour of the relevant Non-Defaulting Party(ies) or in such manner as agreed to by the Defaulting Party and the Non-Defaulting Party(ies) in writing. In the event that the Defaulting Party fails to deliver the requisite amount of stamp duty to the relevant Non-Defaulting Party(ies) as aforesaid, the Non-Defaulting Party(ies) shall be entitled to offset such amount of stamp duty from the purchase price payable for the relevant number of Default Option Shares and shall pay to the Defaulting Party the balance of the purchase price (after deducting stamp duty payable for the transfer of the relevant Default Option Shares) on the Default Option Completion pursuant to Clause 22.12.

22.17 The restrictions on transfer of shares contained in Clauses 17 (except Clauses 17.2(a), 17.2(c) and 17.13) and 19 and in the Articles shall not apply to the sale and transfer of the Default Option Shares pursuant to any exercise of a Default Call Option or, as the case may be, a Default Put Option.

22.18 Without prejudice to the provisions of Clause 22.13, the Defaulting Party hereby irrevocably and unconditionally appoints the Director(s) appointed by the Non-Defaulting Party(ies) to be its attorney and on its behalf and in its name or otherwise to execute and do all such assurances, acts and things which the Defaulting Party ought to do under the undertakings and provisions contained in this Clause 22 and generally in its name or otherwise and on its behalf to seal and deliver and otherwise perfect any deed, assurance, agreement, instrument or act which a Non-Defaulting Party may deem proper in or for the purpose of fulfilling the obligations of the Defaulting Party hereunder. The Defaulting Party hereby ratifies and confirms and agrees to ratify and confirm whatever any such attorney(s) as is mentioned in this Clause 22.18 shall do or purport to do in the exercise or purported exercise of all or any of the powers, authorities and discretions referred to in this Clause 22.

The Shareholders shall exercise all voting and other rights available to them to ensure the implementation of this Clause 22 and the registration of any transfer of any Shares pursuant to this Clause 22.

23. NON-COMPETITION

23.1 (a) PHIC covenants with and undertakes to the other Shareholders that it shall not, and shall procure that its Prescribed Entities shall not, singly or collectively, without the prior written consent of the Local Partner Representative, make any equity investment of more than 5% in aggregate; and

(b) each of the Local Partner Shareholders covenants with and undertakes to PHIC that it shall not, and shall procure that its Prescribed Entities shall not, singly or together with the other Local Partner Shareholders or their Prescribed Entities collectively, without the prior written consent of PHIC, make any equity investment of more than 5% in aggregate,

in, or provide advisory services on the management of the post-construction operations of, any hospital:

(i) in Yangon, for as long as this Agreement remains in force in relation to such Shareholder and for a period of 12 months thereafter; and

(ii) in Mandalay, from the date of this Agreement and ending on the earlier of (A) the date falling two (2) years from the date of this Agreement; and (B) the date this Agreement ceases to be in force in relation to such Shareholder.

23.2 Each Shareholder shall, within two (2) weeks from the close of each financial year, notify the Company and the other Shareholders in writing of the extent of the direct and indirect equity investments that it, or any of its Prescribed Entities, has in any hospital in Yangon or in Mandalay, if any. The obligations of each Shareholder under this Clause 23.2 shall subsist:

(a) in the case of any hospital in Yangon, for as long as this Agreement remains in force in relation to such Shareholder and for a period of 12 months thereafter; and

(b) in the case of any hospital in Mandalay, from the date of this Agreement and ending on the earlier of (i) the date falling two (2) years from the date of this Agreement; and (ii) the date this Agreement ceases to be in force in relation to such Shareholder.

23.3 Each and every obligation under this Clause 23 shall be treated as a separate obligation and shall be severally enforceable as such and in the event of any obligation or obligations being or becoming unenforceable in whole or in part such part or parts as are unenforceable shall be deleted from this Clause 23 and any such deletion shall not affect the enforceability of all such parts of this Clause 23 as remain not so deleted.

23.4 While the restrictions contained in this Clause 23 are considered by the Shareholders to be reasonable in all the circumstances, it is recognised that restrictions of the nature in question may fail for technical reasons unforeseen and accordingly it is hereby agreed and declared that if any of such restrictions shall be adjudged to be void as going beyond what is reasonable in all the circumstances for the protection of the interests of the Company but would be valid if part of the wording thereof were deleted or the periods thereof reduced or the range of activities or area dealt with thereby reduced in scope the said restriction shall apply with such modifications as may be necessary to make it valid and effective.

23.5 This Clause 23 shall survive the termination of this Agreement in relation to any of the Parties.

24. CONFIDENTIALITY

24.1 Each Party undertakes to the other Parties that it shall (and shall procure that its agents and

where applicable its officers and employees shall):

(a) not, without the prior written consent of the other Parties, use or disclose to any person Confidential Information or Third Party Confidential Information it has or acquires; and

(b) make every effort to prevent the use or disclosure of Confidential Information or Third Party Confidential Information.

24.2 The confidentiality obligation under Clause 24.1 shall not apply to:

(a) any information which becomes generally known to the public, other than by reason of any wilful or negligent act or omission of a Party;

(b) any information which is required to be disclosed pursuant to any applicable laws or any requirement of any competent governmental or statutory authority or pursuant to rules or regulations of any relevant regulatory, administrative or supervisory body (including without limitation, any relevant stock exchange or securities council);

(c) any information which is required to be disclosed pursuant to any legal process issued by any court or tribunal whether in Myanmar, Singapore or elsewhere;

(d) any information disclosed by a Party to its bankers, financial advisers, consultants and legal or other advisers for the purpose of this Agreement (provided that such persons have a professional obligation to keep such matters confidential or agree to be bound by confidential obligations substantially similar to the foregoing); and

(e) any information disclosed by a Party to its directors, officers, employees, agents, advisors or investors and its subsidiaries and/or related corporations.

24.3 Notwithstanding Clause 24.1, a Party may disclose Confidential Information to any potential Buyer of the Shares held by it at the relevant time Provided Always that it shall:

(a) inform the other Parties in writing of the identity of the potential Buyer and the scope of the Confidential Information to be disclosed; and

(b) procure that the potential Buyer sign a confidentiality undertaking on terms which are reasonable for the protection of the interests of the Company.

24.4 The obligations contained in this Clause shall endure, notwithstanding the termination of this Agreement, without limit in point of time except and until any Confidential Information or Third Party Confidential Information enters the public domain as set out above.

25. ANNOUNCEMENTS

25.1 No Party shall make or authorise the making of any announcement or other disclosure concerning the existence or subject matter of this Agreement unless the other Parties shall have given their respective consent to such announcement or disclosure (such consent not to be unreasonably withheld or delayed).

25.2 Clause 25.1 shall not apply to:

(a) any information which is required to be disclosed pursuant to any applicable laws or any requirement of any competent governmental or statutory authority or rules or regulations of any relevant regulatory, administrative or supervisory body (including

without limitation, any relevant stock exchange or securities council);

(b) any information which is required to be disclosed pursuant to any legal process issued by any court or tribunal whether in Myanmar, Singapore or elsewhere; and

(c) any information disclosed by any Party to its bankers, financial advisers, consultants and legal or other advisers for the purpose of this Agreement (provided that such persons have a professional obligation to keep such matters confidential or agree to be bound by confidential obligations substantially similar to the foregoing).

25.3 Where any announcement or disclosure is made in reliance on the exceptions set out in Clause 25.2, the Party making the announcement or disclosure shall consult with the other Parties, where practicable and permissible, in advance as to the form, content and timing of such announcement or disclosure.

26. COSTS

Each Party shall bear its own legal and other costs and expenses of and incidental to the negotiation, preparation, execution and performance by it of this Agreement and all ancillary documents and the subscription hereby agreed to be made.

27. GENERAL

27.1 As all Parties have participated in the drafting of this Agreement, the Parties agree that any applicable rule requiring the construction of this Agreement or any provision hereof against the Party drafting this Agreement shall not apply.

27.2 Without prejudice to Clause 14, where this Agreement provides that any particular transaction or matter requires the consent, approval or agreement of any Party:

(a) such consent, approval or agreement may be given subject to such terms and conditions as such Part(ies) may impose and any breach of such terms and conditions by any person subject thereto shall *ipso facto* be deemed to be a breach of the terms of this Agreement; and

(b) the consent, approval or agreement of the Directors nominated by such Part(ies) to that transaction or matter (either in writing or given orally at a duly convened meeting of the Board (provided the same is accurately minuted)) shall be deemed to be the consent, approval or agreement of such Party for the purposes of this Agreement.

27.3 If the consent, approval or agreement of any Party is required under more than one provision of this Agreement for any one transaction or matter, then any consent, approval or agreement given in relation to that transaction or matter by such Part(ies) shall be deemed to cover all consents, approvals or agreement required for that transaction or matter unless otherwise specified by such Part(ies).

27.4 In the event of any conflict between the provisions of this Agreement and the Articles, the provisions of this Agreement shall prevail and the Shareholders shall, where possible, forthwith cause such necessary alterations to be made to the Articles as are required so as to remove such conflict.

28. ILLEGALITY

The illegality, invalidity or unenforceability of any provision of this Agreement under the law of any jurisdiction shall not affect its legality, validity or enforceability under the law of any other jurisdiction nor the legality, validity or enforceability of any other provision.

29. NOTICES

Each and every communication under this Agreement shall be made by facsimile or otherwise in writing. Each communication or document to be delivered to any Party shall be sent to that Party at the facsimile number or address and marked for the attention of the person (if any), from time to time designated by that Party for the purpose of this Agreement. The initial addresses and facsimile numbers of the Parties are:

AMMK

Fax Number	:	+95-1-534986
Address	:	33, Pyay Road, 6 ½ Miles, (11) Quarter, Hlaing Township, Yangon, the Republic of the Union of Myanmar
Attention	:	U Aung Moe Kyaw

GSC

Fax Number	:	+95-1-504-528
Address	:	No. (2) Bayint Naung Main Road, Ywama Curve, Ward No. (2), Hlaing Township, Yangon, the Republic of the Union of Myanmar
Attention	:	U Thurane Aung @ Christopher Aung

MHPL

Fax Number	:	+65 6323 2939
Address	:	78 Shenton Way, #28-01, Singapore (079120)
Attention	:	Mr. Ng How Kiat Charlie

PHIC

Fax Number	:	+65 6734 8917
Address	:	111 Somerset Road #15-01 Tripleone Somerset Singapore (238164)
Attention	:	Mr. Liaw Yit Ming

A demand, notice or other communication made or given by one Party to another Party in accordance with this Clause 29 shall be effected and deemed to be duly served:

(a) if it is delivered, when left at the address required by this Clause 29; or

(b) if it is sent by prepaid post (air-mail, if international), five (5) days after it is posted; or

(c) if it sent by facsimile, on the day of despatch.

In proving such service it shall be sufficient to prove that delivery by hand was made or that the envelope containing such notice or document was properly addressed and posted as a prepaid ordinary mail or that the facsimile confirmation note indicates the transmission was successful.

30. FURTHER ASSURANCE

Each Party shall do and execute or procure to be done and executed all such further acts, deeds, things and documents as may be necessary to give effect to the terms of this Agreement, and (so far as it is able) to provide such assistance as the other Parties may reasonably request (including without limitation, exercising its power as shareholders) to give effect to the spirit and intent of this Agreement.

31. ENTIRE AGREEMENT

This Agreement, and the documents referred to in it, constitutes the entire agreement and understanding between the Parties relating to the subject matter of this Agreement and no Party has entered into this Agreement in reliance upon any representation, warranty or undertaking of the other Parties which is not set out or referred to in this Agreement. Nothing in this Clause 31 shall however operate to limit or exclude liability for fraud.

32. ASSIGNMENT

Save as specifically provided in this Agreement, no Party shall (nor shall it purport to) assign, transfer, charge or otherwise deal with all or any of its rights under this Agreement nor grant, declare or dispose of any right or interest in it without the prior written consent of the other Parties.

33. VARIATIONS

32.1 No variation of this Agreement (or of any of the documents referred to in this Agreement) shall be valid unless it is in writing and signed by or on behalf of each Party. The expression "**variation**" shall include any amendment, supplement, deletion or replacement however effected.

32.2 Unless expressly agreed, no variation shall constitute a general waiver of any provisions of this Agreement, nor shall it affect any rights, obligations or liabilities under or pursuant to this Agreement which have already accrued up to the date of variation, and the rights and obligations of the Parties under or pursuant to this Agreement shall remain in full force and effect, except and only to the extent that they are so varied.

34. REMEDIES AND WAIVERS

No failure on the part of any Party to exercise, and no delay on its part in exercising, any right or remedy under this Agreement will operate as a waiver thereof, nor will any single or partial exercise of any right or remedy preclude any other or further exercise thereof or the exercise of any other right or remedy. The rights provided in this Agreement are cumulative and not exclusive of any rights or remedies provided by law.

35. SEVERAL OBLIGATIONS

All covenants, undertakings and other obligations given or entered into by the Parties are given or entered into severally unless the context otherwise requires.

36. NO PARTNERSHIP

Nothing in this Agreement shall be deemed to constitute a partnership between the Shareholders nor constitute either Party the agent of the other Party for any purpose.

37. SPIRIT OF AGREEMENT AND INTENTION

In entering into this Agreement, the Shareholders recognise that it is impractical to make provision for every contingency that may arise in the course of the observance or performance thereof. Accordingly, the Shareholders hereby declare it to be a cardinal principle of this Agreement and it to be their common intention that this Agreement shall operate between them with fairness and without detriment to the interests of any of them and if in the course of the performance of this Agreement unfairness to a Shareholder is disclosed or anticipated then the Shareholders shall use their best endeavours to agree upon such action as may be necessary and equitable to remove the cause or causes of the same.

38. TIME OF ESSENCE

Any date, time or period mentioned in any provision of this Agreement may be extended by mutual agreement between the Parties but as regards any time, date or period originally fixed and not extended or any time, date or period so extended as aforesaid, time shall be of the essence.

39. FORCE MAJEURE

Save as is otherwise specifically provided in this Agreement, the Parties shall not be liable for failures or delays in performing their obligations hereunder arising from any cause beyond their control, including without limitation, acts of God, acts of civil or military authority, fires, strikes, lockouts or labour disputes, epidemics, governmental restrictions, wars, riots, earthquakes, storms, typhoons, floods and breakdowns in electronic and computer information and communications systems and in the event of any such delay, the time for all Parties' performance shall be extended for a period equal to the time lost by reason of the delay which shall be remedied with all due despatch in the circumstances.

40. COUNTERPARTS

This Agreement may be signed in any number of counterparts, all of which taken together shall constitute one and the same instrument. The Parties may enter into this Agreement by signing any such counterpart and each counterpart shall be as valid and effectual as if executed as an original.

41. JOINT AND SEVERAL LIABILITY

Any provision of this Agreement which is expressed to bind more than one person shall, save where inconsistent with the context, bind them jointly and each of them severally.

42. RIGHTS OF THIRD PARTIES

A person who is not party to this Agreement has no rights to enforce any term of this Agreement.

43. GOVERNING LAW

This Agreement shall be governed by, and construed in accordance with, the laws of the Republic of the Union of Myanmar.

44. DISPUTE RESOLUTION

44.1 The Shareholders shall, and shall procure that the Shareholders shall, amicably settle any claims, disputes and matters of differences between Shareholders arising out of or connected with this Agreement. If such amicable settlement cannot be reached within 30 days of the commencement of settlement negotiations, the Shareholders agree that any dispute arising out of or in connection with this Agreement, including any question as to the validity, existence or termination of this Agreement, shall be submitted to a single arbitrator to be appointed by the Parties or, failing agreement within 14 days after a Party has given to the other Parties a written request to concur in the appointment of an arbitrator, a single arbitrator to be appointed on the request of any Party by the President of the Court of Arbitration for the time being of the SIAC. Such submission shall be a submission to arbitration in accordance with the Arbitration Rules of the SIAC for the time being in force by which the Parties agree to be so bound. The place of arbitration shall be Singapore and the arbitration shall be conducted wholly in the English language. The award of the arbitral tribunal shall be final and binding on the Parties. No action shall be brought in respect of any dispute among the Parties arising under or in connection with this Agreement until such action has been submitted to arbitration in accordance with this Clause 44.

44.2 During the process of arbitration, all the Shareholders shall perform their respective rights and obligations under this Agreement, except for those matters under arbitration.

44.3 Notwithstanding anything to the contrary, any Party may before commencement of, during or after the termination of the arbitration proceedings, apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction, or other interim or conservatory relief, as necessary. Such application shall not be deemed to be an infringement or a waiver of the arbitration agreement herein and shall not affect the relevant powers reserved to the arbitral tribunal.

SCHEDULE 1

FORM OF EQUITY DRAWDOWN NOTICE

[On the letterhead of the Company]

Date : [●]

To : [*insert name of the Shareholder*]

Equity Drawdown Notice

1. The Board of Directors (the "**Board**") of Andaman Alliance Healthcare Limited ("**Company**") refers to the joint venture agreement (the "**Joint Venture Agreement**") dated [●] made between AMMK Medicare Company Ltd, Global Star Company, Ltd, Macondray Holdings Pte. Ltd. and Parkway Healthcare Indo-China Pte. Ltd..

2. Unless otherwise defined, terms defined in the Joint Venture Agreement have the same meaning herein.

3. Pursuant to the Joint Venture Agreement, the Board hereby gives you notice that you are required to subscribe for [●] Shares at the subscription price of US$[A].

4. In view of the foregoing, please arrange to:

   (a) make payment of US$[A] in immediately available and freely transferable funds to the following bank account designated by the Company:

   Designated Account

   Bank name: [●]
   Account Name: [●]
   US$ Account Number: [●]
   Beneficiary bank: [●]
   Bank code: [●]
   Branch code: [●]
   SWIFT code: [●]
   Bank address: [●]; and

   (b) [such other instructions/terms as the Board may decide].

5. Please pay S$[A] to the designated account above by [*time*] p.m./a.m. (Myanmar time) on or before [*date*].

Yours faithfully

____
[●Name of Director]
Director
for and on behalf of
[●]

SCHEDULE 2

FORM OF LOAN DRAWDOWN NOTICE

[*On the letterhead of the Company*]

Date : [●]

To : [*insert name of the Shareholder*]

Loan Drawdown Notice

1. The Board of Directors (the "**Board**") of Andaman Alliance Healthcare Limited ("**Company**") refers to the joint venture agreement (the "**Joint Venture Agreement**") dated [●] made between AMMK Medicare Company Ltd, Global Star Company, Ltd, Macondray Holdings Pte. Ltd. Parkway Healthcare Indo-China Pte. Ltd..

2. Unless otherwise defined, terms defined in the Joint Venture Agreement have the same meaning herein.

3. Pursuant to the Joint Venture Agreement, the Board hereby gives you notice that we require you to provide a Shareholders' Loan of US$[B] [interest-free/at an interest rate of [●] per cent. ([●]%) per annum].

4. In view of the foregoing, please arrange to:

   (a) make payment of US$[B] in immediately available and freely transferable funds to the following bank account designated by the Company:

   Designated Account
   Bank name: [●]
   Account Name: [●]
   S$ Account Number: [●]
   Beneficiary bank: [●]
   Bank code: [●]
   Branch code: [●]
   SWIFT code: [●]
   Bank address: [●]; and

   (b) [such other instructions/terms as the Board may decide].

5. Please pay US$ [B] to the designated account above by [●*time*] p.m./a.m. (Myanmar time) on or before [*date*].

Yours faithfully

____
[●Name of Director]
Director
for and on behalf of
[●]

SCHEDULE 3

RESERVED MATTERS

(a) any investment by the Company in excess of (i) 2% of the net tangible asset of the Company as stated in its audited accounts for the preceding financial year (if any); or (ii) US$250,000, whichever is higher;

(b) incurrence of any capital expenditure (including the acquisition of any undertaking or asset whether under lease or hire purchase or otherwise):

  (i) for purposes other than for the acquisition of medical equipment in the ordinary course of business of the Hospital, in excess of (A) 2% of the net tangible asset of the Company as stated in its audited accounts for the preceding financial year (if any); or (B) US$250,000, whichever is higher; and

  (ii) for the purpose of acquisition of medical equipment necessary in the ordinary course of business of the Hospital, in excess of US$3,000,000 (for the avoidance of doubt, this paragraph is without prejudice to sub-paragraph (A));

(c) the appointment of (and any subsequent change in) the auditors of the Company Provided That the auditor of the Company shall at all times be an Approved Accounting Firm;

(d) any initial public offering or public issue of Shares with a view to obtaining the listing of the Company on any stock exchange including the filing of any forms or statements for a public offering of the Company's interests;

(e) the payment of any remuneration or Director's fees to any of the Directors;

(f) other than in the ordinary course of business, the entry by the Company into any transaction of a financial nature including incurrence of any borrowing under any existing or future banking and credit facilities and granting of any guarantee, indemnity, performance bond, lien, pledge, charge (including fixed and floating charge), mortgage or other security and the incurrence of any other form of indebtedness in excess of (i) 2% of the net tangible asset of the Company as stated in its audited accounts for the preceding financial year (if any); or (ii) US$250,000, whichever is higher;

(g) the lending of any moneys other than placing of deposits with banks and financial institutions;

(h) loans to Directors or to any corporation in which any Director or the Directors cumulatively has or have an interest in the issued share capital of that corporation;

(i) with the exception of the Trade Mark Licence Agreement, the Consultancy Services Agreement, the Hospital Management Agreement and the Management Services Agreement in the respective forms agreed and set out in this Agreement in Appendices A to D, inter-company transactions of a value in excess of US$250,000 with any company or businesses in which the Shareholders or any one of them have a financial interest;

(j) any amendment or modification in respect of the fees payable of the Trade Mark Licence Agreement, the Consultancy Services Agreement, the Hospital Management Agreement or the Management Services Agreement;

(k) any matter involving the Company with (i) any Director or with another firm, company or corporation in which any Director is interested as a proprietor, partner, director or other officer or creditor of or a shareholder in, except as a shareholder of a public company or a public corporation whose shares are listed on a stock exchange or (ii) any Shareholder or (iii) a corporation related to any of the Shareholders (other than the Company and its subsidiaries);

(l) the sale, transfer or disposal of the whole or a substantial part of the Company's undertaking, assets or property or purchase, sale, transfer, disposal, lease or licence of any real property or any interest therein;

(m) other than in the ordinary course of business, the entry into of contracts (whether relating to services or otherwise) for a duration exceeding one (1) year and with a value in excess of (i) 2% of the net tangible asset of the Company as stated in its audited accounts for the preceding financial year (if any); or (ii) US$250,000, whichever is higher;

(n) the amalgamation or reconstruction of the Company, or merger, consolidation or amalgamation with any company, association, partnership or legal entity;

(o) any change in the nature and/or scope of the business for the time being of the Company not being ancillary or incidental to or an extension of the scope of operation or type of the business of the Company;

(p) any amendment to the memorandum and/or articles of association or other constitutive documents of the Company that has an adverse effect on the rights, preferences and privileges attaching to the Shares as a class;

(q) the declaration, recommendation, making and payment of any distribution (whether in cash or in kind) other than in accordance with the terms of this Agreement;

(r) the establishment and terms of any employee stock option scheme or phantom employee stock option scheme;

(s) (i) the increase, reduction or other alteration to the issued share capital of the Company, including the terms of any share issue;

(ii) the issue or grant of any option over the unissued share capital of the Company; and

(iii) the issue of any new class of shares in the capital of the Company,

except in the event of a funding requirement for the Initial Capital Requirement or where an Insolvency Event will occur or is likely to occur within the next 12 months;

(t) the transfer of any Shares, other than in accordance with this Agreement;

(u) subject to the provisions of this Agreement, the winding up, dissolution or liquidation of the Company unless it shall have become insolvent; and

(v) the remuneration (including benefits) of the Chief Executive Officer, Chief Financial Officer and Deputy Chief Executive Officer where such remuneration is to be in excess of remuneration rates typically applied in other hospitals of like reputation and standing and which are owned or managed by Parkway Group Entities.

SCHEDULE 4

DEFAULT CALL OPTION NOTICE

Date : [●]

To : [*insert name of Defaulting Party*]

From : [*insert name of Non-Defaulting Party*]

We refer to the joint venture agreement (the "**Joint Venture Agreement**") dated [●] made between AMMK Medicare Company Ltd, Global Star Company, Ltd, Macondray Holdings Pte. Ltd. and Parkway Healthcare Indo-China Pte. Ltd. in relation to Andaman Alliance Healthcare Limited (the "**Company**").

Terms defined in the Joint Venture Agreement have the same meaning herein.

We hereby give you notice that we require you to sell to us in accordance with the terms and conditions of the Default Call Option, all the shares in the capital of the Company for the time being held by you, such sale to be completed on the date specified in Clause 22.11 of the Joint Venture Agreement.

Yours faithfully

____
[Name]
[Designation]
for and on behalf of
[*Non-Defaulting Party*]

SCHEDULE 5

DEFAULT PUT OPTION NOTICE

Date : [●]

To : [*insert name of Defaulting Party*]

From : [*insert name of Non-Defaulting Party*]

We refer to the joint venture agreement (the "**Joint Venture Agreement**") dated [●]made between AMMK Medicare Company Ltd, Global Star Company, Ltd, Macondray Holdings Pte. Ltd. and Parkway Healthcare Indo-China Pte. Ltd. in relation to Andaman Alliance Healthcare Limited (the "**Company**").

Terms defined in the Joint Venture Agreement have the same meaning herein.

We hereby give you notice that we require you to purchase from us in accordance with the terms and conditions of the Default Put Option, all the shares in the capital of the Company for the time being held by us, such sale to be completed on the date specified in Clause 22.11 of the Joint Venture Agreement.

Yours faithfully

____

[Name]
[Designation]
for and on behalf of
[*Non-Defaulting Party*]

SCHEDULE 6

DEED OF RATIFICATION AND ACCESSION

THIS DEED OF RATIFICATION AND ACCESSION is made and issued on [●]

BY:

[●] (the "**Transferee**"), a company incorporated in [●] with its registered office at [●],

IN FAVOUR OF and for the benefit of each and all of the following (other than the Transferor (as herein defined)):

(1) the parties to the joint venture agreement (the "**Joint Venture Agreement**") dated [●] made between AMMK Medicare Company Ltd, Global Star Company, Ltd, Macondray Holdings Pte. Ltd. and Parkway Healthcare Indo-China Pte. Ltd.; and

(2) all persons who are or subsequently become shareholders of Andaman Alliance Healthcare Limited (the "**Company**"),

(collectively, the "**Relevant Parties**").

WHEREAS:

(A) The Joint Venture Agreement sets out the terms and conditions under which the Shareholders shall regulate their rights as shareholders of the Company.

(B) The Transferee is the transferee of [*state the number of shares*] shares (the "**Transferred Shares**") in the issued capital of the Company by virtue of the instrument(s) of transfer in respect thereof executed by [*state the name of the Transferor*] (the "**Transferor**").

(C) By the terms of the Joint Venture Agreement, it is a condition precedent to the registration by the Company of the transfer to the Transferee of the Transferred Shares that the Transferee executes this Deed.

NOW THIS DEED WITNESSETH as follows:

1. In this Deed:

   (a) all terms and references used in this Deed and which are defined or construed in the Joint Venture Agreement but are not defined or construed in this Deed shall have the same meaning and construction in this Deed; and

   (b) all references to "**Joint Venture Agreement**" are to the Joint Venture Agreement as from time to time amended, modified or supplemented, including the amendments, additions and variations thereto agreed between the parties thereto as contained or evidenced by the following documents:

   [*state the documents, if any*]

2. The Transferee hereby covenants and agrees with each of the Relevant Parties as follows:

(a) that in consideration of and upon the registration in the Company's register of members of the Transferee as the holder of the Transferred Shares, the Transferee will as from the date of the registration of the Transferee as a holder of the Transferred Shares observe and discharge all the terms and conditions of the Joint Venture Agreement which are applicable to it as a Shareholder in all respects as if it had been a party thereto, and references to "**Party**" or "**Parties**" in the Joint Venture Agreement shall, where applicable, refer to or include the Transferee, as the case may be;

(b) that the liability of the Transferee by virtue of this Deed to each of the Relevant Parties shall be joint and several with the Transferor; and

(c) that this Deed is enforceable against the Transferee by any of the Relevant Parties.

3. For the purpose of Clause 29 of the Joint Venture Agreement, the address and facsimile number of the Transferee is:

Fax Number	:	[●]
Address	:	[●]
Attention	:	[●]

4. Save as may be expressly provided in the Joint Venture Agreement, nothing in this Deed shall operate to release or discharge the Transferor from any of the Transferor's obligations and liabilities under the Joint Venture Agreement.

5. This Deed shall be governed by, and construed in accordance with, the laws of the Republic of the Union of Myanmar.

IN WITNESS WHEREOF this Deed has been entered into by the Transferee.

THE TRANSFEREE

The COMMON SEAL of)
[●] was affixed)
hereunto in the presence of:)

____
Director

____
Director/Secretary

APPENDIX A

TRADE MARK LICENCE AGREEMENT

APPENDIX B

HOSPITAL MANAGEMENT AGREEMENT

APPENDIX C

CONSULTANCY SERVICES AGREEMENT

APPENDIX D

MANAGEMENT SERVICES AGREEMENT

IN WITNESS WHEREOF this Agreement has been entered into by the Parties as a Deed.

AMMK

The COMMON SEAL of	)
AMMK MEDICARE COMPANY LTD was affixed	)
hereunto in the presence of:	)

____
Aung Moe Kyaw
Director

GSC

The COMMON SEAL of	)
GLOBAL STAR COMPANY, LTD was affixed	)
hereunto in the presence of:	)

____
Thurane Aung @ Christopher Aung
Director

MHPL

The COMMON SEAL of	)
MACONDRAY HOLDINGS PTE. LTD. was affixed	)
hereunto in the presence of:	)

____
Ng How Kiat Charlie
Director

____
Tan Chay Hoon
Secretary

PHIC

The COMMON SEAL of)
PARKWAY HEALTHCARE INDO-CHINA PTE. LTD.)
was affixed hereunto in the presence of:)

____
Tan See Leng
Director

____
Liaw Yit Ming
Director

TRADE MARK LICENCE AGREEMENT

<u>A&GComments: 18December 2015</u>

DATED THIS DAY OF 2015

BETWEEN

PARKWAY HOLDINGS LTD

AND

ANDAMAN ALLIANCE HEALTHCARE LIMITED

****

TRADE MARK LICENCE AGREEMENT

****

TRADE MARK LICENCE AGREEMENT

THIS AGREEMENT is made the day of 2015 between:

1. **PARKWAY HOLDINGS LTD**, a company incorporated in the Republic of Singapore and having its registered address at 111 Somerset Road, #15-01 TripleOne Somerset, Singapore 238164 (hereinafter called the "**Licensor**") of the first part; and

2. **ANDAMAN ALLIANCE HEALTHCARE LIMITED**, a company incorporated in the Republic of the Union of Myanmar and having its registered address at office at 33 Pyay Road, 6 ½ Miles, Hlaing Township, Yangon (hereinafter called the "**Licensee**") of the second part,

(collectively, the "**Parties**" and each, a "**Party**").

WHEREAS

(A) The Licensor is the proprietor and owner of the Trade Mark(s) (as hereinafter defined).

(B) The Licensee is a joint venture between AMMK Medicare Company, Ltd, Global Star Company, Ltd, Macondray Holdings Pte. Ltd. and the Licensor's related company, Parkway Healthcare Indo-China Pte. Ltd. formed pursuant to a joint venture agreement dated [●] (the "**Joint Venture Agreement**").

(C) The Licensee is desirous of obtaining and the Licensor agrees to grant to the Licensee the right to use the Trade Mark(s) on the terms herein contained.

NOW IT IS HEREBY AGREEDas follows:

1. DEFINITIONS

1.1 In this Agreement (including the above recitals) and in the Appendix hereto, unless the context otherwise requires, the following expressions shall have the respective meanings set out against them:

"Accounts"	Includes where relevant, the directors' reports, relevant balance sheets and profit and loss accounts together with all documents which are or would be required by law to be annexed to the accounts of the Licensee, and prepared in accordance with International Financial Reporting Standardsand Legal Requirements.
"Applicable Laws"	All applicable laws, statutes, rules, regulations, ordinances, requirements, directions, guidelines, announcements or other binding actions or requirements of any government or department, agency or instrumentality of any government, departments, bodies, regulatory authorities, government authorities, any court or arbitral tribunal; and the governing body of any securities exchange or other securities self-regulatory body.
"Audited Accounts"	The audited Accounts of the Licensee in respect of the Business for the financial year (or part thereof, as the case may be) ended the Balance Sheet Date, as audited by the Auditors.

"Auditors"	The auditors for the time being of the Licensee.
"Balance Sheet Date"	31 March of each financial year.
"Business"	Has the meaning ascribed to it in the Joint Venture Agreement.
"Business Day"	A day (other than a Saturday, Sunday or public holiday) on which banks are open for business in the Territory and in Singapore.
"Defaulting Party"	Has the meaning ascribed to it in Clause 7.3
"Disclosing Party"	Has the meaning ascribed to it in Clause 8.1
"Hospital"	Has the meaning ascribed to it in the Joint Venture Agreement.
"Joint Venture Agreement"	Has the meaning ascribed to it in Recital (B).
"Legal Requirements"	All laws, statutes, ordinances, orders, rules, regulations, permits, licences, authorisations, directions and requirements of all governments and governmental authorities which, now or hereafter, may be applicable to the Parties, or the Hospital and the operation thereof, including without limitation all employment and labour, medical, zoning, building, life or safety, environmental and hazardous waste management, exchange control and other Applicable Laws, ordinances, rules and regulations of all governmental bodies and agencies and self-regulatory entities having jurisdiction over the Parties, the Hospital or the Business.
"Licence"	Has the meaning ascribed to it in Clause 2.1.
"Licence Fees"	Has the meaning ascribed to it in Clause 2.3.
"Management Accounts"	The unaudited management Accounts, including a detailed profit and loss account, balance sheet and cash-flow statement, an analysis of sales and other revenue, with revenue and capital budgets for the corresponding month or quarter or year (as the case may be), and a statement of the source and application of funds for such month or quarter or year (as the case may be), of or relating to the Business for each month or quarter or year (as the case may be) during the Term, as prepared by the management of the Licensee.
"Myanmar Kyat"	The lawful currency of the Republic of the Union of Myanmar.
"Opening Date"	The date of the soft opening of the Hospital whereby the Hospital is open to the general public for the provision of

	medical services.
"Payment Currency"	Has the meaning ascribed to it in Clause 2.4.
“**Quarter**”	A period of three calendar months (or part thereof, as the case may be) within a Reference Period ending on 30 June, 30 September, 31 December and 31 March respectively, and “**Quarterly**” shall be construed accordingly;
"Receiving Party"	Has the meaning ascribed to it in Clause 8.1
"Recognised Stock Exchange"	Any recognised stock exchange under Singapore law, Malaysia law, or under the laws of the Territory, or such other stock exchange as may be agreed between the Parties;
"Reference Period"	Any financial year (or part thereof, as the case may be) during the Term of this Agreement, by reference to which the Licence Fees are calculated in accordance with Appendix B.
"Reference Rate"	The aggregate of (a) the average of the Singapore Interbank Offered Rate quoted by the three largest local banks in Singapore for six(6)-month deposit in United States Dollars from time to time prevailing; and (b) three per. cent. (3%).
"Register"	The office of the Registrar of Deeds established pursuant to the Myanmar Registration Act (1909) or such other competent authority as may be established to regulate the registration and protection of trademarks within the Territory.
"Revenue"	All income of or relating to the Hospital (on an accrual basis) after netting off reserves for bad debts, uncollectible accounts and discounts and shall include: income of every kind received from the operation of the Hospital and all of its facilities or arising from the Hospital, including without limitation, all income from patients, out-patients, including resident doctors’ fees, service charges collected from visiting physicians or others rendering services to the Hospital's patients or others, rental of consultation rooms in the Hospital, income from car-parks and retail outlets and other non-patient related income attributable to the Hospital generated within the premises of the Hospital, computed in accordance with generally accepted accounting principles in the Territory.
"Services"	Hospital services and medical services and such other services as may from time to time be rendered by the Licensee from the Hospital.
"Singapore Dollar"	The lawful currency of the Republic of Singapore.

"Taxation Authorities"	The relevant governmental or other authorities competent and authorised to impose Taxes whether in the Territory or elsewhere.
"Taxes"	All forms of taxation of the Territory including all state or local taxation, past, present and deferred including without limitation, income (including net and gross income) tax, business tax, corporate tax, service tax, commercial tax, VAT (i.e., value-added tax), withholding tax, sales tax, goods, occupation, real and personal property, social security, use, ad valorem, franchise, profits, licence, payroll, employment, excise, severance, premium or windfall profit taxes, estate duty, stamp duty, customs and other import or export duties, or charges of any kind whatsoever, estimated and other taxes, together with any interest and levies and all penalties, charges, costs and additions to tax, payable by or due from the Licensee or the Licensor(as the case may be), or any additional amounts imposed by any government, governmental agency, statutory body or any revenue authority in the Territory or otherwise, upon the Parties (as the case may be).
"Term"	The period commencing on the Opening Date until terminated in accordance with Clause 7.
"Territory"	The Republic of the Union of Myanmar.
"Trade Mark(s)"	The Trade Mark(s) as listed in Appendix A.
"United States Dollar"	The lawful currency of the United States of America.

1.2 In this Agreement:

(a) Any reference in this Agreement to "**this Agreement**" includes all amendments, additions, and variations hereto agreed between the Parties in writing.

(b) The term "**financial year**", for the purposes of this Agreement, means the period commencing on 1 April and ended or ending 31 March in each year (or part thereof, as the casemay be).

(c) The word "**subsidiary**", in relation to a corporation, means a corporation (a) which the first-mentioned corporation controls the composition of the board of directors of, or controls more than half of the voting power of, or in which the first-mentioned corporation holds more than half of the issued share capital of (excluding any part thereof which consists of preference shares and treasury shares, where applicable), or (b) which is a subsidiary of the first-mentioned corporation's subsidiary; and a "**related corporation**" of a corporation shall mean a corporation which is (a) the holding company of the first-mentioned corporation; (b) a subsidiary of the first-mentioned corporation; or (c) a subsidiary of the holding company of the first-mentioned corporation.

(d) A reference to a "**month**" is a reference to a period starting on one day in a calendar

month and ending on the day immediately preceding the numerically corresponding day in the next succeeding calendar month.

(e) The words "**written**" and "**in writing**" include any means of visible reproduction.

(f) Unless the context otherwise requires, words importing the singular include the plural and *vice versa* and words denoting a gender include all other genders.

(g) References to Clauses shall mean references to the clauses of this Agreement and references to Appendices shall mean references to the appendices appended to this Agreement.

(h) The headings in this Agreement are for convenience of reference only and shall not affect the interpretation of the provisions of this Agreement.

1.3 The Appendices form part of this Agreement and have the same force and effect as if expressly set out in the body of this Agreement.

2. GRANT OF LICENCE AND LICENCE FEE

2.1 Subject to the terms set out in this Agreement, the Licensor grants to the Licensee a non-exclusive, non-transferable and non-assignable right and licence to use the Trade Mark(s) in the Territory in relation to the Services (the "**Licence**"). The Trade Mark(s) shall not be used with any other mark, logo, trade name, etc. not owned or controlled by the Licensor.

2.2 The Licence is granted to the Licensee for the sole purpose of the Licensee's use in relation to the Services and the grant does not provide any right to the Licensee to sub-licence the Trade Mark(s) to any third party for any purpose or reasons whatsoever.

2.3 In consideration of the Licence granted herein, the Licensee shall pay the Licensor fees (the "**Licence Fees**") in the amounts and manner and at the times and on the bases set out in Appendix B.

2.4 All Licence Fees and other amounts payable to the Licensor under this Agreement are, unless otherwise stated, expressed in Myanmar Kyat but payment shall be made in full in Singapore Dollars or in such other currency as the Licensor may from time to time notify the Licensee in writing (the "**Payment Currency**") in accordance with Paragraph 2 and Appendix B unless otherwise agreed to or instructed by the Licensor, in the form of bank draft, cashier's order or telegraphic transfer payable to the order of such person(s) as may be designated from time to time in writing by the Licensor no later than the relevant due date for payment. All Licence Fees and other amounts payable to the Licensor under this Agreement that would otherwise be due on a day other than a Business Day instead, shall be due on the immediately preceding Business Day.

2.5 Any Licence Fees and other amounts payable to the Licensor under this Agreement or any portion thereof which is not paid on the expiry of the due date for payment, shall accrue interest for each day elapsed thereafter from and including the relevant due date for payment, at the Reference Rate (compounded monthly from the relevant due date for payment) until they are paid, before as well as after any judgment. Such amounts as well as any accrued but unpaid interest thereon shall be payable on demand.

3. TERM

This Agreement shall be deemed to have taken effect from the date hereof and shall continue in full force and effect until the expiry of the Term.

4. **USE OF TRADE MARK(S)**

4.1 The Licensee shall:

(a) use the Trade Mark(s) only in the manner and for the purpose set out in Clauses 2.1 and 2.2 above;

(b) maintain the good standing of the Trade Mark(s) and operate the Hospital in a professional manner;

(c) have no right to transfer the Trade Mark(s) or authorize any third party to use the Trade Mark(s);

(d) comply with such specifications and standards as the Licensor shall provide in relation to the use of the Trade Mark(s) in connection with the Services at the commencement of this Agreement and of any modifications thereto from time to time; and

(e) use the Trade Mark(s) only in the form stipulated by the Licensor and shall observe all directions given by the Licensor as to colours and size of the representations of the Trade Mark(s) and their manner and disposition in the provision of the Services including the use of Trade Mark(s) on any accompanying leaflets, brochures or other material, and in any advertising material prepared by the Licensee.

4.2 The Licensee shall submit designs of all printed materials using the Trade Mark(s) to the Licensor for approval as to the manner and the context of the intended use of the Trade Mark(s) and shall not make use of any such designs or materials until they have been approved by the Licensor, which approval shall not be unreasonably withheld or delayed. The Licensee shall however be responsible for ensuring that all other requirements of the Licensor relating to the use of the Trade Mark(s) for advertising, application of the Trade Mark(s) and other such matters are complied with.

4.3 The use of the Trade Mark(s) by the Licensee shall at all times be in keeping with and seeking to maintain their distinctiveness and reputation as reasonably determined by the Licensor, and the Licensee shall forthwith cease any use not consistent therewith as the Licensor may reasonably require.

4.4 Save as expressly provided herein, the Licensee shall not use the Trade Mark(s) for any other purposes or in relation to any other products or services or use any names or marks confusingly similar to the Trade Mark(s) in respect of the Services and/or any other services similar thereto.

4.5 For the purpose of ensuring that the Licensee is complying with the Licensor's specifications and standards, the Licensor by its authorised representative may on reasonable notice and at its own expense visit the Licensee's premises during normal business hours to inspect the use of the Trade Mark(s) in relation to the provision of the Services.

5. **INTELLECTUAL PROPERTY RIGHTS**

5.1 The Licensee hereby acknowledges that the Licensor is the owner of the Trade Mark(s) and the valuable goodwill attached thereto and no title to the Trade Mark(s) or goodwill attached thereto will pass hereunder to or through the Licensee, and only the rights expressly granted in or pursuant to this Agreement are provided to the Licensee and that all goodwill arising from the

use of the Trade Mark(s) (whether by the Licensee or otherwise) shall accrue solely to the benefit of the Licensor.

5.2 The Licensee undertakes not to do or permit to be done any act which would or might jeopardise or invalidate any application or registration of the Trade Mark(s) in the Territory nor to do any act which might assist or give rise to an application to remove the registered Trade Mark(s) from the Register or which might prejudice the right or title of the Licensor to the Trade Mark(s) or otherwise bring disrepute to the reputation and high standing of the Trade Mark(s).

5.3 The Licensee shall on the reasonable request of the Licensor, give to the Licensor or its authorised representative any information as to its use of the Trade Mark(s) which the Licensor may reasonably require and shall at all times render any assistance reasonably required by the Licensor at the sole costs and expenses of the Licensor in maintaining the validity and registration of the Trade Mark(s).

5.4 The Licensee will not make any representation or do any act which may have taken to indicate that it has any right title or interest in or to the ownership or use of the Trade Mark(s) except under the terms of this Agreement, and acknowledges that nothing contained in this Agreement shall give the Licensee any right, title or interest in or to the Trade Mark(s) save as granted hereby.

5.5 The Licensee shall assist the Licensor as may be necessary (including executing any necessary documents) in recording the Licensee as a registered user of the registered Trade Mark(s) on the Register (including such of the Trade Mark(s) applications, if any, as shall mature into registrations during the period of this Agreement) if required by the applicable laws of the Territory, and the Licensee hereby agrees that such entry may be cancelled by the Licensor on termination of this Agreement, for whatever reason, and that it will assist the Licensor so far as may be necessary to achieve such cancellation including by executing any necessary documents.

5.6 The Licensor warrants to the Licensee that it is the owner of the Trade Mark(s) and to the best of the Licensor’s knowledge as at the date of this Agreement, none of the Trade Mark(s) are being used or claimed, by any other person in the Territory. The Licensor warrants further thatto the best of the Licensor’s knowledge as at the date of this Agreement,no claims have been made by any third party in the Territory alleging that the Trade Marks infringe the right of any third party in the Territory.

6. INFRINGEMENTS

6.1 The Licensee shall as soon as reasonably practicable after it has become aware of any use or proposed use by any other person, firm or company of a trade name, trade mark or get-up of goods or mode of promotion or advertising which amounts or might amount either to infringement of the Licensor's rights in relation to the Trade Mark(s) or to passing-off, give the Licensor in writing full particulars and information within its knowledge and possession thereof.

6.2 The Licensor shall have the conduct of all proceedings relating to the Trade Mark(s) and shall in its discretion decide on the type of action, if any, to be taken in respect of any infringement or alleged infringement of the Trade Mark(s) or passing-off or any other claim or counter-claim brought or threatened in respect of the use or registration of the Trade Mark(s) provided always that the Licensor shall not be obliged to bring or defend any proceedings in relation to the Trade Mark(s) if it decides in its discretion not to do so. The Licensee shall, as far as practicable, at all times comply with the Licensor's reasonable stipulations, directions and advice concerning the aforesaid.

6.3 The Licensee shall, as far as practicable, at the reasonable request of the Licensor render its full co-operation and assistance to the Licensor at the sole costs and expenses of the Licensor in any actions, claims or proceedings brought or threatened in respect of the Trade Mark(s).

6.4 The Licensee agrees that it shall not enter into any negotiations, settlements or agreements or compromise any claims, suits or proceedings in respect of the use of the Trade Mark(s) without the prior written consent and agreement of the Licensor.

7. TERMINATION

7.1 The Licensor may terminate this Agreement by giving the Licensee six (6) months' prior notice in writing without assigning any reason whatsoever.

7.2 The Licensor may terminate this Agreement immediately by giving the Licensee notice in writing upon the happening of any of the following events:

(a) the termination of the Joint Venture Agreement for whatever reason;

(b) the termination, for whatever reason, of the hospital management services agreement dated **[•]**and entered into between Gleneagles Management Services Pte Ltd and the Licensee;

(c) the termination, for whatever reason, of the consultancy services agreement dated **[•]**and entered into between Gleneagles Management Services Pte Ltd and the Licensee;and

(d) Parkway Healthcare Indo-China Pte.Ltd.orits related nominee company ceasing to directly or indirectly hold at least fifty per cent. (50%) of the issued share capital of the Licensee for whatever reason.

7.3 Additionally, either Party may without prejudice to its other rights and remedies under this Agreement or at lawforthwith terminate this Agreement by notice in writing to the other Party (the "**Defaulting Party**") if:

(a) the Defaulting Party commits a breach of this Agreement and fails to remedy the same within one (1) month of having been given notice in writing by non-Defaulting specifying the breach and requiring it to be remedied; or

(b) the Defaulting Party goes into liquidation (whether voluntary or involuntary) or is unable to pay its debts;

(c) the Defaulting Party convenes a meeting with its creditors or has a receiver or manager or an administrator appointed over its assets or becoming or threatening to become or being in jeopardy or becoming subject to any form of insolvency administration; or

(d) the Defaulting Party ceases or threatens to cease carrying on the business.

7.4 Termination of this Agreement for whatever reason shall not affect the accrued rights of any Party arising under this Agreement or at law as at the date of termination and in particular but without limitation the right to recover damages from the other.

7.5 Upon the termination of this Agreement for whatever reason:

(a) the Licensee shall not later than three monthsfrom the date of termination cease to

make any use of,or make any reference to, the Trade Mark(s)PROVIDED THAT the Licensee shall continue to comply with the provisions in Clause 4 in all respects for so long as it continues to make any use or any reference to the Trade Mark(s) pursuant to this Clause 7.5(a), failing which the Licensor may by notice to the Licensee immediately terminate the benefit conferred to the Licensee under this Clause 7.5(a);

(b) the Licensee shall cooperate with the Licensor to file the necessary application with the registrar and execute such documents as may be required to de-register or cancel any record of the Licensee as a registered user of the Trade Mark(s);

(c) the Licensee shall, on the Licensor's request, execute such documents as may be reasonably required to assign any goodwill arising from the Licensee's use of the Trade Marks(s) in respect of the Services and any right title or interest in and to the goodwill to the Licensor;

(d) the Licensee shall make full payment to the Licensor for any sums due and owing to the Licensor by the Licensee under this Agreement within fourteen (14) days following the date of termination of this Agreement, or such later date that the amounts due are determined as provided for in this Agreement in accordance with Clauses 2.4 and 2.5 above; and

(e) the Licensee undertakes not to use any trade mark, business name or identifier that is identical to or similar to the Trade Marks, do or permit to be done any act which would or might jeopardise or invalidate any application or registration of the Trade Mark(s) in the Territory nor to do any act which might assist or give rise to an application to remove the registered Trade Mark(s) from the Register or which might prejudice the right or title of the Licensor to the Trade Mark(s) or otherwise bring disrepute to the reputation and high standing of the Trade Mark(s).

7.6 Notwithstanding the termination of this Agreement, Clauses 7.4 to 7.6, 8, 10, 15, 17 and 18 shall remain in full force and effect thereafter.

8. CONFIDENTIALITY

8.1 Each Party hereby undertakes with the other, on behalf of itself and its related corporations, and each of its and their related corporations' directors, shareholders, employees and agents ("**Receiving Party**"), to keep all information and documents shared between the Parties and relating to this Agreement, in the strictest confidence, as may be reasonably done and not to disclose or divulge any such information or documents to any third parties (other than to its related corporations for the purposes of this Agreement) without the prior written consent of the disclosing Party ("**Disclosing Party**"), which consent may be withheld by the Disclosing Party without being obliged to give any reason therefor whatsoever, or in the sole discretion of the Disclosing Party, given on such terms and conditions as the Disclosing Party considers appropriate.

8.2 The restrictions in Clause 8.1 as to non-disclosure shall not apply:

(a) to any information or knowledge which was known to the Receiving Party prior to disclosure pursuant to this Agreement or subsequently comes to the knowledge of the Receiving Party from a source not under an obligation of confidentiality, or which may properly come into the public domain through no fault or breach of the Receiving Party;

(b) to any information whatsoever requested or required to be disclosed by Applicable

Laws or pursuant to any legal process issued by any court or tribunal of competent jurisdiction or by any requirement of any competent governmental or regulatory authority or rules or regulations of any relevant regulatory, administrative or supervisory body (including without limitation, any relevant stock exchange or securities council) whether in the Territory, Singapore, Malaysia or elsewhere;

(c) to any disclosure required by any Recognised Stock Exchange or regulatory or governmental body to which the Receiving Party or any holding company, subsidiary or substantial shareholder of the Receiving Party is subject or submits;

(d) to any disclosure of any information whatsoever to the legal or other professional advisers (including auditors and bankers) of the Receiving Party for the purposes of this Agreement;

(e) if such disclosure or use is necessary for the performance of the Receiving Party's obligations under this Agreement; or

(f) if such disclosure is for a specific purpose and is approved in writing by the Disclosing Party prior to any such disclosure being made.

PROVIDED THAT any such information disclosed pursuant to sub-Clauses (b), (c) shall, to the extent permitted and practicable, be disclosed only after prior consultation with each other as to the form, content and timing of such announcement or disclosure.

8.3 For the purpose of this Clause 8, any communication between the Parties and any information and other material supplied to or received by a Party which is either marked "confidential" or is by its nature intended to be confidential or exclusively for the knowledge of the recipient alone, and any information concerning the business, affairs or the financial arrangements of a Party and/or its related corporations coming to the knowledge of the other Party shall be considered confidential. In any case of uncertainty, a Party shall treat information and material as confidential until written clearance is obtained from the other Party.

9. ASSIGNMENT

Neither Party will assign this Agreement or any benefits or interests arising under this Agreement without the prior written consent of the other Party which will not be unreasonably withheld or delayed.

10. INDEMNITY

10.1 The Licensee shall indemnify and hold harmless the Licensor from any and all liability, claim, litigation, loss, damages and expenses (including attorney fees) which it may suffer:

(a) by reason of any breach by the Licensee of any covenant or agreement made by it in this Agreement; or

(b) as a result of any claim or action filed by a third party arising out of or in relation to the provision of the Services.

10.2 The Licensor shall indemnify and hold harmless the Licensee from any and all liability, claim, litigation, loss, damages and expenses (including attorney fees) which it may sufferby reason of any breach by the Licensor of any warranty, covenant or agreement made by it in this Agreement.

11. TAX

11.1 All payments to be made by the Licensee under this Agreement shall be made (a) free of any restriction or condition, (b) free and clear of and without deduction or withholding for on account of any Taxes, and (c) without deduction or withholding on account of any other amount, whether by way of set-off, counterclaim or otherwise. If at any time the Licensee is required to make any deduction or withholding for applicable Taxes in the Territory from any payments due under this Agreement for the account of the Licensor pursuant to the laws of the Territory, the Licensee shall:

(a) where the Licensor is not a resident in Myanmar for purposes of the Myanmar Income Tax Act, forthwith increase the sum payable to such sum as will ensure that, after such deduction and withholding has been madeand paid to the Taxation Authorities, the Licensor receives on the due date for such payment a sum equal to the sum that it would have received in the absence of such Taxesprovided and to the extent that the Licensor thereafter recovers or receives from the relevant Taxation Authorities any part of such amounts so deducted or withheld, then upon its receipt thereof, the Licensor shall remit to the Licensee such amount so recovered or received;

(b) indemnify the Licensor against any losses of costs incurred by it by reason of any failure of the Licensee to make such deduction or withholding; and

(c) promptly deliver to the Licensor any receipts, certificates or other proof evidencing the amounts (if any) paid or payable in respect of any such deduction or withholding as aforesaid

.

11.2 The Licensee shall bear the cost of all stamp duty, any notarial fees and all registration taxes and duties or their equivalents in the Territoryif such taxes, fees, and duties are payable as a result of the execution of this Agreement. The Licensee shall be responsible for arranging the payment of such taxes, fees, and duties, including fulfilling any administrative or reporting obligation imposed by the Territory in question in connection with the payment of such taxes, fees and duties. The Licensee shall indemnify the Licensor against any losses suffered by the Licensor as a result of the Licensee failing to comply with its obligations under this Clause11.2.

12. ENTIRE AGREEMENT AND VARIATIONS

12.1 This Agreement constitutes the entire agreement between the Parties. Each Party confirms that it has not relied upon any representation not recorded in this document inducing it to enter into this Agreement. No variation or these terms and conditions will be valid unless confirmed in writing by authorised signatories of both Parties on or after the date of this Agreement. The expression "**variation**" shall include any amendment, supplement, deletion or replacement however effected.

12.2 Unless expressly agreed, no variation shall constitute a general waiver of any provisions of this Agreement, nor shall it affect any rights, obligations or liabilities under or pursuant to this Agreement which have already accrued up to the date of variation, and the rights and obligations of the Parties under or pursuant to this Agreement shall remain in full force and effect, except and only to the extent that they are so varied.

13. SEVERABILITY

If any of the provisions of this Agreement is judged to be illegal or unenforceable, the continuation in full force and effect of the remainder of them will not be prejudiced unless the substantive purpose of this Agreement is then frustrated, in which case either Party may terminate this Agreement forthwith on written notice.

14. WAIVER

No forbearance or delay by either Party in enforcing its respective rights will prejudice or restrict the rights of that Party and no waiver of any such rights or of any breach of any contractual terms will be deemed to be a waiver of any other right or of any later breach.

15. NOTICES

15.1 Each and every communication under this Agreement shall be made by facsimile or otherwise in writing. Each communication or document to be delivered to any Party shall be sent to that Party at the facsimile number, email address or address and marked for the attention of the person (if any), from time to time designated by that Party for the purpose of this Agreement. The initial addresses and facsimile numbers of the Parties are:

The Licensor

Fax Number	:	+65 6734 8917
Email Address	:	
Address	:	111 Somerset Road, #15-01, TripleOne Somerset, Singapore 238164
Attention	:	

The Licensee

Fax Number	:	
Email Address	:	
Address	:	
Attention	:	

15.2 A demand, notice or other communication made or given by one Party to the other Party in accordance with this Clause 15shall be effected and deemed to be duly served and received:

(a) if delivered by hand, at the time of delivery;

(b) if posted by prepaid ordinary mail, at the expiration of five (5) Business Days after the envelope containing the same shall have been put into the post;

(c) if sent by facsimile, upon the receipt by the sender of the transmission report indicating that the notice or communication has been sent in full to the recipient's facsimile machine, or such other similar medium of receipt;

(d) if sent by courier, at the expiration of four (4) Business Days after the package containing the same shall have been received by the relevant courier company; or

(e) if sent by email, the earlier of:

(i) when the sender receives an automated message confirming delivery; or

(ii) four hours after the time sent (as recorded on the device from which the sender sent the email) unless the sender receives an automated message that the email has not been delivered,

provided that where such delivery or transmission occurs after 5 p.m. on a Business Day or on a day which is not a Business Day, service shall be deemed to occur at 9 a.m. on the next following Business Day.

In proving such service and receipt, it shall be sufficient to prove that delivery by hand was made or that the envelope containing such notice or document was properly addressed and posted as a prepaid ordinary mail or that the facsimile confirmation note indicates the transmission was successful or that the package containing the same was properly addressed and delivered to the relevant courier company.

16. RIGHTS OF THIRD PARTIES

A person who is not party to this Agreement has no rights to enforce any term of this Agreement.

17. GOVERNING LAW

This Agreement is governed by the laws of the Territory.

18. DISPUTE RESOLUTION

18.1 In case any dispute or difference shall arise between the Parties as to the construction of this Agreement or as to any matter of whatsoever nature arising hereunder or in connection therewith, including any question regarding its existence, validity or termination, such dispute or difference shall be submitted to arbitration at Singapore International Arbitration Centre ("**Arbitration Institution**") in accordance with the arbitration rules of the Arbitration Institution then in force. The seat of the arbitration shall be Singaporeand the arbitration shall be conducted in English. The award of the arbitration tribunal shall be final and binding on the Parties. The arbitration tribunal shall consist of one (1) arbitrator to be appointed by the Parties or, failing agreement within fourteen (14) days after a Party has given to the other Party a written request to concur in the appointment of an arbitrator, a single arbitrator to be appointed on the request of either Party by the President of the Court of Arbitration of the Arbitration Institution for the time being.

18.2 The arbitral award made and granted by the arbitrator shall be final, binding and incontestable and may be used as a basis for judgement thereon in the Territory, Singapore, or elsewhere.

18.3 Neither of the Parties shall be entitled to commence or maintain any action in a court of law upon any matter in dispute arising from or in relation to this Agreement except for the enforcement of an arbitral award granted pursuant to this Clause 18, and save and except in connection with interim relief, pursuant to commencement of arbitration proceedings.

18.4 During the period of submission to arbitration and thereafter until the granting of the arbitral

award, the Parties shall, except in the event of termination, continue to perform their obligations under and the terms and conditions of this Agreement that are not in dispute, to the extent possible, without prejudice to a final adjustment in accordance with the said award.

18.5 Notwithstanding anything to the contrary, either Party may before commencement of, during or after the termination of the proceedings referred to in Clause18.1, apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction, or other interim or conservatory relief, as necessary. Such application shall not be deemed to be an infringement or a waiver of the arbitration agreement herein and shall not affect the relevant powers reserved to the arbitral tribunal.

IN WITNESS THEREOF the Parties hereto, by their respective duly authorised representatives have hereunto set their respective hands the day and year first above written.

SIGNED by)
for and on behalf of)
PARKWAY HOLDINGS LTD)
in the presence of:)

Witness's signature
Name:
Address:

SIGNED by)
for and on behalf of)
ANDAMAN ALLIANCE HEALTHCARE LIMITED)
in the presence of:)

Witness's signature
Name:
Address:

APPENDIX A

Trade Mark(s)

Number	Trade Mark(s)
1.	[Parkway logo]
2.	[Parkway]

APPENDIX B

Licence Fees

1. The Licence Fees payable in respect of each Reference Period shall be one per. cent. (1**%)**of Revenue commencing on the Opening Date and ending on the date of termination of this Agreement.

2. For the convenience of the Parties, the first Reference Period shall commence on the Opening Date and end on the Balance Sheet Date of the same financial year and the last Reference Period shall commence on the first day of the financial year to which it relates and end on the date of termination of this Agreement.

3. The Licence Fees shall:

   (a) be calculated on an annual basis; and

   (b) in respect of each Reference Period, be payable by the Licensee on an interim basis in arrears Quarterly within ten (10) Business Days from the end of each Quarter based on the Quarterly Management Accounts of the Licensee,

   provided that for the purpose of calculating the Quarterly Licence Fees, the Quarterly Revenue for each applicable Quarter shall be annualized (i.e. multiplied by a factor of four (4)) first and the percentages set out in Paragraph 1 of this Appendix B will apply to derive the annualized Licence Fees and the Quarterly Licence Fees payable shall be twenty-five per. cent. (25%) of the annualized Licence Fees.

4. In connection with the calculation of the Licence Fees, the Licensee shall procure that the Audited Accounts are prepared and approved withinfive (5) months from the end of each Reference Period.

5. The Licensee shall procure that the Auditors audit the Revenue, for the purpose of settling the annual Licence Fees, in accordance with the definition in this Agreement. The Parties agree that the Revenue accumulated from any previous financial year(s) (whether positive or negative) shall not be brought forward into the computation, and the Revenue shall be computed by the Auditors solely and exclusively on a current financial year basis.Within ten (10) Business Days of the finalization of the Revenue, the Parties will settle the Licence Fees. Any shortfall will be paid by the Licensee to the Licensor within five (5) Business Days thereafter and any overpaid amount from the Quarterly payments of the License Fees by the Licensee for the first three Quarters of any financial year will be deducted from subsequent payments to the Licensor or, and only in the case where there are no subsequent payments to be made to the Licensor, reimbursed to the Licensee.

6. For the purposes of the first and the last Reference Period or in the event of the termination of this Agreement, if such Reference Period is of less than a full financial year or if termination occurs or ends other than at the end of the Licensee's financial year, the Licensee shall (at its sole cost and expense) commission an interim audit for the period ending on the end of the month on which such Reference Period or the effective date of termination of this Agreement falls, if there is dispute with respect to the relevant Management Accounts for such month or period. Such audited results shall constitute the basis for settlement of the License Fees due to the Licensor (or the reimbursement of any excess amount to the Licensee), in such Reference Period in respect of which the Licensee Feesare payable.

A&GComments: 18December 2015

Dated thisday of

BETWEEN

GLENEAGLES MANAGEMENT SERVICES PTE LTD
as GMS

AND

ANDAMAN ALLIANCE HEALTHCARE LIMITED
as the Company

HOSPITAL MANAGEMENT SERVICES AGREEMENT

TABLE OF CONTENTS

CLAUSE	HEADING	PAGE
1.	DEFINITIONS AND INTERPRETATION	3
2.	THE SERVICES	9
3.	SERVICES NOT WITHIN SCOPE OF WORK OF GMS	9
4.	SERVICES FEES AND OTHER EXPENSES	10
5.	PAYMENT OF SERVICES FEES AND OTHER EXPENSES	11
6.	PERSONNEL	12
7.	OBLIGATIONS OF GMS	14
8.	OBLIGATIONS OF THE COMPANY	14
9.	COVENANTS AND AGREEMENTS RELATING TO THE KNOW-HOW	15
10.	IMPROVEMENTS	17
11.	INSURANCE	17
12.	ACCESS	18
13.	DURATION AND TERMINATION	18
14.	DISCLAIMERS AND INDEMNITIES	21
15.	CONFIDENTIALITY AND RESTRICTIVE COVENANTS	23
16.	FORCE MAJEURE	27
17.	REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS	27
18.	MISCELLANEOUS	29
19.	GOVERNING LAW	32
APPENDIX 1	SCOPE OF SERVICES	34
APPENDIX 2	SERVICES FEES	37
APPENDIX 3	FORM OF LICENCE AGREEMENT	39
APPENDIX 4	FORM OF CONSULTANCY SERVICES AGREEMENT	40

THIS AGREEMENT is made on2015

BETWEEN

(1) **GLENEAGLES MANAGEMENT SERVICES PTE LTD** (Company Registration Number 198904110D), a company incorporated in Singapore and having its registered office at 111 Somerset Road, #15-01, TripleOne Somerset, Singapore 238164("**GMS**")

AND

(2) **ANDAMAN ALLIANCE HEALTHCARE LIMITED**(Company Registration Number **[•]**) a company incorporated in Myanmar and having its registered office at 33 Pyay Road, 6 ½ Miles, Hlaing Township, Yangon, Myanmar(“**Company**”)

WHEREAS:

(A) The Company is a joint venture between AMMK Medicare Company, Ltd, Global Star Company, Ltd, Macondray Holdings Pte. Ltd. and GMS's related corporation, Parkway Healthcare Indo-China Pte. Ltd., formed pursuant to a joint venture agreement dated [●] ("**Joint Venture Agreement**").

(B) The Company intends to develop an international hospital in Yangon, Myanmar. The Company is the owner of, and has obtained (or will be able to obtain in time for the Parties' lawful performance of their respective obligations under this Agreement), all rights, permits and licences to own, establish and operate, the Hospital (defined below) and the Hospital Business (defined below).

(C) GMS, a wholly-owned subsidiary of Parkway Holdings Ltd, is in the business of providing hospital consultancy and management services.

(D) The Company desires to engage GMS, and GMS has agreed to be engaged, to provide the Services (as defined below) to the Company in respect of the Hospital in the manner and on the terms and conditions set out in this Agreement.

IT IS AGREED as follows:

1. DEFINITIONS AND INTERPRETATION

1.1 In this Agreement and in the Appendices, in addition to the words defined above, and unless the context otherwise requires, the following words shall have the meaning stated hereunder:

"**Accounts**" shall include where relevant, the directors' reports, relevant balance sheets and profit and loss accounts together with all documents which are or would be required by law to be annexed to the accounts of the Company, and prepared in accordance with International Financial Reporting Standards and Legal Requirements;

"**Applicable Laws**" means all applicable laws, statutes, rules, regulations, ordinances, requirements, directions, guidelines, announcements or other binding actions or requirements of any government or department, agency or instrumentality of any government, departments, bodies, regulatory authorities, government authorities, any court or arbitral tribunal; and the governing body of any securities exchange or other securities self-regulatory body;

"**Arbitration Institution**"has the meaning ascribed to it in Clause 20.1;

"**Audited Accounts**" means the audited Accountsof the Company in respect of the Hospital Business for the financial year (or part thereof, as the case may be) ended the Balance Sheet Date, as audited by the Auditors;

"**Auditors**" mean the auditors for the time being of the Company;

"**Balance Sheet Date**" means 31 March of each financial year;

"**Business Day**" means a day (other than a Saturday, Sunday or public holiday) on which banks are open for business in Myanmarand Singapore;

“**Capital Expenditure**” means expenditure for or on account of all alterations, additions, substitutions, renewals, replacements and improvements to the Hospital that are considered to be of a capital nature by the Auditors, including, alterations, additions, substitutions, renewals, replacements and improvements to the Hospital, medical and non-medical equipment, surgical instrumentations, fixtures and fittings, and furnishings, structural repairs and changes or replacements of structural components;

"**Connected Persons**", in relation to a corporation, means its respective shareholders, directors, officers or employees;

“**Consultancy Services Fees**” means the fees payable by the Company to GMS in respect of the Consultancy Services Agreement;

“**Consultancy Services Agreement**” means the Consultancy ServicesAgreement, to be executed between the Parties contemporaneously with the execution of this Agreement,in substantially the form set out in Appendix 4,in relation to the provision of consultancy services to the Company by GMS in connection with the construction, development, establishment, furnishing and equipping of the Hospital;

“**Contractors**” means all contractors, sub-contractors, suppliers, service providers and other consultants employed by the Company in connection with the running, operation and/or maintenance of the Hospital;

"**Control**" means, as to any person, the power and/or authority (whether exercised or not) to manage, directly or indirectly, the operation of the business of or control the business and affairs of or control the composition of the board of directors or management of such person, whether through the ownership of voting securities, by contract or otherwise (which authority shall conclusively be presumed to exist upon possession of beneficial ownership or power to direct the vote of more than fifty per cent. (50%) of the votes entitled to be cast), or in the case of a trust, if such person is a trustee or the principal beneficiary under such a trust, or is a manager of the funds of the trust, and "**Controlled**" and "**Controls**" shall have the corresponding meanings;

"**defaulting Party**" has the meaning ascribed to it in Clause 13.2;

"**Disclosing Party**" has the meaning ascribed to it in Clause 15.1;

"**EBITDA**", for each Reference Period, means Revenue less reserves for bad debts, uncollectible accounts and discountsand less Gross Operating Expenses, as audited by the Auditors;

"**EBITDA Fees**" has the meaning ascribed to it in Appendix 2, Paragraph 1(a);

"**Encumbrance**" means any mortgage, assignment of receivables, debenture, lien, charge, pledge, title retention, right to acquire, security interest, options, rights of first refusal and any other encumbrance or condition whatsoever, and "**Encumbrances**" shall be construed accordingly;

"**Force Majeure Event**" has the meaning ascribed to it in Clause 16.2;

"**Force Majeure Event Notice**" has the meaning ascribed to it in Clause 16.1;

"**Gross Operating Expenses**", for each Reference Period, means all expenses (determined on an accrual basis) of every kind incurred in relation to the normal operation of the Hospital Business including staff salaries, medical supplies, drugs and consumables, service fees to external consultants, marketing expenses, repairs and maintenance costs, utilities costs, lease costs, administrative expenses, and any other costs and expenses in relation to the operation of the Hospital which shall all be calculated as part of the Gross Operating Expenses of the Hospital Business, but excluding (i) Capital Expenditure(ii) net interest expenses, (iii) depreciation, (iv) amortisation, (v) Taxes, (vi) the Services Fees; (vii) Consultancy Services Fees; and (viii) the LicenceFeesall as audited by the Auditors;

"**Hospital**" is a multi-specialty hospital located at the Hospital Land;

"**Hospital Business**" means such of the business and assets of the Company as relate to the Hospital;

“**Hospital Land**” means the plot of land located in the Yangon CBD at the corner of Pyay Road and Bo Gyoke Roadat Plot number 10, Block number 20F, Lanmadaw Townshipwhich premises are the subject of the Lease Agreement;

“**Hospital Staff**” means all individuals employed at or for the direct benefit of, or performing services in or about, the Hospital including the Key Personnel;

"**Improvements**" means all improvements and modifications or adaptations, to any part of the Know-How which are required to adapt the Know-How to suit the local circumstances inMyanmaror to comply with any controls or requirements imposed by any governmental or regulatory body in Myanmar;

“**Joint Venture Agreement**” has the meaning ascribed to it in Recital (A);

"**Key Personnel**" means the Chief Executive Officer, Chief Operating Officer, Chief Medical Officer, Chief Financial Officer and the Director of Nursing of the Hospital Business;

"**Know-How**" means any and all trade secrets, proprietary information, standard operating procedures, policies, protocols, manuals, expertise, and know-how relating to or in connection with the management, finance, service standards, promotion and methods, techniques or systems of operation to be employed in connection with the construction, establishment, development, furnishing, equipping,running, operation and/or maintenance of hospitals and/or the Hospital, and relating to the establishment of the management and medical systems and practices of the Hospitals and/or any otherhospital developed by GMS and/or its related

corporations which are confidential to GMS and/or its related corporations and do not constitute information that is in the public domain or form part of generally or widely accepted/known practices and information within the medical, pharmaceutical or healthcare industry and any other industrial, intellectual property or protected right similar to the foregoing (whether registered, registrable or unregistered) in any country and in any form, media or technology, all as has been developed by GMS and/or its related corporations;

"**Legal Requirements**" means all laws, statutes, ordinances, orders, rules, regulations, permits, licences, authorisations, directions and requirements of all governments and governmental authorities which, now or hereafter, may be applicable to GMS or the Company, or the Hospital and the operation thereof, including without limitation all employment and labour, medical, zoning, building, life or safety, environmental and hazardous waste management, exchange control and other Applicable Laws, ordinances, rules and regulations of all governmental bodies and agencies and self-regulatory entities having jurisdiction over GMS, the Company, the Hospital or the Hospital Business;

"Licence Agreement" means the Trade Mark Licence Agreement, to be executed between Parkway Holdings Limited and the Company contemporaneously with the execution of this Agreement,in substantially the form set out in Appendix 3,in relation to the provision of certain non-exclusive licences to the Company in respect of the use of certain service marks of Parkway Holdings Limited in connection with the Hospital Business;

"**Liability Cap**" has the meaning ascribed to it in Clause 14.7;

"**Licence Fees**" means the fees payable by the Company to Parkway Holdings Limited in respect of the Licence Agreement;

"**Management Accounts**" means the unaudited management Accounts, including a detailed profit and loss account, balance sheet and cash-flow statement, an analysis of sales and other revenue, with revenue and capital budgets for the corresponding month or quarter or year (as the case may be), and a statement of the source and application of funds for such month or quarter or year (as the case may be), of or relating to the Hospital Business for each month or quarter or year (as the case may be) during the Term and each Renewed Term, as prepared by the management of the Company;

"**Materials**"has the meaning ascribed to it in Clause 13.5(b);

"**Myanmar**" means the Republic of the Union of Myanmar;

"**Myanmar Kyat**" and "**MMK**" means the lawful currency of Myanmar;

"**non-defaulting Party**" has the meaning ascribed to it in Clause 13.2;

"**Opening Date**" means the date of the soft opening of the Hospital whereby the Hospital is open to the general public for the provision of medical services;

"**Parkway Group**" means Parkway Healthcare Indo-China Pte. Ltd.and its related corporations;

"**PBT**" has the meaning ascribed to it in Appendix 2, Paragraph 5;

"**Proprietary Information**" has the meaning ascribed to it in Clause 15.1;

"**Quarter**" means a period of three calendar months(or part thereof, as the case may be) within a Reference Period ending on 30 June, 30 September, 31 December and 31 March

respectively, and "**Quarterly**" shall be construed accordingly;

"**ReceivingParty**" has the meaning ascribed to it in Clause 15.3;

"**Recognised Stock Exchange**" means any recognised stock exchange under Singapore law, Malaysian law, or under the laws of Myanmar, or such other stock exchange as may be agreed between the Parties;

"**Reference Period**" means any financial year (or part thereof, as the case may be) during the Term or any Renewed Term, by reference to which the Services Fees are calculated in accordance with Appendix 2;

"**Reference Rate**" means the aggregate of (a) the average of the Singapore Interbank Offered Rate quoted by the three largest local banks in Singapore for six-month deposit in United States Dollars from time to time prevailing; and (b) three per.cent. (3%);

"**Reimbursable Expenses**" has the meaning ascribed to it in Clause 4.2;

"**Renewed Term**" has the meaning ascribed to it in Clause 13.1;

"**Revenue**" means all income of or relating to the Hospital (on an accrual basis) after netting off reserves for bad debts, uncollectible accounts and discounts and shall include: income of every kind received from the operation of the Hospital and all of its facilities or arising from the Hospital, including without limitation, all income from patients, out-patients, including resident doctors fees, service charges collected from visiting physicians or others rendering services to the Hospital's patients or others, rental of consultation rooms in the Hospital, income from car-parks and retail outlets and other non-patient related income attributable to the Hospital generated within the premises of the Hospital, computed in accordance with generally accepted accounting principles in Myanmar;

"**Revenue Fees**" has the meaning ascribed to it in Appendix 2, Paragraph 1(c);

"**Revenue Fees A**" has the meaning ascribed to it in Appendix 2, Paragraph 1(b);

"**Revenue Fees B**" has the meaning ascribed to it in Appendix 2, Paragraph 1(c);

"**Services**" means the hospital management services described in Appendix 1 (or as may be mutually amended by the Parties in writing), which are to be provided by GMS in accordance with the terms of this Agreement;

"**Services Fees**" means the hospital management services fees described in Appendix 2 (or as may be mutually amended by the Parties in writing) which are payable by the Company to GMSin respect of the Services;

Singapore Dollar" and "**S$**" shall mean the lawful currency of the Republic of Singapore;

"**Taxation Authorities**" means the relevant governmental or other authorities competent and authorised to impose Taxes whether in Myanmaror elsewhere;

"**Taxes**" or "**Taxation**" means all forms of taxation of Myanmarincluding all state or local taxation, past, present and deferred including without limitation, income (including net and gross income) tax, business tax, corporate tax, service tax, commercial tax, VAT (i.e., value-added tax), withholding tax, sales tax, goods, occupation, real and personal property, social security, use, *ad valorem*, franchise, profits, licence, payroll, employment, excise, severance, premium or windfall profit taxes, estate duty, stamp duty, customs and other import or export

duties, or charges of any kind whatsoever, estimated and other taxes, together with any interest and levies and all penalties, charges, costs and additions to tax, payable by or due from the Company or GMS (as the case may be), or any additional amounts imposed by any government, governmental agency, statutory body or any revenue authority in Myanmar or otherwise, upon the Company or GMS (as the case may be);

"**Term**"means the period commencing on the Opening Date and expiring on the day immediately prior to the tenth (10^{th}) anniversary of the Opening Date; and

"**United States Dollar**" and "**US$**" shall mean the lawful currency of the United States of America.

1.2 Any reference in this Agreement or the Appendices to a statutory provision shall include that provision and any regulations made in pursuance thereof as from time to time modified or re-enacted, whether before or after the date of this Agreement.

1.3 In this Agreement:

(a) The headings in this Agreement are inserted for convenience only and shall not affect the construction of this Agreement.

(b) Any reference in this Agreement to "**this Agreement**" includes all amendments, additions, and variations hereto agreed between the Parties in writing.

(c) The expressions "**Party**" or "**the Parties**" with their grammatical variations and cognate expressions shall mean the parties to this Agreement, whether original or pursuant to the novation of this Agreement.

(d) Unless the context otherwise requires, words importing the singular shall include the plural and *vice versa* and words importing a specific gender shall include the other genders (male, female or neuter), and "**person**" shall include an individual, corporation, company, partnership, firm, trustee, trust, executor, administrator or other legal personal representative, unincorporated association, joint venture, syndicate or other business enterprise, any governmental, administrative or regulatory authority or agency (notwithstanding that "**person**" may be sometimes used herein in conjunction with some of such words), and their respective successors, legal personal representatives and permitted assigns, as the case may be, and pronouns shall have a similarly extended meaning.

(e) The term "**financial year**", for the purposes of this Agreement, means the period commencing on 1 April and ended or ending 31 March in each year (or part thereof, as the case may be).

(f) The word "**subsidiary**", in relation to a corporation, means a corporation (a) which the first-mentioned corporation controls the composition of the board of directors of, or controls more than half of the voting power of, or in which the first-mentioned corporation holds more than half of the issued share capital of (excluding any part thereof which consists of preference shares and treasury shares, where applicable), or (b) which is a subsidiary of the first-mentioned corporation's subsidiary; and a "**related corporation**" of a corporation shall mean a corporation which is (a) the holding company of the first-mentioned corporation; (b) a subsidiary of the first-mentioned corporation; or (c) a subsidiary of the holding company of the first-mentioned corporation.

(g) A reference to a "**month**" is a reference to a period starting on one day in a calendar month and ending on the day immediately preceding the numerically corresponding day in the next succeeding calendar month.

(h) The words "**written**" and "**in writing**" include any means of visible reproduction.

(i) References to "**Recitals**", "**Clauses**" and "**Appendices**" are to the recitals, clauses of, and the appendices to, this Agreement (unless the context otherwise requires).

(j) Any reference to a "**paragraph**" is a reference to a paragraph of the Clause or Appendix in which such reference appears.

1.3 The Appendices form part of this Agreement and have the same force and effect as if expressly set out in the body of this Agreement.

1.4 Any thing or obligation to be done under this Agreement which is required or falls to be done on a stipulated day, shall be done on the immediately preceding Business Day, if the day upon which that thing or obligation is required or falls to be done falls on a day which is not a Business Day.

2. THESERVICES

2.1 The Company hereby exclusively authorises, engages and appoints GMS to provide to the Hospital and the Companythe Services as described in Appendix 1,to assist the Company in managing the Hospital for the duration of the Term and each Renewed Term.

2.2 GMShereby accepts such appointment subject to and upon the terms and conditions contained in this Agreement.

2.3 For the avoidance of doubt, the Company agrees and acknowledges that the Company shall appoint GMS as the sole and exclusive provider of Services for the duration of this Agreement.

3. SERVICES NOT WITHIN SCOPE OF WORK OF GMS

For the avoidance of doubt, the scope of the Services as set out in Appendix 1 is intended to be exhaustive and all other services not expressly set out therein, including but not limited to that which is set out below, shall not form part of theServices and are not included in the scope of work of GMS under this Agreement:

(a) financial, tax, audit, legal, computer, and hospital information systems;

(b) architectural, interior and exterior design, mechanical and electrical engineering, quantity surveying, structural and civil engineering and project management services for the construction of the Hospital or otherwise;

(c) application for the approvals, permits, licences and consents in accordance with the Legal Requirements required or necessary in relation to or in connection with any aspect of the Hospital and the provision of any part of the Services in Myanmar;

(d) selection of non-medical equipment, fixtures and fittings, and furnishings (however GMS may, but shall not be obligated to, review the proposed list of such items from the specialist consultancy provider from the perspective of the operator of the

Hospital, and suggest improvements and possible savings opportunities/alternatives);

(e) maintenance of equipment (either medical or otherwise);

(f) ensuring that the Hospital, the operations of the Hospital Business, or any component thereof meets the Legal Requirements;

(g) technical requirements and drawings on civil, electrical, electronic, mechanical, sanitary or structural matters;

(h) landscaping;

(i) assessment on insurance requirements of the Company or the Hospital Business;

(j) other specialist services as may be requiredother than the Services, including acoustic facade, greenmark/building sustainability, kitchen, land surveyor, signage, lighting, traffic and interior design, etc;

(k) professional environmental impact assessment;

(l) replacement work necessitated by any event for whatever reason;

(m) arrangement of work in the event of the termination or abandonment of the Hospital or the Hospital Business, resulting in the termination of this Agreement;

(n) inspection and advice on the selection and suitability of the Hospital Land;

(o) preparation of walk through animation; and

(p) advice to be given in the event of litigation and/or arbitration.

4. SERVICES FEES AND OTHER EXPENSES

4.1 In consideration of the Services to be provided by GMS under the terms of this Agreement, the Company shall pay to GMS, or such other person as GMS may in writing direct, the Services Fees in the amounts and manner and at the times and on the bases set out in Appendix 2.

4.2 In addition to the Services Fees payable to GMS under this Agreement, the Companyagrees and undertakes to arrange and pay for and incur directly, and failing which, to reimburse GMS in full,for all costs and expenses reasonably incurred by GMS in respect of the Services(the "**ReimbursableExpenses**"). GMS shall not incur any particular item of ReimbursableExpenses directly unless the Company fails or is unable to incur it directly or in a timely manner. The Company hereby undertakes to reimburse GMS for any such payment made by GMS, PROVIDED THATany item of Reimbursable Expense exceeding US$250,000or where the aggregate amount of Reimbursable Expenses incurred during a Quarter has exceeded US$250,000, subsequent items of Reimbursable Expense to be incurred during the Quarteris made with the Company's prior written approval; and GMS submitsall such claims with supporting invoices or receipts or other evidence of actual payment of such expenses that the Company may reasonably require. The Company shall:

(a) where the Company has extended prior written approval for any Reimbursable Expense, advance to GMS an amount equal to the Reimbursable Expense so approved; and

(b) in all other situations, promptly reimburse GMS for all claims for Reimbursable Expenses within thirty (30) days of receipt of such claims from GMS or on the fifteenth (15^{th}) day of the following month, whichever is the earlier.

The ReimbursableExpenses shall include, but not be limited to the following:

(i) travel, local transportation, accommodation, food, laundry and out-of-pocket costs and expenses for all the employees of GMS or GMS's related corporations who are required by GMSto travel to Myanmar from Singapore or elsewhere as additional resources for assisting GMS in performing any part of the Services and/or its duties and responsibilities under this Agreement; and

(ii) costs and professional fees of any adviser, consultant or other professional consulted or instructed by GMS upon instructions from the Company in connection with matters not within the scope of the Services to be performed by GMS under this Agreement.

For the purposes of this provision, the guidelines for air travel, accommodation, mealstransportationlaundry and other out-of-pocket costs and expensesof assigned employees of GMSshall be based on GMS’s internal policies. For the avoidance of doubt, it is clarified that the ReimbursableExpenses shall notinclude the salaries of the employees of GMS or its related corporations whether directly or indirectly in connection with the Services provided by GMS under this Agreement.

4.3 For the avoidance of doubt, GMS shall not be required to perform any services outside the scope of theServices and, if required to do so by the Company and agreed to by GMS, shall be entitled to require the payment of additional fees to be agreed between the Parties in connection therewith, failing which GMS shall not be required to perform any such out-of-scope services.

4.4 In addition to all other remedies that GMS may have at law and in equity,in the event of the termination of this Agreement for any reason, or the expiration of the Term or the last Renewed Term, the Company shall pay to GMSall Services Fees due and owing to GMS based on the effective date of termination or,as the case may be, the last day of the expiration of the Term or the last Renewed Term.

4.5 In addition to the foregoing, all:

(a) operating expenses incurred in connection with the day to day management of the Hospital or the Hospital Business incurred or made by GMS in relation to the Hospital in performing its duties under this Agreement; and

(b) Capital Expenditure,

as provided herein or otherwise deemed to be necessary by GMS (acting reasonably) for the operation of the Hospital or the Hospital Business, shall be borne exclusively by the Company. The Parties agree that GMS shall not, under any circumstances, be required to advance any of its funds or procure any funding for the management of the Hospital or the Hospital Business, or to incur any liability for its own account in connection therewith. To the extent required working capital is not generated by the Hospital Business in an adequate amount or on a timely basis, working capital shall be supplied by the Company to GMS.

5. <u>PAYMENT OF SERVICES FEES AND OTHER EXPENSES</u>

5.1 All Services Fees, costs and expenses and other amounts payable to GMS under this

Agreement (including any Reimbursable Expenses and any amounts due to GMS pursuant to Clause 4.4)are, unless otherwise stated, expressed in Myanmar Kyat but payment shall be made in full inSingapore Dollars or in such other currency as GMS may from time to time notify the Company in writing in accordance with Clauses 4 and 5 and Appendix 2 unless otherwise agreed to or instructed by GMS, in the form of bank draft, cashier's order or telegraphic transfer payable to the order of GMS (as may be designated from time to time in writing by GMS) no later than the relevant due date for payment. All Services Fees, costs and expensesand other amounts payable to GMS under this Agreement (including any Reimbursable Expenses and any amounts payable to GMS pursuant to Clause 4.4)that would otherwise be due on a day other than a Business Day instead, shall be due on the immediately preceding Business Day.

5.2 Any Services Fees, or costs and expenses and other amounts payable to GMS under this Agreement (including any Reimbursable Expenses and any amounts due to GMS pursuant to Clause 4.4)or any portion thereof which is not paid on the expiry of the due date for payment, shall accrue interest for each day elapsed thereafter from and including the relevant due date for payment, at the Reference Rate (compounded monthly from the relevant due date for payment) until they are paid, before as well as after any judgment. Such amounts as well as any accrued but unpaid interest thereon shall, subject to Applicable Laws, be payable on demand.

5.3 All payments to be made by the Company under this Agreement (including without limitation all Services Fees,Reimbursable Expensesand any amounts due to GMS pursuant to Clause 4.4)shall be made (a) free of any restriction or condition, (b) free and clear of and without deduction or withholding for or on account of any Taxes, and (c) without deduction or withholding on account of any other amount, whether by way of set-off, counterclaim or otherwise. If at any time the Company is required to make any deduction or withholding for applicable Taxes in Myanmar from any payments due under this Agreement for the account of GMS, or such other person as may be appointed by GMS pursuant to Clause18.11, pursuant to Applicable Laws, the Company shall:

(a) where the recipient of such payments is not a resident in Myanmar for purposes of the Myanmar Income Tax Act, forthwith increase the sum payable to such sum as will ensure that, after such deduction and withholding has been made and paid to the Taxation Authorities,the recipient receives on the due date for such payment a sum equal to the sum that it would have received in the absence of such Taxesprovided and to the extent that the recipient thereafter recovers or receives from the relevant Taxation Authorities any part of such amounts so deducted or withheld, then upon its receipt thereof, GMS shall procure that the recipient remit to the Company such amount so recovered or received;

(b) indemnify the recipient against any losses or costs incurred by it by reason of any failure of the Company to make such deduction or withholding; and

(c) promptly deliver to the recipient any receipts, certificates or other proof evidencing the amounts (if any) paid or payable in respect of any such deduction or withholding as aforesaid.

6. <u>PERSONNEL</u>

6.1 Except as otherwise provided in this Agreement, all Contractors and members of the Hospital Staff shall be the contractors or employees of the Company and the Company shall assume all legal liabilities and responsibilities as the employer of such Contractors or Hospital

Staff (including for the avoidance of doubt, all legal liability in respect of the payment of the service fees of the Contractors, and the salaries, benefits and other remuneration of the Hospital Staff). Notwithstanding the foregoing and subject to Clause 6.3, GMS shall have the right to engage in negotiations with Contractors, Hospital Staff and the trade unions or representatives of the Hospital Staff and the right to enter into agreements, acting as agent for the Company, with such Contractors, Hospital Staff and the trade unions or representatives of the Hospital Staff (including collective agreements).

6.2 The Company acknowledges and agrees that, in performing its duties and responsibilities hereunder, GMS may use its personnel or those of its related corporations andmay supplement the same with such outside consultants as shall be selected by GMS in its sole discretion, including sub-contract a variety of such Services to such persons as it may deem fit provided that GMS shall be solely responsible for the costs and expenses in connection with such sub-contracting which should not constitute Reimbursable Expenses.Notwithstanding the foregoing, GMS shall remain responsible for performing this Agreement as if GMS had not sub-contracted the performance of all or any part of its obligations under this Agreement to such person, firm or corporation and shall remain primarily liable to the Company.

6.3 In relation to services falling outside the scope of the Services and agreed to between the Parties, in addition to the additional fees referred to in Clause 4.3, the costs and expenses of such personnel, outside consultants and sub-contractors shall, for the avoidance of doubt, be borne by the Company.

6.4 In connection with the running, operating and managementof the Hospital or the operation of the Hospital Business,GMS:

(a) shall be entitled to nominate the Key Personnel for the Hospital;

(b) may in its sole discretion, subject to the Company's prior written approvaland the Company making the payments set out below, second to the Hospital its employees or employees of its related corporations; and

(c) may, with the Company's prior written approval, engage and employ on behalf of the Company and as the Company’s agentsuch persons approved by the Company to be Contractors.

6.5 The Company undertakes to appoint the Key Personnel upon the nomination by GMS in accordance with the articles of association of the Company. Without prejudice to the foregoing, the appointment of the Key Personnel shall be by the Company and provided always that, where the Company has appointed any of the Key Personnel at the nomination of Parkway Healthcare Indo-China Pte Ltd, pursuant to the Joint Venture Agreement, it should be regarded as that the Company has fulfilled its obligations under this Clause 6.4 in respect of such Key Personnel.Key Personnel shall not be reassigned by the Company during their tenure, without the prior consent in writing of GMS. In the event of a secondment by GMSand/or its related corporations of Contractors and Hospital Staff (excluding the Key Personnel) to the Hospital, the Company shall pay the adjusted salary (on an expatriate basis), including any bonuses, annual wage supplements and social insurance and public housing fund, benefits, tax equalisation and accommodation expenses as well as all travelling, local transportation and cost-of-living adjustments of suchsecondeeContractors and Hospital Staff (excluding Key Personnel).

6.6 For the avoidance of doubt, and notwithstanding anything else in this Agreement, any nomination, engagement or employment by GMS on behalf of the Company of any candidates for the position of any Contractor orHospital Staff (including any Key

Personnel)shall not amount to a representation or warranty of their level of performance and GMS shall not in any way be liable or deemed to be in breach of this Agreement by reason of any negligence, fraud or unsatisfactory performance of, or any breach or wrong-doing by, such Contractor or Hospital Staff (including any Key Personnel).

7. OBLIGATIONS OF GMS

7.1 GMSshall providethe Services for the duration of the Term and each Renewed Termat a level consistent with efficient and business-like conduct, and in accordance with the terms and conditions set out in this Agreement, unless and until this Agreement is terminated pursuant to the provisions of this Agreement.

7.2 GMS shall from the Opening Date maintain proper accounts and records of all expense incurred by it on the Company's behalf in the course of the performance of the Services under this Agreement and for the avoidance of doubt, such accounts and records shall be the property of the Company which the Company is entitled to access and inspect with reasonable advance notice to GMS in writing.

7.3 GMS shall provide the Company with such relevant and material policies and procedures as are necessary for the operation of the Hospital (whether in written or electronically recorded form).

7.4 GMS shall,if it encounters problems which are likely to hinder the smooth operation of the Hospital, promptly notify the Company of such fact and the Company and GMS shall co-operate to deal with such problems.

8. OBLIGATIONS OF THE COMPANY

8.1 The Company shall, for the duration of this Agreement,

(a) promptly make payments to GMS for the Services when due and in accordance with the provisions of this Agreement;

(b) ratify all acts, deeds and things done by GMS in connection with the provision of services within the scope of the Services;and any additional services as agreed between the Parties pursuant to this Agreement;

(c) give its full co-operation and assistance to GMS to enable GMS to carry out its duties and responsibilities under or by virtue of this Agreement and shall, within a reasonable period of time, review and respond to all recommendations and requests made by GMS and/or its representatives in connection with theServices;

(d) promptly advise GMS of any event or possible event which may adversely affect GMS and the performance of its duties and responsibilities hereunder, upon the same coming to the knowledge of the Company;

(e) use its best endeavours to obtain all necessary initial licences and permits required to develop and operate the Hospital and appoint the relevant professionals to advise the Company and GMS on the Legal Requirements relating to the Hospital and the Hospital Business;

(f) upon receiving advice from the relevant professionals appointed to advise the Company on the Legal Requirements relating to the Hospital and the Hospital

Business, use its best endeavours to obtain and maintain all necessary approvals, licences and permits required to operate the Hospital, the Hospital Business or which pertain to any matter covered by this Agreement;

(g) in the event that any non-residents of Myanmar (including members of the staff of GMS or its related corporations) shall be required in connection with the provision of theServices or to work in or travel to Myanmar in connection with the Hospital or the Hospital Business, apply for and use its best endeavours to procure all necessary visas, work permits and any other documentation necessary under the laws of Myanmar for such persons;

(h) not require GMS to implement any unlawful measures or programmes; and

(i) enter into the Licence Agreement and to renew any expiring Licence Agreement (if applicable) at the request of GMS, upon the same terms and conditions unless mutually agreed otherwise.

9. COVENANTS AND AGREEMENTS RELATING TO THE KNOW-HOW

9.1 The Company hereby acknowledges, agrees and undertakes that:

(a) GMS and/or its related corporations are the legal and beneficial owners of the Know-How and all the goodwill relating thereto;

(b) the Know-How at all times shall be and remain the sole and exclusive property of GMS and/or its related corporations (as the case may be);

(c) the Company, by reason of this Agreement or the use thereof or otherwise, has not acquired and shall not acquire any right, title, interest, or claim or ownership in the Know-How, except the non-exclusive licence to use them only for the Term and each Renewed Termsolely in connection with the design and operation of the Hospital and in the manner and subject to the terms and conditions set forth in this Agreement, and nothing in this Agreement shall prevent any use by GMS and/or its related corporations of any part of the Know-How;

(d) the use by the Company of the Know-How and any and all goodwill arising from such use shall inure solely to the benefit of GMS and/or its related corporations;

(e) the Company shall take no action inconsistent with GMS's and/or its related corporations' title and rights to the Know-How nor assert any rights in relation thereto;

(f) the Company shall, at the request of (and at the cost and expense of) GMS at any time during the Term and any Renewed Term, execute on a reasonable basis any and all documents confirming and/or vesting in GMS and/or its related corporations, the interest and proprietorship of GMS and/or its related corporations in the Know-How; and

(g) for the avoidance of doubt, the Company shall use the Know-How (including Improvements arising from work carried out by GMS and/or its related corporations alone) and where relevant, the Proprietary Information procured from GMS, only for the operation of the Hospital, and acknowledges and undertakes that it will not make use of any part thereof in any manner (not even for other facilities of the Company), nor commercialize it in any manner directly or indirectly.

9.2 When appropriate, or when directed by GMS, the Company shall mark all materials containing any of the Know-How and/or the Proprietary Information of GMS and/or its Connected Persons with a proper registration or proprietorship notice.

9.3 The Company shall promptly notify GMS of any unauthorised use of the Know-How or of the Proprietary Information of GMS and/or its Connected Personsor of any other intellectual property belonging to GMS and/or its related corporations by any person and of any infringement or passing off or other torts involving any of the Know-How, the Proprietary Information of GMS and/or its Connected Personsand/or the intellectual property belonging to GMS and/or its related corporations, as soon as the Company receives or is aware of such information.

9.4 GMS and/or its related corporations shall have the sole right and full discretion (but not the obligation) to bring an infringement or other proceedings or action against any persons using without authorisation, the Know-How, the Proprietary Information of GMS and/or its Connected Personsand/or the intellectual property belonging to GMS and/or its related corporations. At the request and expense of GMS, the Company shall co-operate with GMS and/or its related corporations in opposing or otherwise defending or contesting any use or registration by any other person of the Know-How, the Proprietary Information of GMS and/or its Connected Personsor of any intellectual property belonging to GMS and/or its related corporations. Notwithstanding anything to the contrary contained in Clause 20, GMS and/or its related corporations have the right to obtain restraining orders or injunctive relief from a court of competent jurisdiction, in accordance with the relevant laws, for any unauthorized use or registration by third parties of any Know-How, the Proprietary Information of GMS and/or its Connected Personsand/or the intellectual property belonging to GMS and/or its related corporations.

9.5 For the avoidance of doubt, GMS's failure toobject to any aspect of the use of the Know-How and/or the Proprietary Information of GMSand/or its Connected Persons by the Company in connection with the Hospital shall notconstitute a representation or acknowledgment that the Company is in compliance with thisAgreement or that GMS or its related corporations have waived any of their rights, title andinterest in and to the Know-How and/or the Proprietary Information of GMS and/or itsConnected Persons and/or under this Agreement, which rights, title and interest are expressly reserved.

9.6 The Company shall use the Know-How, the Proprietary Information of GMS and/or its Connected Personsand all other intellectual property belonging to GMS and/or its related corporations in compliance with all Applicable Laws and regulations in Myanmar.

9.7 The Company shall refrain from committing any act or pursuing any course of conduct that will or is likely to bring GMS and/or its related corporations, the Know-How, the Proprietary Information of GMS and/or its Connected Personsor any other intellectual property belonging to GMS and/or its related corporations, into disrepute.

9.8 The Company will acquire no rights to the Know-How, the Improvements, the Proprietary Information of GMS and/or its Connected Personsor any other intellectual property belonging to GMS or its related corporations or any derivations thereof except as provided in Clause 9.10.

9.9 The Company hereby acknowledges the exclusive rights of GMS and/or its related corporations to own the Know-How, the Proprietary Information of GMS and/or its Connected Personsand all matters and rights comprised therein and of GMS and/or its related corporations themselves to utilise the same and to grant to any other person a licence to use the Know-How, the Proprietary Information of GMS and/or its Connected Persons and any or all intellectual property subsisting therein, and to amend and modify the same by variation,

revision, addition, renewal, substitution or howsoever otherwise.

9.10 Subject to the other provisions of this Agreement and subject always to the due and timely performance by the Company of its obligations under this Agreement, GMS hereby grants the Company the non-exclusive, non-transferable licence to use and reproduce the Know-How and the Improvements exclusively owned by GMS and/or its related corporations, solely for the purposes of the operation of the Hospital during the Term and any Renewed Term.

9.11 In the event of the termination or expiration of this Agreement for any reason whatsoever, the rights granted to the Company in Clause 9.10 shall forthwith terminate.

10. IMPROVEMENTS

10.1 The Company shall forthwith disclose to GMS in such detail as GMS may reasonably require, all Improvements that it may develop or acquire during the course of the performance of this Agreement.

10.2 For the purposes of and subject to the terms of this Agreement, all Improvements arising from work carried out by:

(a) GMS and/or its related corporations, whether alone or in collaboration with third parties;or

(b) the Company, whether alone or in collaboration with GMS or any third party,

together with all original documents, systems and materials prepared and provided by GMS and/or its related corporations for the use of the Hospital pursuant to this Agreement, shall:

(i) as between the Parties, remain the exclusive property of GMS and/or its related corporations, as the case may be; and

(ii) bedeemed to be part of the Know-How for the purposes of this Agreement.

11. INSURANCE

11.1 The Company shall, from the date of this Agreement (or such other date as may be agreed between the Parties), take out and maintain adequate insurance coverage to cover all types of risks normally associated with the operation of the Hospital and the Hospital Business including but not limited to general and public liability insurance and all other insurance coverage as may be decided jointly by GMS and the Company. All insurance policies shall be in appropriate amounts and forms and with reputable licenced insurance companies reasonably acceptable to GMS.

11.2 The Company shall be responsible for the payment of all *premia* required to maintain the insurances pursuant to Clause 11.1.

11.3 All insurance provided for in this Clause 11 shall be written in the name of the Company and GMS and shall contain a provision requiring the insurance company to notify each Party of any cancellation or material change at least 60 days prior thereto. All liability insurance provided for in this Clause 11shall name each of the Company and GMS as named insured.

11.4 The property damage insurance policies obtained by or for the account of the Company shall provide for payment of loss to the Company and GMS in accordance with their respective

interests.

12. ACCESS

12.1 The Company hereby undertakes and agrees with GMS that GMS and its representatives shall:

(a) have full and uninterrupted access to the Hospital,the Hospital Land and any facility and component related to the operation of the Hospital:

(i) for the duration of this Agreement, for the purposes of the provision of the Services;and

(ii) for the duration of this Agreementand for a period of ninety (90) days thereafter,to determine whether the Company is in compliance with the terms of this Agreement,

and the Company shall make available for inspection such items as may be reasonably requested by GMS;

(b) be entitled to inspect the Hospital at all times when providing the Services and conducting on-site inspections; and

(c) be entitled to be present at any site meetings which the Company may have with its Contractorsand for this purpose the Company shall keep GMS informed of the time and place of such meetings.

12.2 The Company hereby further undertakes and agrees with GMS that for the duration of this Agreement and for a period of ninety (90) days after the termination of this Agreement or the expiry of the Term of the last Renewed Term, as the case may be, GMS shall have access to the Hospital, the Hospital Land and the Company's records, documents and other materials relating to the Hospital and its operations and to this Agreement, for the purposes of verifying the Services Fees and any other amounts to be paid to GMS pursuant to this Agreement. The provision of this Clause 12 shall survive the expiry or termination of this Agreement for a period of ninety (90) days after the termination of this Agreement or the expiry of the Term of the last Renewed Term.

13. DURATION AND TERMINATION

13.1 This Agreement shall commence on the date hereofand shall continue until the expiry of the Term or the last Renewed Term, as the case may be, unless terminated earlier by notice in writing in accordance with this Clause 13.Upon the expiry of the Term and of each Renewed Term, and provided this Agreement has not been terminated in accordance with Clauses13.2 or 13.3, this Agreement shall automatically renew and be binding on the Parties for subsequent periods of ten (10) years each and upon the same terms and conditions, including the Services Fees (each such automatic renewal shall be called a "**Renewed Term**"), unless GMS, by written notice delivered to the Company at least three months' prior to the expiry of the Term or the last Renewed Term, as the case may be,chooses not to renew this Agreement, in which event this Agreement shall expire upon the expiry of the Term or the last Renewed Term, as the case may be.

13.2 This Agreement may be terminated immediately by a Party (the "**non-defaulting Party**") in respect of the other Party (the "**defaulting Party**"), in the event that any of the following events arises or occurs with respect to the defaulting Party:

(a) without prejudice to Clauses 13.3, 13.4 and 13.5, the breach by the defaulting Party of any of its representations, warranties and/or undertakings in this Agreement (including without limitation, in Clause 17) if such breach is not capable of remedy, or if such breach (being capable of remedy) is not remedied within sixty (60) days after written notice specifying such breach is received by the defaulting Party from the non-defaulting Party;

(b) without prejudice to Clauses 13.3, 13.4 and 13.5, the failure of the defaulting Party to observe, perform, keep or fulfil any material covenant, agreement, provision, undertaking or obligation under this Agreement if such failure has or is likely to have a material adverse effect on the operation of the Hospital or the rights and duties of the non-defaulting Party, if such failure is not capable of remedy, or if such failure (being capable of remedy) is not remedied within sixty(60) days after written notice specifying such failure is received by the defaulting Party from the non-defaulting Party;

(c) the application or filing by a third party or by the defaulting Party for, or consent by the defaulting Party to the appointment by any person of, or the appointment of or the entry by any court of competent jurisdiction of an order, judgement or decree for, the appointment of a receiver, judicial manager, trustee, administrator or liquidator for all or a substantial part of the defaulting Party's assets or for the bankruptcy, liquidation, insolvency, dissolution, reorganisation (other than a reorganisation pursuant to a restructuring not involving insolvency), composition or arrangement with creditors of or similar actions against, the defaulting Party;

(d) the making by the defaulting Party of a general assignment for the benefit of, or its entry into arrangements with, its creditors;

(e) the filing by the defaulting Party of a voluntary petition in bankruptcy or a petition seeking reorganisation (other than those pursuant to a restructuring not involving insolvency), composition, arrangement with creditors, liquidation, or similar relief under any present or future statute, law or regulation;

(f) the entry by any court of competent jurisdiction of an order, judgement or decree for the adjudication of the defaulting Party as bankrupt or insolvent; or the filing by the defaulting Party of an answer admitting the material allegations of a petition filed against it in any proceedings pertaining to its insolvency; or the initiation by the defaulting Party of any action in furtherance of dissolution; or the dissolution of the defaulting Party either by action of its shareholders or law;

(g) the filing of any petition or complaint with respect to the defaulting Party without the application, approval or consent of the defaulting Party seeking reorganisation, composition, arrangement with creditors, appointment of an administrator, liquidation, or similar relief under any present or future statute law or regulation with respect to the defaulting Party seeking appointment of a receiver, trustee, or liquidator for all or a substantial part of the defaulting Party's assets, and such petition or complaint shall be pending and not withdrawn or dismissed for an aggregate of thirty (30) days (excluding any days during which such petition or complaint shall be stayed), whether or not consecutive; and

(h) anyevent occurs or proceeding or step is taken or suffered with respect to the

defaulting Party in any jurisdiction to which it is subject, which has an effect equivalent or similar to any of the foregoing events.

13.3 This Agreement may further be terminated immediately by GMS in respect of the Company in the event that any of the following events arises or occurs:

(a) the failure by the Company to pay any sum of money to GMS when due and owing, if such failure is not remedied within ninety(90) days after written notice specifying such failure is received by the Company from GMS;

(b) if any necessary licences, permits or approvals for the operation of the Hospital or the Hospital Business under any of the Legal Requirements are at any time not granted, suspended, terminated or revoked (and if the Hospital has commenced operations, such suspension, termination or revocation has caused the Hospital to cease operating for a period of more than ninety (90) consecutive days), without fault on the part of GMS or not due to negligence on the part of GMS;

(c) if the Hospital Business ceases to be in the ownership of the Company, or if the Hospital Business is not carried out by the Company, or is (or is permitted or suffered to be) sold, transferred, disposed of, assigned or novated to any third parties;

(d) ifParkway Healthcare Indo-China Pte. Ltd., its related corporationor its nominee company ceasing to directly or indirectly hold at least fifty per. cent. (50%) of the issued share capital of the Company for whatever reason;

(e) if the Company interferes with the performance by GMS of the Services or any part thereof or fails or refuses to co-operate with GMS in such a manner which shall materially affect the ability of GMS to perform its obligations under this Agreement or inadequately staffs or equips the Hospital for it tooperate as a hospital of an international standard and such failure is not remedied within sixty (60) days after written notice specifying such failure is received by the Company from GMS;

(f) if the Hospital is not constructed and ready for use by the end of forty-eight(48) monthsfrom the date of this Agreement or such laterdate as may be agreed between the Parties;

(g) if the Hospital or any portion thereof shall be damaged or destroyed by fire, flood, earthquake, typhoon, war, insurrections or other casualty or any acts of God such that there is a material impact on its operations or it is condemned by any competent authority and is not repaired, restored or replaced within sixty (60) days or such other period as may be agreed between the Company and GMS after such fire or other casualty or condemnation or if the Company shall fail to prosecute such work diligently;

(h) if the Joint Venture Agreement is terminated for whatever reason; or

(i) iftheLicence Agreement entered into in accordance with Clause 8.1 (i) hereunder is terminated for whatever reason.

13.4 The expiration or termination of this Agreement shall be without prejudice to the accrued rights of the Parties, and any provision hereof which relates to or governs the acts of the Parties subsequent to such expiry or termination hereof (including without limitation Clauses 4, 5, 9, 10, 12, 14, 15, 18, 19 and 20) or which is expressed to survive such terminationshall remain in full force and effect and shall be enforceable notwithstanding such expiry or termination.

13.5 For the avoidance of doubt, Clauses 4, 5 and 14 shall survive the expiry or termination of this Agreement only to the extent necessary to ensure that the Company continues to be obliged to pay to GMS such amount of the Services Fees, Reimbursable Expenses, costs and expenses, interests and other amounts as are due (including any amounts due to GMS pursuant to Clause 4.4), owing and payable to GMS up to and including the date of expiry or termination of this Agreement. The Company shall also forthwith pay or cause to be paid to GMS all accrued and unpaidServices Fees, interest and all amounts due, owing and payable to GMS (including any amounts due to GMS pursuant to Clause 4.4) under this Agreement up to the date of expiry or termination of this Agreement.Each of GMS and the Company shall:

(a) immediately refrain from any action that would or may indicate any relationship between it and the other;

(b) return to the other or otherwise dispose of or destroy as the other shall direct, all materials, stationery, invoices, forms, specifications, designs, records, data, samples, models, programmes and drawings belonging solely to the other ("**Materials**") but only to the extent that the return or destruction of such Materialswould not be inconsistent with the use of such Materials in connection with any applicable laws, rules, regulations or existing bona fide internal retention policies and provided that any Materials held in any computer, word processing system, database or document retrieval system shall only be destroyed to the extent reasonably practicable. For the avoidance of doubt, the obligations of confidentiality contained in this Agreement shall continue to apply to any Materials retained by GMS or the Company pursuant to this Clause;

(c) return all items of good, supplies and/or equipment held on loan or hire from the other under the terms of this Agreement; and

(d) co-operate and do all such acts and things and execute all such documents as the other shall reasonably require, including to effect a handover to another operator of the Hospital, if any.

13.6 The remedies available upon termination contained in this Clause 13 shall not be deemed or construed to limit or derogate from any and all other remedies, rights, and recourse available by law or in equity, except as expressly may be provided in this Agreement.

14. DISCLAIMERS AND INDEMNITIES

14.1 Except in the case of gross negligence, fraud or breach of this Agreement, but subject always to Clause 6.6, neither GMS, its related corporations,nor their Connected Persons shall be liable to the Company (either actually or contingently, presently or in the future) in respect of any action, decision, consent, approval, rejection, omission to act, delay or any other matter or thing taken, made, given or otherwise occurring in the course of any exercise of its or his rights, powers and authorities, and performance of its or his duties and obligations, contained in this Agreement nor shall GMS, its related corporations or any of their Connected Persons be liable (absent gross negligence, fraud or breach of this Agreement) for any losses,

liabilities, costs or expenses which result (either directly or indirectly) in respect thereof including, without limitation, any liability in respect of:

(a) prosecuting or defending any action or suit in respect of the provisions of this Agreement or in respect of or in connection with any matters pertaining to the Company or the Hospital;

(b) any act or thing which GMS and its representatives is hindered, prevented or forbidden from doing or performing by applicable legislation or court order; or

(c) any reliance upon any notice, resolution, direction, consent, certificate, receipt, affidavit, statement or other paper or document reasonably believed by GMS, its related corporations or their Connected Persons, to be genuine and to have been passed or signed by the proper parties.

14.2 For the avoidance of doubt, GMS, its related corporations and their Connected Persons shall not bear any portion of any losses (including economic losses) arising out of or related to the ownership or operation of the Hospital or the Hospital Business by the Company. All debts and liabilities to third parties incurred by GMS, its related corporations and their Connected Persons in the course of the performance of the Services in accordance with this Agreement with the prior approval and knowledge of the Company (including the Reimbursable Expenses), shall be the debts and liabilities of the Company only and GMS, its related corporations and their Connected Persons shall not be liable for any such debts and liabilities by reason of the performance of any acts, duties and responsibilities hereunder in connection with the Hospital or the Hospital Business and may so inform third parties with whom GMS, its related corporations or their Connected Persons deal on behalf of the Company.

14.3 GMS, its related corporations and their Connected Persons shall not be responsible to the Company for any of their actions or omissions or the effects thereof that are the direct or indirect result of any controls or requirements (whether or not having the force of law) imposed upon the Company or any of GMS, its related corporations and their Connected Persons by any government, governmental or regulatory authority that may exercise jurisdiction or control over them directly or indirectly.For the avoidance of doubt, any actions or omissions of GMS pursuant to this Clause 14.3 shall not constitute a breach of this Agreement.

14.4 The Company irrevocably undertakes to keep GMS, its related corporations and their Connected Persons fully and effectively indemnified from and against any and all losses, costs, damages, claims, demands, actions, proceedings, liabilities (whether present or future, actual or contingent) and expenses whatsoever (including but not limited to all legal costs or attorneys' fees on a full indemnity basis) which may be incurred or suffered by GMS, its related corporations or any of their Connected Persons in the course of performing this Agreement or in connection with or resulting or arising from any act, omission, neglect, default, negligence or breach of the Company, its related corporations and/or their Connected Persons or arising from any claims by any third party in respect of any matter arising from the provision of services within the scope of the Services or for the infringement of any intellectual property rights, unless GMS has acted fraudulently or in a grossly negligent manner or in breach of this Agreement.

14.5 GMS irrevocably undertakes to keep the Companyand its Connected Persons fully and effectively indemnified from and against any and all losses, costs, damages, claims, demands, actions, proceedings, liabilities (whether present or future, actual or contingent) and expenses whatsoever (including but not limited to all legal costs or attorneys' fees on a full indemnity basis) which may be incurred or suffered by the Company or its Connected Persons arising from any successful claims by any third party in Myanmar in respect of any

infringement of any intellectual property rights comprised in the Know-How or the Proprietary Information.

14.6 GMS, its related corporations and their Connected Persons may act on the opinion or advice of, or information obtained from any financial adviser, solicitor or any such other professional adviser. GMS, its related corporations and their Connected Persons may act upon statements of, or information in relation to, the Company, the Hospital or the Hospital Business, obtained from the auditors, any financial adviser, banker, accountant or such other professional adviser, believed by them in good faith and on reasonable grounds to be expert in relation to the matters upon which they are consulted and GMS, its related corporations and their Connected Persons shall not be liable for any thing done, or suffered, by any of them in good faith in reliance upon such opinion, advice, statement or information in relation to the Company,the Hospital or the Hospital Business and shall not be responsible for any misconduct, mistake, error of judgement or want of prudence on the part of such person.

14.7 Notwithstanding anything to the contrary in this Agreement, the aggregate liability of GMS under this Agreement for each Reference Period shall not exceed an aggregate of S$2,000,000 ("**Liability Cap**"). Where any Reference Period is less than a full financial year, the Liability Cap for such Reference Period shall be pro-rated based on the number of days within such Reference Period.

15. CONFIDENTIALITY AND RESTRICTIVE COVENANTS

15.1 The Company acknowledges that GMS and/or its related corporations will make available to the Company and its Connected Persons certain trade secrets, Know-How, confidential and/or proprietary knowledge (including advice, technology, documents, know-how, techniques, procedures, methods, plans and all other materials) and information as a result of entering into this Agreement and in connection with the provision of the Servicesto the Company and the Hospital and in connection therewith may provide the Company and its Connected Persons with certain documentation and information regarding GMS, GMS's related corporations, their respective businesses, and the Hospital (collectively, the "**Proprietary Information**") including without prejudice to the generality of the foregoing, any information as a result of entering into or performing this Agreement which relates to or in connection with:

(a) the provision of the Services to the Company and the Hospital including but not limited to the Know-How (including any Improvements);

(b) the provisions of this Agreement or any other agreements, documents or transactions referred to or contemplated herein;

(c) the negotiations relating to this Agreement or any other agreements, documents or transactions referred to or contemplated herein; or

(d) the subject matter of this Agreement or any other agreements, documents or transactions referred to or contemplated herein.

15.2 In consideration of receiving the Proprietary Information, the Company hereby undertakes with GMS, on behalf of itself and its Connected Persons and each of its and its Connected Persons' directors, shareholders, employees and agents, whether or not any such Proprietary Information is strictly confidential or proprietary:

(a) not to exploit or make any use of the Proprietary Information for any purpose other than in accordance with this Agreement, and in particular, but without limitation, not to

use any of the Proprietary Information for any commercial purpose, except to the extent permitted by this Agreement;

(b) except to the extent permitted by this Agreement, to hold all of the Proprietary Information in the strictest confidence, as may be reasonably done and not to disclose or divulge any part of the Proprietary Information to any third parties without the prior written consent of GMS, which consent may be withheld by GMS without being obliged to give any reason therefor whatsoever, or in the sole discretion of GMS, given on such terms and conditions as GMS considers appropriate;

(c) not to make or solicit any announcement or disclosure regarding GMS or its related corporations unless GMS gives its express prior written consent;

(d) to restrict access to the Proprietary Information to those of its employees and professional advisers who absolutely require such access for the purposes of this Agreement and to impose upon all such employees and professional advisers obligations of confidentiality equivalent to those contained in this Agreement;

(e) not to copy, reproduce, or part with possession of any of the Proprietary Information except as is strictly necessary and as is consistent with its obligations contained in this Agreement;

(f) except to the extent permitted by this Agreement, not to, in any way, form or manner whatsoever, make or permit any use of the Proprietary Information or any of the ideas, concepts, materials, or documents comprising the Proprietary Information, whether in connection with the Hospital or otherwise; and

(g) not to disclose the terms or conditions of this Agreement unless GMSgives its express prior written consent.

15.3 Each Party hereby undertakes with the other, on behalf of itself and its Connected Persons and each of its and its Connected Persons' directors, shareholders, employees and agents ("**<u>Receiving Party</u>**"), to keep all information and documents shared between the Parties and relating to the Hospital Business including but not limited to the Know-How and the Improvements, in the strictest confidence, as may be reasonably done and not to disclose or divulge any such information or documents to any third parties (other than to its related corporations or Connected Persons for the purposes of this Agreement) without the prior written consent of the disclosing Party ("**<u>Disclosing Party</u>**"), which consent may be withheld by the Disclosing Party without being obliged to give any reason therefor whatsoever, or in the sole discretion of the Disclosing Party, given on such terms and conditions as the Disclosing Party considers appropriate.

15.4 The restrictions in Clauses 15.1, 15.2 and 15.3 as to non-disclosure shall not apply:

(a) to any information or knowledge which was known to the ReceivingParty prior to disclosure pursuant to this Agreement or subsequently comes to the knowledge of the ReceivingParty from a source not under an obligation of confidentiality, or which may properly come into the public domain through no fault or breach of the Receiving Party;

(b) to any information whatsoever requested or required to be disclosed by Applicable Laws or pursuant to any legal process issued by any court or tribunal of competent jurisdiction or by any requirement of any competent governmental or regulatory authority or rules or regulations of any relevant regulatory, administrative or supervisory body (including without limitation, any relevant stock exchange or

securities council) whether in Myanmar, Singapore, Malaysia or elsewhere;

(c) to any disclosure required by any Recognised Stock Exchange or regulatory or governmental body to which the Receiving Party or any holding company, subsidiary or substantial shareholder of the Receiving Party is subject or submits;

(d) to any disclosure of any information whatsoever to the legal or other professional advisers (including auditors and bankers) of the Receiving Party for the purposes of this Agreement;

(e) if such disclosure or use is necessary for the performance of the ReceivingParty's obligations under this Agreement; or

(f) if such disclosure is for a specific purpose and is approved in writing by the Disclosing Party prior to any such disclosure being made.

PROVIDED THAT any such information disclosed pursuant to sub-Clauses (b), (c) shall be disclosed, to the extent permitted and practicable, only after prior consultation with each other as to the form, content and timing of such announcement or disclosure.

15.5 For the purpose of this Clause 15, any communication between the Parties and any information and other material supplied to or received by a Party which is either marked "confidential" or is by its nature intended to be confidential or exclusively for the knowledge of the recipient alone, and any information concerning the business, affairs or the financial arrangements of a Party and/or its related corporations coming to the knowledge of the other Party shall be considered confidential. In any case of uncertainty, a Party shall treat information and material as confidential until written clearance is obtained from the other Party.

15.6 Except as may otherwise be permitted elsewhere in this Agreement or as may be required by law or regulatory requirement or existing bona fide internal retention policies, the Companyshall return to GMS all documents, files, tapes, disks and any other things on or in which any Proprietary Information relating or belonging to GMS may be recorded or contained, upon the expiration or earlier termination of this Agreement provided that any such Proprietary Information held in any computer, word processing system, database or document retrieval system shall only be returned to the extent reasonably practicable. For the avoidance of doubt, the obligations of confidentiality contained in this Agreement shall continue to apply to any Proprietary Information retained by the Company pursuant to this Clause.

15.7 The Company shall not and shall procure with reasonable ability, that its Connected Persons and entities under its Control shall not, for the duration of this Agreement (except in the limited circumstances as provided in Clause 6.2) and for a period of two (2) years thereafter:

(a) either on their own account or for any person, firm, company, organisation or entity, directly or indirectly solicit or entice away or endeavour to solicit or entice away from GMS or of any of its Connected Persons, any Key Personnel seconded by GMS and/or its Connected Persons to the Company or manager, officer or employee employed in an executive position of GMS or any of its related corporations whether or not such person would commit any breach of his or her contract of employment by reason of leaving the service of the relevant company; or

(b) directly or indirectly employ, appoint or engage any Key Personnel seconded by GMS and/or its Connected Persons to the Company,manager, officer or employee employed in an executive position of GMS or any of its related corporations, who by reason of such employment is or is likely to be in possession of any Proprietary

Information of GMS and/or its Connected Personsor trade secrets relating to any member of GMS's and its Connected Persons' business or the business of the customers of any of them.

The placing of an advertisement of a post available to a member of the public generally and the recruitment of a person through an employment agency shall not constitute a breach of this Clause 15.7 provided that the Company or any of its Connected Persons and entities under its Control, does not encourage or advise such agency to approach any such Key Personnel seconded by GMS and/or its Connected Persons to the Company or director, manager, officer or employee employed in an executive position of GMS or any of its related corporations.

15.8 GMS shall not and shall procure with reasonable ability, that its Connected Persons and entities under its Control shall not, for the duration of this Agreement (except in the limited circumstances as provided in Clause 6.2) and for a period of two (2) years thereafter:

(a) either on their own account or for any person, firm, company, organisation or entity, directly or indirectly solicit or entice away or endeavour to solicit or entice away from the Company, any Key Personnel (with the exception of the Chief Executive Officer, Chief Financial Officer and the Director of Nursing) or manager, officer or employee employed in an executive position of theCompany whether or not such person would commit any breach of his or her contract of employment by reason of leaving the service of the Company; or

(b) directly or indirectly employ, appoint or engage any Key Personnel (with the exception of the Chief Executive Officer, Chief Financial Officer and the Director of Nursing), manager, officer or employee employed in an executive position of the Company, who by reason of such employment is or islikely to be in possession of any trade secrets relating to the Company or the business of itscustomers.

The placing of an advertisement of a post available to a member of the public generally and the recruitment of a person through an employment agency shall not constitute a breach of this Clause 15.8 provided that GMS or any of its Connected Persons and entities under its Control, does not encourage or advise such agency to approach any such Key Personnel or director, manager, officer or employee employed in an executive position of the Company.

15.9 Each and every obligation under this Clause 15 shall be treated as a separate obligation and shall be severally enforceable as such and in the event of any obligation or obligations being or becoming unenforceable in whole or in part such part or parts as are unenforceable shall be deleted from this Clause 15 and any such deletion shall not affect the enforceability of all such parts of this Clause 15 as remain not so deleted.

15.10 While the restrictions contained in this Clause 15 are considered by the Parties to be reasonable in all circumstances, it is recognised that restrictions of the nature in question may fail for technical reasons unforeseen and accordingly it is hereby agreed and declared that if any such restrictions shall be adjudged to be void as going beyond what is reasonable in all the circumstances for the protection of the interests of GMS and/or its related corporations or of the Company (as the case may be) but would be valid if part of the wording thereof were deleted or the periods thereof were reduced or the range of activities or area dealt with thereby were reduced in scope, the said restrictions shall apply with such modifications as may be necessary to make it valid and effective.

15.11 Each Party hereby agrees that any breach of this Clause 15 will cause irreparable injury to the other Party and that monetary damages will not provide an adequate remedy therefor. Each Party agrees that the other Party shall, in addition to monetary damages, be entitled to

temporary or permanent injunctive relief and such costs as may be awarded by the Arbitration Institution or any court of competent jurisdiction in respect of the enforcement of this Clause 15.11.

16. FORCE MAJEURE

16.1 Except as otherwise provided hereafter, each Party shall be entitled to an extension of the date of any performance required of such Party under this Agreement if the failure of the Party to duly perform was solely because of a Force Majeure Event (defined below); provided, however, that a Force Majeure Event shall not be recognised under this Agreement unless (a) the Party seeking to assert such an event gives notice of the existence of such event to the other Party, which notice shall explain in reasonable detail the nature of the Force Majeure Event, the obligations that have been affected by the Force Majeure Event and how such Force Majeure Event has impaired the performance of such obligations ("**Force Majeure Event Notice**"), and (b) such Force Majeure Event actually and materially impairs the due performance of such Party's obligations and continues for not less than fourteen (14) consecutive days. On receipt of the Force Majeure Event Notice by the other Party and the continuation of such Force Majeure Event for fourteen (14) consecutive days, the performance required of the notifying Party shall be suspended commencing on the date the Force Majeure Event Notice was given until such Force Majeure Event has ceased.

16.2 A "**Force Majeure Event**" shall be an event beyond the control of the Party relying on it pursuant to Clause 16.1, including an act of God, riot, war, severance, suspension or deterioration of diplomatic ties, civil unrest, flood, earthquake, energy or labour strikes, industrial disturbances, lockouts, trade or labour disputes (other than those caused by that Party), fire, accident, acts or restraints of governments or courts of law (but excluding failure caused by a Party's financial condition or negligence and excluding production hold-ups and shortage of raw materials), revocation or non-issuance of visas, consents and authorisations and includes any change or any development involving a change or prospective change in political condition in Myanmar or internationally (including any local, national or international outbreak or escalation of hostility, insurrection or armed conflict), or any significant event anywhere inMyanmar or internationally, or the occurrence of any combination of any changes or developments in such conditions or any other occurrence or event of any nature whatsoever which causes or results in or is likely to cause or result in it becoming inadvisable or inexpedient for the transactions contemplated herein to commence or be proceeded with.

16.3 Notwithstanding the provisions of this Clause 16, the Company shall under no circumstances be excused from paying the Services Fees in respect of Services that had already been renderedwhen due notwithstanding the occurrence of any Force Majeure Event.

17. REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS

17.1 Each of the Parties represents and warrants to the other Party that:

(a) it is a corporation duly organised and validly existing under the laws of its country of incorporation; it has not been and is not in the process of being wound up or liquidated; and it has full corporate power to carry on its business as contemplated by this Agreement;

(b) it has all requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated hereby, and this Agreement:

(i) has been duly executed and delivered to the other Party;

(ii) has been effectively authorised by all necessary action, corporate or otherwise; and

(iii) constitutes legal, valid and binding obligations of it;

(c) none of the execution, delivery, or performance of this Agreement, the consummation of any of the transactions contemplated hereby, or the fulfilment by it of each of the terms and conditions hereof shall violate or conflict with, result in a breach of any of the terms and conditions of, constitute a default (or any event which, with notice or lapse of time or both, would constitute a default) under, result in the termination of, accelerate the performance required by, result in the forfeiture of any of its right under, or create any lien, security interest, charge, or Encumbrance on any of its properties pursuant to, any material agreement, indenture, mortgage, bond, deed of trust, promissory note, lease, franchise, permit, licence, registration, qualification, or other obligation or instruments to which it is a party or by which it or any of its properties or assets is bound or affected, pursuant to the terms, conditions, and provisions of:

(i) any such agreement or instrument;

(ii) any law, rule or regulation applicable to it;

(iii) any order, writ, injunction, decree, or judgment of any court, governmental body, or arbitrator by which it is bound; or

(iv) its memorandum and articles of association, bye laws, deed of establishment and other constitutive, organisational and governing documents.

17.2 The Company recognises and acknowledges that the willingness of GMS to perform the Services for the Services Fees and otherwise upon the terms and conditions of this Agreement, are made on the basis of the Company's representations, warranties and undertakings in this Agreement, and without prejudice to any of its other representations, warranties or undertakings in this Agreement, the Company hereby represents, warrants and undertakes to GMS that:

(a) it is the owner and developer of, and has obtained and will use commercially reasonable endeavours to maintain and keep current, all rights, licences, consents, approvals, permissions, registrations and acknowledgements that are necessary for it to own, construct, develop, establish and operate, the Hospital and for the Parties' lawful performance of their respective obligations under this Agreement for the duration of this Agreement;

(b) the Hospital Business is, and will for the duration of this Agreement be, in the ownership of the Company and such Hospital Business shall for the duration of this Agreement be carried out by the Company, and shall not be (and shall not be permitted or suffered to be) sold, transferred, disposed of, assigned or novated to any third parties;

(c) it shall not interfere with the performance by GMS of the Services or any part thereof nor fail or refuse to co-operate with GMS in such a manner which shall materially affect the ability of GMS to perform its obligations under this Agreement nor inadequately staff or equip the Hospital to operate it as a hospital of an international standard;

(d) it shall reasonably maintain verifiable and separate books of accounts and financial records in respect of the Hospital Business separately from its other businesses (if any) and procure that such accounts and records are properly maintained so as to facilitate an audit thereof by the Auditors, and shall further ensure that the business and assets of the Hospital Business are not co-mingled with the assets and liabilities of its other businesses (if any) but that they are kept separate;

(e) the number of beds at the Hospital shall not materially deviate from a minimum of250; and

(f) the Hospital shall be operated predominantly as a multi-specialty hospital.

17.3 GMS warrants to the Company that it and/or its related corporations is/are the owner(s) of the Know-How and Proprietary Information. GMS warrants further thatto the best of GMS' knowledge,as at the date of this Agreement, no claims have been made by any third parties in Myanmar alleging that the Know-How and Proprietary Information infringes the right of any third party in Myanmar.

18. MISCELLANEOUS

18.1 As all Parties have participated in the drafting of this Agreement, the Parties agree that any applicable rule requiring the construction of this Agreement or any provision hereof against the Party drafting this Agreement shall not apply.

18.2 This Agreement shall be binding upon and inure for the benefit of the successors and permitted assigns of the Parties.

18.3 Where this Agreement provides that any particular transaction or matter requires the consent, approval or agreement of a Party:

(a) such consent, approval or agreement may be given subject to such terms and conditions as such Party may impose and any breach of such terms and conditions by any person subject thereto shall *ipso facto* be deemed to be a breach of the terms of this Agreement; and

(b) the consent, approval or agreement of the representative nominated by such Party to that transaction or matter (either in writing or given orally at a duly convened meeting of the Parties (provided the same is accurately minuted) shall be deemed to be the consent, approval or agreement of such Party for the purposes of this Agreement.

18.4 If the consent, approval or agreement of either Party is required under more than one provision of this Agreement for any one transaction or matter, then any consent, approval or agreement given in relation to that transaction or matter by such Party shall be deemed to cover all consents, approvals or agreement required for that transaction or matter unless otherwise specified by such Party.

18.5 The subject-matter of this Agreement is comprised of separately specified parts, and the illegality, invalidity or unenforceability of any provision of this Agreement under the law of any jurisdiction shall not affect its legality, validity or enforceability under the law of any other jurisdiction nor the legality, validity or enforceability of any other provision, and the illegal, invalid or unenforceable provision shall be deemed not to have been included in this Agreement.

18.6 Each and every communication under this Agreement shall be made by facsimile or otherwise in writing. Each communication or document to be delivered to either Party shall be sent to

that Party at the facsimile number, Email address or address and marked for the attention of the person (if any), from time to time designated by that Party for the purpose of this Agreement. The initial addresses and facsimile numbers of the Parties are:

GMS

Fax Number	:	+65 6734 8917
Email Address	:	
Address	:	111 Somerset Road, #15-01, TripleOne Somerset, Singapore 238164
Attention	:	

The Company

Fax Number	:	
Email Address	:	
Address	:	
Attention	:	

18.7 A demand, notice or other communication made or given by one Party to the other Party in accordance with this Clause 18 shall be effected and deemed to be duly served and received:

(a) if delivered by hand, at the time of delivery; or

(b) if posted by prepaid ordinary mail, at the expiration of five (5) Business Days after the envelope containing the same shall have been put into the post; or

(c) if sent by facsimile, upon the receipt by the sender of the transmission report indicating that the notice or communication has been sent in full to the recipient's facsimile machine, or such other similar medium of receipt; or

(d) if sent by courier, at the expiration of four (4) Business Days after the package containing the same shall have been received by the relevant courier company; or

(e) if sent by email, the earlier of:

(i) when the sender receives an automated message confirming delivery; or

(ii) four hours after the time sent (as recorded on the device from which the sender sent the email) unless the sender receives an automated message that the email has not been delivered,

provided that where such delivery or transmission occurs after 5 p.m. on a Business Day or on a day which is not a Business Day, service shall be deemed to occur at 9 a.m. on the next following Business Day.

In proving such service and receipt, it shall be sufficient to prove that delivery by hand was made or that the envelope containing such notice or document was properly addressed and

posted as a prepaid ordinary mail or that the facsimile confirmation note indicates the transmission was successful or that the package containing the same was properly addressed and delivered to the relevant courier company.

18.8 Each Party shall do and execute or procure to be done and executed all such further acts, deeds, things and documents as may be necessary to give effect to the terms of this Agreement, and (so far as it is able) provide such assistance as the other Party may reasonably request to give effect to the spirit and intent of this Agreement.

18.9 This Agreement and the documents referred to in it, constitute the entire agreement and understanding between the Parties relating to the subject matter of this Agreement and no Party has entered into this Agreement in reliance upon any representation, warranty or undertaking of the other Party which is not set out or referred to in this Agreement. Nothing in this Clause 18 shall however operate to limit or exclude liability for fraud.

18.10 Subject to Clause 18.11 below and save as may be specifically provided in this Agreement, no Party shall (nor shall it purport to) assign, transfer, charge or otherwise deal with all or any of its rights under this Agreement nor grant, declare or dispose of any right or interest in it without the prior written consent of the other Party. This Agreement shall be binding upon the successors, legal representatives or permitted assignees of the Parties hereto.

18.11 Notwithstanding anything to contrary, GMS shall upon notice in writing to the Company be entitled to appoint its related corporation to carry out any portion of the Services as it may deem necessary, or to novate this Agreement in favour of such related corporation and the Company shall do all things so as to give effect to the novation of this Agreement in favour of GMS' related corporation.

18.12 No variation of this Agreement (or of any of the documents referred to in this Agreement) shall be valid unless it is in writing and signed by or on behalf of each Party. The expression "variation" shall include any amendment, supplement, deletion or replacement however effected. Unless expressly agreed, no variation shall constitute a general waiver of any provisions of this Agreement, nor shall it affect any rights, obligations or liabilities under or pursuant to this Agreement which have already accrued up to the date of variation, and the rights and obligations of the Parties under or pursuant to this Agreement shall remain in full force and effect, except and only to the extent that they are so varied.

18.13 No failure on the part of a Party to exercise, and no delay on its part in exercising, any right or remedy under this Agreementwilloperate as a waiver thereof, nor will any single or partial exercise of any right or remedy preclude any other or further exercise thereof or the exercise of any other right or remedy. The rights provided in this Agreement are cumulative and not exclusive of any rights or remedies provided by law.

18.14 Either Party may release or compromise the liability hereunder of the other Party or grant to such other Party time or other indulgence without affecting the liability of such other Party under any other provision of this Agreement.

18.15 All covenants, undertakings and other obligations given or entered into by the Parties are given or entered into severally unless the context otherwise requires.

18.16 Nothing in this Agreement shall be deemed to constitute a partnership between the Parties nor constitute a Party the agent of the other Party for any purpose save that GMS shall be the agent of the Company for the purposes described in Clause 6.1.

18.17 Each Party shall bear its own legal and other professional costs and expenses in connection with the negotiation, preparation and implementation of this Agreement.The Company shall

bear the cost of all stamp duty, any notarial fees and all registration taxes and duties or their equivalents in Myanmar where such taxes, fees, and duties are payable as a result of the execution of this Agreement. The Company shall be responsible for arranging the payment of such taxes, fees, and duties, including fulfilling any administrative or reporting obligation imposed by Myanmar in question in connection with the payment of such taxes, fees and duties. The Company shall indemnify the GMS against any losses suffered by the GMS as a result of the Company failing to comply with its obligations under this Clause 18.17.

18.18 In entering into this Agreement, the Parties recognise that it is impractical to make provision for every contingency that may arise in the course of the observance or performance thereof. Accordingly, the Parties hereby declare it to be a cardinal principle of this Agreement and it to be their common intention that this Agreement shall operate between them with fairness and without detriment to the interests of either of them; and if in the course of the performance of this Agreement, unfairness to a Party is disclosed or anticipated, then the Parties shall use their best endeavours to agree upon such action as may be necessary and equitable to remove the cause or causes of the same.

18.19 Any date, time or period mentioned in any provision of this Agreement may be extended by mutual agreement between the Parties but as regards any time, date or period originally fixed and not extended or any time, date or period so extended as aforesaid, time shall be of the essence.

18.20 This Agreement may be signed in any number of counterparts, all of which taken together shall constitute one and the same instrument. Either Party may enter into this Agreement by signing any such counterpart and each counterpart shall be as valid and effectual as if executed as an original.

18.21 This Agreement is not intended to create any rights to enforce any term of this Agreement in favour of any person or entity who is not a party to this Agreement, and no such rights are created hereunder, except as contemplated in this Agreement (including without limitation, in Clauses 9, 10, 14 and 15). For the avoidance of doubt, GMS' related corporation appointed by GMS pursuant to Clause 18.11 to carry the Services (or any portion thereof) shall have the right to enforce this Agreement as if it were a party hereto.This does not affect any right or remedy of a third party which exists or is available apart from this Agreement.

19. GOVERNING LAW

19.1 This Agreement shall be governed by, and construed in accordance with, the laws of Singapore.

20 DISPUTE RESOLUTION

20.1 In case any dispute or difference shall arise between the Parties as to the construction of this Agreement or as to any matter of whatsoever nature arising hereunder or in connection therewith, including any question regarding its existence, validity or termination, such dispute or difference shall be submitted to arbitration at Singapore International Arbitration Centre("**Arbitration Institution**") in accordance with the arbitration rules of the Arbitration Institution then in force. The seat of the arbitration shall be Singaporeand the arbitration shall be conducted in English. The award of the arbitration tribunal shall be final and binding on the Parties. The arbitration tribunal shall consist of one (1) arbitrator to be appointed by the Parties or, failing agreement within 14 days after a Party has given to the other Party a written request to concur in the appointment of an arbitrator, a single arbitrator to be appointed on the request of either Party by the President of the Court of Arbitration of the Arbitration Institution

for the time being.

20.2 The arbitral award made and granted by the arbitrator shall be final, binding and incontestable and may be used as a basis for judgement thereon in Singapore, Myanmar or elsewhere.

20.3 Neither of the Parties shall be entitled to commence or maintain any action in a court of law upon any matter in dispute arising from or in relation to this Agreement except for the enforcement of an arbitral award granted pursuant to this Clause 20, and save and except in connection with interim relief, pursuant to commencement of arbitration proceedings.

20.4 During the period of submission to arbitration and thereafter until the granting of the arbitral award, the Parties shall, except in the event of termination, continue to perform their obligation under and the terms and conditions of this Agreement that are not in dispute, to the extent possible, without prejudice to a final adjustment in accordance with the said award.

20.5 Notwithstanding anything to the contrary, either Party may before commencement of, during or after the termination of the proceedings referred to in Clause 20.1, apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction, or other interim or conservatory relief, as necessary. Such application shall not be deemed to be an infringement or a waiver of the arbitration agreement herein and shall not affect the relevant powers reserved to the arbitral tribunal.

APPENDIX 1

SCOPE OF SERVICES

1. GENERAL OBLIGATIONS

GMS shall, as from the Opening Date and during the Term and any Renewed Term:

(a) assist to supervise, manage and operate the Hospital in a safe, efficient and proper and prudent manner;

(b) consult with the Company and keep it advised in a timely manner as to all significant matters relating to the Hospital; and

(c) subject to the Company's approval, provide advice in determining all operating policies affecting the appearance, maintenance, standards of operation, equipment required, quality of service and any other matter affecting the Hospital or the operation thereof.

2. GENERAL SERVICES

GMS shall, as from the Opening Date and during the Term and any Renewed Term:

(a) assist in reviewing the manpower capabilities and needs (including medical and other professional staff) of the Hospital from time to time, make recommendations to the Company in respect thereof,conduct internal continuous improvement trainings, where GMS deems appropriate, review the performance of, and recommend to the Company the discharge or replacement of any of the employees (including any Hospital Staff) of the Company;

(b) provide advice in respect of the management of the day to day operations of the Hospital in the following areas on a continuing basis:

(i) accident and emergency services;

(ii) biomedical engineering equipment consultancy;

(iii) clinical laboratory services;

(iv) central sterile services department;

(v) dietary services;

(vi) environmental requirements;

(vii) housekeeping;

(viii) human resources services;

(ix) imaging services;

(x) intensive care wards;

(xi) in-patient wards;

(xii) materials management;

(xiii) medical advisory board establishment;

(xiv) medical records;

(xv) mortuary;

(xvi) nursing services;

(xvii) operating theatres;

(xviii) pharmacy operations;

(xix) physiotherapy;

(xx) out-patient departments;

(xxi) medical waste management;

(xxii) hospital maintenance consultancy, including mechanical and electrical equipment maintenance consultancy, IT systems and facilities (provided for the avoidance of doubt that GMS shall be entitled, at the Company's cost and expense, to outsource this to an external consultant with the prior approval of the Company);

(xxiii) medical insurance claims management;

(xxiv) procurement of medical equipment and surgical instruments;

(xxv) marketing and public relations; and

(xxvi) security (provided for the avoidance of doubt that GMS shall be entitled, at the Company's cost and expense, to outsource this to an external consultant with the prior approval of the Company).

(c) recommend to the Company for the implementation of the appropriate fees and rates chargeable to in-patients, out-patients and any other persons to whom services are rendered by the Hospital and assist in drawing up a price schedule in respect of the fees and charges payable in respect of the services which may be provided by the Hospital, and up-date such schedule from time to time;

(d) advise and make recommendations on the Hospital's requirements for medical supplies and equipment;

(e) assist in co-ordinating the Company's purchases so as to minimize the cost of the Company's purchasing, without detracting from the quality of patient care acceptable to the Company, acting reasonably;

(f) assist in developing appropriate administrative policies and procedures of the Hospital;

(g) advise the Company in setting up a maintenance system to maintain and keep the

Hospital in good repair; and

(h) advise the Company on the granting of leases and tenancies for the Hospital units.

GMSshall perform such other services on such terms as may be mutually agreed between the Company and GMS, from time to time, by entering into a supplemental agreement for the same.

APPENDIX 2

SERVICES FEES

1. The Services Fees payable in respect of each Reference Period shall be:

   (a) six per. cent. (6**%**)of EBITDA ("**EBITDA Fees**");

   (b) halfa per. cent. (0.5%) of Revenue ("**Revenue Fees A**"); and

   (c) one per. cent (1%) of Revenue ("**Revenue Fees B**", and together with the Revenue Fees A, the "**Revenue Fees**"),

   commencing on the Opening Date and ending on the expiry of the Term or the last RenewedTerm, or the termination of this Agreement, whichever is the earlier.

2. For the avoidance of doubt, in the event that EBITDA is a negative, then the EBITDA Fees shall be zero (0).

3. For the convenience of the Parties, the first Reference Period shall commence on the Opening Date and end on the Balance Sheet Date of the same financial year and the last Reference Period shall commence on the first day of the financial year to which it relates and end on the date of termination of this Agreement or the expiration of the Term or the last Renewed Term, as the case may be.

4. The Services Feesshall:

   (a) be calculated on an annual basis; and

   (b) in respect of each Reference Period of this Appendix 2, be paid by the Company on an interim basis in arrears Quarterly within ten (10) Business Days from the end of each Quarter based on the Quarterly Management Accounts of the Company,

   provided that for the purpose of calculating the Quarterly Services Fees, the Quarterly EBITDA and the Quarterly Revenue for each applicable Quarter shall be annualized (i.e. multiplied by a factor of four (4)) first and

   (i) the percentage set out in Paragraph 1(a) of this Appendix 2 will apply to derive the annualized EBITDA Fees and the Quarterly EBITDA Fees to be paid shall be twenty-five per. cent.(25%) of the annualized EBITDA Fees; and

   (ii) the percentage set out in Paragraph 1(b) and 1(c) of this Appendix 2 will apply to derive the annualized Revenue Fees and the Quarterly Revenue Fees to be paid shallbe twenty-five per. cent. (25%) of the annualized Revenue Fees.

5. Where payment of the EBITDA Fees in respect of the final Quarter for any financial year would result in the Company's profit before tax based on the Company's management accounts ("**PBT**") for such financial year being negative, the Company shall pay the maximum portion of the EBITDA Fees for such final Quarter in order that the PBT after such payment does not become negative. Where the Quarterly payments of the EBIDTA Fees by the Company for the first three Quarters of any financial year in accordance with Paragraph 4 of this Appendix 2 has resulted in the PBT of such financial year becoming negative, the excess amount paid shall be carried over and deducted from the calculation of the PBT for the following financial year.

6. All unpaid EBITDA Fees shall continue to accrue so long as they are unpaid and shall be paid out in subsequent financial years to the extent where payment of such accrued EBITDA Fees (together with the EBITDA Fees for those subsequent financial years) will not result in the PBT of any financial year being negative (after taking into account the carrying over and deduction of any excess amount paid as described in Paragraph 5 of this Appendix 2).

7. Notwithstanding Paragraph 4, the Company shall not pay any portion of the Revenue Fees B until the aggregate value of the Revenue Fees B accruing from the Opening Date is in excess of Singapore Dollars TwoMillion (S$2,000,000), at which time:

   (a) the amount of all Revenue Fees Baccrued in excess of S$2,000,000 shall be paid at the end of the relevant Quarter; and

   (b) all Revenue Fees payable thereafter shall be paid in accordance with Paragraph 4.

8. In connection with the calculation of the Services Fees, the Company shall procure that the Audited Accounts are prepared and approved within five (5) months from the end of each Reference Period.

9. The Company shall procure that the Auditors audit the EBITDA and the Revenue, for the purpose of settling the annual Services Fees, in accordance with the definition in this Agreement. The Parties agree that the EBITDA or the Revenue accumulated from any previous financial year(s) (whether positive or negative) shall not be brought forward into the computation, and the EBITDA and the Revenueshall be computed by the Auditors solely and exclusively on a current financial year basis.Within ten (10)Business Days of the finalization of the EBITDA and the Revenue, the Parties will settle the Services Fees. Any shortfall will be paid by the Company to GMS within five (5)Business Days thereafter and any overpaid amount will be deducted from subsequent payments to GMSor, and only in the case where there are no subsequent payments to be made to GMS, reimbursed to the Company.

10. For the purposes of the first and the last Reference Period or in the event of the expiration or early termination of this Agreement, if such Reference Period is of less than a full financial year or if such event occurs or ends other than at the end of the Company's financial year, the Company shall (at its sole cost and expense) commission an interim audit for the period ending on the end of the month on which such Reference Period or the effective date of expiry or termination of this Agreement falls, if there is dispute with respect to the relevant Management Accounts for such month or period. Such audited results shall constitute the basis for settlement of the Services Fees due to GMS(including the reimbursement of any excess amount due to the Company) in such Reference Period in respect of which the Services Fees are payable.

For the avoidance of doubt, the Services Fees do not include (a) the costs of the Contractors or the Hospital Staff which, upon appointment, will be paid by the Company, nor (b) the Reimbursable Expenses, which are separately and additionally payable by the Company.

APPENDIX 3

FORM OF LICENCE AGREEMENT

APPENDIX 4

FORM OF CONSULTANCY SERVICES AGREEMENT

IN WITNESS WHEREOF the Parties have executed this on the date set out at the beginning of this Agreement.

SIGNED by)
[•])
for and on behalf of)
GLENEAGLES MANAGEMENT SERVICES)
PTE LTD)
in the presence of:)

____
Witness's signature
Name:
Address:

SIGNED by
[•])
for and on behalf of)
ANDAMAN ALLIANCE HEALTHCARE)
LIMITED)
in the presence of:)
)

____
Witness's signature
Name:
Address:

A&G Comments: 18 December 2015

Dated this day of

BETWEEN

GLENEAGLES MANAGEMENT SERVICES PTE LTD
as GMS

AND

ANDAMAN ALLIANCE HEALTHCARE LIMITED
as the Company

CONSULTANCY SERVICES AGREEMENT

TABLE OF CONTENTS

CLAUSE	HEADING	PAGE
1.	DEFINITIONS AND INTERPRETATION	3
2.	THE SERVICES	8
3.	SERVICES NOT WITHIN SCOPE OF WORK OF GMS	8
4.	SERVICES FEES AND OTHER EXPENSES	9
5.	PAYMENT OF SERVICES FEES AND OTHER EXPENSES	11
6.	PERSONNEL	12
7.	OBLIGATIONS OF GMS	12
8.	OBLIGATIONS OF THE COMPANY	12
9.	COVENANTS AND AGREEMENTS RELATING TO THE KNOW-HOW	13
10.	IMPROVEMENTS	15
11.	INSURANCE	15~~16~~
12.	ACCESS	16
13.	DURATION AND TERMINATION	16~~17~~
14.	DISCLAIMERS AND INDEMNITIES	19
15.	CONFIDENTIALITY AND RESTRICTIVE COVENANTS	21
16.	FORCE MAJEURE	25
17.	REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS	25
18.	MISCELLANEOUS	27~~26~~
19.	GOVERNING LAW	30
APPENDIX 1	SCOPE OF SERVICES	32~~31~~
APPENDIX 2	SERVICES FEES	34~~33~~
APPENDIX 3	FORM OF HOSPITAL MANAGEMENT AGREEMENT	35~~35~~

THIS AGREEMENT is made on 2015

BETWEEN

(1) **GLENEAGLES MANAGEMENT SERVICES PTE LTD** (Company Registration Number 198904110D), a company incorporated in Singapore and having its registered office at 111 Somerset Road, #15-01, TripleOne Somerset, Singapore 238164 ("**GMS**")

AND

(2) **ANDAMAN ALLIANCE HEALTHCARE LIMITED** (Company Registration Number **[•]**) a company incorporated in Myanmar and having its registered office at 33 Pyay Road, 6 ½ Miles, Hlaing Township, Yangon, Myanmar ("**Company**")

WHEREAS:

(A) The Company is a joint venture between AMMK Medicare Company, Ltd, Global Star Company, Ltd, Macondray Holdings Pte. Ltd. and GMS's related corporation, Parkway Healthcare Indo-China Pte. Ltd., formed pursuant to a joint venture agreement dated [•] ("**Joint Venture Agreement**").

(B) The Company intends to develop an international hospital in Yangon, Myanmar. The Company is the owner of, and has obtained (or will be able to obtain in time for the Parties' lawful performance of their respective obligations under this Agreement), all rights, permits and licences to own, Construct and operate, the Hospital (defined below) and the Hospital Business (defined below).

(C) GMS, a wholly-owned subsidiary of Parkway Holdings Ltd, is in the business of providing hospital consultancy and management services.

(D) The Company desires to engage GMS, and GMS has agreed to be engaged, to provide the Services (as defined below) to the Company in respect of the Hospital in the manner and on the terms and conditions set out in this Agreement.

IT IS AGREED as follows:

1. DEFINITIONS AND INTERPRETATION

1.1 In this Agreement and in the Appendices, in addition to the words defined above, and unless the context otherwise requires, the following words shall have the meaning stated hereunder:

"**Accounts**" shall include where relevant, the directors' reports, relevant balance sheets and profit and loss accounts together with all documents which are or would be required by law to be annexed to the accounts of the Company, and prepared in accordance with International Financial Reporting Standards and Legal Requirements;

"**Applicable Laws**" means all applicable laws, statutes, rules, regulations, ordinances, requirements, directions, guidelines, announcements or other binding actions or requirements of any government or department, agency or instrumentality of any government, departments, bodies, regulatory authorities, government authorities, any court or arbitral tribunal; and the governing body of any securities exchange or other securities self-regulatory body;

"**Arbitration Institution**" has the meaning ascribed to it in Clause 20.1;

"**Audited Accounts**" means the audited Accounts of the Company in respect of the Hospital Business for the financial year (or part thereof, as the case may be) ended the Balance Sheet Date, as audited by the Auditors;

"**Auditors**" mean the auditors for the time being of the Company;

"**Balance Sheet Date**" means 31 March of each financial year;

"**Business Day**" means a day (other than a Saturday, Sunday or public holiday) on which banks are open for business in Myanmar and Singapore;

“**Capital Expenditure**” means expenditure for or on account of the Construction of the Hospital considered by the Auditors to be of a capital nature, medical and non-medical equipment, surgical instrumentations, fixtures and fittings, and furnishings;

"**Connected Persons**", in relation to a corporation, means its respective shareholders, directors, officers or employees;

“**Contractors**” means all contractors, sub-contractors, suppliers, service providers and other consultants employed by the Company in connection with the Construction of the Hospital;

"**Control**" means, as to any person, the power and/or authority (whether exercised or not) to manage, directly or indirectly, the operation of the business of or control the business and affairs of or control the composition of the board of directors or management of such person, whether through the ownership of voting securities, by contract or otherwise (which authority shall conclusively be presumed to exist upon possession of beneficial ownership or power to direct the vote of more than fifty per cent. (50%) of the votes entitled to be cast), or in the case of a trust, if such person is a trustee or the principal beneficiary under such a trust, or is a manager of the funds of the trust, and "**Controlled**" and "**Controls**" shall have the corresponding meanings;

“**Construction**” shall include all construction, development, establishment, furnishing and equipping activities and all other activities undertaken in preparation of the opening of the Hospital to the general public for the provision of medical services, and “**Construct**” shall be construed accordingly;

"**defaulting Party**" has the meaning ascribed to it in Clause 13.2;

"**Disclosing Party**" has the meaning ascribed to it in Clause 15.3;

"**Encumbrance**" means any mortgage, assignment of receivables, debenture, lien, charge, pledge, title retention, right to acquire, security interest, options, rights of first refusal and any other encumbrance or condition whatsoever, and "**Encumbrances**" shall be construed accordingly;

"**Force Majeure Event**" has the meaning ascribed to it in Clause 16.2;

"**Force Majeure Event Notice**" has the meaning ascribed to it in Clause 16.1;

"**Hospital**" is a multi-specialty hospital located at the Hospital Land;

"**Hospital Business**" means such of the business and assets of the Company as relate to the Hospital;

"**Hospital Land**" means the plot of land located in the Yangon CBD at the corner of Pyay Road and Bo Gyoke Road at Plot number 10, Block number 20F, Lanmadaw Township which premises are the subject of the Lease Agreement;

"Hospital Management Agreement" means the hospital management agreement, executed or to be executed between the Parties contemporaneously with the execution of this Agreement, in substantially the form set out in Appendix 3, in relation to the provision of certain hospital management services to the Company in connection with the operation of the Hospital Business;

"**Hospital Staff**" means all individuals employed at or for the direct benefit of, or performing services in connection with the Hospital including the Key Personnel;

"**Improvements**" means all improvements and modifications or adaptations, to any part of the Know-How which are required to adapt the Know-How to suit the local circumstances in Myanmar or to comply with any controls or requirements imposed by any governmental or regulatory body in Myanmar;

"**Joint Venture Agreement**" has the meaning ascribed to it in Recital (A);

"**Key Personnel**" means the Chief Executive Officer, Chief Operating Officer, Chief Medical Officer, Chief Financial Officer and the Director of Nursing of the Hospital Business;

"**Know-How**" means any and all trade secrets, proprietary information, standard operating procedures, policies, protocols, manuals, expertise, and know-how relating to or in connection with the management, finance, service standards, promotion and methods, techniques or systems of operation to be employed in connection with the Construction of hospitals and/or the Hospital developed by GMS and/or its related corporations which are confidential to GMS and/or its related corporations and do not constitute information that is in the public domain or form part of generally or widely accepted/known practices and information within the medical, pharmaceutical or healthcare industry and any other industrial, intellectual property or protected right similar to the foregoing (whether registered, registrable or unregistered) in any country and in any form, media or technology, all as has been developed by GMS and/or its related corporations;

"**Last Quarter**" shall have the meaning ascribed to it in paragraph 3 of Appendix 2;

"**Legal Requirements**" means all laws, statutes, ordinances, orders, rules, regulations, permits, licences, authorisations, directions and requirements of all governments and governmental authorities which, now or hereafter, may be applicable to GMS or the Company, or the Hospital and the operation thereof, including without limitation all employment and labour, medical, zoning, building, life or safety, environmental and hazardous waste management, exchange control and other Applicable Laws, ordinances, rules and regulations of all governmental bodies and agencies and self-regulatory entities having jurisdiction over GMS, the Company, the Hospital or the Hospital Business;

"**Materials**" has the meaning ascribed to it in Clause 13.5(b);

"**Milestone**" shall have the meaning ascribed to it in paragraph 1 of Appendix 2;

"**Myanmar**" means the Republic of the Union of Myanmar;

"**Myanmar Kyat**" and "**MMK**" means the lawful currency of Myanmar;

"**non-defaulting Party**" has the meaning ascribed to it in Clause 13.2;

"**Opening Date**" means the date of the soft opening of the Hospital whereby the Hospital is open to the general public for the provision of medical services;

"**Parkway Group**" means Parkway Healthcare Indo-China Pte. Ltd. and its related corporations;

"**Proprietary Information**" has the meaning ascribed to it in Clause 15.1;

"**Quarter**" means a period of three calendar months (or part thereof, as the case may be) within a Reference Period (or part thereof, as the case may be) ending on 30 June, 30 September, 31 December and 31 March respectively, and "**Quarterly**" shall be construed accordingly;

"**Receiving Party**" has the meaning ascribed to it in Clause 15.3;

"**Recognised Stock Exchange**" means any recognised stock exchange under Singapore law, Malaysian law, or under the laws of Myanmar, or such other stock exchange as may be agreed between the Parties;

"**Reference Period**" means any financial year (or part thereof, as the case may be) after the Opening Date;

"**Reference Rate**" means the aggregate of (a) the average of the Singapore Interbank Offered Rate quoted by the three largest local banks in Singapore for six-month deposit in United States Dollars from time to time prevailing; and (b) three per. cent. (3%);

"**Reimbursable Expenses**" has the meaning ascribed to it in Clause 4.2;

"**Revenue**" means all income of or relating to the Hospital (on an accrual basis) after netting off reserves for bad debts, uncollectible accounts and discounts and shall include: income of every kind received from the operation of the Hospital and all of its facilities or arising from the Hospital, including without limitation, all income from patients, out-patients, including resident doctors fees, service charges collected from visiting physicians or others rendering services to the Hospital's patients or others, rental of consultation rooms in the Hospital, income from car-parks and retail outlets and other non-patient related income attributable to the Hospital generated within the premises of the Hospital, computed in accordance with generally accepted accounting principles in Myanmar;

"**Services**" means the consultancy services described in Appendix 1 (or as may be mutually amended by the Parties in writing), which are to be provided by GMS in accordance with the terms of this Agreement;

"**Services Fees**" means the consultancy services fees described in Appendix 2 (or as may be mutually amended by the Parties in writing) which are payable by the Company to GMS in respect of the Services;

"**Singapore Dollar**" and "**S$**" shall mean the lawful currency of the Republic of Singapore;

"**Taxation Authorities**" means the relevant governmental or other authorities competent and authorised to impose Taxes whether in Myanmar or elsewhere;

"**Taxes**" or "**Taxation**" means all forms of taxation of Myanmar including all state or local taxation, past, present and deferred including without limitation, income (including net and gross income) tax, business tax, corporate tax, service tax, commercial tax, VAT (i.e., value-

added tax), withholding tax, sales tax, goods, occupation, real and personal property, social security, use, *ad valorem*, franchise, profits, licence, payroll, employment, excise, severance, premium or windfall profit taxes, estate duty, stamp duty, customs and other import or export duties, or charges of any kind whatsoever, estimated and other taxes, together with any interest and levies and all penalties, charges, costs and additions to tax, payable by or due from the Company or GMS (as the case may be), or any additional amounts imposed by any government, governmental agency, statutory body or any revenue authority in Myanmar or otherwise, upon the Company or GMS (as the case may be); and

"**Term**" means the period commencing on the date of this Agreement and ending on the earlier of (a) the day immediately prior to the Opening Date; and (b) day immediately prior to the day falling forty-eight (48) months after the date of this Agreement or such later date as may be agreed between the Parties.

"**United States Dollar**" and "**US$**" shall mean the lawful currency of the United States of America.

1.2 Any reference in this Agreement or the Appendices to a statutory provision shall include that provision and any regulations made in pursuance thereof as from time to time modified or re-enacted, whether before or after the date of this Agreement.

1.3 In this Agreement:

(a) The headings in this Agreement are inserted for convenience only and shall not affect the construction of this Agreement.

(b) Any reference in this Agreement to "**this Agreement**" includes all amendments, additions, and variations hereto agreed between the Parties in writing.

(c) The expressions "**Party**" or "**the Parties**" with their grammatical variations and cognate expressions shall mean the parties to this Agreement, whether original or pursuant to the novation of this Agreement.

(d) Unless the context otherwise requires, words importing the singular shall include the plural and *vice versa* and words importing a specific gender shall include the other genders (male, female or neuter), and "**person**" shall include an individual, corporation, company, partnership, firm, trustee, trust, executor, administrator or other legal personal representative, unincorporated association, joint venture, syndicate or other business enterprise, any governmental, administrative or regulatory authority or agency (notwithstanding that "**person**" may be sometimes used herein in conjunction with some of such words), and their respective successors, legal personal representatives and permitted assigns, as the case may be, and pronouns shall have a similarly extended meaning.

(e) The term "**financial year**", for the purposes of this Agreement, means the period commencing on 1 April and ended or ending 31 March in each year (or part thereof, as the case may be).

(f) The word "**subsidiary**", in relation to a corporation, means a corporation (a) which the first-mentioned corporation controls the composition of the board of directors of, or controls more than half of the voting power of, or in which the first-mentioned corporation holds more than half of the issued share capital of (excluding any part thereof which consists of preference shares and treasury shares, where applicable), or (b) which is a subsidiary of the first-mentioned corporation's subsidiary; and a "**related corporation**" of a corporation shall mean a corporation which is (a) the

holding company of the first-mentioned corporation; (b) a subsidiary of the first-mentioned corporation; or (c) a subsidiary of the holding company of the first-mentioned corporation.

(g) A reference to a "**month**" is a reference to a period starting on one day in a calendar month and ending on the day immediately preceding the numerically corresponding day in the next succeeding calendar month.

(h) The words "**written**" and "**in writing**" include any means of visible reproduction.

(i) References to "**Recitals**", "**Clauses**" and "**Appendices**" are to the recitals, clauses of, and the appendices to, this Agreement (unless the context otherwise requires).

(j) Any reference to a "**paragraph**" is a reference to a paragraph of the Clause or Appendix in which such reference appears.

1.3 The Appendices form part of this Agreement and have the same force and effect as if expressly set out in the body of this Agreement.

1.4 Any thing or obligation to be done under this Agreement which is required or falls to be done on a stipulated day, shall be done on the immediately preceding Business Day, if the day upon which that thing or obligation is required or falls to be done falls on a day which is not a Business Day.

2. THE SERVICES

2.1 The Company hereby exclusively authorises, engages and appoints GMS to provide to the Company and the Hospital (where applicable) the Services as described in Appendix 1 to assist the Company with the Construction of the Hospital for the duration of the Term.

2.2 GMS hereby accepts such appointment subject to and upon the terms and conditions contained in this Agreement.

2.3 For the avoidance of doubt, the Company agrees and acknowledges that the Company shall appoint GMS as the sole and exclusive provider of Services for the duration of this Agreement.

2.4 For the avoidance of doubt, the Company agrees and acknowledges that GMS's appointment under this Agreement is not exclusive to the Company and GMS shall be at liberty to provide pre-start up or pre-opening services and other services similar or identical to the Services and other services of all kinds for other bodies corporate, trusts, joint ventures, partnerships or associations, state-owned enterprises, government bodies, departments or agencies whether engaged in businesses of a similar or different nature to that of the Company, and whether in Myanmar or otherwise.

3. SERVICES NOT WITHIN SCOPE OF WORK OF GMS

For the avoidance of doubt, the scope of the Services as set out in Appendix 1 is intended to be exhaustive and all other services not expressly set out therein**,** including but not limited to that which is set out below, shall not form part of the Services and are not included in the scope of work of GMS under this Agreement:

(a) financial (except for the services under Appendix 1), tax, audit and legal services;

(b) project management for the Construction of the Hospital;

(c) application for the approvals, permits, licences and consents in accordance with the Legal Requirements required or necessary in relation to or in connection with any aspect of the Hospital or the provision of the Services in Myanmar;

(d) ensuring that the Hospital or any component or aspect thereof meet the Legal Requirements;

(e) assisting in the acquisition of equipment other than medical equipment (except for the services under Appendix 1);

(f) equipment (either medical or otherwise) maintenance;

(g) technical requirements and drawings on civil, electrical, electronic, mechanical, sanitary or structural matters; and

(h) any other specialist consultancy services.

4. SERVICES FEES AND OTHER EXPENSES

4.1 In consideration of the Services to be provided by GMS under the terms of this Agreement, the Company shall pay to GMS, or such other person as GMS may in writing direct, the Services Fees in the amounts and manner and at the times set out in Appendix 2.

4.2 In addition to the Services Fees payable to GMS under this Agreement, the Company agrees and undertakes to arrange and pay for and incur directly, and failing which, to reimburse GMS in full, for all costs and expenses reasonably incurred by GMS in respect of the Services (the "**Reimbursable Expenses**"). GMS shall not incur any particular item of Reimbursable Expenses directly unless the Company fails or is unable to incur it directly or in a timely manner. The Company hereby undertakes to reimburse GMS for any such payment made by GMS, PROVIDED THAT any item of Reimbursable Expense exceeding US$250,000 or where the aggregate amount of Reimbursable Expenses incurred during a Quarter has exceeded US$250,000, subsequent items of Reimbursable Expense to be incurred during the Quarter is made with the Company's prior written approval; and GMS submits all such claims with supporting invoices or receipts or other evidence of actual payment of such expenses that the Company may reasonably require. The Company shall:

(a) where the Company has extended prior written approval for any Reimbursable Expense, advance to GMS an amount equal to the Reimbursable Expense so approved; and,

(b) in all other situations, promptly reimburse GMS for all claims for Reimbursable Expenses within thirty (30) days of receipt of such claims from GMS or on the fifteenth (15^{th}) day of the following month, whichever is the earlier.

The Reimbursable Expenses shall include, but not be limited to the following:

(i) travel, local transportation, accommodation, food, laundry and out-of-pocket costs and expenses for all the employees of GMS or GMS's related corporations who are required by GMS to travel to Myanmar from Singapore or elsewhere as additional resources for assisting GMS in performing any part of the Services and/or its duties and responsibilities under this Agreement; and

(ii) costs and professional fees of any adviser, consultant or other professional consulted or instructed by GMS upon instructions from the Company in connection with matters not within the scope of the Services to be performed by GMS under this Agreement.

For the purposes of this provision, the guidelines for air travel, accommodation, meals, transportation, laundry and other out-of-pocket costs and expenses of assigned employees of GMS shall be based on GMS's internal policies. For the avoidance of doubt, it is clarified that the Reimbursable Expenses shall not include the salaries of the employees of GMS or its related corporations whether directly or indirectly in connection with the Services provided by GMS under this Agreement.

4.3 For the avoidance of doubt, GMS shall not be required to perform any services outside the scope of the Services and, if required to do so by the Company and agreed to by GMS, shall be entitled to require the payment of additional fees to be agreed between the Parties in connection therewith, failing which GMS shall not be required to perform any such out-of-scope services.

4.4 In addition to all other remedies that GMS may have at law and in equity, the Company shall pay to GMS:

(a) in the event of the termination of this Agreement for any reason, all accrued Services Fees due and owing to GMS based on the completion of the relevant Milestone(s); and

(b) in the event of termination of this Agreement by GMS under Clause 13.2 where the Company is the defaulting Party or under Clause 13.3 (except for Clauses 13.3(d), 13.3(h) and 13.3(j)(i)), where any Services have been rendered toward the completion of the subsequent Milestone, the Services Fees in respect of such subsequent Milestone shall be paid as follows:

(i) where more than 50% of the subsequent Milestone has been achieved, the Company shall pay all Services Fees in respect of such subsequent Milestone to GMS; and

(ii) where 50% or less of the subsequent Milestone has been achieved, the Company shall pay, on a *pro rata* basis, the Services Fees in respect of such proportion of the subsequent Milestone that had been achieved to GMS.

For the avoidance of doubt, no payments shall be made to GMS under Clause 4.4.(b)(ii) in the event of termination of this Agreement by the Company under Clause 13.2 where GMS is the defaulting Party or where this Agreement is terminated under Clauses 13.3(d); 13.313.3(h)(h) or 13.3(j)(i) .

Formatted: Font: (Default) Arial, 10 pt, English (Singapore)

Formatted: Font: (Default) Arial, 10 pt, English (Singapore)

4.5 In addition to the foregoing, all:

(a) operating expenses incurred in connection with the day to day management of Construction of the Hospital incurred or made by GMS in relation to the Hospital in performing its duties under this Agreement; and

(b) Capital Expenditure,

as provided herein or otherwise deemed to be necessary by GMS (acting reasonably) for the Construction of the Hospital, shall be borne exclusively by the Company. The Parties agree that GMS shall not, under any circumstances, be required to advance any of its funds or procure any funding for the Construction of the Hospital, or to incur any liability for its own

account in connection therewith. For the avoidance of doubt, all working capital shall be supplied by the Company to GMS.

5. PAYMENT OF SERVICES FEES AND OTHER EXPENSES

5.1 All Services Fees, costs and expenses and other amounts to be paid to GMS under this Agreement (including any Reimbursable Expenses and any amounts due to GMS pursuant to Clause 4.4) are, unless otherwise stated, expressed in Myanmar Kyat but payment shall be made in full in Singapore Dollars or in such other currency as GMS may from time to time notify the Company in writing in accordance with Clauses 4 and 5 and Appendix 2 unless otherwise agreed to or instructed by GMS, in the form of bank draft, cashier's order or telegraphic transfer payable to the order of GMS (as may be designated from time to time in writing by GMS) no later than the relevant due date for payment. All Services Fees, costs and expenses and other amounts to be paid to GMS under this Agreement (including any Reimbursable Expenses and any amounts due to GMS pursuant to Clause 4.4) that would otherwise be due on a day other than a Business Day instead, shall be due on the immediately preceding Business Day.

5.2 Any Services Fees, or costs and expenses and other amounts to be paid to GMS under this Agreement (including any Reimbursable Expenses and any amounts due to GMS pursuant to Clause 4.4) or any portion thereof which is not paid on the expiry of the due date for payment, shall accrue interest for each day elapsed thereafter from and including the relevant due date for payment, at the Reference Rate (compounded monthly from the relevant due date for payment) until they are paid, before as well as after any judgment. Such amounts as well as any accrued but unpaid interest thereon shall, subject to Applicable Laws, be paid on demand.

5.3 All payments to be made by the Company under this Agreement (including without limitation all Services Fees, Reimbursable Expenses and any amounts due to GMS pursuant to Clause 4.4) shall be made (a) free of any restriction or condition, (b) free and clear of and without deduction or withholding for on account of any Taxes, and (c) without deduction or withholding on account of any other amount, whether by way of set-off, counterclaim or otherwise. If at any time the Company is required to make any deduction or withholding for applicable Taxes in Myanmar from any payments due under this Agreement for the account of GMS, or such other person as may be appointed by GMS pursuant to Clause **Error! Reference source not found.**~~18.11~~, pursuant to Applicable Laws, the Company shall:

(a) where the recipient of such payments is not a resident in Myanmar for purposes of the Myanmar Income Tax Act, forthwith increase the sum payable to such sum as will ensure that, after such deduction and withholding has been made and paid to the Taxation Authorities, the recipient receives on the due date for such payment a sum equal to the sum that it would have received in the absence of such Taxes provided and to the extent that the recipient thereafter recovers or receives from the relevant Taxation Authorities any part of such amounts so deducted or withheld, then upon its receipt thereof, GMS shall procure that the recipient remit to the Company such amount so recovered or received;

(b) indemnify the recipient against any losses or costs incurred by it by reason of any failure of the Company to make such deduction or withholding; and

(c) promptly deliver to the recipient any receipts, certificates or other proof evidencing the amounts (if any) paid or payable in respect of any such deduction or withholding as aforesaid.

6. PERSONNEL

6.1 The Company acknowledges and agrees that, in performing its duties and responsibilities hereunder, GMS may use its personnel or those of its related corporations and may supplement the same with such outside consultants as shall be selected by GMS in its sole discretion, including sub-contract a variety of such Services to such persons as it may deem fit provided that GMS shall be solely responsible for the costs and expenses in connection with such sub-contracting which should not constitute Reimbursable Expenses. Notwithstanding the foregoing, GMS shall remain responsible for performing this Agreement as if GMS had not sub-contracted the performance of all or any part of its obligations under this Agreement to such person, firm or corporation and shall remain primarily liable to the Company.

6.2 In relation to services falling outside the scope of the Services and agreed to between the Parties, in addition to the additional fees referred to in Clause 4.3, the costs and expenses of such personnel, outside consultants and sub-contractors shall, for the avoidance of doubt, be borne by the Company.

7. OBLIGATIONS OF GMS

7.1 GMS shall provide the Services for the duration of the Term at a level consistent with efficient and business-like conduct, and in accordance with the terms and conditions set out in this Agreement, unless and until this Agreement is terminated pursuant to the provisions of this Agreement.

7.2 GMS shall from the date of this Agreement maintain proper accounts and records of all expense incurred by it on the Company's behalf in the course of the performance of the Services under this Agreement and for the avoidance of doubt, such accounts and records shall be the property of the Company which the Company is entitled to access and inspect with reasonable advance notice to GMS in writing.

7.3 GMS shall, if it encounters problems which are likely to hinder the smooth construction, or development of the Hospital, promptly notify the Company of such fact and the Company and GMS shall co-operate to deal with such problems.

8. OBLIGATIONS OF THE COMPANY

8.1 The Company shall, for the duration of this Agreement,

(a) promptly make payments to GMS for the Services when due and in accordance with the provisions of this Agreement;

(b) ratify all acts, deeds and things done by GMS in connection with the provision of services within the scope of the Services; and any additional services as agreed between the Parties pursuant to this Agreement;

(c) give its full co-operation and assistance to GMS to enable GMS to carry out its duties and responsibilities under or by virtue of this Agreement and shall, within a reasonable period of time, review and respond to all recommendations and requests made by GMS and/or its representatives in connection with the Services;

(d) promptly advise GMS of any event or possible event which may adversely affect GMS and the performance of its duties and responsibilities hereunder, upon the same coming to the knowledge of the Company;

(e) use its best endeavours to obtain all necessary initial licences and permits required to Construct the Hospital and appoint the relevant professionals to advise the Company and GMS on the Legal Requirements relating to the Hospital and the Hospital Business;

(f) upon receiving advice from the relevant professionals appointed to advise the Company on the Legal Requirements relating to the Hospital and the Hospital Business, use its best endeavours to obtain and maintain all necessary approvals, licences and permits required to Construct the Hospital and operate the Hospital Business or which pertain to any matter covered by this Agreement;

(g) in the event that any non-residents of Myanmar (including members of the staff of GMS or its related corporations) shall be required in connection with the provision of the Services or to work in or travel to Myanmar in connection with the Hospital or the Construction thereof, apply for and use its best endeavours to procure all necessary visas, work permits and any other documentation necessary under the laws of Myanmar for such persons; and

(h) not require GMS to implement any unlawful measures or programmes.

9. <u>COVENANTS AND AGREEMENTS RELATING TO THE KNOW-HOW</u>

9.1 The Company hereby acknowledges, agrees and undertakes that:

(a) GMS and/or its related corporations are the legal and beneficial owners of the Know-How and all the goodwill relating thereto;

(b) the Know-How at all times shall be and remain the sole and exclusive property of GMS and/or its related corporations (as the case may be);

(c) the Company, by reason of this Agreement or the use thereof or otherwise, has not acquired and shall not acquire any right, title, interest, or claim or ownership in the Know-How, except as provided herein and subject to the terms and conditions set forth in this Agreement, and nothing in this Agreement shall prevent any use by GMS and/or its related corporations of any part of the Know-How;

(d) the use by the Company of the Know-How and any and all goodwill arising from such use shall inure solely to the benefit of GMS and/or its related corporations;

(e) the Company shall take no action inconsistent with GMS's and/or its related corporations' title and rights to the Know-How nor assert any rights in relation thereto;

(f) the Company shall, at the request of (and at the cost and expense of) GMS at any time during the Term including, for the avoidance of doubt, any extension thereof, execute on a reasonable basis any and all documents confirming and/or vesting in GMS and/or its related corporations, the interest and proprietorship of GMS and/or its related corporations in the Know-How; and

(g) for the avoidance of doubt, the Company shall use the Know-How (including

Improvements arising from work carried out by GMS and/or its related corporations alone) and where relevant, the Proprietary Information procured from GMS, only for the Construction of the Hospital, and acknowledges and undertakes that it will not make use of any part thereof in any manner (not even for other facilities of the Company), nor commercialize it in any manner directly or indirectly.

9.2 When appropriate, or when directed by GMS, the Company shall mark all materials containing any of the Know-How and/or the Proprietary Information of GMS and/or its Connected Persons with a proper registration or proprietorship notice.

9.3 The Company shall promptly notify GMS of any unauthorised use of the Know-How or of the Proprietary Information of GMS and/or its Connected Persons or of any other intellectual property belonging to GMS and/or its related corporations by any person and of any infringement or passing off or other torts involving any of the Know-How, the Proprietary Information of GMS and/or its Connected Persons and/or the intellectual property belonging to GMS and/or its related corporations, as soon as the Company receives or is aware of such information.

9.4 GMS and/or its related corporations shall have the sole right and full discretion (but not the obligation) to bring an infringement or other proceedings or action against any persons using without authorisation, the Know-How, the Proprietary Information of GMS and/or its Connected Persons and/or the intellectual property belonging to GMS and/or its related corporations. At the request and expense of GMS, the Company shall co-operate with GMS and/or its related corporations in opposing or otherwise defending or contesting any use or registration by any other person of the Know-How, the Proprietary Information of GMS and/or its Connected Persons or of any intellectual property belonging to GMS and/or its related corporations. Notwithstanding anything to the contrary contained in Clause 20, GMS and/or its related corporations have the right to obtain restraining orders or injunctive relief from a court of competent jurisdiction, in accordance with the relevant laws, for any unauthorized use or registration by third parties of any Know-How, the Proprietary Information of GMS and/or its Connected Persons and/or the intellectual property belonging to GMS and/or its related corporations.

9.5 For the avoidance of doubt, GMS's failure to object to any aspect of the use of the Know-How and/or the Proprietary Information of GMS and/or its Connected Persons by the Company in connection with the Hospital shall not constitute a representation or acknowledgment that the Company is in compliance with this Agreement or that GMS or its related corporations have waived any of their rights, title and interest in and to the Know-How and/or the Proprietary Information of GMS and/or its Connected Persons and/or under this Agreement, which rights, title and interest are expressly reserved.

9.6 The Company shall use the Know-How, the Proprietary Information of GMS and/or its Connected Persons and all other intellectual property belonging to GMS and/or its related corporations in compliance with all Applicable Laws and regulations in Myanmar.

9.7 The Company shall refrain from committing any act or pursuing any course of conduct that will or is likely to bring GMS and/or its related corporations, the Know-How, the Proprietary Information of GMS and/or its Connected Persons or any other intellectual property belonging to GMS and/or its related corporations, into disrepute.

9.8 The Company will acquire no rights to the Know-How, the Improvements, the Proprietary Information of GMS and/or its Connected Persons or any other intellectual property belonging to GMS or its related corporations or any derivations thereof except as provided in Clause 9.10.

9.9 The Company hereby acknowledges the exclusive rights of GMS and/or its related corporations to own the Know-How, the Proprietary Information of GMS and/or its Connected Persons and all matters and rights comprised therein and of GMS and/or its related corporations themselves to utilise the same and to grant to any other person a licence to use the Know-How, the Proprietary Information of GMS and/or its Connected Persons and any or all intellectual property subsisting therein, and to amend and modify the same by variation, revision, addition, renewal, substitution or howsoever otherwise.

9.10 Subject to the other provisions of this Agreement and subject always to the due and timely performance by the Company of its obligations under this Agreement, GMS hereby grants the Company the non-exclusive, non-transferable licence to use and reproduce the Know-How and the Improvements exclusively owned by GMS and/or its related corporations, solely for the purposes of the Construction of the Hospital during the Term.

9.11 In the event of the termination or expiration of this Agreement for any reason whatsoever, the rights granted to the Company in Clause 9.10 shall forthwith terminate.

10. <u>IMPROVEMENTS</u>

10.1 The Company shall forthwith disclose to GMS in such detail as GMS may reasonably require, all Improvements that it may develop or acquire during the course of the performance of this Agreement.

10.2 For the purposes of and subject to the terms of this Agreement, all Improvements arising from work carried out by:

(a) GMS and/or its related corporations, whether alone or in collaboration with third parties; or

(b) the Company, whether alone or in collaboration with GMS or any third party,

together with all original documents, systems and materials prepared and provided by GMS and/or its related corporations for the use of the Hospital pursuant to this Agreement, shall:

(i) as between the Parties, remain the exclusive property of GMS and/or its related corporations, as the case may be; and

(ii) be deemed to be part of the Know-How for the purposes of this Agreement.

11. <u>INSURANCE</u>

11.1 The Company shall, from the date of this Agreement (or such other date as may be agreed between the Parties), take out and maintain adequate insurance coverage to cover all types of risks normally associated with the Construction of hospitals including but not limited to general and public liability insurance and all other insurance coverage as may be decided jointly by GMS and the Company. All insurance policies shall be in appropriate amounts and forms and with reputable licenced insurance companies reasonably acceptable to GMS.

11.2 The Company shall be responsible for the payment of all *premia* required to maintain the insurances pursuant to Clause 11.1.

11.3 All insurance provided for in this Clause 11 shall be written in the name of the Company and GMS and shall contain a provision requiring the insurance company to notify each Party of

any cancellation or material change at least 60 days prior thereto. All liability insurance provided for in this Clause 11 shall name each of the Company and GMS as named insured.

11.4 The property damage insurance policies obtained by or for the account of the Company shall provide for payment of loss to the Company and GMS in accordance with their respective interests.

12. <u>ACCESS</u>

12.1 The Company hereby undertakes and agrees with GMS that GMS and its representatives shall:

(a) have full and uninterrupted access to the Hospital, the Hospital Land and any facility and component related to the operation of the Hospital:

(i) for the duration of this Agreement, for the purposes of the provision of the Services; and

(ii) for the duration of this Agreement and for a period of ninety (90) days thereafter, to determine whether the Company is in compliance with the terms of this Agreement,

and the Company shall make available for inspection such items as may be reasonably requested by GMS;

(b) be entitled to inspect the Hospital at all times when providing the Services and conducting on-site inspections; and

(c) be entitled to be present at any site meetings which the Company may have with its Contractors and for this purpose the Company shall keep GMS informed of the time and place of such meetings.

12.2 The Company hereby further undertakes and agrees with GMS that for the duration commencing from the date of this Agreement and ending ninety (90) days after the end of the Last Quarter, GMS shall have access to the Hospital, the Hospital Land and the Company's records, documents and other materials relating to the Hospital and its operations and to this Agreement, for the purposes of verifying the Services Fees and any other amounts to be paid to GMS pursuant to this Agreement. The provision of this Clause 12 shall survive the expiry or termination of this Agreement for a period of ninety (90) days after the termination of this Agreement.

13. <u>DURATION AND TERMINATION</u>

13.1 This Agreement shall commence on the date hereof and shall continue until the expiry of the Term including, for the avoidance of doubt, any extension thereof, as the case may be, unless terminated earlier by notice in writing in accordance with this Clause 13. For the avoidance of doubt, notwithstanding the termination of this Agreement due to the expiry of the Term or otherwise, the Company’s obligation to pay the Services Fees to GMS shall survive until such time as all Services Fees that are due and owing to GMS have been fully paid.

13.2 This Agreement may be terminated immediately by a Party (the "**non-defaulting Party**") in respect of the other Party (the "**defaulting Party**"), in the event that any of the following events arises or occurs with respect to the defaulting Party:

(a) without prejudice to Clauses 13.3, 13.4 and 13.5, the breach by the defaulting Party of any of its representations, warranties and/or undertakings in this Agreement (including without limitation, in Clause 17) if such breach is not capable of remedy, or if such breach (being capable of remedy) is not remedied within sixty (60) days after written notice specifying such breach is received by the defaulting Party from the non-defaulting Party;

(b) without prejudice to Clauses 13.3, 13.4 and 13.5, the failure of the defaulting Party to observe, perform, keep or fulfil any material covenant, agreement, provision, undertaking or obligation under this Agreement if such failure has or is likely to have a material adverse effect on the Construction of the Hospital or the rights and duties of the non-defaulting Party, if such failure is not capable of remedy, or if such failure (being capable of remedy) is not remedied within sixty (60) days after written notice specifying such failure is received by the defaulting Party from the non-defaulting Party;

(c) the application or filing by a third party or by the defaulting Party for, or consent by the defaulting Party to the appointment by any person of, or the appointment of or the entry by any court of competent jurisdiction of an order, judgement or decree for, the appointment of a receiver, judicial manager, trustee, administrator or liquidator for all or a substantial part of the defaulting Party's assets or for the bankruptcy, liquidation, insolvency, dissolution, reorganisation (other than a reorganisation pursuant to a restructuring not involving insolvency), composition or arrangement with creditors of or similar actions against, the defaulting Party;

(d) the making by the defaulting Party of a general assignment for the benefit of, or its entry into arrangements with, its creditors;

(e) the filing by the defaulting Party of a voluntary petition in bankruptcy or a petition seeking reorganisation (other than those pursuant to a restructuring not involving insolvency), composition, arrangement with creditors, liquidation, or similar relief under any present or future statute, law or regulation;

(f) the entry by any court of competent jurisdiction of an order, judgement or decree for the adjudication of the defaulting Party as bankrupt or insolvent; or the filing by the defaulting Party of an answer admitting the material allegations of a petition filed against it in any proceedings pertaining to its insolvency; or the initiation by the defaulting Party of any action in furtherance of dissolution; or the dissolution of the defaulting Party either by action of its shareholders or law;

(g) the filing of any petition or complaint with respect to the defaulting Party without the application, approval or consent of the defaulting Party seeking reorganisation, composition, arrangement with creditors, appointment of an administrator, liquidation, or similar relief under any present or future statute law or regulation with respect to the defaulting Party seeking appointment of a receiver, trustee, or liquidator for all or a substantial part of the defaulting Party's assets, and such petition or complaint shall be pending and not withdrawn or dismissed for an aggregate of thirty (30) days (excluding any days during which such petition or complaint shall be stayed), whether or not consecutive; and

(h) any event occurs or proceeding or step is taken or suffered with respect to the

defaulting Party in any jurisdiction to which it is subject, which has an effect equivalent or similar to any of the foregoing events.

13.3 This Agreement may further be terminated immediately by GMS in respect of the Company in the event that any of the following events arises or occurs:

(a) the failure by the Company to pay any sum of money to GMS when due and owing, if such failure is not remedied within ninety (90) days after written notice specifying such failure is received by the Company from GMS;

(b) if any necessary licences, permits or approvals for the Construction or the operation of the Hospital or the Hospital Business under any of the Legal Requirements are at any time not granted, suspended, terminated or revoked (and if the Hospital has commenced operations, such suspension, termination or revocation has caused the Construction of the Hospital to cease for a period of more than ninety (90) consecutive days), without fault on the part of GMS or not due to negligence on the part of GMS;

(c) if the Hospital Land ceases to be in the possession of the Company, if the Hospital, the lease hold interest in the Hospital Land or the Hospital Business is (or is permitted or suffered to be) sold, transferred, disposed of, assigned or novated to any third parties; or if GMS reasonably anticipates that the Company would not be able to operate the Hospital Business after the Opening Date;

(d) if Parkway Healthcare Indo-China Pte. Ltd., its related corporation or its nominee company ceases to directly or indirectly hold at least fifty per. cent. (50%) of the issued share capital of the Company for whatever reason;

(e) if the Company interferes with the performance by GMS of the Services or any part thereof or fails or refuses to co-operate with GMS in such a manner which shall materially affect the ability of GMS to perform its obligations under this Agreement or is inadequately staffed or equipped such that GMS is unable to Construct the Hospital to international standards and such failure is not remedied within sixty (60) days after written notice specifying such failure is received by the Company from GMS;

(f) if the Hospital is not Constructed and ready for use by the end of forty-eight (48) months from the date of this Agreement or such later date as may be agreed between the Parties;

(g) if the Hospital Land or the Hospital or any portion thereof shall be damaged or destroyed by fire, flood, earthquake, typhoon, war, insurrections or other casualty or any acts of God such that there is a material impact on its operations or it is condemned by any competent authority and is not repaired, restored or replaced within sixty (60) days or such other period as may be agreed between the Company and GMS after such fire or other casualty or condemnation or if the Company shall fail to prosecute such work diligently;

(h) if the Joint Venture Agreement is terminated by the Local Partner Shareholders (as defined in the Joint Venture Agreement) due to a default by Parkway Healthcare Indo-China Pte. Ltd.;

(i) if the Joint Venture Agreement is terminated for any reason other than by the Local Partner Shareholders (as defined in the Joint Venture Agreement) due to a default by Parkway Healthcare Indo-China Pte. Ltd.; or

(j) if the Hospital Management Agreement is terminated either (i) by the Company due to a default by GMS; or (ii) due to a default by the Company.

13.4 The expiration or termination of this Agreement shall be without prejudice to the accrued rights of the Parties, and any provision hereof which relates to or governs the acts of the Parties subsequent to such expiry or termination hereof (including without limitation Clauses 4, 5, 9, 10, 12, 14, 15, 18, 19 and 20) or which is expressed to survive such termination shall remain in full force and effect and shall be enforceable notwithstanding such expiry or termination.

13.5 For the avoidance of doubt, Clauses 4, 5 and 14 shall survive the expiry or termination of this Agreement only to the extent necessary to ensure that the Company continues to be obliged to pay to GMS such amount of the Services Fees, Reimbursable Expenses, costs and expenses, interests and other amounts as are due (including any amounts due to GMS pursuant to Clause 4.4), owing and payable to GMS up to and including the date of expiry of the Term including, for the avoidance of doubt, any extension thereof or termination of this Agreement. The Company shall also forthwith pay or cause to be paid to GMS all accrued and unpaid Services Fees, interest and all amounts due, owing and payable to GMS including any amounts due to GMS pursuant to Clause 4.4) under this Agreement up to the date of expiry or termination of this Agreement. Each of GMS and the Company shall:

(a) immediately refrain from any action that would or may indicate any relationship between it and the other;

(b) return to the other or otherwise dispose of or destroy as the other shall direct, all materials, stationery, invoices, forms, specifications, designs, records, data, samples, models, programmes and drawings belonging solely to the other ("**Materials**") but only to the extent that the return or destruction of such Materials would not be inconsistent with the use of such Materials in connection with any applicable laws, rules, regulations or existing bona fide internal retention policies and provided that any Materials held in any computer, word processing system, database or document retrieval system shall only be destroyed to the extent reasonably practicable. For the avoidance of doubt, the obligations of confidentiality contained in this Agreement shall continue to apply to any Materials retained by GMS or the Company pursuant to this Clause;

(c) return all items of good, supplies and/or equipment held on loan or hire from the other under the terms of this Agreement; and

(d) co-operate and do all such acts and things and execute all such documents as the other shall reasonably require, including to effect a handover to another operator of the Hospital, if any.

13.6 The remedies available upon termination contained in this Clause 13 shall not be deemed or construed to limit or derogate from any and all other remedies, rights, and recourse available by law or in equity, except as expressly may be provided in this Agreement.

14. DISCLAIMERS AND INDEMNITIES

14.1 Except in the case of gross negligence, fraud or breach of this Agreement, neither GMS, its related corporations, nor their Connected Persons shall be liable to the Company (either actually or contingently, presently or in the future) in respect of any action, decision, consent, approval, rejection, omission to act, delay or any other matter or thing taken, made, given or otherwise occurring in the course of any exercise of its or his rights, powers and authorities,

and performance of its or his duties and obligations, contained in this Agreement nor shall GMS, its related corporations or any of their Connected Persons be liable (absent gross negligence, fraud or breach of this Agreement) for any losses, liabilities, costs or expenses which result (either directly or indirectly) in respect thereof including, without limitation, any liability in respect of:

(a) prosecuting or defending any action or suit in respect of the provisions of this Agreement or in respect of or in connection with any matters pertaining to the Company or the Hospital;

(b) any act or thing which GMS and its representatives is hindered, prevented or forbidden from doing or performing by applicable legislation or court order; or

(c) any reliance upon any notice, resolution, direction, consent, certificate, receipt, affidavit, statement or other paper or document reasonably believed by GMS, its related corporations or their Connected Persons to be genuine and to have been passed or signed by the proper parties.

14.2 For the avoidance of doubt, GMS, its related corporations and their Connected Persons shall not bear any portion of any losses (including economic losses) arising out of or related to the ownership or operation of the Hospital or the Hospital Business by the Company. All debts and liabilities to third parties incurred by GMS, its related corporations and their Connected Persons in the course of the performance of the Services in accordance with this Agreement with the prior approval and knowledge of the Company (including the Reimbursable Expenses), shall be the debts and liabilities of the Company only and GMS, its related corporations and their Connected Persons shall not be liable for any such debts and liabilities by reason of the performance of any acts, duties and responsibilities hereunder in connection with the Hospital or the Hospital Business and may so inform third parties with whom GMS, its related corporations or their Connected Persons deal on behalf of the Company.

14.3 GMS, its related corporations and their Connected Persons shall not be responsible to the Company for any of their actions or omissions or the effects thereof that are the direct or indirect result of any controls or requirements (whether or not having the force of law) imposed upon the Company or any of GMS, its related corporations and their Connected Persons by any government, governmental or regulatory authority that may exercise jurisdiction or control over them directly or indirectly. For the avoidance of doubt, any actions or omissions of GMS pursuant to this Clause 14.3 shall not constitute a breach of this Agreement.

14.4 The Company irrevocably undertakes to keep GMS, its related corporations and their Connected Persons fully and effectively indemnified from and against any and all losses, costs, damages, claims, demands, actions, proceedings, liabilities (whether present or future, actual or contingent) and expenses whatsoever (including but not limited to all legal costs or attorneys' fees on a full indemnity basis) which may be incurred or suffered by GMS, its related corporations or any of their Connected Persons in the course of performing this Agreement or in connection with or resulting or arising from any act, omission, neglect, default, negligence or breach of the Company, its related corporations and/or their Connected Persons or arising from any claims by any third party in respect of any matter arising from the provision of services within the scope of the Services or for the infringement of any intellectual property rights, unless GMS has acted fraudulently or in a grossly negligent manner or in breach of this Agreement.

14.5 GMS irrevocably undertakes to keep the Company and its Connected Persons fully and effectively indemnified from and against any and all losses, costs, damages, claims, demands, actions, proceedings, liabilities (whether present or future, actual or contingent) and

expenses whatsoever (including but not limited to all legal costs or attorneys' fees on a full indemnity basis) which may be incurred or suffered by the Company or its Connected Persons arising from any successful claims by any third party in Myanmar in respect of any infringement of any intellectual property rights comprised in the Know-How or the Proprietary Information.

14.6 GMS, its related corporations and their Connected Persons may act on the opinion or advice of, or information obtained from any financial adviser, solicitor or any such other professional adviser. GMS, its related corporations and their Connected Persons may act upon statements of, or information in relation to, the Company, the Hospital, or the Construction of the Hospital, obtained from the auditors, any financial adviser, banker, accountant or such other professional adviser, believed by them in good faith and on reasonable grounds to be expert in relation to the matters upon which they are consulted and GMS, its related corporations and their Connected Persons shall not be liable for any thing done, or suffered, by any of them in good faith in reliance upon such opinion, advice, statement or information in relation to the Company, the Hospital, or the Construction of the Hospital and shall not be responsible for any misconduct, mistake, error of judgement or want of prudence on the part of such person.

14.7 Notwithstanding anything in this Agreement, the aggregate liability of GMS under this Agreement shall not exceed S$1,500,000.

15. CONFIDENTIALITY AND RESTRICTIVE COVENANTS

15.1 The Company acknowledges that GMS and/or its related corporations will make available to the Company and its Connected Persons certain trade secrets, Know-How, confidential and/or proprietary knowledge (including advice, technology, documents, know-how, techniques, procedures, methods, plans and all other materials) and information as a result of entering into this Agreement and in connection with the provision of the Services to the Company and the Construction of the Hospital and in connection therewith may provide the Company and its Connected Persons with certain documentation and information regarding GMS, GMS's related corporations, their respective businesses, and the Construction of the Hospital (collectively, the "**Proprietary Information**") including without prejudice to the generality of the foregoing, any information as a result of entering into or performing this Agreement which relates to or in connection with:

(a) the provision of the Services to the Company and the Construction of the Hospital including but not limited to the Know-How (including any Improvements);

(b) the provisions of this Agreement or any other agreements, documents or transactions referred to or contemplated herein;

(c) the negotiations relating to this Agreement or any other agreements, documents or transactions referred to or contemplated herein; or

(d) the subject matter of this Agreement or any other agreements, documents or transactions referred to or contemplated herein.

15.2 In consideration of receiving the Proprietary Information, the Company hereby undertakes with GMS, on behalf of itself and its Connected Persons and each of its and its Connected Persons' directors, shareholders, employees and agents, whether or not any such Proprietary Information is strictly confidential or proprietary:

(a) not to exploit or make any use of the Proprietary Information for any purpose other

than in accordance with this Agreement, and in particular, but without limitation, not to use any of the Proprietary Information for any commercial purpose, except to the extent permitted by this Agreement;

(b) except to the extent permitted by this Agreement, to hold all of the Proprietary Information in the strictest confidence, as may be reasonably done and not to disclose or divulge any part of the Proprietary Information to any third parties without the prior written consent of GMS, which consent may be withheld by GMS without being obliged to give any reason therefor whatsoever, or in the sole discretion of GMS, given on such terms and conditions as GMS considers appropriate;

(c) not to make or solicit any announcement or disclosure regarding GMS or its related corporations unless GMS gives its express prior written consent;

(d) to restrict access to the Proprietary Information to those of its employees and professional advisers who absolutely require such access for the purposes of this Agreement and to impose upon all such employees and professional advisers obligations of confidentiality equivalent to those contained in this Agreement;

(e) not to copy, reproduce, or part with possession of any of the Proprietary Information except as is strictly necessary and as is consistent with its obligations contained in this Agreement;

(f) except to the extent permitted by this Agreement, not to, in any way, form or manner whatsoever, make or permit any use of the Proprietary Information or any of the ideas, concepts, materials, or documents comprising the Proprietary Information, whether in connection with the Hospital or otherwise; and

(g) not to disclose the terms or conditions of this Agreement unless GMS gives its express prior written consent.

15.3 Each Party hereby undertakes with the other, on behalf of itself and its Connected Persons and each of its and its Connected Persons' directors, shareholders, employees and agents ("**Receiving Party**"), to keep all information and documents shared between the Parties and relating to the Construction of the Hospital including but not limited to the Know-How and the Improvements, in the strictest confidence, as may be reasonably done and not to disclose or divulge any such information or documents to any third parties (other than to its related corporations or Connected Persons for the purposes of this Agreement) without the prior written consent of the disclosing Party ("**Disclosing Party**"), which consent may be withheld by the Disclosing Party without being obliged to give any reason therefor whatsoever, or in the sole discretion of the Disclosing Party, given on such terms and conditions as the Disclosing Party considers appropriate.

15.4 The restrictions in Clauses 15.1, 15.2 and 15.3 as to non-disclosure shall not apply:

(a) to any information or knowledge which was known to the Receiving Party prior to disclosure pursuant to this Agreement or subsequently comes to the knowledge of the Receiving Party from a source not under an obligation of confidentiality, or which may properly come into the public domain through no fault or breach of the Receiving Party;

(b) to any information whatsoever requested or required to be disclosed by Applicable Laws or pursuant to any legal process issued by any court or tribunal of competent jurisdiction or by any requirement of any competent governmental or regulatory authority or rules or regulations of any relevant regulatory, administrative or

supervisory body (including without limitation, any relevant stock exchange or securities council) whether in Myanmar, Singapore, Malaysia or elsewhere;

(c) to any disclosure required by any Recognised Stock Exchange or regulatory or governmental body to which the Receiving Party or any holding company, subsidiary or substantial shareholder of the Receiving Party is subject or submits;

(d) to any disclosure of any information whatsoever to the legal or other professional advisers (including auditors and bankers) of the Receiving Party for the purposes of this Agreement;

(e) if such disclosure or use is necessary for the performance of the Receiving Party's obligations under this Agreement; or

(f) if such disclosure is for a specific purpose and is approved in writing by the Disclosing Party prior to any such disclosure being made.

PROVIDED THAT any such information disclosed pursuant to sub-Clauses (b), (c) shall be disclosed, to the extent permitted and practicable, only after prior consultation with each other as to the form, content and timing of such announcement or disclosure.

15.5 For the purpose of this Clause 15, any communication between the Parties and any information and other material supplied to or received by a Party which is either marked "confidential" or is by its nature intended to be confidential or exclusively for the knowledge of the recipient alone, and any information concerning the business, affairs or the financial arrangements of a Party and/or its related corporations coming to the knowledge of the other Party shall be considered confidential. In any case of uncertainty, a Party shall treat information and material as confidential until written clearance is obtained from the other Party.

15.6 Except as may otherwise be permitted elsewhere in this Agreement or as may be required by law or regulatory requirement or existing bona fide internal retention policies, the Company shall return to GMS all documents, files, tapes, disks and any other things on or in which any Proprietary Information relating or belonging to GMS may be recorded or contained, upon the expiration or earlier termination of this Agreement provided that any such Proprietary Information held in any computer, word processing system, database or document retrieval system shall only be returned to the extent reasonably practicable. For the avoidance of doubt, the obligations of confidentiality contained in this Agreement shall continue to apply to any Proprietary Information retained by the Company pursuant to this Clause.

15.7 The Company shall not and shall procure with reasonable ability, that its Connected Persons and entities under its Control shall not, for the duration of this Agreement (except in the limited circumstances as provided in Clause 6.2) the Hospital Management Agreement and for a period of two (2) years thereafter:

(a) either on their own account or for any person, firm, company, organisation or entity, directly or indirectly solicit or entice away or endeavour to solicit or entice away from GMS or of any of its Connected Persons, any Key Personnel seconded by GMS and/or its Connected Persons to the Company or manager, officer or employee employed in an executive position of GMS or any of its related corporations whether or not such person would commit any breach of his or her contract of employment by reason of leaving the service of the relevant company; or

(b) directly or indirectly employ, appoint or engage any Key Personnel seconded by GMS and/or its Connected Persons to the Company, manager, officer or employee

employed in an executive position of GMS or any of its related corporations, who by reason of such employment is or is likely to be in possession of any Proprietary Information of GMS and/or its Connected Persons or trade secrets relating to any member of GMS's and its Connected Persons' business or the business of the customers of any of them.

The placing of an advertisement of a post available to a member of the public generally and the recruitment of a person through an employment agency shall not constitute a breach of this Clause 15.7 provided that the Company or any of its Connected Persons and entities under its Control, does not encourage or advise such agency to approach any such Key Personnel seconded by GMS and/or its Connected Persons to the Company or director, manager, officer or employee employed in an executive position of GMS or any of its related corporations.

15.8 GMS shall not and shall procure with reasonable ability, that its Connected Persons and entities under its Control shall not, for the duration of this Agreement (except in the limited circumstances as provided in Clause 6.2) the Hospital Management Agreement and for a period of two (2) years thereafter:

(a) either on their own account or for any person, firm, company, organisation or entity, directly or indirectly solicit or entice away or endeavour to solicit or entice away from the Company, any Key Personnel (with the exception of the Chief Executive Officer, Chief Financial Officer and the Director of Nursing) or manager, officer or employee employed in an executive position of the Company whether or not such person would commit any breach of his or her contract of employment by reason of leaving the service of the Company; or

(b) directly or indirectly employ, appoint or engage any Key Personnel (with the exception of the Chief Executive Officer, Chief Financial Officer and the Director of Nursing), manager, officer or employee employed in an executive position of the Company, who by reason of such employment is or is likely to be in possession of any trade secrets relating to the Company or the business of its customers.

The placing of an advertisement of a post available to a member of the public generally and the recruitment of a person through an employment agency shall not constitute a breach of this Clause 15.8 provided that GMS or any of its Connected Persons and entities under its Control, does not encourage or advise such agency to approach any such Key Personnel or director, manager, officer or employee employed in an executive position of the Company.

15.9 Each and every obligation under this Clause 15 shall be treated as a separate obligation and shall be severally enforceable as such and in the event of any obligation or obligations being or becoming unenforceable in whole or in part such part or parts as are unenforceable shall be deleted from this Clause 15 and any such deletion shall not affect the enforceability of all such parts of this Clause 15 as remain not so deleted.

15.10 While the restrictions contained in this Clause 15 are considered by the Parties to be reasonable in all circumstances, it is recognised that restrictions of the nature in question may fail for technical reasons unforeseen and accordingly it is hereby agreed and declared that if any such restrictions shall be adjudged to be void as going beyond what is reasonable in all the circumstances for the protection of the interests of GMS and/or its related corporations or of the Company (as the case may be) but would be valid if part of the wording thereof were deleted or the periods thereof were reduced or the range of activities or area dealt with thereby were reduced in scope, the said restrictions shall apply with such modifications as may be necessary to make it valid and effective.

15.11 Each Party hereby agrees that any breach of this Clause 15 will cause irreparable injury to the other Party and that monetary damages will not provide an adequate remedy therefor. Each Party agrees that the other Party shall, in addition to monetary damages, be entitled to temporary or permanent injunctive relief and such costs as may be awarded by the Arbitration Institution or any court of competent jurisdiction in respect of the enforcement of this Clause **Error! Reference source not found.**~~15.11~~.

16. FORCE MAJEURE

16.1 Except as otherwise provided hereafter, each Party shall be entitled to an extension of the date of any performance required of such Party under this Agreement if the failure of the Party to duly perform was solely because of a Force Majeure Event (defined below); provided, however, that a Force Majeure Event shall not be recognised under this Agreement unless (a) the Party seeking to assert such an event gives notice of the existence of such event to the other Party, which notice shall explain in reasonable detail the nature of the Force Majeure Event, the obligations that have been affected by the Force Majeure Event and how such Force Majeure Event has impaired the performance of such obligations ("**Force Majeure Event Notice**"), and (b) such Force Majeure Event actually and materially impairs the due performance of such Party's obligations and continues for not less than fourteen (14) consecutive days. On receipt of the Force Majeure Event Notice by the other Party and the continuation of such Force Majeure Event for fourteen (14) consecutive days, the performance required of the notifying Party shall be suspended commencing on the date the Force Majeure Event Notice was given until such Force Majeure Event has ceased.

16.2 A "**Force Majeure Event**" shall be an event beyond the control of the Party relying on it pursuant to Clause 16.1, including an act of God, riot, war, severance, suspension or deterioration of diplomatic ties, civil unrest, flood, earthquake, energy or labour strikes, industrial disturbances, lockouts, trade or labour disputes (other than those caused by that Party), fire, accident, acts or restraints of governments or courts of law (but excluding failure caused by a Party's financial condition or negligence and excluding production hold-ups and shortage of raw materials), revocation or non-issuance of visas, consents and authorisations and includes any change or any development involving a change or prospective change in political condition in Myanmar or internationally (including any local, national or international outbreak or escalation of hostility, insurrection or armed conflict), or any significant event anywhere in Myanmar or internationally, or the occurrence of any combination of any changes or developments in such conditions or any other occurrence or event of any nature whatsoever which causes or results in or is likely to cause or result in it becoming inadvisable or inexpedient for the transactions contemplated herein to commence or be proceeded with.

16.3 Notwithstanding the provisions of this Clause 16, the Company shall under no circumstances be excused from paying the Services Fees in respect of Services that had already been rendered when due notwithstanding the occurrence of any Force Majeure Event.

17. REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS

17.1 Each of the Parties represents and warrants to the other Party that:

(a) it is a corporation duly organised and validly existing under the laws of its country of incorporation; it has not been and is not in the process of being wound up or liquidated; and it has full corporate power to carry on its business as contemplated by this Agreement;

(b) it has all requisite corporate power and authority to enter into this Agreement and to

consummate the transactions contemplated hereby, and this Agreement:

(i) has been duly executed and delivered to the other Party;

(ii) has been effectively authorised by all necessary action, corporate or otherwise; and

(iii) constitutes legal, valid and binding obligations of it; and

(c) none of the execution, delivery, or performance of this Agreement, the consummation of any of the transactions contemplated hereby, or the fulfilment by it of each of the terms and conditions hereof shall violate or conflict with, result in a breach of any of the terms and conditions of, constitute a default (or any event which, with notice or lapse of time or both, would constitute a default) under, result in the termination of, accelerate the performance required by, result in the forfeiture of any of its right under, or create any lien, security interest, charge, or Encumbrance on any of its properties pursuant to, any material agreement, indenture, mortgage, bond, deed of trust, promissory note, lease, franchise, permit, licence, registration, qualification, or other obligation or instruments to which it is a party or by which it or any of its properties or assets is bound or affected, pursuant to the terms, conditions, and provisions of:

(i) any such agreement or instrument;

(ii) any law, rule or regulation applicable to it;

(iii) any order, writ, injunction, decree, or judgment of any court, governmental body, or arbitrator by which it is bound; or

(iv) its memorandum and articles of association, bye laws, deed of establishment and other constitutive, organisational and governing documents.

17.2 The Company recognises and acknowledges that the willingness of GMS to perform the Services for the Services Fees and otherwise upon the terms and conditions of this Agreement, are made on the basis of the Company's representations, warranties and undertakings in this Agreement, and without prejudice to any of its other representations, warranties or undertakings in this Agreement, the Company hereby represents, warrants and undertakes to GMS that:

(a) it is the owner and developer of, and has obtained and will use commercially reasonable endeavours to maintain and keep current, all rights, licences, consents, approvals, permissions, registrations and acknowledgements that are necessary for it to Construct, own, and operate, the Hospital and for the Parties' lawful performance of their respective obligations under this Agreement for the duration of this Agreement;

(b) the Hospital Land shall, for the duration of this Agreement, be leased to, and remain in the possession of, the Company and the Hospital Business shall for the duration of this Agreement after the Opening Date, be carried out by the Company, and neither of which shall not be (and shall not be permitted or suffered to be) sold, transferred, disposed of, assigned or novated to any third parties; and

(c) it shall not interfere with the performance by GMS of the Services or any part thereof nor fail or refuse to co-operate with GMS in such a manner which shall materially affect the ability of GMS to perform its obligations under this Agreement nor be

inadequately staffed or equipped so as to be unable to Construct the Hospital as a hospital of an international standard.

17.3 GMS warrants to the Company that it and/or its related corporations is/are the owner(s) of the Know-How and Proprietary Information. GMS warrants further that to the best of GMS' knowledge, as at the date of this Agreement, no claims have been made by any third parties in Myanmar alleging that the Know-How and Proprietary Information infringes the right of any third party in Myanmar.

18. MISCELLANEOUS

18.1 As all Parties have participated in the drafting of this Agreement, the Parties agree that any applicable rule requiring the construction of this Agreement or any provision hereof against the Party drafting this Agreement shall not apply.

18.2 This Agreement shall be binding upon and inure for the benefit of the successors and permitted assigns of the Parties.

18.3 Where this Agreement provides that any particular transaction or matter requires the consent, approval or agreement of a Party:

(a) such consent, approval or agreement may be given subject to such terms and conditions as such Party may impose and any breach of such terms and conditions by any person subject thereto shall *ipso facto* be deemed to be a breach of the terms of this Agreement; and

(b) the consent, approval or agreement of the representative nominated by such Party to that transaction or matter (either in writing or given orally at a duly convened meeting of the Parties (provided the same is accurately minuted) shall be deemed to be the consent, approval or agreement of such Party for the purposes of this Agreement.

18.4 If the consent, approval or agreement of either Party is required under more than one provision of this Agreement for any one transaction or matter, then any consent, approval or agreement given in relation to that transaction or matter by such Party shall be deemed to cover all consents, approvals or agreement required for that transaction or matter unless otherwise specified by such Party.

18.5 The subject-matter of this Agreement is comprised of separately specified parts, and the illegality, invalidity or unenforceability of any provision of this Agreement under the law of any jurisdiction shall not affect its legality, validity or enforceability under the law of any other jurisdiction nor the legality, validity or enforceability of any other provision, and the illegal, invalid or unenforceable provision shall be deemed not to have been included in this Agreement.

18.6 Each and every communication under this Agreement shall be made by facsimile or otherwise in writing. Each communication or document to be delivered to either Party shall be sent to that Party at the facsimile number, Email address or address and marked for the attention of the person (if any), from time to time designated by that Party for the purpose of this Agreement. The initial addresses and facsimile numbers of the Parties are:

GMS

Fax Number : +65 6734 8917

Email Address	:	
Address	:	111 Somerset Road, #15-01, TripleOne Somerset, Singapore 238164
Attention	:	

The Company

Fax Number	:	
Email Address	:	
Address	:	
Attention	:	

18.7 A demand, notice or other communication made or given by one Party to the other Party in accordance with this Clause 18 shall be effected and deemed to be duly served and received:

(a) if delivered by hand, at the time of delivery; or

(b) if posted by prepaid ordinary mail, at the expiration of five (5) Business Days after the envelope containing the same shall have been put into the post; or

(c) if sent by facsimile, upon the receipt by the sender of the transmission report indicating that the notice or communication has been sent in full to the recipient's facsimile machine, or such other similar medium of receipt; or

(d) if sent by courier, at the expiration of four (4) Business Days after the package containing the same shall have been received by the relevant courier company; or

(e) if sent by email, the earlier of:

(i) when the sender receives an automated message confirming delivery; or

(ii) four hours after the time sent (as recorded on the device from which the sender sent the email) unless the sender receives an automated message that the email has not been delivered,

provided that where such delivery or transmission occurs after 5 p.m. on a Business Day or on a day which is not a Business Day, service shall be deemed to occur at 9 a.m. on the next following Business Day.

In proving such service and receipt, it shall be sufficient to prove that delivery by hand was made or that the envelope containing such notice or document was properly addressed and posted as a prepaid ordinary mail or that the facsimile confirmation note indicates the transmission was successful or that the package containing the same was properly addressed and delivered to the relevant courier company.

18.8 Each Party shall do and execute or procure to be done and executed all such further acts, deeds, things and documents as may be necessary to give effect to the terms of this Agreement, and (so far as it is able) provide such assistance as the other Party may reasonably request to give effect to the spirit and intent of this Agreement.

18.9 This Agreement and the documents referred to in it, constitute the entire agreement and understanding between the Parties relating to the subject matter of this Agreement and no Party has entered into this Agreement in reliance upon any representation, warranty or undertaking of the other Party which is not set out or referred to in this Agreement. Nothing in this Clause 18 shall however operate to limit or exclude liability for fraud.

18.10 Subject to Clause 18.11 below and save as may be specifically provided in this Agreement, no Party shall (nor shall it purport to) assign, transfer, charge or otherwise deal with all or any of its rights under this Agreement nor grant, declare or dispose of any right or interest in it without the prior written consent of the other Party. This Agreement shall be binding upon the successors, legal representatives or permitted assignees of the Parties hereto.

18.11 Notwithstanding anything to contrary, GMS shall upon notice in writing to the Company be entitled to appoint its related corporation to carry out any portion of the Services as it may deem necessary, or to novate this Agreement in favour of such related corporation and the Company shall do all things so as to give effect to the novation of this Agreement in favour of GMS' related corporation.

18.12 No variation of this Agreement (or of any of the documents referred to in this Agreement) shall be valid unless it is in writing and signed by or on behalf of each Party. The expression "variation" shall include any amendment, supplement, deletion or replacement however effected. Unless expressly agreed, no variation shall constitute a general waiver of any provisions of this Agreement, nor shall it affect any rights, obligations or liabilities under or pursuant to this Agreement which have already accrued up to the date of variation, and the rights and obligations of the Parties under or pursuant to this Agreement shall remain in full force and effect, except and only to the extent that they are so varied.

18.13 No failure on the part of a Party to exercise, and no delay on its part in exercising, any right or remedy under this Agreement will operate as a waiver thereof, nor will any single or partial exercise of any right or remedy preclude any other or further exercise thereof or the exercise of any other right or remedy. The rights provided in this Agreement are cumulative and not exclusive of any rights or remedies provided by law.

18.14 Either Party may release or compromise the liability hereunder of the other Party or grant to such other Party time or other indulgence without affecting the liability of such other Party under any other provision of this Agreement.

18.15 All covenants, undertakings and other obligations given or entered into by the Parties are given or entered into severally unless the context otherwise requires.

18.16 Nothing in this Agreement shall be deemed to constitute a partnership between the Parties nor constitute a Party the agent of the other Party for any purpose.

18.17 Each Party shall bear its own legal and other professional costs and expenses in connection with the negotiation, preparation and implementation of this Agreement. The Company shall bear the cost of all stamp duty, any notarial fees and all registration taxes and duties or their equivalents in Myanmar where such taxes, fees, and duties are payable as a result of the execution of this Agreement. The Company shall be responsible for arranging the payment of such taxes, fees, and duties, including fulfilling any administrative or reporting obligation imposed by Myanmar in question in connection with the payment of such taxes, fees and duties. The Company shall indemnify the GMS against any losses suffered by the GMS as a result of the Company failing to comply with its obligations under this Clause **Error! Reference source not found.**~~18.17~~.

18.18 In entering into this Agreement, the Parties recognise that it is impractical to make provision for every contingency that may arise in the course of the observance or performance thereof. Accordingly, the Parties hereby declare it to be a cardinal principle of this Agreement and it to be their common intention that this Agreement shall operate between them with fairness and without detriment to the interests of either of them; and if in the course of the performance of this Agreement, unfairness to a Party is disclosed or anticipated, then the Parties shall use their best endeavours to agree upon such action as may be necessary and equitable to remove the cause or causes of the same.

18.19 Any date, time or period mentioned in any provision of this Agreement may be extended by mutual agreement between the Parties but as regards any time, date or period originally fixed and not extended or any time, date or period so extended as aforesaid, time shall be of the essence.

18.20 This Agreement may be signed in any number of counterparts, all of which taken together shall constitute one and the same instrument. Either Party may enter into this Agreement by signing any such counterpart and each counterpart shall be as valid and effectual as if executed as an original.

18.21 This Agreement is not intended to create any rights to enforce any term of this Agreement in favour of any person or entity who is not a party to this Agreement, and no such rights are created hereunder, except as contemplated in this Agreement (including without limitation, in Clauses 9, 10, 14 and 15). For the avoidance of doubt, GMS' related corporation appointed by GMS pursuant to Clause 18.11 to carry the Services (or any portion thereof) shall have the right to enforce this Agreement as if it were a party hereto. This does not affect any right or remedy of a third party which exists or is available apart from this Agreement.

19. GOVERNING LAW

19.1 This Agreement shall be governed by, and construed in accordance with, the laws of Singapore.

20 DISPUTE RESOLUTION

20.1 In case any dispute or difference shall arise between the Parties as to the construction of this Agreement or as to any matter of whatsoever nature arising hereunder or in connection therewith, including any question regarding its existence, validity or termination, such dispute or difference shall be submitted to arbitration at Singapore International Arbitration Centre ("**Arbitration Institution**") in accordance with the arbitration rules of the Arbitration Institution then in force. The seat of the arbitration shall be Singapore and the arbitration shall be conducted in English. The award of the arbitration tribunal shall be final and binding on the Parties. The arbitration tribunal shall consist of one (1) arbitrator to be appointed by the Parties or, failing agreement within 14 days after a Party has given to the other Party a written request to concur in the appointment of an arbitrator, a single arbitrator to be appointed on the request of either Party by the President of the Court of Arbitration of the Arbitration Institution for the time being.

20.2 The arbitral award made and granted by the arbitrator shall be final, binding and incontestable and may be used as a basis for judgement thereon in Singapore, Myanmar or elsewhere.

20.3 Neither of the Parties shall be entitled to commence or maintain any action in a court of law upon any matter in dispute arising from or in relation to this Agreement except for the enforcement of an arbitral award granted pursuant to this Clause 20, and save and except in

connection with interim relief, pursuant to commencement of arbitration proceedings.

20.4 During the period of submission to arbitration and thereafter until the granting of the arbitral award, the Parties shall, except in the event of termination, continue to perform their obligation under and the terms and conditions of this Agreement that are not in dispute, to the extent possible, without prejudice to a final adjustment in accordance with the said award.

20.5 Notwithstanding anything to the contrary, either Party may before commencement of, during or after the termination of the proceedings referred to in Clause 20.1, apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction, or other interim or conservatory relief, as necessary. Such application shall not be deemed to be an infringement or a waiver of the arbitration agreement herein and shall not affect the relevant powers reserved to the arbitral tribunal.

APPENDIX 1

SCOPE OF SERVICES

1. DESIGN AND DEVELOPMENT PHASE

The primary focus of GMS during the design and development phase is to assist the development of the Hospital as set out below:

(a) GMS shall support the management of the overall procurement plan including bidding, evaluation and selection/award. This includes preparing, inviting, evaluating and negotiating bids for various consultancy services and construction bids.

(b) GMS shall assist the Company on the procurement of design consultancy and contractors engagement, including preparation of terms, bidding documents and advising the Board in evaluation and selection of the required services.

(c) GMS shall advise on the development of the design of the Hospital.

2. PRE-COMMISSIONING PHASE

The following services listed hereunder in this paragraph 2 of this Appendix will be performed by GMS in Singapore and as appropriate, in Yangon, Myanmar.

(a) GMS will review the equipment requirements and listings prepared by specialist consultants engaged by the Company and recommend the necessary equipment for the Company to purchase.

(b) GMS will work with the Key Personnel to assist the planning of the operational aspects of the Hospital, such as clinical programme development, housekeeping and linen, medical records, material management and plant and building maintenance, and nursing.

(c) GMS will advise the Company on the development of goals and objectives for the Hospital and define and measure department-wise key performance indicators, to be ready at least two (2) months before the Opening Date.

3. COMMISSIONING PHASE - ACTIVITIES AT THE HOSPITAL

GMS will work with the Key Personnel and heads of departments to oversee the taking over of the physical facilities of the Hospital at the Hospital Land and plan the following activities:

(a) Working with and assisting the Company to inspect the Hospital for compliance with the design brief and to support the handover of the Hospital.

(b) Assisting in the planning and conducting of orientation programmes with Hospital Staff to ensure smooth functioning of each department.

(c) Assisting in the organising and supervising of a dry run for all departments (subject to the departments having engaged the appropriate number and description of Hospital Staff to participate in such a dry run).

(d) As part of the pre-opening orientation, availing to the Key Personnel of the Hospital, vocational attachments to such hospitals or other medical facilities of GMS and/or its related corporations, as GMS shall in its sole discretion determine. The duration of each attachment shall range from five (5) days for non-nursing staff to forty (40) days for nursing staff, and all air travel, accommodation, food and other out-of-pocket expenses (including *per diem* expenses) of such attachees while on such attachment shall be borne solely by the Company.

For the avoidance of doubt, the services listed under paragraphs 3(a), 3(b) and 3(c) above shall be performed completely at the Hospital or its associated training or clinical locations. The attachments referred to in paragraph 3(d) shall be outside of Myanmar.

APPENDIX 2

SERVICES FEES

1. The Services Fees shall be Singapore Dollars Two Million (S$2,000,000), and shall be payable following completion of the relevant milestones of the Services ("**Milestone**") in accordance with Appendix 1 and as follows:

Milestone	**Services Fees**
(a) Completion of the detailed design of the Hospital	S$ 350,000
(b) Recept of the building completion certificate from the relevant authorities in respect of any section of the Hospital (i.e. construction handover)	S$ 350,000
(c) The Opening Date having occurred	S$ 1,300,000

2. Subject to Clause 4.4, payment to GMS of the Services Fees (which, for the avoidance of doubt is Singapore Dollars Two Million (S$2,000,000)) shall be

   (a) made at the rate at of one per. cent. (1%) of Revenue of each Reference Period; and

   (b) paid in Quarterly instalments commencing after the Opening Date with each instalment being paid within ten (10) Business Days from the end of each Quarter,

   until such time as the Services Fees have been fully paid.

3. For the purpose of calculating the portion of Services Fees to be paid for any Quarter, the Quarterly Revenue for such Quarter shall be annualized (i.e. multiplied by a factor of four (4)) first and the percentage set out in paragraph 2(a) of this Appendix 2 will apply to derive the annualized Services Fees for each Quarter. The portion of the Services Fees to be paid for each Quarter prior to the Last Quarter shall be twenty-five per. cent. (25%) of the annualized Services Fees for that Quarter. For the avoidance of doubt, where the amount of Services Fees outstanding in a Quarter ("**Last Quarter**") is, prior to payment being made, less than a quarter per. cent. (0.25%) of the annualized Revenue (calculated in accordance with paragraph 3) for the Last Quarter, the portion of Services Fees to be paid for the Last Quarter shall be the outstanding amount.

4. In connection with the calculation of the portion of Services Fees to be paid in respect of any Reference Period, the Company shall procure that the Audited Accounts are prepared and approved within five (5) months from the end of the relevant Reference Period.

5. The Company shall procure that the Auditors audit the Revenue, for the purpose of settling the portion of the Services Fees to be paid in respect of any Reference Period, in accordance with the definition in this Agreement. The Parties agree that the Revenue accumulated from any previous financial year(s) (whether positive or negative) shall not be brought forward into the computation, and the Revenue shall be computed by the Auditors solely and exclusively on a current financial year basis. Within ten (10) Business Days of the finalization of the Revenue, the Parties will settle the portion of the Services Fees to be paid in respect of such Reference Period. Any shortfall will be paid by the Company to GMS within five (5) Business Days thereafter and any overpaid amount will be deducted from subsequent payments to GMS or, and only in the case where there are no subsequent payments to be made to GMS under this Agreement, reimbursed to the Company.

For the avoidance of doubt the Services Fees do not include the Reimbursable Expenses nor the costs of the GMS-appointed Key Personnel which, upon appointment, will be paid directly by the Company.

APPENDIX 3

FORM OF HOSPITAL MANAGEMENT AGREEMENT

IN WITNESS WHEREOF the Parties have executed this on the date set out at the beginning of this Agreement.

SIGNED by)
[•])
for and on behalf of)
GLENEAGLES MANAGEMENT SERVICES)
PTE LTD)
in the presence of)

____
Witness's signature
Name:
Address:

SIGNED by
[•])
for and on behalf of)
ANDAMAN ALLIANCE HEALTHCARE)
LIMITED)
in the presence of)
)

____
Witness's signature
Name:
Address:

- **Annex F IEE and Environmental Management Plan**


Parkway
YANGON

BACKGROUND

The Parkway Group, a leading international provider of premium healthcare services in various markets with strong and rapidly growing demand for quality healthcare services, has decided for its presence in Myanmar.

PROJECT RATIONALE

The project is committed to establishing a long term presence in Myanmar and developing a world-class hospital to contribute to building a robust healthcare industry in Myanmar. Myanmar is faced with a growing need for healthcare services and an increasing demand for quality healthcare.



World Health Organization

Myanmar: WHO statistical profile

Basic statistics

Indicators	Statistics	Year
Population (thousands)	53259	2013
Population aged under 15 (%)	25	2013
Population aged over 60 (%)	8	2013
Median age (years)	29	2013
Population living in urban areas (%)	33	2013
Total fertility rate (per woman)	1.9	2013
Number of live births (thousands)	916.5	2013
Number of deaths (thousands)	444.9	2013
Birth registration coverage (%)	72	2009-2010
Cause-of-death registration coverage (%)	...	
WHO region	South-East Asia	2013
World Bank income classification	Low	2013

... Data from 2007 onwards not available.

Source:
Country statistics and global health estimates
by WHO and UN partners

For more information visit the Global Health Observatory
(http://www.who.int/gho/en/)

Last updated: January 2015

Life expectancy (years), 2012

		Country	WHO region	World Bank income group
Life expectancy	At birth	66	67	62
	At age 60	17	17	17
Healthy life expectancy	At birth	57	59	53

Life expectancy at birth for both sexes increased by 3 year(s) over the period of 2000-2012; the WHO region average increased by 5 year(s) in the same period.

In 2012, healthy expectancy in both sexes was 9 year(s) lower than overall life expectancy at birth. This lost healthy life expetancy represents 9 equivalent year(s) of full health lost through years lived with morbidity and disability.

Millennium Development Goals (MDGs)

Indicators	Statistics Baseline*	Latest**
Under-five mortality rate (per 1000 live births)	109	51
Maternal mortality ratio (per 100 000 live births)	580	200
Deaths due to HIV/AIDS (per 100 000 population)	17.3	21.6
Deaths due to malaria (per 100 000 population)	7.1	5.4
Deaths due to tuberculosis among HIV-negative people (per 100 000 population)	135	49

*1990 for under-five mortality and maternal mortality; 2000 for other indicators
**2012 for deaths due to HIV/AIDS and malaria ; 2013 for other indicators

Figure 1 WHO statistical profile (Source: http://www.who.int/gho/countries/mmr.pdf?ua=1)

Due to the lack of high quality healthcare in Myanmar today, hundreds of thousands of Myanmar patients seek medical treatment overseas on an annual basis. There is a need for healthcare of international standards and this development will help to meetthe demand and enable patients who currently seek medical treatment overseas to receive the same level of medical care locally.

The project aims to elevate the standards of the healthcare industry by adopting international benchmarks for patient service and clinic quality. The hospital will draw patients from all over Myanmar, and with a hope to become a healthcare hub in Indochina.

Project management recognizesto work closely together with the community in order to understand the local needs and to better serve the population in Yangon and, subsequently, the rest of Myanmar. The management believes in hiring and training local staff and ensuring that there is adequate knowledge transfer from within the network. Understanding and serving the community well will take time and the JV Company is prepared to commit resources toward developing a long term relationship with the Myanmar community.

HOSPITAL SERVICES

The hospital will have an emergency department, an acute care services department (including ICU, HDU, NICU, Anaesthetic etc), diagnostic imaging services department, health screening department, rehabilitation department, and an extensive range of outpatient specialty clinics, including -

- General Medicine and Surgery
- Obstetrics and Gynaecology
- Oncology
- Cardiology
- Orthopaedic
- Internal Medicine
- Otolaryngology
- Paediatrics

Specialised centres of excellence will be established to enhance the clinical practice for complex diseases, for example in Oncology, Cardiology, Neuroscience, or Orthopaedics.

Other benefits

In addition, the project is expected to bring other benefits including not limited to the following:

- Improving the healthcare standard in Myanmar generally
- Training local healthcare professionals and administrative staff to attain an international standard
- Technology and management skills transfer

OBJECTIVE AND SCOPE OF IEE

The overall objective of this IEE is to present the findings of the assessment on the potential impacts that the Project may have on the surrounding environment. The report will aim to assist the relevant authorities in evaluating the activities and mitigation actions proposed under the Project, as well as to guide the Project Proponent in implementing the prescribed actions.

The scope of the IEE includes the following:

1. An assessment of the current baseline conditions of the Project Site and its surroundings to establish the existing environmental quality and to identify the receptors that may be at risk from the impacts of the Project;

2. The identification of potential concerns that may arise from the Project activities and the significance of their impacts on the identified receptors;

3. Recommendations on appropriate mitigation measures to reduce and abate the severity of any negative impacts resulting from the Project as to protect these receptors; and

4. A proposal on appropriate environmental management and monitoring programmes during the Project construction and operation as a means to ascertain

appropriateness and effectiveness of mitigation measures identified.

APPROACH

The preparation of this IEE report was carried out through a variety of methods which aimed to gather accurate information relevant for the assessment within a timeframe that would allow for the planning of the Project to proceed without
hindrance. The main approaches undertaken are summarized as follows:

- Visual observations during visits to the site and surrounding areas;
- Discussion with members of the Project team including
  - planners, engineers and project staff;
- Data obtained from the Project Proponent
- Other literature obtained from secondary sources such as reports, papers,
  - news articles etc.

LEGAL REQUIREMENTS

Foreign Investment Law, 2012

Myanmar's latest Foreign Investment Law (No. 21/2012) was enacted in November 2012. The enactment aimed to ensure that any foreign investment results in equitable benefits for the country in terms of employment and business opportunities, while targeting critical sectors e.g. infrastructure, transportation, finance and banking, information technology and telecommunications, etc.

The enactment highlights a number of basic principles that need to be adhered to by all investors, one of which is the 'protection and conservation of the environment'. Among the related types of business that are prescribed as either restricted or prohibited are those which (1) can affect public health, (2) can cause damage to the natural environment and ecosystem, (3) can bring hazardous or poisonous waste into the country, and (4) factories that produce or use hazardous chemicals.

The enactment is presently enforced through the Myanmar Investment Commission whose duties, among other things, is to evaluate all investment proposals for not only financial credibility, economic justification, appropriateness of technology but also on the protection

and conservation of the environment. The investors duties under the enactment are also listed, one of which is that investors, in carrying out their business, are not to cause environmental pollution and damage.

ENVIRONMENTAL BASELINE CONDITIONS

4.0 SECTION 4: ENVIRONMENTAL

Yangon, also known as Rangoon, was the former capital city of Myanmar and is the largest city with an estimated population of six million people.It is the main trading hub for all kinds of goods and services, and there are at least nine main industrial zones around the city. Tourism now represents a significant contributor to the economy.

The Yangon Region accounts for around 12% of the national population and contributes around 22% of the country's gross domestic product (GDP), therefore it is no coincidence that Yangon City is referred to as the Economic Center of Myanmar. In the past two decades, Yangon City experienced an annual population growth rate of 2.58%, from 2.47 million in 1998 to 5.14 million in 2011. Average population growth rates of the central business district (CBD) are approximately zero or negative while the suburbs recorded high growth rates of between 6-7%. As of 2011, the ratio of the labour population to the total population in Yangon City stood at 50.8% or a total of 2.61 million. The labour population in the suburbs has been growing rapidly in recent years, with around 70% of the working population (1.78 million) are engaged in tertiary industries (The Strategic Urban Development Plan of the Greater Yangon, Yangon City Development Committee, 2013).

Project Location

The project site is in the areas of biggest government hospitals, university of nursing, and adjacent diplomatic areas. The site is located at the corner of Pyay Road and Bo Gyoke Road in Yangon, Myanmar.

Local Drainage

YCDC public drainage system surrounds the site. No flood occurrence has however been reported at the Project site and its immediate surrounding area.

Traffic

As the project site is in hospital areas and southwards of its is adjacent diplomatic areas,

traffic situation around is fairly good compared to many areas of severe traffic condition in Yangon.

1. IMPACTS DURING CONSTRUCTION STAGE

1.1. Construction Related Noise

Best practices will be adopted by the contractor to manage the noise levels in accordance to local requirements. Points of references, where applicable/ possible, may include:

- Provision of lined and sealed acoustic covers for equipment. In addition, equipment should be placed with consideration to neighbouring developments.
- Turning off plant and equipment when not in use. Machinery must also be maintained regularly to prevent degradation.
- Installation of noise monitoring equipment to track noise levels and to mitigate if levels exceed the limits (70dDA) set by the Yangon City Development Committee.
- Noisy works to be carried out within allowable hours. Operation hours for heavy vehicles shall be restricted to timing as required by the Yangon City Development Committee. However, considerations should be placed to avoid complains from surrounding existing hospital and residents.
- Acoustic screens may be considered on the hoardings if necessary to reduce noise transmission to the surrounding areas.

1.2. Construction Related Vibration

The contractor will be required to install vibration monitoring equipment within the proximity of the site and surround areas to ascertain and monitor the impact of vibration. A pre-condition survey will be carried out to determine if the heavy works conducted on the site has an adverse effect on nearby buildings. If needed, isolators and attenuation dampers should be provided to reduce vibration from piling activities. Where possible, alternate construction methods with low vibration generation may be considered.

1.3. Dust Management

The contractor will provide road cleaning equipment to remove dirt, mud or dust dropped or accumulating on the haulage or site roads to ensure that the public roads remain unaffected. All vehicles exiting the site will have their wheels washed using water jet inside the wash trough at site entrances/ exits. To further mitigate dust occurrence, the site may be covered with plastic tarpaulin in areas where material is being transported in an out. This prevents spillage of the material onto the public roads.

1.4. Soil Erosion and Sediment Control

To prevent soil erosion and to control sediment, installation of silt trap, silty water treatment system or equivalent earth control measure facility on site for removal of bed load and heavier suspended sediments prior to discharge into external drains. All run-off as a result of the construction works is to be channelled through the control facility before entering the municipal drain. Soil should be well compacted to minimize erosion before the construction of the building.

1.5. Water Pollution Management

Adequate satisfactory levels of toilet shall be installed on site (eg. Portable, pit, dry toilet). Sewage effluent shall be treated to comply with the requirements set by the Pollution Control and Cleansing Department, the Committee for Quality Control of High-rise Building Projects, the Yangon City Development committee or any other regulatory body, prior to discharge to external drains. If there is a kitchen on site, grease traps should be installed to remove the oil and grease before waste water enters the drain.

1.6. Waste Management

Throughout the development process, best attempts will be made to reduce the amount of waste going to land fill and to maximise the use of recycling facilities and opportunities to reuse materials. All wastes shall be segregated, collected and stored according to type and disposed periodically at the designated landfill or areas approved by the Yangon City Development Committee. Where possible, recyclable construction material can be considered instead of conventional methods. It is critical to have good housekeeping practices at all times to minimize presence of pests and disease vectors. In order to achieve this, adequate number of waste bins is to be provided at the works camp. Open burning should be avoided.

1.7. Traffic Management

A traffic study may be carried out if necessary to determine if construction works will have an adverse impact on the surrounding traffic conditions. Should it be deemed necessary, public path diversions or traffic flow will be managed by the contractor team in the form of traffic marshals. Appropriate signage will also be displayed in areas with high traffic to alert pedestrians and motorist on the development works. Movement of construction vehicles is to adhere to Yangon City Development Committee requirements.

1.8. Public Awareness and Communication

Prior to the commencement of construction works, the contractor will be required to issue notices to the surrounding development to notify on the details of the project. In addition, a project signboard is to be erected at a location with high visibility to inform on contact detail, start and end date of the project, the stakeholders involved as well as the nature of the

development. The personnel listed should be contactable at all times in order to address possible concerns called in by the public.

1.9. Employment opportunities during construction

The Project would require 200 workers, especially during the construction stage. The current trend of labour in Myanmar is to employ local people. The demand for construction workers from the local workforce, although temporary, would create an increase in employment opportunities and be beneficial to the local community.

2. IMPACTS DURING OPERATION STAGE

2.1. Employment Opportunities during operation

The Project will open up employment opportunities at health care service professional level of about 1000 local workforces during the operation of the Project.

The Project will also likely to open up employment opportunities for foreign doctors and specialists to work and care for patients as well as to share experience and expertise in certain areas which the hospital may be lacking in. This will also be beneficial to the local doctors and nurses since they are able to gain knowledge from foreign experts.

2.2. Downstream Economic Activities

Existing food businesses and retail shops located nearby, which are mainly operated by the locals, are likely to benefit from the Project through increased business opportunities. With the Project, this means more patients can be accommodated and there would be an increase in the number of visiting family members and friends. These visitors would then drop by at the restaurants or retail shops nearby during non-visiting hours or long waiting period. In addition, the Project is expected to encourage more small businesses, particularly restaurants and retail shops, to open around the Project area.

2.3. Landscape and Environment

At present, the Project site is a vacant land. This landscape will change when the Project,

a8-storey building, comprising of offices, staff facilities and hospital wards building, is constructed.

2.4. Disposal of Medical Waste

2.4.1. Wastewater Management

If the hospital is not connected to any municipal treatment plant, it will have its own sewage treatment plants, on-site treatment or pre-treatment of wastewater.

The efficient on-site treatment of hospital sewage includes the following operations.

i. Primary Treatment
ii. Secondary Biological Purification
iii. Tertiary Treatment
iv. Chlorine disinfection




Figure 1 Wastewater Treatment Management

Hence, the hospital will provide space for on-site treatment plant, decontamination tank & disinfection tank in full attention of the following potentially hazardous components.

a) Microbiological pathogens

The principal area of concern is wastewater with a high content of enteric pathogens, including bacteria, viruses, and helminths, which are easily transmitted through water. Contaminated wastewater is produced by wards treating patients with enteric diseases and is a particular problem during outbreaks of diarrheal disease.

b) Hazardous chemicals

Small amounts of chemicals from cleaning and disinfection operations are regularly discharged into sewers.

c) Pharmaceuticals

Small quantities of pharmaceuticals are usually discharged to the sewers from hospital pharmacies and from the various wards.

d) Radioactive isotopes

Small amounts of radioactive isotopes will be discharged into sewers by oncology departments.

e) Non-risk waste

Which is comparable to normal domestic garbage and presents no greater risk, therefore, than waste from a normal home. This general waste is generated by almost everybody in the hospital, I.e., administration, patient's risk, cafeterias rooms, cafeterias and nursing station.

s/n	Activity	Potential Impact	Mitigation Measures
1	Non-risk waste	Contamination of soil and water, odour, proliferation of vectors (rodents, flies, others)	Non-risk waste will be disposed with the municipal waste Proper storage arrangements (such as dumpsters) avoiding any spill-over/over-flowing Regular transportation of waste from healthcare facility to the municipal waste disposal site.
2	Water supply	Health hazard for staff and patients	Ensure that drinking water complies with local standards; Carry out water analysis periodically.
3	Sewage disposal	Health hazard for staff and patients	Ensure that the treatment system (eg, septic tank) is properly working

Figure 2 Table showing impact and mitigation measure for wastewater management

2.4.2. Waste Management

Wastes from the hospital includes infectious waste, pathological waste, contaminated sharps, routine clinical waste, cytotoxic waste, radioactive waste, pharmaceutical waste, chemical waste and general waste. The hospital waste management programme should incorporate the following steps:

- Identification of waste types
- Segregation of waste
- Transport & storage of waste
- Proper disposal of waste
- Implementation of contingency plans
- Identify the need for use of personal protective equipment

Three categories

- Infectious waste - Red bags
- Domestic waste - Green Bags
- Sharps - Needle cutters / Puncture proof containers
- Segregation at Source (ward, operation theatre, laboratory, labour room, other places)

Transportation

- Containers: puncture proof, leak proof,
- Bags: sturdy, properly tied
- Transport trolleys: designated & timely
- Staff protection: provided with protective clothing and other items
- Never put hands in a bag

Waste storage

- Closed covered area
- Away from the normal passages
- Easily accessible for transportation
- Radioactive waste special containers/ special treatment and disposal

Proper disposal of waste

- All infectious waste and sharps containers :Incineration
- All Domestic waste : Landfill
- All hazardous waste : Chemical treatment before disposal

Implementation of contingency plans

- Contingency plans have to be in place to be implemented whenever any of the steps in the chain breaks and everyone should be aware of their responsibilities in case of breakdown.

Identify the need for use of personal protective equipment

- Special clothing, gloves, masks and eye protection should be identified and provided to the healthcare workers responsible for waste transportation and disposal.

Hospital Waste and its disposal method can be categorised as follow:

Option	Waste Category	Treatment & Disposal
Category 1	Human anatomical waste	Incineration/ deep burial
Category 2	Animal waste	Incineration/ deep burial
Category 3	Microbiology & Biotechnology waste	Incineration/ deep burial
Category 4	Sharps	Incineration/ disinfection/ chemical treatment/ mutilation
Category 5	Medicines and cytotoxic drugs	Incineration/ destruction and disposal in secured landfill

Category 6	Solid waste (blood and body fluids)	Autoclave/ chemical treatment/ burial
Category 7	Solid waste (disposable items)	Autoclave/ chemical treatment/ burial
Category 8	Liquid waste (blood & body fluids)	Disinfection by chemicals/ discharge into drains
Category 9	Incineration Ash	Disposal in municipal landfill
Category 10	Chemical waste	Chemical treatment/ secure landfill

Figure 3 Table showing waste category and disposal method

The risks on the method of disposal can be mitigated in the following manner:

s/n	Activity	Potential Impact	Mitigation Measures
1	Waste segregation	Health and safety risk for staff and patients	• Use of infection control protocol. • Use of PPE • Use of colour coded buckets with thick, puncture resistant plastic bags • Ensuring that bags are not punctured (disinfection of the bucket/area to be carried out in case of leakage from bags) • Awareness raising of patients and their attendants.
2	Infectious waste collection and transportation	Health and safety risks for waste handlers	• Use of infection control protocol Use of PPEs • Ensuring that waste bags are not opened or punctured during transportation • Ensuring that bags are not punctured (disinfection of the trolleys/area to be carried out in case of leakage from bags) • Proper documentation and handover-takeover protocol along with "chain of custody" protocol • Implement measures to forestall any pilferage of medical waste for recycling.
3	Infectious waste storage	Health and safety risks for waste handlers	• Use of infection control protocol; • Proper controlled-access storage • Ensuring that waste bags are not opened or punctured in the storage • Ensuring that bags are not punctured (disinfection of the trolleys /area to be carried out in

			case of leakage from bags) • Use of PPEs; Weighing of waste • Proper documentation and handover-takeover protocol • Security arrangements to avoid theft/pilferage.
4	Infectious waste disposal (burial)	Health and safety risks for waste handlers, waste pickers; Soil and water contamination	• Use of infection control protocol • Use of PPEs • Proper documentation and handover-takeover protocol • Using impervious lining in the pits to avoid soil and water contamination • Locating the pit at least 50 m from any water source • Using proper signage for pit location • Maintain complete record of waste disposal and pit location in each facility.
5	Infectious waste disposal (burning/ incineration)	Health and safety risks for waste handlers; Air contamination	• Use of infection control protocol; • Uncontrolled, open burning of infectious waste particularly containing plastics and PVC objects will be avoided to the extent possible • Proper documentation and handover-takeover protocol • Use of PPEs • Maintain complete record of waste disposal.

Figure 4 Table showing mitigation on disposal methods

PROPOSED DEVELOPMENT OF A PRIVATE GENERAL HOSPITAL IN YANGON CITY, REPUBLIC OF THE UNION OF MYANMAR

Environmental Management Plan

November 2015


Contents

1. INTRODUCTION 1
1.1. Project Description 1
1.2. Specialties Services 1
1.3. Other Support Services 1
2. ENVIRONMENTAL MANAGEMENT PLAN 3
2.1. Introduction 3
2.2. Construction Stage 3
2.2.1. Construction Related Noise 3
2.2.2. Construction Related Vibration 4
2.2.3. Dust Management 4
2.2.4. Soil Erosion and Sediment Control 4
2.2.5. Water Pollution Management 4
2.2.6. Waste Management 4
2.2.7. Traffic Management 5
2.2.8. Public Awareness and Communication 5
2.3. Operation Stage 5
2.3.1. Wastewater Management 6
2.3.2. Waste Management 8
2.4. Environmental Monitoring 11
2.4.1. Environmental Inspection 11
2.4.2. Monitoring of Environmental Quality 11
2.4.2.1. Noise Levels 11
2.4.2.2. Vibration 12
2.4.2.3. Water Quality 12

1. INTRODUCTION

1.1. Project Description

The subject site is approximately 5 acres and it is proposed to be developed into a private multi-tertiary hospital with 250 beds and associated specialties services. The site is located at the corner of Pyay Road and Bo Gyoke Road in Yangon, Myanmar, as appended below as highlighted in Red. It is strategically located in a commercial area with close proximity to other general hospitals.



Phase 1 is planned for 100 beds (as detailed in Annex B – Phasing Plan) and a basement with related support facilities such as sewerage treatment plant, main mechanical & electrical plant rooms and other support facilities.   The infrastructure for the entire hospital is also to be completed in Phase 1. The remaining 150 beds will be built in Phase 2 with other support services. It will be developed in 3 years or more after completion of Phase 1.

1.2. Specialties Services

- Oncology
- Cardiac (Surgical/ Medical/ Intervention Cardiology)
- Endoscopy
- Obstetrics and Gynaecology
- Paediatrics (Medical and Surgical)
- General Surgery
- Internal Medicine
- Orthopaedics

1.3. Other Support Services

- Radiology

- Pharmacy
- Laboratory
- Rehabilitation
- Kitchen
- Laundry
- Mortuary

2. ENVIRONMENTAL MANAGEMENT PLAN

2.1. Introduction

The environmental management plan is developed to address concerns during the construction stage and subsequently, the operation of the hospital. The purpose of this document is to outline how the developer, contractor and operation team will manage and where practical or possible, minimize the impact and mitigate potential risks during the different stages of the development. We are committed in achieving high environmental standards and working closely with the local community and other stakeholders throughout the development period.

The EMP is a ‘live’ document and is to be assessed periodically between consultants and contractor. An essential element of the EMP is the environmental monitoring framework which forms the bases upon which the effectiveness of the implementation of the EMP is assessed. It also provides information against which compliance to the relevant conditions and regulations can be checked to help identify areas for correction and improvement.

2.2. Construction Stage

A detailed EMP will be developed by the awarded Main Contractor which addresses specific site conditions. An Environmental Health Officer may be appointed, if necessary, to mitigate the following construction areas.

2.2.1. Construction Related Noise

Best practices will be adopted by the contractor to manage the noise levels in accordance to local requirements. Points of references, where applicable/ possible, may include:

- Provision of lined and sealed acoustic covers for equipment. In addition, equipment should be placed with consideration to neighbouring developments.
- Turning off plant and equipment when not in use. Machinery must also be maintained regularly to prevent degradation.
- Installation of noise monitoring equipment to track noise levels and to mitigate if levels exceed the limits (70dDA) set by the Yangon City Development Committee.
- Noisy works to be carried out within allowable hours.Operation hours for heavy vehicles shall be restricted to timing as required by the Yangon City Development Committee. However, considerations should be placed to avoid complains from surrounding existing hospital and residents.
- Acoustic screens may be considered on the hoardings if necessary to reduce noise transmission to the surrounding areas.

2.2.2. Construction Related Vibration

The contractor will be required to install vibration monitoring equipment within the proximity of the site and surround areas to ascertain and monitor the impact of vibration. A pre-condition survey will be carried out to determine if the heavy works conducted on the site has an adverse effect on nearby buildings. If needed, isolators and attenuation dampers should be provided to reduce vibration from piling activities. Where possible, alternate construction methods with low vibration generation may be considered.

2.2.3. Dust Management

The contractor will provide road cleaning equipment to remove dirt, mud or dust dropped or accumulating on the haulage or site roads to ensure that the public roads remain unaffected. All vehicles exiting the site will have their wheels washed using water jet inside the wash trough at site entrances/ exits. To further mitigate dust occurrence, the site may be covered with plastic tarpaulin in areas where material is being transported in an out. This prevents spillage of the material onto the public roads.

2.2.4. Soil Erosion and Sediment Control

To prevent soil erosion and to control sediment, installation of silt trap, silty water treatment system or equivalent earth control measure facility on site for removal of bed load and heavier suspended sediments prior to discharge into external drains. All run-off as a result of the construction works is to be channelled through the control facility before entering the municipal drain. Soil should be well compacted to minimize erosion before the construction of the building.

2.2.5. Water Pollution Management

Adequate satisfactory levels of toilet shall be installed on site (eg. Portable, pit, dry toilet). Sewage effluent shall be treated to comply with the requirements set by the Pollution Control and Cleansing Department, the Committee for Quality Control of High-rise Building Projects, the Yangon City Development committee or any other regulatory body, prior to discharge to external drains. If there is a kitchen on site, grease traps should be installed to remove the oil and grease before waste water enters the drain.

2.2.6. Waste Management

Throughout the development process, best attempts will be made to reduce the amount of waste going to land fill and to maximise the use of recycling facilities and opportunities to reuse materials. All wastes shall be segregated, collected and stored according to type and disposed periodically at the designated landfill or areas approved by the Yangon City Development Committee. Where possible, recyclable construction material can be considered instead of conventional methods. It is critical to have good housekeeping practices at all times to minimize presence of pests and disease vectors. In order to achieve

this, adequate number of waste bins is to be provided at the works camp. Open burning should be avoided.

2.2.7. Traffic Management

A traffic study may be carried out if necessary to determine if construction works will have an adverse impact on the surrounding traffic conditions. Should it be deemed necessary, public path diversions or traffic flow will be managed by the contractor team in the form of traffic marshals. Appropriate signage will also be displayed in areas with high traffic to alert pedestrians and motorist on the development works. Movement of construction vehicles is to adhere to Yangon City Development Committee requirements.

2.2.8. Public Awareness and Communication

Prior to the commencement of construction works, the contractor will be required to issue notices to the surrounding development to notify on the details of the project. In addition, a project signboard is to be erected at a location with high visibility to inform on contact detail, start and end date of the project, the stakeholders involved as well as the nature of the development. The personnel listed should be contactable at all times in order to address possible concerns called in by the public.

2.3. Operation Stage

Environment management in the operation of healthcare sector comprises of:

- waste management
- water and sanitation
- infection control
- occupational health
- safety of healthcare workers, patients, and nearby communities.

Mitigation and management of these issues has an overarching impact on health service delivery by reducing the risk of infection, safety and health hazards, and providing a safe and hygienic healthcare infrastructure. Among the environment management strategies associated with healthcare facilities, Healthcare Waste Management Plan (HWMP) and infection control practices constitute the highest potential risk of environmental pollution and infection. Most of the waste generated in the healthcare facilities can be treated as ordinary municipal solid waste. However, generally a small portion of the Healthcare Waste (HCW) requires special attention; these wastes include sharps (needles, razors, and scalpels), pathological waste, other potentially infectious waste, pharmaceutical waste, biological waste, hazardous chemical waste, and waste from microbiological laboratories.

Mismanagement of HCW poses risks to people and environment. The healthcare workers, patients, waste handlers, waste pickers, and general public are exposed to health risks from infectious waste, chemicals, and other special healthcare waste. Improper disposal of special healthcare waste, including open dumping and uncontrolled burning, increases the risk of spreading infections and exposure to toxic emissions from uncontrolled combustion. Proper management of HCW can minimize the risks both within and outside healthcare facility. The first priority in this respect is waste segregation, preferably at the point of waste generation. Other important steps are institution of the sharp management system, waste reduction, ensuring workers safety, providing secure method of waste collection and transportation, minimization of hazardous substances wherever possible (eg, PVC-containing products and mercury), and installing safe treatment and disposal mechanisms.

2.3.1. Wastewater Management

If the hospital is not connected to any municipal treatment plant, it will have its own sewage treatment plants, on-site treatment or pre-treatment of wastewater.

The efficient on-site treatment of hospital sewage includes the following operations.

i. Primary Treatment
ii. Secondary Biological Purification
iii. Tertiary Treatment
iv. Chlorine disinfection




Figure 1 Wastewater Treatment Management

Hence, the hospital will provide space for on-site treatment plant, decontamination tank & disinfection tank in full attention of the following potentially hazardous components.

a) Microbiological pathogens

The principal area of concern is wastewater with a high content of enteric pathogens, including bacteria, viruses, and helminths, which are easily transmitted through

water. Contaminated wastewater is produced by wards treating patients with enteric diseases and is a particular problem during outbreaks of diarrheal disease.

b) Hazardous chemicals

Small amounts of chemicals from cleaning and disinfection operations are regularly discharged into sewers.

c) Pharmaceuticals

Small quantities of pharmaceuticals are usually discharged to the sewers from hospital pharmacies and from the various wards.

d) Radioactive isotopes

Small amounts of radioactive isotopes will be discharged into sewers by oncology departments.

e) Non-risk waste

Which is comparable to normal domestic garbage and presents no greater risk, therefore, than waste from a normal home. This general waste is generated by almost everybody in the hospital, I.e., administration, patient's risk, cafeterias rooms, cafeterias and nursing station.

s/n	Activity	Potential Impact	Mitigation Measures
1	Non-risk waste	Contamination of soil and water, odour, proliferation of vectors (rodents, flies, others)	Non-risk waste will be disposed with the municipal waste Proper storage arrangements (such as dumpsters) avoiding any spill-over/over-flowing Regular transportation of waste from healthcare facility to the municipal waste disposal site.
2	Water supply	Health hazard for staff and patients	Ensure that drinking water complies with local standards; Carry out water analysis periodically.
3	Sewage disposal	Health hazard for staff and patients	Ensure that the treatment system (eg, septic tank) is properly working

Figure 2 Table showing impact and mitigation measure for wastewater management

2.3.2. Waste Management

Wastes from the hospital includes infectious waste, pathological waste, contaminated sharps, routine clinical waste, cytotoxic waste, radioactive waste, pharmaceutical waste, chemical waste and general waste. The hospital waste management programme should incorporate the following steps:

- Identification of waste types
- Segregation of waste
- Transport & storage of waste
- Proper disposal of waste
- Implementation of contingency plans
- Identify the need for use of personal protective equipment

Three categories

- Infectious waste - Red bags
- Domestic waste - Green Bags
- Sharps - Needle cutters / Puncture proof containers
- Segregation at Source (ward, operation theatre, laboratory, labour room, other places)

Transportation

- Containers: puncture proof, leak proof,
- Bags: sturdy, properly tied
- Transport trolleys: designated & timely
- Staff protection: provided with protective clothing and other items
- Never put hands in a bag

Waste storage

- Closed covered area
- Away from the normal passages
- Easily accessible for transportation
- Radioactive waste special containers/ special treatment and disposal

Proper disposal of waste

- All infectious waste and sharps containers :Incineration
- All Domestic waste : Landfill
- All hazardous waste : Chemical treatment before disposal

Implementation of contingency plans

- Contingency plans have to be in place to be implemented whenever any of the steps in the chain breaks and everyone should be aware of their responsibilities in case of breakdown.

Identify the need for use of personal protective equipment

- Special clothing, gloves, masks and eye protection should be identified and provided to the healthcare workers responsible for waste transportation and disposal.

Hospital Waste and its disposal method can be categorised as follow:

Option	Waste Category	Treatment & Disposal
Category 1	Human anatomical waste	Incineration/ deep burial
Category 2	Animal waste	Incineration/ deep burial
Category 3	Microbiology & Biotechnology waste	Incineration/ deep burial
Category 4	Sharps	Incineration/ disinfection/ chemical treatment/ mutilation
Category 5	Medicines and cytotoxic drugs	Incineration/ destruction and disposal in secured landfill
Category 6	Solid waste (blood and body fluids)	Autoclave/ chemical treatment/ burial
Category 7	Solid waste (disposable items)	Autoclave/ chemical treatment/ burial
Category 8	Liquid waste (blood & body fluids)	Disinfection by chemicals/ discharge into drains
Category 9	Incineration Ash	Disposal in municipal landfill
Category 10	Chemical waste	Chemical treatment/ secure landfill

Figure 3 Table showing waste category and disposal method

The risks on the method of disposal can be mitigated in the following manner:

s/n	Activity	Potential Impact	Mitigation Measures
1	Waste segregation	Health and safety risk for staff and patients	• Use of infection control protocol. • Use of PPE • Use of colour coded buckets with thick, puncture resistant plastic bags • Ensuring that bags are not punctured (disinfection of the bucket/area to be carried out in case of leakage from bags) • Awareness raising of patients and their attendants.
2	Infectious waste collection and transportation	Health and safety risks for waste handlers	• Use of infection control protocol Use of PPEs • Ensuring that waste bags are not opened or punctured during transportation • Ensuring that bags are not punctured (disinfection of the trolleys/area to be carried out in case of leakage from bags) • Proper documentation and

			handover-takeover protocol along with “chain of custody” protocol • Implement measures to forestall any pilferage of medical waste for recycling.
3	Infectious waste storage	Health and safety risks for waste handlers	• Use of infection control protocol; • Proper controlled-access storage • Ensuring that waste bags are not opened or punctured in the storage • Ensuring that bags are not punctured (disinfection of the trolleys /area to be carried out in case of leakage from bags) • Use of PPEs; Weighing of waste • Proper documentation and handover-takeover protocol • Security arrangements to avoid theft/pilferage.
4	Infectious waste disposal (burial)	Health and safety risks for waste handlers, waste pickers; Soil and water contamination	• Use of infection control protocol • Use of PPEs • Proper documentation and handover-takeover protocol • Using impervious lining in the pits to avoid soil and water contamination • Locating the pit at least 50 m from any water source • Using proper signage for pit location • Maintain complete record of waste disposal and pit location in each facility.
5	Infectious waste disposal (burning/ incineration)	Health and safety risks for waste handlers; Air contamination	• Use of infection control protocol; • Uncontrolled, open burning of infectious waste particularly containing plastics and PVC objects will be avoided to the extent possible • Proper documentation and handover-takeover protocol • Use of PPEs • Maintain complete record of waste disposal.

Figure 4 Table showing mitigation on disposal methods

2.4. Environmental Monitoring

Environmental monitoring forms the basis upon which the effectiveness of the implementation of the EMP is assessed. Environmental monitoring also provides information against which compliance to the relevant regulations can be checked to help identify areas for improvement.

2.4.1. Environmental Inspection

To evaluate, monitor and maintain the effectiveness of the EMP, monthly site inspections can be conducted with the assistance of an Environmental Officer or advisor to investigate any non-compliances and to take necessary corrective and preventative actions where needed. Corrective action may be the responsibility of the contractor responsible for the works within an area.

Qualitative measures are proposed to be applied to assess the effectiveness of the measures and protective action proposed. This will be mainly through visual observations which are proposed to focus on the following aspects:

- Quality or the integrity of water quality discharging from the Project site (such things as water appearance; turbidity, colour, oily residue and metallic sheen; degree of siltation; presence of solid waste).
- Implementation and maintenance of the protection and mitigation measures (for example, silt trap appearance (whether silted up or clean), condition of drains, and other structures, toilet conditions, waste collection, storage and disposal).
- Level of dust arising during construction activities and cause of the problem (wind, moving vehicle, dumping, etc).
- General housekeeping within the Project site (spillages of oil, rubbish on ground or in drains, ponding of water, odour, flies and other pests).
- Oil leakage from the skid tank or fuel storage drums from the storage area.

2.4.2. Monitoring of Environmental Quality

Baseline monitoring is to enable comparison with the monitoring results during the duration of the Project. The baseline monitoring is ideally carried out before the start of the construction works. However, should no baseline monitoring be undertaken, the first sample collected from the monitoring locations can be used for future comparisons.

2.4.2.1. Noise Levels

In absence of noise limits and control for Myanmar, the noise guidelines must adhere to the limits set by the Yangon City Development Committee (YCDC) which shall not exceed 70dBA.

2.4.2.2. Vibration

Vibration measurements are recommended be carried out on need-to basis only, and not on a regular periodic schedule. The measurements for building vibration and for assessment of human response & annoyance shall be carried should upon complaints of excessive felt vibrations or structural damage by the immediate surroundings of the Project site.

2.4.2.3. Water Quality

Water quality monitoring is recommended to be monitored at these points:

- The final discharge point(s) from the Project site before entering YCDC public drainage
- Discharge point(s) from the silt traps/ponds or similar sediment control measures, if any

The parameters to be analysed include the following:
Final Discharge Points: pH, Biochemical Oxygen Demand, Chemical Oxygen Demand, Ammoniacal Nitrogen, Dissolved Oxygen, Total Suspended Solids, Oil and Grease.

Silt Trap/ Pond or Sediment Control: Total Suspended Solids, Turbidity
The frequency of monitoring is recommended to be taken on a monthly basis. No monitoring is required if there is no discharge from the site into the perimeter drains.

- **Annex G   Fire Protection**

Parkway
YANGON

The Chairman
The Myanmar Foreign Investment Commission
Nay Pyi Taw
The Republic of Union of Myanmar

Date: __ _________ 2015

Subject: Submission of Fire Safety Procedures and Workplace Safety Policies

The Joint Venture Consortium ("JVCo") is applying to operate a multi-disciplinary hospital in Yangon under the Myanmar Foreign Investment Law. The JVCo together with our engaged design consultants and construction specialists will design production facilities to minimize the occurrence of fire, and implement high standards and procedures for staff to adhere to.

Smoke detectors, water sprinklers and portable fire extinguishers will be located at all strategic locations and fire safety handbooks will be on-hand and available to workers. The JVCo will comply with all instructions and all existing rules and regulations issued by the Fire Services Department under the Ministry of Social Welfare, Relief and Resettlement. The company will install fire-fighting equipment and accessories in relevant locations.

A fire protection plan for the hospital is attached in the Annex. The hospital will also obtain and maintain a suitable fire insurance policy.

Workplace Safety

The well-being of our employees and patients is of utmost importance to the JVCo. The company is committed to ensuring their safety through:

- Providing a safe and conducive work environment for all employees.
- Establishing a safety management system and stringent workplace policies based on recognised best practices
- Continuous and regular training and drills in fire safety procedures.

To continually meet and exceed our safety goals, the hospital will engage management and employees through regular workshops and trainings. Compliance with local health and safety requirements and regulations (including fire safety measures) will remain a top priority for the hospital.

Yours truly,

PROPOSED FIRE PROTECTION PLAN FOR HOSPITAL IN YANGON

Patient and employee safety is utmost importance to us to provide an appropriate and effective combination of in-place fire safety features along with hospital emergency response plan.

Hospital Fire Alarm System

Fire alarms are the first response system to enable a fire to be detected at a sufficiently early stage so that people such as hospital staff, visitors and patients at risk can be alerted by escaping from the fire and/or by extinguishing the fire. Fire Alarm Systems are used to protect life and property by:

a) detecting a fire at an early stage
b) alerting and evacuating occupants
c) notifying the relevant personnel
d) activating auxiliary functions e.g. smoke controls, lift homing etc
e) identifying and guiding fire fighters

The components of the fire alarm system of the hospital are:

a) Smoke and Heat Detectors
b) Alarm Panels (Control and Indicating Equipment)
c) Alarm Bells
d) Manual Call Points
e) Extinguishing Panels (Control for automatic fire protection equipment)
f) Gas/Sprinkler System (Automatic fire protection equipment)
g) Fire Doors & Other opening protective

The hospital will engaged skilled and experienced fire safety team to perform annual fire alarm testing for the facilities to make sure the building's fire alarm system will operate if and when a fire emergency occurs.

A variety of firefighting equipment can be installed in different locations in the hospital to combat specific types of fires, with special consideration to the patients occupying each area and the medical equipment housed in those areas. They are:

1. Fire Extinguishers

Portable fire extinguishers effectively extinguish majority of all reported fires making them an absolute necessity for the hospitals. In accordance with codes and regulations, the hospital will provide a sufficient number of fire extinguishers throughout each floor.

Extinguishers will be conspicuously located and readily accessible for immediate use in the event of fire. They will be maintained in a fully charged and operable condition. They will be kept in their designated locations at all times when not being used. When extinguishers are

removed for maintenance or testing, a fully charged and operable replacement unit will be provided.

2. Fire Hose Reel

Water hose reels will be located on every floor of the hospital, to provide a realistically accessible and controlled supply of water to fight a fire. Fire hoses are connected to the main water supply or an independent water storage system.

3. Fire Hydrants

Fire hydrants will be provided and located such that in the event of an emergency, there is adequate coverage for the entire building perimeter.

4. Fire Sprinklers

Automatic fire sprinkler systems and fire pumps provide hospitals 24-hour fire protection. Fire sprinklers will be installed throughout the smoke compartments containing patient sleeping rooms.

5. Clean Agent Fire Suppression Systems

Where there is a need for quick reaction to a fire, where patients are present, where fire may strike day or night and where damage from conventional agents cannot be tolerated. Clean Agent Fire Suppression systems such as ANSUL and FM-200 fire suppression systems will be used.

6. Emergency & Exit Lighting

Proper emergency and exit lights are essential to keep individuals safe in exiting the hospital in case of an emergency situation. During serious power outage situations, emergency lighting will illuminates all exit passages, including corridors, stairwells, ramps and escalators, exit lighting points the way to safe exits.

Maintenance of the Fire Protection System

We will ensure that regular maintenance is conducted to ensure continuous system reliability by engaging competent contractor or manufacturer to have all fire protection systems and equipment inspected, tested, and maintained in accordance with adopted nationally recognized standards and state regulations. Persons that are qualified, based on competence through training and experience, shall perform all required inspections, testing, and maintenance. All required maintenance, repairs, and third party services shall be documented.

Annex H Electricity, Water Requirement

Parkway YANGON

Annex-H

Andaman Alliance Healthcare Limited
Water and Electricity Requirement

	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028
Electricity										
Total KWh required	2,400,000	5,333,333	8,000,000	10,666,667	12,000,000	12,000,000	12,000,000	12,000,000	12,000,000	12,000,000
Water										
Total Cubic Meter required	34,800	74,400	82,800	190,800	212,400	212,400	212,400	212,400	212,400	212,400

- **Annex I Labor Welfare Plan**

Parkway
YANGON

Annex-I

Staff Welfare Plan

- Leave allowance in accordance with the Law
- Benefit under Social Security Act
- Other social welfare program benefit from the Company

- **Annex J CSR Plan**

Parkway
YANGON

CSR Plan

Proposed Approach for the Hospital's Corporate Social Responsibility

The JVCo believes in being an active member of the community where we operate in, and to ensure that we contribute back especially in ways where we can add the most value. In other countries where Parkway Pantai operates in, Parkway hospitals have sponsored and performed free treatments for more than 200 patients in Singapore and Malaysia, as well as having participated in disaster relief efforts such as the Iran earthquake and the Asian Tsunami of 2004.

Similarly in Myanmar, we are committed to helping in areas of most pressing needs. We intend to allocate at least 2% of our profits to the following –

1. Education
   a. Sponsorship of talks/training for government doctors and nurses
   b. Sponsorship of nursing trainings
   c. Health Education talks, especially targeting rural areas

2. Free/Sponsored Medical Treatments

   a. Health Screenings
   b. Cataract Surgery
   c. Cleft Palate Repair
   d. Other general practice medicine
   e. General Dental Surgery

While this is a proposed area of work, we would appreciate any feedback from the Myanmar government with regards to best way to serve the needs of lower-income patients.

- **Annex K References for business and financial standing**

Parkway
YANGON

Company No: 200723244M

CERTIFICATE CONFIRMING INCORPORATION OF COMPANY

This is to confirm PARKWAY EDUCATION PTE. LTD. is incorporated under the Companies Act (Cap 50), on and from 18/12/2007 and that the company is a PRIVATE COMPANY LIMITED BY SHARES.

GIVEN UNDER MY HAND AND SEAL ON 15/09/2015.

ER SIEW LENG
ASSISTANT REGISTRAR
ACCOUNTING AND CORPORATE REGULATORY AUTHORITY (ACRA)
SINGAPORE

REGISTRAR OF COMPANIES & BUSINESSES
ACRA
ACCOUNTING AND CORPORATE REGULATORY AUTHORITY
SINGAPORE

Company No: 200723244M

CERTIFICATE CONFIRMING INCORPORATION OF COMPANY UNDER THE NEW NAME

This is to confirm that PARKWAY EDUCATION PTE. LTD. incorporated under the Companies Act on 18/12/2007 did by a special resolution resolve to change its name to PARKWAY HEALTHCARE INDO-CHINA PTE. LTD. and that the company is now known by its new name with effect from 13/08/2015.

GIVEN UNDER MY HAND AND SEAL ON 09/09/2015.

LINDA LEE
ASSISTANT REGISTRAR
ACCOUNTING AND CORPORATE REGULATORY AUTHORITY (ACRA)
SINGAPORE

REGISTRAR OF COMPANIES & BUSINESSES
ACRA
ACCOUNTING AND CORPORATE REGULATORY AUTHORITY
SINGAPORE

INFORMATION RESOURCES

Business Profile (Company) of PARKWAY HEALTHCARE INDO-CHINA PTE. LTD. (200723244M)

Date: 13/08/2015

The Following Are The Brief Particulars of :

Registration No. :	200723244M
Company Name. :	PARKWAY HEALTHCARE INDO-CHINA PTE. LTD.(w.e.f. 13/08/2015)
Former Name if any :	PARKWAY EDUCATION PTE. LTD.
Incorporation Date :	18/12/2007
Company Type :	LIMITED PRIVATE COMPANY
Status :	Live Company
Status Date :	18/12/2007

Principal Activities

Activities (I) :	64202
Description :	INVESTMENT HOLDING
Activities (II) :	
Description :	

Capital

Issued Share Capital * (AMOUNT)	Number of shares	Currency	Share Type
1.00	1	SINGAPORE, DOLLARS	ORDINARY

Number of Shares includes number of Treasury Shares

Paid-Up Capital (AMOUNT)	Number of shares	Currency	Share Type
1.00		SINGAPORE, DOLLARS	ORDINARY

COMPANY HAS THE FOLLOWING ORDINARY SHARES HELD AS TREASURY SHARES

Number Of Shares	Currency

Registered Office Address :	111 SOMERSET ROAD #15-01 TRIPLEONE SOMERSET SINGAPORE (238164)
Date of Address :	15/02/2008

INFORMATION RESOURCES

Business Profile (Company) of PARKWAY HEALTHCARE INDO-CHINA PTE. LTD. (200723244M)

Date: 13/08/2015

Date of Last AGM	: 09/06/2015
Date of Last AR	: 17/06/2015
Date of A/C Laid at Last AGM	: 31/12/2014
Date of Lodgment of AR, A/C	: 17/06/2015

Audit Firms

NAME
KPMG LLP

Charges

Charge No.	Date Registered	Currency	Amount Secured	Chargee(s)

ACCOUNTING AND CORPORATE REGULATORY AUTHORITY
(ACRA)

bizFILE

INFORMATION RESOURCES

Business Profile (Company) of PARKWAY HEALTHCARE INDO-CHINA PTE. LTD. (200723244M)

Date: 13/08/2015

Officers/Agents				
Name / **Address**	**ID**	**Nationality** / **Position Held**	**Source of Address**	**Date of Appointment**
TAN SEE LENG	S1654774C	SINGAPORE CITIZEN	ACRA	31/07/2015
16 SIGLAP PLAIN FRANKEL ESTATE SINGAPORE (456005)		DIRECTOR		
NG SIEW HONG	S1660739H	SINGAPORE CITIZEN	ACRA	31/10/2011
215 SERANGOON AVENUE 4 #09-132 SINGAPORE (550215)		SECRETARY		
DR LIM SUET WUN	S1670356G	SINGAPORE CITIZEN	ACRA	31/10/2013
11 JALAN CHENGAM SEMBAWANG HILLS ESTATE SINGAPORE (578295)		DIRECTOR		
FANG SOON HOOI	S2687651F	SINGAPORE P.R.	OSCARS	31/10/2011
30 MARINE CRESCENT #07-179 MARINE CRESCENT VILLE SINGAPORE (440030)		SECRETARY		
LIAW YIT MING	S8189876F	MALAYSIAN	ACRA	31/07/2015
6 KENG CHIN ROAD #05-05 CYAN SINGAPORE (258709)		DIRECTOR		
TAN HUI ANN SHERRY	S8210419D	SINGAPORE CITIZEN	ACRA	07/01/2013
28 LEONIE HILL #14-28 LEONIE TOWERS SINGAPORE (239227)		SECRETARY		

Business Profile (Company) of PARKWAY HEALTHCARE INDO-CHINA PTE. LTD. (200723244M)

Date: 13/08/2015

Shareholder (s)

	Name / Address	ID	Nationality/Place of incorporation/Origin	Source of Address	Address Changed
1	PARKWAY PANTAI LIMITED	201106772W	SINGAPORE	ACRA	
	111 SOMERSET ROAD #15-01 TRIPLEONE SOMERSET SINGAPORE (238164)				

Ordinary (Number)	Currency
1	SINGAPORE, DOLLARS

Abbreviation

UL - Local Entity not registered with ACRA

UF - Foreign Entity not registered with ACRA

V/Share - Value Per Share

AR - Annual Return

AGM - Annual General Meeting

A/C - Accounts

OSCARS - One Stop Change of Address Reporting Service by Immigration & Checkpoint Authority.

Business Profile (Company) of PARKWAY HEALTHCARE INDO-CHINA PTE. LTD. (200723244M)

Date: 13/08/2015

FOR REGISTRAR OF COMPANIES AND BUSINESSES
SINGAPORE

RECEIPT NO. : ACR0000006211791A

DATE : 13/08/2015

This is computer generated. Hence no signature required.

Parkway Education Pte Ltd.
Registration Number: 200723244M

Annual Report
Year ended 31 December 2014

Directors' report

We are pleased to submit this annual report to the member of the Company together with the audited financial statements for the financial year ended 31 December 2014.

Directors

The directors in office at the date of this report are as follows:

Low Teck Seng
Dr Lim Suet Wun
Dr Lee Hong Huei (Appointed on 2 December 2014)

Directors' interests

According to the register kept by the Company for the purposes of Section 164 of the Companies Act, Chapter 50 (the Act), particulars of interests of directors who held office at the end of the financial year (including those held by their spouses and infant children) in shares, debentures, warrants and share options in related corporations are as follows:

Name of director and corporation in which interests are held	Holdings at date of appointment	Holdings at end of the year
Related Corporation		
Parkway Holdings Limited	**Parkway Long Term Incentive Plan[1]**	
Dr Lee Hong Huei		
- 2012 Grant	46,000	46,000
- 2013 Grant	81,000	81,000
- 2014 Grant	84,000	84,000
Ultimate Holding Company		
IHH Healthcare Berhad	**Ordinary Shares of RM1 each**	
Dr Lee Hong Huei	911,000	911,000
	2011 Equity Participant Plan[2] Options to subscribe for ordinary shares of RM1 each	
Dr Lee Hong Huei	1,250,000	1,250,000

Name of director and corporation in which interests are held	Holdings at date of appointment	Holdings at end of the year
Related Corporation		
Parkway Life REIT	**Units in real estate investment trust**	
Dr Lee Hong Huei	52,562	52,562

[1] The Long Term Incentive Plan ("LTIP") Units were granted in accordance with the Parkway Long Term Incentive Plan Bye Laws (as the same may from time to time be amended) (the "Bye Laws") as set out in the Directors' Report of Parkway Pantai Limited for the year ended 31 December 2014. Subject to the Bye Laws, the LTIP Units that have vested may be surrendered to subscribe for shares in IHH Healthcare Berhad ("IHHHB"), the ultimate holding company of Parkway Pantai Limited.

[2] The Options were granted under IHH Healthcare Berhad's 2011 Equity Participation Plan as set out in the Directors' Report of IHHHB for the year ended 31 December 2014. Subject to the terms of the 2011 Equity Participation Plan Bye Laws (as the same may from time to time be amended) ("EPP Bye Laws"), the Options will vest in the Participant over a four-year period, with two-thirds of the Options to be vested in equal proportions on a yearly basis on each anniversary of the date of grant over such four-year period and the remainder one-third to be vested in equal proportions on the same basis upon the Group Company (as defined in the EPP Bye Laws) meeting the Performance Targets for each grant.

Dr Lim Suet Wun is also a director of the Company's intermediate holding company, Parkway Pantai Limited. His interests in the shares, debentures, warrants and share options of related corporations are recorded in the register kept by the intermediate holding company and are disclosed in the Directors' Report of that company.

Except as disclosed in this report, no director who held office at the end of the financial year had interests in shares, debentures, warrants or share options of the Company, or of related corporations, either at the beginning of the year or at the date of appointment if later, or at the end of the financial year.

Neither at the end of, nor at any time during the financial year, was the Company a party to any arrangement whose objects are, or one of whose objects is, to enable the directors of the Company to acquire benefits by means of the acquisition of shares in or debentures of the Company or any other body corporate.

Except for salaries, bonuses and fees and those benefits that are disclosed in this report and in note 9 to the financial statements, since the end of the last financial year, no director has received or become entitled to receive, a benefit by reason of a contract made by the Company or a related corporation with the director, or with a firm of which he is a member, or with a company in which he has a substantial financial interest.

Share options

During the financial year, there were:

(i) no options granted by the Company to any person to take up unissued shares in the Company; and

(ii) no shares issued by virtue of any exercise of option to take up unissued shares of the Company.

There were no unissued shares of the Company under options granted by the Company as at the end of the financial year.

Auditors

The auditors, KPMG LLP, have indicated their willingness to accept re-appointment.

On behalf of the Board of Directors

Dr Lim Suet Wun
Director

Dr Lee Hong Huei
Director

30 March 2015

Statement by Directors

In our opinion:

(a) the financial statements set out on pages FS1 to FS12 are drawn up so as to give a true and fair view of the state of affairs of the Company as at 31 December 2014 and the results, changes in equity and cash flows of the Company for the year ended on that date in accordance with the provisions of the Singapore Companies Act, Chapter 50 and Singapore Financial Reporting Standards; and

(b) at the date of this statement, having regards to the financial support given by the intermediate holding company, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due, notwithstanding the deficiency in net assets.

The Board of Directors has, on the date of this statement, authorised these financial statements for issue.

On behalf of the Board of Directors

Dr Lim Suet Wun
Director

Dr Lee Hong Huei
Director

30 March 2015

KPMG LLP
16 Raffles Quay #22-00
Hong Leong Building
Singapore 048581

Telephone +65 6213 3388
Fax +65 6225 0984
Internet www.kpmg.com.sg

Independent auditors' report

Member of the Company
Parkway Education Pte Ltd.

Report on the financial statements

We have audited the accompanying financial statements of Parkway Education Pte Ltd. (the Company), which comprise the statement of financial position as at 31 December 2014, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information, as set out on pages FS1 to FS12.

Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Singapore Companies Act, Chapter 50 (the Act) and Singapore Financial Reporting Standards, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair profit and loss accounts and balance sheets and to maintain accountability of assets.

Auditors' responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Singapore Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements of the Company are properly drawn up in accordance with the provisions of the Act and Singapore Financial Reporting Standards to give a true and fair view of the state of affairs of the Company as at 31 December 2014 and the results, changes in equity and cash flows of the Company for the year ended on that date.

Report on other legal and regulatory requirements

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.

KPMG

KPMG LLP
Public Accountants and
Chartered Accountants

Singapore
30 March 2015

Statement of financial position
As at 31 December 2014

	Note	2014 $	2013 $
Current asset			
Cash and cash equivalents		9,273	–
Total asset		9,273	–
Equity attributable to owner of the Company			
Share capital	5	1	1
Accumulated losses		(16,928)	(14,714)
Total deficit in equity		(16,927)	(14,713)
Non-current liability			
Amount due to immediate holding company (non-trade)	6	24,000	10,337
Current liability			
Other payables	7	2,200	4,376
Total liabilities		26,200	14,713
Total equity and liabilities		9,273	–

The accompanying notes form an integral part of these financial statements.

Statement of comprehensive income
Year ended 31 December 2014

	Note	2014 $	2013 $
Revenue		–	–
Other operating expenses		(2,214)	(2,241)
Loss before tax		(2,214)	(2,241)
Tax expense	8	–	–
Loss for the year		(2,214)	(2,241)
Other comprehensive income, net of tax		–	–
Total comprehensive income for the year		(2,214)	(2,241)

The accompanying notes form an integral part of these financial statements.

Statement of changes in equity
Year ended 31 December 2014

	Share capital $	Accumulated losses $	Total $
At 1 January 2013	1	(12,473)	(12,472)
Loss for the year	–	(2,241)	(2,241)
Other comprehensive income			
Total other comprehensive income	–	–	–
Total comprehensive income for the year	1	(2,241)	(2,241)
At 31 December 2013	1	(14,714)	(14,713)
At 1 January 2014	1	(14,714)	(14,713)
Loss for the year	–	(2,214)	(2,214)
Other comprehensive income			
Total other comprehensive income	–	–	–
Total comprehensive income for the year	1	(2,214)	(2,214)
At 31 December 2014	1	(16,928)	(16,927)

The accompanying notes form an integral part of these financial statements.

Statement of cash flows
Year ended 31 December 2014

	2014
	$
Cash flows from operating activities	
Loss before tax	(2,214)
Change in other payables	(2,176)
Net cash used in operating activities	(4,390)
Cash flows from investing activity	
Amount due to immediate holding company	13,663
Net cash from investing activity	13,663
Net increase in cash and cash equivalents	9,273
Cash and cash equivalents at 1 January	–
Cash and cash equivalents at 31 December	9,273

The Company did not prepare a cash flow statement for the year ended 31 December 2013 as the Company does not have cash balances. All expenses were paid on its behalf by its immediate holding company.

Company No: 201317874R

CERTIFICATE CONFIRMING INCORPORATION OF COMPANY

This is to confirm that MACONDRAY HOLDINGS PTE. LTD. is incorporated under the Companies Act (Cap 50), on and from 02/07/2013 and that the company is a PRIVATE COMPANY LIMITED BY SHARES.

GIVEN UNDER MY HAND AND SEAL ON 04/07/2013.

LINDA LEE
ASSISTANT REGISTRAR
ACCOUNTING AND CORPORATE REGULATORY AUTHORITY (ACRA)
SINGAPORE

REGISTRAR OF COMPANIES & BUSINESSES
ACRA
ACCOUNTING AND CORPORATE REGULATORY AUTHORITY
★ SINGAPORE ★

INFORMATION RESOURCES

Business Profile (Company) of MACONDRAY HOLDINGS PTE. LTD. (201317874R)

Date: 20/07/2015

The Following Are The Brief Particulars of :

Registration No. :	201317874R
Company Name. :	MACONDRAY HOLDINGS PTE. LTD.
Former Name if any :	
Incorporation Date :	02/07/2013
Company Type :	LIMITED PRIVATE COMPANY
Status :	Live Company
Status Date :	02/07/2013

Principal Activities

Activities (I) :	64202
Description :	OTHER INVESTMENT HOLDING COMPANIES
Activities (II) :	
Description :	

Capital

Issued Share Capital * (AMOUNT)	Number of shares	Currency	Share Type
1000000.00	100000000	UNITED STATES OF AMERICA, DOLLARS	ORDINARY

**** Number of Shares includes number of Treasury Shares***

Paid-Up Capital (AMOUNT)	Number of shares	Currency	Share Type
1000000.00		UNITED STATES OF AMERICA, DOLLARS	ORDINARY

COMPANY HAS THE FOLLOWING ORDINARY SHARES HELD AS TREASURY SHARES

Number Of Shares	Currency
9793210	UNITED STATES OF AMERICA, DOLLARS

Registered Office Address :	78 SHENTON WAY #28-01 SINGAPORE (079120)
Date of Address :	02/07/2013

INFORMATION RESOURCES

Business Profile (Company) of MACONDRAY HOLDINGS PTE. LTD. (201317874R)

Date: 20/07/2015

Date of Last AGM	: 30/09/2014
Date of Last AR	: 14/10/2014
Date of A/C Laid at Last AGM	: 31/12/2013
Date of Lodgment of AR, A/C	: 14/10/2014

Audit Firms

NAME
HENG LEE SENG LLP

Charges

Charge No.	Date Registered	Currency	Amount Secured	Chargee(s)

INFORMATION RESOURCES

Business Profile (Company) of MACONDRAY HOLDINGS PTE. LTD. (201317874R)

Date: 20/07/2015

Officers/Agents

Name / Address	ID	Nationality / Position Held	Source of Address	Date of Appointment
CHEW LEONG CHEE 6B CLUNY PARK CLUNY PARK SINGAPORE (259615)	S0690146H	SINGAPORE CITIZEN DIRECTOR	ACRA	02/07/2013
HENRY TAY YUN CHWAN 40C NASSIM ROAD SINGAPORE (258428)	S1223385Z	SINGAPORE CITIZEN DIRECTOR	OSCARS	09/10/2013
TAN CHAY HOON 15 SURIN ROAD SINGAPORE (535532)	S1563522C	SINGAPORE CITIZEN SECRETARY	ACRA	02/07/2013
MELANIE CHEW NG FUNG NING 6B CLUNY PARK CLUNY PARK SINGAPORE (259615)	S2157786C	SINGAPORE CITIZEN DIRECTOR	ACRA	09/10/2013
NG HOW KIAT CHARLIE 25 MOONSTONE LANE #19-03 MOONSTONE RESIDENCES SINGAPORE (328465)	S7041731F	SINGAPORE CITIZEN DIRECTOR	OSCARS	02/07/2013

INFORMATION RESOURCES

Business Profile (Company) of MACONDRAY HOLDINGS PTE. LTD. (201317874R)

Date: 20/07/2015

Shareholder (s)

	Name / Address	ID	Nationality/Place of incorporation/Origin	Source of Address	Address Changed
1	ASIA RESOURCE CORPORATION PTE LTD	198402056N	SINGAPORE	ACRA	
	78 SHENTON WAY #28-01 SINGAPORE (079120)				
	Ordinary (Number): 71413580	**Currency**: UNITED STATES OF AMERICA, DOLLARS			
2	HENRY TAY YUN CHWAN	S1223385Z	SINGAPORE CITIZEN	OSCARS	
	40C NASSIM ROAD SINGAPORE (258428)				
	Ordinary (Number): 14293210	**Currency**: UNITED STATES OF AMERICA, DOLLARS			
3	TAN CHAY HOON	S1563522C	SINGAPORE CITIZEN	ACRA	22/09/2008
	15 SURIN ROAD SINGAPORE (535532)				
	Ordinary (Number): 200000	**Currency**: UNITED STATES OF AMERICA, DOLLARS			
4	TAN KHENG KIT	S7020989F	SINGAPORE CITIZEN	ACRA	22/09/2008
	582 PASIR RIS STREET 53 #10-19 SINGAPORE (510582)				
	Ordinary (Number): 600000	**Currency**: UNITED STATES OF AMERICA, DOLLARS			
5	NG HOW KIAT CHARLIE	S7041731F	SINGAPORE CITIZEN	OSCARS	26/09/2005

INFORMATION RESOURCES

Business Profile (Company) of MACONDRAY HOLDINGS PTE. LTD. (201317874R)

Date: 20/07/2015

Shareholder (s)

	Name / Address	ID	Nationality/Place of incorporation/Origin	Source of Address	Address Changed
	25 MOONSTONE LANE #19-03 MOONSTONE RESIDENCES SINGAPORE (328465)				
	Ordinary (Number): 2600000	**Currency**: UNITED STATES OF AMERICA, DOLLARS			
6	HO CHUN PANG (HE CUNBANG)	S7513831H	SINGAPORE CITIZEN	ACRA	16/01/2008
	11 LORONG 8 TOA PAYOH #11-308 SINGAPORE (310011)				
	Ordinary (Number): 400000	**Currency**: UNITED STATES OF AMERICA, DOLLARS			
7	CHAN POH HOON VERINE	S7721328G	SINGAPORE CITIZEN	ACRA	
	637B PUNGGOL DRIVE #13-415 SINGAPORE (822637)				
	Ordinary (Number): 50000	**Currency**: UNITED STATES OF AMERICA, DOLLARS			
8	ANTO	S7977999G	SINGAPORE CITIZEN	ACRA	16/05/2013
	88 TELOK BLANGAH HEIGHTS #10-357 SINGAPORE (100088)				
	Ordinary (Number): 200000	**Currency**: UNITED STATES OF AMERICA, DOLLARS			
9	IGNATIUS QUEK FENGHONG	S8127152F	SINGAPORE CITIZEN	ACRA	
	110 TAGORE AVENUE TEACHER'S HOUSING ESTATE SINGAPORE (787700)				
	Ordinary (Number)	**Currency**			

Business Profile (Company) of MACONDRAY HOLDINGS PTE. LTD. (201317874R)

Date: 20/07/2015

Shareholder (s)

	Name / Address	ID	Nationality/Place of incorporation/Origin	Source of Address	Address Changed
	400000	UNITED STATES OF AMERICA, DOLLARS			
10	TAN SHU-MEI	S8131280Z	SINGAPORE CITIZEN	OSCARS	10/06/2014
	335C YISHUN STREET 31 #09-45 SINGAPORE (763335)				
	Ordinary (Number)	**Currency**			
	50000	UNITED STATES OF AMERICA, DOLLARS			

Abbreviation

UL - Local Entity not registered with ACRA

UF - Foreign Entity not registered with ACRA

V/Share - Value Per Share

AR - Annual Return

AGM - Annual General Meeting

A/C - Accounts

OSCARS - One Stop Change of Address Reporting Service by Immigration & Checkpoint Authority.

INFORMATION RESOURCES

Business Profile (Company) of MACONDRAY HOLDINGS PTE. LTD. (201317874R)

Date: 20/07/2015

FOR REGISTRAR OF COMPANIES AND BUSINESSES
SINGAPORE

RECEIPT NO.	: ACR0001034668134
DATE	: 20/07/2015

This is computer generated. Hence no signature required.

UOB 大華銀行 | Far Eastern Bank 遠東銀行

United Overseas Bank Limited
Channel Operations Centre
396 Alexandra Rd #23-00 Singapore 119954
Tel: 1800 222 2121 (Personal)
Tel: 1800 226 6121 (Corporate)
www.uobgroup.com
Co. Reg. No. 193500026Z

21 September 2015

The Director General
Directorate of Investment and Company Administration
Ministry of National Planning & Economic Development
No. 1 Thit Sar Road
Yankin Township
Yangon, Myanmar

Dear Sir/Madam

Letter of Reference for Macondray Holdings Pte Ltd

Our Customer, Macondray Holdings Pte Ltd has requested that we provide the following information for its application.

Customer's Name:	Macondray Holdings Pte Ltd	
Date Established:	02 July 2013	
Type of Company:	Private Limited Company	
Principals:	Chew Leong Chee Ng Fung Ning Melanie Ng How Kiat Charlie Henry Tay Yun Chwan	
Nature of Business:	Investment Holding Company to Hold Listed & Unlisted Securities & Equities	
Account Maintained With Bank:	SGD Current Account	USD Global Current Account
Account No.:	450-309-266-7	450-905-201-2
Date Account Opened:	12 August 2013	12 August 2013
Account Balance As At:		USD395,721-73

The Customer is a valued client of the Bank and the accounts are well conducted to-date.

The Bank assumes no responsibility for your reliance on this letter which is given based on current knowledge of the Customer's relationship with the Bank.

Yours faithfully,
For United Overseas Bank Limited

Janet Tay Guat Kiew (Ms)
Senior Officer
Account Maintenance Group
Channel Operations Centre

Macondray Holdings Pte. Ltd.
(Incorporated in the Republic of Singapore)
Reg. No. 201317874R

Corporate Information

Board of Directors	:	Chew Leong Chee Melanie Chew Ng Fung Ning Henry Tay Yun Chwan Ng How Kiat Charlie
Company Secretary	:	Tan Chay Hoon
Registered Office	:	78 Shenton Way #28-01 Singapore 079120
Independent Auditor	:	Heng Lee Seng LLP 15 Hoe Chiang Road #12-02 Tower Fifteen Singapore 089316
Banker	:	United Overseas Bank

Directors' Report
for the financial year ended 31 December 2014

The directors present their report to the members together with the audited consolidated financial statements of the group and the balance sheet of the company for the financial year ended 31 December 2014.

1. Directors

The directors of the company in office at the date of this report are as follows:

Chew Leong Chee
Melanie Chew Ng Fung Ning
Henry Tay Yun Chwan
Ng How Kiat Charlie

2. Arrangements to enable directors to acquire shares and debentures

Neither at the end of nor at any time during the financial year was the company a party to any arrangement whose object is to enable the directors of the company to acquire benefits by means of the acquisition of shares in, or debentures of, the company or any other body corporate.

3. Directors' interests in shares and dehentures

None of the directors holding office at the end of the financial year had any interest in shares and debentures of the company and related corporations according to the Register of Directors' Shareholdings except as detailed below:

	No. of ordinary shares			
	Direct interests		Deemed interests	
	At 01.01.2014	At 31.12.2014	At 01.01.2014	At 31.12.2014
Company				
Henry Tay Yun Chwan	14,293,210	14,293,210	-	-
Ng How Kiat Charlie	1,000,000	1,000,000	-	-
Ultimate holding company				
Asia Resource Corporation Pte Ltd				
Chew Leong Chee	6,399,000	6,399,000	7,192,000	7,192,000
Melanie Chew Ng Fung Ning	-	-	13,591,000	13,591,000
Ng How Kiat Charlie	100,000	100,000	-	-

By virtue of Section 7 of the Singapore Companies Act Chew Leong Chee and Melanie Chew Ng Fung Ning who have interests of not less than 20% in the issued share capital of the ultimate holding company, are deemed to have an interest in the share capital of the company and of all related corporations at the beginning and at the end of the financial year.

4. Directors' receipt and entitlement to contractual benefits

Since the beginning of the financial year no director has received or become entitled to receive a benefit which is required to be disclosed under Section 201(8) of the Singapore Companies Act by reason of a contract made by the company or a related corporation with the director or with a firm of which he is a member or with a company in which he has a substantial financial interest except as disclosed in the financial statements.

5. Share options

During the financial year, there were:

(i) no options granted by the company to any person to take up unissued shares in the company; and

(ii) no shares issued by virtue of any exercise of option to take up unissued shares of the company.

As at the end of the financial year, there were no unissued shares of the company under option.

6. Independent Auditor

Heng Lee Seng LLP, the independent auditor, has expressed its willingness to accept re-appointment.

On behalf of the directors

Director

Director

Singapore: 29 July 2015

Statement by Directors
for the financial year ended 31 December 2014

In the opinion of the directors:

(a) the accompanying consolidated financial statements of the group and the balance sheet of the company, as set out on pages 5 to 42 are drawn up so as to give a true and fair view of the financial position of the group and of the company as at 31 December 2014 and of the financial performance of the business, changes in equity and cash flows of the group for the financial year then ended; and

(b) at the date of this statement there are reasonable grounds to believe that the company will be able to pay its debts as and when they fall due.

On behalf of the directors

Director

Director

Singapore: 29 July 2015

HLS | HENG LEE SENG LLP

15 Hoe Chiang Road
#12-02 Tower Fifteen
Singapore 089316
t : (65) 6423 9969
f : (65) 6423 9979
e : ca@hlsllp.com.sg
www.hlsllp.com.sg
Regn No: T09LL1999D

Independent Auditor's Report
to the members of Macondray Holdings Pte. Ltd.

Report on the Financial Statements
We have audited the accompanying financial statements of Macondray Holdings Pte. Ltd. ("the company") and its subsidiary corporations ("the group"), as set out on pages 5 to 42 which comprise the balance sheet of the group and of the company as at 31 December 2014, and the consolidated statement of comprehensive income, statement of changes in equity and statement of cash flows of the group for the financial year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements
Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Singapore Companies Act (Cap. 50) ("the Act") and Singapore Financial Reporting Standards, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

Auditor's Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Singapore Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal controls relevant to the entity's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.

Basis for Qualified Opinion
The financial information disclosed in Note 13 includes those attributable to financial statements of associates which are unaudited.

Qualified Opinion
In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion paragraph, the consolidated financial statements of the group and the balance sheet of the company are properly drawn up in accordance with the provisions of the Act and Singapore Financial Reporting Standards so as to give a true and fair view of the financial position of the group and of the company as at 31 December 2014 and the financial performance, changes in equity and cash flows of the group for the financial year ended on that date.

Report on Other Legal and Regulatory Requirements
In our opinion, the accounting and other records required by the Act to be kept by the company and by those subsidiary corporations incorporated in Singapore of which we are the auditors have been properly kept in accordance with the provisions of the Act.

HENG LEE SENG LLP

Heng Lee Seng LLP
Public Accountants and
Chartered Accountants
Singapore

29 July 2015

Member of msi Global Alliance
Independent Legal & Accounting Firms

Macondray Holdings Pte. Ltd.
and its subsidiaries

Consolidated Statement of Comprehensive Income
for the financial year ended 31 December 2014

	Note	2014 US$	2013 US$
Revenue	4	3,318,597	4,385,163
Other income	5	827,240	-
Other losses	6	(1,136,225)	(5,259,926)
Administrative expenses		(1,712,281)	(451,036)
Share of results of associates after tax	13	2,143,512	2,554,285
Profit before income tax	7	3,440,843	1,228,486
Income tax expense	8	-	-
Profit for the year		3,440,843	1,228,486
Profit/(loss) attributable to:			
Owners of the parent		3,374,587	1,291,308
Non-controlling interests		66,256	(62,822)
		3,440,843	1,228,486
Items that may be reclassified subsequently to profit or loss			
Available-for-sale financial assets			
- fair value loss	25	(1,236,373)	(3,102,958)
- reclassification to profit or loss	25	290,221	4,737,779
Currency translation differences arising from translation of financial statements of foreign operations		76,791	(110,871)
Share of currency translation reserve of associates	13	108,421	(1,230,185)
Other comprehensive income		(760,940)	293,765
Total comprehensive income		2,679,903	1,522,251
Total comprehensive income attributable to:			
Owners of the parent		2,639,679	1,597,392
Non-controlling interests		40,224	(75,141)
		2,679,903	1,522,251

The annexed notes form an integral part of these financial statements.

Macondray Holdings Pte. Ltd.
and its subsidiaries

Balance Sheets
as at 31 December 2014 (Note 33)

	Note	Group 2014 US$	Group 2013 US$	Company 2014 US$	Company 2013 US$
ASSETS					
Current assets					
Cash and cash equivalents	9	8,865,488	4,480,924	457,549	1,027,435
Other receivables	10	5,386,901	7,339,436	8,685,347	2,372,479
		14,252,389	11,820,360	9,142,896	3,399,914
Non-current assets					
Available-for-sale financial assets	11	11,160,265	16,711,246	-	-
Investments in associates	13	16,168,394	11,888,619	-	-
Investments in subsidiaries	14	-	-	26,097,661	25,097,661
Property, plant and equipment	15	4,945	4,457	2,887	-
Intangible assets	16	1,727,118	1,724,426	-	-
		29,060,722	30,328,748	26,100,548	25,097,661
Total assets		43,313,111	42,149,108	35,243,444	28,497,575
LIABILITIES					
Current liabilities					
Trade payables	17	752,723	508,711	98,138	26,513
Other payables	18	10,456	3,604	10,456	3,337
		763,179	512,315	108,594	29,850
Non-current liabilities					
Long-term payables	19	27,227,645	28,858,408	32,855,871	27,300,367
Total liabilities		27,990,824	29,370,723	32,964,465	27,330,217
Net assets		15,322,287	12,778,385	2,278,979	1,167,358
EQUITY					
Capital and reserves attributable to owners of the parent					
Share capital	20	980,000	980,000	980,000	980,000
Treasury shares	21	(2,212,772)	(2,210,772)	(2,212,772)	(2,210,772)
Currency translation reserve	22	3,591,028	3,600,656	-	-
Capital reserve	23	1,346	-	-	-
Restructuring reserve	24	(11,024,343)	(11,024,343)	-	-
Fair value reserve	25	(5,358,081)	(4,632,801)	-	-
Retained earnings		27,304,562	25,429,975	3,511,751	2,398,130
Equity attributable to owners of the parent		13,281,740	12,142,715	2,278,979	1,167,358
Non-controlling interests	26	2,040,547	635,670	-	-
Total equity		15,322,287	12,778,385	2,278,979	1,167,358

The annexed notes form an integral part of these financial statements.

Macondray Holdings Pte. Ltd.
and its subsidiaries

Consolidated Statement of Changes in Equity
for the financial year ended 31 December 2014

	Note	Share capital US$	Treasury shares US$	Currency translation reserve US$	Capital reserve US$	Restructuring reserve US$	Fair value reserve US$	Retained earnings US$	Equity attributable to owners of the parent US$	Non-controlling interests US$	Total equity US$
2014											
At beginning of financial year		980,000	(2,210,772)	3,600,656	-	(11,024,343)	(4,632,801)	25,429,975	12,142,715	635,670	12,778,385
Acquisition of subsidiaries	26	-	-	-	-	-	-	-	-	1,365,999	1,365,999
Acquisition of non-controlling interests	26	-	-	-	1,346	-	-	-	1,346	(1,346)	-
Profit for the year		-	-	-	-	-	-	3,374,587	3,374,587	66,256	3,440,843
Other comprehensive income		-	-	(9,628)	-	-	(725,280)	-	(734,908)	(26,032)	(760,940)
Total comprehensive income		-	-	(9,628)	-	-	(725,280)	3,374,587	2,639,679	40,224	2,679,903
Dividends declared	27	-	-	-	-	-	-	(1,500,000)	(1,500,000)	-	(1,500,000)
Purchase of treasury shares	21	-	(2,000)	-	-	-	-	-	(2,000)	-	(2,000)
At end of financial year		980,000	(2,212,772)	3,591,028	1,346	(11,024,343)	(5,358,081)	27,304,562	13,281,740	2,040,547	15,322,287

The annexed notes form an integral part of these financial statements.

Consolidated Statement of Changes in Equity
for the financial year ended 31 December 2014 (continued)

	Note	Share capital US$	Treasury shares US$	Currency translation reserve US$	Restructuring reserve US$	Fair value reserve US$	Retained earnings US$	Equity attributable to owners of the parent US$	Non-controlling interests US$	Total equity US$
2013										
At date of incorporation	20	100	-	-	-	-	-	100	-	100
Acquisition of subsidiaries		-	-	4,979,269	(11,024,343)	(6,317,498)	24,138,667	11,776,095	710,811	12,486,906
Profit for the year		-	-	-	-	-	1,291,308	1,291,308	(62,822)	1,228,486
Other comprehensive income		-	-	(1,378,613)	-	1,684,697	-	306,084	(12,319)	293,765
Total comprehensive income		-	-	(1,378,613)	-	1,684,697	1,291,308	1,597,392	(75,141)	1,522,251
Issue of shares	20	1,028,900	-	-	-	-	-	1,028,900	-	1,028,900
Purchase of treasury shares	21	-	(2,210,772)	-	-	-	-	(2,210,772)	-	(2,210,772)
Capital reduction	20	(49,000)	-	-	-	-	-	(49,000)	-	(49,000)
At end of financial year		980,000	(2,210,772)	3,600,656	(11,024,343)	(4,632,801)	25,429,975	12,142,715	635,670	12,778,385

The annexed notes form an integral part of these financial statements.

Macondray Holdings Pte. Ltd.
and its subsidiaries

Consolidated Statement of Cash Flows
for the financial year ended 31 December 2014

	Note	2014 US$	2013 US$
Operating activities			
Profit before income tax		3,440,843	1,228,486
Adjustments for:			
Allowance for impairment losses arising from other receivables	6	259,049	241,743
Available-for-sale financial assets			
- impairment loss	6	145,186	-
- reclassification of fair value reserve to profit or loss upon disposal	6	10,167	2,874
- reclassification of fair value reserve to profit or loss upon impairment	6	280,521	4,734,905
Depreciation of property, plant and equipment	15	2,600	561
Gain on disposal of investments in associates	5	(527,240)	-
Impairment loss of other receivables no longer required	5	(300,000)	-
Interest income	4	(99,899)	(14,418)
Dividend income		(1,943,086)	(1,874,945)
Share of results of associates after tax	13	(2,143,512)	(2,554,285)
Currency translation differences		543,157	427,112
Operating cash flows before changes in working capital		(332,214)	2,192,033
Changes in working capital net of effects from acquisition and disposal of subsidiaries:			
Increase/(decrease) in trade payables		244,012	(53,332)
Net cash flows (used in)/generated from operating activities		(88,202)	2,138,701
Investing activities			
Decrease/(increase) in other receivables		1,993,486	(3,439,839)
Dividend received		3,177,669	4,335,645
Net cash inflow/(outflow) on acquisition of subsidiaries		7,697	(18,855,101)
Interest received		99,899	14,418
Purchases of:			
- property, plant and equipment	15	(3,190)	(1,978)
- available-for-sale financial assets	11	(1,054,113)	-
Proceed from disposal of:			
- investments in associates		527,240	-
- available-for-sale financial assets		4,756,804	-
Investments in associates	13	(3,262,425)	(609,898)
Net cash flows generated from/(used in) investing activities		6,243,067	(18,556,753)
Financing activities			
(Decrease)/increase in other payables		(3,134,300)	22,129,748
Contribution of capital by non-controlling interests		1,365,999	-
Proceeds from issuance of ordinary shares		-	1,028,900
Capital reduction		-	(49,000)
Purchase of treasury shares	21	(2,000)	(2,210,772)
Net cash flows (used in)/generated from financing activities		(1,770,301)	20,898,876
Cash and cash equivalents			
Net increase		4,384,564	4,480,824
At beginning of financial year/date of incorporation		4,480,924	100
At end of financial year	9	8,865,488	4,480,924

The annexed notes form an integral part of these financial statements.

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

1. General information

Macondray Holdings Pte. Ltd., Registration No. 201317874R ("the company") which is a limited liability company, is incorporated and domiciled in the Republic of Singapore. The address of its registered office is 78 Shenton Way #28-01 Singapore 079120.

The immediate and ultimate parent is Asia Resource Corporation Pte Ltd, incorporated in the Republic of Singapore.

The principal activities of the company during the financial year are those of an investment holding company. The principal activities of the subsidiaries during the financial year are stated in Note 14.

The consolidated financial statements of the group and the balance sheet of the company were authorised for issue in accordance with a resolution of the directors on 29 July 2015.

2. Significant accounting policies

2.1 Basis of preparation

These financial statements have been prepared in accordance with Singapore Financial Reporting Standards ("FRS"). The financial statements have been prepared under the historical cost convention, except as disclosed in the accounting policies below.

The preparation of financial statements in conformity with FRS requires management to exercise its judgement in the process of applying the group's accounting policies. It also requires the use of certain critical accounting estimates and assumptions. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Note 3.

Interpretations and amendments to published standards effective in 2014

On 1 January 2014, the group adopted the new or amended FRS and Interpretations of FRS ("INT FRS") that are mandatory for application for the financial year. Changes to the group's accounting policies have been made as required, in accordance with the transitional provisions in the respective FRS and INT FRS.

The adoption of these new or amended FRS and INT FRS did not result in substantial changes to the accounting policies of the group and the company and had no material effect on the amounts reported for the current or prior financial years except for the following:

(i) FRS 110 *Consolidated Financial Statements* and Amendment to FRS 27 (Revised 2011) *Separate Financial Statements*

As a result of FRS 110 *Consolidated Financial Statements*, the group has changed its accounting policy for determining whether it has control over and consequently whether it consolidates its investees. FRS 110 introduces a new control model that focuses on whether the group has power over an investee, exposure or rights to variable returns from its involvement with the investee and ability to use its power to affect those returns.

2. Significant accounting policies (continued)

2.1 Basis of preparation (continued)

Interpretations and amendments to published standards effective in 2014 (continued)

(ii) FRS 111 *Joint Arrangements* and Amendment to FRS 28 (Revised 2011) *Investments in Associates and Joint Ventures*

As a result of FRS 111 *Joint Arrangements*, the group has changed its accounting policy for its interests in joint arrangements. Under FRS 111, the group has classified its interests in joint arrangements as either joint operations (if the group has rights to the assets, and obligations for the liabilities, relating to an arrangement) or joint ventures (if the group has rights only to the net assets of an arrangement). When making this assessment, the group considered the structure of the arrangements, the legal form of any separate vehicles, the contractual terms of the arrangements and other facts and circumstances. Previously, the structure of the arrangement was the sole focus of classification.

(iii) FRS 112 *Disclosure of Interests in Other Entities*

It sets out the required disclosures for entities reporting under the new FRS 110 *Consolidated Financial Statements* and FRS 111 *Joint Arrangements*, and replaces the disclosure requirements currently found in FRS 27 (revised 2011) *Separate Financial Statements* and FRS 28 (revised 2011) *Investments in Associates and Joint Ventures*.

(iv) Amendments to FRS 32 Financial Instruments: *Presentation (Offsetting Financial Assets and Financial Liabilities)*

Under the Amendments to FRS 32 Financial Instruments: *Presentation (Offsetting Financial Assets and Financial Liabilities)*, to qualify for offsetting, the right to set off a financial asset and a financial liability must not be contingent on a future event and must be enforceable both in the normal course of business and in the event of default, insolvency or bankruptcy of the entity and all counterparties.

(v) Amendments to FRS 36 *Impairment of Assets (Recoverable Amount Disclosures for Non-financial Assets)*

As a result of the Amendments to FRS 36 *Impairment of Assets (Recoverable Amount Disclosures for Non-financial Assets)*, the group has expanded its disclosures of recoverable amounts when they are based on fair value less costs of disposals and an impairment is recognised.

2.2 Group accounting

(a) Subsidiaries

(i) Consolidation

Subsidiaries are all entities (including structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date on which control ceases.

2. Significant accounting policies (continued)

2.2 Group accounting (continued)

(a) Subsidiaries (continued)

(i) Consolidation (continued)

In preparing the consolidated financial statements, transactions, balances and unrealised gains on transactions between group entities are eliminated. Unrealised losses are also eliminated but are considered an impairment indicator of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group.

Non-controlling interests comprise the portion of a subsidiary's net results of operations and its net assets, which is attributable to the interests that are not owned directly or indirectly by the owners of the company. They are shown separately in the consolidated statement of comprehensive income, statement of changes in equity, and balance sheet. Total comprehensive income is attributed to the non-controlling interests based on their respective interests in a subsidiary, even if this results in the non-controlling interests having a deficit balance.

(ii) Acquisitions

The acquisition method of accounting is used to account for business combinations entered into by the group.

The consideration transferred for the acquisition of a subsidiary or business comprises the fair value of the assets transferred, the liabilities incurred and the equity interests issued by the group. The consideration transferred also includes any contingent consideration arrangement and any pre-existing equity interest in the subsidiary measured at their fair values at the acquisition date.

Acquisition-related costs are expensed as incurred.

Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date.

On an acquisition-by-acquisition basis, the group recognises any non-controlling interests in the acquiree at the date of acquisition either at fair value or at the non-controlling interests' proportionate share of the acquiree's identifiable net assets.

The excess of (a) the consideration transferred, the amount of any non-controlling interests in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the (b) fair value of the identifiable net assets acquired is recorded as goodwill. Please refer to the paragraph "Intangible assets – Goodwill" for the subsequent accounting policy on goodwill.

2. Significant accounting policies (continued)

2.2 Group accounting (continued)

(a) Subsidiaries (continued)

(iii) Disposals

When a change in the group's ownership interest in a subsidiary results in a loss of control over the subsidiary, the assets and liabilities of the subsidiary including any goodwill are derecognised. Amounts previously recognised in other comprehensive income in respect of that entity are also reclassified to profit or loss or transferred directly to retained earnings if required by a specific Standard.

Any retained equity interest in the entity is remeasured at fair value. The difference between the carrying amount of the retained interest at the date when control is lost and its fair value is recognised in profit or loss.

Please refer to the paragraph "Investments in subsidiaries" for the accounting policy on investments in subsidiaries in the separate financial statements of the company.

(iv) Transactions with non-controlling interests

Changes in the group's ownership interest in a subsidiary that do not result in a loss of control over the subsidiary are accounted for as transactions with owners of the company. Any difference between the change in the carrying amounts of the non-controlling interests and the fair value of the consideration paid or received is recognised within equity attributable to the owners of the company.

(b) Associates

(i) Acquisitions

Associates are entities over which the group has significant influence, but not control, generally accompanied by a shareholding giving rise to voting rights of 20% and above but not exceeding 50%.

Investments in associates are accounted for in the consolidated financial statements using the equity method of accounting less impairment losses, if any.

Investments in associates are initially recognised at cost. The cost of an acquisition is measured at the fair value of the assets given, equity instruments issued or liabilities incurred or assumed at the date of exchange, plus costs directly attributable to the acquisition. Goodwill on associates represents the excess of the cost of acquisition of the associates over the group's share of the fair value of the identifiable net assets of the associates and is included in the carrying amount of the investments.

(ii) Equity method of accounting

In applying the equity method of accounting, the group's share of its associates' post-acquisition profits or losses are recognised in profit or loss and its share of post-acquisition other comprehensive income is recognised in other comprehensive income. These post-acquisition movements and distributions received from the associates are adjusted against the carrying amount of the investments. When the group's share of losses in an associate equals to or exceeds its interest in the associate or joint venture, the group does not recognise further losses, unless it has legal or constructive obligations to make, or has made, payments on behalf of the associate. If the associate subsequently reports profits, the group resumes recognising its share of those profits only after its share of the profits equals the share of losses not recognised.

2. Significant accounting policies (continued)

2.2 Group accounting (continued)

(b) Associates (continued)

(ii) Equity method of accounting (continued)

Unrealised gains on transactions between the group and its associates are eliminated to the extent of the group's interest in the associates. Unrealised losses are also eliminated unless the transactions provide evidence of impairment of the assets transferred. The accounting policies of associates are changed where necessary to ensure consistency with the accounting policies adopted by the group.

(iii) Disposals

Investments in associates are derecognised when the group loses significant influence or joint control. If the retained equity interest in the former associates is a financial asset, the retained equity interest is measured at fair value. The difference between the carrying amount of the retained interest at the date when significant influence or joint control is lost, and its fair value and any proceeds on partial disposal, is recognised in profit or loss.

Please refer to the paragraph "Investments in associates" for the accounting policy on investments in associates in the separate financial statements of the company.

2.3 Revenue recognition

Revenue comprise the fair value of the consideration received or receivable for in the ordinary course of the group's activities. Revenue is presented, net of goods and services tax/value-added tax, net of rebates and discounts, and after eliminating revenue within the group.

The group recognises revenue when the amount of revenue and related costs can be reliably measured, it is probable that the collectability of the related receivables is reasonably assured and when the specific criteria for each of the group's activities are met as follows:

(a) Dividend income

Dividend income is recognised when the right to receive payment is established.

(b) Interest income

Interest income is recognised using the effective interest method.

2.4 Employee benefits

Employee benefits are recognised as an expense, unless the cost qualifies to be capitalised as an asset.

(a) Defined contribution plans

Defined contribution plans are post-employment benefit plans under which the group pays fixed contributions into separate entities such as the Central Provident Fund on a mandatory basis. The group has no further payment obligations once the contributions have been paid.

(b) Short-term benefits

All short-term employee benefits including wages, salaries, bonuses, paid leave and sick leave are recognised in profit or loss in the period in which the employees rendered their services to the company.

2. Significant accounting policies (continued)

2.5 Income taxes

Current income tax for current and prior periods is recognised at the amount expected to be paid to, or recovered from, the tax authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of each reporting period.

Deferred income tax is recognised for all temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profit or loss at the time of the transaction.

A deferred income tax asset is recognised to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences and tax losses can be utilised.

Deferred income tax is measured:

(i) at the tax rates that are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted by the end of each reporting period; and

(ii) based on the tax consequence that will follow from the manner in which the group expects, at the end of each reporting period, to recover or settle the carrying amounts of its assets and liabilities except for investment properties. Investment property measured at fair value is presumed to be recovered entirely through sale.

Current and deferred income taxes are recognised as income or expense in profit or loss, except to the extent that the tax arises from a business combination or a transaction which is recognised directly in equity. Deferred tax arising from a business combination is adjusted against goodwill on acquisition.

2.6 Financial assets

Financial assets are recognised on the balance sheet when, and only when, the group becomes a party to the contractual provisions of the financial instrument.

(a) Classification

The group classifies its financial assets in the following categories: at fair value through profit or loss, loans and receivables, held-to-maturity and available-for-sale. The classification depends on the nature of the asset and the purpose for which the assets were acquired. Management determines the classification of its financial assets at initial recognition and in the case of assets classified as held-to-maturity, re-evaluates this designation at the end of each reporting period.

(i) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are presented as current assets, except for those expected to be realised later than 12 months after the end of each reporting period which are presented as non-current assets. Loans and receivables are presented as "trade and other receivables" and "cash and cash equivalents" on the balance sheet.

2. Significant accounting policies (continued)

2.6 Financial assets (continued)

(a) Classification (continued)

(ii) Available-for-sale financial assets

Available-for-sale financial assets are non-derivatives that are either designated in this category or not classified in any of the other categories. They are presented as non-current assets unless the investment matures or management intends to dispose of the assets within 12 months after the end of each reporting period.

(b) Recognition and derecognition

Regular way purchases and sales of financial assets are recognised on trade date – the date on which the group commits to purchase or sell the asset.

Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has transferred substantially all risks and rewards of ownership. On disposal of a financial asset, the difference between the carrying amount and the sale proceeds is recognised in profit or loss. Any amount previously recognised in other comprehensive income relating to that asset is reclassified to profit or loss.

(c) Initial measurement

Financial assets are initially recognised at fair value plus transaction costs.

(d) Subsequent measurement

Available-for-sale financial assets are subsequently carried at fair value. Loans and receivables are subsequently carried at amortised cost using the effective interest method.

Interest and dividend income on available-for-sale financial assets are recognised separately in profit or loss. Changes in the fair values of available-for-sale debt securities (i.e. monetary items) denominated in foreign currencies are analysed into currency translation differences on the amortised cost of the securities and other changes; the currency translation differences are recognised in profit or loss and the other changes are recognised in other comprehensive income and accumulated in the fair value reserve. Changes in fair values of available-for-sale equity securities (i.e. non- monetary items) are recognised in other comprehensive income and accumulated in the fair value reserve, together with the related currency translation differences.

(e) Impairment

The group assesses at the end of each reporting period whether there is objective evidence that a financial asset or a group of financial assets is impaired and recognises an allowance for impairment when such evidence exists.

(i) Loans and receivables

Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy, and default or significant delay in payments are objective evidence that these financial assets are impaired.

The carrying amount of these assets is reduced through the use of an impairment allowance account which is calculated as the difference between the carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. When the asset becomes uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are recognised against the same line item in profit or loss.

2. **Significant accounting policies (continued)**

2.6 Financial assets (continued)

(e) Impairment (continued)

(i) Loans and receivables (continued)

The impairment allowance is reduced through profit or loss in a subsequent period when the amount of impairment loss decreases and the related decrease can be objectively measured. The carrying amount of the asset previously impaired is increased to the extent that the new carrying amount does not exceed the amortised cost had no impairment been recognised in prior periods.

(ii) Available-for-sale financial assets

In addition to the objective evidence of impairment described in (i) above, a significant or prolonged decline in the fair value of an equity security below its cost is considered as an indicator that the available-for-sale financial asset is impaired.

If any evidence of impairment exists, the cumulative loss that was previously accumulated in other comprehensive income is reclassified to profit or loss. The cumulative loss is measured as the difference between the acquisition cost (net of any principal repayments and amortisation) and the current fair value, less any impairment loss previously recognised as an expense. The impairment losses recognised as an expense on equity securities are not reversed through profit or loss.

2.7 Cash and cash equivalents

For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents include cash on hand, deposits with financial institutions which are subject to an insignificant risk of change in value, and bank overdrafts. Bank overdrafts are presented as current borrowings on the balance sheet.

2.8 Investments in associates

Investments in associates are carried at cost less accumulated impairment losses in the company's balance sheet. On disposal of investments in associates, the difference between disposal proceeds and the carrying amounts of the investments are recognised in profit or loss.

2.9 Investments in subsidiaries

Investments in subsidiaries are carried at cost less accumulated impairment losses in the company's balance sheet. On disposal of investments in subsidiaries, the difference between disposal proceeds and the carrying amounts of the investments are recognised in profit or loss.

2.10 Property, plant and equipment

(a) Measurement

All items of property, plant and equipment are initially recognised at cost and subsequently carried at cost less accumulated depreciation and accumulated impairment losses.

The cost of an item of property, plant and equipment initially recognised includes its purchase price and any cost that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

(b) Depreciation

Depreciation on property, plant and equipment is calculated using the straight-line method to allocate their depreciable amounts over their estimated useful lives of 3 years of the assets.

2. Significant accounting policies (continued)

2.10 Property, plant and equipment (continued)

(b) Depreciation (continued)

The residual values, estimated useful lives and depreciation method of property, plant and equipment are reviewed, and adjusted as appropriate, at the end of each reporting period. The effects of any revision are recognised in profit or loss when the changes arise.

(c) Subsequent expenditure

Subsequent expenditure relating to property, plant and equipment that has already been recognised is added to the carrying amount of the asset only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. All other repair and maintenance expenses are recognised in profit or loss when incurred.

(d) Disposal

On disposal of an item of property, plant and equipment, the difference between the disposal proceeds and its carrying amount is recognised in profit or loss.

2.11 Intangible assets

Goodwill on acquisitions

Goodwill on acquisitions of subsidiaries and businesses represents the excess of (i) the consideration transferred, the amount of any non-controlling interests in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over (ii) the fair value of the net identifiable assets acquired.

The consideration transferred does not include amounts related to settlement of pre-existing relationships. Such amounts are generally recognised in profit or loss.

Goodwill on subsidiaries is recognised separately as intangible assets and carried at cost less accumulated impairment losses.

Goodwill on associates is included in the carrying amount of the investments.

Gains and losses on the disposal of subsidiaries and associates include the carrying amount of goodwill relating to the entity sold, except for goodwill arising from acquisitions prior to 1 January 2001. Such goodwill was adjusted against retained earnings in the year of acquisition and is not recognised in profit or loss on disposal.

2.12 Impairment of non-financial assets

(a) Goodwill

Goodwill recognised separately as an intangible asset is tested for impairment annually and whenever there is indication that the goodwill may be impaired.

For the purpose of impairment testing of goodwill, goodwill is allocated to each of the group's cash-generating unit (CGU) expected to benefit from synergies arising from the business combination.

An impairment loss is recognised when the carrying amount of a CGU, including the goodwill, exceeds the recoverable amount of the CGU. The recoverable amount of a CGU is the higher of the CGU's fair value less cost to sell and value-in-use.

2. **Significant accounting policies (continued)**

2.12 Impairment of non-financial assets (continued)

(a) Goodwill (continued)

The total impairment loss of a CGU is allocated first to reduce the carrying amount of goodwill allocated to the CGU and then to the other assets of the CGU pro-rata on the basis of the carrying amount of each asset in the CGU.

An impairment loss on goodwill is recognised as an expense and is not reversed in a subsequent period.

(b) Property, plant and equipment and investments in subsidiaries and associates

Property, plant and equipment and investments in subsidiaries and associates are tested for impairment whenever there is any objective evidence or indication that these assets may be impaired.

For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash inflows that are largely independent of those from other assets. If this is the case, the recoverable amount is determined for the cash-generating unit (CGU) to which the asset belongs.

If the recoverable amount of the asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount.

The difference between the carrying amount and recoverable amount is recognised as an impairment loss in profit or loss.

An impairment loss for an asset other than goodwill is reversed if, and only if, there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. The carrying amount of this asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortisation or depreciation) had no impairment loss been recognised for the asset in prior years.

A reversal of impairment loss for an asset other than goodwill is recognised in profit or loss.

2.13 Financial liabilities

Financial liabilities are recognised on the balance sheet when, and only when, the group becomes a party to the contractual provisions of the financial instrument.

Financial liabilities are recognised initially at fair value, plus, in the case of financial liabilities other than derivatives, directly attributable transaction costs.

Subsequent to initial recognition, all financial liabilities are measured at amortised cost using the effective interest method, except for derivatives, which are measured at fair value.

A financial liability is derecognised when the obligation under the liability is extinguished. For financial liabilities other than derivatives, gain and loss is recognised in profit or loss when the liabilities are derecognised, and through the amortisation process. Any gain or loss arising from changes in fair value of derivatives is recognised in profit or loss. Net gain or loss on derivatives includes exchange differences.

2. Significant accounting policies (continued)

2.14 *Trade and other payables*

Trade and other payables represent liabilities for goods, services or funds provided to the group prior to the end of financial year which are unpaid. They are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities.

Trade and other payables are initially recognised at fair value, and subsequently carried at amortised cost using the effective interest method.

2.15 *Borrowings*

Borrowings are presented as current liabilities unless the group has an unconditional right to defer settlement for at least 12 months after the end of each reporting period, in which case they are presented as non-current liabilities.

Borrowings are initially recognised at fair value (net of transaction costs) and subsequently carried at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption value is recognised in profit or loss over the period of the borrowings using the effective interest method.

Borrowings are derecognised when the obligation is discharged, cancelled or expired. The difference between the carrying amount and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss.

2.16 *Borrowing costs*

Borrowing costs are recognised in profit or loss using the effective interest method.

2.17 *Share capital and treasury shares*

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issuance of new ordinary shares are deducted against the share capital account.

When any entity within the group purchases the company's ordinary shares ("treasury shares"), the consideration paid including any directly attributable incremental cost is presented as a component within equity attributable to the company's equity holders, until they are cancelled, sold or reissued.

When treasury shares are subsequently cancelled, the cost of treasury shares are deducted against the share capital account if the shares are purchased out of capital of the company, or against the retained profits of the company if the shares are purchased out of earnings of the company.

When treasury shares are subsequently sold or reissued pursuant to an employee share option scheme, the cost of treasury shares is reversed from the treasury share account and the realised gain or loss on sale or reissue, net of any directly attributable incremental transaction costs and related income tax, is recognised in the capital reserve.

2.18 *Dividends declared to owners of the company and non-controlling interests*

Dividends declared to owners of the company and non-controlling interests during the financial year are recognised in the financial statements.

2. Significant accounting policies (continued)

2.19 Currency translation

(a) Functional and presentation currency

Items included in the financial statements of each entity in the group are measured using the currency of the primary economic environment in which the entity operates ("functional currency"). The consolidated financial statements are presented in United States dollar, which is the functional currency of the company.

(b) Transactions and balances

Transactions in a currency other than the functional currency ("foreign currency") are translated into the functional currency using the exchange rates at the dates of the transactions. Currency translation differences resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at the closing rates at the end of each reporting period are recognised in profit or loss. However, in the consolidated financial statements, currency translation differences arising from borrowings in foreign currencies and other currency instruments designated and qualifying as net investment hedges and net investments in foreign operations, are recognised in other comprehensive income and accumulated in the currency translation reserve.

When a foreign operation is disposed of or any borrowings forming part of the net investment of the foreign operation are repaid, a proportionate share of the accumulated translation differences is reclassified to profit or loss, as part of the gain or loss on disposal.

Currency exchange gains and losses that relate to borrowings are presented in profit or loss within "finance expenses". All other curreney exchange gains and losses are recognised in profit or loss within "other income" or "other losses".

Non-monetary items measured at fair values in foreign currencies are translated using the exchange rates at the date when the fair values are determined.

(c) Translation of group entities' financial statements

The results and financial position of all the group entities (none of which has the currency of a hyperinflationary eeonomy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

(i) Assets and liabilities are translated at the closing exchange rates at the end of each reporting period;

(ii) Income and expenses are translated at average exchange rates (unless the average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated using the exchange rates at the dates of the transactions); and

(iii) All resulting currency translation differences are recognised in other comprehensive income and accumulated in the currency translation reserve.

3. Critical accounting estimates, assumptions and judgements

Estimates, assumptions and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

3. Critical accounting estimates, assumptions and judgements (continued)

3.1 Critical accounting estimates and assumptions

Impairment of loans and receivables

Management reviews its loans and receivables for objective evidence of impairment annually. Significant financial difficulties of the debtor, the probability that the debtor will enter bankruptcy, and default or significant delay in payments are considered objective evidence that a receivable is impaired. In determining this, management makes judgement as to whether there is observable data indicating that there has been a significant change in the payment ability of the debtor, or whether there have been significant changes with adverse effect in the technological, market, economic or legal environment in which the debtor operates in.

Where there is objective evidence of impairment, management makes judgements as to whether an impairment loss should be recorded as an expense. In determining this, management uses estimates based on historical loss experience for assets with similar credit risk characteristics. The methodology and assumptions used for estimating both the amount and timing of future cash flows are reviewed regularly to reduce any differences between the estimated loss and actual loss experience.

3.2 Critical judgements made in applying the accounting policies

Impairment of available-for-sale financial assets

The group follows the guidance of FRS 39 in determining when a financial asset is considered impaired. This determination requires significant judgement. The group evaluates, among other factors, the duration and extent to which the fair value of a financial asset is less than its cost; and the financial health of and the near-term business outlook for the issuer of the instrument, including factors such as industry and sector performance, changes in technology and operational and financing cash flow.

4. Revenue

	Group	
	2014	**2013**
	US$	US$
Dividend income	3,177,669	4,335,645
Interest income	99,899	14,418
Management fees income	41,029	35,100
	3,318,597	4,385,163

5. Other income

		Group	
		2014	**2013**
	Note	US$	US$
Gain on disposal of investments in associates	7	527,240	-
Impairment loss of other receivables no longer required	10	300,000	-
		827,240	-

6. Other losses

	Note	Group 2014 US$	Group 2013 US$
Allowance for impairment losses arising from other receivables		259,049	241,743
Available-for-sale financial assets			
- impairment loss	11	145,186	-
- fair value loss reclassified from other comprehensive income on disposal	25	10,167	2,874
- fair value loss reclassified from other comprehensive income on impairment	25	280,521	4,734,905
Currency exchange loss – net		441,302	280,404
		1,136,225	5,259,926

7. Profit before income tax

The following items have been included in arriving at profit before income tax:

	Note	Group 2014 US$	Group 2013 US$
Depreciation of property, plant and equipment	15	2,600	561
Gain on disposal of investments in associates	5	(527,240)	-
Staff costs (including those of key management personnel)			
- salaries and other short-term employee benefits		657,078	62,288
- employer's contribution to defined contribution plans		61,254	-

8. Income tax expense

The income of the company mainly arises from dividends received from companies incorporated in Singapore which are not taxable.

9. Cash and cash equivalents

	Group 2014 US$	Group 2013 US$	Company 2014 US$	Company 2013 US$
Cash and bank balances	8,865,488	4,480,924	457,549	1,027,435

Acquisition of subsidiaries
On 30 May 2014, the company acquired 100% interest of the issued share capital of Alliance Asia Holdings Pte. Ltd. for a cash consideration of US$2.24.

On 2 June 2014, Alliance Asia Holdings Pte. Ltd. increased its share capital by 1,999,998 shares of which the company subscribed 49.99% for a consideration of US$999,997.76. Capital contribution received for the non-controlling interests for the remaining subscription amounted to US$1,000,000.

9. Cash and cash equivalents (continued)

As a result of the issuance, the effective interest of the company in the subsidiary decreased to 50%. The effect of the acquisition of the non-controlling interests amounted to US$1,346 has been recognised as "capital reserve" within equity (Note 23 and 26).

The aggregate cash inflow arising from the acquisition of subsidiaries of the group were:

	Note	Group *Acquisition* US$
Identifiable assets and liabilities		
Cash and cash equivalents		7,699
Total assets		7,699
Other payables		10,389
Total liabilities		10,389
Identifiable net assets acquired		(2,690)
Add: Goodwill	16	2,692
Cash consideration paid		2
Less: Cash and cash equivalents in subsidiaries acquired		(7,699)
Net cash inflow on acquisition		7,697

10. Other receivables

	Note	Group 2014 US$	Group 2013 US$	Company 2014 US$	Company 2013 US$
Due from unrelated parties		3,696,384	3,624,029	618	-
Less: Allowance for impairment losses	29(b)(i)	(3,592,605)	(3,501,310)	-	-
		103,779	122,719	618	-
Due from related parties:					
- subsidiaries		-	-	8,684,729	2,372,479
- associates		5,847,819	7,954,053	-	-
Less: Allowance for impairment losses	29(b)(i)	(921,463)	(810,518)	-	-
- other related parties		356,766	73,182	-	-
		5,386,901	7,339,436	8,685,347	2,372,479

(a) The amounts due from unrelated parties are repayable on demand or within one year from the balance sheet date. The amounts bearing interest are as follows:

	2014 US$	2013 US$
Interest-bearing at 4% per annum	2,282,375	2,282,375

(b) The amounts due from related parties are unsecured and repayable on demand. The amounts bearing interest are as follows:

	2014 US$	2013 US$
Interest-bearing at 13% and 20% per annum up to 31 March 2014	332,796	332,796

11. Available-for-sale financial assets

	Note	Group 2014 US$	Group 2013 US$
Fair value			
At beginning of financial year/date of incorporation		17,211,246	-
Acquisition of subsidiaries		-	20,852,058
Additions		1,054,113	-
Disposal		(4,756,804)	-
Fair value loss recognised in other comprehensive income	25	(1,236,373)	(3,102,958)
Impairment losses	6	(145,186)	-
Currency translation difference		(466,731)	(537,854)
At end of financial year		11,660,265	17,211,246
Accumulated impairment losses			
At beginning of financial year/date of incorporation		500,000	-
Acquisition of subsidiaries		-	500,000
At end of financial year		500,000	500,000
Total		11,160,265	16,711,246

Available-for-sale financial assets are analysed as follows:

	2014 US$	2013 US$
Listed equity securities:		
- Australia	-	249,244
- Singapore	7,897,673	9,487,389
- United States	210,753	-
Stated at fair value	8,108,426	9,736,633
Unlisted equity securities		
- People's Republic of China	563,120	725,058
- Singapore	439,840	4,590,533
- Socialist Republic of Vietnam	913,069	920,889
- Union of Myanmar	1,136,610	988,533
- United States	499,200	249,600
Impairment losses	(500,000)	(500,000)
Stated at the lower of cost and net tangible assets of investee	3,051,839	6,974,613
Total	11,160,265	16,711,246

12. Long-term receivables

	Group 2014 US$	Group 2013 US$
Loan to unrelated parties	-	300,000
Less: Allowance for impairment losses	-	(300,000)
	-	-

12. Long-term receivables (continued)

Analysis of allowance for impairment losses:

	Group	
	2014	2013
	US$	US$
At beginning of financial year/date of incorporation	(300,000)	-
Acquisition of subsidiaries	-	(300,000)
Transfer to current portion	300,000	-
At end of financial year	-	(300,000)

13. Investments in associates

		Group	
		2014	2013
	Note	US$	US$
Equity accounting			
At beginning of financial year/date of incorporation		11,888,619	-
Acquisition of subsidiaries		-	12,415,321
Additions		3,262,425	609,898
Share of associates foreign currency translation reserve	22	108,421	(1,230,185)
Share of post-acquisition profits or losses, net of tax		2,143,512	2,554,285
Dividend		(1,234,583)	(2,460,700)
At end of financial year		16,168,394	11,888,619

Set out below are the associates of the group. The associates have share capital consisting solely of ordinary shares, which are held directly by the group; the country of incorporation is also their principal place of business.

Name of entity	Principal activities	Place of business/ country of incorporation	% of ownership interest 2014	% of ownership interest 2013
Held by subsidiaries				
Macondray & Company, Inc.				
KFC-Vietnam Joint Venture Company Limited	Operation of a chain of restaurants	Socialist Republic of Vietnam	25	25
Myanmar Winery and Distillery Company Ltd	Distributing, trading and selling of liquor products	Republic of the Union of Myanmar	20	20
Alliance Resources Limited	Investment holding, provision of management service, general importers and exporters	Hong Kong	20	20

13. Investments in associates (continued)

Name of entity	Principal activities	Place of business/ country of incorporation	% of ownership interest 2014	2013
Held by subsidiaries (continued)				
Macondray & Company, Inc.				
Associated Brands Pte Ltd	Investment holding	Singapore	20	20
International Property Development Corporation	Real estate investment	Socialist Republic of Vietnam	-	50
ARC Ventures Limited	Investment holding	Hong Kong	20	20
Montex Investments Limited	Investment holding	British Virgin Islands	20	20
Alliance Brewery Co., Ltd	Production and packaging of beer	Republic of the Union of Myanmar	25	20
Alliance Properties Co., Ltd	Buy, sell and development of real estate	Republic of the Union of Myanmar	20	20
Automobile Century Co., Ltd	Investment holding	Republic of the Union of Myanmar	23.81	23.81
Viet Asia Consultancy Company Limited	Dormant	Republic of the Union of Myanmar	50	50
International Sun Moon Star Agriculture Co., Ltd	Farming, cultivation and sale of rice	Republic of the Union of Myanmar	20	20
The Strand Trading Co., Ltd	Dormant	Republic of the Union of Myanmar	20	20
Total Supply Chain Co., Ltd	Supply logistics, warehousing and transport services	Republic of the Union of Myanmar	20	20
Macondray Corporation Pte Ltd				
Advance Crown Manufacture Joint-Venture Company	Manufacturing of bottle products	Socialist Republic of Vietnam	50	50
International Beverages Trading Company Limited	Distribution, trading and selling of liquor products	Republic of the Union of Myanmar	20	20

Notes to the Financial Statements (continued)

13. Investments in associates (continued)

Summarised balance sheet (US$'000)

	KFC-Vietnam Joint Venture Company Limited		Myanmar Winery and Distillery Company Ltd		Alliance Properties Co., Ltd		International Beverages Trading Company Limited	
	2014	**2013**	**2014**	**2013**	**2014**	**2013**	**2014**	**2013**
	US$	US$	US$	US$	US$	US$	US$	US$
Current assets	6,944	4,744	15,449	60,605	28,150	12,534	49,369	50,103
Current liabilities	(8,101)	(13,011)	(42,407)	(94,181)	(60,798)	(44,699)	(39,502)	(35,346)
Non-current assets	16,968	20,441	28,662	33,477	53,648	52,665	3,168	2,071
Non-current liabilities	(716)	(2,697)	-	-	-	-	-	-
Net assets/(liabilities)	15,095	9,477	1,704	(99)	21,000	20,500	13,035	16,828

Summarised statement of comprehensive income (US$'000)

	KFC-Vietnam 2014	KFC-Vietnam 2013	Myanmar Winery 2014	Myanmar Winery 2013	Alliance Properties 2014	Alliance Properties 2013	International Beverages 2014	International Beverages 2013
Revenue	55,432	50,008	1,465	68,196	16	45	167,985	130,704
Cost of sales	(49,451)	(45,424)	(1,336)	(67,022)	-	-	(159,472)	(79,058)
Other income	451	224	1,037	918	583	65	118	61
Expenses	(6,644)	(6,301)	(439)	(1,465)	(307)	(81)	(5,762)	(27,752)
Profit/(loss) before income tax	(212)	(1,493)	727	627	292	29	2,869	23,955
Income tax expense	(4)	(7)	143	(737)	-	-	(840)	(5,980)
Profit/(loss) for the year	(216)	(1,500)	870	(110)	292	29	2,029	17,975
Other comprehensive income	-	-	-	-	-	-	-	-
Total comprehensive income	(216)	(1,500)	870	(110)	292	29	2,029	17,975
Dividend received from associates	-	-	-	-	-	-	1,207	1,156

The information above reflects the amounts presented in the audited/unaudited financial statements of the associates (and not the group's share of those amounts), adjusted for differences in accounting policies between the company and the associates, if any.

Goodwill amounting to US$116,860 is included in the carrying amount of investments in associates.

14. Investments in subsidiaries

	Company	
	2014	2013
	US$	US$
Cost		
At beginning of financial year/date of incorporation	25,097,661	-
Acquisitions	1,000,000	25,097,661
At end of financial year	26,097,661	25,097,661

Further details are set out on page 30.

15. Property, plant and equipment

		Computers	
		2014	2013
	Note	US$	US$
Group			
Cost			
At beginning of financial year/date of incorporation		18,498	-
Acquisition of subsidiaries		-	17,110
Additions		3,190	1,978
Currency translation differences		(797)	(590)
At end of financial year		20,891	18,498
Accumulated depreciation			
At beginning of financial year/date of incorporation		14,041	-
Acquisition of subsidiaries		-	13,941
Charge for the financial year	7	2,600	561
Currency translation differences		(695)	(461)
At end of financial year		15,946	14,041
Carrying amount			
At end of financial year		4,945	4,457
Company			
Cost			
At beginning of financial year/date of incorporation		-	-
Additions		3,190	-
At end of financial year		3,190	-
Accumulated depreciation			
At beginning of financial year/date of incorporation		-	-
Charge for the financial year		303	-
At end of financial year		303	-
Carrying amount			
At end of financial year		2,887	-

Notes to the Financial Statements (continued)

14. Investments in subsidiaries (continued)

The group had the following subsidiaries:

Name of entity	Principal activities	Country of business/ incorporation	% of ordinary shares directly held by parent		% of ordinary shares held by the group		% of ordinary shares held by non-controlling interests	
			2014	**2013**	**2014**	**2013**	**2014**	**2013**
Held by company								
Macondray & Company, Inc.	Investment holding	British Virgin Islands	100	100	100	100	-	-
Macondray Corporation Pte Ltd	Investment holding	Singapore	100	100	100	100	-	-
Amtrek Investment Pte. Ltd.	Investment holding	Singapore	60	60	60	60	40	40
Alliance Asia Holdings Pte. Ltd.	Investment holding	Singapore	50	-	50	-	50	-
Held by subsidiaries								
Macondray & Company, Inc.								
Macondray Company Limited	Investment holding	Hong Kong	100	100	100	100	-	-
Representations International Inc	Investment holding	British Virgin Islands	100	100	100	100	-	-
Macondray Corporation Pte Ltd								
MCI Investment Pte. Ltd.	Investment holding	Singapore	75	75	75	75	25	25
Alliance Asia Holdings Pte. Ltd.								
Alliance Asia Duty Free Pte. Ltd.	Investment holding	Singapore	80	-	40	-	60	60
Alliance Asia Enterprise Pte. Ltd.	Investment holding	Singapore	55	-	27.5	-	72.5	72.5
Alliance Asia Duty Free Pte. Ltd.								
Duty Free Century Pte. Ltd.	General wholesale trade including general importers	Singapore	60	-	24	-	76	76

Significant restrictions
There are no significant restrictions on the group's ability to access or use assets and settle liabilities of the group.

No subsidiaries that has NCI in the opinion of the directors are material to the group.

16. Intangible assets

	Note	Group 2014 US$	Group 2013 US$
Goodwill			
Cost			
At beginning of financial year/date of incorporation		1,724,426	-
Acquisition of subsidiaries	9	2,692	1,724,426
At end of financial year		1,727,118	1,724,426

Goodwill on acquisition of subsidiaries were tested for impairment annually. There were no objective evidence of indication that these assets may be impaired.

17. Trade payables

	Group		Company	
	2014	2013	2014	2013
	US$	US$	US$	US$
Due to an unrelated party	-	24,141	-	24,141
Accrued operating expenses	752,723	484,570	98,138	2,372
	752,723	508,711	98,138	26,513

The amounts due to an unrelated party are normally settled on 60-day terms.

18. Other payables

	Group		Company	
	2014	2013	2014	2013
	US$	US$	US$	US$
Due to related parties:				
- subsidiaries	-	-	-	3,337
- other related parties	10,456	3,604	10,456	-
	10,456	3,604	10,456	3,337

The amounts due to related parties are unsecured, interest-free and repayable on demand.

19. Long-term payables

	Group		Company	
	2014	2013	2014	2013
	US$	US$	US$	US$
Due to an unrelated party	4,264,827	5,264,826	4,264,827	5,264,826
Due to related parties:				
- ultimate parent	15,014,235	15,014,235	15,014,235	15,014,235
- subsidiaries	-	-	10,571,755	4,016,252
- a shareholder	3,005,054	3,005,054	3,005,054	3,005,054
- other related parties	4,943,529	5,574,293	-	-
	27,227,645	28,858,408	32,855,871	27,300,367

19. Long-term payables (continued)

(a) The amounts due to related parties are unsecured, interest-free and are not expected to be repaid within the next twelve months.

(b) It is not practicable to estimate the fair value of the long-term payables due primarily to a lack of fixed repayment terms. However, the group and the company do not anticipate the carrying amounts recorded at the end of each reporting period to be significantly different from the value that would eventually be paid.

20. Share capital

	Group and Company			
	2014		2013	
	No. of ordinary shares	US$	No. of ordinary shares	US$
At beginning of financial year/date of incorporation	98,000,000	980,000	10,000	100
Issue of shares during financial year	-	-	102,890,000	1,028,900
Capital reduction	-	-	(4,900,000)	(49,000)
At end of financial year	98,000,000	980,000	98,000,000	980,000

The holders of ordinary shares which have no par value are entitled to receive dividends as declared from time to time and are entitled to one vote per share at general meetings of the company. All shares rank equally with regard to the company's residual assets.

21. Treasury shares

	Group and Company			
	2014		2013	
	No. of treasury shares	US$	No. of treasury shares	US$
At beginning of financial year/date of incorporation	9,393,210	(2,210,772)	-	-
Acquired during the financial year	200,000	(2,000)	9,393,210	(2,210,772)
At end of financial year	9,593,210	(2,212,772)	9,393,210	(2,210,772)

Treasury shares relate to the company's ordinary shares held by the company. The amount paid to acquire the shares is presented as a component within shareholder's equity.

22. Currency translation reserve

		Group	
		2013	**2013**
	Note	US$	US$
At beginning of financial year/date of incorporation		3,600,656	-
Acquisition of subsidiaries		-	4,979,269
Exchange difference arising on translation of financial statements of its foreign operations		(144,081)	(160,747)
Share of associates' foreign currency translation reserve	13	108,421	(1,230,185)
Share of non-controlling interests	26	26,032	12,319
At end of financial year		3,591,028	3,600,656

The currency translation reserve represents exchange differences arising from the translation of the financial statements of foreign operations.

23. Capital reserve

Capital reserve represents the effect of changes in ownership interests in subsidiaries that do not result to loss of control (Note 14).

24. Restructuring reserve

Restructuring reserve represents the excess of the consideration paid over the share capital of the subsidiaries acquired in a group reorganisation.

25. Fair value reserve

		Group	
		2014	**2013**
	Note	US$	US$
At beginning of financial year/date of incorporation		(4,632,801)	-
Acquisition of subsidiaries		-	(6,317,498)
Available-for-sale financial assets			
- fair value loss	11	(1,236,373)	(3,102,958)
- transfer to profit or loss on disposal	6	10,167	2,874
- transfer to profit or loss on impairment	6	280,521	4,734,905
Currency translation differences		220,405	49,876
At end of financial year		(5,358,081)	(4,632,801)

The fair value reserve represents the cumulative net change in the fair value of available-for-sale financial assets until the investments are derecognised or impaired.

26. Non-controlling interests

		Group	
		2014	**2013**
	Note	US$	US$
At beginning of financial year/date of incorporation		635,670	-
Acquisition of subsidiaries		1,365,999	710,811
Acquisition of non-controlling interests		(1,346)	-
Share of results after tax of subsidiaries		66,256	(62,822)
Share of currency translation reserve	22	(26,032)	(12,319)
At end of financial year		2,040,547	635,670

The non-controlling interests represent the equity in subsidiaries not attributable, directly or indirectly, to owners of the company.

27. Dividends declared

	Group	
	2014	**2013**
	US$	US$
Dividends declared		
Dividend (exempt one-tier) of US$0.01697 per share	1,500,000	-

28. Significant related party transactions

In addition to the information disclosed elsewhere in the financial statement, the following transactions took place between the group and related parties at terms agreed between the parties:

	Group	
	2014	**2013**
	US$	US$
(i) Management fee paid to:		
- fellow subsidiaries	-	10,498
- other related parties	151,000	748,517
	151,000	759,015
(ii) Key management personnel compensation		
- wages, salaries, bonuses and fees	330,775	62,288
- employer's contribution to defined contribution plans	7,560	-

Other related parties comprise mainly companies which are controlled by the group's key management personnel and their close family members.

29. Financial risks and management

(a) General risk management principles

Risk management is integral to the whole business of the group. The group has a system of controls in place to create an acceptable balance between the cost of risks occurring and the cost of managing the risks. The management continually monitors the group's risk management process to ensure that an appropriate balance between risk and control is achieved. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the group's activities.

29. Financial risks and management (continued)

(b) *Financial risks and management*

The main risks arising from the group's financial instruments are credit risk, liquidity risk, interest rate risk and foreign currency risk. The management reviews and agrees policies for managing each of these risks and they are summarised below:

(i) *Credit risk*

Credit risk is the risk of financial loss to the group if a counterparty to a financial instrument fails to meet the contractual obligations, and arises principally from the company's receivables. The maximum exposure to credit risk for trade and other receivables at the reporting date was as follows:

	Group		Company	
	2014	**2013**	**2014**	**2013**
	US$	US$	US$	US$
Other receivables				
- Unrelated parties	103,779	122,719	618	-
- Related parties	5,283,122	7,216,717	8,684,729	2,372,479
	5,386,901	7,339,436	8,685,347	2,372,479

The group has a credit policy in place which establishes credit limits for counterparties and monitors their balances on an ongoing basis. Credit evaluations are performed on all counterparties requiring credit over a certain amount. The credit quality is assessed after taking into account its financial position and past experience with the counterparties.

The group establishes an allowance for impairment that represents its estimate of incurred losses in respect of trade and other receivables. The allowance is a specific loss that relates to individually significant exposures.

The allowance account is used to record impairment losses unless the group is satisfied that no recovery of the amount owing is possible. At that point, the financial asset is considered irrecoverable and the amount charged to the allowance account is written off against the carrying amount of the impaired financial asset.

Cash and cash equivalent are placed with banks and financial institutions which are regulated.

Other receivables (Note 10)

Analysis of allowance for impairment losses

	Group	
	2014	**2013**
	US$	US$
Due from unrelated parties		
At beginning of financial year/date of incorporation	(3,501,310)	-
Acquisition of subsidiaries	-	(3,259,567)
Allowance made during financial year	(91,295)	(241,743)
Transfer from long-term portion	(300,000)	-
Allowance no longer required	300,000	-
At end of financial year	(3,592,605)	(3,501,310)

29. Financial risks and management (continued)

(b) Financial risks and management (continued)

(i) Credit risk (continued)

Analysis of allowance for impairment losses (continued)

	Group 2014 US$	Group 2013 US$
Due from related parties		
At beginning of financial year/date of incorporation	(810,518)	-
Acquisition of subsidiaries	-	(810,518)
Allowance made during financial year	(167,754)	-
Written off against allowance	56,809	-
At end of financial year	(921,463)	(810,518)

(ii) Liquidity risk

Liquidity risk is the risk that the group will encounter difficulty in meeting financial obligations due to shortage of funds. The group's exposure to liquidity risk arises primarily from mismatches of the maturities of financial assets and liabilities.

The table below summarises the maturity profile of the group's financial assets and financial liabilities at the end of each reporting period based on contractual undiscounted payments.

	One year or less US$	More than one to five years US$	Total US$
Group			
2014			
Financial liabilities			
Trade and other payables	763,179	-	763,179
Long-term payables	-	27,227,645	27,227,645
	763,179	27,227,645	27,990,824
Financial assets			
Cash and cash equivalents	8,865,488	-	8,865,488
Other receivables	5,386,901	-	5,386,901
Available-for-sale financial assets	-	11,160,265	11,160,265
	14,252,389	11,160,265	25,412,654
Net financial assets/(liabilities)	13,489,210	(16,067,380)	(2,578,170)
2013			
Financial liabilities			
Trade and other payables	512,315	-	512,315
Long-term payables	-	28,858,408	28,858,408
	512,315	28,858,408	29,370,723
Financial assets			
Cash and cash equivalents	4,480,924	-	4,480,924
Other receivables	7,339,436	-	7,339,436
Available-for-sale financial assets	-	16,711,246	16,711,246
	11,820,360	16,711,246	28,531,606
Net financial assets/(liabilities)	11,308,045	(12,147,162)	(839,117)

29. Financial risks and management (continued)

(b) Financial risks and management (continued)

(ii) Liquidity risk (continued)

	One year or less US$	More than one to five years US$	Total US$
Company			
2014			
Financial liabilities			
Trade and other payables	108,594	-	108,594
Long-term payables	-	32,855,871	32,855,871
	108,594	32,855,871	32,964,465
Financial assets			
Cash and cash equivalents	457,549	-	457,549
Other receivables	8,685,347	-	8,685,347
	9,142,896	-	9,142,896
Net financial assets/(liabilities)	9,034,302	(32,855,871)	(23,821,569)
2013			
Financial liabilities			
Trade and other payables	29,850	-	29,850
Long-term payables	-	27,300,367	27,300,367
	29,850	27,300,367	27,330,217
Financial assets			
Cash and cash equivalents	1,027,435	-	1,027,435
Other receivables	2,372,479	-	2,372,479
	3,399,914	-	3,399,914
Net financial assets/(liabilities)	3,370,064	(27,300,367)	(23,930,303)

The group has made arrangements with ultimate parent (Note 19) for continuing financial support to the group as and when the need arises.

(iii) Interest rate risk

The group is not exposed to interest rate risk as the group does not have significant variable interest-bearing financial instruments.

(iv) Foreign currency risk

The group is exposed to foreign currency risk on transactions that are denominated in a currency other than the functional currency of each entity of the group. The currencies giving rise to this risk are primarily Singapore dollar, Vietnam dong and Myanmar kyat.

29. Financial risks and management (continued)

(b) Financial risks and management (continued)

(iv) Foreign currency risk (continued)

The group's exposures to foreign currency risk are as follows:

	Singapore dollar US$	Vietnam dong US$	Myanmar kyat US$
Group			
2014			
Other receivables	21,083	120,356	512,922
Cash and cash equivalents	754,016	302	151
Trade and other payables	(4,703,618)	-	-
Net exposure	(3,928,519)	120,658	513,073
2013			
Other receivables	191,082	1,583,329	1,543,888
Cash and cash equivalents	751,873	-	-
Trade and other payables	(4,652,378)	-	-
Net exposure	(3,709,423)	1,583,329	1,543,888
Company			
2014			
Other receivables	8,685,346	-	-
Cash and cash equivalents	105,973	-	-
Trade and other payables	(10,771,972)	-	-
Net exposure	(1,980,653)	-	-
2013			
Other receivables	2,372,479	-	-
Cash and cash equivalents	427,071	-	-
Trade and other payables	(4,043,602)	-	-
Net exposure	(1,244,052)	-	-

The group does not have any formal policy on managing its foreign currency risk. The group maintains a natural hedge, whenever possible, by matching the foreign currency assets against its liabilities. As a result, the group continues to be exposed to foreign currency risks relating to any unmatched amounts.

Sensitivity analysis
A 10% strengthening of foreign currencies against the United States dollar (functional currency) at the end of each reporting period would increase profit after tax by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant.

29. Financial risks and management (continued)

(b) Financial risks and management (continued)

(iv) Foreign currency risk (continued)

	Profit after tax			
	Group		Company	
	2014	2013	2014	2013
	US$	US$	US$	US$
Singapore dollar	(326,067)	(307,882)	(164,394)	(103,256)
Vietnam dong	10,015	131,416	-	-
Myanmar kyat	42,585	128,143	-	-

A 10% weakening of foreign currencies against the United States dollar would have had the equal but opposite effect on the above currencies to the amounts shown above, on the basis that all other variables remain constant.

30. Capital management

The group manages its capital to ensure that it will be able to continue as a going concern and to sustain future development of the business while maximising the return to stakeholders through the optimisation of the debt and equity balance.

The group manages its capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust the capital structure the group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The group is not subject to any externally imposed capital requirements.

The group's overall strategy in the financial year remains unchanged compared with that in the previous financial year.

31. Fair value measurements

The fair value measurements by level of hierarchy are as follows:

i. quoted prices (unadjusted) in active markets for identical assets or liabilities [Level 1];
ii. inputs other than quoted prices, included within Level 1 that are observable for the asset or liability, either directly or indirectly [Level 2]; and
iii. inputs for the asset or liability that are not based on observable market data (unobservable inputs) [Level 3].

The following table presents the assets and liabilities measured at fair values at 31 December 2014.

	Level 1
	US$
Group	
Assets	
Available-for-sale financial assets	8,108,426

32. New or revised accounting standards and interpretations issued but not yet effective

Below are the mandatory standards, amendments and interpretations to existing standards that have been published, and are relevant for the group's accounting periods beginning on or after the effective date and which the group has not early adopted:

	Effective for annual periods beginning on or after
- FRS 16 *Property, Plant and Equipment* The standard is amended to clarify how the gross carrying amount and the accumulated depreciation are treated where an entity uses the revaluation model. The carrying amount of the asset is restated to the revalued amount. The split between gross carrying amount and accumulated depreciation is treated in one of the following ways: - either the gross carrying amount is restated in a manner consistent with the revaluation of the carrying amount, and the accumulated depreciation is adjusted to equal the difference between the gross carrying amount and the carrying amount after taking into account accumulated impairment losses; or - the accumulated depreciation is eliminated against the gross carrying amount of the asset. This amendment is not expected to have any significant impact on the financial statements of the group.	1 July 2014
- FRS 24 *Related Party Disclosures* The standard is amended to include, as a related party, an entity that provides key management personnel services to the reporting entity or to the parent of the reporting entity ("the management entity"). The reporting entity is not required to disclose the compensation paid by the management entity to the management entity's employees or directors, but it is required to disclose the amounts charged to the reporting entity by the management entity for services provided. This amendment will not result in any changes to the group's accounting policies but will require more disclosures in the financial statements.	1 July 2014
- FRS 40 *Investment Property* The standard is amended to clarify that FRS 40 and FRS 103 are not mutually exclusive. The guidance in FRS 40 assists preparers to distinguish between investment property and owner-occupied property. Preparers also need to refer to the guidance in FRS 103 to determine whether the acquisition of an investment property is a business combination. The group will apply this amendment for acquisition of investment property taking place on or after 1 January 2015.	1 July 2014

32. New or revised accounting standards and interpretations issued but not yet effective (continued)

	Effective for annual periods beginning on or after
- FRS 102 *Share-based Payment* The amendment clarifies the definition of vesting condition and separately defines 'performance condition' and 'service condition'. The group will apply this amendment from 1 January 2015, but this is not expected to have any significant impact on the financial statements of the group.	1 July 2014
- FRS 103 *Business Combinations* The standard is amended to clarify that an obligation to pay contingent consideration which meets the definition of a financial instrument is classified as a financial liability or as equity, on the basis of the definitions in FRS 32 *Financial Instruments: Presentation.* The standard is further amended to clarify that all non-equity contingent consideration, both financial and non-financial, is measured at fair value at each reporting date, with changes in fair value recognised in profit or loss.	1 July 2014
- FRS 113 *Fair Value Measurement* The amendment clarifies that the portfolio exception in FRS 113, which allows an entity to measure the fair value of a group of financial assets and financial liabilities on a net basis, applies to all contracts (including non-financial contracts) within the scope of FRS 39. This amendment is not expected to have any significant impact on the financial statements of the company.	1 July 2014
- Amendments to FRS 38 *Intangible Assets* The standard is amended to clarify how the gross carrying amount and the accumulated depreciation are treated where an entity uses the revaluation model. The carrying amount of the asset is restated to the revalued amount. The split between gross carrying amount and accumulated depreciation is treated in one of the following ways: - either the gross carrying amount is restated in a manner consistent with the revaluation of the carrying amount, and the accumulated depreciation is adjusted to equal the difference between the gross carrying amount and the carrying amount after taking into account accumulated impairment losses; or - the accumulated depreciation is eliminated against the gross carrying amount of the asset.	1 July 2014

33. Comparative information

Certain reclassifications have been made to the prior years' financial statements to enhance comparability with current year's financial statements. As a result, certain line items have been amended on the face of the balance sheet and related notes to the financial statements. Comparative figures have been adjusted to conform with current year's presentation.

The group has reclassified the following in the financial statements:

	As restated US$	As previously stated US$
2013		
Group		
Current assets		
Other receivables	7,339,436	2,703,448
Non-current assets		
Long-term receivables	-	4,635,988
	7,339,436	7,339,436

The financial statements for 2013 cover the financial year since incorporation from 2 July 2013 to 31 December 2013. The financial statements for 2014 cover the twelve months ended 31 December 2014.

The comparative amounts for the consolidated statement of comprehensive income, statement of cash flows, statement of changes in equity and relevant disclosure notes are not entirely comparable.

Registration no:

201317874R

The Companies Act, (Cap. 50)

COMPANY LIMITED BY SHARES

Memorandum

and

Articles of Association

of

Macondray Holdings Pte. Ltd.

(Incorporated on the 2nd day of July 2013)

THE COMPANIES ACT, (CAP.50)
LIMITED PRIVATE COMPANY

MEMORANDUM AND ARTICLES OF ASSOCIATION OF
MACONDRAY HOLDINGS PTE LTD.

1. The name of the company is **MACONDRAY HOLDINGS PTE. LTD.**

2. The Registered Office of the Company will be situated in the Republic of Singapore.
78 SHENTON WAY, #28-01, SINGAPORE (079120)

3. The liability of the members is limited.

3A. The objects of the Company for which the Company is established are mainly for restructuring purpose and the Company shall have full power and authority to carry out any object not prohibited by the laws of the Republic of Singapore. The Company has full power and authority to engage in such other activities as the Company deems necessary, advisable, convenient or incidental to the foregoing.

4. The share capital of the company upon incorporation is UNITED STATES OF AMERICA, DOLLARS (USD) 100.

5. I/We, the several persons/person whose name(s), address(es) and occupation(s) is/are hereunto subscribed is/are desirous of being formed into a company in pursuance of this Memorandum of Association and I/we respectively agree to take the number of shares in the capital of the Company set opposite our respective name(s).

Names, Addresses and occupation of subscribers	Number of Shares	Class of Shares	Currency
ASIA RESOURCE CORPORATION PTE. LTD. 78 SHENTON WAY, #28-01, SINGAPORE (079120)	10,000	ORDINARY	UNITED STATES OF AMERICA, DOLLARS

[signature]
Chow leong Chee

Dated this 02 JUL' 2013

Witness by

[signature]
Tan Chay Hoon

ARTICLES OF ASSOCIATION
OF
MACONDRAY HOLDINGS PTE. LTD.
(Incorporated in the Republic of Singapore)

Interpretation

1. In these Regulations —
"Act" means the Companies Act (Cap. 50);
"seal" means the common seal of the company;
"secretary" means any person appointed to perform the duties of a secretary of the company;
expressions referring to writing shall, unless the contrary intention appears, be construed as including references to printing, lithography, photography and other modes of representing or reproducing words in a visible form;
words or expressions contained in these Regulations shall be interpreted in accordance with the provisions of the Interpretation Act (Cap. 1), and of the Act as in force at the date at which these Regulations become binding on the company.

Share capital and variation of rights

2. Without prejudice to any special rights previously conferred on the holders of any existing shares or class of shares but subject to the Act, shares in the company may be issued by the directors and any such shares may be issued with such preferred, deferred, or other special rights or such restrictions, whether in regard to dividend, voting, return of capital, or otherwise, as the directors, subject to any ordinary resolution of the company, determine. The company shall have not more than 50 members (counting joint holders of shares as one person and not counting any person in the employment of the company or of its subsidiary or any person who while previously in the employment of the company or of its subsidiary was and thereafter has continued to be a member of the company).

3. Subject to the Act, any preference shares may, with the sanction of an ordinary resolution, be issued on the terms that they are, or at the option of the company are liable, to be redeemed.

4. If at any time the share capital is divided into different classes of shares, the rights attached to any class (unless otherwise provided by the terms of issue of the shares of that class) may, whether or not the company is being wound up, be varied with the consent in writing of the holders of 75% of the issued shares of that class, or with the sanction of a special resolution passed at a separate general meeting of the holders of the shares of the class. To every such separate general meeting the provisions of these Regulations relating to general meetings shall with the necessary modifications apply, but so that the necessary quorum shall be 2 persons at least holding or representing by proxy one-third of the issued shares of the class and that any holder of shares of the class present in person or by proxy may demand a poll. To every such special resolution section 184 shall with such adaptations as are necessary apply.

5. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking equally therewith.

6. The company may exercise the powers of paying commissions conferred by the Act, provided that the rate per cent or the amount of the commission paid or agreed to be paid shall be disclosed in the manner required by the Act and the commission shall not exceed the rate of 10% of the price at which the shares in respect whereof the same is paid are issued or an amount equal to 10% of that price (as the case may be). Such commission may be satisfied by the payment of cash or the allotment of fully or partly paid shares or partly in one way and partly in the other. The company may also on any issue of shares pay such brokerage as may be lawful.

7. Except as required by law, no person shall be recognised by the company as holding any share upon any trust, and the company shall not be bound by or be compelled in any way to recognise (even when having notice thereof) any equitable, contingent, future or partial interest in any share or unit of a share or (except only as by these Regulations or by law otherwise provided) any other rights in respect of any share except an absolute right to the entirety thereof in the registered holder.

8. Every person whose name is entered as a member in the register of members shall be entitled without payment to receive a certificate under the seal of the company in accordance with the Act but in respect of a share or shares held jointly by several persons the company shall not be bound to issue more than one certificate, and delivery of a certificate for a share to one of several joint holders shall be sufficient delivery to all such holders.

8A. The company may, subject to and in accordance with the Act, purchase or otherwise acquire shares issued by it on such terms and in such manner as the company may from time to time think fit. Any share which is so purchased or acquired by the company shall, unless held in treasury in accordance with the Act, be deemed to be cancelled immediately on purchase or acquisition by the company. On the cancellation of any share as aforesaid, the rights and privileges attached to that share shall expire. Where ordinary shares are purchased or otherwise acquired by the company in accordance with the Act, the company may hold such shares as treasury shares. The company shall not exercise any rights in respect of the treasury shares other than as provided by the Act. Subject thereto, the company may hold or deal with its treasury shares in the manner authorised by, or prescribed pursuant to, the Act.

Lien

9. The company shall have a first and paramount lien on every share (not being a fully paid share) for all money (whether presently payable or not) called or payable at a fixed time in respect of that share, and the company shall also have a first and paramount lien on all shares (other than fully paid shares) registered in the name of a single person for all money presently payable by him or his estate to the company; but the directors may at any time declare any share to be wholly or in part exempt from the provisions of this regulation. The company's lien, if any, on a share shall extend to all dividends payable thereon.

10. The company may sell, in such manner as the directors think fit, any shares on which the company has a lien, but no sale shall be made unless a sum in respect of which the lien exists is presently payable, nor until the expiration of 14 days after a notice in writing, stating and demanding payment of such part of the amount in respect of which the lien exists as is presently payable, has been given to the registered holder for the time being of the share, or the person entitled thereto by reason of his death or bankruptcy.

11. To give effect to any such sale the directors may authorise some person to transfer the shares sold to the purchaser thereof. The purchaser shall be registered as the holder of the shares comprised in any such transfer, and he shall not be bound to see to the application of the purchase money, nor shall his title to the shares be affected by any irregularity or invalidity in the proceedings in reference to the sale.

12. The proceeds of the sale shall be received by the company and applied in payment of such part of the amount in respect of which the lien exists as is presently payable, and the residue, if any, shall (subject to a like lien for sums not presently payable as existed upon the shares before the sale) be paid to the person entitled to the shares at the date of the sale.

Calls on shares

13. The directors may from time to time make calls upon the members in respect of any money unpaid on their shares and not by the conditions of allotment thereof made payable at fixed times, provided that no call shall be payable at less than one month from the date fixed for the payment of the last preceding call, and each member shall (subject to receiving at least 14 days' notice specifying the time or times and place of payment) pay to the company at the time or times and place so specified the amount called on his shares. A call may be revoked or postponed as the directors may determine.

14. A call shall be deemed to have been made at the time when the resolution of the directors authorising the call was passed and may be required to be paid by instalments.

15. The joint holders of a share shall be jointly and severally liable to pay all calls in respect thereof.

16. If a sum called in respect of a share is not paid before or on the day appointed for payment thereof, the person from whom the sum is due shall pay interest on the sum from the day appointed for payment thereof to the time of actual payment at such rate not exceeding 8% per annum as the directors may determine, but the directors shall be at liberty to waive payment of that interest wholly or in part.

17. Any sum which by the terms of issue of a share becomes payable on allotment or at any fixed date shall for the purposes of these Regulations be deemed to be a call duly made and payable on the date on which by the terms of issue the same becomes payable, and in case of non-payment all the relevant provisions of these Regulations as to payment of interest and expenses, forfeiture, or otherwise shall apply as if the sum had become payable by virtue of a call duly made and notified.

18. The directors may, on the issue of shares, differentiate between the holders as to the amount of calls to be paid and the times of payment.

19. The directors may, if they think fit, receive from any member willing to advance the same all or any part of the money uncalled and unpaid upon any shares held by him, and upon all or any part of the money so advanced may (until the same would, but for the advance, become payable) pay interest at such rate not exceeding (unless the company in general meeting shall otherwise direct) 8% per annum as may be agreed upon between the directors and the member paying the sum in advance.

Transfer of shares

20. No transfer of shares is to be made except to a person approved by the directors of the company.

20A. Subject to these Regulations, any member may transfer all or any of his shares by instrument in writing in any usual or common form or in any other form which the directors may approve. The instrument shall be executed by or on behalf of the transferor and the transferor shall remain the holder of the shares transferred until the transfer is registered and the name of the transferee is entered in the register of members in respect thereof.

21. The instrument of transfer must be left for registration at the registered office of the company together with such fee, not exceeding $1 as the directors from time to time may require, accompanied by the certificate of the shares to which it relates and such other evidence as the directors may reasonably require to show the right of the transferor to make the transfer, and thereupon the company shall subject to the powers vested in the directors by these Regulations register the transferee as a shareholder and retain the instrument of transfer.

22. The directors may decline to register any transfer of shares, not being fully paid shares to a person of whom they do not approve and may also decline to register any transfer of shares on which the company has a lien.

23. The registration of transfers may be suspended at such times and for such periods as the directors may from time to time determine not exceeding in the whole 30 days in any year.

Transmission of shares

24. In case of the death of a member the survivor or survivors where the deceased was a joint holder, and the legal personal representatives of the deceased where he was a sole holder, shall be the only persons recognised by the company as having any title to his interest in the shares; but nothing herein contained shall release the estate of a deceased joint holder from any liability in respect of any share which had been jointly held by him with other persons.

25. Any person becoming entitled to a share in consequence of the death or bankruptcy of a member may, upon such evidence being produced as may from time to time properly be required by the directors and subject as hereinafter provided, elect either to be registered himself as holder of the share or to have some person nominated by him registered as the transferee thereof, but the directors shall, in either case, have the same right to decline or suspend registration as they would have had in the case of a transfer of the share by that member before his death or bankruptcy.

26. If the person so becoming entitled elects to be registered himself, he shall deliver or send to the company a notice in writing signed by him stating that he so elects. If he elects to have another person registered he shall testify his election by executing to that person a transfer of the share. All the limitations, restrictions, and provisions of these Regulations relating to the right to transfer and the registration of transfers of shares shall be applicable to any such notice or transfer as aforesaid as if the death or bankruptcy of the member had not occurred and the notice or transfer were a transfer signed by that member.

27. Where the registered holder of any share dies or becomes bankrupt his personal representative or the assignee of his estate, as the case may be, shall, upon the production of such evidence as may from time to time be properly required by the directors in that behalf, be entitled to the same dividends and other advantages, and to the same rights (whether in relation to meetings of the company, or to voting, or otherwise), as the registered holder would have been entitled to if he had not died or become bankrupt; and where 2 or more persons are jointly entitled to any share in consequence of the death of the registered holder they shall, for the purposes of these Regulations, be deemed to be joint holders of the share.

Forfeiture of shares

28. If a member fails to pay any call or instalment of a call on the day appointed for payment thereof, the directors may, at any time thereafter during such time as any part of the call or instalment remains unpaid serve a notice on him requiring payment of so much of the call or instalment as is unpaid, together with any interest which may have accrued.

29. The notice shall name a further day (not earlier than the expiration of 14 days from the date of service of the notice) on or before which the payment required by the notice is to be made, and shall state that in the event of non-payment at or before the time appointed the shares in respect of which the call was made will be liable to be forfeited.

30. If the requirements of any such notice as aforesaid are not complied with, any share in respect of which the notice has been given may at any time thereafter, before the payment required by the notice has been made, be forfeited by a resolution of the directors to that effect. Such forfeiture shall include all dividends declared in respect of the forfeited shares and not actually paid before the forfeiture.

31. A forfeited share may be sold or otherwise disposed of on such terms and in such manner as the directors think fit, and at any time before a sale or disposition the forfeiture may be cancelled on such terms as the directors think fit.

32. A person whose shares have been forfeited shall cease to be a member in respect of the forfeited shares, but shall, notwithstanding, remain liable to pay to the company all money which, at the date of forfeiture, was payable by him to the company in respect of the shares (together with interest at the rate of 8% per annum from the date of forfeiture on the money for the time being unpaid if the directors think fit to enforce payment of such interest), but his liability shall cease if and when the company receives payment in full of all such money in respect of the shares.

33. A statutory declaration in writing that the declarant is a director or the secretary of the company, and that a share in the company has been duly forfeited on a date stated in the declaration, shall be conclusive evidence of the facts therein stated as against all persons claiming to be entitled to the share.

34. The company may receive the consideration, if any, given for a forfeited share on any sale or disposition thereof and may execute a transfer of the share in favour of the person to whom the share is sold or disposed of and he shall thereupon be registered as the holder of the share, and shall not be bound to see to the application of the purchase money, if any, nor shall his title to the share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale, or disposal of the share.

35. The provisions of these Regulations as to forfeiture shall apply in the case of non-payment of any sum which, by the terms of issue of a share, becomes payable at a fixed time as if the same had been payable by virtue of a call duly made and notified.

Conversion of shares into stock

36. The company may by ordinary resolution passed at a general meeting convert any paid-up shares into stock and reconvert any stock into paid-up shares.

37. The holders of stock may transfer the same or any part thereof in the same manner and subject to the same regulations as and subject to which the shares from which the stock arose might previously to conversion have been transferred or as near thereto as circumstances admit; but the directors may from time to time fix the minimum amount of stock transferable and restrict or forbid the transfer of fractions of that minimum.

38. The holders of stock shall according to the amount of the stock held by them have the same rights, privileges and advantages as regards dividends voting at meetings of the company and other matters as if they held the shares from which the stock arose, but no such privilege or advantage (except participation in the dividends and profits of the company and in the assets on winding up) shall be conferred by any such aliquot part of stock which would not if existing in shares have conferred that privilege or advantage.

39. Such of the regulations of the company as are applicable to paid-up shares shall apply to stock, and the words "share" and "shareholder" therein shall include "stock" and "stockholder".

Alteration of capital

40. The company may from time to time by ordinary resolution do one or more of the following:
   (a) increase the share capital by such sum as the resolution shall prescribe;
   (b) consolidate and divide all or any of its share capital;
   (c) subdivide its shares or any of them, so however that in the subdivision the proportion between the amount paid and the amount, If any, unpaid on each reduced share shall be the same as it was in the case of the share from which the reduced share is derived;
   (d) cancel the number of shares which at the date of the passing of the resolution in that behalf have not been taken or agreed to be taken by any person or which have been forfeited and diminish the amount of its share capital by the number of the shares so cancelled.

41. Subject to any direction to the contrary that may be given by the company in general meeting, all new shares shall, before issue, be offered to such persons as at the date of the offer are entitled to receive notices from the company of general meetings in proportion, as nearly as the circumstances admit, to the amount of the existing shares to which they are entitled. The offer shall be made by notice specifying the number of shares offered, and limiting a time within which the offer, if not accepted, will be deemed to be declined, and, after the expiration of that time, or on the receipt of an intimation from the person to whom the offer is made that he declines to accept the shares offered, the directors may dispose of those shares in such manner as they think most beneficial to the company. The directors may likewise so dispose of any new shares which (by reason of the ratio which the new shares bear to shares held by persons entitled to an offer of new shares) cannot, in the opinion of the directors, be conveniently offered under this regulation.

42. The company may by special resolution reduce its share capital in any manner and with, and subject to, any incident authorised, and consent required by law.

General meeting

43. An annual general meeting of the company shall be held in accordance with the provisions of the Act. All general meetings other than the annual general meetings shall be called extraordinary general meetings.

44. Any director may, whenever he thinks fit, convene an extraordinary general meeting, and extraordinary general meetings shall be convened on such requisition or in default may be convened by such requisitionists as provided by the Act.

45. Subject to the provisions of the Act relating to special resolutions and agreements for shorter notice, 14 days' notice at the least (exclusive of the day on which the notice is served or deemed to be served, but inclusive of the day for which notice is given) specifying the place, the day and the hour of meeting and in case of special business the general nature of that business shall be given to such persons as are entitled to receive such notices from the company.

46. All business shall be special that is transacted at an extraordinary general meeting, and also all that is transacted at an annual general meeting, with the exception of declaring a dividend, the consideration of the accounts, balance-sheets, and the report of the directors and auditors, the election of directors in the place of those retiring, and the appointment and fixing of the remuneration of the auditors.

Proceedings at general meetings

47. No business shall be transacted at any general meeting unless a quorum of members is present at the time when the meeting proceeds to business. Except as herein otherwise provided, 2 members present in person shall form a quorum except that where the company has only one member, that sole member shall constitute a quorum for any general meeting. For the purposes of this article "member" includes a person attending as a proxy or as representing a corporation or a limited liability partnership which is a member. One person attending both as member and as proxy or corporate representative shall not constitute a quorum.

48. If within half an hour from the time appointed for the meeting a quorum is not present, the meeting, if convened upon the requisition of members, shall be dissolved; in any other case it shall stand adjourned to the same day in the next week at the same time and place, or to such other day and at such other time and place as the directors may determine.

49. The chairman, if any, of the board of directors shall preside as chairman at every general meeting of the company, or if there is no such chairman, or if he is not present within 15 minutes after the time appointed for the holding of the meeting or is unwilling to act, the members present shall elect one of their number to be chairman of the meeting.

50. The chairman may, with the consent of any meeting at which a quorum is present, and shall if so directed by the meeting, adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place. When a meeting is adjourned for 30 days or more, notice of the adjourned meeting shall be given as in the case of an original meeting. Except as aforesaid it shall not be necessary to give any notice of an adjournment or of the business to be transacted at an adjourned meeting.

51. At any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands unless a poll is (before or on the declaration of the result of the show of hands) demanded -
(a) by the chairman;
(b) by at least 2 members present in person or by proxy;

(c) by any member or members present in person or by proxy and representing not less than 10% of the total voting rights of all the members having the right to vote at the meeting; or

(d) by a member or members holding shares in the company conferring a right to vote at the meeting being shares on which an aggregate sum has been paid up equal to not less than 10% of the total sum paid up on all the shares conferring that right.

Unless a poll is so demanded a declaration by the chairman that a resolution has on a show of hands been carried or carried unanimously, or by a particular majority, or lost, and an entry to that effect in the book containing the minutes of the proceedings of the company shall be conclusive evidence of the fact without proof of the number or proportion of the votes recorded in favour of or against the resolution. The demand for a poll may be withdrawn.

52. If a poll is duly demanded it shall be taken in such manner and either at once or after an interval or adjournment or otherwise as the chairman directs, and the result of the poll shall be the resolution of the meeting at which the poll was demanded, but a poll demanded on the election of a chairman or on a question of adjournment shall be taken immediately.

53. In the case of an equality of votes, whether on a show of hands or on a poll, the chairman of the meeting at which the show of hands takes place or at which the poll is demanded shall be entitled to a second or casting vote.

54. Subject to any rights or restrictions for the time being attached to any class or classes of shares, at meetings of members or classes of members, each member entitled to vote may vote in person or by proxy or by attorney and on a show of hands every person present who is a member or a representative of a member shall have one vote, and on a poll every member present in person or by proxy or by attorney or other duly authorised representative shall have one vote for each share he holds.

55. In the case of joint holders the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders; and for this purpose seniority shall be determined by the order in which the names stand in the register of members.

56. A member who is mentally disordered or whose person or estate is liable to be dealt with in any way under the law relating to mental capacity may vote, whether on a show of hands or on a poll, by such other person as properly has the management of his estate, and any such person may vote by proxy or attorney.

57. No member shall be entitled to vote at any general meeting unless all calls or other sums presently payable by him in respect of shares in the company have been paid.

58. No objection shall be raised to the qualification of any voter except at the meeting or adjourned meeting at which the vote objected to is given or tendered, and every vote not disallowed at such meeting shall be valid for all purposes. Any such objection made in due time shall be referred to the chairman of the meeting, whose decision shall be final and conclusive.

59. The instrument appointing a proxy shall be in writing, in the common or usual form, under the hand of the appointer or of his attorney duly authorised in writing or, if the appointer is a corporation or limited liability partnership, either under seal or under the hand of an officer or attorney duly authorised. A proxy may but need not be a member of the company. The instrument appointing a proxy shall be deemed to confer authority to demand or join in demanding a poll.

60. Where it is desired to afford members an opportunity of voting for or against a resolution the instrument appointing a proxy shall be in the following form or a form as near thereto as circumstances admit:

I/We, __________ , of being a member/members of the above named company, hereby appoint __________, of __________, or failing him, __________ of __________, __________ , as my/our proxy to vote for me/us on my/our behalf at the [annual or extraordinary, *as the case may be*] general meeting of the company, to be held on the day of 20__ , and at any adjournment thereof.
Signed this day of 20__.
This form is to be used *in favour of the resolution.
against
*Strike out whichever is not desired. [Unless otherwise instructed, the proxy may vote as he thinks fit.]

61. The instrument appointing a proxy and the power of attorney or other authority, if any, under which it is signed or a notarially certified copy of that power or authority shall be deposited at the registered office of the company, or at such other place in Singapore as is specified for that purpose in the notice convening the meeting, not less than 48 hours before the time for holding the

meeting or adjourned meeting at which the person named in the instrument proposes to vote, or, in the case of a poll, not less than 24 hours before the time appointed for the taking of the poll, and in default the instrument of proxy shall not be treated as valid.

62. A vote given in accordance with the terms of an instrument of proxy or attorney shall be valid notwithstanding the previous death or mental disorder of the principal or revocation of the instrument or of the authority under which the instrument was executed, or the transfer of the share in respect of which the instrument is given, if no intimation in writing of such death, mental disorder, revocation, or transfer as aforesaid has been received by the company at the registered office before the commencement of the meeting or adjourned meeting at which the instrument is used.

62A. An ordinary resolution is passed by written means if the resolution does not indicate that it is a special resolution and if it has been formally agreed on any date by one or more members of the company who on that date represent a majority of the total voting rights of all the members who on that date would have the right to vote on that resolution at a general meeting of the company.

62B. A special resolution is passed by written means if the resolution indicates that it is a special resolution and if it has been formally agreed on any date by one or more members of the company who on that date represents at least 75% of the total voting rights of all the members who on that date would have the right to vote on that resolution at a general meeting of the company.

62C. The Company may pass a resolution by the member recording the resolution and signing the record if the Company has only one member.

Directors: Appointment, etc.

63. At the first annual general meeting of the company all the directors shall retire from office, and at the annual general meeting in every subsequent year one-third of the directors for the time being, or, if their number is not 3 or a multiple of 3, then the number nearest one-third, shall retire from office.

64. A retiring director shall be eligible for re-election.

65. The directors to retire in every year shall be those who have been longest in office since their last election, but as between persons who became directors on the same day those to retire shall (unless they otherwise agree among themselves) be determined by lot.

66. The company at the meeting at which a director so retires may fill the vacated office by electing a person thereto, and in default the retiring director shall if offering himself for re-election and not being disqualified under the Act from holding office as a director be deemed to have been re-elected, unless at that meeting it is expressly resolved not to fill the vacated office or unless a resolution for the re-election of that director is put to the meeting and lost.

67. The company may from time to time by ordinary resolution passed at a general meeting increase or reduce the number of directors, and may also determine in what rotation the increased or reduced number is to go out of office.

68. The directors shall have power at any time, and from time to time, to appoint any person to be a director, either to fill a casual vacancy or as an addition to the existing directors, but so that the total number of directors shall not at any time exceed the number fixed in accordance with these Regulations. Any director so appointed shall hold office only until the next following annual general meeting, and shall then be eligible for re-election but shall not be taken into account in determining the directors who are to retire by rotation at that meeting.

69. The company may by ordinary resolution remove any director before the expiration of his period of office, and may by an ordinary resolution appoint another person in his stead; the person so appointed shall be subject to retirement at the same time as if he had become a director on the day on which the director in whose place he is appointed was last elected a director.

70. The remuneration of the directors shall from time to time be determined by the company in general meeting. That remuneration shall be deemed to accrue from day to day. The directors may also be paid all travelling, hotel, and other expenses properly incurred by them in attending and returning from meetings of the directors or any committee of the directors or general meetings of the company or in connection with the business of the company.

71. The shareholding qualification for directors may be fixed by the company in general meeting.

72. The office of director shall become vacant if the director -
(a) ceases to be a director by virtue of the Act;
(b) becomes bankrupt or makes any arrangement or composition with his creditors generally;
(c) becomes prohibited from being a director by reason of any order made under the Act;
(d) becomes disqualified from being a director by virtue of section 148, 149, 154 or 155;
(e) becomes mentally disordered and incapable of managing himself or his affairs or a person whose person or estate is liable to be dealt with in any way under the law relating to mental capacity;
(f) subject to section 145, resigns his office by notice in writing to the company;
(g) for more than 6 months is absent without permission of the directors from meetings of the directors held during that period;
(h) without the consent of the company in general meeting, holds any other office of profit under the company except that of executive director, managing director or manager; or
(i) is directly or indirectly interested in any contract or proposed contract with the company and fails to declare the nature of his interest in manner required by the Act.

Powers and duties of directors

73. The business of a company shall be managed by or under the direction of the directors. The directors may exercise all the powers of a company except any power that this Act or the memorandum and articles of the company require the company to exercise in general meeting.

74. Subject to the provisions of the Act, the directors may exercise all the powers of the company to borrow money and to mortgage or charge its undertaking, property, and uncalled capital, or any part thereof, and to issue debentures and other securities whether outright or as security for any debt, liability, or obligation of the company or of any third party.

75. The directors may exercise all the powers of the company in relation to any official seal for use outside Singapore and in relation to branch registers.

76. The directors may from time to time by power of attorney appoint any corporation, firm, limited liability partnership or person or body of persons, whether nominated directly or indirectly by the directors, to be the attorney or attorneys of the company for such purposes and with such powers, authorities, and discretions (not exceeding those vested in or exercisable by the directors under these Regulations) and for such period and subject to such conditions as they may think fit, and any such powers of attorney may contain such provisions for the protection and convenience of persons dealing with any such attorney as the directors may think fit and may also authorise any such attorney to delegate all or any of the powers, authorities, and discretions vested in him.

77. All cheques, promissory notes, drafts, bills of exchange, and other negotiable instruments, and all receipts for money paid to the company, shall be signed, drawn, accepted, endorsed, or otherwise executed, as the case may be, by any 2 directors or in such other manner as the directors from time to time determine.

78. The directors shall cause minutes to be made -
(a) of all appointments of officers to be engaged in the management of the company's affairs;
(b) of names of directors present at all meetings of the company and of the directors; and
(c) of all proceedings at all meetings of the company and of the directors.
Such minutes shall be signed by the chairman of the meeting at which the proceedings were held or by the chairman of the next succeeding meeting.

Proceedings of directors

79. The directors may meet together for the despatch of business, adjourn and otherwise regulate their meetings as they think fit. A director may at any time and the secretary shall on the requisition of a director summon a meeting of the directors.

80. Subject to these Regulations, questions arising at any meeting of directors shall be decided by a majority of votes and a determination by a majority of directors shall for all purposes be deemed a determination of the directors. In case of an equality of votes the chairman of the meeting shall have a second or casting vote.

81. A director shall not vote in respect of any contract or proposed contract with the company in which he is interested, or any matter arising thereout, and if he does so vote, his vote shall not be counted.

82. Any director with the approval of the directors may appoint any person, whether a member of the company or not, to be an alternate or substitute director in his place during such period as he thinks fit. Any person while he so holds office as an alternate or substitute director shall be entitled to notice of meetings of the directors and to attend and vote thereat accordingly, and to exercise

all the powers of the appointor in his place. An alternate or substitute director shall not require any share qualification, and shall ipso facto vacate office if the appointor vacates office as a director or removes the appointee from office. Any appointment or removal under this regulation shall be effected by notice in writing under the hand of the director making the same.

83. The quorum necessary for the transaction of the business of the directors may be fixed by the directors, and unless so fixed shall be 2.

84. The continuing directors may act notwithstanding any vacancy in their body, but if and so long as their number is reduced below the number fixed by or pursuant to the regulations of the company as the necessary quorum of directors, the continuing directors or director may act for the purpose of increasing the number of directors to that number or of summoning a general meeting of the company, but for no other purpose.

85. The directors may elect a chairman of their meetings and determine the period for which he is to hold office; but if no such chairman is elected, or if at any meeting the chairman is not present within 10 minutes after the time appointed for holding the meeting, the directors present may choose one of their number to be chairman of the meeting.

86. The directors may delegate any of their powers to committees consisting of such member or members of their body as they think fit; any committee so formed shall in the exercise of the powers so delegated conform to any regulations that may be imposed on it by the directors.

87. A committee may elect a chairman of its meetings; if no such chairman is elected, or if at any meeting the chairman is not present within 10 minutes after the time appointed for holding the meeting, the members present may choose one of their number to be chairman of the meeting.

88. A committee may meet and adjourn as it thinks proper. Questions arising at any meeting shall be determined by a majority of votes of the members present, and in the case of an equality of votes the chairman shall have a second or casting vote.

89. All acts done by any meeting of the directors or of a committee of directors or by any person acting as a director shall, notwithstanding that it is afterwards discovered that there was some defect in the appointment of any such director or person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such person had been duly appointed and was qualified to be a director.

90. A resolution in writing, signed by majority of the directors for the time being entitled to receive notice of a meeting of the directors, shall be as valid and effectual as if it had been passed at a meeting of the directors duly convened and held. Any such resolution may consist of several documents in like form, each signed by one or more directors.

90A. Where the company has only one director, he may pass a resolution by recording it and signing the record.

Managing directors

91. The directors may from time to time appoint one or more of their body to the office of managing director for such period and on such terms as they think fit and, subject to the terms of any agreement entered into in any particular case, may revoke any such appointment. A director so appointed shall not, while holding that office, be subject to retirement by rotation or be taken into account in determining the rotation of retirement of directors, but his appointment shall be automatically determined if he ceases from any cause to be a director.

92. A managing director shall, subject to the terms of any agreement entered into in any particular case, receive such remuneration, whether by way of salary, commission, or participation in profits, or partly in one way and partly in another, as the directors may determine.

93. The directors may entrust to and confer upon a managing director any of the powers exercisable by them upon such terms and conditions and with such restrictions as they may think fit, and either collaterally with or to the exclusion of their own powers, and may from time to time revoke, withdraw, alter, or vary all or any of those powers.

Associate Directors

94. The directors may from time to time appoint any person to be an associate director and may from time to time cancel any such appointment. The directors may fix, determine and vary the powers, duties and remuneration of any person so appointed, but a person so appointed shall not be required to hold any shares to qualify him for appointment nor have any right to attend or vote at any meeting of directors except by the invitation and with the consent of the directors.

Secretary

95. The secretary shall in accordance with the Act be appointed by the directors for such term, at such remuneration, and upon such conditions as they may think fit; and any secretary so appointed may be removed by them.

Seal

96. The directors shall provide for the safe custody of the seal, which shall only be used by the authority of the directors or of a committee of the directors authorised by the directors in that behalf, and every instrument to which the seal is affixed shall be signed by a director and shall be countersigned by the secretary or by a second director or by some other person appointed by the directors for the purpose.

Accounts

97. The directors shall cause proper accounting and other records to be kept and shall distribute copies of balance-sheets and other documents as required by the Act and shall from time to time determine whether and to what extent and at what times and places and under what conditions or regulations the accounting and other records of the company or any of them shall be open to the inspection of members not being directors, and no member (not being a director) shall have any right of inspecting any account or book or paper of the company except as conferred by statute or authorised by the directors or by the company in general meeting.

Dividends and reserves

98. The company in general meeting may declare dividends, but no dividend shall exceed the amount recommended by the directors.

99. The directors may from time to time pay to the members such interim dividends as appear to the directors to be justified by the profits of the company.

100. No dividend shall be paid otherwise than out of profits or shall bear interest against the company.

101. The directors may, before recommending any dividend, set aside out of the profits of the company such sums as they think proper as reserves which shall, at the discretion of the directors, be applicable for any purpose to which the profits of the company may be properly applied, and pending any such application may, at the like discretion, either be employed in the business of the company or be invested in such investments (other than shares in the company) as the directors may from time to time think fit. The directors may also without placing the same to reserve carry forward any profits which they may think prudent not to divide.

102. Subject to the rights of persons, if any, entitled to shares with special rights as to dividend, all dividends shall be declared and paid according to the amounts paid or credited as paid on the shares in respect of which the dividend is paid, but no amount paid or credited as paid on a share in advance of calls shall be treated for the purposes of this regulation as paid on the share. All dividends shall be apportioned and paid proportionately to the amounts paid or credited as paid on the shares during any portion or portions of the period in respect of which the dividend is paid; but if any share is issued on terms providing that it shall rank for dividend as from a particular date that share shall rank for dividend accordingly.

103. The directors may deduct from any dividend payable to any member all sums of money, if any, presently payable by him to the company on account of calls or otherwise in relation to the shares of the company.

104. Any general meeting declaring a dividend or bonus may direct payment of such dividend or bonus wholly or partly by the distribution of specific assets and in particular of paid-up shares, debentures or debenture stock of any other company or in any one or more of such ways and the directors shall give effect to such resolution, and where any difficulty arises in regard to such distribution, the directors may settle the same as they think expedient, and fix the value for distribution of such specific assets or any part thereof and may determine that cash payments shall be made to any members upon the footing of the value so fixed in order to adjust the rights of all parties, and may vest any such specific assets in trustees as may seem expedient to the directors.

105. Any dividend, interest, or other money payable in cash in respect of shares may be paid by cheque or warrant sent through the post directed to the registered address of the holder or, in the case of joint holders, to the registered address of that one of the joint holders who is first named on the register of members or to such person and to such address as the holder or joint holders may in writing direct. Every such cheque or warrant shall be made payable to the order of the person to whom it is sent. Any one of two or more joint holders may give effectual receipts for any dividends, bonuses, or other money payable in respect of the shares held by them as joint holders.

Capitalisation of profits

106. The company in general meeting may upon the recommendation of the directors resolve that it is desirable to capitalise any part of the amount for the time being standing to the credit of any of the company's reserve accounts or to the credit of the profit and loss account or otherwise available for distribution, and accordingly that such sum be set free for distribution amongst the members who would have been entitled thereto if distributed by way of dividend and in the same proportions on condition that the same be not paid in cash but be applied either in or towards paying up any amounts for the time being unpaid on any shares held by such members respectively or paying up in full unissued shares or debentures of the company to be allotted, distributed and credited as fully paid up to and amongst such members in the proportion aforesaid, or partly in the one way and partly in the other, and the directors shall give effect to such resolution.

107. Whenever such a resolution as aforesaid shall have been passed the directors shall make all appropriations and applications of the undivided profits resolved to be capitalised thereby, and all allotments and issues of fully paid shares or debentures, if any, and generally shall do all acts and things required to give effect thereto, with full power to the directors to make such provision by the issue of fractional certificates or by payment in cash or otherwise as they think fit for the case of shares or debentures becoming distributable in fractions, and also to authorise any person to enter on behalf of all the members entitled thereto into an agreement with the company providing for the allotment to them respectively, credited as fully paid up, of any further shares or debentures to which they may be entitled upon such capitalisation, or, as the case may require, for the payment up by the company on their behalf, by the application thereto of their respective proportions of the profits resolved to be capitalised, of the amounts or any part of the amounts remaining unpaid on their existing shares, and any agreement made under such authority shall be effective and binding on all such members.

Notices

108. A notice may be given by the company to any member either personally or by sending it by post to him at his registered address, or, if he has no registered address in Singapore, to the address, if any, in Singapore supplied by him to the company for the giving of notices to him. Where a notice is sent by post, service of the notice shall be deemed to be effected by properly addressing, prepaying, and posting a letter containing the notice, and to have been effected in the case of a notice of a meeting on the day after the date of its posting, and in any other case at the time at which the letter would be delivered in the ordinary course of post.

109. A notice may be given by the company to the joint holders of a share by giving the notice to the joint holder first named in the register of members in respect of the share.

110. A notice may be given by the company to the persons entitled to a share in consequence of the death or bankruptcy of a member by sending it through the post in a prepaid letter addressed to them by name, or by the title of representatives of the deceased, or assignee of the bankrupt, or by any like description, at the address, if any, in Singapore supplied for the purpose by the persons claiming to be so entitled, or, until such an address has been so supplied, by giving the notice in any manner in which the same might have been given if the death or bankruptcy had not occurred.

111. Notice of every general meeting shall be given in any manner hereinbefore authorised to -
(a) every member;
(b) every person entitled to a share in consequence of the death or bankruptcy of a member who, but for his death or bankruptcy, would be entitled to receive notice of the meeting; and
(c) the auditor for the time being of the company.

No other person shall be entitled to receive notices of general meetings.

Winding up

112. If the company is wound up, the liquidator may, with the sanction of a special resolution of the company, divide amongst the members in kind the whole or any part of the assets of the company, whether they consist of property of the same kind or not, and may for that purpose set such value as he considers fair upon any property to be divided as aforesaid and may determine how the division shall be carried out as between the members or different classes of members. The liquidator may, with the like sanction, vest the whole or any part of any such assets in trustees upon such trusts for the benefit of the contributories as the liquidator, with the like sanction, thinks fit, but so that no member shall be compelled to accept any shares or other securities whereon there is any liability.

Indemnity

113. Subject to the provisions of the Act, every director, managing director, agent, auditor, secretary, and other officer for the time being of the company shall be indemnified out of the assets of the company against any liability incurred by him in defending any proceedings, whether civil or criminal, in which judgment is given in his favour or in which he is acquitted or in connection with any application under the Act in which relief is granted to him by the Court in respect of any negligence, default, breach of duty or breach of trust.

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ
အမျိုးသားစီမံကိန်းနှင့်စီးပွားရေးဖွံ့ဖြိုးတိုးတက်မှုဝန်ကြီးဌာန
ရင်းနှီးမြှုပ်နှံမှုနှင့်ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန
အမှတ်(၁)၊ သစ္စာလမ်း၊ ရန်ကင်းမြို့နယ်၊ ရန်ကုန်မြို့

☎ ၀၁-၆၅၇၈၉၁
၀၁-၆၅၈၁၃၅

စာအမှတ်၊ ရက- ၁၀/၁/၂၀၁၅ (၁၄၅၃၇)
ရက်စွဲ ၊ ၂၀၁၅ ခုနှစ် ဩဂုတ် လ ၅ ရက်

သို့

အဆိုပြုဒါရိုက်တာ
အေအမ်အမ်ကေ မယ်ဒီကဲ ကုမ္ပဏီ လီမိတက်
အမှတ်(၃၃)၊ ပြည်လမ်း၊ (၆)မိုင်ခွဲ၊
လှိုင်မြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး

အကြောင်းအရာ။ **ကုမ္ပဏီ မှတ်ပုံတင် လက်မှတ် ထုတ်ပေးခြင်း**

၁။ **အေအမ်အမ်ကေ မယ်ဒီကဲ ကုမ္ပဏီ လီမိတက်**သည် မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေနှင့် အညီ မှတ်ပုံတင်ခွင့် လျှောက်ထားခဲ့ရာဤ ရုံးတွင်း မှတ်ပုံတင် အမှတ် - **၁၃၉၇/၂၀၁၅-၂၀၁၆ (ရက)** ဖြင့် **(၄-၈-၂၀၁၅)** နေ့၌ ပေးရန်တာဝန်ခွဲဝေ ကန့်သတ်ထားသော အများနှင့် မသက်ဆိုင်သည့် ကုမ္ပဏီအဖြစ် မှတ်ပုံတင်ထားပြီး ဖြစ်ပါ၍ ဤမှတ်ပုံတင် လက်မှတ်ကို ထုတ်ပေး လိုက်သည်။

၂။ အဆိုပါ မှတ်ပုံတင် လက်မှတ်သည် မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေအရ **အေအမ်အမ်ကေ မယ်ဒီကဲ ကုမ္ပဏီ လီမိတက်** အမည်ကို တရားဝင် အသုံးပြုရန် အတွက်သာ ထုတ်ပေးခြင်း ဖြစ်ပြီး၊ သင်းဖွဲ့မှတ်တမ်း ရည်ရွယ်ချက်ပါ လုပ်ငန်းများကို လုပ်ကိုင် ခွင့်ပေးခြင်း မဟုတ်ပါ၊ သို့ဖြစ်ပါ၍ ယင်းလုပ်ငန်းများကို လုပ်ကိုင်ဆောင်ရွက်ရာတွင် တည်ဆဲဥပဒေ စည်းမျဉ်း စည်းကမ်း များနှင့် အညီ လိုက်နာဆောင်ရွက်ကြပါရန်ဖြစ်ကြောင်း သိသာပါရန် ဖော်ပြ ပါသည်။

၃။ ဤကုမ္ပဏီမှာ မြန်မာနိုင်ငံ ကုမ္ပဏီများအက်ဥပဒေအရ တည်ထောင်ခွင့်ပြုပြီးသော ကုမ္ပဏီ ဖြစ်သည့် အလျှောက် ယင်းဥပဒေအရ ပူးတွဲပါ အချက်အလက်များကို မပျက်မကွက် လိုက်နာ ဆောင်ရွက်ရန် ဖြစ်ကြောင်းဖော်ပြပါသည်။

၄။ ဤကုမ္ပဏီ မှတ်ပုံတင်လက်မှတ်၏ သက်တမ်းသည်(၅)နှစ်သာ ဖြစ်ပါသည်။ သက်တမ်း မကုန်ဆုံးမီ(၃)လအလိုတွင် သက်တမ်းတိုးရန် ဤဌာနသို့ တင်ပြလျှောက်ထားရမည် ဖြစ်ပါသည်။

ညွှန်ကြားရေးမှူးချုပ်(ကိုယ်စား)
(နီလာမူ၊ ညွှန်ကြားရေးမှူး)

မိတ္တူကို

ရန်ကုန်တိုင်းဒေသကြီးစီမံကိန်းဦးစီးရုံး
ရုံးလက်ခံ/ မျှောစာတွဲ

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR
MINISTRY OF NATIONAL PLANNING AND ECONOMIC DEVELOPMENT
DIRECTORATE OF INVESTMENT AND COMPANY ADMINISTRATION
CERTIFICATE OF REGISTRATION OF DOCUMENTS

No. **1397** of **2015 - 2016 (YGN)**

IN THE MATTER OF **AMMK MEDICARE COMPANY LIMITED**

I do hereby certify that pursuant to the Myanmar Companies Act.

1. Memorandum and Articles of Association.
2. Declaration of Registration of Company.
3. Situation of Registered Office.
4. List of Directors.

Has / Have been this day duly filed and registered in this office

Dated Yangon, this **FOURTH** day of **AUGUST ,**
TWO THOUSAND AND **FIFTEEN.**

MEMORANDUM OF FEES PAID

Registering / For .... / Filing

			K.	P.
1.	Memorandum of Association	....		
2.	Article of Association	....		
3.	Notice of situation of registered Office and changes therein	....		
4.	Return of allotments	....		
5.	Annual list of members and summary of share Capital (Form E)	....		
6.	Balance sheet	....		
7.	Special or extraordinary resolution	....		
8.	Particular of mortgages and charges	....		
9.	Copy of Register of Directors, Managers, or Managing Agents and changes therein	....		
10.	Return of persons authorized to accept Services of process and changes therein	....		
11.	Registration Fees For A/U Capital.	....	**1,000,000 .**	**00**
		Total :	**1,000,000 .**	**00**

FOR DIRECTOR GENERAL
(THANDAR SOE – DEPUTY DIRECTOR)

014618

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ

အမျိုးသားစီမံကိန်းနှင့် စီးပွားရေးဖွံ့ဖြိုးတိုးတက်မှုဝန်ကြီးဌာန

ကုမ္ပဏီမှတ်ပုံတင်လက်မှတ်

အမှတ် ...၁၃၉၇....../ ၂၀၁၅- ၂၀၁၆ (ရက)

မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေအရ ...အေအမ်အမ်ကေ မယ်ဒီကဲ ကုမ္ပဏီ လီမိတက်...

.................................အား ပေးရန်တာဝန် ကန့်သတ်ထားသော လီမိတက်

ကုမ္ပဏီအဖြစ် ...၂၀၁၅...နှစ်၊ ...ဩဂုတ်...လ၊ ...၄...ရက်နေ့တွင် မှတ်ပုံတင်ခွင့်ပြုလိုက်သည်။

ညွှန်ကြားရေးမှူးချုပ်(ကိုယ်စား)

(နီလာမူ၊ ညွှန်ကြားရေးမှူး)

ရင်းနှီးမြှုပ်နှံမှုနှင့်ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF NATIONAL PLANNING AND ECONOMIC DEVELOPMENT

CERTIFICATE OF INCORPORATION

NO. ......1397...... of 2015 - 2016 (YGN)

I hereby certify that ......AMMK MEDICARE COMPANY LIMITED......

.................................is this day incorporated under the Myanmar Companies Act and that the company is Limited.

Given under my hand at Yangon this ......FOURTH...... day of ......AUGUST, TWO THOUSAND AND FIFTEEN......

For Director General

(Nilar Mu, Director)

Directorate of Investment and Company Administration

ကုမ္ပဏီနှင့်သက်ဆိုင်သည့်အချက်အလက်များ

(က) အုပ်ချုပ်မှုဒါရိုက်တာအမည်၊ ဦးအောင်မိုးကျော် (၁၂/မရက(နိုင်)၁၀၆၃၉၇)

(ခ) ကုမ္ပဏီ ရုံးခန်းလိပ်စာ၊ အမှတ်(၃၃)၊ ပြည်လမ်း၊ (၆)မိုင်ခွဲ၊ လှိုင်မြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး

(ဂ) ဆက်သွယ်ရန် ဖုန်းနံပါတ်၊ ၀၁-၆၅၄၃၉၈

(ဃ) ဒါရိုက်တာများ အမည်စာရင်း - (၁) ဒေါ်မာမာထွန်း ၁၂/ဗဟန(နိုင်)၀၈၃၈၇၆

မှတ်ချက်။ (၁) ဤကုမ္ပဏီမှတ်ပုံတင်လက်မှတ်သည်မှတ်ပုံတင်ရက်စွဲ(၄-၈-၂၀၁၅)မှ (၃-၈-၂၀၂၀)ရက်နေ့အထိ(၅)နှစ်သက်တမ်းအတွက်သာ ဖြစ်သည်။ သက်တမ်း မကုန်ဆုံးမီ (၃)လအလိုတွင် သက်တမ်းတိုးရန် ရင်းနှီးမြှုပ်နှံမှုနှင့် ကုမ္ပဏီများ ညွှန်ကြားမှု ဦးစီးဌာနသို့ လျှောက်ထား ရမည်။

(၂) ကုမ္ပဏီ အနေဖြင့် သင်းဖွဲ့မှတ်တမ်းတွင်အဆိုပြု တင်ပြထားသော လုပ်ငန်းရည်ရွယ်ချက်များကိုသာ လုပ်ကိုင်ရမည်။

(၃) သင်းဖွဲ့မှတ်တမ်းပါ ရည်ရွယ်ချက်များသည် သက်ဆိုင်ရာ ပြည်ထောင်စု ဝန်ကြီးဌာန၏ တည်ဆဲဥပဒေ၊ နည်းဥပဒေ၊ လုပ်ထုံးလုပ်နည်း များနှင့်အညီ ခွင့်ပြုချက် ရရှိမှသာ ဆောင်ရွက်ခွင့် ရှိမည် ဖြစ်ပါသည်။

(၄) လုပ်ငန်းရည်ရွယ်ချက် ပြောင်းလဲ လုပ်ကိုင်လိုပါက ပြောင်းလဲ လုပ်ကိုင်လိုသည့် လုပ်ငန်း ရည်ရွယ်ချက်များအား သင်းဖွဲ့မှတ်တမ်းတွင် ပြင်ဆင်မှတ်ပုံတင်ရန်အတွက် ဒါရိုက်တာအဖွဲ့(BOD)၏ အထူး အစည်းအဝေး ဆုံးဖြတ်ချက် မှတ်တမ်းနှင့်အတူ ရင်းနှီးမြှုပ်နှံမှုနှင့်ကုမ္ပဏီများ ညွှန်ကြားမှု ဦးစီးဌာန သို့ လျှောက်ထား ရမည် ။

Sm

ညွှန်ကြားရေးမှူးချုပ် (ကိုယ်စား)
(သန္တာစိုး၊ ဒုတိယညွှန်ကြားရေးမှူး)

လာရောက်ထုတ်ယူသည့် ရက်စွဲ၊

အကြောင်းအရာ။ ။ Seed payment USD ၃၆၉၆၀/- အနက်မှ အချို့ထုတ်ပေးရန်ကိစ္စ။

Seed payment USD ၃၆,၉၆၀/- အနက်မှ USD 5,000/- ငွေအား ဒေါ်မြတ်စုငွေ (HR Manager) အား ထုတ်ယူခွင့်ပြုပါရန် တင်ပြအပ်ပါသည်။

ကျန်ငွေများကို နောက်လများတွင် ဆက်လက်ထုတ်ယူမည် ဖြစ်ပါသည်။

Best Regards

နွယ်

Group Chairman

OK

8/11

မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ

အစုရှယ်ယာများဖြင့် ပေးရန်တာဝန် ကန့်သတ်ထားသော အများနှင့် မသက်ဆိုင်သည့် ကုမ္ပဏီ

အေအမ်အမ်ကေ မယ်ဒီကဲ ကုမ္ပဏီ လီမိတက်

၏

သင်းဖွဲ့မှတ်တမ်း

နှင့်

သင်းဖွဲ့စည်းမျဉ်းများ

❖ ❖ ❖ ❖ ❖ ❖ ❖ ❖

THE MYANMAR COMPANIES ACT

PRIVATE COMPANY LIMITED BY SHARES

Memorandum Of Association

AND

Articles Of Association

OF

AMMK MEDICARE COMPANY LIMITED

မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ

အစုရှယ်ယာများဖြင့် ပေးရန်တာဝန် ကန့်သတ်ထားသော အများနှင့် မသက်ဆိုင်သည့် ကုမ္ပဏီ

အေအမ်အမ်ကေ မယ်ဒီကဲ ကုမ္ပဏီ လီမိတက်

၏

သင်းဖွဲ့မှတ်တမ်း

❖ ❖ ❖ ❖ ❖ ❖ ❖

၁။ ကုမ္ပဏီ၏အမည်သည် **အေအမ်အမ်ကေ မယ်ဒီကဲ ကုမ္ပဏီ လီမိတက်** ဖြစ်ပါသည်။

၂။ ကုမ္ပဏီ၏ မှတ်ပုံတင် အလုပ်တိုက်သည်ပြည်ထောင်စု မြန်မာနိုင်ငံတော်အတွင်း တည်ရှိရမည်။

၃။ အစုဝင်များ၏ ပေးရန်တာဝန်ကို ကန့်သတ်ထားသည်။

၄။ ကုမ္ပဏီ၏ သတ်မှတ်မတည်ငွေရင်းသည် ကျပ် ၅၀၀၀၀၀၀၀၀၀၀ /-(ကျပ် သန်းငါးသောင်း တိတိ) ဖြစ်၍ ငွေကျပ် ၁၀၀၀၀.၀၀ /-(ကျပ် တစ်သောင်း တိတိ) တန်အစုရှယ်ယာပေါင်း (၅၀၀၀၀၀၀) ခွဲထားပါသည်။ ကုမ္ပဏီ၏ ရင်းနှီးငွေကို ကုမ္ပဏီ၏ စည်းမျဉ်းများနှင့် လက်ရှိတရားဝင် တည်ဆဲဖြစ်နေသော တရားဥပဒေ အထွေထွေ ပြဋ္ဌာန်းချက်များ နှင့်အညီ အထွေထွေ သင်းလုံးကျွတ် အစည်းအဝေး၌ တိုးမြှင့်နိုင်ခွင့်၊ လျှော့ချနိုင်ခွင့် နှင့် ပြင်ဆင်နိုင်ခွင့် အာဏာရှိစေရမည်။

၅။ ကုမ္ပဏီတည်ထောင်ရခြင်း၏ ရည်ရွယ်ချက်များမှာ

၁။ လယ်ယာကိုင်းကျွန်းနှင့် ဥယာဉ်ခြံမြေထွက်ကုန်ပစ္စည်းများရောင်းဝယ်ခြင်း
၂။ သစ်တောထွက်ပစ္စည်းနှင့် ထပ်ဆင့်တိုးတန်ဖိုးမြင့် သစ်အခြေခံ ကုန်ပစ္စည်းများရောင်းဝယ်ခြင်း
၃။ တိရစ္ဆာန်ထွက် ကုန်ပစ္စည်းနှင့် တိရစ္ဆာန်အစားအစာရောင်းဝယ်ခြင်း
၄။ ရေထွက်ကုန်ပစ္စည်းများရောင်းဝယ်ခြင်း
၅။ ဓါတ်မြေဩဇာနှင့် ပိုးသတ်ဆေးများရောင်းဝယ်ခြင်း
၆။ ဓာတုဗေဒနှင့် ဓာတ်ဆေးဆိုးဆေးများရောင်းဝယ်ခြင်း
၇။ စက်ရုံသုံးပစ္စည်းများနှင့် ကုန်ကြမ်းပစ္စည်းများရောင်းဝယ်ခြင်း
၈။ အိမ်သုံးကုန်ပစ္စည်းများရောင်းဝယ်ခြင်း
၉။ လူသုံးကုန်ပစ္စည်းများရောင်းဝယ်ခြင်း
၁၀။ ဆောက်လုပ်ရေးလုပ်ငန်းသုံး ပစ္စည်းများနှင့် သုတ်ဆေးများရောင်းဝယ်ခြင်း
၁၁။ လျှပ်စစ်နှင့်အီလက်ထရောနစ် ကုန်ပစ္စည်းများရောင်းဝယ်ခြင်း
၁၂။ ယာဉ်နှင့်စက်ကိရိယာနှင့် အပိုပစ္စည်းများရောင်းဝယ်ခြင်း
၁၃။ ကိရိယာတန်ဆာပလာအမျိုးမျိုးရောင်းဝယ်ခြင်း
၁၄။ ဆေးနှင့်ဆေးပစ္စည်းများရောင်းဝယ်ခြင်း
၁၅။ စားသောက်ကုန်နှင့် အထွေထွေကုန်ပစ္စည်းများရောင်းဝယ်ခြင်း
၁၆။ အထည်အလိပ်နှင့် အဝတ်အထည်များရောင်းဝယ်ခြင်း
၁၇။ စက္ကူ၊ စာရေးကိရိယာနှင့် ဓာတ်ပုံပစ္စည်းများရောင်းဝယ်ခြင်း
၁၈။ ရုံးသုံးပစ္စည်းများနှင့် ပညာရေးအထောက်အကူ ပစ္စည်းများရောင်းဝယ်ခြင်း
၁၉။ လယ်ယာကိုင်းကျွန်းနှင့် ဥယာဉ်ခြံမြေထွက် ကုန်ပစ္စည်းများကို စိုက်ပျိုးခြင်း၊ ထုတ်လုပ်ခြင်း၊ ရိပ်သိမ်းခြင်း၊ တာရှည်ခံအောင်ပြုပြင်ခြင်း၊ ထုတ်ပိုးခြင်း၊ ကြိတ်ခွဲခြင်းနှင့် ကုန်ထုတ်လုပ်ခြင်း၊
၂၀။ (ကျွန်းမှအပ) သစ်နှင့် သစ်တောထွက်ပစ္စည်းများအား (သက်ဆိုင်ရာဌာန၏ခွင့်ပြုချက်ဖြင့်) ခုတ်လှဲခြင်း၊ထုတ်ယူခြင်း၊ ခွဲစိတ်ခြင်း၊ ကုန်ထုတ်လုပ်ခြင်း၊ တာရှည်ခံအောင်ပြုပြင်ခြင်းနှင့် အသားသေစေခြင်း၊
၂၁။ တိရိစ္ဆာန်မွေးမြူခြင်းနှင့် တိရိစ္ဆာန်ထွက်ကုန်ပစ္စည်းများအား ပြုပြင်ထုတ်လုပ်ခြင်း၊ စည်သွပ်ခြင်း၊
၂၂။ ရေထွက်ကုန်ပစ္စည်းများအား ဖမ်းယူခြင်း၊ တာရှည်ခံအောင်ပြုပြင်ခြင်း၊ ကြိတ်ခွဲခြင်း၊ စည်သွပ်ခြင်းနှင့် ပြုပြင်ထုတ်လုပ်ခြင်း၊
၂၃။ ဓါတ်မြေဩဇာ၊ ပိုးသတ်ဆေးနှင့် တိရိစ္ဆာန်အစားအစာများထုတ်လုပ်ခြင်း၊
၂၄။ လူသုံးကုန်ပစ္စည်းများ ထုတ်လုပ်ခြင်း၊
၂၅။ အိမ်သုံးကုန်ပစ္စည်းများ ထုတ်လုပ်ခြင်း၊
၂၆။ ယာဉ်နှင့်စက်ကိရိယာများ၊ အပိုပစ္စည်းများ ထုတ်လုပ်ခြင်း၊
၂၇။ လက်မှုအနုပညာပစ္စည်းများ၊ ယွန်းထည်များနှင့် ပရိဘောဂများ ထုတ်လုပ်ခြင်း၊
၂၈။ ဆောက်လုပ်ရေးပစ္စည်းများနှင့် သုတ်ဆေးများ ထုတ်လုပ်ခြင်း၊
၂၉။ စက်ရုံသုံးပစ္စည်းများ ထုတ်လုပ်ခြင်း၊
၃၀။ လျှပ်စစ်နှင့်အီလက်ထရောနစ် ကုန်ပစ္စည်းများ ထုတ်လုပ်ခြင်း၊
၃၁။ အထည်အလိပ်နှင့် အဝတ်အထည်များ ထုတ်လုပ်ခြင်း၊
၃၂။ အစိုးရ၏ ခွင့်ပြု ချက်ဖြင့် သတ္တုရှာဖွေခြင်း၊ တူးဖော်ခြင်း၊ ထုတ်လုပ်ခြင်း၊ ပြုပြင်ခြင်းနှင့် ထွက်ရှိသောကုန်ပစ္စည်းများကို ရောင်းချခြင်းလုပ်ကိုင်ရန်၊
၃၃။ အေဂျင်စီလုပ်ငန်းအမျိုးမျိုး၊ ကျွမ်းကျင်မှုအတိုင်ပင်ခံများ၊ လုပ်ငန်းအတိုင်ပင်ခံများ၊ အုပ်ချုပ်မှု အတိုင်ပင်ခံများနှင့် အကြံပေး ဝန်ဆောင်မှုလုပ်ငန်းများ၊
၃၄။ ကြော်ငြာနှင့် ကြော်ငြာ ကိုယ်စားလှယ် လုပ်ငန်းများ၊
၃၅။ ဖျော်ဖြေရေးလုပ်ငန်းနှင့် ယင်းနှင့် ပတ်သက်သည့် လုပ်ငန်းများ
၃၆။ ဆေးဝန်ဆောင်မှု လုပ်ငန်းအမျိုးမျိုး၊
၃၇။ သယ်ယူပို့ဆောင်ရေး လုပ်ငန်း၊ (မီးရထားနှင့် လေကြောင်းမှအပ)
၃၈။ ပုံနှိပ်ထုတ်ဝေခြင်း လုပ်ငန်း၊
၃၉။ တိုင်းတာရေးနှင့် စစ်ဆေးရေး လုပ်ငန်း၊
၄၀။ စီမံကိန်းသစ်များ၌ ဖြစ်မြောက်နိုင်စွမ်း ရှိမရှိ လေ့လာခြင်း၊ စီမံကိန်းပုံစံများချမှတ်ခြင်း၊ စီမံကိန်း ကုန်ကျစရိတ်ခန့်မှန်းခြင်းနှင့် တန်ဖိုးတွက်ချက်ခြင်းလုပ်ငန်းများ၊
၄၁။ စာရင်းရေးသွင်းခြင်း၊ စာရင်းစစ်ဆေးခြင်းနှင့် ဥပဒေ အကြံပေး ဝန်ဆောင်မှု လုပ်ငန်းများ၊
၄၂။ ယာဉ်နှင့် စက်ကိရိယာအမျိုးမျိုး ကြံ့ခိုင်ရေးပြုလုပ်ခြင်း၊ မွမ်းမံခြင်းနှင့် ပြင်ဆင်ခြင်းလုပ်ငန်းများ၊
၄၃။ လျှပ်စစ်နှင့် အီလက်ထရောနစ် ကုန်ပစ္စည်းများ တပ်ဆင်ခြင်း၊ ပြုပြင်ခြင်းနှင့် မွမ်းမံ တည်ဆောက်ခြင်း လုပ်ငန်းများ၊
၄၄။ ဆောက်လုပ်ရေးလုပ်ငန်း
၄၅။ ကျောက်မျက်လုပ်ငန်း
၄၆။ ခရီးသွားလုပ်ငန်း
၄၇။ ဟိုတယ်လုပ်ငန်း
၄၈။ အသေးစားငွေရေးကြေးရေးလုပ်ငန်း

၆။ ကုမ္ပဏီမှ သင့်တော်လျော်ကပ်သည်ဟု ယူဆပါက ကုမ္ပဏီ၏ စီးပွားရေးလုပ်ငန်းတွင် အကျိုးရှိ စေရန် အတွက် မည်သည့်ပုဂ္ဂိုလ်၊ စီးပွားရေးအဖွဲ့အစည်း၊ ကုမ္ပဏီ၊ ဘဏ်၊ သို့မဟုတ်၊ ငွေကြေး အဖွဲ့အစည်း ထံမှမဆို ငွေချေးယူရန်။

ခြွင်းချက်။ ကုမ္ပဏီသည် အထက်ဖော်ပြပါ ရည်ရွယ်ချက်များကို ပြည်ထောင်စုသမ္မတနိုင်ငံတော် အတွင်း၌ ဖြစ်စေ၊ အခြားမည်သည့် အရပ်ဒေသ၌ဖြစ်စေ၊ အချိန်ကာလအလိုက် တည်မြဲနေသော တရားဥပဒေများ၊ အမိန့်ကြော်ငြာစာများ၊ အမိန့်များက ခွင့်ပြုထားသည့် လုပ်ငန်းများမှအပ အခြားလုပ်ငန်းများကို လုပ်ကိုင်ဆောင်ရွက်ခြင်းမပြုပါ။ ထို့အပြင် ပြည်ထောင်စု သမ္မတမြန်မာနိုင်ငံတော်အတွင်း၌ အချိန် ကာလအားလျော်စွာ တည်မြဲနေသည့် တရားဥပဒေ ပြဋ္ဌာန်းချက်များ၊ အမိန့်ကြော်ငြာစာများ၊ အမိန့်များနှင့် လျော်ညီသင့်တော်ခြင်း သို့မဟုတ်၊ခွင့်ပြုထားခြင်းရှိမှသာလျှင် လုပ်ငန်းများကို ဆောင်ရွက်မည်ဟု ခြွင်းချက်ထား ရှိပါသည်။

အောက်တွင် အမည်၊ နိုင်ငံသား၊ နေရပ်နှင့် အကြောင်းအရာစုံလင်စွာပါသော ဇယားတွင် လက်မှတ်ရေးထိုးသူ ကျွန်ုပ်တို့ ကိုယ်စီကိုယ်ငှသည် ဤသင်းဖွဲ့မှတ်တမ်းအရ ကုမ္ပဏီတစ်ခုဖွဲ့စည်းရန် လိုလားသည့်အလျောက် ကျွန်ုပ်တို့၏ အမည် အသီးသီးနှင့် ယှဉ်တွဲ ပြထားသော အစုရှယ်ယာများကို ကုမ္ပဏီ၏ မတည်ရင်းနှီးငွေတွင် ထည့်ဝင်ရယူကြရန် သဘောတူကြပါသည်။

စဉ်	အစုထည့်ဝင်သူများ၏အမည်၊ နေရပ်လိပ်စာနှင့် အလုပ်အကိုင်	နိုင်ငံသားနှင့်အမျိုးသား မှတ်ပုံတင်အမှတ်	ဝယ်ယူသော အစုရှယ်ယာ ဦးရေ	ထိုးမြဲ လက်မှတ်
၁	ဦး အောင်မိုးကျော် ကုန်သည် အမှတ်-၁၈၊ အောင်မင်္ဂလာလမ်းသွယ်၊ အောင်သိဒ္ဓိလမ်း၊ ၃-ရပ်ကွက်၊ မရမ်းကုန်းမြို့နယ် ရန်ကုန်တိုင်းဒေသကြီး	၁၂/မရက(နိုင်)၁၀၆၃၉၇	၃၅၀	
၂	ဒေါ် မာမာထွန်း ကုန်သည် အမှတ်-၅၂/ဘီ၊ ရွှေတောင်ကြား ၂-ရပ်ကွက်၊ ရွှေတောင်ကြားလမ်း၊ ဗဟန်းမြို့နယ် ရန်ကုန်တိုင်းဒေသကြီး	၁၂/ဗဟန(နိုင်)၀၈၃၈၇၆	၁၅၀	

နေ့စွဲ ၊ ၂၀၁၅ ခုနှစ်၊ ဇူလိုင် လ၊ ၂၇ ရက်။

အထက်ပါလက်မှတ်ရှင်များသည် ကျွန်ုပ်၏ရှေ့မှောက်တွင် လက်မှတ်ရေးထိုးကြပါသည်။

Kyu Kyu Win & Associates
No. ......
Kyu Kyu Win
B.Com, C.P.A, M.B.A
D.B.L, D.M.L

မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ
အစုရှယ်ယာများဖြင့် ပေးရန်တာဝန် ကန့်သတ်ထားသော အများနှင့် မသက်ဆိုင်သည့် ကုမ္ပဏီ

အေအမ်အမ်ကေ မယ်ဒီကဲ ကုမ္ပဏီ လီမိတက်

၏

သင်းဖွဲ့စည်းမျဉ်းများ

❖ ❖ ❖ ❖ ❖ ❖ ❖

၁။ ဤသင်းဖွဲ့စည်းမျဉ်းနှင့် လိုက်လျောညီထွေမဖြစ်သည့် စည်းမျဉ်းများမှအပ၊ မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေ နောက်ဆက်တွဲ ပထမဇယားပုံစံ 'က' ပါ စည်းမျဉ်းများသည် ဤကုမ္ပဏီနှင့် သက်ဆိုင် စေရမည်။ မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒပုဒ်မ ၁၇(၂)တွင် ဖော်ပြပါရှိသည့် မလိုက်နာ မနေရ စည်းမျဉ်း များသည် ဤကုမ္ပဏီနှင့် အစဉ်သဖြင့် သက်ဆိုင်စေရမည်။

အများနှင့် မသက်ဆိုင်သော ကုမ္ပဏီ

၂။ ဤကုမ္ပဏီသည် အများနှင့်မသက်ဆိုင်သည့် ကုမ္ပဏီဖြစ်၍ အောက်ပါ သတ်မှတ်ချက်များသည် အကျိုး သက်ရောက် စေရမည်။

(က) ဤကုမ္ပဏီက ခန့်အပ်ထားသော ဝန်ထမ်းများမှအပ၊ ဤကုမ္ပဏီ၏ အစုရှင် အရေအတွက်ကို ငါးဆယ် အထိသာ ကန့်သတ်ထားသည်။

(ခ) ဤကုမ္ပဏီ၏ အစုရှယ်ယာ သို့မဟုတ် ဒီဘင်ချာ သို့မဟုတ် ဒီဘင်ချာစတော့(ခ်) တစ်ခုခုအတွက် ငွေထည့်ဝင်ရန် အများပြည်သူတို့အား ကမ်းလှမ်းခြင်း မပြုလုပ်ရန် တားမြစ်ထားသည်။

မ,တည် ရင်းနှီးငွေနှင့် အစုရှယ်ယာ

၃။ ကုမ္ပဏီ၏ သတ်မှတ်မ,တည်ငွေရင်းမှာ ကျပ်မှာ ၅၀၀၀၀၀၀၀၀၀၀ /-(ကျပ် သန်းငါးသောင်း တိတိ)ဖြစ်၍ ငွေကျပ် ၁၀၀၀၀.၀၀ /-(ကျပ် တစ်သောင်း တိတိ)တန်အစုရှယ်ယာပေါင်း ၅၀၀၀၀၀၀ ခွဲထားပါသည်။
ကုမ္ပဏီ၏ ရင်းနှီးငွေကို ကုမ္ပဏီ၏ စည်းမျဉ်းများနှင့် လက်ရှိတရားဝင် တည်ဆဲဖြစ်နေသော တရားဥပဒေ ပြဋ္ဌာန်းချက်များ နှင့်အညီ အထွေထွေ သင်းလုံးကျွတ် အစည်းအဝေး၌ တိုးမြှင့်နိုင်ခွင့်၊ လျှော့ချနိုင်ခွင့်နှင့် ပြင်ဆင်နိုင်ခွင့် အာဏာ ရှိစေရမည်။

၄။ မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေပါ ပြဋ္ဌာန်းချက်များကို မထိခိုက်စေလျက် အစုရှယ်ယာများသည် ဒါရိုက်တာများ၏ ကြီးကြပ်ကွပ်ကဲမှု အောက်တွင် ရှိစေရမည်။ ၎င်းဒါရိုက်တာများသည် သင့်လျော်သော ပုဂ္ဂိုလ်များအား သတ်မှတ်ချက် အခြေအနေ တစ်စုံတစ်ရာဖြင့် အစုရှယ်ယာများကို ခွဲဝေချထားခြင်း
သို့မဟုတ် ထုခွဲရောင်းချခြင်းတို့ကို ဆောင်ရွက်နိုင်သည်။

၅။ အစုရှယ်ယာလက်မှတ်များကို အထွေထွေမန်နေဂျာ သို့မဟုတ် ဒါရိုက်တာအဖွဲ့က သတ်မှတ်သည့် အခြား ပုဂ္ဂိုလ်များက လက်မှတ်ရေးထိုး၍ ကုမ္ပဏီ၏တံဆိပ်ရိုက်နှိပ်ထုတ်ပေးရမည်။ အစုရှယ်ယာ လက်မှတ်သည် ပုံပန်းပျက်ခြင်း၊ ပျောက်ဆုံးခြင်း သို့မဟုတ် ပျက်စီးခြင်းဖြစ်ပါက အဖိုးအခဖြင့် ပြန်လည်အသစ်ပြုလုပ်ပေးမှုကို သော်လည်းကောင်း၊ ဒါရိုက်တာများက သင့်လျော်သည်ဟု ယူဆသော အခြား သက်သေခံ အထောက်အထား တစ်စုံတစ်ရာကို တင်ပြစေ၍ သော်လည်းကောင်း ထုတ်ပေးနိုင်သည်။ ကွယ်လွန်သွားသော အစုရှယ်ယာရှင်တစ်ဦး၏ တရားဝင်ကိုယ်စားလှယ်ကို ဒါရိုက်တာများက အသိအမှတ်ပြုပေးရမည် ဖြစ်သည်။

၆။ ဒါရိုက်တာများသည် အစုရှင်များက ၎င်းတို့၏ အစုရှယ်ယာများအတွက် မပေးသွင်းရသေးသော ငွေများကို အခါအားလျော်စွာ တောင်းဆိုနိုင်သည်။ အစုရှင်တိုင်းကလည်း ၎င်းတို့ထံတောင်းဆိုသည့် အကြိမ်တိုင်း အတွက် ဒါရိုက်တာများက သတ်မှတ်ထားသည့် ပုဂ္ဂိုလ်များထံ သတ်မှတ်သည့်အချိန်နှင့် နေရာတွင် ပေးသွင်းစေရန် တာဝန်ရှိစေရမည်။ ဆင့်ခေါ်မှုတစ်ခုအတွက် အရစ်ကျပေးသွင်းစေခြင်း၊ သို့မဟုတ် ပယ်ဖျက်ခြင်း သို့မဟုတ် ရွှေ့ဆိုင်းခြင်းတို့ကို ဒါရိုက်တာများက သတ်မှတ်နိုင်သည်။

ဒါရိုက်တာများ

၇။ သင်းလုံးကျွတ် အစည်းအဝေးက တစ်စုံတစ်ရာ သတ်မှတ်ပြဋ္ဌာန်းမှု မပြုလုပ်သမျှ ဒါရိုက်တာများ၏ အရေ အတွက်သည် (၂) ဦးထက်မနည်း၊ (၅၀) ဦးထက်မများစေရ။

ပထမဒါရိုက်တာများသည်-

(၁) ဦး အောင်မိုးကျော် (၂) ဒေါ် မာမာထွန်း

တို့ဖြစ်ကြပါသည်။

၈။ ဒါရိုက်တာများသည် ၎င်းတို့အနက်မှတစ်ဦးကို မန်နေဂျင်းဒါရိုက်တာအဖြစ် အချိန်အခါအလိုက် သင့်လျော်သော သတ်မှတ်ချက်များ၊ ဉာဏ်ပူဇော်ခများဖြင့် ခန့်ထားရမည်ဖြစ်ပြီး အခါအားလျော်စွာ ဒါရိုက်တာအဖွဲ့က ပေးအပ်သော အာဏာများ အားလုံးကို ၎င်းကအသုံးပြုနိုင်သည်။

၉။ ဒါရိုက်တာတစ်ဦး ဖြစ်မြောက်ရန်လိုအပ်သော အရည်အချင်းသည် ကုမ္ပဏီ၏ အစုရှယ်ယာ အနည်းဆုံး (-)စု ကိုပိုင်ဆိုင်ခြင်းဖြစ်၍ ၎င်းသည် မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေပုဒ်မ ၈၅ ပါ ပြဋ္ဌာန်းချက် များကို လိုက်နာရန်တာဝန်ရှိသည်။

၁၀။ အစုရှယ်ယာများ လွှဲပြောင်းရန် တင်ပြချက်ကို မည်သည့် အကြောင်းပြချက်မျှ မပေးပဲ ဒါရိုက်တာ အဖွဲ့သည် ၎င်းတို့၏ ပြည့်စုံ၍ ချုပ်ချယ်ခြင်းကင်းသော ဆင်ခြင်တွက်ဆမှုဖြင့် မှတ်ပုံတင်ရန် ငြင်းဆိုနိုင်သည်။

ဒါရိုက်တာများ၏ ဆောင်ရွက်ချက်များ

၁၁။ ဒါရိုက်တာများသည်၎င်းတို့သင့်လျော်သည် ထင်မြင်သည့်အတိုင်း လုပ်ငန်းဆောင်ရွက်ရန် တွေ့ဆုံ ဆွေးနွေးခြင်း၊ အစည်းအဝေးရွှေ့ဆိုင်းခြင်း၊ အချိန်မှန်စည်းဝေးခြင်း၊ အစည်းအဝေးအထမြောက်ရန် အနည်းဆုံး ဒါရိုက်တာဦးရေ သတ်မှတ်ခြင်းတို့ကိုဆောင်ရွက်နိုင်သည်။ ယင်းသို့ မသတ်မှတ်ပါက ဒါရိုက်တာနှစ်ဦး တက်ရောက်လျှင် အစည်းအဝေးထမြောက်ရမည်။ အစည်းအဝေးတွင် မည်သည့် ပြဿနာမဆို ပေါ်ပေါက်ပါက မန်နေးဂျင်းဒါရိုက်တာ၏ အဆုံးအဖြတ်သည် အတည်ဖြစ်ရမည်။ မည်သည့်ကိစ္စများကိုမဆို မဲခွဲဆုံးဖြတ်ရာတွင် မဲအရေအတွက်တူနေပါက သဘာပတိသည် ဒုတိယမဲ သို့မဟုတ် အနိုင်မဲကို ပေးနိုင်သည်။

၁၂။ ဒါရိုက်တာများ၏အစည်းအဝေးကို မည်သည့်ဒါရိုက်တာကမဆို အချိန်မရွေး ခေါ်နိုင်သည်။

၁၃။ ဒါရိုက်တာအားလုံးက လက်မှတ် ရေးထိုးထားသော ရေးသားထားသည့် ဆုံးဖြတ်ချက် တစ်ရပ်သည် နည်းလမ်းတကျ ခေါ်ယူ ကျင်းပသော အစည်းအဝေးက အတည်ပြုသည့် ဆုံးဖြတ်ချက် ကဲ့သို့ပင် ကိစ္စ အားလုံး အတွက် အကျိုးသက် ရောက်စေရမည်။

ဒါရိုက်တာများ၏ လုပ်ပိုင်ခွင့်နှင့် တာဝန်များ

၁၄။ မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ နောက်ဆက်တွဲဇယားပုံစံ(က)ပါ စည်းမျဉ်းအပိုဒ် ၇၁ တွင် ပေးအပ်ထားသော အထွေထွေ အာဏာများကို မထိခိုက်စေဘဲ ဒါရိုက်တာများသည် အောက်ဖော်ပြပါ အာဏာများ ရှိရမည်ဟု အတိအလင်း ထုတ်ဖော်ကြေငြာသည်။ အာဏာဆိုသည်မှာ -

(၁) ဒါရိုက်တာများက သင့်လျော်သည်ဟု ယူဆသော တန်ဖိုးနှင့် စည်းကမ်းများ ၊ အခြေအနေ များ သတ်မှတ်၍ ကုမ္ပဏီက ရယူရန် အာဏာရှိသည့် မည်သည့်ပစ္စည်း ၊ အခွင့်အရေးများ၊ အခွင့်အလမ်းများ မဆို ဝယ်ယူရန် သို့မဟုတ် အခြားနည်းလမ်းများဖြင့် ရယူပိုင်ဆိုင်ရန် အပြင် ကုမ္ပဏီက ပိုင်ဆိုင်ခွင့်ရှိသော မည်သည့်ပစ္စည်း၊ အခွင့်အရေးများ ၊ အခွင့်အလမ်း များကိုမဆို သင့်တော်သော စည်းကမ်းချက်များသတ်မှတ်၍ ရောင်းချခြင်း၊ အငှားချခြင်း ၊ စွန့်လွှတ်ခြင်း သို့မဟုတ် အခြားနည်းလမ်းများဖြင့် ဆောင်ရွက် ခြင်းတို့ကို ပြုလုပ်ရန် ။

(၂) သင့်လျော်သော စည်းကမ်းသတ်မှတ်ချက်များဖြင့် ငွေကြေးများကို ချေးငှားရန် သို့မဟုတ် အဆိုပါ ချေးငှားသော ငွေကြေးများကို ပြန်လည်ပေးဆပ်ရန် အတွက်အာမခံများ ထားရှိ ရန် အပြင်၊ အထူးသဖြင့် ဤ ကုမ္ပဏီ၏ ဒီဘင်ချာများ ၊ ဒီဘင်ချာစတော့ခ်များ ၊ ခေါ်ယူခြင်းမပြုရသေးသော ရင်းနှီးငွေများ အပါအဝင် ယခုလက်ရှိ နှင့် နောင်ရှိမည့် ပစ္စည်းများအားလုံး သို့မဟုတ် တစ်စိတ်တဒေသ ကို အပေါင်ပြု၍ ထုတ်ဝေရန် ။

(၃) ဤကုမ္ပဏီက ရယူထားသော အခွင့်အရေးများ သို့မဟုတ် ဝန်ဆောင်မှုများ အားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကို ငွေကြေးအားဖြင့် ပေးချေရန်၊ သို့မဟုတ် အစုရှယ်ယာ များ၊ ငွေချေးစာချုပ်များ ၊ သို့မဟုတ် ဒီဘင်ချာများ သို့မဟုတ် ဤကုမ္ပဏီ၏ အခြားသော အာမခံ စာချုပ်များကိုထုတ်ပေးရန်၊ ထို့အပြင် အဆိုပါအစုရှယ်ယာများ ထုတ်ပေးရာ၌ ငွေအပြည့်ပေးသွင်းပြီး သော အစုရှယ်ယာအနေဖြင့် သော်လည်းကောင်း ၊ တစ်စိတ်တစ်ဒေသ ပေးသွင်းပြီးသော အစုရှယ်ယာများ အနေဖြင့် သော် လည်းကောင်း ၊သဘောတူညီ သကဲ့သို့ ထုတ်ဝေပေးရန်နှင့် အဆိုပါ ငွေချေးစာချုပ်များ ၊ ဒီဘင်ချာများ သို့မဟုတ် ကုမ္ပဏီ၏ အခြားသော အာမခံ စာချုပ်များဖြင့် ထုတ်ဝေပေးရာ၌ ခေါ်ဆိုခြင်း မပြုရသေးသော ရင်းနှီးငွေများ အပါအဝင် ဤကုမ္ပဏီ၏ ပစ္စည်းအားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကို အပေါင်ပြု၍ ဖြစ်စေ ၊ ထိုကဲ့သို့ မဟုတ်ဘဲ ဖြစ်စေ ထုတ်ပေးရန်။

(၄) ဤကုမ္ပဏီနှင့် ပြုလုပ်ထားသော ကန်ထရိုက်စာချုပ်များ ၊ တာဝန်ယူထားသည့် လုပ်ငန်း များ ပြီးစီးအောင် ဆောင်ရွက်ခြင်း အလို့ငှာ ခေါ်ယူခြင်းမပြုရသေးသော ရင်းနှီးငွေများ အပါအဝင်ဤကုမ္ပဏီ၏ပစ္စည်းရပ်များအားလုံးသို့မဟုတ်တစ်စိတ်တစ်ဒေသကို ပေါင်နှံ၍ သော် လည်းကောင်း၊ အပေါင်ပြု၍သော် လည်းကောင်း ၊ သို့မဟုတ် အစုရှယ်ယာများ အတွက် ငွေများတောင်းခံခေါ်ယူ၍သော်လည်းကောင်း၊ ခွင့်ပြုရန် သို့မဟုတ် သင့်လျော် သည့် အတိုင်း ဆောင်ရွက်ရန် ။

(၅) မန်နေဂျာများ ၊ အတွင်းရေးမှူးများ အရာရှိများ ၊ စာရေးများ ၊ ကိုယ်စားလှယ်များနှင့် ဝန်ထမ်း များကို အမြဲ တမ်းယာယီ သို့မဟုတ် အထူးကိစ္စရပ်များအတွက် ခန့်ထားခြင်း ၊ ရပ်စဲခြင်း၊ဆိုင်းငံ့ခြင်းများအတွက် လည်းကောင်း ၊အဆိုပါပုဂ္ဂိုလ်တို့၏ တာဝန်များ၊ အာဏာများ ၊ လစာငွေများ ၊ အခြားငွေကြေးများကို သတ်မှတ်ရာ၌ လည်းကောင်း ၊ အာမခံပစ္စည်းများ တောင်းခံရာ၌ လည်းကောင်း သင့်လျော်သလို ဆောင် ရွက်ရန် ၊ ထို့အပြင် အဆိုပါကိစ္စများ အတွက် ကုမ္ပဏီ၏ မည်သည့်အရာရှိကိုမဆို ကိစ္စရပ်များ အားလုံးကို ဖြစ်စေ ၊ တစ်စိတ်တစ်ဒေကို ဖြစ်စေ ဒါရိုက်တာများ၏ ကိုယ်စား ဆောင်ရွက်နိုင်ရေးအတွက် တာဝန်လွှဲအပ် ရန် ။

(၆) ဤ ကုမ္ပဏီ၏ ဒါရိုက်တာ တစ်ဦးအား ဒါရိုက်တာရာထူးနှင့် တွဲဖက်၍ မန်နေးဂျင်း ဒါရိုက်တာ၊ အထွေထွေ မန်နေဂျာ ၊ အတွင်းရေးမှူး သို့မဟုတ် ဌာနခွဲမန်နေဂျာ အဖြစ် ခန့်ထားရန် ။

(၇) မည်သည့်အစုရှင် ထံမှမဆို ၄င်းတို့ ၏ အစုရှယ်ယာများ အားလုံးကို ဖြစ်စေ ၊ အချို့အဝက်ကို ဖြစ်စေ စွန့်လွှတ်ခြင်းအား သဘောတူညီသော စည်းကမ်းချက်များဖြင့် လက်ခံရန် ။

(၈) ဤ ကုမ္ပဏီက ပိုင်ဆိုင်သော သို့မဟုတ် ပိုင်ဆိုင်ခွင့်ရှိသော သို့မဟုတ် အခြား အကြောင်းများကြောင့် ဖြစ်သော မည်သည့်ပစ္စည်းကိုမဆို ကုမ္ပဏီ၏ ကိုယ်စား လက်ခံထိန်းသိမ်းထားရန်အတွက် မည်သည့် ပုဂ္ဂိုလ် သို့မဟုတ်ပုဂ္ဂိုလ်များကို မဆို ခန့်ထားရန်နှင့်အဆိုပါ ယုံမှတ်အပ်နှံခြင်းများနှင့် ပတ်သက်၍ လိုအပ်သော စာချုပ် စာတမ်း များ ချုပ်ဆို ပြုလုပ်ရန် ။

(၉) ဤကုမ္ပဏီ၏ အရေးအရာများနှင့် စပ်လျဉ်း၍ ဤကုမ္ပဏီကပြုလုပ်သော သို့မဟုတ် ဤကုမ္ပဏီပေါ် သို့မဟုတ် ဤကုမ္ပဏီ၏အရာရှိများအပေါ် ပြုလုပ်သော တရားဥပဒေအရ စွဲဆိုဆောင်ရွက်မှုများကို တရားစွဲဆို ၊အရေးယူ ၊ခုခံကာကွယ်ရန် သို့မဟုတ်ခွင့်လွှတ်ရန် ၊ ထို့အပြင် ဤကုမ္ပဏီက ရရန်ရှိသော ကြွေးမြီများနှင့် ဤကုမ္ပဏီအပေါ်တောင်းခံသော ကြွေးမြီးများနှင့်ပတ်သက်၍ ပေးဆပ်ရန် အချိန်ကာလရွှေ့ဆိုင်းခွင့်ပြုခြင်း သို့မဟုတ် နှစ်ဦးနှစ်ဖက်သဘောတူ ကျေအေးခြင်းများ ပြုလုပ်ရန် ။

(၁၀) ဤကုမ္ပဏီက ပေးရန်ရှိသော သို့မဟုတ်ရရန် ရှိသောငွေတောင်းခံခြင်းများကို ဖြန်ဖြေရေးခုံသမာဓိထံသို့ဖြေရှင်းရန်အတွက် အပ်နှံရန်အပြင် ဖြန်ဖြေရေးခုံသမာဓိ၏ ဆုံးဖြတ်ချက် အတိုင်း လိုက်နာဆောင်ရွက်ရန်။

(၁၁) ဤကုမ္ပဏီက ရရန်ရှိသော တောင်းဆိုချက်၊ တောင်းခံချက်များနှင့် ကုမ္ပဏီသို့ ပေးရန် ရှိသော ငွေကြေးများအတွက် ပြေစာများပြုလုပ်ခြင်း၊ လျှော်ပစ်ခြင်းနှင့် အခြားသော နည်းဖြင့် စွန့်လွှတ်ခြင်းများကို ပြုလုပ်ရန်။

(၁၂) လူမွဲစာရင်းခံရခြင်း၊ကြွေးမြီးမဆပ်နိုင်ခြင်းကိစ္စများနှင့် ပတ်သက်၍ ဤကုမ္ပဏီ၏ ကိုယ်စား ဆောင်ရွက်ရန်။

(၁၃) ငွေလွှဲစာတမ်းများ၊ချက်လက်မှတ်များ၊ဝန်ခံကတိစာချုပ်များ ၊ ထပ်ဆင့်လက်မှတ်ရေးထိုးခြင်းများ၊ လျှော်ပစ်ခြင်းများ၊ ကန်ထရိုက်စာချုပ်များနှင့် စာရွက်စာတမ်းများကို ကုမ္ပဏီ၏ ကိုယ်စား မည်သူက လက်မှတ်ရေးထိုးခွင့် ရှိသည်ကို စိစစ်သတ်မှတ်ရန်။

(၁၄) ဒါရိုက်တာများက သင့်လျော်သည်ဟု ယူဆပါက သင့်လျော်လျှောက်ပတ်သော နည်းလမ်းများဖြင့် လတ်တလော အသုံးပြုရန် မလိုသေးသော ကုမ္ပဏီပိုင်ငွေများကို အာမခံပစ္စည်းပါသည်ဖြစ်စေ၊ မပါသည်ဖြစ်စေ ရင်းနှီးမြှုပ်နှံမှုထားရန်နှင့် စီမံခန့်ခွဲထား ရန်၊ ထို့အပြင် အချိန်ကာလအားလျော်စွာ မြှုပ်နှံထား သောငွေများကိုပြန်လည် ရယူရန်နှင့် ပြင်ဆင်ပြောင်းလွှဲရန် ။

(၁၅) ဤ ကုမ္ပဏီ၏ အကျိုးအတွက် ငွေကြေးစိုက်ထုတ် ကုန်ကျခံထားသော ဒါရိုက်တာ သို့မဟုတ် အခြား ပုဂ္ဂိုလ်များက ကုမ္ပဏီ၏ (လက်ရှိနောင်တွင်ရှိမည့်) ပစ္စည်းများကို ဤကုမ္ပဏီ၏ အမည်ဖြင့်ဖြစ်စေ၊ ဤကုမ္ပဏီ၏ ကိုယ်စားဖြစ်စေ ပေါင်နှံခြင်းများကို သင့်လျော်သည်ဟု ယူဆပါကဆောင်ရွက်ခွင့်ပြုရန် အဆိုပါပေါင်နှံခြင်းဆိုရာ၌ ရောင်းချ နိုင်သည့် အာဏာနှင့် အခြားသော သဘောတူညီထားသည့် တရားဝင်သဘောတူညီချက်များနှင့် ဥပဒေ ပြဋ္ဌာန်းချက်များ ပါပါဝင်သည်။

(၁၆) ဤကုမ္ပဏီက ခန့်အပ်ထားသော မည်သည့်အရာရှိ သို့မဟုတ် ပုဂ္ဂိုလ်ကိုမဆို အတိအကျ ဆောင်ရွက်ခဲ့သောလုပ်ငန်း သို့မဟုတ် ဆောင်ရွက်မှုတစ်ခုအတွက်ရရှိသော အမြတ်ငွေမှ ကော်မရှင်ပေးခြင်းသို့မဟုတ်ကုမ္ပဏီ၏အထွေထွေအမြတ်အစွန်းမှ ခွဲဝေပေးခြင်းများ ပြုလုပ်ရန်နှင့် အဆိုပါကော်မရှင်များ အမြတ်များ ခွဲဝေပေးခြင်းစသည်တို့ကို ဤကုမ္ပဏီ၏ လုပ်ငန်းကုန်ကျစရိတ် တစ်စိတ်တစ်ဒေသ အဖြစ် သတ်မှတ်ရန်။

(၁၇) ဤ ကုမ္ပဏီ၏ လုပ်ငန်းများ အရာရှိများ ဝန်ထမ်းများနှင့် အစုရှင်များအတွက် ထုတ်ပြန်ထားသော စည်းမျဉ်းများ၊ စည်းကမ်းချက်များ ၊ စည်းကမ်းဥပဒေများကို အခါ အားလျော်စွာ သတ်မှတ်ခြင်း ၊ ပြင်ဆင်ခြင်း ၊ ဖြည့်စွက်ခြင်း များ ဆောင်ရွက်ရန်။

(၁၈) ဤ ကုမ္ပဏီ၏ လုပ်ငန်းအတွက် ဤကုမ္ပဏီ အမည်ဖြင့်ဖြစ်စေ ၊ ဤကုမ္ပဏီ၏ ကိုယ်စားဖြစ်စေ လိုအပ်သည် ဟု ယူဆလျှင် ညှိနှိုင်းဆွေးနွေးခြင်းနှင့် ကန်ထရိုက်စာချုပ် ချုပ်ဆိုခြင်းများ ကို ပြုလုပ်ရန် ၊ ဖျက်သိမ်းရန်နှင့် ပြင်ဆင်ရန် အပြင် အဆိုပါ ဆောင်ရွက်ချက် စာချုပ်များနှင့် ကိစ္စရပ်များကို လည်းကောင်း ၊ ၎င်းတို့နှင့် စပ်လျဉ်း သော ကိစ္စရပ်များကို လည်းကောင်း လုပ်ကိုင်ဆောင်ရွက်ရန် ။

(၁၉) ဒါရိုက်တာများက သင့်လျော်သည်ဟု ယူဆပါက ကုမ္ပဏီ၏ စီးပွားရေးလုပ်ငန်းတွင် အကျိုးရှိစေရန် အတွက် မည်သည့် ပြည်တွင်းပြည်ပပုဂ္ဂိုလ်၊ စီးပွားရေးအဖွဲ့အစည်းများ၊ ကုမ္ပဏီသို့မဟုတ်ဘဏ် သို့မဟုတ် ငွေကြေးအဖွဲ့အစည်း ထံမှ မဆို ငွေချေးယူရန် ။

အထွေထွေ အစည်းအဝေးကြီးများ

၁၅။ ကုမ္ပဏီကို ဥပဒေအရ ဖွဲ့စည်းတည်ထောင်ပြီးသည့် နေ့မှ တစ်ဆယ့်ရှစ်လအတွင်း အထွေထွေ သင်းလုံးကျွတ် အစည်းအဝေးကြီးကို ကျင်းပရမည်။ ထို့နောက် ဒါရိုက်တာအဖွဲ့က သတ်မှတ်ပေး သည့် အချိန်နှင့် နေရာများတွင် ပြက္ခဒိန်နှစ် တစ်နှစ်လျှင် အနည်းဆုံး တစ်ကြိမ် (နောက်ဆုံး ကျင်းပသည့် အထွေထွေအစည်း အဝေးကြီးနှင့် တစ်ဆယ့်ငါးလထက် မပိုသည့် အချိန်၌) ကျင်းပရမည်။ သင်းလုံးကျွတ် အစည်းအဝေး စတင်၍ လုပ်ငန်းအတွက် ဆွေးနွေးချိန်တွင် အစည်းအဝေးအထမြောက်ရန် သတ်မှတ်သည့် အစုရှင် အရေ အတွက် မတက်ရောက်သော မည်သည့်သင်းလုံးကျွတ် အစည်းအဝေးတွင်မဆို လုပ်ငန်းနှင့် ပတ်သက်၍ ဆုံးဖြတ် ဆောင်ရွက်ခြင်း မပြုရ ၊ ဤတွင် အခြားနည်းသတ်မှတ် ပြဋ္ဌာန်းခြင်း မရှိလျှင်ထုတ်ဝေထားသည့် မ,တည်ရင်းနှီးငွေ အစုရှယ်ယာများ၏ ငါးဆယ်ရာခိုင်နှုန်းထက် မနည်း ပိုင်ဆိုင်ကြသည့် (နှစ်ဦးထက် မနည်းသော) အစုရှင်များကိုယ်တိုင် တက်ရောက်လျှင် လုပ်ငန်းကိစ္စ အားလုံး ဆောင်ရွက်ရန် အတွက် အစည်းအဝေး အထမြောက်သည့် ဦးရေ ဖြစ်သည်။ အကယ်၍ ကုမ္ပဏီတွင် အစုရှင် အရေအတွက် နှစ်ဦးတည်းသာရှိသည့် ကိစ္စတွင်မူ ထိုနှစ်ဦးတည်း သည်ပင်လျှင် အစည်းအဝေး အထမြောက်ရန် သတ်မှတ်သည့် အရေအတွက် ဖြစ်စေ ရမည်။

အမြတ်ဝေစုများ

၁၆။ သင်းလုံးကျွတ် အစည်းအဝေးတွင် ဤကုမ္ပဏီ၏အစုရှင်များအား ခွဲဝေပေးသည့် အမြတ်ဝေစုကို ကြေငြာရမည်။ သို့ရာတွင် အမြတ်ဝေစုသည် ဒါရိုက်တာများက ထောက်ခံသော ငွေပမာဏထက် မကျော်လွန်စေရ။ သက်ဆိုင်ရာနှစ်၏ အမြတ်ပမာဏ သို့မဟုတ် အခြားမခွဲဝေ ရသေးသည့် အမြတ်ပမာဏမှအပ အမြတ် ဝေစုကို ခွဲဝေမပေးရ ။

ရုံးဝန်ထမ်းများ

၁၇။ ကုမ္ပဏီသည် လုပ်ငန်းတစ်ခုကို ဖွင့်လှစ်၍ဆောင်ရွက်မည်ဖြစ်ပြီး အရည်အချင်းပြည့်မီသူ ပုဂ္ဂိုလ် တစ်ဦးအား အထွေထွေ မန်နေဂျာအဖြစ် ခန့်အပ်ရန်နှင့် အခြားအရည်အချင်း ပြည့်မီသူများ အား ရုံးဝန်ထမ်းများအဖြစ် ခန့်အပ်မည်ဖြစ်သည်။ လစာ ၊ ခရီးသွားလာစရိတ် နှင့် အခြား အသုံးစရိတ်များကဲ့သို့သော ဘဏ် ပူဇော်ခ များနှင့် အခကြေးငွေများကို ဒါရိုက်တာအဖွဲ့က သတ်မှတ်မည်ဖြစ်ပြီး ၎င်း သတ်မှတ်ချက်များကို သင်းလုံးကျွတ် အစည်းအဝေးက အတည်ပြု ရမည်။ အထွေထွေမန်နေဂျာသည် လုပ်ငန်းရုံး၏ ထိရောက်စွာ လုပ်ငန်းလည်ပတ်မှု အားလုံး အတွက် တာဝန်ရှိစေရမည်ဖြစ်ပြီး မန်နေဂျင်းဒါရိုက်တာအား တာဝန်ခံ၍ ဆောင်ရွက်ရမည်။

ငွေစာရင်းများ

၁၈။ ဒါရိုက်တာများသည် သင့်လျော်သည့် ငွေစာရင်းစာအုပ်များကိုအောက်ဖော်ပြပါသတ်မှတ်ချက်များ နှင့်အညီ ထားသို ထိန်းသိမ်းဆောင်ရွက်သွားရမည် ။

(၁) ကုမ္ပဏီ၏ရငွေ၊ သုံးငွေများ၏ပမာဏနှင့် ၎င်းရငွေ ၊ သုံးငွေများ ဖြစ်ပေါ်ခြင်းနှင့် စပ်လျဉ်းသည့်အကြောင်း ကိစ္စများ ။

(၂) ကုမ္ပဏီ ၏ ကုန်ပစ္စည်းများ ရောင်းချခြင်းနှင့် ဝယ်ယူခြင်းများ။

(၃) ဤ ကုမ္ပဏီ၏ ရရန် ပိုင်ခွင့် နှင့် ပေးရန် တာဝန်များ။

၁၉။ ငွေစာရင်းစာအုပ် အားလုံးကို ဤကုမ္ပဏီ၏ မှတ်ပုံတင်ထားသော လုပ်ငန်းရုံးများ သို့မဟုတ် ဒါရိုက်တာများက သင့်လျော်သည်ဟု ထင်မြင်ယူဆသော အခြားနေရာများတွင် သိမ်းဆည်းထားရမည်ဖြစ်ပြီး ၊ ရုံးချိန် အတွင်း၌ ဒါရိုက်တာများက စစ်ဆေးနိုင်ရန် ပြသထားရမည်။

စာရင်းစစ်

၂၀။ စာရင်းစစ်များကိုခန့်အပ်ထားရမည်။ ၎င်းစာရင်းစစ်များ၏တာဝန်သည် မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ သို့မဟုတ် အခါအားလျော်စွာ ပြင်ဆင်သတ်မှတ်သည့် စည်းမျဉ်း စည်းကမ်း များနှင့် လိုက်လျော ညီထွေ ဖြစ်ရမည်။

နို့တစ်စာ

၂၁။ ဤကုမ္ပဏီသည် မည်သည့်အစုရှင်ထံသို့မဆို နို့တစ်စာကို လက်ရောက်ပေးအပ်ခြင်း သို့မဟုတ် နို့တစ်စာပါသော စာကိုစာတိုက်ခ ကြိုတင်ပေးထား၍ ၎င်းအစုရှင်ထံ မှတ်ပုံတင်လိပ်စာအတိုင်း စာတိုက်မှ တဆင့်လိပ်မူပေးပို့ခြင်းအားဖြင့် ပေးပို့နိုင်ပါသည်။

တံဆိပ်

၂၂။ ဒါရိုက်တာများသည် တံဆိပ်ကို လုံခြုံစွာ ထိန်းသိမ်းထားရန်အတွက် စီမံဆောင်ရွက်ရမည်။ ထိုတံဆိပ်ကို ဒါရိုက်တာများကကြိုတင်ပေး အပ်ထားသည့် ခွင့်ပြုချက်ဖြင့်မှတပါး၊ ထို့အပြင် အနည်းဆုံး ဒါရိုက်တာ တစ်ဦး ရှေ့မှောက်တွင်မှတပါး မည်သည့်အခါမျှ မသုံးရ။ တံဆိပ်ရိုက်နှိပ် ထားသည့် စာရွက်စာတမ်းတိုင်းတွင် ထိုဒါရိုက်တာက လက်မှတ်ရေးထိုးရမည်။

လျော်ကြေး

၂၃။ မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေပုဒ်မ ၈၆(င) တွင် ဖော်ပြပါရှိသည့် ပြဋ္ဌာန်းချက်များ၊ လက်ရှိတရားဝင် တည်ဆဲဥပဒေ ပြဋ္ဌာန်းချက်များနှင့် မဆန့်ကျင်စေဘဲ ကုမ္ပဏီ၏ဒါရိုက်တာ၊ စာရင်းစစ်၊ အတွင်းရေးမှူး သို့မဟုတ် အခြားအရာရှိတစ်ဦးဦးမှာ မိမိတာဝန်ဝတ္တရားများကို ဆောင်ရွက်ရာ၌ဖြစ်စေ ထိုတာဝန် ဝတ္တရားများနှင့် စပ်လျဉ်း၍ဖြစ်စေ ကျခံခဲ့သည့်စရိတ်များ၊ တောင်းခံငွေများ ၊ဆုံးရှုံးငွေများ၊ ကုန်ကျငွေ များ နှင့် ကြွေးမြီးတာဝန်များအတွက် ကုမ္ပဏီထံမှ လျော်ကြေးရထိုက်ခွင့်ရှိစေရမည်။

ဖျက်သိမ်းခြင်း

၂၄။ ကုမ္ပဏီ၏ အထွေထွေ အစည်းအဝေး ဆုံးဖြတ်ချက်ဖြင့် ကုမ္ပဏီအား ဖျက်သိမ်း နိုင်သည်။ ယင်းသို့ ဖျက်သိမ်းရာတွင် မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေများနှင့် ယင်းဥပဒေများအား အခါအားလျော်စွာ ပြင်ဆင် ပြောင်းလဲထားသည့် တရားဥပဒေများတွင် ပါဝင်သည့် စည်းမျဉ်းများအတိုင်း လိုက်နာပြုလုပ်ရမည်။

အောက်တွင် အမည်၊ နိုင်ငံသား၊ နေရပ်နှင့် အကြောင်းအရာစုံလင်စွာပါသော ဇယားတွင် လက်မှတ်ရေးထိုးသူ ကျွန်ုပ်တို့ ကိုယ်စီကိုယ်ငှသည် ဤသင်းဖွဲ့စည်းမျဉ်းအရ ကုမ္ပဏီတစ်ခုဖွဲ့စည်းရန် လိုလားသည့်အလျောက် ကျွန်ုပ်တို့၏ အမည် အသီးသီးနှင့် ယှဉ်တွဲ ပြထားသော အစုရှယ်ယာများကို ကုမ္ပဏီ၏ မတည်ရင်းနှီးငွေတွင် ထည့်ဝင်ရယူကြရန် သဘောတူကြပါသည်။

စဉ်	အစုထည့်ဝင်သူများ၏အမည်၊ နေရပ်လိပ်စာနှင့် အလုပ်အကိုင်	နိုင်ငံသားနှင့်အမျိုးသား မှတ်ပုံတင်အမှတ်	ဝယ်ယူသော အစုရှယ်ယာ ဦးရေ	ထိုးမြဲ လက်မှတ်
၁	ဦး အောင်မိုးကျော် ကုန်သည် အမှတ်-၁၈၊ အောင်မင်္ဂလာလမ်းသွယ်၊ အောင်သိဒ္ဓိလမ်း၊ ၃-ရပ်ကွက်၊ မရမ်းကုန်းမြို့နယ် ရန်ကုန်တိုင်းဒေသကြီး	၁၂/မရက(နိုင်)၁၀၆၃၉၇	၃၅၀	(signature)
၂	ဒေါ် မာမာထွန်း ကုန်သည် အမှတ်-၅၂/ဘီ၊ ရွှေတောင်ကြား ၂-ရပ်ကွက်၊ ရွှေတောင်ကြားလမ်း၊ ဗဟန်းမြို့နယ် ရန်ကုန်တိုင်းဒေသကြီး	၁၂/ဗဟန(နိုင်)၀၈၃၈၇၆	၁၅၀	(signature)

နေ့စွဲ ၊ ၂၀၁၅ ခုနှစ်၊ ဇူလိုင် လ၊ ၂၇ ရက်။

အထက်ပါလက်မှတ်ရှင်များသည် ကျွန်ုပ်၏ရှေ့မှောက်တွင် လက်မှတ်ရေးထိုးကြပါသည်။

Kyu Kyu Win & Associates
No. ....
Date ....
2, Myanma Gon Yi Housing, Upper Pansodan St, Mingalar Taung Nyunt Tsp, Ygn.

27/7/15

Kyu Kyu Win
B.Com, C.P.A, M.B.A
D.B.L, D.M.L

THE MYANMAR COMPANY ACT

PRIVATE COMPANY LIMITED BY SHARES

Memorandum Of Association

OF

AMMK MEDICARE COMPANY LIMITED

❖ ❖ ❖ ❖ ❖ ❖ ❖

I. The name of the Company is **AMMK MEDICARE COMPANY LIMITED**

II. The registered office of the Company will be situated in the Union of Myanmar.

III. The liability of the members is limited.

IV. The authorised capital of the Company is Ks- **50000000000** /-(Kyats **Fifty Thousand Million** Only) divided into (**5000000**) shares of Ks. **10000.00** /-(Kyats **Ten Thousand** Only) each, with power in General Meeting either to increase, reduce or alter such capital from time to time in accordance with the regulations of the Company and the legislative provisions for the time being in force in this behalf.

V. The Objective For Which The company is established are

1. Trading of Agricultural and farm produces.
2. Trading of Forest products and value-added wood-based products.
3. Trading of Animal by-products and Animal feed.
4. Trading of Marine products.
5. Trading of Fertilizer and insecticides.
6. Trading of Chemicals and dyes.
7. Trading of Factory utencils and raw material.
8. Trading of Household goods.
9. Trading of Personal goods.
10. Trading of Construction materials and paints.
11. Trading of Electrical and electronic products.
12. Trading of Vehicles, Machinery and spares.
13. Trading of Tools and implement.
14. Trading of Medicines and medical equipment.
15. Trading of Foodstuff and general merchandise.
16. Trading of Textile and garment.
17. Trading of Paper, stationery and photographic stores.
18. Trading of Office equipment and educational supplies.
19. Growing, producing, harvesting, preserving, packing, milling and manufacturing of agricultural and farm products.
20. Felling, extracting (with the permission from the authorities concerned) milling, manufacturing, preserving and seasoning of timber(excluding-teak) and forest products.
21. Livestock breeding, processing and canning of livestock products.
22. Finishing, preserving, milling, canning and processing of marine products.
23. Producing fertilizers, insecticides and animal feeds.
24. Manufacturing of personal goods.
25. Manufacturing of household goods.
26. Manufacturing of vehicles, machineries and spares.
27. Manufacturing of arts and crafts, lacquerwares and furniture.
28. Manufacturing of construction materials and paints.
29. Manufacturing of factory utencils.
30. Manufacturing of electrical and electronic goods.
31. Manufacturing of textile, garments and clothing.
32. To carry on the business of explanation, exploitation, production, processing of minerals and marketing of its products with the permission of the Government.
33. All kinds of agency business, technical consultants, business consultants, management consultants and advisory services.
34. Advertising and its agency business.
35. Business of entertainments and related activities.
36. Business of all kinds of medical services.
37. Business of transportation (except railways and airways)
38. Business of printing and publishing.
39. Business of surveying and inspection.
40. Business of feasibility study on new projects, projects formulation, project appraisal and project evaluation.
41. Business of Account writing, Auditing and legal advisory services.
42. Business of servicing, maintenance of repairing of all kinds of vehicles and machines.
43. Business of installation, maintenance and renovation of electrical and electronic goods.
44. Consturuction
45. Gems
46. Travels & Tours
47. Hotel
48. Macro Finance

VI. To borrow money for the benefit of the Company's business from any person,firm,company, bank or financial organization in the manner that the Company shall think fit.

PROVISO: Provided that the Company shall not exercise any of the above objects whether in the Union of Myanmar or elsewhere,save in so for as it may be entitled so as to do in accordance with the Laws,Orders and Notifications in force from time to time and only subject to such permission and or approval as may be prescribed by the Laws, Orders and Notifications of the Union of Myanmar for the time being in force.

We, the several persons, whose names, nationalities, addresses and descriptions are subscribed below, are desirous of being formed into a Company in pursuance of this Memorandum of Association, and we respectively agree to take the number of shares in the Capital of the Company set opposite our respective names.

Sr. No.	Name, Address and Occupation of Subscribers	Nationality & N.R.C No.	Number of Shares taken	Signatures
1	**U Aung Moe Kyaw** Merchant No-18, Aung Mingalar Lane, Aung Theikdi Street, 3-Ward,Mayangone Township,YANGON	12/MAYAKA(NAING)106397	350	
2	**Daw Mar Mar Tun** Merchant No-52/B, Shwe Taung Gyar 2-Wardm Shwe Taung Gyar Street,Bahan Township,YANGON	12/BAHANA(NAING)083876	150	

Dated 27 the 7 day of 2015

It is hereby certified that the persons mentioned above

put their signatures in my presence.

27/7/15

Kyu Kyu Win
B.Com, C.P.A, M.B.A
D.B.L, D.M.L
Certified Public Accountant

THE MYANMAR COMPANIES ACT

PRIVATE COMPANY LIMITED BY SHARES

Articles Of Association

AMMK MEDICARE COMPANY LIMITED

❖ ❖ ❖ ❖ ❖ ❖ ❖

1. The regulations contained in Table 'A' in the First Schedule to the Myanmar Companies Act shall apply to the Company save in so far as such regulations which are inconsistent with the following Articles. The compulsory regulations stipulated in Section 17 (2) of the Myanmar Companies Act shall always be deemed to apply to the Company.

PRIVATE COMPANY

2. The Company is to be a Private Company and accordingly following provisions shall have effect:-

   (a) The number of members of the Company, exclusive of persons who are in the employment of the Company, shall be limited to fifty.

   (b) Any invitation to the public to subscribe for any share or debenture or debenture stock of the Company is hereby prohibited.

CAPITAL AND SHARES

3. The Authorised Capital of the Company is Ks. **50000000000** /-(Kyats **Fifty Thousand Million** only) divided into (**5000000**) shares of Ks **10000.00** /-(Kyats **Ten Thousand** only) each, with power in General Meeting either to increase, reduce or alter such capital from time to time in accordance with the regulations of the Company and the legislative provisions for the time being in force in this behalf.

4. Subject to the provisions of the Myanmar Companies Act the shares shall be under the control of the Directors, who may allot or otherwise dispose of the same to such persons and on such terms and conditions as they may determine.

5. The certificate of title to share shall be issued under the Seal of the Company, and signed by the General Manager or some other persons nominated by Board of Directors. If the share certificate is defaced, lost or destroyed, it may be renewed on payment of such fee, if any, and on such terms, if any, as to evidence and indemnity as the Directors may think fit. The legal representive of a deceased member shall be recognized by the Directors.

6. The Directors may, from time to time make call upon the members in respect of any money unpaid on their shares, and each member shall be liable to pay the amount of every call so made upon him to the persons, and at the times and places appointed by the Directors. A call may be made payable by instalments or may be revoked or postponed as the Directors may determine.

DIRECTORS

7. Unless otherwise determined by a General Meeting the number of Directors shall not be less than (2) and not more than (50).

The First Directors shall be:-

(1) U Aung Moe Kyaw (2) Daw Mar Mar Tun

8. The Directors may from time to time appoint one of their body to the office of the Managing Director for such terms and at such remuneration as they think fit and he shall have all the powers delegated to him by the Board of Directors from time to time.

9. The qualification of Director shall be the holding of at least (-) shares in the Company in his or her own name and it shall be his duty to comply with the provision of Section (85) of the Myanmar Companies Act.

10. The Board of Directors may in their absolute and uncontrolled discretion refuse to register any proposed transfer of shares without assigning any reason.

PROCEEDINGS OF DIRECTORS

11. The Director may meet together for the despatch of business, adjourn and otherwise regulate their meeting as they think fit and determine the quorum necessary for the transaction of business. Unless otherwise determined, two shall form a quorum. If any question arising at any meeting the Managing Director's decision shall be final. When any matter is put to a vote and if there shall be an equality of votes, the Chairman shall have a second or casting vote.

12. Any Director may at any time summon a meeting of Directors.

13. A resolution in writing signed by all the Directors shall be as effective for all purposes as a resolution passed out at meeting of the Directors, duly called, held and constituted.

POWERS AND DUTIES OF DIRECTORS

14. Without prejudice to the general power conferred by Regulation 71 of the Table "A" of the Myanmar Companies Act, it is hereby expressly declared that the Directors shall have the following powers, that is to say power;-

(1) To purchase or otherwise acquire for the Company any property, rights or privileges which the Company is authorized to acquire at such price, and generally on such terms and conditions as they think fit: also to sell, lease, abandon or otherwise deal with any property, rights or privileges to which the Company may be entitled, on such terms and conditions as they may think fit.

(2) To raise, borrow or secure the payment of such sum or sums in such manner and upon such terms and conditions in all respects as they think fit and in particular by the issue of debentures or debenture stocks of the Company charged upon all or any part of the property of the Company (both present and future) including its uncalled capital for the time being,

(3) At their discretion, to pay for any rights acquired or services rendered to the Company, either wholly or partially in cash or in shares, bonds , debentures or other securities of the Company and any such shares may be issued either as fully paid up or with such amount credited as paid up there on as may be agreed upon ; and any such bonds, debentures or other securities may be either specifically charged up on all or any part of the property of the Company and its uncalled capital or not so charged.

(4) To secure the fulfillment of any contract or engagement entered into by the Company by mortgage or charge upon all or any of the property of the Company and its uncalled capital for the time being or by granting calls on shares or in such manner as they may think fit.

(5) To appoint at their discretion, remove or suspend such Managers, Secretaries, Officers, Clerks, Agents and Servants for permanent, temporary or special services as they may from time to time think fit and, to determine their duties and powers and fix their salaries or emoluments and to require security in such instances in such amount as they think fit and to depute any officers of the Company to do all or any of these things on their behalf.

(6) To appoint a Director as Managing Director, General Manager, Secretary or Departmental Manager in conjunction with his Directorship of the Company.

(7) To accept from any member on such terms and conditions as shall be agreed on the surrender of his shares or any part thereof.

(8) To appoint any person or persons to accept and hold in trust for the Company any property belonging to the Company or in which it is interested or for any other purposes and to execute and do all such deeds and things as may be requisite in relation to any such trust.

(9) To institute , conduct , defend of abandon any legal proceedings by or against the Company or its officers or otherwise concerning the affairs of the Company and also to compound and allow time for payment or satisfaction of any debts due to or of any claims and demands by or against the Company.

(10) To refer claims and demands by or against the Company to arbitration and to observe and perform the awards.

(11) To make and give receipts, releases and other discharges for money payable to the Company and for the claims and demands of the Company.

(12) To act on behalf of the Company in all matters relating to bankruptcy and insolvency.

(13) To determine who shall be entitled to sign bills of exchange, cheques, promissory notes, receipts, endorsements, releases contracts and documents for or on behalf of the Company.

(14) To invest, place on deposit and otherwise deal with any of the moneys of the Company not immediately required for the purpose thereof , upon securities or without securities and in such manners as the Directors may think fit, and from time to time vary or realize such investments.

(15) To execute in the name and on behalf of the Company in favour any Director or other person who may incur or be about to incur any personal liability for the benefit of the Company, such mortgages of the Company's property (present and future) as they think fit and any such mortgage may contain a power of sale and such other powers, covenants and provisions as shall be agreed on.

(16) To give any officer or other person employed by the Company a commission on the profits of any particular business or transaction or a share in the general profit of the Company and such commission or share of profit shall be treated as part of the working expenses of the Company.

(17) From time to time, to make, vary and repeal bye- laws for the regulation of the business of the Company, the officers and servants or the members of the Company or any section thereof.

(18) To enter into all such negotiations and contracts and rescind and vary all such contracts and execute and do all such acts , deeds and things in the name and on behalf of the Company as they may consider expedient for or in relation to any of the matter aforesaid or otherwise for the purposes of the Company.

(19) To borrow money for the benefit of the Company's business from any person, firm or company or bank or financial organization of local and abroad in the manner that the Directors shall think fit .

15. A general meeting shall be held within eighteen months from the date of its incorporation and thereafter at least once in every calendar year at such time (not being more than fifteen months after the holding of the last preceding general meeting) and places as may be fixed by the Board of Directors. No business shall be transacted at any general meeting unless a quorum of members is presented at the time when the meeting proceeds to business, save as herein otherwise provided Member holding not less than 50 percent of the issued shares capital (not less than two members) personally present, shall form a quorum for all purposes. And if and when in the case of there are only two number of members in the Company, those two members shall form a quorum.

DIVIDENDS

16. The Company in general meeting may declare a dividend to be paid to the members, but no dividend shall exceed the amount recommended by the Directors .No dividends shall be paid otherwise than out of the profits of the year or any other undistributed profits.

OFFICE STAFF

17. The Company shall maintain an office establishment and appoint a qualified person as General Manager and other qualified persons as office staffs . The remunerations and allowances such as salaries , travelling allowances and other expenditures incidental to the business shall be determined by the Board of Directors, and approved by the general meeting .The General Manager shall be responsible for the efficient operation of the office in every respect and shall be held accountable at all times to the Managing Director.

ACCOUNTS

18. The Directors shall cause to be kept proper books of account with respect to:-
    (1) *all sums of money received and expended by the Company and the matters in respect of which the receipts and expenditures take place:*
    (2) *all sales and purchases of goods by the Company ;*
    (3) *all assets and liabilities of the Company.*

19. The books of account shall be kept at the registered office of the Company or at such other place as the Directors shall think fit and shall be opened to inspection by the Directors during office hours.

AUDIT

20. Auditors shall be appointed and their duties regulated in accordance with the provisions of the Myanmar Companies Act or any statutory modifications thereof for the time being in force.

NOTICE

21. A notice may be given by the Company to any member either personally or sending it by post in a prepaid letter addressed to his registered address.

THE SEAL

22. The Directors shall provide for the safe custody of the Seal, and the Seal shall never be used except by the authority of the Directors previously given, and in the presence of one Director at least, who shall sign every instrument to which the Seal is affixed.

INDEMNITY

23. Subject to the provisions of Section 86 (C) of the Myanmar Companies Act and the existing laws, every Director, Auditor, Secretary or other officers of the Company shall be entitled to be indemnified by the Company against all costs, charges. losses, expenses and liabilities incurred by him in the execution and discharge of the duties or in relation thereto.

WINDING - UP

24. Subject to the provisions contained in the Myanmar Companies Act and the statutory modification thereupon, the Company may be wound up voluntarily by the resolution of General Meeting.

We, the several persons, whose names, nationalities, addresses and descriptions are subscribed below, are desirous of being formed into a Company in pursuance of this Articles of Association, and we respectively agree to take the number of shares in the Capital of the Company set opposite our respective names.

Sr. No.	Name, Address and Occupation of Subscribers	Nationality & N.R.C No.	Number of Shares taken	Signatures
1	**U Aung Moe Kyaw** Merchant No-18, Aung Mingalar Lane, Aung Theikdi Street, 3-Ward,Mayangone Township,YANGON	12/MAYAKA(NAING)106397	350	
2	**Daw Mar Mar Tun** Merchant No-52/B, Shwe Taung Gyar 2-Wardm Shwe Taung Gyar Street,Bahan Township,YANGON	12/BAHANA(NAING)083876	150	

Dated 27 the 7 day of 2015

It is hereby certified that the persons mentioned above put their signatures in my presence.

Kyu Kyu Win & Associates
No.
Date...............................
Myanma Gon Yi Housing,Upper Pansoedan St,Mingalar Taung Nyunt Tsp, Yangon

27/7/15

Kyu Kyu Win
B.Com, C.P.A, M.B.A
D.B.L, D.M.L
Certified Public Accountant

AMMK MEDICARE CO.,LTD.

No.33, 6 ½ Miles, Pyay Road, Hlaing Township, (11) Quarter,Yangon. Union of Myanmar
Tel; (951) 654938 to 654948 Fax : (951) 534986

AMMK Medicare Co., Ltd.
No........
Date........

သို့

ညွှန်ကြားရေးမှူးချုပ်
ရင်းနှီးမြုပ်နှံမှုနှင့်ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန
အမျိုးသားစီမံကိန်းနှင့်စီးပွားရေးဖွံ့ဖြိုးတိုးတက်မှုဝန်ကြီးဌာန
ရန်ကုန်တိုင်းဒေသကြီး။

ရက်စွဲ၊ ၂၀၁၅ ခုနှစ် ဩဂုတ်လ၊ (၇)ရက်။

အကြောင်းအရာ။ ။ <u>ပုံစံ (၆)၊ (၂၆) ပေးပို့မှတ်ပုံတင်ခြင်း။</u>

ကျွန်တော်တို့၏ AMMK MEDICARE COMPANY LIMITED (အေအမ်အမ်ကေ မယ်ဒီကဲ ကုမ္ပဏီလီမိတက်) သည် ကုမ္ပဏီမှတ်ပုံတင် အမှတ် {၁၃၉၇ /၂၀၁၅ -၂၀၁၆ /၄ -၈ -၂၀၁၅ } ဖြင့် မှတ်ပုံတင်ထားသည့် ကုမ္ပဏီဖြစ်ပါသည်။

ယခုအခါ ကျွန်တော်တို့ကုမ္ပဏီ၏ (၇ -၈ -၂၀၁၅) နေ့တွင်ကျင်းပပြုလုပ်သည့် ဒါရိုက်တာအဖွဲ့အစည်းအဝေးဆုံးဖြတ်ချက်အရ အစုရှယ်ယာရောင်းချခြင်း ပုံစံ(၆) နှင့် ဒါရိုက်တာအဖွဲ့ခန့်ထားခြင်း ပုံစံ(၂၆)တို့ကို သတ်မှတ်ပုံစံများတွင်ဖြည့်စွက်လျက် ကုမ္ပဏီများမှတ်ပုံတင်ရုံးသို့ ပေးပို့မှတ်ပုံတင်အပ်ပါသည်။

ကျသင့်သည့်မှတ်ပုံတင်ကြေးများကိုလည်း ပေးသွင်းပြီးဖြစ်ပါ၍ချလံကိုပူးတွဲ တင်ပြအပ်ပါသည်။

ပူးတွဲလျက်။

(၁) ပုံစံ(၆)တစ်စောင်
(၂) ပုံစံ(၂၆)တစ်စောင်
(၃) အစည်းအဝေးမှတ်တမ်းတစ်စောင်

လေးစားမှုဖြင့်

U Aung Moe Kyaw
Managing Director
AMMK Medicare Co., Ltd.

AMMK MEDICARE CO.,LTD.

No.33, 6 ½ Miles, Pyay Road, Hlaing Township, (11) Quarter,Yangon. Union of Myanmar
Tel; (951) 654938 to 654948 Fax : (951) 534986

AMMK Medicare Co., Ltd.
No...............
Date.............

<u>ဒါရိုက်တာအဖွဲ့အစည်းအဝေးမှတ်တမ်း</u>

ကျင်းပသည့်အချိန် ။ ။ နံနက် ၁၀း၀၀ နာရီ
ကျင်းပသည့်နေ့ ။ ။ ၇-၈-၂၀၁၅
ကျင်းပသည့်နေရာ ။ ။ ကုမ္ပဏီရုံးခန်း

တက်ရောက်ကြသူများ

စဉ်	အမည်	လက်မှတ်
(၁)	ဦးအောင်မိုးကျော်	(signed)
(၂)	ဒေါ်မာမာထွန်း	(signed)

အစည်းအဝေးဆုံးဖြတ်ချက်

(၁) ကျပ်တစ်သောင်း (၁၀,၀၀၀/-) တန် အစုရှယ်ယာများကို ခွဲဝေရောင်းချရန်
(၂) ဒါရိုက်တာအဖွဲ့ ဖွဲ့စည်းရန် ဆုံးဖြတ်ကြပါသည်။

စဉ်	အမည်	ရာထူး	အစုရှယ်ယာအရေအတွက်
(၁)	ဦးအောင်မိုးကျော်	မန်နေးဂျင်းဒါရိုက်တာ	(၃၅၀) စု
(၂)	ဒေါ်မာမာထွန်း	ဒါရိုက်တာ	(၁၅၀) စု

အစည်းအဝေးကို နေ့လည် (၁၂း၀၀) နာရီတွင် ရုပ်သိမ်းလိုက်ပါသည်။

မှတ်တမ်းတင်သူ

Daw Mar Mar Tun
Director
AMMK Medicare Co., Ltd.

အတည်ပြုသူ

U Aung Moe Kyaw
Managing Director
AMMK Medicare Co., Ltd.

ရင်းနှီးမြှုပ်နှံမှုနှင့် ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန၊ ရန်ကုန်မြို့ 012767

(63) 17 - ဇီ . . ၁

ငွေလက်ခံ/ရရှိပြေစာ

ရက်စွဲ၊ ၁၇ - ၈ - ၂၀၁၇

၁။ ★ ကုမ္ပဏီ အမည် (အမည်)၊

(အင်္ဂလိပ်)၊ AMMK Medicare Co., ltd

၂။ ငွေပေးသွင်းသည့် အကြောင်းအရာ၊ ပုံစံ (၆ / ၂၆)

တရင်းသွင်းပြီး

၃။ ပေးသွင်းသည့်ငွေ (ဂဏန်းဖြင့်) ၊ ၅၀၀၀၀/-

ငွေလက်ခံပြီး

(စာဖြင့်) ၊ ငါးသောင်း

ငွေပေးသွင်းသူလက်မှတ်

ငွေလက်ခံသူလက်မှတ်

အမည် ၊ ကြွယ်မာန်ဝင်း

အမည် ရွှေဝ

012505

FORM VI

RETURN OF ALLOTMENTS
THE MYANMAR COMPANIES ACT.

(See Section 104)

(To be filed with the Registrar within one month after the allotment is made)

Return of allotment from the 7th of August, 200 2015.

on the of 200 of the * AMMK MEDICARE COMPANY LIMITED

Made pursuant to Section 104 (1)

Number of the shares allotted payable in cash ......500 Shares

" " " " ....

Nominal amount of the shares so allotted ....Ks. 5,000,000/-

" " " " ....

Amount paid or due and payable on cash such share ....Ks. 10,000/- (Fully Paid Up)

" " " " ....

Number of ordinary shares allotted for a consideration other than cash

Nominal amount to be ordinary shares so allotted ....

Amount to be treated as paid on each such share ....

The consideration for which such share have been allotted is as follow : -

---

NOTE In making a return of allotments under Section 104 (1) the Myanmar Companies Act., it is to be noted that -

1. When a return include several allotments made on different dates, the actual date of only the first and last of such allotment should be entered at the tip of the front page, and the registration of the return should be effected within one month of the first date.
2. When a return relates to one allotment only, made on one particular date, that date only should be inserted and the spaces for the second date struck out and the world made substituted for the world "From" after the world "allotments" above.

Here insert name of Company.

Distinguish between preference, ordinary, or other description of shares.

012505

Presented for filing by : U Aung Moe Kyaw (M.D)

Name, Address and Description of Allotees

Name & N.R.C No	Address	Description	Number of the shares allotted	
			Preference	Ordinary
1. U Aung Moe Kyaw 12/Ma Ya Ka (Naing)106397	No.18,Aung Mingalar Lane, Aung Theikdi Street,(3) Ward,Mayangone Township, Yangon.	Merchant		350
2. Daw Mar Mar Tun 12/Ba Ha Na (Naing)083876	No.(52/B),Shwe Taung Gyar (2) Ward, Shwe Taung Gyar Street,Bahan Township Yangon.	Merchant		150
				500 Shares

Signature

Date , August , 2015.

U Aung Moe Kyaw
Managing Director
AMMK Medicare Co., Ltd

FORM VI

FORM XXVI

PARTICULARS OF DIRECTORS, MANAGERS AND MANAGING AGENTS AND OF ANY CHANGES THEREIN

(Myanmar Companies Act, See Section 87)

Name of Company : AMMK MEDICARE COMPANY LIMITED

Presented by : U Aung Moe Kyaw (Managing Director)

The Present Christian name or names of surnames	Nationality, National Registration Card No.	Usual Residential Address	Other Business Occupation	Changes
1. U Aung Moe Kyaw	Myanmar 12/Ma Ya Ka (Naing)106397	No.18,Aung Mingalar Lane, Aung Theikdi Street, 3-Ward ,Mayangone Township,Yangon.	Merchant	Appointed as Managing Director w.e.f (၇.၈.2015)
2. Daw Mar Mar Tun	Myanmar 12/Ba Ha Na (Naing)083876	No.52/B,Shwe Taung Gyar 2-Ward,Shwe Taung Gyar Street,Bahan Township,Yangon.	Merchant	Appointed as Director w.e.f (၇.၈.2015)

NOTE : (1) A Complete list of the Directors or Managers or Managing Agents shown as existing in the last particulars.

(2) A note of the changes since the last list should be made in the column for "Changes" by placing against the new Director's name the word "in place of .... and by writing against any former Director's name the the word "dead" "resigned" or as the case may be giving the date of change against the entry.

Dated this 7th , August, 2015.

Signature ....

Designation U Aung Moe Kyaw
Managing Director
AMMK Medicare Co., Ltd.

Form (26)

Kanbawza Bank Ltd.Kamayut Branch
615/1 ,5 1/2 Miles,Pyay Road,Kamayut Township,Yangon
Ph : 538072,538073,538074
Fax : 538067,538068,503008

Date : 07 August , 2015

ACCOUNT NO. : 0211130011657

NAME : AMMK MEDICARE CO.,LTD
NRC :
ADDRESS : NO(33)6 1/2MILES PYAY ROAD HLAING
PHONE : 098622971

KANBAWZA BANK LTD. KMY Branch

Statement Of Transaction For The Date Between 07/08/2015 And 07/08/2015

Date_Time	Description	Withdrawal Amount	Deposit Amount	Balance
07 / 08 / 2015	Opening Balance			0.00
07 / 08 / 2015	Cash Deposit 021		5,000,000.00	5,000,000.00
07 / 08 / 2015	Closing Balance			5,000,000.00

No. of Withdrawals : 0
No. of Deposits : 1

Thank You For Banking With Kanbawza Bank Ltd.Kamayut Branch

Please report any descrepencies found on your statement immediately.
N.B - Statement will not be sent unless there is a change of transaction.

For Kanbawza Bank Ltd.Kamayut Branch

Asst: / DY Manager

Manager
Kanbawza Bank Ltd.
Kamayut Branch

သက်တမ်းတိုး

007793

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ

အမျိုးသားစီမံကိန်းနှင့် စီးပွားရေးဖွံ့ဖြိုးတိုးတက်မှုဝန်ကြီးဌာန

ကုမ္ပဏီမှတ်ပုံတင်လက်မှတ်

အမှတ် ......၁၅၀၇.../ ၂၀၀၈–၂၀၀၉

မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေအရ ...ကမ္ဘာလုံးကြယ် ကုမ္ပဏီ လီမိတက်...

...အား ပေးရန်တာဝန် ကန့်သတ်ထားသော လီမိတက်

ကုမ္ပဏီအဖြစ် .၂၀၀၉.နှစ်၊ ..ဖေဖော်ဝါရီ..လ၊ ...၂၇ရက်နေ့တွင် မှတ်ပုံတင်ထားခြင်းအား

.၂၀၁၃.နှစ်၊ဖေဖော်ဝါရီ..လ၊ ..၂၇. ရက်နေ့မှစ၍ သက်တမ်းတိုး ခွင့်ပြုလိုက်သည်။

ညွှန်ကြားရေးမှူးချုပ်(ကိုယ်စား)

(နန်းရီရီသန်း ၊ ညွှန်ကြားရေးမှူး)

ရင်းနှီးမြှုပ်နှံမှုနှင့်ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF NATIONAL PLANNING AND ECONOMIC DEVELOPMENT

CERTIFICATE OF INCORPORATION

NO. ......1507...... of 2008-2009

I hereby certify that the tenure of ...GLOBAL STAR COMPANY...

...LIMITED...incorporated under the

Myanmar Companies Act on ...27th FEBRUARY, 2009...

is renewed with effected from ...27th FEBRUARY, 2013...

For Director General

(Nang Yi Yi Than, Director)

Directorate of Investment and Company Administration

ကုမ္ပဏီနှင့်သက်ဆိုင်သည့်အချက်အလက်များ

(က) အုပ်ချုပ်မှုဒါရိုက်တာအမည်၊ ဦးကျော်ဇောအောင် (၁၂/ စခန(နိုင်) ၀၄၃၇၃၆)

(ခ) ကုမ္ပဏီ ရုံးခန်းလိပ်စာ၊ အမှတ်(၂)၊ ဘုရင့်နောင်လမ်းမကြီး၊ ရွာမကွေ့(၂)ရပ်ကွက်၊ လှိုင်မြို့နယ်၊ ရန်ကုန်မြို့။

(ဂ) ဆက်သွယ်ရန် ဖုန်းနံပါတ်၊ ၀၁-၅၀၃၈၇၃၃၊ ၀၁-၅၁၄၂၂၃

(ဃ) ဒါရိုက်တာများ အမည်စာရင်း–

(၁) ဒေါ်မြင့်မြင့်သောင်း
၆/ထဝန(နိုင်) ၀၂၆၅၃၃

(၂) ဒေါ်သီတာသော်
၁၂/စခန(နိုင်) ၀၀၉၆၉၃

(၃) ဦးအောင်ကြီး
၁၄/ဝခမ(နိုင်) ၀၀၇၄၄၄

မှတ်ချက်။ (၁) ဤကုမ္ပဏီမှတ်ပုံတင်လက်မှတ်သည်မှတ်ပုံတင်ရက်စွဲ(၂၇-၂-၂၀၁၃)မှ (၂၆-၂-၂၀၁၈)ရက်နေ့အထိ(၅)နှစ်သက်တမ်းအတွက်သာ ဖြစ်သည်။ သက်တမ်း မကုန်ဆုံးမီ (၃)လအလိုတွင် သက်တမ်းတိုးရန် ရင်းနှီးမြှုပ်နှံမှုနှင့် ကုမ္ပဏီများ ညွှန်ကြားမှု ဦးစီးဌာနသို့ လျှောက်ထား ရမည်။

(၂) ကုမ္ပဏီ အနေဖြင့် သင်းဖွဲ့မှတ်တမ်းတွင်အဆိုပြု တင်ပြထားသော လုပ်ငန်းရည်ရွယ်ချက်များကိုသာ လုပ်ကိုင်ရမည်။

(၃) သင်းဖွဲ့မှတ်တမ်းပါ ရည်ရွယ်ချက်များသည် သက်ဆိုင်ရာ ပြည်ထောင်စုဝန်ကြီးဌာန၏ တည်ဆဲဥပဒေ၊ နည်းဥပဒေ၊ လုပ်ထုံးလုပ်နည်း များနှင့်အညီ ခွင့်ပြုချက် ရရှိမှသာ ဆောင်ရွက်ခွင့် ရှိမည် ဖြစ်ပါသည်။

(၄) လုပ်ငန်းရည်ရွယ်ချက် ပြောင်းလဲ လုပ်ကိုင်လိုပါက ပြောင်းလဲ လုပ်ကိုင်လိုသည့် လုပ်ငန်း ရည်ရွယ်ချက်များအား သင်းဖွဲ့မှတ်တမ်းတွင် ပြင်ဆင်မှတ်ပုံတင်ရန်အတွက် ဒါရိုက်တာအဖွဲ့(BOD)၏ အထူး အစည်းအဝေး ဆုံးဖြတ်ချက် မှတ်တမ်းနှင့်အတူ ရင်းနှီးမြှုပ်နှံမှုနှင့်ကုမ္ပဏီများ ညွှန်ကြားမှု ဦးစီးဌာန သို့ လျှောက်ထား ရမည် ။

ညွှန်ကြားရေးမှူးချုပ်(ကိုယ်စား)
(မြင့်လွင်၊ ဒုတိယညွှန်ကြားရေးမှူး)

မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ

အစုရှယ်ယာများဖြင့် ပေးရန်တာဝန် ကန့်သတ်ထားသော အများနှင့် မသက်ဆိုင်သည့်ကုမ္ပဏီ

ကမ္ဘာ ၁ လုံး ကြယ် ကုမ္ပဏီ လီမိတက်

၏

သင်းဖွဲ့မှတ်တမ်း

နှင့်

သင်းဖွဲ့စည်းမျဉ်းများ

THE MYANMAR COMPANIES ACT

PRIVATE COMPANY LIMITED BY SHARES

Memorandum Of Association

AND

Articles Of Association

OF

GLOBAL STAR COMPANY LIMITED

မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ

အစုရှယ်ယာများဖြင့် ပေးရန်တာဝန် ကန့်သတ်ထားသော အများနှင့် မသက်ဆိုင်သည့် ကုမ္ပဏီ

တမ္မ ၁လုံး ကြယ် **ကုမ္ပဏီ လီမိတက်**

၏

သင်းဖွဲ့မှတ်တမ်း

❖ ❖ ❖ ❖ ❖ ❖ ❖

၁။ ကုမ္ပဏီ၏ အမည်သည် " တမ္မ ၁လုံး ကြယ် ကုမ္ပဏီ လီမိတက် " ဖြစ်ပါသည်။

၂။ ကုမ္ပဏီ၏ မှတ်ပုံတင် အလုပ်တိုက်သည် ပြည်ထောင်စု မြန်မာနိုင်ငံတော်အတွင်း တည်ရှိရမည်။

၃။ ကုမ္ပဏီ တည်ထောင်ရခြင်း၏ ရည်ရွယ်ချက်များမှာ တစ်ဖက်စာမျက်နှာပါအတိုင်း ဖြစ်ပါသည်။

၄။ အစုဝင်များ၏ ပေးရန်တာဝန်ကို ကန့်သတ်ထားသည်။

၅။ ကုမ္ပဏီ၏ သတ်မှတ်ရင်းမြစ်တည်ငွေရင်းသည် ကျပ် ၁၀၀,၀၀၀,၀၀၀/-(ကျပ် သိန်း တစ်ရာ တိတိ) ဖြစ်၍ ငွေကျပ် ၁၀၀,၀၀၀/-(ကျပ် တစ်သိန်း တိတိ) တန် အစုရှယ်ယာပေါင်း (၁,၀၀၀) ခွဲထားပါသည်။ ကုမ္ပဏီ၏ ရင်းနှီးငွေကိုကုမ္ပဏီ၏ စည်းမျဉ်းများနှင့် လက်ရှိတရားဝင် တည်ဆဲဖြစ်နေသော တရားဥပဒေပြဋ္ဌာန်းချက်များနှင့် အညီ အထွေထွေ သင်းလုံးကျွတ် အစည်းအဝေး၌ တိုးမြှင့်နိုင်ခွင့်၊ လျှော့ချနိုင်ခွင့် နှင့် ပြင်ဆင်နိုင်ခွင့် အာဏာရှိစေရမည်။

(၁) အောက်ဖော်ပြပါ အစိုးရက ခွင့်ပြုသော ကုန်ပစ္စည်းများနှင့် ထုတ်ကုန်များကို မိမိတစ်ဦးတည်းဖြစ်စေ၊ မည်သည့်ပြည်တွင်း၊ ပြည်ပပုဂ္ဂိုလ်များနှင့် ဖက်စပ်၍ဖြစ်စေ၊ သွင်းကုန်လုပ်ငန်းရှင်များ၊ ထုတ်ကုန် လုပ်ငန်းရှင်များ၊လက်လီလက်ကားရောင်းချသူများ၏ ကူးသန်းရောင်းဝယ်ရေးဆိုင်ရာ လုပ်ငန်းများကို လုပ်ကိုင်ရန်။

(က) လယ်ယာကိုင်းကျွန်းနှင့် ဥယျာဉ်ခြံမြေထွက် ကုန်ပစ္စည်းများ၊

(ခ) သစ်တောထွက်ပစ္စည်းနှင့် ထပ်ဆင့်တိုးတန်ဖိုးမြှင့် သစ်အခြေခံကုန်ပစ္စည်းများ၊

(ဂ) တိရစ္ဆာန်ထွက်ကုန်ပစ္စည်းနှင့် တိရစ္ဆာန်အစားအစာ၊

(ဃ) ရေထွက်ကုန်ပစ္စည်းများ၊

(င) ဓာတ်မြေဩဇာနှင့် ပိုးသတ်ဆေးများ၊

(စ) ဓာတုဗေဒနှင့် ဓာတ်ဆေးဆိုးဆေးများ၊

(ဆ) စက်ရုံသုံးပစ္စည်းများနှင့် ကုန်ကြမ်းပစ္စည်းများ၊

(ဇ) အိမ်သုံးကုန်ပစ္စည်းများ၊

(ဈ) လူသုံးကုန်ပစ္စည်းများ၊

(ည) ဆောက်လုပ်ရေးလုပ်ငန်းသုံးပစ္စည်းများနှင့် သုတ်ဆေးများ၊

(ဋ) လျှပ်စစ်နှင့် အီလက်ထရောနစ်ကုန်ပစ္စည်းများ၊

(ဌ) ယာဉ်နှင့် စက်ကိရိယာနှင့် အပိုပစ္စည်းများ၊

(ဍ) ကိရိယာတန်ဆာပလာအမျိုးမျိုး၊

(ဎ) ဆေးနှင့်ဆေးပစ္စည်းများ၊

(ဏ) စားသောက်ကုန်နှင့် အထွေထွေကုန်ပစ္စည်းများ၊

(တ) အထည်အလိပ်နှင့် အဝတ်အထည်များ၊

(ထ) စက္ကူ၊ စာရေးကိရိယာနှင့် ဓာတ်ပုံပစ္စည်းများ၊

(ဒ) ရုံးသုံးပစ္စည်းများနှင့် ပညာရေးအထောက်အကူပြုပစ္စည်းများ၊

(၂) ကုမ္ပဏီမှ သင့်လျော်လျောက်ပတ်သည်ဟု ယူဆပါက ကုမ္ပဏီ၏စီးပွားရေးလုပ်ငန်းတွင် အကျိုးရှိစေရန်အတွက် မည်သည့်ပုဂ္ဂိုလ်၊ စီးပွားရေးအဖွဲ့အစည်း၊ ကုမ္ပဏီ၊ ဘဏ်၊ သို့မဟုတ်၊ ငွေကြေးအဖွဲ့အစည်းထံမှမဆို ငွေချေးယူရန်။

ခြွင်းချက်။ ကုမ္ပဏီသည် အထက်ဖော်ပြပါ ရည်ရွယ်ချက်များကို ပြည်ထောင်စုမြန်မာနိုင်ငံတော်အတွင်း၌ဖြစ်စေ၊ အခြားမည်သည့် အရပ်ဒေသ၌ဖြစ်စေ၊ အချိန်ကာလအလိုက် တည်ဆဲဖြစ်နေသော တရားဥပဒေများ၊ အမိန့်ကြော်ငြာစာများ၊ အမိန့်များက ခွင့်ပြုထားသည့် လုပ်ငန်းများမှအပ အခြားလုပ်ငန်းများကို လုပ်ကိုင်ဆောင်ရွက်ခြင်းမပြုပါ။ ထို့အပြင် ပြည်ထောင်စု မြန်မာနိုင်ငံတော်အတွင်း၌ အချိန်ကာလအားလျော်စွာ တည်ဆဲဖြစ်နေသည့် တရားဥပဒေပြဋ္ဌာန်းချက်များ၊ အမိန့်ကြော်ငြာစာများ၊ အမိန့်များနှင့် လျော်ညီသင့်တော်ခြင်း၊ သို့မဟုတ်၊ ခွင့်ပြုထားရှိခြင်းရှိမှသာလျှင် လုပ်ငန်းများကို ဆောင်ရွက်မည်ဟု ခြွင်းချက်ထားရှိပါသည်။

(၃)

[illegible] အမည်၊ နိုင်ငံသား၊ နေရပ်နှင့် အကြောင်းအရာစုံလင်စွာပါသော [illegible] လက်မှတ်ရေးထိုးသူ ကျွန်ုပ်တို့ ကိုယ်စီကိုယ်ငှသည် ဤသင်းဖွဲ့မှတ်တမ်းအရ ကုမ္ပဏီတစ်ခုဖွဲ့စည်းရန် လိုလားသည့်အလျောက် ကျွန်ုပ်တို့၏ အမည်အသီးသီးနှင့် ယှဉ်တွဲ၍ပြထားသော အစုရှယ်ယာများကို ကုမ္ပဏီ၏ မတည်ရင်းနှီးငွေတွင် ထည့်ဝင်ရယူကြရန် သဘောတူကြပါသည်။

စဉ်	အစုထည့်ဝင်သူများ၏ အမည်၊ နေရပ်လိပ်စာနှင့် အလုပ်အကိုင်	နိုင်ငံသားနှင့် အမျိုးသား မှတ်ပုံတင်အမှတ်	ဝယ်ယူသော အစုရှယ်ယာ ဦးရေ	ထိုးမြဲလက်မှတ်
၁။	ဒေါ်မြင့်မြင့်သောင်း ၄၂၊ ရတနာဘုံမြိုင်လမ်း၊ ကမာရွတ်မြို့နယ်၊ ရန်ကုန်မြို့။ (ကုန်သည်)	မြန်မာ ၆/ထဝန (နိုင်) ၀၂၆၅၇၃	၂၅	(signature)
၂။	ဒေါ်သီတာသော် ၁၆၊ တိုက်လက်လမ်း၊ လင်းတောင်ရပ်ကွက်၊ စမ်းချောင်းမြို့နယ်၊ ရန်ကုန်မြို့။ (ကုန်သည်)	မြန်မာ ၁၂/စခန (နိုင်) ၀၀၄၆၄၃	၂၅	(signature)
၃။				

ရန်ကုန်။ နေ့စွဲ၊ ၂၀၀၄ ခုနှစ် ဖေဖော်ဝါရီ လ ရက်။

အထက်ပါလက်မှတ်ရှင်များသည် ကျွန်ုပ်တို့၏ ရှေ့မှောက်တွင် လက်မှတ်ရေးထိုးကြပါသည်။

ဦးငြိမ်းတင် LL.B
[illegible]

[illegible]

မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ

အစုရှယ်ယာများဖြင့် ပေးရန်တာဝန် ကန့်သတ်ထားသော အများနှင့်မသက်ဆိုင်သည့် ကုမ္ပဏီ

ကမ္ဘာ့ဝလုံးကြယ် ကုမ္ပဏီ လီမိတက်

၏

သင်းဖွဲ့စည်းမျဉ်းများ

❖ ❖ ❖ ❖ ❖ ❖ ❖

၁။ ဤသင်းဖွဲ့စည်းမျဉ်းနှင့် လိုက်လျောညီထွေမဖြစ်သည့် စည်းမျဉ်းများမှအပ၊ မြန်မာနိုင်ငံ ကုမ္ပဏီများအက်ဥပဒေ နောက်ဆက်တွဲ ပထမဇယားပုံစံ 'က' ပါ စည်းမျဉ်းများသည် ဤကုမ္ပဏီနှင့် သက်ဆိုင်စေရမည်။ မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေပုဒ်မ ၁၇(၂)တွင် ဖော်ပြပါရှိသည့် မလိုက်နာ မနေရ စည်းမျဉ်းများသည် ဤကုမ္ပဏီနှင့် အစဉ်သဖြင့် သက်ဆိုင်စေရမည်။

အများနှင့် မသက်ဆိုင်သော ကုမ္ပဏီ

၂။ ဤကုမ္ပဏီသည် အများနှင့် မသက်ဆိုင်သည့် ကုမ္ပဏီဖြစ်၍ အောက်ပါသတ်မှတ်ချက်များသည် အကျိုးသက်ရောက်စေရမည်။

(က) ဤကုမ္ပဏီက ခန့်အပ်ထားသော ဝန်ထမ်းများမှအပ၊ ဤကုမ္ပဏီ၏ အစုရှင်အရေအတွက်ကို ငါးဆယ်အထိသာ ကန့်သတ်ထားသည်။

(ခ) ဤကုမ္ပဏီ၏ အစုရှယ်ယာ သို့မဟုတ် ဒီဘင်ချာ သို့မဟုတ် ဒီဘင်ချာစတော့(ခ်) တစ်စုံတစ်ရာအတွက် ငွေထည့်ဝင်ရန် အများပြည်သူတို့အား ကမ်းလှမ်းခြင်းမပြုလုပ်ရန် တားမြစ်ထားသည်။

မ,တည်ရင်းနှီးငွေနှင့် အစုရှယ်ယာ

၃။ ကုမ္ပဏီ၏ သတ်မှတ် မ,တည်ငွေရင်း မှာ ကျပ် ၁၀၀,၀၀၀,၀၀၀ /-(ကျပ် - သန်း တစ်ရာ တိတိ) ဖြစ်၍ ငွေကျပ် ၁၀၀၀၀၀ /-(ကျပ် - တစ်သိန်း တိတိ) တန် အစုရှယ်ယာပေါင်း (၁,၀၀၀) ခွဲထားပါသည်။ ကုမ္ပဏီ၏ ရင်းနှီးငွေကို ကုမ္ပဏီ၏ စည်းမျဉ်းများ နှင့် လက်ရှိတရားဝင် တည်ဆဲဖြစ်နေသော တရားဥပဒေ ပြဋ္ဌာန်းချက်များနှင့်အညီ အထွေထွေသင်းလုံးကျွတ် အစည်းအဝေး၌ တိုးမြှင့်နိုင်ခွင့်၊ လျှော့ချနိုင်ခွင့်နှင့် ပြင်ဆင်နိုင်ခွင့် အာဏာရှိစေရမည်။

၄။ မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေပါ ပြဋ္ဌာန်းချက်များကို မထိခိုက်စေလျက် အစုရှယ်ယာများသည် ဒါရိုက်တာများ၏ ကြီးကြပ်ကွပ်ကဲမှု အောက်တွင် ရှိစေရမည်။ ၎င်းဒါရိုက်တာများသည် သင့်လျော်သော ပုဂ္ဂိုလ်များအား သတ်မှတ်ချက် အခြေအနေ တစ်စုံတစ်ရာဖြင့် အစုရှယ်ယာများကို ခွဲဝေချထားခြင်း သို့မဟုတ် ထုခွဲရောင်းချခြင်းကို ဆောင်ရွက်နိုင်သည်။

၅။ အစုရှယ်ယာလက်မှတ်များကို အထွေထွေမန်နေဂျာ သို့မဟုတ် ဒါရိုက်တာအဖွဲ့က သတ်မှတ်သည့် အခြားပုဂ္ဂိုလ်များကလက်မှတ်ရေးထိုး၍ ကုမ္ပဏီ၏ တံဆိပ် ရိုက်နှိပ်ထုတ်ပေးရမည်။ အစုရှယ်ယာလက်မှတ်သည် ပုံပန်းပျက်ခြင်း၊ ပျောက်ဆုံးခြင်း သို့မဟုတ် ပျက်စီးခြင်းဖြစ်ပါက အဖိုးအခဖြင့် ပြန်လည်အသစ်ပြုလုပ်ပေးမှုကို သော်လည်းကောင်း၊ ဒါရိုက်တာများက သင့်လျော်သည်ဟု ယူဆသော အခြားသက်သေခံ အထောက်အထား တစ်စုံတစ်ရာကို တင်ပြစေ၍သော်လည်းကောင်း ထုတ်ပေးနိုင်သည်။ ကွယ်လွန်သွားသော အစုရှယ်ယာရှင်တစ်ဦး၏ တရားဝင် ကိုယ်စားလှယ်ကို ဒါရိုက်တာများက အသိအမှတ် ပြုပေးရမည်ဖြစ်သည်။

၆။ ဒါရိုက်တာများသည် အစုရှင်များက ၎င်းတို့၏ အစုရှယ်ယာများအတွက် မပေးသွင်းရသေးသော ငွေများကိုအခါအားလျော်စွာ တောင်းဆိုနိုင်သည်။ အစုရှင်တိုင်းကလည်း ၎င်းတို့ထံတောင်းဆိုသည့် အကြိမ်တိုင်း အတွက် ဒါရိုက်တာများက သတ်မှတ်သည့် ပုဂ္ဂိုလ်များထံ သတ်မှတ်သည့်အချိန်နှင့် နေရာတွင် ပေးသွင်းစေရန် တာဝန်ရှိစေရမည်။ ဆင့်ခေါ်မှုတစ်ခုအတွက် အရစ်ကျပေးသွင်းစေခြင်း၊ သို့မဟုတ် ပယ်ဖျက်ခြင်း သို့မဟုတ် ရွှေ့ဆိုင်းခြင်းတို့ကို ဒါရိုက်တာများက သတ်မှတ်နိုင်သည်။

ဒါရိုက်တာများ

၇။ သင်းလုံးကျွတ် အစည်းအဝေးက တစ်စုံတစ်ရာ သတ်မှတ်ပြဌာန်းမှု မပြုလုပ်သမျှ ဒါရိုက်တာများ၏ အရေအတွက်သည် (၂)ဦး ထက်မနည်း၊ (၆) ဦးထက်မများစေရ။

ပထမဒါရိုက်တာများသည် -

(၁) ဒေါ်မြင့်မြင့်သော်င်း

(၂) ဒေါ်သီတာသော်

(၃)

(၄)

(၅) တို့ဖြစ်ကြပါသည်။

၈။ ဒါရိုက်တာများသည် ၎င်းတို့အနက်မှ တစ်ဦးကို မန်နေဂျင်းဒါရိုက်တာအဖြစ် အချိန်အခါအလိုက် သင့်လျော်သော သတ်မှတ်ချက်များ၊ ဥာဏ်ပူဇော်ခများဖြင့် ခန့်ထားရမည်ဖြစ်ပြီး အခါအားလျော်စွာ ဒါရိုက်တာအဖွဲ့က ပေးအပ်သော အာဏာများ အားလုံးကို ၎င်းက အသုံးပြုနိုင်သည်။

၉။ ဒါရိုက်တာတစ်ဦးဖြစ်မြောက်ရန် လိုအပ်သော အရည်အချင်းသည် ကုမ္ပဏီ၏ အစုရှယ်ယာ အနည်းဆုံး (-)စုကို ပိုင်ဆိုင်ခြင်းဖြစ်၍ ၎င်းသည် မြန်မာနိုင်ငံ ကုမ္ပဏီများအက်ဥပဒေပုဒ်မ ၈၅ ပါ ပြဌာန်းချက်များကို လိုက်နာရန် တာဝန်ရှိသည်။

၁၀။ အစုရှယ်ယာများ လွှဲပြောင်းရန် တင်ပြချက်ကို မည်သည့် အကြောင်းပြချက်မျှ မပေးဘဲ ဒါရိုက်တာအဖွဲ့သည် ၎င်းတို့၏ပြည့်စုံ၍ ချုပ်ချယ်ခြင်းကင်းသော ဆင်ခြင်တွက်ဆမှုဖြင့် မှတ်ပုံတင်ရန် ငြင်းဆိုနိုင်သည်။

ဒါရိုက်တာများ၏ ဆောင်ရွက်ချက်များ

၁၁။ ဒါရိုက်တာများသည် ၎င်းတို့သင့်လျော်သည် ထင်မြင်သည့်အတိုင်း လုပ်ငန်းဆောင်ရွက်ရန် တွေ့ဆုံ ဆွေးနွေးခြင်း၊ အစည်းအဝေး ရွှေ့ဆိုင်းခြင်း၊ အချိန်မှန်စည်းဝေးခြင်း၊ အစည်းအဝေးအထမြောက်ရန် အနည်းဆုံး ဒါရိုက်တာဦးရေ သတ်မှတ်ခြင်းတို့ကို ဆောင်ရွက်နိုင်သည်။ ယင်းသို့ မသတ်မှတ်ပါက ဒါရိုက်တာနှစ်ဦး တက်ရောက်လျှင် အစည်းအဝေးထမြောက်ရမည်။ အစည်းအဝေးတွင် မည်သည့်ပြဿနာမဆို ပေါ်ပေါက်ပါက မန်နေဂျင်းဒါရိုက်တာ၏အဆုံးအဖြတ်သည် အတည်ဖြစ်ရမည်။ မည်သည့် ကိစ္စများကိုမဆို မဲခွဲဆုံးဖြတ်ရာတွင် မဲအရေအတွက် တူနေပါက သဘာပတိသည် ဒုတိယမဲ သို့မဟုတ် အနိုင်မဲကို ပေးနိုင်သည်။

၁၂။ ဒါရိုက်တာများ၏ အစည်းအဝေးကို မည်သည့်ဒါရိုက်တာကမဆို အချိန်မရွေး ခေါ်နိုင်သည်။

၁၃။ ဒါရိုက်တာအားလုံးက လက်မှတ်ရေးထိုးထားသော ရေးသားထားသည့်ဆုံးဖြတ်ချက်တစ်ရပ်သည် နည်းလမ်းတကျ ခေါ်ယူကျင်းပသော အစည်းအဝေးက အတည်ပြုသည့် ဆုံးဖြတ်ချက်ကဲ့သို့ပင် ကိစ္စအားလုံး အတွက် အကျိုးသက်ရောက်စေရမည်။

ဒါရိုက်တာများ၏ လုပ်ပိုင်ခွင့်နှင့်တာဝန်များ

၁၄။ မြန်မာနိုင်ငံ ကုမ္ပဏီများအက်ဥပဒေ နောက်ဆက်တွဲဇယားပုံစံ (က)ပါ စည်းမျဉ်းအပိုဒ် ၇၁ တွင် ပေးအပ်ထားသော အထွေထွေ အာဏာများကို မထိခိုက်စေဘဲ ဒါရိုက်တာများသည် အောက်ဖော်ပြပါ အာဏာများ ရှိရမည်ဟု အတိအလင်း ထုတ်ဖော်ကြေညာသည်။ အာဏာဆိုသည်မှာ -

(၁) ဒါရိုက်တာများက သင့်လျော်သည်ဟုယူဆသော တန်ဖိုးနှင့်စည်းကမ်းများ၊ အခြေအနေများ သတ်မှတ်၍ ကုမ္ပဏီကရယူရန်အာဏာရှိသည့် မည်သည့်ပစ္စည်း၊ အခွင့်အရေးများ၊ အခွင့်အလမ်းများကိုမဆိုဝယ်ယူရန် သို့မဟုတ် အခြားနည်းလမ်းများဖြင့်ရယူပိုင်ဆိုင်ရန်အပြင် ကုမ္ပဏီကပိုင်ဆိုင်ခွင့်ရှိသောမည်သည့်ပစ္စည်း၊ အခွင့်အရေးများ၊ အခွင့်အလမ်းများကိုမဆို သင့်တော်သောစည်းကမ်းချက်များ သတ်မှတ်၍ရောင်းချခြင်း၊ အငှားချခြင်း၊ စွန့်လွှတ်ခြင်း၊ သို့မဟုတ် အခြားနည်းလမ်းများဖြင့် ဆောင်ရွက်ခြင်းတို့ကို ပြုလုပ်ရန်။

(၂) သင့်လျော်သောစည်းကမ်းသတ်မှတ်ချက်များဖြင့်ငွေကြေးများကိုချေးငှားရန် သို့မဟုတ်အဆိုပါချေးငှား သော ငွေကြေးများကို ပြန်လည်ပေးဆပ်ရန်အတွက် အာမခံများထားရှိရန်အပြင်၊ အထူးသဖြင့် ဤကုမ္ပဏီ၏ ဒီဘင်ချာများ၊ ဒီဘင်ချာစတော့(ခ်)များ၊ ခေါ်ယူခြင်းမပြုရသေးသော ရင်းနှီးငွေများအပါအဝင် ယခုလက်ရှိနှင့် နောင်ရှိမည့် ပစ္စည်းများအားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကို အပေါင်ပြု၍ ထုတ်ဝေရန်။

(၃) ဤကုမ္ပဏီက ရယူထားသော အခွင့်အရေးများ သို့မဟုတ် ဝန်ဆောင်မှုများအတွက် အားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကို ငွေကြေးအားဖြင့် ပေးချေရန်၊ သို့မဟုတ် အစုရှယ်ယာများ၊ ငွေချေးစာချုပ်များ၊ ဒီဘင်ချာများ သို့မဟုတ် ဤကုမ္ပဏီ၏အခြားသော အာမခံစာချုပ်များကို ထုတ်ပေးရန်၊ ထို့အပြင် အဆိုပါ အစုရှယ်ယာများ ထုတ်ပေးရာ၌ ငွေအပြည့် ပေးသွင်းပြီးသော အစုရှယ်ယာအနေဖြင့် သော်လည်းကောင်း၊ တစ်စိတ်တစ်ဒေသ ပေးသွင်းပြီးသော အစုရှယ်ယာများ အနေဖြင့်သော်လည်းကောင်း သဘောတူညီသကဲ့သို့ ထုတ်ဝေပေးရန်နှင့် အဆိုပါ ငွေချေးစာချုပ်များ၊ ဒီဘင်ချာများ သို့မဟုတ် ကုမ္ပဏီ၏ အခြားသော အာမခံ စာချုပ်များဖြင့် ထုတ်ဝေပေးရာ၌ ခေါ်ဆိုခြင်း မပြုရသေးသော ရင်းနှီးငွေများ အပါအဝင် ဤကုမ္ပဏီ၏ ပစ္စည်းအားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကို အပေါင်ပြု၍ဖြစ်စေ၊ ထိုကဲ့သို့မဟုတ်ဘဲဖြစ်စေ ထုတ်ပေးရန်။

(၄) ဤကုမ္ပဏီနှင့် ပြုလုပ်ထားသော ကန်ထရိုက်စာချုပ်များ၊ တာဝန်ယူထားသည့်လုပ်ငန်းများ ပြီးစီးအောင် ဆောင်ရွက်စေခြင်း အလို့ငှာခေါ်ယူခြင်း မပြုရသေးသော ရင်းနှီးငွေများ အပါအဝင် ဤကုမ္ပဏီ၏ ပစ္စည်းရပ်များ အားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကို ပေါင်နှံ၍ သော်လည်းကောင်း၊ အပေါင်ပြု၍ သော်လည်းကောင်း သို့မဟုတ် အစုရှယ်ယာများအတွက် ငွေများ တောင်းခံခေါ်ယူ၍ သော်လည်းကောင်း ခွင့်ပြုရန် သို့မဟုတ် သင့်လျော်သည့်အတိုင်း ဆောင်ရွက်ရန်။

(၅) မန်နေဂျာများ၊ အတွင်းရေးမှူးများ၊ အရာရှိများ၊ စာရေးများ၊ ကိုယ်စားလှယ်များနှင့် ဝန်ထမ်းများကိုအမြဲတမ်း၊ ယာယီ သို့မဟုတ် အထူးကိစ္စရပ်များအတွက်ခန့်ထားခြင်း၊ ရပ်စဲခြင်း၊ ဆိုင်းငံ့ခြင်းများအတွက်လည်းကောင်း၊ အဆိုပါ ပုဂ္ဂိုလ်တို့၏တာဝန်များ၊ အာဏာများ၊ လစာငွေများ၊ အခြားငွေကြေးများကို သတ်မှတ်ရာ၌ လည်းကောင်း၊ အာမခံပစ္စည်းများ တောင်းခံရာ၌ လည်းကောင်း၊ သင့်လျော်သလို ဆောင်ရွက်ရန်၊ ထို့အပြင် အဆိုပါ ကိစ္စရပ်များတွက် ကုမ္ပဏီ၏ မည်သည့် အရာရှိကိုမဆို ကိစ္စရပ်အားလုံးကိုဖြစ်စေ၊ တစ်စိတ် တစ်ဒေသကို ဖြစ်စေ ဒါရိုက်တာများ၏ကိုယ်စား ဆောင်ရွက်နိုင်ရေးအတွက် တာဝန်လွှဲအပ်ရန်။

(၆) ဤကုမ္ပဏီ၏ ဒါရိုက်တာတစ်ဦးအား ဒါရိုက်တာရာထူးနှင့် တွဲဖက်၍ မန်နေဂျင်း ဒါရိုက်တာ၊ အထွေထွေ မန်နေဂျာ၊ အတွင်းရေးမှူး သို့မဟုတ် ဌာနခွဲ မန်နေဂျာအဖြစ် ခန့်ထားရန်။

(၇) မည်သည့် အစုရှင်ထံမှမဆို ၎င်းတို့၏ အစုရှယ်ယာများအားလုံးကို ဖြစ်စေ၊ အချို့အဝက်ကိုဖြစ်စေ စွန့်လွှတ်ခြင်းအား သဘောတူညီသောစည်းကမ်းများဖြင့် လက်ခံရန်။

(၈) ဤကုမ္ပဏီက ပိုင်ဆိုင်သော သို့မဟုတ် ပိုင်ဆိုင်ခွင့်ရှိသော သို့မဟုတ် အခြားအကြောင်းများကြောင့်ဖြစ်သော မည်သည့် ပစ္စည်းကိုမဆို ကုမ္ပဏီ၏ကိုယ်စား လက်ခံထိန်းသိမ်းထားရန်အတွက် မည်သည့်ပုဂ္ဂိုလ် သို့မဟုတ် ပုဂ္ဂိုလ်များကိုမဆို ခန့်ထားရန်နှင့် အဆိုပါ ယုံမှတ် အပ်နှံခြင်းများနှင့် ပတ်သက်၍ လိုအပ်သော စာချုပ်စာတမ်းများ ချုပ်ဆို ပြုလုပ်ရန်။

(၉) ဤကုမ္ပဏီ၏ အရေးအရာများနှင့် စပ်လျဉ်း၍ ဤကုမ္ပဏီက ပြုလုပ်သော သို့မဟုတ် ဤကုမ္ပဏီအပေါ် သို့မဟုတ် ဤကုမ္ပဏီ၏ အရာရှိများအပေါ် ပြုလုပ်သော တရားဥပဒေအရ စွဲဆို ဆောင်ရွက်မှုများကို တရားစွဲဆို၊ အရေးယူ၊ ခုခံကာကွယ်ရန် သို့မဟုတ် ခွင့်လွှတ်ရန်၊ ထို့အပြင် ဤကုမ္ပဏီက ရရန်ရှိသော ကြွေးမြီများနှင့် ဤကုမ္ပဏီအပေါ် တောင်းခံသော ကြွေးမြီများနှင့်ပတ်သက်၍ ပေးဆပ်ရန် အချိန်ကာလ ရွှေ့ဆိုင်းခွင့်ပြုခြင်း သို့မဟုတ် နှစ်ဦးနှစ်ဖက် သဘောတူ ကျေအေးခြင်းများ ပြုလုပ်ရန်။

(၁၀) ဤကုမ္ပဏီက ပေးရန်ရှိသော သို့မဟုတ် ရရန်ရှိသော ငွေတောင်းခံခြင်းများကို ဖြန်ဖြေရေး ခုံသမာဓိထံသို့ ဖြေရှင်းရန်အတွက် အပ်နှံရန်အပြင် ဖြန်ဖြေရေး ခုံသမာဓိ၏ ဆုံးဖြတ်ချက်အတိုင်း လိုက်နာဆောင်ရွက်ရန်။

(၁၁) ဤကုမ္ပဏီကရရန်ရှိသောတောင်းဆိုချက်၊ တောင်းခံချက်များနှင့် ကုမ္ပဏီသို့ပေးရန်ရှိသော ငွေကြေးများအတွက် ပြေစာများ ပြုလုပ် ထုတ်ပေးခြင်း၊ လျှော်ပစ်ခြင်းနှင့် အခြားသောနည်းဖြင့်ခွင့်လွှတ်ခြင်းများကို ပြုလုပ်ရန်။

(၁၂) လူမွဲစာရင်းခံရခြင်း၊ ကြွေးမြီ မဆပ်နိုင်ခြင်း၊ ကိစ္စများနှင့် ပတ်သက်၍ ကုမ္ပဏီ၏ကိုယ်စား ဆောင်ရွက်ရန်။

(၁၃) ငွေလွှဲစာတမ်းများ၊ ချက်လက်မှတ်များ၊ ဝန်ခံကတိစာချုပ်များ၊ ထပ်ဆင့် လက်မှတ်ရေးထိုးခြင်းများ၊ လျှော်ပစ်ခြင်းများ၊ ကန်ထရိုက် စာချုပ်များနှင့်စာရွက်စာတမ်းများကို ကုမ္ပဏီ၏ကိုယ်စား မည်သူက လက်မှတ် ရေးထိုးခွင့်ရှိသည်ကို စိစစ်သတ်မှတ်ရန်။

(၁၄) ဒါရိုက်တာများက သင့်လျော်သည်ဟု ယူဆပါက သင့်လျော် လျောက်ပတ်သောနည်းလမ်းများဖြင့် လတ်တလော အသုံးပြုရန် မလိုသေးသော ကုမ္ပဏီပိုင် ငွေများကို အာမခံပစ္စည်း ပါသည်ဖြစ်စေ၊ မပါသည်ဖြစ်စေ ရင်းနှီးမြှုပ်နှံထားရန်နှင့် စီမံခန့်ခွဲထားရန်။ ထို့အပြင် အချိန်ကာလအားလျော်စွာ မြှုပ်နှံထားသောငွေကို ပြန်လည်ရယူရန်နှင့် ပြင်ဆင်ပြောင်းလဲရန်။

(၁၅) ဤကုမ္ပဏီ၏ အကျိုးအတွက် ငွေကြေး ဒိုက်ထုတ် ကုန်ကျခံထားသော ဒါရိုက်တာ သို့မဟုတ် အခြား ပုဂ္ဂိုလ်များက ကုမ္ပဏီ၏ (လက်ရှိနှင့် နောင်တွင်ရှိမည့်) ပစ္စည်းများကို ဤကုမ္ပဏီ၏ အမည်ဖြင့်ဖြစ်စေ၊ ဤကုမ္ပဏီ၏ ကိုယ်စားဖြစ်စေ ပေါင်နှံခြင်းကို သင့်လျော်သည်ဟု ယူဆပါက ဆောင်ရွက်ခွင့်ပြုရန်။ အဆိုပါ ပေါင်နှံခြင်းဆိုရာ၌ ရောင်းချနိုင်သည့် အာဏာနှင့် အခြားသော သဘောတူညီထားသည့် တရားဝင် သဘော တူညီချက်များနှင့် ဥပဒေပြဋ္ဌာန်းချက်များပါ ပါဝင်သည်။

(၁၆) ဤကုမ္ပဏီကခန့်အပ်ထားသော မည်သည့်အရာရှိသို့မဟုတ် ပုဂ္ဂိုလ်ကိုမဆို အထူးအကျဆောင်ရွက်ခဲ့သည့်လုပ်ငန်း သို့မဟုတ် ဆောင်ရွက်မှုတစ်ခုအတွက် ရရှိသော အမြတ်ငွေမှ ကော်မရှင်ပေးခြင်း သို့မဟုတ် ကုမ္ပဏီ၏ အထွေထွေ အမြတ်အစွန်းမှ ခွဲဝေပေး ခြင်းများ ပြုလုပ်ရန်နှင့် အဆိုပါကော်မရှင်များ၊ အမြတ်များခွဲဝေပေးခြင်း စသည်တို့ကို ဤကုမ္ပဏီ၏လုပ်ငန်းကုန်ကျစရိတ် တစ်စိတ်တစ်ဒေသအဖြစ် သတ်မှတ်ရန်။

(၁၇) ဤကုမ္ပဏီ၏လုပ်ငန်းများ၊ အရာရှိများ ဝန်ထမ်းများနှင့် အစုရှင်များအတွက် ထုတ်ပြန်ထားသော စည်းမျဉ်းများ၊ စည်းကမ်းချက်များ၊ စည်းကမ်းဥပဒေများကို အခါအားလျော်စွာ သတ်မှတ်ခြင်း၊ ပြင်ဆင်ခြင်း၊ ဖြည့်စွက်ခြင်းများ ဆောင်ရွက်ရန်။

(၁၈) ဤကုမ္ပဏီ၏လုပ်ငန်းအတွက် ဤကုမ္ပဏီ၏အမည်ဖြင့်ဖြစ်စေ၊ ဤကုမ္ပဏီ၏ကိုယ်စားဖြစ်စေ လိုအပ်သည်ဟု ယူဆလျှင် ညှိနှိုင်းဆွေးနွေးခြင်းနှင့် ကန်ထရိုက်စာချုပ် ချုပ်ဆိုခြင်းများကို ပြုလုပ်ရန်၊ ဖျက်သိမ်းရန်နှင့် ပြင်ဆင်ရန် အပြင် အဆိုပါ ဆောင်ရွက်ချက် စာချုပ်များနှင့် ကိစ္စရပ်များကိုလည်းကောင်း ၎င်းတို့နှင့် စပ်လျဉ်းသော ကိစ္စရပ်များကို လည်းကောင်း လုပ်ကိုင်ဆောင်ရွက်ရန်။

(၁၉) ဒါရိုက်တာများက သင့်လျော်လျောက်ပတ်သည်ဟု ယူဆပါက ကုမ္ပဏီ၏ စီးပွားရေးလုပ်ငန်းတွင် အကျိုးရှိစေရန်အတွက် မည်သည့် ပြည်တွင်းပြည်ပ ပုဂ္ဂိုလ်၊ စီးပွားရေး အဖွဲ့အစည်း၊ ကုမ္ပဏီ သို့မဟုတ် ဘဏ် သို့မဟုတ် ငွေကြေးအဖွဲ့အစည်းထံမှ မဆို ငွေချေးယူရန်။

အထွေထွေအစည်းအဝေးကြီးများ

၁၅။ ကုမ္ပဏီကိုဥပဒေအရ ဖွဲ့စည်းတည်ထောင်ပြီးသည့်နေ့မှ တစ်ဆယ့်ရှစ်လအတွင်း အထွေထွေသင်းလုံးကျွတ် အစည်းအဝေးကြီးကိုကျင်းပရမည်။ ထို့နောက် ဒါရိုက်တာအဖွဲ့က သတ်မှတ်ပေးသည့် အချိန်နှင့် နေရာများတွင် ပြက္ခဒိန်နှစ်တစ်နှစ်လျှင် အနည်းဆုံးတစ်ကြိမ် (နောက်ဆုံးကျင်းပသည့် အထွေထွေအစည်းအဝေးကြီးနှင့် တစ်ဆယ့်ငါးလထက် မပိုသည့်အချိန်၌) ကျင်းပရမည်။ သင်းလုံးကျွတ် အစည်းအဝေးစတင်၍ လုပ်ငန်းအတွက် ဆွေးနွေးချိန်တွင် အစည်းအဝေးအထမြောက်ရန် သတ်မှတ်သည့် အစုရှင်အရေအတွက် မတက်ရောက်သော မည်သည့်သင်းလုံးကျွတ် အစည်းအဝေးတွင်မဆို လုပ်ငန်းနှင့် ပတ်သက်၍ ဆုံးဖြတ်ဆောင်ရွက်ခြင်းမပြုရ။ ဤတွင်အခြားနည်း သတ်မှတ်ပြဋ္ဌာန်းခြင်း မရှိလျှင် ထုတ်ဝေထားသည့် မ,တည် ရင်းနှီးငွေ အစုရှယ်ယာများ၏ ငါးဆယ်ရာခိုင်နှုန်းထက်မနည်း ပိုင်ဆိုင်ကြသည့် (နှစ်ဦးထက်မနည်းသော) အစုရှင်များ ကိုယ်တိုင်တက်ရောက်လျှင် လုပ်ငန်းကိစ္စအားလုံး ဆောင်ရွက်ရန်အတွက် အစည်းအဝေးအထမြောက်သည့်ဦးရေ ဖြစ်သည်။ အကယ်၍ ကုမ္ပဏီတွင်အစုရှင်အရေအတွက် နှစ်ဦးတည်းသာရှိသည့် ကိစ္စတွင်မူ ထိုနှစ်ဦးတည်းသည်ပင်လျှင် အစည်းအဝေး အထမြောက်ရန် သတ်မှတ်သည့် အရေအတွက် ဖြစ်စေရမည်။

အမြတ်ဝေစုများ

၁၆။ သင်းလုံးကျွတ်အစည်းအဝေးတွင် ဤကုမ္ပဏီ၏ အစုရှင်များအား ခွဲဝေပေးမည့် အမြတ်ဝေစုကို ကြေညာရမည်။ သို့ရာတွင် အမြတ်ဝေစုသည် ဒါရိုက်တာများက ထောက်ခံသော ငွေပမာဏထက် မကျော်လွန်စေရ။ သက်ဆိုင်ရာနှစ်၏ အမြတ်ပမာဏ သို့မဟုတ် အခြားမခွဲဝေရသေးသည့် အမြတ်ပမာဏမှအပ အမြတ်ဝေစုကို ခွဲဝေမပေးရ။

ရုံးဝန်ထမ်းများ

၁၇။ ကုမ္ပဏီသည် လုပ်ငန်းရုံးတစ်ခုကို ဖွင့်လှစ်၍ ဆောင်ရွက်မည်ဖြစ်ပြီး အရည်အချင်း ပြည့်မီသူပုဂ္ဂိုလ်တစ်ဦးအား အထွေထွေမန်နေဂျာအဖြစ် ခန့်အပ်ရန်နှင့် အခြားအရည်အချင်း ပြည့်မီသူများအား ရုံးဝန်ထမ်းများအဖြစ် ခန့်အပ်မည်ဖြစ်သည်။ လစာ၊ ခရီးသွားလာစရိတ်နှင့် အခြားအသုံးစရိတ်များကဲ့သို့သော ဥာဏ်ပူဇော်ခများနှင့် အခကြေးငွေများကို ဒါရိုက်တာအဖွဲ့က သတ်မှတ်မည်ဖြစ်ပြီး ၎င်းသတ်မှတ်ချက်များကို သင်းလုံးကျွတ် အစည်းအဝေးက အတည်ပြုရမည်။ အထွေထွေမန်နေဂျာသည် လုပ်ငန်းရုံး၏ ထိရောက်စွာလုပ်ငန်း လည်ပတ်မှုအားလုံးအတွက် တာဝန်ရှိစေရမည်ဖြစ်ပြီး မန်နေဂျင်း ဒါရိုက်တာအားတာဝန်ခံ၍ ဆောင်ရွက်ရမည်။

ငွေစာရင်းများ

၁၈။ ဒါရိုက်တာများသည် သင့်လျော်သည့် ငွေစာရင်းစာအုပ်များကို အောက်ဖော်ပြပါ သတ်မှတ်ချက်များနှင့်အညီ ထားသိုထိန်းသိမ်း ဆောင်ရွက်ရမည်။

(၁) ကုမ္ပဏီ၏ ရငွေ၊ သုံးငွေများ၏ ပမာဏနှင့် ၎င်းရငွေ၊ သုံးငွေများ ဖြစ်ပေါ်ခြင်းနှင့် စပ်လျဉ်းသည့် အကြောင်းကိစ္စများ။

(၂) ကုမ္ပဏီ၏ ကုန်ပစ္စည်းများ ရောင်းချခြင်းနှင့် ဝယ်ယူခြင်းများ။

(၃) ဤကုမ္ပဏီ၏ ရရန်ပိုင်ခွင့်နှင့် ပေးရန်တာဝန်များ။

၁၉။ ငွေစာရင်းစာအုပ်အားလုံးကို ဤကုမ္ပဏီ၏ မှတ်ပုံတင်ထားသော လုပ်ငန်းရုံး သို့မဟုတ် ဒါရိုက်တာများက သင့်လျော်သည်ဟု ထင်မြင်ယူဆသော အခြားနေရာတွင် သိမ်းဆည်းထားရမည်ဖြစ်ပြီး၊ ရုံးချိန်အတွင်း၌ ဒါရိုက်တာများက စစ်ဆေးနိုင်ရန် ပြသထားရမည်။

စာရင်းစစ်

၂၀။ စာရင်းစစ်များကို ခန့်အပ်ထားရမည်။ ၎င်းစာရင်းစစ်များ၏ တာဝန်သည် မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ သို့မဟုတ် အခါအားလျော်စွာ ပြင်ဆင်သတ်မှတ်သည့် စည်းမျဉ်း စည်းကမ်းများနှင့် လိုက်လျောညီထွေ ဖြစ်ရမည်။

နို့တစ်စာ

ဤကုမ္ပဏီသည် မည်သည့်အစုရှင်ထံသို့မဆို နို့တစ်စာကို လက်ရောက်ပေးအပ်ခြင်း သို့မဟုတ် နို့တစ်စာပါသော စာကို စာတိုက်ခ ကြိုတင်ပေးထား၍ ၎င်းအစုရှင်ထံ မှတ်ပုံတင်လိပ်စာအတိုင်း စာတိုက်မှတစ်ဆင့် လိပ်မူ ပေးပို့ခြင်းအားဖြင့် ပေးပို့နိုင်သည်။

တံဆိပ်

ဒါရိုက်တာများသည် တံဆိပ်ကို လုံခြုံစွာထိန်းသိမ်းထားရန်အတွက် စီမံဆောင်ရွက်ရမည်။ ထိုတံဆိပ်ကို ဒါရိုက်တာများကကြိုတင်ပေးအပ်ထားသည့် ခွင့်ပြုချက်ဖြင့်မှတစ်ပါး၊ ထို့အပြင် အနည်းဆုံး ဒါရိုက်တာတစ်ဦး ရှေ့မှောက်တွင်မှတစ်ပါး မည်သည့်အခါမျှ မသုံးရ။ တံဆိပ်ရိုက်နှိပ်ထားသည့် စာရွက်စာတမ်းတိုင်းတွင် ထိုဒါရိုက်တာက လက်မှတ်ရေးထိုးရမည်။

လျော်ကြေး

မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေ ပုဒ်မ ၈၆ (ဂ) တွင် ဖော်ပြပါရှိသည့် ပြဋ္ဌာန်းချက်များ၊ လက်ရှိတရားဝင်တည်ဆဲဥပဒေပြဋ္ဌာန်းချက်များနှင့် မဆန့်ကျင်စေဘဲ ကုမ္ပဏီ၏ ဒါရိုက်တာ၊ စာရင်းစစ်၊ အတွင်းရေးမှူး သို့မဟုတ် အခြားအရာရှိ တစ်ဦးဦးမှာ မိမိ၏ တာဝန် ဝတ္တရားများကို ဆောင်ရွက်ရာ၌ဖြစ်စေ၊ ထိုတာဝန် ဝတ္တရားများနှင့် စပ်လျဉ်း၍ဖြစ်စေ ကျခံခဲ့ရသည့်စရိတ်များ၊ တောင်းခံငွေများ၊ ဆုံးရှုံးငွေများ၊ ကုန်ကျငွေများနှင့် ကြွေးမြီတာဝန်များအတွက် ကုမ္ပဏီထံမှ လျော်ကြေး ရထိုက်ခွင့်ရှိစေရမည်။

ဖျက်သိမ်းခြင်း

ကုမ္ပဏီ၏ အထွေထွေအစည်းအဝေး ဆုံးဖြတ်ချက်ဖြင့် ကုမ္ပဏီအား ဖျက်သိမ်းနိုင်သည်။ ယင်းသို့ ဖျက်သိမ်းရာတွင် မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေများနှင့် ယင်းဥပဒေများအား အခါအားလျော်စွာ ပြင်ဆင်ပြောင်းလဲထားသည့် တရားဥပဒေများတွင် ပါဝင်သည့် စည်းမျဉ်းများအတိုင်း လိုက်နာပြုလုပ်ရမည်။

❖ ❖ ❖ ❖ ❖ ❖ ❖

အောက်တွင် အမည်၊ နိုင်ငံသား၊ နေရပ်နှင့် အကြောင်းအရာ စုံလင်စွာပါသော ဇယားတွင် လက်မှတ်ရေးထိုးသူ ကျွန်ုပ်တို့ ကိုယ်စီကိုယ်ငှသည် ဤသင်းဖွဲ့စည်းမျဉ်းအရ ကုမ္ပဏီတစ်ခုဖွဲ့စည်းရန် လိုလားသည့်အလျောက် ကျွန်ုပ်တို့၏ အမည်အသီးသီးနှင့် ယှဉ်တွဲ၍ ပြထားသော အစုရှယ်ယာများကို ကုမ္ပဏီ၏ မတည်ရင်းနှီးငွေတွင် ထည့်ဝင်ရယူကြရန် သဘောတူကြပါသည်။

စဉ်	အစုထည့်ဝင်သူများ၏ အမည်၊ နေရပ်လိပ်စာနှင့် အလုပ်အကိုင်	နိုင်ငံသားနှင့် အမျိုးသား မှတ်ပုံတင်အမှတ်	ဝယ်ယူသော အစုရှယ်ယာ ဦးရေ	ထိုးမြဲလက်မှတ်
၁။	ဒေါ်မြင့်မြင့်သောင်း ၉၂၊ ရတနာမိုင်လမ်း ၊ တမာဂွတ်မြို့နယ်၊ ရန်ကုန်မြို့။ (ကုန်သည်)	မြန်မာ ၆/ထဝန (နိုင်) ၀၂၆၅၃၃	၂၁	
၂။	ဒေါ်သီတာသော် ၁၆၊ တိုက်လက်လမ်း ၊ လင်း တောင်ရပ်ကွက် စမ်း ချောင်း မြို့နယ်၊ ရန်ကုန်မြို့။ (ကုန်သည်)	မြန်မာ ၁၂/စခန (နိုင်) ၀၀၉၆၉၃	၂၁	
၃။				

ရန်ကုန်။ နေ့စွဲ၊ ၂၀၀၉ ခုနှစ်၊ ဖေဖော်ဝါရီ လ၊ [illegible] ရက်။

အထက်ပါ လက်မှတ်ရှင်များသည် ကျွန်ုပ်၏ ရှေ့မှောက်တွင် လက်မှတ်ရေးထိုးကြပါသည်။

ဦးငြိမ်းတင့် L.L.B
တရားရုံးချုပ်ရှေ့နေ
မှတ် ၁၄ တိုက် ၁၆ ပြည်ရိပ်မွန်အိမ်ရာ၊ [illegible]

THE MYANMAR COMPANIES ACT

PRIVATE COMPANY LIMITED BY SHARES

Memorandum Of Association

OF

GLOBAL STAR COMPANY LIMITED

❖ ❖ ❖ ❖ ❖ ❖ ❖

I. The name of the Company is GLOBAL STAR COMPANY LIMITED.

II. The registered office of the Company will be situated in the Union of Myanmar.

III. The objects for which the Company is established are as on the next page.

IV. The liability of the members is limited.

V. The authorised capital of the Company is Ks. 100,000,000 /- (Kyats ONE HUNDRED MILLION Only) divided into (1,000) shares of Ks. 100,000 /- (Kyats ONE HUNDRED THOUSAND Only) each, with power in General Meeting either to increase, reduce or alter such capital from time to time in accordance with the regulations of the Company and the legislative provisions for the time being in force in this behalf.

(1) To carry on the trading business of importers, exporters, wholesalers and retailers of the following commodities and products permitted by the Government, solely on its own or in join-venture with any foreign or local partners.

(a) Agricultural and farm produces.

(b) Forest products and value-added wood-based products.

(c) Animal by-products and Animal feed.

(d) Marine products.

(e) Fertilizer and insecticides.

(f) Chemicals and dyes.

(g) Factory utencils and raw material

(h) Household goods.

(i) Personal goods.

(j) Construction materials and paints.

(k) Electrical and electronic products.

(l) Vehicles, Machinery and spares.

(m) Tools and implement.

(n) Medicines and medical equipment.

(o) Foodstuff and general merchandise.

(p) Textile and garment.

(q) Paper, stationery and photographic stores.

(r) Office equipment and educational supplies.

(2) To borrow money for the benefit of the Company's business from any person, firm, company, bank or financial organization in the manners that the Company shall think fit.

PROVISO: - *Provided that the Company shall not exercise any of the above objects whether in the Union of Myanmar or elsewhere, save in so far as it may be entitled so as to do in accordance with the Laws, Orders and Notifications in force from time to time and then only subject to such permission and or approval as may be prescribed by the Laws, Orders and Notifications of the Union of Myanmar for the time being in force.*

We, the several persons, whose names, nationalities, addresses and descriptions are subscribed below, are desirous of being formed into a Company in pursuance of this Memorandum of Association, and we respectively agree to take the number of shares in the capital of the Company set opposite our respective names.

Sr. No:	Name, Address and Occupation of Subscribers	Nationality & N. R. C No.	Number of shares taken	Signatures
1.	DAW MYINT MYINT THAUNG 92,YADANAR MYAING STREET, KAMAYUT TOWNSHIP, YANGON. (MERCHANT)	MYANMAR 6/HTA-WA-NA (NAING) 026533	25	[signature]
2.	DAW THIDA THAW 16,KYAIK LATT STREET,LIN TAUNG WARD, SANCHAUNG TOWNSHIP, YANGON. (MERCHANT)	MYANMAR 12/SA-KHA-NA(NAING) 009693	25	[signature]
3.				

Yangon. Dated the 24th day of February 20 09

It is hereby certified that the persons mentioned above put their signatures in my presence.

U NYEIN TIN
LL.B
ADVOCATE

အမှတ် ၁၄ ထိုင်း ၁၆ ပြည်ထောင်စုမြန်မာနိုင်ငံ

THE MYANMAR COMPANIES ACT

PRIVATE COMPANY LIMITED BY SHARES

Articles Of Association

OF

GLOBAL STAR COMPANY LIMITED

❖ ❖ ❖ ❖ ❖ ❖ ❖

1. The regulations contained in Table 'A' in the First Schedule to the Myanmar Companies Act shall apply to the Company save in so far as such regulations which are inconsistent with the following Articles. The compulsory regulations stipulated in Section 17 (2) of the Myanmar Companies Act shall always be deemed to apply to the Company.

PRIVATE COMPANY

2. The Company is to be a Private Company and accordingly following provisions shall have effect:-

   (a) The number of members of the Company, exclusive of persons who are in the employment of the Company, shall be limited to fifty.

   (b) Any invitation to the public to subscribe for any share or debenture or debenture stock of the Company is hereby prohibited.

CAPITAL AND SHARES

3. The Authorised Capital of the Company is Ks. 100,000,000 /- (Kyats ONE HUNDRED MILLION Only) divided into(1,000) shares of K 100,000 /- (Kyats ONE HUNDRED THOUSAND Only) each, with power in General Meeting either to increase, reduce or alter such capital from time to time in accordance with the regulations of the Company and the legislative provisions for the time being in force in this behalf.

4. Subject to the provisions of the Myanmar Companies Act the shares shall be under the control of the Directors, who may allot or otherwise dispose of the same to such persons and on such terms and conditions as they may determine.

5. The certificate of title to share shall be issued under the Seal of the Company, and signed by the General Manager or some other persons nominated by the Board of Directors. If the share certificate is defaced, lost or destroyed, it may be renewed on payment of such fee, if any, and on such terms, if any, as to evidence and indemnity as the Directors may think fit. The legal representative of a deceased member shall be recognised by the Directors.

6. The Directors may, from time to time make call upon the members in respect of any money unpaid on their shares, and each member shall be liable to pay the amount of every call so made upon him to the persons, and at the times and places appointed by the Directors. A call may be made payable by instalments or may be revoked or postponed as the Directors may determine.

DIRECTORS

7. Unless otherwise determined by a General Meeting the number of Directors shall not be less than (2) and not more than (9).

The First Directors shall be:-

(1) DAW MYINT MYINT THAUNG

(2) DAW THIDA THAW

(3)

(4)

(5)

8. The Directors may from time to time appoint one of their body to the office of the Managing Director for such terms and at such remuneration as they think fit and he shall have all the powers delegated to him by the Board of Directors from time to time.

9. The qualification of a Director shall be the holding of at least (-) shares in the Company in his or her own name and it shall be his duty to comply with the provision of Section (85) of the Myanmar Companies Act.

10. The Board of Directors may in their absolute and uncontrolled discretion refuse to register any proposed transfer of shares without assigning any reason.

PROCEEDINGS OF DIRECTORS

11. The Director may meet together for the despatch of business, adjourn and otherwise regulate their meeting as they think fit and determine the quorum necessary for the transaction of business. Unless otherwise determined, two shall form a quorum. If any question arising at any meeting the Managing Director's decision shall be final. When any matter is put to a vote and if there shall be an equality of votes, the Chairman shall have a second or casting vote.

12. Any Director may at any time summon a meeting of Directors.

13. A resolution in writing signed by all the Directors shall be as effective for all purposes as a resolution passed out at meeting of the Directors, duly called, held and constituted.

POWERS AND DUTIES OF DIRECTORS

14. Without prejudice to the general power conferred by Regulation 71 of the Table "A" of the Myanmar Companies Act, it is hereby expressly declared that the Directors shall have the following powers, that is to say power:-

(1) To purchase or otherwise acquire for the Company any property, rights or privileges which the Company is authorized to acquire at such price, and generally on such terms and conditions as they think fit; also to sell, lease, abandon or otherwise deal with any property, rights or privileges to which the Company may be entitled, on such terms and conditions as they may think fit.

(2) To raise, borrow or secure the payment of such sum or sums in such manner and upon such terms and conditions in all respects as they think fit and in particular by the issue of debentures or debenture stocks of the Company charged upon all or any part of the property of the Company (both present and future) including its uncalled capital for the time being.

(3) At their discretion, to pay for any rights acquired or services rendered to the Company, either wholly or partially in cash or in shares, bonds, debentures or other securities of the Company and any such shares may be issued either as fully paid up or with such amount credited as paid up thereon as may be agreed upon; and any such bonds, debentures or other securities may be either specifically charged upon all or any part of the property of the Company and its uncalled capital or not so charged.

(4) To secure the fulfilment of any contract or engagement entered into by the Company by mortgage or charge upon all or any of the property of the Company and its uncalled capital for the time being or by granting calls on shares or in such manner as they may think fit.

(5) To appoint at their discretion, remove or suspend such Managers, Secretaries, Officers, Clerks, Agents and Servants for permanent, temporary or special services as they may from time to time think fit and to determine their duties and powers and fix their salaries or emoluments and to require security in such instances in such amount as they think fit and to depute any officers of the Company to do all or any of these things on their behalf.

(6) To appoint a Director as Managing Director, General Manager, Secretary or Departmental Manager in conjunction with his Directorship of the Company.

(7) To accept from any member on such terms and conditions as shall be agreed on the surrender of his shares or any part thereof.

(8) To appoint any person or persons to accept and hold in trust for the Company any property belonging to the Company or in which it is interested or for any other purposes and to execute and do all such deeds and things as may be requisite in relation to any such trust.

(9) To institute, conduct, defend of abandon any legal proceedings by or against the Company or its officers or otherwise concerning the affairs of the Company and also to compound and allow time for payment or satisfaction of any debts due to or of any claims and demands by or against the Company.

(10) To refer claims and demands by or against the Company to arbitration and to observe and perform the awards.

(11) To make and give receipts, releases and other discharges for money payable to the Company and for the claims and demands of the Company.

(12) To act on behalf of the Company in all matters relating to bankruptcy and insolvency.

(13) To determine who shall be entitled to sign bills of exchange, cheques, promissory notes, receipts, endorsements, releases, contracts and documents for or on behalf of the Company.

(14) To invest, place on deposit and otherwise deal with any of the moneys of the Company not immediately required for the purpose thereof, upon securities or without securities and in such manners as the Directors may think fit, and from time to time vary or realize such investments.

(15) To execute in the name and on behalf of the Company in favour of any Director or other person who may incur or be about to incur any personal liability for the benefit of the Company, such mortgages of the Company's property (present and future) as they think fit and any such mortgage may contain a power of sale and such other powers, covenants and provisions as shall be agreed on.

(16) To give any officer or other person employed by the Company a commission on the profits of any particular business or transaction or a share in the general profit of the Company and such commission or share of profit shall be treated as part of the working expenses of the Company.

(17) From time to time, to make, vary and repeal bye-laws for the regulation of the business of the Company, the officers and servants or the members of the Company or any section thereof.

(18) To enter into all such negotiations and contracts and rescind and vary all such contracts and execute and do all such acts, deeds and things in the name and on behalf of the Company as they may consider expedient for or in relation to any of the matter aforesaid or otherwise for the purposes of the Company.

(19) To borrow money for the benefit of the Company's business from any person, firm or company or bank or financial organization of local and abroad in the manner that the Directors shall think fit.

GENERAL MEETINGS

15. A general meeting shall be held within eighteen months from the date of its incorporation and thereafter at least once in every calendar year at such time (not being more than fifteen months after the holding of the last preceding general meeting) and places as may be fixed by the Board of Directors. No business shall be transacted at any general meeting unless a quorum of members' is presented at the time when the meeting proceeds to business, save as herein otherwise provided Member holding not less than 50 percent of the issued shares capital (not less than two members) personally present, shall form a quorum for all purposes. And if and when in the case of there are only two number of members in the Company, those two members shall form a quorum.

DIVIDENDS

16. The Company in general meeting may declare a dividend to be paid to the members, but no dividend shall exceed the amount recommended by the Directors. No dividends shall be paid otherwise than out of the profits of the year or any other undistributed profits.

OFFICE STAFF

17. The Company shall maintain an office establishment and appoint a qualified person as General Manager and other qualified persons as office staffs. The remunerations and allowances such as salaries, travelling allowances and other expenditures incidental to the business shall be determined by the Board of Directors, and approved by the general meeting. The General Manager shall be responsible for the efficient operation of the office in every respect and shall be held accountable at all times to the Managing Director.

ACCOUNTS

18. The Directors shall cause to be kept proper books of account with respect to:-
    (1) all sums of money received and expended by the Company and the matters in respect of which the receipts and expenditures take place;
    (2) all sales and purchases of goods by the Company;
    (3) all assets and liabilities of the Company.

19. The books of account shall be kept at the registered office of the Company or at such other place as the Directors shall think fit and shall be opened to inspection by the Directors during office hours.

AUDIT

20. Auditors shall be appointed and their duties regulated in accordance with the provisions of the Myanmar Companies Act or any statutory modifications thereof for the time being in force.

NOTICE

21. A notice may be given by the Company to any member either personally or sending it by post in a prepaid letter addressed to his registered address.

THE SEAL

22. The Directors shall provide for the safe custody of the Seal, and the Seal shall never be used except by the authority of the Directors previously given, and in the presence of one Director at least, who shall sign every instrument to which the Seal is affixed.

INDEMNITY

23. Subject to the provisions of Section 86 (C) of the Myanmar Companies Act and the existing laws, every Director, Auditor, Secretary or other officers of the Company shall be entitled to be indemnified by the Company against all costs, charges, losses, expenses and liabilities incurred by him in the execution and discharge of the duties or in relation thereto.

WINDING-UP

24. Subject to the provisions contained in the Myanmar Companies Act and the statutory modification thereupon, the Company may be wound up voluntarily by the resolution of General Meeting.

❖ ❖ ❖ ❖

We, the several persons, whose names, nationalities, addresses and descriptions are subscribed below, are desirous of being formed into a Company in pursuance of this Articles of Association, and we respectively agree to take the number of shares in the capital of the Company set opposite our respective names.

Sr. No:	Name, Address and Occupation of Subscribers	Nationality & N. R. C. No.	Number of shares taken	Signatures
1.	DAW MYINT MYINT THAUNG 92, YADANAR MYAING STREET, KAMAYUT TOWNSHIP, YANGON. (MERCHANT)	MYANMAR 6/HTA-WA-NA (NAING) 026533	25	(signature)
2.	DAW THIDA THAW 16, KYAIK LATT STREET, LIN TAUNG WARD, SANCHAUNG TOWNSHIP, YANGON. (MERCHANT)	MYANMAR 12/SA-KHA-NA(NAING) 009693	25	(signature)
3.				

Yangon. Dated the 24th day of February 2009

It is hereby certified that the persons mentioned above put their signatures in my presence.

U NYEIN TIN
LL.B
ADVOCATE

GLOBAL STAR COMPANY LIMITED.

No. 2, Bayint Naung Main Road, Ywama Curve, Block (2), Hlaing Township, Yangon, Myanmar.
Tel : 95 - 1 - 503873, 514223 Fax : 95 - 1 - 504528

GLOBAL STAR COMPANY LIMITED
No GSCL/2015/0654
Date 8.9.2015
YANGON, MYANMAR

သို့

ညွှန်ကြားရေးမှူးချုပ်
ရင်းနှီးမြှုပ်နှံမှုနှင့်ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန
အမျိုးသားစီမံကိန်းနှင့်စီးပွားရေးဖွံ့ဖြိုးတိုးတက်မှုဝန်ကြီးဌာန
ရန်ကုန်မြို့။

အကြောင်းအရာ။ ။ ပုံစံ(၆)နှင့်(၂၆) အားတင်သွင်းခြင်း။

ကျွန်တော်များ Global Star Co., Ltd. တွင်ဦးသူရိန်အောင် (၁၂/ကမရ(နိုင်)၀၅၀၈၃၉) အား အစုရှယ်ယာထည့်ဝင်ရန်နှင့် ဒါရိုက်တာခန့်အပ်ရန် အစည်းအဝေးကို ကျင်းပပြီးဖြစ်ပါသဖြင့် အစည်းအဝေး ဆုံးဖြတ်ချက်နှင့်အတူ ပုံစံ(၆)နှင့်(၂၆)ကို တင်ပြအစီရင်ခံအပ်ပါသည်။

ကျသင့်သည့်မှတ်ပုံတင်ကြေးများကိုလည်း ပေးသွင်းမည်ဖြစ်ပါသည်။

လေးစားစွာဖြင့်

IHIDA THAW
DIRECTOR
GLOBAL STAR CO., LTD.

GLOBAL STAR COMPANY LIMITED.
No. 2, Bayint Naung Main Road, Ywama Curve, Block (2), Hlaing Township, Yangon, Myanmar.
Tel : 95 - 1 - 503873, 514223
Fax : 95 - 1 - 504528

ဒါရိုက်တာအဖွဲ့အစည်းအဝေးမှတ်တမ်း

ကျင်းပသည့်နေ့ ။ ။ ၂၅.၈.၂၀၁၅
ကျင်းပသည့်အချိန် ။ ။ နံနက်(၁၀)နာရီ
ကျင်းပသည့်နေရာ ။ ။ အမှတ် ၂၊ ဘုရင့်နောင်လမ်းမကြီး၊ရွာမကွေ့၊ (၂) ရပ်ကွက်၊ လှိုင်မြို့နယ်၊ ရန်ကုန်မြို့။

အစည်းအဝေးတက်ရောက်သူများ

၁။ ဦးကျော်ဇောအောင် ၁၂/စခန(နိုင်)၀၄၃၇၃၆
၂။ ဒေါ်မြင့်မြင့်သောင်း ၆/ထဝန(နိုင်)၀၂၆၅၃၃
၃။ ဒေါ်သီတာသော် ၁၂/စခန(နိုင်)၀၀၉၆၉၃
၄။ ဦးအောင်ကြီး ၁၄/ဝခမ(နိုင်)၀၀၇၄၄၄

အစည်းအဝေးဆုံးဖြတ်ချက်

Global Star Co., Ltd. တွင် ဦးသူရိန်အောင် မှတ်ပုံတင်အမှတ် (၁၂/ကမရ(နိုင်)၀၅၀၈၃၉) အား အစုရှယ်ယာ (၉၂၅ စု) (တန်ဘိုး ကျပ် ၉၂,၅၀၀,၀၀၀/-) ကိုထည့်ဝင်ရန်နှင့် ဒါရိုက်တာအဖြစ် ခန့်အပ်ရန် တင်ပြလာခြင်းအပေါ် သဘောတူကြောင်း ဆုံးဖြတ်ကြပါသည်။

မှတ်တမ်းတင်သူ

IHIDA THAW
DIRECTOR
GLOBAL STAR CO., LTD.
ဒေါ်သီတာသော်
ဒါရိုက်တာ

အတည်ပြုသူ

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD.
ဦးကျော်ဇောအောင်
မန်နေးဂျင်းဒါရိုက်တာ

FORM VI

RETURN OF ALLOTMENTS
THE MYANMAR COMPANIES ACT.

(See Section 104)

(To be filed with the Registrar within one month after the allotment is made)

Return of allotment from the 25th of AUGUST ~~200~~ 2015

on the of 200 of the * GLOBAL STAR COMPANY LIMITED.

Made pursuant to Section 104 (1)

Number of the shares allotted payable in cash	.... 925 SHARES
" " " "	....
Nominal amount of the shares so allotted	.... KS. 92,500,000/-
" " " "	....
Amount paid or due and payable on cash such share	.... KS. 100,000/- (FULLY PAID UP)
" " " "	....

Number of ordinary shares allotted for a consideration other than cash

Nominal amount to be ordinary shares so allotted ....

Amount to be treated as paid on each such share ....

The consideration for which such share have been allotted is as follow : -

---

NOTE In making a return of allotments under Section 104 (1) the Myanmar Companies Act., it is to be noted that -

1. When a return include several allotments made on different dates, the actual date of only the first and last of such allotment should be entered at the tip of the front page, and the registration of the return should be effected within one month of the first date.
2. When a return relates to one allotment only, made on one particular date, that date only should be inserted and the spaces for the second date struck out and the world made substituted for the world "From" after the world "allotments" above.

Here insert name of Company.

Distinguish between preference, ordinary, or other description of shares.

Presented for filing by : U KYAW ZAW AUNG (MANAGING DIRECTOR)

Name, Address and Description of Allotees

Name & N.R.C No	Address	Description	Number of the shares allotted	
			Preference	Ordinary
U THURANE AUNG 12/KA MA YA(NAING) 050839	NO.105,UNIVERSITY AVENUE ROAD,KAMAYUT TOWNSHIP,YANGON.	MERCHANT		925 SHARES

Signature

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD.

Date 25/8/201

FORM XXVI

PARTICULARS OF DIRECTORS, MANAGERS AND MANAGING AGENTS AND OF ANY CHANGES THEREIN

(Myanmar Companies Act, See Section 87)

Name of Company : GLOBAL STAR COMPANY LIMITED.

Presented by : U KYAW ZAW AUNG

The Present Christian name or names of surnames	Nationality, National Registration Card No.	Usual Residential Address	Other Business Occupation	Changes
U KYAW ZAW AUNG	MYANMAR 12/SA KHA NA(NAING) 043736	NO.68,THANDAR STREET,WARD NO.1,KAMAYUT TOWNSHIP,YANGON,MYANMAR.	MERCHANT	MANAGING DIRECTOR
DAW THIDA THAW	MYANMAR 12/SA KHA NA(NAING) 009693	NO.16,KYAIK LAT STREET,LIN TAUNG WARD, SANCHAUNG TOWNSHIP,YANGON,MYANMAR.	MERCHANT	DIRECTOR
DAW MYINT MYINT THAUNG	MYANMAR 6/HTA WA NA(NAING) 026533	NO.92,YADANA MYAING STREET,KAMAYUT TOWNSHIP, YANGON,MYANMAR.	MERCHANT	DIRECTOR
U AUNG GYI	MYANMAR 14/WA KHA MA(NAING) 007444	NO.19,THURANE YEIK MON,YWAMA CURVE,BLOCK NO.2, HLAING TOWNSHIP,YANGON,MYANMAR.	MERCHANT	DIRECTOR
U THET TIN	MYANMAR 7/PA KHA NA(NAING) 187383	32,165TH STREET,TAMWE GYI(B) BLOCK, TAMWE TOWNSHIP,YANGON,MYANMAR.	MERCHANT	GENERAL MANAGER
U THURANE AUNG	MYANMAR 12/KA MA YA(NAING) 050839	NO.105,UNIVERSITY AVENUE ROAD,KAMAYUT TOWNSHIP,YANGON,MYANMAR.	MERCHANT	APPOINTED AS DIRECTOR WITH EFFECT FROM 25/8/2015

NOTE : (1) A Complete list of the Directors or Managers or Managing Agents shown as existing in the last particulars.

(2) A note of the changes since the last list should be made in the column for " Changes" by placing against the new Director's name the word " in place of .... and by writing against any former Director's name the word "dead " " resigned" or as the case may be giving the date of change against the entry.

Signature ... KYAW ZAW AUNG MANAGING DIRECTOR

Designation GLOBAL STAR CO., LTD.

Dated this 25/8/2015

MYAYNIGONE BRANCH
NO-272,PYAY ROAD,DNH TOWER,MYAYNIGONE(NORTH)SANCHUNG
Ph : 534829,505496
Fax : 505494,505495

Date : 03 July , 2015

ACCOUNT NO. : 0291130000086

NAME : GLOBAL STAR CO,LTD
NRC :
ADDRESS : NO(2),BAYINT NAUNG RD,YWAMA CURVE,BLOCK(2),HLAING SANCHAUNG
PHONE : 503873/514223

Statement Of Transaction For The Date Between 01/04/2015 And 03/07/2015

Date_Time	Description	Withdrawal Amount	Deposit Amount	Balance
01 [illegible] 2015	Opening Balance			2,000,010,000.00
30 04 2015	Closing Balance			2,000,010,000.00
01 05 2015	Opening Balance			2,000,010,000.00
31 05 2015	Closing Balance			2,000,010,000.00
01 06 2015	Opening Balance			2,000,010,000.00
03 07 2015	Closing Balance			2,000,010,000.00

No. of Withdrawals : 0
No. of Deposits : 0

Thank You For Banking With MYAYNIGONE BRANCH

Please report any descrepencies found on your statement immediately.
N.B - Statement will not be sent unless there is a change of transaction.

For MYAYNIGONE BRANCH

Asst: / DY Manager

ခွင့်ပြုလုပ်ငန်း (၅) မျိုး

၁။ လယ်ယာကိုင်းကျွန်းနှင့် ဥယျာဉ်ခြံမြေ ထွက်ကုန်ပစ္စည်းများ ။

၂။ သစ်တောထွက်ပစ္စည်းနှင့် တပ်ဆင်ထိုး၊ တန်ဖိုးမြှင့်သစ်အခြေခံကုန်ပစ္စည်းများ ။

၃။ စက်မှုသုံး ပစ္စည်းများနှင့် ကုန်ကြမ်းပစ္စည်းများ ။

၄။ ဆောက်လုပ်ရေးလုပ်ငန်းသုံး ပစ္စည်းများနှင့် သုတ်ဆေးများ ။

၅။ စားသောက်ကုန်နှင့် အထွေထွေကုန်ပစ္စည်းများ ။

CHANGE OF ADDRESS

NO.2,BAYINTNAUNG MAIN ROAD,
WARD NO.2,HLAING T/S,YANGON.

(4) 27-2-2013 to 28-7-2013 (ယာယီ)

(5) 29.7.2013 to 26.2.2018
ပေ.၂သက်တမ်းအရ

(လက်ထောက်ညွှန်ကြားရေးမှူး)

(လက်ထောက်ညွှန်ကြားရေးမှူး)

(လက်ထောက်ညွှန်ကြားရေးမှူး)

GLOBAL STAR COMPANY LIMITED.

No. 2, Bayint Naung Main Road, Ywama Curve, Block (2), Hlaing Township, Yangon, Myanmar.

Tel : 95 - 1 - 503873, 514223 Fax : 95 - 1 - 504528

GLOBAL STAR COMPANY LIMITED
YANGON, MYANMAR
Date

သို့

ညွှန်ကြားရေးမှူးချုပ်
ရင်းနှီးမြှုပ်နှံမှုနှင့်ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန
အမျိုးသားစီမံကိန်းနှင့်စီးပွားရေးဖွံ့ဖြိုးတိုးတက်မှုဝန်ကြီးဌာန
ရန်ကုန်မြို့။

အကြောင်းအရာ ။ ။ **အစည်းအဝေးဆုံးဖြတ်ချက်ကို တင်သွင်းခြင်း။**

ကျွန်တော်များ GLOBAL STAR CO., LTD. ၏နှစ်ပတ်လည်အစည်းအဝေးကို ကျင်းပပြီးဖြစ်ပါသဖြင့် ပုံစံ(င)ကို တင်ပြအစီရင်ခံအပ်ပါသည်။

ကျသင့်သည့်မှတ်ပုံတင်ကြေးများကိုလည်း ပေးသွင်းမည်ဖြစ်ပါသည်။

လေးစားစွာဖြင့်

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD.

GLOBAL STAR COMPANY LIMITED.

No. 2, Bayint Naung Main Road, Ywama Curve, Block (2), Hlaing Township, Yangon, Myanmar.
Tel : 95 - 1 - 503873, 514223 Fax : 95 - 1 - 504528

GLOBAL STAR COMPANY LIMITED, YANGON, MYANMAR
Date 21.8.2015

သို့

ညွှန်ကြားရေးမှူးချုပ်
ရင်းနှီးမြှုပ်နှံမှုနှင့်ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန
အမျိုးသားစီမံကိန်းနှင့်စီးပွားရေးဖွံ့ဖြိုးတိုးတက်မှုဝန်ကြီးဌာန
ရန်ကုန်မြို့။

အကြောင်းအရာ ။ ။ **အစည်းအဝေးဆုံးဖြတ်ချက်ကို တင်သွင်းခြင်း။**

ကျွန်တော်များ GLOBAL STAR CO., LTD. ၏နှစ်ပတ်လည်အစည်းအဝေးကို ကျင်းပပြီးဖြစ်ပါသဖြင့် ပုံစံ(င)ကို တင်ပြအစီရင်ခံအပ်ပါသည်။

ကျသင့်သည့်မှတ်ပုံတင်ကြေးများကိုလည်း ပေးသွင်းမည်ဖြစ်ပါသည်။

လေးစားစွာဖြင့်

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD.

THE MYANMAR COMPANIES ACT

LIST OF SHAREHOLDERS.

FORM E.

(As required by part II of the Act. See Section 32)

010622

* * ● * *

SUMMARY OF SHARE CAPITAL AND SHARES OF THE

GLOBAL STAR CO., LTD. COMPANY LIMITED

Made up to the 26TH *day of* AUGUST *being the day of the first Ordinary General Meeting in* 2015

Nominal Share Capital - K 100,000,000/-	
Divided into * Shares of K. 100,000/- each	
and Shares of K. each	
and Shares of K. each	
and Shares of K. each	
Total number of shares taken up to the 26TH day AUG 2015	75 SHARES
(This number must agree, with the total shown in the list; as held by existing members)	
Numbers of Shares issued subject to payment wholly in cash	75 SHARES
Numbers of Shares issued as fully paid-up otherwise than in cash	NIL
Numbers of Shares issued as partly paid-up to the extent of per share Otherwise than in cash	
● There has been called up on each of Shares K.	100,000/-
There has been called up on each of Shares K.	NIL
There has been called up on each of Shares K.	NIL
+ Total amount of calls received including payments on application and allotment ... ... K.	7,500,000/- (FULLY PAID UP)
Total amount agree to be considered as paid shares which have been issued as fully paid up otherwise than in cash .... K.	NIL
Total amount agreed to be considered as paid shares which have been issued as Partly paid-up to the extent of .... per Share ... . K.	NIL
Total amount of Calls unpaid ... . K.	NIL
Total amount of sums paid by way of commission in respect of shares or debentures or allowed by way of discount since date of last summary ... ... K.	NIL
Total amount of shares forfeited ... ... K.	NIL
Aggregate number of shares forfeited ... ... K.	NIL
Total amount of Shares and stock for which share-warrants are outstanding ... ... K.	NIL
Total amount of share-warrants issued ... ... K.	NIL
Do do surrendered since date of last summary K.	NIL
Number of shares or amount of stock comprised in each share-warrant ... ... K.	NIL
Total amount of debt due from the Company in respect of all Mortgages and Charges which are required to be registered with the Registrar under this Act ... ... K.	NIL

When there are shares of different kind of mounts (e.g., Preference and Ordinary or K.2000 or 1000) state the numbers and nominal values separately.

● Where various amounts have been called, or there are shares of different kinds state them separately.

\+ Include what has been received or forfeited as on existing shares.

FORM E-Contd. **LIST OF PERSONS HOLDING SHARES IN THE** GLOBAL

On the 26TH day of AUGUST

And of Persons who have held shares here in at any time

Addresses and account

NAMES ADDRESSES AND OCCUPATIONS.

Folio in register	Name in Full	Father's Name.	Address	Occupation or Casts	*Nationally
1.	U KYAW ZAW AUNG	U HTAY AUNG	68,THANDAR STREET, WARD NO.1,KAMAYUT TOWNSHIP,YANGON, MYANMAR.	MERCHANT	MYANMAR
2.	DAW MYINT MYINT THAUNG	U THAUNG SHEIN	92,YADANA MYAING STREET,KAMAYUT TOWNSHIP,YANGON, MYANMAR.	MERCHANT	MYANMAR
3.	DAW THIDA THAW	U THAW DAR MYINT	16,KYAIK LAT STREET,LIN TAUNG WARD,SANCHAUNG TOWNSHIP,YANGON, MYANMAR.	MERCHANT	MYANMAR

• State the aggregate number of shares forfeited (if any)

- The aggregate number of shares held and not the distinctive numbers, must be stated, and the column must be added up throughout so as to make one total to agree with that stated in the summary to have been taken up.

When the shares are of different classes, these columns may be subdivided, so that the number of each class held or transferred may be shown.

FORM E

STAR CO., LTD.
....**COMPANY LIMITED**
2015
....

Since the date of last return, showing their names and
Of the shares so held

Date and number of certificate of citizenship if issued by Government of the Union of Myanmar	ACCOUNT OF SHARES					REMARKS
	*Number of shares held by existing Members at date of return	** Particulars of Shares Transferred since the date of the last return by persons who are still Members		** Particulars of Shares Transferred since the date of the last return by persons who Ceased to be Members		
		-Number	Date of Registration of Transfer	# Number	Date of Registration of Transfer	
12/SA KHA NA (NAING)043736	25 SHARES					
6/HTA WA NA (NAING)026533	25 SHARES					
12/SA KHA NA (NAING)009693	25 SHARES					
	75 SHARES					

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD.

** The date of Registration of each transfer should be given as well as the Number of Shares transferred on each date. The particulars should be placed opposite the name of the Transferor and not opposite that of the Transferee, but the name of the Transferor may be inserted in the "Remarks" column, Immediately opposite the particulars of each Transfer.

FORM 1

ORM E-Contd.

Names and addresses of the persons who are the DIRECTORS of the GLOBAL STAR CO., LTD. COMPANY LIMITED

On the 26TH day of AUGUST 2015

NAME	ADDRESS	FOREIGNERS	Nationality Citizens of the Union of Myanmar
1. U KYAW ZAW AUNG	68,THANDAR STREET, WARD NO.1,KAMAYUT TOWNSHIP,YANGON, MYANMAR.		MYANMAR 12/SA KHA NA(NAING) 043736
2. DAW THIDA THAW	16,KYAIK LAT STREET, LIN TAUNG WARD, SANCHAUNG TOWNSHIP, YANGON,MYANMAR.		MYANMAR 12/SA KHA NA(NAING) 009693
3. DAW MYINT MYINT THAUNG	92,YADANA MYAING STREET,KAMAYUT TOWNSHIP,YANGON, MYANMAR.		MYANMAR 6/HTA WA NA(NAING) 026533
4. U AUNG GYI	19,THURANE YEIK MON, YWAMA CURVE,BLOCK NO.2,HLAING TOWNSHIP, YANGON,MYANMAR.		MYANMAR 14/WA KHA MA(NAING) 007444

FORM E-Contd.

Names and addresses of the persons who are the **MANAGERS** of the GLOBAL STAR CO., LTD. **COMPANY LIMITED**

On the 26TH day of AUGUST 2015

NAME	ADDRESS	FOREIGNERS	Nationality Citizens of the Union of Myanmar
U THET TIN	32,165th STREET,TAMWE GYI (B) BLOCK,TAMWE TOWNSHIP, YANGON,MYANMAR.		MYANMAR, 7/PA KHA NA(NAING) 187383

WE ALSO HEREBY CERTIFY THAT COMPANY HAS NOT SINCE THE DATE OF LAST RETURN ISSUED ANY INVITATION TO THE PUBLIC OR SUBSCRIBE FOR THE SHARE OF DEBENTURE OF THE COMPANY.

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD.

Note-Banking Companies must add a list of all their places of business.

I U KYAW ZAW AUNG (MANAGING DIRECTOR) do here by certify that the above list and summary truly and correctly state the facts as they stood on the 26TH day of AUGUST 2015

Signature

(State whether Director Manager or Secretary)

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD

THE MYANMAR COMPANIES ACT

_____:O:_____

FORM E.

_____:O:_____

NAME OF THE COMPANY

GLOBAL STAR CO., LTD.

REGISITERED OFFICE

NO.2,BAYINT NAUNG MAIN ROAD,WARD NO.2,
HLAING TOWNSHIP,YANGON.

MANAGING AGENIS :

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD.

Summary of share Capital and Shares.

List of Persons holding Shares.

Names and Addresses of Directors.

Names and Addresses of Managers.

Dated, 26TH,AUGUST 2015

GLOBAL STAR COMPANY LIMITED

(INCORPORATED IN THE REPUBLIC OF THE UNION OF MYANMAR)

FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2015

KHIN SU HTAY & ASSOCIATES LIMITED
CERTIFIED PUBLIC ACCOUNTANTS

GLOBAL STAR COMPANY LIMITED
(INCORPORATED IN THE REPUBLIC OF THE UNION OF MYANMAR)

FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2015

Contents

	Page
Statement by Directors	**1**
Auditors' Report to the Members	**2-3**
Timber Extraction	**4**
Statement of Financial Position	**5**
Statement of Comprehensive Income	**6**
Schedules to the Financial Statements	**7-9**
Statement of Changes in Equity	**10**
Statement of Cash Flows	**11**
Notes to the Financial Statements	**12-17**

STATEMENT BY DIRECTORS

OF

GLOBAL STAR COMPANY LIMITED

FOR THE YEAR ENDED 31 MARCH 2015

We, being the Managing Director and Director of **GLOBAL STAR COMPANY LIMITED,** do hereby state that, in the opinion of the Directors:

(1) the accompanying financial statements set out on pages 4 to 17 are drawn up in accordance with the provisions of Myanmar Companies Act and MFRS for SMEs so as to give a true and fair view of the state of affairs of the Company as at 31 March 2015 and of the results, changes in equity and cash flows of the Company for the year then ended ; and

(2) at the date of this Statement there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

(3) the Statement of Financial Position and the Statement of Comprehensive Income were signed by us as authentication required under Section 133 (1) & (2) of the Myanmar Companies Act.

The Board of Directors has, on the date of this Statement, authorised these financial statements for issue.

On behalf of the Board of Directors

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD.

AUNG GYI
DIRECTOR
GLOBAL STAR CO., LTD.

Yangon,
Date:

AUDITORS' REPORT TO THE MEMBERS

OF

GLOBAL STAR COMPANY LIMITED

FOR THE YEAR ENDED 31 MARCH 2015

We have audited the financial statements of **GLOBAL STAR COMPANY LIMITED ("the Company"),** which comprise the statement of financial position of the Company as at 31 March 2015, the statement of comprehensive income, statement of changes in equity and statement of cash flows of the Company for the year ended on that date, and a summary of significant accounting policies and other explanatory notes, as set out on pages 12 to 17.

Management's responsibility for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with the provisions of Myanmar Companies Act ("the Act") and MFRS for SMEs.

Management has acknowledged that its responsibility includes:

(a) devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair profit and loss account and balance sheet and to maintain accountability of assets;

(b) selecting and applying appropriate accounting policies; and

(c) making accounting estimates that are reasonable in the circumstances.

Auditors' responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Myanmar Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor

considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion:

- the financial statements of the Company are properly drawn up in accordance with the applicable standards of MFRS for SMEs so as to give a true and fair view of the state of affairs of the Company as at 31 March 2015 and the result, changes in equity and cash flows of the Company for the year ended on that date.

Report on Myanmar Companies Act requirements

Further to our above opinion we report as follows:

(a) The books of account subject to Notes the Statements No.20 (i) have been kept by the Company in accordance with the provisions of Section 130 of the Act.

(b) In accordance with the provisions of Section 145 (1) and (2):

- we have obtained all the information and explanations we have required;
- the financial statements are drawn up in conformity with the provisions of the Act.

(c) The Statement of Financial Position and the Statement of Comprehensive Income were signed by the Managing Director and the Director as authentication required under Section 133 (1) & (2) of the Act.

Than Tint
CPA (P.A 103)
Managing Director
Khin Su Htay & Associates Limited
Certified Public Accountants

Yangon,
Date: 30 JUN 2015

GLOBAL STAR COMPANY LIMITED

TIMBER EXTRACTION

FOR THE YEAR ENDED 31 MARCH 2015

Schedule 2

		31.3.2015 (Kyats)	31.3.2014 (Kyats)
OPENING STOCK AT FOREST		-	99,292,475.20
EXTRACTION COST			
Logging Fees (Elephant)		117,641,216.00	358,855,224.00
Cutting Fees		-	89,713,806.00
Forest Expenses		5,604,950.00	900,000.00
Transportation Charges		190,578,770.00	1,226,036,467.00
Crane/ Loader Charges		88,230,912.00	278,774,205.00
Bulldozer Rental		101,308,250.00	176,988,000.00
Repair & Maintenance		4,936,100.00	13,573,086.93
Rental Fees		3,735,000.00	-
Diesel		195,511,000.00	736,618,975.00
Field Expense		-	1,197,900.00
Salaries		58,880,000.00	108,510,000.00
Travelling Expenses		3,195,434.00	2,051,383.00
Stationery & Printing		398,610.00	-
Meal Expense		-	46,908,000.00
Medical Expense		271,145.00	302,460.00
Sundry		1,200,450.00	3,654,800.00
Entertainment		-	455,300.00
		771,491,837.00	3,143,832,082.13
LESS:CLOSING STOCK AT FOREST		-	-
EXTRACTION LOG TOTAL COST (14,705.152 HT)		771,491,837.00	3,143,832,082.13
ADD:OPENING STOCK AT DEPOT (616.819 HT)		48,637,206.33	1,951,174,626.01
TOTAL LOG AT DEPOT (15,321.971 HT)		820,129,043.33	5,095,006,708.14
LESS:CLOSING STOCK AT DEPOT (616.819 HT)	3	(33,016,064.08)	(48,637,206.33)
		787,112,979.25	5,046,369,501.81
TRADING ACCOUNT (AD-AE 14,705.152HT)		787,112,979.25	2,549,930,077.62
TRADING ACCOUNT		-	2,496,439,424.19
		787,112,979.25	5,046,369,501.81

GLOBAL STAR COMPANY LIMITED
STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2015

	Notes	31-Mar-15 Total Kyats	31-Mar-14 Total Kyats
NON - CURRENT ASSETS			
PROPERTY, PLANT AND EQUIPMENT	Sch 1	69,654,431.90	83,756,289.70
(At cost less accumulated depreciation)			
PRELIMINARY EXPENSES			
Company Formation Fees	5	1,160,000.00	1,160,000.00
INVESTMENT	6	127,500,000.00	127,500,000.00
CURRENT ASSETS			
Inventories	Sch 3/ Note 9	33,016,064.08	48,637,206.33
Receivables	8	528,427,820.99	4,820,000.00
Advances	7	27,656,894.84	30,324,142.77
Cash & Cash Equivalents	10	216,849,060.41	257,703,684.82
		805,949,840.32	341,485,033.92
CURRENT LIABILITIES			
Payables	11	50,000,000.00	350,000,000.00
Advance Received For Export(Fresh Vegetables)	12	11,297,000.00	10,604,000.00
Accrued Expenses	13	700,000.00	700,000.00
Provision For Commercial Tax		30,003,200.00	-
		92,000,200.00	361,304,000.00
NET CURRENT LIABILITIES		713,949,640.32	(19,818,966.08)
NON-CURRENT LIABILITIES			
NET ASSETS		912,264,072.22	192,597,323.62
Represented By:			
CAPITAL AND RESERVES			
CAPITAL			
Authorized Capital			
10000 Shares of K 10,000/- each	18	100,000,000.00	100,000,000.00
Issued, Subscribed & Paid Up Capital			
75 Shares of K 100,000/- each	18	7,500,000.00	7,500,000.00
EXCHANGE TRANSLATION RESERVE	20	228,606,637.75	228,606,637.75
ACCUMULATED PROFIT / LOSS		676,157,434.47	(43,509,314.13)
		912,264,072.22	192,597,323.62

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO. LTD.

AUNG GYI
DIRECTOR
GLOBAL STAR CO., LTD.

Date:

GLOBAL STAR COMPANY LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2015

	Notes	31.3.2015 Total Kyats	31.3.2014 Total Kyats
Income			
Received From MTE for Export Log		-	8,449,771,373.30
Less: Cost Of Sales			
Opening Balance		-	(1,062,811,878.26)
Extraction cost		-	(2,496,439,424.19)
Royalty Fees		-	(14,773,375.05)
Transportation Charges			(2,252,150,323.00)
		-	2,623,596,372.80
Less:Closing Stock		-	-
Export log For The Year		-	2,623,596,372.80
Add: Export Charges			(1,521,036,254.00)
		-	1,102,560,118.80
Received From MTE for AD-AE (14,705.152)		618,292,820.99	1,536,211,430.88
Less:Extraction Cost(AD-AE)	Sch 2	(787,112,979.25)	(2,549,930,077.62)
		(168,820,158.26)	88,841,472.06
Received From MTE for Transporation Charges		1,263,329,408.68	-
Less:Transporation Charges		(1,364,059,505.00)	-
		(100,730,096.32)	-
Rental Income (Dozer)		58,342,325.00	-
Local Sale			
Sales of Imported Goods			42,840,000.00
Less:Cost of Sales			
Purchases		-	(38,318,456.96)
Import Charges		-	(3,530,431.78)
		-	991,111.26
Gross Loss		(211,207,929.58)	89,832,583.32
Less: Administrative & General Expenses	14	(52,055,633.38)	(205,755,650.07)
Less:Commercial Tax	15	(32,220,723.00)	(426,746,703.39)
Less:Depreciation		(14,101,857.80)	(22,302,260.24)
Add:Exchange Rate Differential		(744,150.16)	132,281,708.09
Total Comprehensive Loss For The Year		(310,330,293.92)	(432,690,322.29)
Retained Profit/(Loss) Brought forward as previously reported		(43,509,314.13)	(4,269,401,561.05)
Profit as per Assessment order(Demand Notice)(11-12)		-	3,159,471,802.72
Profit as per Assessment order(Demand Notice)(12-13)		-	1,808,229,282.64
Profit as per Assessment order(Demand Notice)(13-14)		1,252,097,649.29	-
Income Tax as per Assessment Order (11-12)(Ks)		-	(45,334,218.68)
Income Tax as per Assessment Order (11-12)(US$ 164,797.90)		-	(145,351,747.80)
Income Tax as per Assessment Order (12-13)(Ks)		-	(118,474,299.67)
Income Tax as per Assessment Order (13-14)		(222,100,606.77)	-
Prior Year Adjustment		-	41,750.00
As Restated		986,487,728.39	389,181,008.16
Accumulated Profit Carried Forward		676,157,434.47	(43,509,314.13)

KYAW ZAW AUNG
MANAGING DIRECTOR
GLOBAL STAR CO., LTD

Date:

AUNG GYI
DIRECTOR
GLOBAL STAR CO., LTD.

The annexed accounting policies and explanatory notes form an integral part of the financial statements.

GLOBAL STAR COMPANY LIMITED

SCHEDULES ANNEXED TO AND FORMING PART OF THE STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2015

SCHEDULE (1) SUMMARY OF PROPERTY, PLANT AND EQUIPMENT

No	Description	Dep: Rate	As at 1.4.2014	Additions During the year	As at 31.3.2015
	COST				
	HEAD OFFICE				
1	Rice Transplanter (8) units		277,703.09	-	277,703.09
2	Reconditioned Rice Milling plant(1 Set)		3,941,885.51	-	3,941,885.51
3	Mixer Truck (5C/4792)		13,684,794.00	-	13,684,794.00
4	Mixer Truck (5C/4793)		13,684,794.00	-	13,684,794.00
5	Mixer Truck (2D/7390)		11,815,814.77	-	11,815,814.77
6	Mixer Truck (2D/7391)		11,815,814.77	-	11,815,814.77
7	Deck Cargo Bargo "MN S 2"		10,260,472.89	-	10,260,472.89
8	Deck Cargo Bargo "MN S 1"		10,260,472.89	-	10,260,472.89
9	Deck Cargo Bargo "S B P 2"		11,137,724.55	-	11,137,724.55
10	Open Type Generator (200 KVA)		2,627,954.80	-	2,627,954.80
11	Open Type Generator (250 KVA)		2,649,242.00	-	2,649,242.00
12	Open Type Generator (500 KVA)		2,734,390.81	-	2,734,390.81
13	Bulldozer D85 E-SS-J 11512 (Model-2004)		12,456,383.55	-	12,456,383.55
14	Bulldozer D85 E-SS-J 11603 (Model-2004)		12,456,383.55	-	12,456,383.55
15	Bulldozer D85 E-SS-J 12070 (Model-2006)		12,537,586.05	-	12,537,586.05
16	Bulldozer D85 E-SS-J 12110 (Model-2006)		12,537,586.06	-	12,537,586.06
17	Water Purifier (4 Items)		225,038.33	-	225,038.33
	Office Furniture				
18	Table (1) Nos.		75,000.00	-	75,000.00
19	Chairs (5) Nos.		59,125.00	-	59,125.00
			145,238,166.62	-	145,238,166.62
	DEPRECIATION				
	HEAD OFFICE				
1	Rice Transplanter (8) units	-	-	-	-
2	Reconditioned Rice Milling plant(1 Set)	-	-	-	-
3	Mixer Truck (5C/4792)	10%	10,947,835.20	1,368,479.40	12,316,314.60
4	Mixer Truck (5C/4793)	10%	10,947,835.20	1,368,479.40	12,316,314.60
5	Mixer Truck (2D/7390)	10%	5,317,116.65	1,181,581.48	6,498,698.13
6	Mixer Truck (2D/7391)	10%	5,317,116.65	1,181,581.48	6,498,698.13
7	Deck Cargo Bargo "MN S 2"	10%	1,368,063.05	1,026,047.29	2,394,110.34
8	Deck Cargo Bargo "MN S 1"	10%	1,368,063.05	1,026,047.29	2,394,110.34
9	Deck Cargo Bargo "S B P 2"	10%	1,485,029.95	1,113,772.46	2,598,802.40

No	Description	Dep: Rate	As at 1.4.2014	Additions During the year	As at 31.3.2015
10	Open Type Generator (200 KVA)	10%	437,992.47	262,795.48	700,787.95
11	Open Type Generator (250 KVA)	10%	441,540.33	264,924.20	706,464.53
12	Open Type Generator (500 KVA)	10%	455,731.80	273,439.08	729,170.88
13	Bulldozer D85 E-SS-J 11512 (Model-2004)	10%	5,812,978.99	1,245,638.36	7,058,617.35
14	Bulldozer D85 E-SS-J 11603 (Model-2004)	10%	5,812,978.99	1,245,638.36	7,058,617.35
15	Bulldozer D85 E-SS-J 12070 (Model-2006)	10%	5,850,873.49	1,253,758.61	7,104,632.10
16	Bulldozer D85 E-SS-J 12110 (Model-2006)	10%	5,850,873.49	1,253,758.61	7,104,632.10
17	Water Purifier (4 Items)	10%	41,022.61	22,503.83	63,526.44
	Office Furniture				-
18	Table (1) Nos.	10%	15,000.00	7,500.00	22,500.00
19	Chairs (5) Nos.	10%	11,825.00	5,912.50	17,737.50
				-	
			61,481,876.92	14,101,857.80	75,583,734.72
	NET BOOK VALUE				
	HEAD OFFICE				
1	Rice Transplanter (8) units		277,703.09		277,703.09
2	Reconditioned Rice Milling plant(1 Set)		3,941,885.51		3,941,885.51
3	Mixer Truck (5C/4792)		2,736,958.80		1,368,479.40
4	Mixer Truck (5C/4793)		2,736,958.80		1,368,479.40
5	Mixer Truck (2D/7390)		6,498,698.12		5,317,116.65
6	Mixer Truck (2D/7391)		6,498,698.12		5,317,116.65
7	Deck Cargo Bargo "MN S 2"		8,892,409.84		7,866,362.55
8	Deck Cargo Bargo "MN S 1"		8,892,409.84		7,866,362.55
9	Deck Cargo Bargo "S B P 2"		9,652,694.61		8,538,922.15
10	Open Type Generator (200 KVA)		2,189,962.33		1,927,166.85
11	Open Type Generator (250 KVA)		2,207,701.67		1,942,777.47
12	Open Type Generator (500 KVA)		2,278,659.01		2,005,219.93
13	Bulldozer D85 E-SS-J 11512 (Model-2004)		6,643,404.56		5,397,766.21
14	Bulldozer D85 E-SS-J 11603 (Model-2004)		6,643,404.56		5,397,766.21
15	Bulldozer D85 E-SS-J 12070 (Model-2006)		6,686,712.56		5,432,953.96
16	Bulldozer D85 E-SS-J 12110 (Model-2006)		6,686,712.57		5,432,953.96
17	Water Purifier (4 Items)		184,015.72		161,511.89
	Office Furniture				
18	Table (1) Nos.		60,000.00		52,500.00
19	Chairs (5) Nos.		47,300.00		41,387.50
			83,756,289.71	-	69,654,431.90

The annexed accounting policies and explanatory notes form an integral part of the financial statements.

GLOBAL STAR COMPANY LIMITED

Closing Stock as at 31 March 2015

Schedule 3

(Kyats)

Particulars	Qty(HT)	Extraction Cost	Total
TIMBER LOG (DEPOT)	616.819	33,016,064.08	33,016,064.08
CLOSING STOCK(31 MARCH 2015)	**616.819**	**33,016,064.08**	**33,016,064.08**

The annexed accounting policies and explanatory notes form an integral part of the financial statements.

GLOBAL STAR COMPANY LIMITED

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2015

(Total Kyats)

	SHARE CAPITAL	EXCHANGE TRANSLATION RESERVE	ACCUMULATED LOSSES	TOTAL
AS AT 31 MARCH 2013	7,500,000.00	228,606,637.75	(4,269,401,561.05)	(4,033,294,923.30)
Profit as per Assessment order(Demand Notice)(11-12)			3,159,471,802.72	3,159,471,802.72
Profit as per Assessment order(Demand Notice)(12-13)			1,808,229,282.64	1,808,229,282.64
Income Tax as per Assessment Order (11-12)(Ks)			(45,334,218.68)	(45,334,218.68)
Income Tax as per Assessment Order (11-12)(US$ 164,797.90)			(145,351,747.80)	(145,351,747.80)
Income Tax as per Assessment Order (12-13)(Ks)			(118,474,299.67)	(118,474,299.67)
Prior Year Adjustment			41,750.00	41,750.00
Total Comprehensive Loss For The Year			(432,690,322.29)	(432,690,322.29)
AS AT 31 MARCH 2014	7,500,000.00	228,606,637.75	(43,509,314.13)	192,597,323.62
Profit as per Assessment order(Demand Notice)(13-14)			1,252,097,649.29	1,252,097,649.29
Income Tax as per Assessment Order (13-14)(Ks)			(222,100,606.77)	(222,100,606.77)
Total Comprehensive Loss For The Year			(310,330,293.92)	(310,330,293.92)
AS AT 31 MARCH 2015	7,500,000.00	228,606,637.75	676,157,434.47	912,264,072.22

The annexed accounting policies and explanatory notes form an integral part of the financial statements.

GLOBAL STAR COMPANY LIMITED

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2015

		31.3.2015 (Total Kyats)	31.3.2014 (Total Kyats)
Cash flows from operating activities			
Net Loss before taxation & extraordinary item		(310,330,294)	(432,690,322)
Adjustment for			
Depreciation		14,101,858	22,302,260
Commercial Tax for the year		32,220,723	-
Profit as per assessment order(Demand Notice)(11-12)		-	3,159,471,803
Profit as per assessment order(Demand Notice)(12-13)		-	1,808,229,283
Profit as per assessment order(Demand Notice)(13-14)		1,252,097,649	-
Prior Year Adjustment		-	41,750
Operating Profit before working capital changes		988,089,936	4,557,354,773
(Increase)/Decrease in Inventory		15,621,142	3,064,641,773
(Increase)/Decrease in Receivables		(523,607,821)	304,655,581
(Increase)/Decrease in Advances		(53,500)	-
Increase/(Decrease) in Payables		(300,000,000)	(4,656,460,889)
Increase/(Decrease) in Advance Received		693,000	902,000
Increase/(Decrease) in Accrued Expenses		-	(200,000)
Cash generated from operations		180,742,757	3,270,893,238
Commercial Tax paid (2014-2015)		(2,217,523)	-
Income Tax Paid (2013-2014)		(191,776,464)	(94,016,039)
Advance Income Tax Paid (2014-2015)		(27,603,395)	(38,468,313)
Net cash from operating activities	**A**	(40,854,624)	3,138,408,886
Cash flows from investing activities			
Investment in Global Woodcraft Industries Limited		-	(127,500,000)
Net cash used in investing activities	**B**	-	(127,500,000)
Cash flows from financing activities			
Increase/(Decrease) in Advance from Shareholders		-	(3,193,300,000)
Net cash provided from financing activities	**C**	-	(3,193,300,000)
Net increase/(decrease) in cash & cash equivalents	**A+B+C**	(40,854,624)	(182,391,114)
Cash & cash equivalents at beginning of the year		257,703,684	440,094,798
Cash & cash equivalents at the end of the year		216,849,060	257,703,684

The annexed accounting policies and explanatory notes form an integral part of the financial statements.

These notes form an integral part of the accompanying financial statements.

The financial statements were authorised for issue by the Board of Directors.

1. Domicile and principal activities

Global Star Company Limited is domiciled and incorporated in the Republic of the Union of Myanmar with its registered office at No.2, Bayint Naung Main Road, Ward No.2, Hlaing Township, Yangon, Myanmar under Certificate of Incorporation No.1507/2008-2009 dated 27 February 2009.

The principal activities of the Company are to carry out the general trading business of importers and exporters of agriculture and farm produces, forest products and value added wood-based products, factory utensils and raw material.

2. Basis of preparation

2.1 Statement of compliance

The financial statements are prepared in compliance with the provisions of Myanmar Companies Act ("the Act") and the applicable standards of MFRS for SMEs.

2.2 Basis of measurement

The financial statements have been prepared on the historical cost basis.

2.3 Use of estimates and judgements

The preparation of financial statements in conformity with MFRS for SMEs requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

There are no accounting estimates and judgement made by the management that has a significant effect on the financial statements.

3. Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these financial statements.

3.1 Property, Plant, Equipment and Depreciation

Property, Plant and Equipment are stated at cost less accumulated depreciation. Depreciation is recognised in the statement of comprehensive income on a straight-line basis over their estimated useful lives as follows:

No.	Description	Useful Lives (Years)
1	Rice Transplanter	10
2	Reconditioned Rice Milling Plant	10
3	Mixer Truck	10
4	Deck Cargo Barge	10
5	Open Type Generator	10
6	Bulldozer	10
7	Water Purifier	10
8	Office Furniture	10

All the items not in use are not depreciated.

3.2 Preliminary Expenses

Preliminary Expenses are stated at cost and will be amortised over a period of 3 years starting from the financial year when the Company earns accounting profit.

3.3 Inventories

Stocks are stated at weighted average cost. Cost comprises all costs of extraction, cost of conversion and other costs incurred in bringing the stocks to their present location and condition.

3.4 Revenue Recognition

Revenue from sales are recognised when the goods are delivered.

3.5 Foreign currency translation

Transactions in foreign currencies during the accounting year are translated into Kyats at the official exchange rate ruling at the month the transactions occurred.

The bank balances denominated in US$ outstanding at balance sheet date are translated into kyats at the bank official exchange rate at balance sheet date. i.e. K 1027 per 1US$.

All monetary assets and liabilities denominated in US$ outstanding at balance sheet date are translated into kyats at the bank official exchange rate at balance sheet date i.e. K 1027 per 1US$.

All exchange rate differentials are dealt with through the statement of comprehensive income.

3.6 Administrative and General Expenses

Administrative and General Expenses are expensed off as incurred.

3.7 Corporate Tax expense

Corporate tax expense is determined on the accounting profit for the year.

3.8 Share capital

Ordinary shares are classified as equity.

4. Property, Plant & Equipment

Summary of Property, Plant & Equipment is attached as Schedule 1.
Fully depreciated items of PPE are retained in the financial statements until they are no longer in use.

5. Preliminary Expenses

	2015 TOTAL KYATS	2014 TOTAL KYATS
Company Formation Fees	1,160,000.00	1,160,000.00
	1,160,000.00	1,160,000.00

6. Investment

	2015 TOTAL KYATS	2014 TOTAL KYATS
Global Woodcraft Industries Limited	127,500,000.00	127,500,000.00
	127,500,000.00	127,500,000.00

7. Advances

	2015 TOTAL KYATS	2014 TOTAL KYATS
2% Income Tax (13-14)	-	29,906,789.77
Income Tax - (Kyats) (14-15)	27,603,394.84	417,353.00
Advance (Oil Palm Seeds)	53,500.00	-
	27,656,894.84	30,324,142.77

8. Receivables

	2015 TOTAL KYATS	2014 TOTAL KYATS
Receivable from MTE for AD-AE	523,292,820.99	-
MTE (Bank Guarantee) (US$ 5,000.00)	5,135,000.00	4,820,000.00
	528,427,820.99	4,820,000.00

The balance confirmation certificate from individual debtors was not available but the balances were certified by the Director to be correct and collectable.
The Company needs to follow-up for the release of MTE Bank Guarantee amounting US$ 5,000.

9. Inventories

	2015 TOTAL KYATS	2014 TOTAL KYATS
Stock at Depot (616.819 HT)	33,016,064.08	48,637,206.33
	33,016,064.08	48,637,206.33

Inventories are valued at cost using weighted average cost method.

Year end physical counting was not performed by the Company and the valuation sheet of inventory is not available at the time of this report but certified by the Director to be correct and the inventories are in existence as at 31 March 2013.

10. Cash and bank balances

	2015 TOTAL KYATS	2014 TOTAL KYATS
Cash in Hand (Kyats)	211,591,801.59	88,381,367.02
Cash at Bank (MICB) – Kyats	10,000.00	10,000.00
Cash at Bank (MEB) – Kyats	250,398.85	236,035.76
Cash at Bank (MCB) – Kyats	107,200.00	54200.00
Cash at Bank (MFTB) - (US$ 4,761.11)	4,889,659,97	169,022,082.04
	216,849,060.41	257,703,684.82

Cash in hand balances were certified by the Director to be correct and in existence. Year end cash count report is not available at the time of this report.

11. Payable

	2015 TOTAL KYATS	2014 TOTAL KYATS
Export Charges (Log)	-	350,000,000.00
Payable for Extraction	50,000,000.00	-
	50,000,000.00	350,000,000.00

The balance confirmation certificates from individual creditors were not available but the balances were certified by the Director to be correct and payable.

12. Advance Received

	2015 TOTAL KYATS	2014 TOTAL KYATS
Advanced Received from Export (Fresh Vegetable)(US$ 11,000.00)	11,297,000.00	10,604,000.00
	11,297,000.00	10,604,000.00

13. Accrued Expenses

	2015 TOTAL KYATS	2014 TOTAL KYATS
Professional Fees (2014-2015)	700,000.00	700,000.00
	700,000.00	700,000.00

14. Administrative & General Expenses

	2015 TOTAL KYATS	2014 TOTAL KYATS
Salaries	37,200,000.00	37,500,000.00
Society Security Board	2,680,800,00	
Travelling Allowance	335,046.00	2,360,915.00
Donation	27,000.00	8,293,050.00
Printing & Stationery	353,060.00	618,860.00
Postage & Telecommunication	270,000.00	420,000.00
Entertainment	-	3,294,130.00
Car Running	8,698,404.00	899,230.00
Vehicle Repairs & Maintenance	727,000.00	1,024,200.00
Bank Charges	404,013.38	2,035,075.07
Sundry Expenses	660,310.00	910,390.00
Medical Expenses	-	99,800.00
Interest	-	147,600,000.00
Professional Fee	700,000.00	700,000.00
	52,055,633.38	205,755,650.07

15. Commercial Tax

	2015 TOTAL KYATS	2014 TOTAL KYATS
Commercial Tax	32,220,723.00	426,746,703.39
	32,220,723.00	426,746,703.39

16. Financial risk management

Risk management is integral to the whole business of the Company. The main risks arising from the Company's financial instruments are credit risk, market risk and liquidity risk including exchange rate fluctuation. The management shall review and agree policies for managing each of these risks to ensure that an appropriate balance between risk and control is achieved.

17. Impairment – non –financial assets

The carrying amount of the Company's non-financial assets should be reviewed at each reporting date (31 March) to determine whether there is any indication of impairment. If any such indication exists, then the assets' recoverable amounts are estimated. An impairment loss is recognised if the carrying amount of an asset or its related cash-generating unit (CGU) exceeds its estimated recoverable amount.

The Company did not perform impairment review on non- financial assets at the reporting date i.e. 31 March 2013.

18. Share Capital

The details are:

	KYATS
Authorized Capital 1000 shares of K 100,000/- each	100,000,000.00
Issued, subscribed & fully paid up capital	
75 Shares of K 100,000/- each	7,500,000.00

19. Exchange Translation for Opening Balances

Current assets, non-current assets and current liabilities as of 1 April 2012 in US$ which was previously translated at Kyat 5.4938 are retranslated at Kyat 818 to 1 US$ (at rate of 2 April 2012).

All exchange gains are disclosed under Exchange Translation Reserve Account.

20. Other Observation

(i) The Company does not furnish the following accounting records.

(a) Fixed Assets Register

(b) Store Ledger

21. Number of Employees

	2015	2014
Number of Employees as at 31 March	45	109

22. Comparative Figures

The figures of the year ended 31 March 2014 were shown in the financial statements to facilitate comparison.

- **Annex L Draft MOA & MOA of the "Andaman Alliance Healthcare Ltd."**

Parkway
YANGON

PARKWAY HEALTHCARE INDO-CHINA PTE. LTD.
(UEN: 200723244M)
(Registered in the Republic of Singapore)
(the "Company")

DIRECTORS' RESOLUTION IN WRITING PURSUANT TO ARTICLE 93

DATED THIS 5TH DAY OF OCTOBER 2015

PROJECT YANGON
- APPROVAL TO SET UP A JV COMPANY FOR A GREENFIELD HOSPITAL PROJECT IN YANGON, MYANMAR

NOTED:-

A. The opportunity in Yangon, Myanmar to design, construct, own and manage a modern premium greenfield hospital with local partners – ("Project Yangon"). Details of the opportunity and Management's proposal can be found in the executive summary dated 23 September 2015 prepared by Ms Sophie Lim and Mr Felix Kuswanto, Strategic Planning and Business Development, a copy of which is attached hereto as Annex 1.

B. To proceed with Project Myanmar, necessary applications with Myanmar Investment Commission ("MIC") have to be submitted. Simultaneously, Joint Venture Agreement with the partners needs to be executed. A copy of the said Joint Venture Agreement between the Company, AMMK Medicare Company Ltd, Global Star Company, Ltd., and Macondray Holdings Pte. Ltd. is attached hereto as Annex 2.

C. Subsequent to the approval from MIC, a subsidiary in Myanmar has to be established.

D. It is in the interests of the Company to proceed with Project Myanmar.

E. Each director confirms by signing these resolutions that he has disclosed all his interest in the subject of the resolution in accordance with the Company's Articles of Association and the Companies Act, Cap. 50 of Singapore.

RESOLVED THAT:-

Investment in Project Yangon

1. Approval be and is hereby given to invest in Project Yangon for no more than SGD49.8million.

2. Mr Liaw Yit Ming be and is hereby authorized to sign, for and on behalf of the Company, all documents, including the approval of any subsequent amendments or modifications, and to all such things in connection with the necessary applications with Myanmar Investment Commission to give effect to Project Yangon.

3. If required, the Common Seal of the Company be and is hereby affixed onto any documents necessary to effect Project Yangon, including the approval of any subsequent amendments or modifications, in accordance with the Articles of Association of the Company.

Joint Venture Agreement

4. Approval be and is hereby given to execute the Joint Venture Agreement between the Company, AMMK Medicare Company Ltd, Global Star Company, Ltd., and Macondray Holdings Pte. Ltd. in substantially the form attached hereto as Annex 2.

5. Any director be and is hereby authorized to sign, for and on behalf of the Company, the Joint Venture Agreement, including the approval of any subsequent amendments or modifications, and to all such things to effect the Joint Venture Agreement.

6. If required, the Common Seal of the Company be and is hereby affixed onto the Joint Venture Agreement, including the approval of any subsequent amendments or modifications, in accordance with the Articles of Association of the Company.

Establishment of subsidiary in Myanmar

7. The Company do establish a company in Myanmar to be known as "**Andaman Healthcare Investments**" or such other name as may be approved by the relevant governmental authorities ("**Myanmar Subsidiary**") with an authorised share capital of US$150,000,000 divided into 150,000,000 shares of US$1.00 each.

8. The objects of the Myanmar Subsidiary shall be to construct, develop, manage and operate a multi-specialty hospital of international standard, as an investment project approved by the Myanmar Investment Commission ("**MIC**") in accordance with the Foreign Investment Law of the Republic of the Union of Myanmar.

9. For purpose of incorporation, the Company shall subscribe to 52% of the share capital of the Myanmar Subsidiary (the "**Subscriber Shares**").

10. Liaw Yit Ming, Nationality: **[Malaysian]** and Passport Number: **[A32825840]** be:

   a. authorised to act as the promoter for the incorporation of the Myanmar Subsidiary with power and authority to sign and execute any documents and to do such acts relating to, ancillary to or expedient in connection with the incorporation of the Myanmar Subsidiary and the completion of all formalities, approvals, registrations and procedures related thereto for and on behalf of the Company including but not limited to the application to the MIC for an investment permit ("**MIC Permit**");

   b. appointed the legal representative of the Company and be authorised to subscribe to the Memorandum and Articles of Association of the Myanmar Subsidiary in respect of the Subscriber Shares, and to execute the Memorandum and Articles of Association of the Myanmar Subsidiary, for and on behalf of the Company; and

11. The following persons be appointed as the first Directors of the Myanmar Subsidiary:

Name	Passport / NRC Number	Nationality
Tan See Leng	E3576314E	Singaporean
Tan Hui Ann Sherry	E4511856F	Singaporean
Lai Kok Peng	A30038099	Malaysian
Liaw Yit Ming	A32825840	Malaysian
Ng How Kiat Charlie	E3133254L	Singaporean
Aung Moe Kyaw	12/ Ma Ka Ya (Naing) 106397	Myanmar
Thurane Aung @ Christopher Aung	12/ Ka Ma Ya (Naing) 050839	Myanmar

12. There shall be no requirement for the Directors of the Myanmar Subsidiary to hold any share in the Myanmar Subsidiary,

13. The number of Directors of the Myanmar Subsidiary shall not be less than seven and not more than ten.

14. Any Director of the Company be authorised and empowered to execute all documents and do such acts, deeds and things for and on behalf of the Company as he may in his discretion deem necessary, desirable or expedient to give effect to the incorporation of the Myanmar Subsidiary, including but not limited to the signing, execution and delivering of any deed, notice, document and communication to be given by or required from the Company by such authorities in connection with or in relation or ancillary to the foregoing, and in the event that any such deed, notice, document or communication is required to be executed under the common seal of the Company, the common seal be so affixed thereto in accordance with the Articles of Association of the Company.

15. An extract of these resolution be provided to the Companies Registration Office of the Republic of the Union of Myanmar, the MIC or such other relevant government authorities as may be necessary.

DR. TAN SEE LENG
Director

DR. LIM SUET WUN
Director

LIAW YIT MING
Director

MACONDRAY HOLDINGS PTE. LTD.

Company Registration Number. 201317874R

(Incorporated in the Republic of Singapore)

DIRECTORS' RESOLUTIONS IN WRITING PURSUANT TO ARTICLE 90 OF THE COMPANY'S ARTICLES OF ASSOCIATION

SETTING UP A JOINT VENTURE COMPANY IN MYANMAR: RESOLVED-

(a) The Company do establish a company in Myanmar to be known as "**Andaman Alliance Healthcare Limited**" or such other name as may be approved by the relevant governmental authorities ("**Myanmar Subsidiary**") with an authorised share capital of US$**150,000,000** divided into **150,000,000** shares of US$**1.00** each.

(b) The objects of the Myanmar Subsidiary shall be to construct, develop, manage and operate a multi-specialty hospital of international standard, as an investment project approved by the Myanmar Investment Commission ("**MIC**") in accordance with the Foreign Investment Law of the Republic of the Union of Myanmar.

(c) The Company shall subscribe for **Ten and Half per cent. (10.5%)** of the issued share capital of the Myanmar Subsidiary (the "**Subscriber Shares**").

(d) **Ng How Kiat Charlie, Nationality: Singaporean, Passport Number: E3133254L**, be appointed the legal representative of the Company and be authorised to subscribe to the Memorandum and Articles of Association of the Myanmar Subsidiary in respect of the Subscriber Shares, and to execute the Memorandum and Articles of Association of the Myanmar Subsidiary, for and on behalf of the Company.

(e) **Liaw Yit Ming, Nationality: Malaysian and Passport Number: A32825840**, be authorised to act as the promoter for the incorporation of the Myanmar Subsidiary with power and authority to sign and execute any documents and to do such acts relating to, ancillary to or expedient in connection with the incorporation of the Myanmar Subsidiary and the completion of all formalities, approvals, registrations and procedures related thereto for and on behalf of the Company including but not limited to the application to the MIC for an investment permit ("**MIC Permit**").

(f) The following persons be appointed as the first Directors of the Myanmar Subsidiary:

Name	Passport Number	Nationality
Ng How Kiat Charlie	E3133254L	Singaporean
Tan See Leng	E3576314E	Singaporean
Tan Hui Ann Sherry	E4511856F	Singaporean
Lai Kok Peng	A30038099	Malaysian
Liaw Yit Ming	A32825840	Malaysian
Aung Moe Kyaw	12/Ma Ka Ya (Naing) 106397	Burmese
Thurane Aung @ Christopher Aung	12/ Ka Ma Ya (Naing) 050839	Burmese

(g) There shall be no requirement for the Directors of the Myanmar Subsidiary to hold any share in the Myanmar Subsidiary.

(h) The number of Directors of the Myanmar Subsidiary shall not be less than **seven** and not more than **ten**.

(i) Any Director of the Company be authorised and empowered to execute all documents and do such acts, deeds and things for and on behalf of the Company as he may in his discretion deem necessary, desirable or expedient to give effect to the incorporation of the Myanmar Subsidiary or to apply to the MIC for an MIC Permit, including but not limited to the signing, execution and delivering of any deed, notice, document and communication to be given by or required from the Company by such authorities in connection with or in relation or ancillary to the foregoing, and in the event that any such deed, notice, document or communication is required to be executed under the common seal of the Company, the common seal be so affixed thereto in accordance with the Articles of Association of the Company.

(j) An extract of these resolution be provided to the Companies Registration Office of the Republic of the Union of Myanmar, the MIC or such other relevant government authorities as may be necessary.

Chew Leong Chee

Henry Tay Yun Chwan

Melanie Chew Ng Fung Ning

Ng How Kiat Charlie

Singapore: 16 October 2015

MACONDRAY HOLDINGS PTE. LTD.

Company Registration Number. 201317874R

(Incorporated in the Republic of Singapore)

To: The Director General - Directorate of Investment and Company Administration Myanmar

We hereby certify that the following Extract of Resolutions of the Board of Directors were passed on 16 October 2015 and have been duly recorded in the Minute Book of the Company:-

SETTING UP A JOINT VENTURE COMPANY IN MYANMAR: RESOLVED-

(a) The Company do establish a company in Myanmar to be known as "**Andaman Alliance Healthcare Limited**" or such other name as may be approved by the relevant governmental authorities ("**Myanmar Subsidiary**") with an authorised share capital of **US Dollars One hundred Fifty Million (US$150,000,000/-)** divided **into One hundred Fifty Million (150,000,000)** ordinary shares of **US Dollars One (US$1)** each.

(b) The objects of the Myanmar Subsidiary shall be to construct, develop, manage and operate a multi-specialty hospital of international standard, as an investment project approved by the Myanmar Investment Commission ("**MIC**") in accordance with the Foreign Investment Law of the Republic of the Union of Myanmar.

(c) The Company shall subscribe for **Ten and Half per cent. (10.5%)** of the issued share capital of the Myanmar Subsidiary (the "**Subscriber Shares**").

(d) **Ng How Kiat Charlie, Nationality: Singaporean, Passport Number: E3133254L**, be appointed the legal representative of the Company and be authorised to subscribe to the Memorandum and Articles of Association of the Myanmar Subsidiary in respect of the Subscriber Shares, and to execute the Memorandum and Articles of Association of the Myanmar Subsidiary, for and on behalf of the Company.

(e) **Liaw Yit Ming, Nationality: Malaysian and Passport Number: A32825840**, be authorised to act as the promoter for the incorporation of the Myanmar Subsidiary with power and authority to sign and execute any documents and to do such acts relating to, ancillary to or expedient in connection with the incorporation of the Myanmar Subsidiary and the completion of all formalities, approvals, registrations and procedures related thereto for and on behalf of the Company including but not limited to the application to the MIC for an investment permit ("**MIC Permit**").

(f) The following persons be appointed as the first Directors of the Myanmar Subsidiary:

Name	Passport Number	Nationality
Ng How Kiat Charlie	E3133254L	Singaporean
Tan See Leng	E3576314E	Singaporean
Tan Hui Ann Sherry	E4511856F	Singaporean
Lai Kok Peng	A30038099	Malaysian
Liaw Yit Ming	A32825840	Malaysian
Aung Moe Kyaw	12/Ma Ka Ya (Naing) 106397	Burmese
Thurane Aung @ Christopher Aung	12/ Ka Ma Ya (Naing) 050839	Burmese

(g) There shall be no requirement for the Directors of the Myanmar Subsidiary to hold any share in the Myanmar Subsidiary

(h) The number of Directors of the Myanmar Subsidiary shall not be less than **seven (7)** and not more than **ten (10)**.

(i) Any Director of the Company be authorised and empowered to execute all documents and do such acts, deeds and things for and on behalf of the Company as he may in his discretion deem necessary, desirable or expedient to give effect to the incorporation of the Myanmar Subsidiary, or to apply to the MIC for an MIC Permit, including but not limited to the signing, execution and delivering of any deed, notice, document and communication to be given by or required from the Company by such authorities in connection with or in relation or ancillary to the foregoing, and in the event that any such deed, notice, document or communication is required to be executed under the common seal of the Company, the common seal be so affixed thereto in accordance with the Articles of Association of the Company.

Chew Leong Chee
Director

Ng How Kiat Charlie
Director

Singapore: 16 October 2015

AMMK MEDICARE COMPANY LIMITED

("the Company")

(Incorporated in the Republic of the Union of Myanmar)

Reg. No. 1397 / 2015 – 2016

Registered Office: 33, Pyay Road, 6 1/2 miles, (11) Quarter, Hlaing Township, Yangon, Union of Myanmar.

To: The Director General - Directorate of Investment and Company Administration Myanmar

We hereby certify that the following Extract of Resolutions of the Board of Directors were passed on 16 October 2015 and have been duly recorded in the Minute Book of the Company:-

SETTING UP A JOINT VENTURE COMPANY IN MYANMAR: RESOLVED-

(a) The Company do establish a company in Myanmar to be known as "**Andaman Alliance Healthcare Limited**" or such other name as may be approved by the relevant governmental authorities ("**Myanmar Subsidiary**") with an authorised share capital of **US Dollars One hundred Fifty Million (US$150,000,000/-)** divided **into One hundred Fifty Million (150,000,000)** ordinary shares of **US Dollars One (US$1)** each.

(b) The objects of the Myanmar Subsidiary shall be to construct, develop, manage and operate a multi-specialty hospital of international standard, as an investment project approved by the Myanmar Investment Commission ("**MIC**") in accordance with the Foreign Investment Law of the Republic of the Union of Myanmar.

(c) The Company shall subscribe for **Twenty-one and half per cent,** 21.5% of the issued share capital of the Myanmar Subsidiary (the "**Subscriber Shares**").

(d) **U Aung Moe Kyaw, Nationality: Burmese, National Registration Card Number:** 12/Ma Ya Ka (Naing) 106397, be appointed the legal representative of the Company and be authorised to subscribe to the Memorandum and Articles of Association of the Myanmar Subsidiary in respect of the Subscriber Shares, and to execute the Memorandum and Articles of Association of the Myanmar Subsidiary, for and on behalf of the Company.

(e) **Liaw Yit Ming, Nationality: Malaysian and Passport Number: A32825840**, be authorised to act as the promoter for the incorporation of the Myanmar Subsidiary with power and authority to sign and execute any documents and to do such acts relating to, ancillary to or expedient in connection with the incorporation of the Myanmar Subsidiary and the completion of all formalities, approvals, registrations and procedures related thereto for and on behalf of the Company including but not limited to the application to the MIC for an investment permit ("**MIC Permit**").

(f) The following persons be appointed as the first Directors of the Myanmar Subsidiary:

Name	Passport/NRC Number	Nationality
Ng How Kiat Charlie	E3133254L	Singaporean
Tan See Leng	E3576314E	Singaporean
Tan Hui Ann Sherry	E4511856F	Singaporean
Lai Kok Peng	A30038099	Malaysian
Liaw Yit Ming	A32825840	Malaysian
Aung Moe Kyaw	12/Ma Ka Ya (Naing) 106397	Burmese
Thurane Aung @ Christopher Aung	12/ Ka Ma Ya (Naing) 050839	Burmese

(g) There shall be no requirement for the Directors of the Myanmar Subsidiary to hold any share in the Myanmar Subsidiary

(h) The number of Directors of the Myanmar Subsidiary shall not be less than **seven (7)** and not more than **ten (10)**.

(i) Any Director of the Company be authorised and empowered to execute all documents and do such acts, deeds and things for and on behalf of the Company as he may in his discretion deem necessary, desirable or expedient to give effect to the incorporation of the Myanmar Subsidiary, or to apply to the MIC for an MIC Permit, including but not limited to the signing, execution and delivering of any deed, notice, document and communication to be given by or required from the Company by such authorities in connection with or in relation or ancillary to the foregoing, and in the event that any such deed, notice, document or communication is required to be executed under the common seal of the Company, the common seal be so affixed thereto in accordance with the Articles of Association of the Company.

U Aung Moe Kyaw
Director

Daw Mar Mar Tun
Director

Myanmar: 16 October 2015

AMMK MEDICARE COMPANY LIMITED

("the Company")

(Incorporated in the Republic of the Union of Myanmar)

Reg. No. 1397 / 2015 – 2016

Registered Office: 33, Pyay Road, 6 1/2 miles, (11) Quarter, Hlaing Township, Yangon, Union of Myanmar.

Directors' Resolutions

(Pursuant to Article 13 of the Articles of Association)

SETTING UP A JOINT VENTURE COMPANY IN MYANMAR: RESOLVED-

(a) The Company do establish a company in Myanmar to be known as "**Andaman Alliance Healthcare Limited**" or such other name as may be approved by the relevant governmental authorities ("**Myanmar Subsidiary**") with an authorised share capital of US$**150,000,000** divided into **150,000,000** shares of US$**1.00** each.

(b) The objects of the Myanmar Subsidiary shall be to construct, develop, manage and operate a multi-specialty hospital of international standard, as an investment project approved by the Myanmar Investment Commission ("**MIC**") in accordance with the Foreign Investment Law of the Republic of the Union of Myanmar.

(c) The Company shall subscribe for **Twenty-one and half per cent.** 21.5% of the issued share capital of the Myanmar Subsidiary (the "**Subscriber Shares**").

(d) **U Aung Moe Kyaw, Nationality: Burmese, National Registration Card Number:** 12/Ma Ya Ka (Naing) 106397, be appointed the legal representative of the Company and be authorised to subscribe to the Memorandum and Articles of Association of the Myanmar Subsidiary in respect of the Subscriber Shares, and to execute the Memorandum and Articles of Association of the Myanmar Subsidiary, for and on behalf of the Company.

(e) **Liaw Yit Ming, Nationality: Malaysian and Passport Number: A32825840**, be authorised to act as the promoter for the incorporation of the Myanmar Subsidiary with power and authority to sign and execute any documents and to do such acts relating to, ancillary to or expedient in connection with the incorporation of the Myanmar Subsidiary and the completion of all formalities, approvals, registrations and procedures related thereto for and on behalf of the Company including but not limited to the application to the MIC for an investment permit ("**MIC Permit**").

(f) The following persons be appointed as the first Directors of the Myanmar Subsidiary:

Name	Passport/NRC Number	Nationality
Ng How Kiat Charlie	E3133254L	Singaporean
Tan See Leng	E3576314E	Singaporean
Tan Hui Ann Sherry	E4511856F	Singaporean
Lai Kok Peng	A30038099	Malaysian
Liaw Yit Ming	A32825840	Malaysian
Aung Moe Kyaw	12/Ma Ka Ya (Naing) 106397	Burmese
Thurane Aung @ Christopher Aung	12/ Ka Ma Ya (Naing) 050839	Burmese

AMMK MEDICARE COMPANY LIMITED

Directors' Resolutions dated 16 October 2015

Setting Up a Joint Venture Company in Myanmar

Page 2

(g) There shall be no requirement for the Directors of the Myanmar Subsidiary to hold any share in the Myanmar Subsidiary.

(h) The number of Directors of the Myanmar Subsidiary shall not be less than **seven** and not more than **ten**.

(i) Any Director of the Company be authorised and empowered to execute all documents and do such acts, deeds and things for and on behalf of the Company as he may in his discretion deem necessary, desirable or expedient to give effect to the incorporation of the Myanmar Subsidiary or to apply to the MIC for an MIC Permit, including but not limited to the signing, execution and delivering of any deed, notice, document and communication to be given by or required from the Company by such authorities in connection with or in relation or ancillary to the foregoing, and in the event that any such deed, notice, document or communication is required to be executed under the common seal of the Company, the common seal be so affixed thereto in accordance with the Articles of Association of the Company.

(j) An extract of these resolution be provided to the Companies Registration Office of the Republic of the Union of Myanmar, the MIC or such other relevant government authorities as may be necessary.

U Aung Moe Kyaw

Daw Mar Mar Tun

Myanmar: 16 October 2015

GLOBAL STAR COMPANY LIMITED

("the Company")

(Incorporated in the Republic of the Union of Myanmar)

Reg. No. 1507 / 2008- 2009

Registered Office:No. (2) Ba yint Naung Road, Ywar Mha Gwe (2) Ward, Hlaing Township, Yangon.

Directors' Resolutions

(Pursuant to Article 13 of the Articles of Association)

SETTING UP A JOINT VENTURE COMPANY IN MYANMAR: RESOLVED-

(a) The Company do establish a company in Myanmar to be known as "**Andaman Alliance Healthcare Limited**" or such other name as may be approved by the relevant governmental authorities ("**Myanmar Subsidiary**") with an authorised share capital of US$**150,000,000** divided into **150,000,000** shares of US$**1.00** each.

(b) The objects of the Myanmar Subsidiary shall be to construct, develop, manage and operate a multi-specialty hospital of international standard, as an investment project approved by the Myanmar Investment Commission ("**MIC**") in accordance with the Foreign Investment Law of the Republic of the Union of Myanmar.

(c) The Company shall subscribe for **Sixteen per cent.**16%of the issued share capital of the Myanmar Subsidiary (the "**Subscriber Shares**").

(d) **U Thurane Aung @ Christopher Aung,** Nationality: Myanmar, National Registration Card Number: 12/ Ka Ma Ya (Naing) 050839, be appointed the legal representative of the Company and be authorised to subscribe to the Memorandum and Articles of Association of the Myanmar Subsidiary in respect of the Subscriber Shares, and to execute the Memorandum and Articles of Association of the Myanmar Subsidiary, for and on behalf of the Company.

(e) **Liaw Yit Ming, Nationality: Malaysian and Passport Number: A32825840,** be authorised to act as the promoter for the incorporation of the Myanmar Subsidiarywith power and authority to sign and execute any documents and to do such acts relating to, ancillary to or expedient in connection with the incorporation of the Myanmar Subsidiary and the completion of all formalities, approvals, registrations and procedures related thereto for and on behalf of the Company including but not limited to the application to the MIC for an investment permit ("**MIC Permit**").

(f) The following persons be appointed as the first Directors of the Myanmar Subsidiary:

Name	Passport/NRC Number	Nationality
Ng How Kiat Charlie	E3133254L	Singaporean
Tan See Leng	E3576314E	Singaporean
Tan Hui Ann Sherry	E4511856F	Singaporean
Lai Kok Peng	A30038099	Malaysian
Liaw Yit Ming	A32825840	Malaysian
Aung Moe Kyaw	12/Ma Ka Ya (Naing) 106397	Myanmar
Thurane Aung @ Christopher Aung	12/ Ka Ma Ya (Naing) 050839	Myanmar

GLOBAL STAR COMPANY LIMITED

Directors' Resolutions dated 16 October 2015

Setting Up a Joint Venture Company in Myanmar

Page 2

(g) There shall be no requirement for the Directors of the Myanmar Subsidiary to hold any share in the Myanmar Subsidiary.

(h) The number of Directors of the Myanmar Subsidiary shall not be less than **seven** and not more than **ten**.

(i) Any Director of the Company be authorised and empowered to execute all documents and do such acts, deeds and things for and on behalf of the Company as he may in his discretion deem necessary, desirable or expedient to give effect to the incorporation of the Myanmar Subsidiary or to apply to the MIC for an MIC Permit, including but not limited to the signing, execution and delivering of any deed, notice, document and communication to be given by or required from the Company by such authorities in connection with or in relation or ancillary to the foregoing, and in the event that any such deed, notice, document or communication is required to be executed under the common seal of the Company, the common seal be so affixed thereto in accordance with the Articles of Association of the Company.

(j) An extract of these resolution be provided to the Companies Registration Office of the Republic of the Union of Myanmar, the MIC or such other relevant government authorities as may be necessary.

U Kyaw Zaw Aung	Daw Thida Thaw
Daw Myint MyintThuang	U Aung Gyi
U Thet Tin	U Thurane Aung

Myanmar: 16 October2015

GLOBAL STAR COMPANY LIMITED

("the Company")

(Incorporated in the Republic of the Union of Myanmar)

Reg. No. 1507 / 2008- 2009

Registered Office: No. (2) Ba yint Naung Road, YwarMhaGwe (2) Ward, Hlaing Township, Yangon.

To: The Director General - Directorate of Investment and Company Administration Myanmar

We hereby certify that the following Extract of Resolutions of the Board of Directors were passed on 16 October 2015 and have been duly recorded in the Minute Book of the Company:-

SETTING UP A JOINT VENTURE COMPANY IN MYANMAR: RESOLVED-

(a) The Company do establish a company in Myanmar to be known as "**Andaman Alliance Healthcare Limited**"or such other name as may be approved by the relevant governmental authorities ("**Myanmar Subsidiary**") with an authorised share capital of **US Dollars One hundred Fifty Million (US$150,000,000/-)** divided **into One hundred Fifty Million (150,000,000)** ordinary shares of **US Dollars One (US$1)** each.

(b) The objects of the Myanmar Subsidiary shall be to construct, develop, manage and operate a multi-specialty hospital of international standard,as an investment project approved by the Myanmar Investment Commission ("**MIC**") in accordance with the Foreign Investment Law of the Republic of the Union of Myanmar.

(c) The Company shall subscribe for Sixteen per cent. (16%) of the issued share capital of the Myanmar Subsidiary (the "**Subscriber Shares**").

(d) **U Thurane Aung @ Christopher Aung,** Nationality: Myanmar, National Registration Card Number: 12/ Ka Ma Ya (Naing) 050839, be appointed the legal representative of the Company and be authorised to subscribe to the Memorandum and Articles of Association of the Myanmar Subsidiary in respect of the Subscriber Shares, and to execute the Memorandum and Articles of Association of the Myanmar Subsidiary, for and on behalf of the Company.

(e) **Liaw Yit Ming, Nationality: Malaysian and Passport Number: A32825840**, be authorised to act as the promoter for the incorporation of the Myanmar Subsidiary with power and authority to sign and execute any documents and to do such acts relating to, ancillary to or expedient in connection with the incorporation of the Myanmar Subsidiary and the completion of all formalities, approvals, registrations and procedures related thereto for and on behalf of the Companyincluding but not limited to the application to the MIC for an investment permit ("**MIC Permit**").

GLOBAL STAR COMPANY LIMITED

Extract of Directors' Resolutions dated 16 October 2015
Setting Up a Joint Venture Company in Myanmar

(f) The following persons be appointed as the first Directors of the Myanmar Subsidiary:

Name	Passport/NRC Number	Nationality
Ng How Kiat Charlie	E3133254L	Singaporean
Tan See Leng	E3576314E	Singaporean
Tan Hui Ann Sherry	E4511856F	Singaporean
Lai Kok Peng	A30038099	Malaysian
Liaw Yit Ming	A32825840	Malaysian
Aung Moe Kyaw	12/Ma Ka Ya (Naing) 106397	Myanmar
Thurane Aung @ Christopher Aung	12/ Ka Ma Ya (Naing) 050839	Myanmar

(g) There shall be no requirement for the Directors of the Myanmar Subsidiary to hold any share in the Myanmar Subsidiary

(h) The number of Directors of the Myanmar Subsidiary shall not be less than **seven (7)** and not more than **ten (10)**.

(i) Any Director of the Company be authorised and empowered to execute all documents and do such acts, deeds and things for and on behalf of the Company as he may in his discretion deem necessary, desirable or expedient to give effect to the incorporation of the Myanmar Subsidiary,or to apply to the MIC for an MIC Permit, including but not limited to the signing, execution and delivering of any deed, notice, document and communication to be given by or required from the Company by such authorities in connection with or in relation or ancillary to the foregoing, and in the event that any such deed, notice, document or communication is required to be executed under the common seal of the Company, the common seal be so affixed thereto in accordance with the Articles of Association of the Company.

U Kyaw Zaw Aung
Director

Daw Thida Thaw
Director

Myanmar: 16 October 2015

000394

မြန်မာနိုင်ငံ ကုမ္ပဏီများအက်ဥပဒေ

အစုရှယ်ယာများဖြင့် ပေးရန်တာဝန် ကန့်သတ်ထားသော အများနှင့် မသက်ဆိုင်သည့် ကုမ္ပဏီ

အန်ဒမန် အလိုင်းယန့်(စ်) ဟဲ့(တ်)ကဲ ကုမ္ပဏီ လီမိတက်

၏

သင်းဖွဲ့မှတ်တမ်း

နှင့်

သင်းဖွဲ့စည်းမျဉ်းများ

❖ ❖ ❖ ❖

THE MYANMAR COMPANIES ACT

PRIVATE COMPANY LIMITED BY SHARES

Memoradum Of Association

AND

Articles Of Association

OF

ANDAMAN ALLIANCE HEALTHCARE COMPANY LIMITED

မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ

အစုရှယ်ယာများဖြင့် ပေးရန်တာဝန် ကန့်သတ်ထားသော အများနှင့် မသက်ဆိုင်သည့် ကုမ္ပဏီ

အန်ဒမန် အလိုင်းယန့်(စ်) ဟဲ့(တ်)ကဲ ကုမ္ပဏီX လီမိတက်

၏

သင်းဖွဲ့မှတ်တမ်း

❖ ❖ ❖ ❖ ❖ ❖ ❖

၁။ **ကုမ္ပဏီ၏ အမည်သည်** အန်ဒမန် အလိုင်းယန့်(စ်) ဟဲ့(တ်)ကဲ ကုမ္ပဏီX **လီမိတက် ဖြစ်ပါသည်။**

၂။ ကုမ္ပဏီ၏ မှတ်ပုံတင် အလုပ်တိုက်သည် ပြည်ထောင်စု မြန်မာနိုင်ငံတော်အတွင်း တည်ရှိရမည်။

၃။ ကုမ္ပဏီ တည်ထောင်ရခြင်း၏ ရည်ရွယ်ချက်များမှာ တစ်ဖက်စာမျက်နှာပါ အတိုင်းဖြစ်ပါသည်။

၄။ အစုဝင်များ၏ ပေးရန်တာဝန်ကို ကန့်သတ်ထားသည်။

၅။ ကုမ္ပဏီ၏ သတ်မှတ်မတည်ငွေရင်းသည် ကျပ်XX အမေရိကန်ဒေါ်လာ ၁၅၀,၀၀၀,၀၀၀ (ကျပ်XX အမေရိကန်ဒေါ်လာ သန်းတစ်ရာ ငါးဆယ် တိတိ) ဖြစ်၍ငွေကျပ်XX ဒေါ်လာ ၁ / - (ကျပ်XX တစ် ဒေါ်လာ တိတိ) တန် အစုရှယ်ယာပေါင်း (၁၅၀,၀၀၀,၀၀၀) ခွဲထားပါသည်။ ကုမ္ပဏီ၏ရင်းနှီးငွေကို ကုမ္ပဏီ၏စည်းမျဉ်းများနှင့် လက်ရှိတရားဝင် တည်ဆဲဖြစ်နေသောတရားဥပဒေအထွေထွေ ပြဋ္ဌာန်းချက်များနှင့်အညီ သင်းလုံးကျွတ်အစည်းအဝေး၌ တိုးမြှင့်နိုင်ခွင့်၊ လျှော့ချနိုင်ခွင့်နှင့် ပြင်ဆင်နိုင်ခွင့် အာဏာ ရှိစေရမည်။

၆။ ကုမ္ပဏီတည်ထောင်ရခြင်း၏ ရည်ရွယ်ချက်များမှာ အောက်ဖော်ပြပါ ဝန်ဆောင်မှုလုပ်ငန်းများကို တစ်ဦးတည်းဖြစ်စေ၊ ပြည်တွင်းပြည်ပ ပုဂ္ဂိုလ်များနှင့် ဖြစ်စေ ဖက်စပ်ဆောင်ရွက်ရန်။

(က) ပုဂ္ဂလိကဆေးရုံလုပ်ငန်း။

၇။ ကုမ္ပဏီမှ သင့်လျော်လျောက်ပတ်သည်ဟုယူဆပါက ကုမ္ပဏီ၏ စီးပွားရေးလုပ်ငန်းတွင် အကျိုးရှိစေရန်အတွက် မည်သည့်ပုဂ္ဂိုလ် စီးပွားရေးအဖွဲ့ အစည်း၊ ကုမ္ပဏီ၊ ဘဏ် သို့ မဟုတ် ငွေကြေးအဖွဲ့ အစည်း ထံမှမဆို ငွေချေးယူရန်။

ခြွင်းချက်။ ။ ကုမ္ပဏီသည် အထက်ဖော်ပြပါ ရည်ရွယ်ချက်များကို ပြည်ထောင်စုမြန်မာနိုင်ငံတော် အတွင်း၌ ဖြစ်စေ၊ အခြားမည်သည့်အရပ်ဒေသ၌ဖြစ်စေ၊ အချိန်ကာလ အလိုက် တည်မြဲ နေသော တရားဥပဒေများ၊ အမိန့်ကြော်ငြာစာ များ၊ အမိန့်များကခွင့်ပြု ထားသည့် လုပ်ငန်းများမှအပ အခြား လုပ်ငန်း များကို လုပ်ကိုင်ဆောင်ရွက်ခြင်းမပြုပါ။ ထို့အပြင် ပြည်ထောင်စု မြန်မာ နိုင်ငံတော် အတွင်း၌ အချိန်ကာလအားလျော်စွာ တည်မြဲနေသည့် တရားဥပဒေ ပြဋ္ဌာန်းချက်များ၊ အမိန့်ကြော်ငြာစာများ၊ အမိန့်များနှင့် လျော်ညီ သင့်တော်ခြင်း သို့မဟုတ် ခွင့်ပြုထားခြင်း ရှိမှသာလျှင် လုပ်ငန်းများကို ဆောင်ရွက် မည်ဟု ခြွင်းချက် ထားရှိပါသည်။

အောက်တွင်အမည်၊ နိုင်ငံသား၊ နေရပ်နှင့် အကြောင်းအရာစုံလင်စွာပါသော ဇယားတွင် လက်မှတ်ရေးထိုးသူ ကျွန်ုပ်တို့ ကိုယ်စီကိုယ်ငှသည် ဤသင်းဖွဲ့မှတ်တမ်းအရ ကုမ္ပဏီတစ်ခုဖွဲ့စည်းရန် လိုလားသည့်အလျောက် ကျွန်ုပ်တို့၏ အမည်အသီးသီးနှင့် ယှဉ်တွဲ၍ပြထားသော အစုရှယ်ယာများကို ကုမ္ပဏီ၏ မတည်ရင်းနှီးငွေတွင် ထည့်ဝင်ကြရန် သဘောတူပါသည်။

စဉ်	အစုထည့်ဝင်သူများ၏အမည်၊ နေရပ်လိပ်စာနှင့်အလုပ်အကိုင်	နိုင်ငံသားနှင့် အမျိုးသား မှတ်ပုံတင်အမှတ်	ဝယ်ယူသော အစုရှယ်ယာ ဦးရေ	ထိုးမြဲ လက်မှတ်
1.	Parkway Healthcare Indo-China Pte. Ltd. 111 Somerset Road, #15-01, Tripleone Somerest, Singapore (238164) <u>Represented By</u> Liaw Yit Ming 6 Keng Chin Road, #05-05 Cyan, Singapore 258709	Incorporated in Singapore (Registration No. 200723244M) Singapore PP No. 32825840	78,000	
2.	Macondray Holdings Pte. Ltd. 78 Shenton Way #28-01 Singapore 079120 <u>Represented By</u> Mr. Ng How Kiat Charlie 25 Moonstone Lane #19-03 Singapore 328465	Incorporated in Singapore (Registration No. 201317874R) Singapore PP No. E3133254L	15,750	
3.	AMMK Medicare Company Limited 33 Pyay Road, 6 1/2Miles, Hlaing Township, Yangon. <u>Represented By</u> U Aung Moe Kyaw No. 18, Aung Mingalar St, Aung Theikdi Road, (3) Ward, Mayangone Township,Yangon.	Incorporated in Myanmar (Registration No. 1397/2015-2016 [YGN]) Myanmar Nation Scrutiny Card No.12/MAYAKA (N) 106397	32,250	
4.	Global Star Company Limited N0. (2), Ba Yint Naung Road, Ywar Mha Gwe (2) Ward, Hlaing Township, Yangon. <u>Represented By</u> U Thurane Aung @ Christopher Aung 105, University Avenue Road, (10) Ward, Kamayut Township, Yangon.	Incorporated in Myanmar (Registration No.1507(2008-2009) Myanmar Nation Scrutiny Card No. 12/KAMAYA (N) 050839	24,000	

ရန်ကုန်။ နေ့စွဲ၊ ၂၀၁၆ ခုနှစ်၊ လ၊ ရက်။

အထက်ပါ လက်မှတ်ရှင်များသည် ကျွန်ုပ်တို့၏ ရှေ့မှောက်တွင် လက်မှတ် ရေးထိုးကြပါသည်။

မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေ

အစုရှယ်ယာများဖြင့် ပေးရန်တာဝန် ကန့်သတ်ထားသောအများနှင့်မသက်ဆိုင်သည့်ကုမ္ပဏီ

အန်ဒမန်အလိုင်းယန့်(စ်) ဟဲ့(တ်)ကဲလီမိတက်

၏

သင်းဖွဲ့စည်းမျဉ်းများ

❖❖❖❖❖❖❖

၁။ ဤသင်းဖွဲ့စည်းမျဉ်းနှင့်လိုက်လျောညီထွေမဖြစ်သည့်စည်းမျဉ်းများမှအပ၊ မြန်မာနိုင်ငံကုမ္ပဏီများအက်ဥပဒေ နောက်ဆက်တွဲ ပထမဇယားပုံစံ 'က' ပါစည်းမျဉ်းများသည်ဤကုမ္ပဏီနှင့်သက်ဆိုင်စေရမည်။ မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေပုဒ်မ ၁၇(၂)တွင်ဖော်ပြပါရှိသည့်မလိုက်နာမနေရစည်းမျဉ်းများသည်ဤကုမ္ပဏီနှင့်အစဉ်သဖြင့်သက်ဆိုင်စေရမည်။

အများနှင့်မသက်ဆိုင်သောကုမ္ပဏီ

၂။ ဤကုမ္ပဏီသည်အများနှင့်မသက်ဆိုင်သည့်ကုမ္ပဏီဖြစ်၍အောက်ပါသတ်မှတ်ချက်များသည်အကျိုးသက်ရောက်စေရမည်။

(က) ဤကုမ္ပဏီကခန့်အပ်ထားသော ဝန်ထမ်းများမှအပ၊ ဤကုမ္ပဏီ၏ အစုရှင်အရေအတွက်ကိုငါးဆယ်အထိသာ ကန့်သတ်ထားသည်။

(ခ) ဤကုမ္ပဏီ၏ အစုရှယ်ယာသို့မဟုတ် ဒီဘင်ချာသို့မဟုတ် ဒီဘင်ချာစတော့(ခ်) တစ်ခုခု အတွက် ငွေထည့်ဝင် ရန် အများပြည်သူတို့အား ကမ်းလှမ်းခြင်းမပြုလုပ်ရန်တားမြစ်ထားသည်။

မ,တည်ရင်းနှီးငွေနှင့်အစုရှယ်ယာ

၃။ ကုမ္ပဏီ၏ သတ်မှတ်မတည်ငွေရင်း မှာအမေရိကန်ဒေါ်လာ ၁၅၀,၀၀၀,၀၀၀/-(အမေရိကန်ဒေါ်လာသန်းတစ်ရာ့ငါးဆယ် တိတိ) ဖြစ်၍အမေရိကန်ဒေါ်လာ ၁/-(အမေရိကန်တစ်ဒေါ်လာတိတိ) တန်အစုရှယ်ယာပေါင်း (၁၅၀,၀၀၀,၀၀၀)ခွဲထားပါသည်။ကုမ္ပဏီ၏ ရင်းနှီးငွေကိုကုမ္ပဏီ၏ စည်းမျဉ်းများ နှင့် လက်ရှိတရားဝင် တည်ဆဲဖြစ်နေသောတရားဥပဒေ ပြဋ္ဌာန်းချက်များနှင့်အညီအထွေထွေသင်းလုံးကျွတ် အစည်းအဝေး၌ တိုးမြှင့်နိုင်ခွင့်၊ လျှော့ချနိုင်ခွင့်နှင့်ပြင်ဆင်နိုင်ခွင့်အာဏာရှိစေရမည်။

၄။ မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေပါပြဋ္ဌာန်းချက်များကိုမထိခိုက်စေလျက် အစုရှယ်ယာများသည်ဒါရိုက်တာများ၏ ကြီးကြပ်ကွပ်ကဲမှု အောက်တွင်ရှိစေရမည်။ ၎င်းဒါရိုက်တာများသည် သင့်လျော်သောပုဂ္ဂိုလ်များအားသတ်မှတ်ချက်အခြေအနေ တစ်စုံတစ်ရာဖြင့်အစုရှယ်ယာများကို ခွဲဝေချထားခြင်း သို့မဟုတ်ထုခွဲရောင်းချခြင်းတို့ကိုဆောင်ရွက်နိုင်သည်။

၅။ အစုရှယ်ယာလက်မှတ်များကိုအထွေထွေမန်နေဂျာသို့မဟုတ် ဒါရိုက်တာအဖွဲ့က သတ်မှတ်သည့်အခြား ပုဂ္ဂိုလ်များက လက်မှတ်ရေးထိုး၍ကုမ္ပဏီ၏တံဆိပ်ရိုက်နှိပ်ထုတ်ပေးရမည်။ အစုရှယ်ယာလက်မှတ်သည်ပုံပန်းပျက်ခြင်း၊ ပျောက်ဆုံးခြင်းသို့မဟုတ်ပျက်စီးခြင်းဖြစ်ပါကအဖိုးအခဖြင့်ပြန်လည်အသစ်ပြုလုပ်ပေးမှုကိုသော်လည်းကောင်း၊ ဒါရိုက်တာများက သင့်လျော်သည်ဟုယူဆသောအခြားသက်သေခံအထောက်အထား တစ်စုံတစ်ရာကိုတင်ပြစေ၍သော်လည်းကောင်း ထုတ်ပေး နိုင်သည်။ ကွယ်လွန်သွားသောအစုရှယ်ယာရှင်တစ်ဦး၏တရားဝင်ကိုယ်စားလှယ်ကို ဒါရိုက်တာများက အသိအမှတ်ပြုပေးရမည်ဖြစ်သည်။

၆။ ဒါရိုက်တာများသည် အစုရှင်များက ၎င်းတို့၏ အစုရှယ်ယာများအတွက် မပေးသွင်းရသေးသောငွေများကို အခါအား လျော်စွာ တောင်းဆိုနိုင်သည်။ အစုရှင်တိုင်းကလည်း ၎င်းတို့ထံတောင်းဆိုသည့်အကြိမ်တိုင်း အတွက်ဒါရိုက်တာများက သတ်မှတ်သည့်ပုဂ္ဂိုလ်များထံ သတ်မှတ်သည့်အချိန်နှင့်နေရာတွင်ပေးသွင်းစေရန် တာဝန်ရှိစေရမည်။ ဆင့်ခေါ်မှုတစ်ခုအတွက် အရစ်ကျပေးသွင်းစေခြင်း၊သို့မဟုတ်ပယ်ဖျက်ခြင်း သို့မဟုတ်ရွှေ့ဆိုင်းခြင်းတို့ကို ဒါရိုက်တာများက သတ်မှတ်နိုင်သည်။

ဒါရိုက်တာများ

၇။ သင်းလုံးကျွတ် အစည်းအဝေးက တစ်စုံတစ်ရာသတ်မှတ်ပြဋ္ဌာန်းမှုမပြုလုပ်သမျှ ဒါရိုက်တာများ၏ အရေအတွက်သည် (၂)ဦးထက်မနည်း၊ (၁၀)ဦးထက်မများစေရ။
ပထမဒါရိုက်တာများသည် -

(၁) Mr. Tan See Leng
(၂) Ms. Tan Hui Ann Sherry
(၃) Mr. Lai Kok Peng
(၄) Mr. LiawYit Ming
(၅) Mr. Ng How Kiat Charlie
(၆) U Aung Moe Kyaw
(၇) U Thurane Aung @ Christopher Aung

၈။ ဒါရိုက်တာများသည် ၎င်းတို့အနက်မှတစ်ဦးကိုမန်နေဂျင်းဒါရိုက်တာအဖြစ် အချိန်အခါအလိုက်သင့်လျော်သောသတ်မှတ်ချက်များ၊ ဉာဏ်ပူဇော်ခများဖြင့်ခန့်ထားရမည်ဖြစ်ပြီး အခါအားလျော်စွာ ဒါရိုက်တာ အဖွဲ့ကပေးအပ်သောအာဏာများအားလုံးကို ၎င်းက အသုံးပြုနိုင်သည်။

၉။ ဒါရိုက်တာတစ်ဦးဖြစ်မြောက်ရန်လိုအပ်သောအရည်အချင်းသည်ကုမ္ပဏီ၏အစုရှယ်ယာအနည်းဆုံး (-) စုကိုပိုင်ဆိုင်ခြင်းဖြစ်၍ ၎င်းသည်မြန်မာနိုင်ငံကုမ္ပဏီများအက်ဥပဒေပုဒ်မ ၈၅ ပါပြဋ္ဌာန်းချက်များကိုလိုက်နာရန် တာဝန်ရှိသည်။

၁၀။ အစုရှယ်ယာများ လွှဲပြောင်းရန်တင်ပြချက်ကိုမည်သည့်အကြောင်းပြချက်မျှမပေးဘဲ ဒါရိုက်တာအဖွဲ့သည်၎င်းတို့၏ပြည့်စုံ၍ချုပ်ချယ်ခြင်းကင်းသောဆင်ခြင်တွက်ဆမှုဖြင့်မှတ်ပုံတင်ရန်ငြင်းဆိုနိုင်သည်။

ဒါရိုက်တာများ၏ဆောင်ရွက်ချက်များ

၁၁။ ဒါရိုက်တာများသည် ၎င်းတို့သင့်လျော်သည်ထင်မြင်သည့်အတိုင်း လုပ်ငန်းဆောင်ရွက်ရန်တွေ့ဆုံ ဆွေးနွေးခြင်း၊ အစည်းအဝေးရွှေ့ဆိုင်းခြင်း၊ အချိန်မှန်စည်းဝေးခြင်း၊ အစည်းအဝေးအထ မြောက်ရန်အနည်းဆုံး ဒါရိုက်တာဦးရေသတ်မှတ်ခြင်း တို့ကိုဆောင်ရွက်နိုင်သည်။ ယင်းသို့မသတ်မှတ်ပါက ဒါရိုက်တာနှစ်ဦး တက်ရောက်လျှင်အစည်းအဝေးအထမြောက်ရမည်။ မည်သည့် ကိစ္စများကိုမဆိုမဲခွဲဆုံးဖြတ်ရာတွင် မဲအရေအတွက်တူနေပါက သဘာပတိသည် ဒုတိယမဲသို့မဟုတ် အနိုင်မဲကို ပေးနိုင်သည်။

၁၂။ ဒါရိုက်တာများ၏ အစည်းအဝေးကို မည်သည့်ဒါရိုက်တာကမဆို အချိန်မရွေး ခေါ်နိုင်သည်။

၁၃။ ဒါရိုက်တာအားလုံးက လက်မှတ်ရေးထိုးထားသော ရေးသားထားသည့်ဆုံးဖြတ်ချက် တစ်ရပ်သည် နည်းလမ်းတကျ ခေါ်ယူကျင်းပသော အစည်းအဝေးက အတည်ပြုသည့် ဆုံးဖြတ်ချက်ကဲ့သို့ပင် ကိစ္စအားလုံးအတွက် အကျိုးသက်ရောက်စေရမည်။

ဒါရိုက်တာများ၏ လုပ်ပိုင်ခွင့်နှင့်တာဝန်များ

၁၄။ မြန်မာနိုင်ငံ ကုမ္ပဏီများအက်ဥပဒေ နောက်ဆက်တွဲဇယားပုံစံ(က)ပါ စည်းမျဉ်းအပိုဒ် ၇၁ တွင် ပေးအပ်ထားသော အထွေထွေ အာဏာများကို မထိခိုက်စေဘဲ ဒါရိုက်တာများသည် အောက်ဖော်ပြပါ အာဏာများ ရှိရမည်ဟု အတိအလင်း ထုတ်ဖော်ကြေညာသည်။ အာဏာဆိုသည်မှာ -

(၁) ဒါရိုက်တာများက သင့်လျော်သည်ဟုယူဆသော တန်ဖိုးနှင့်စည်းကမ်းများ၊ အခြေအနေများ သတ်မှတ်၍ ကုမ္ပဏီကရယူရန် အာဏာရှိသည့် မည်သည့်ပစ္စည်း၊ အခွင့်အရေးများ၊ အခွင့်အလမ်းများကိုမဆို ဝယ်ယူရန် သို့မဟုတ် အခြားနည်းလမ်းများဖြင့် ရယူပိုင်ဆိုင်ရန်အပြင် ကုမ္ပဏီက ပိုင်ဆိုင်ခွင့်ရှိသော မည်သည့်ပစ္စည်း၊ အခွင့်အရေးများ၊ အခွင့်အလမ်းများကိုမဆို သင့်တော်သောစည်းကမ်းချက်များ သတ်မှတ်၍ရောင်းချခြင်း၊ အငှားချခြင်း၊ စွန့်လွှတ်ခြင်း၊ သို့မဟုတ် အခြားနည်းလမ်းများဖြင့် ဆောင်ရွက်ခြင်းတို့ကိုပြုလုပ်ရန်။

(၂) သင့်လျော်သော စည်းကမ်းသတ်မှတ်ချက်များဖြင့် ငွေကြေးများကို ချေးငှားရန် သို့မဟုတ် အဆိုပါချေးငှားသော ငွေကြေးများကို ပြန်လည်ပေးဆပ်ရန်အတွက် အာမခံများထားရှိရန်အပြင်၊ အထူးသဖြင့် ဤကုမ္ပဏီ၏ ဒီဘင်ချာများ၊ ဒီဘင်ချာစတော့(ခ်)များ၊ ခေါ်ယူခြင်းမပြုရသေးသော ရင်းနှီးငွေများအပါအဝင် ယခုလက်ရှိနှင့် နောင်ရှိမည့် ပစ္စည်းများအားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကိုအပေါင်ပြု၍ ထုတ်ဝေရန်။

(၃) ဤကုမ္ပဏီ ရယူထားသော အခွင့်အရေးများ သို့မဟုတ် ဝန်ဆောင်မှုများအတွက် အားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကို ငွေကြေးအားဖြင့် ပေးချေရန်၊ သို့မဟုတ် အစုရှယ်ယာများ၊ ငွေချေးစာချုပ်များ၊ ဒီဘင်ချာများ သို့မဟုတ် ဤကုမ္ပဏီ၏ အခြားသော အာမခံစာချုပ်များကို ထုတ်ပေးရန်၊ ထို့အပြင် အဆိုပါ အစုရှယ်ယာများထုတ်ပေးရာ၌ ငွေအပြည့်ပေးသွင်းပြီးသော အစုရှယ်ယာအနေဖြင့် သော်လည်းကောင်း၊ တစ်စိတ်တစ်ဒေသ ပေးသွင်းပြီးသော အစုရှယ်ယာများ အနေဖြင့်သော်လည်းကောင်း သဘောတူညီသကဲ့သို့ ထုတ်ဝေပေးရန်နှင့် အဆိုပါ ငွေချေးစာချုပ်များ၊ ဒီဘင်ချာများ သို့မဟုတ် ကုမ္ပဏီ၏ အခြားသောအာမခံ စာချုပ်များဖြင့် ထုတ်ဝေပေးရာ၌ ခေါ်ဆိုခြင်း မပြုရသေးသော ရင်းနှီးငွေများ အပါဝင် ဤကုမ္ပဏီ၏ ပစ္စည်းအားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကို အပေါင်ပြု၍ဖြစ်စေ ထိုကဲ့သို့ မဟုတ်ဘဲဖြစ်စေ ထုတ်ပေးရန်။

(၄) ဤကုမ္ပဏီနှင့် ပြုလုပ်ထားသော ကန်ထရိုက်စာချုပ်များ၊ တာဝန်ယူထားသည့်လုပ်ငန်းများ ပြီးစီးအောင် ဆောင်ရွက်စေခြင်း အလို့ငှာခေါ်ယူခြင်း မပြုရသေးသော ရင်းနှီးငွေများ အပါအဝင် ဤကုမ္ပဏီ၏ ပစ္စည်းရပ်များ အားလုံး သို့မဟုတ် တစ်စိတ်တစ်ဒေသကို ပေါင်နှံ၍ သော်လည်းကောင်း၊ အပေါင်ပြု၍သော်လည်းကောင်း သို့မဟုတ် အစုရှယ်ယာများအတွက် ငွေများ တောင်းခံခေါ်ယူ၍သော်လည်းကောင်း ခွင့်ပြုရန် သို့မဟုတ် သင့်လျော်သည့်အတိုင်း ဆောင်ရွက်ရန်။

(၅) မန်နေဂျာများ၊ အတွင်းရေးမှူးများ၊ အရာရှိများ၊ စာရေးများ၊ ကိုယ်စားလှယ်များနှင့် ဝန်ထမ်းများကို အမြဲတမ်း၊ ယာယီ သို့မဟုတ် အထူးကိစ္စရပ်များအတွက်ခန့်ထားခြင်း၊ ရပ်စဲခြင်း၊ ဆိုင်းငံ့ခြင်းများအတွက် လည်းကောင်း အဆိုပါ ပုဂ္ဂိုလ်တို့၏ တာဝန်များ၊ အာဏာများ၊ လစာငွေများ၊ အခြားငွေကြေးများကို သတ်မှတ်ရာ၌လည်းကောင်း၊ အာမခံပစ္စည်းများ တောင်းခံရာ၌လည်းကောင်း သင့်လျော်သလိုဆောင်ရွက်ရန်၊ ထို့အပြင် အဆိုပါကိစ္စရပ်များအတွက် ကုမ္ပဏီ၏ မည်သည့်အရာရှိကိုမဆို ကိစ္စရပ်အားလုံးကိုဖြစ်စေ၊ တစ်စိတ်တစ်ဒေသကိုဖြစ်စေ ဒါရိုက်တာများ၏ကိုယ်စား ဆောင်ရွက်နိုင်ရေးအတွက် တာဝန်လွှဲအပ်ရန်။

(၆) ဤကုမ္ပဏီ၏ ဒါရိုက်တာတစ်ဦးအား ဒါရိုက်တာရာထူးနှင့် တွဲဖက်၍ မန်နေဂျင်း ဒါရိုက်တာ၊ အထွေထွေ မန်နေဂျာ၊ အတွင်းရေးမှူး သို့မဟုတ် ဌာနခွဲ မန်နေဂျာအဖြစ်ခန့်ထားရန်။

(၇) မည်သည့် အစုရှင်ထံမှမဆို ၄င်းတို့၏ အစုရှယ်ယာများအားလုံးကိုဖြစ်စေ၊ အချို့အဝက်ကိုဖြစ်စေ စွန့်လွှတ်ခြင်းအား သဘောတူညီသော စည်းကမ်းများဖြင့် လက်ခံရန်။

(၈) ဤကုမ္ပဏီက ပိုင်ဆိုင်သော သို့မဟုတ် ပိုင်ဆိုင်ခွင့်ရှိသော သို့မဟုတ် အခြားအကြောင်းများကြောင့် ဖြစ်သော မည်သည့် ပစ္စည်းကိုမဆို ကုမ္ပဏီ၏ကိုယ်စား လက်ခံထိန်းသိမ်းထားရန်အတွက် မည်သည့်ပုဂ္ဂိုလ် သို့မဟုတ် ပုဂ္ဂိုလ်များကိုမဆို ခန့်ထားရန်နှင့် အဆိုပါ ယုံမှတ် အပ်နှံခြင်းများနှင့် ပတ်သက်၍ လိုအပ်သော စာချုပ်စာတမ်းများ ချုပ်ဆို ပြုလုပ်ရန်။

(၉) ဤကုမ္ပဏီ၏ အရေးအရာများနှင့် စပ်လျဉ်း၍ ဤကုမ္ပဏီက ပြုလုပ်သော သို့မဟုတ် ဤကုမ္ပဏီအပေါ် သို့မဟုတ် ဤကုမ္ပဏီ၏ အရာရှိများအပေါ် ပြုလုပ်သော တရားဥပဒေအရ စွဲဆို ဆောင်ရွက်မှုများကို တရားစွဲဆို၊ အရေးယူ၊ ခုခံကာကွယ်ရန် သို့မဟုတ် ခွင့်လွှတ်ရန်၊ ထို့အပြင် ဤကုမ္ပဏီက ရရန်ရှိသော ကြွေးမြီများနှင့် ဤကုမ္ပဏီအပေါ် တောင်းခံသော ကြွေးမြီများနှင့်ပတ်သက်၍ ပေးဆပ်ရန် အချိန်ကာလ ရွှေ့ဆိုင်းခွင့်ပြုခြင်း သို့မဟုတ် နှစ်ဦးနှစ်ဖက် သဘောတူ ကျေအေးခြင်းများ ပြုလုပ်ရန်။

(၁၀) ဤကုမ္ပဏီက ပေးရန်ရှိသော သို့မဟုတ် ရရန်ရှိသော ငွေတောင်းခံခြင်းများကို ဖြန်ဖြေရေး ခုံသမာဓိထံသို့ ဖြေရှင်းရန်အတွက် အပ်နှံရန်အပြင် ဖြန်ဖြေရေး ခုံသမာဓိ၏ ဆုံးဖြတ်ချက်အတိုင်းလိုက်နာဆောင်ရွက်ရန်။

(၁၁) ဤကုမ္ပဏီက ရရန်ရှိသောတောင်းဆိုချက်၊ တောင်းခံချက်များနှင့် ကုမ္ပဏီသို့ပေးရန်ရှိသော ငွေကြေးများ အတွက်ပြေစာများ ပြုလုပ်ထုတ်ပေးခြင်း၊ လျှော်ပစ်ခြင်းနှင့် အခြားသောနည်းဖြင့်စွန့်လွှတ်ခြင်းများကို ပြုလုပ်ရန်။

(၁၂) လူမွဲစာရင်းခံရခြင်း၊ ကြွေးမြီး မဆက်နိုင်ခြင်းကိစ္စများနှင့် ပတ်သက်၍ ကုမ္ပဏီ၏ကိုယ်စား ဆောင်ရွက်ရန်။

(၁၃) ငွေလွှဲစာတမ်းများ၊ ချက်လက်မှတ်များ၊ ဝန်ခံကတိစာချုပ်များ ထပ်ဆင့်လက်မှတ်ရေးထိုးခြင်းများ၊ လျှော်ပစ်ခြင်းများ၊ ကန်ထရိုက် စာချုပ်များနှင့်စာရွက်စာတမ်းများကို ကုမ္ပဏီ၏ ကိုယ်စားမည်သူက လက်မှတ် ရေးထိုးခွင့်ရှိသည်ကို စိစစ်သတ်မှတ်ရန်။

(၁၄) ဒါရိုက်တာများက သင့်လျော်သည်ဟု ယူဆပါက သင့်လျော်လျောက်ပတ်သောနည်းလမ်းများဖြင့် လတ်တလော အသုံးပြုရန် မလိုသေးသော ကုမ္ပဏီပိုင် ငွေများကို အာမခံပစ္စည်း ပါသည်ဖြစ်စေ၊ မပါသည်ဖြစ်စေ ရင်းနှီးမြှုပ်နှံ ထားရန်နှင့် စီမံခန့်ခွဲထားရန်။ ထို့အပြင် အချိန်ကာလအားလျော်စွာ မြှုပ်နှံထားသောငွေကို ပြန်လည်ရယူရန်နှင့် ပြင်ဆင်ပြောင်းလွှဲရန်။

(၁၅) ဤကုမ္ပဏီ၏ အကျိုးအတွက် ငွေကြေးစိုက်ထုတ် ကုန်ကျခံထားသော ဒါရိုက်တာ သို့မဟုတ် အခြား ပုဂ္ဂိုလ်များက ကုမ္ပဏီ၏ (လက်ရှိနှင့် နောင်တွင်ရှိမည့်)ပစ္စည်းများကို ဤကုမ္ပဏီ၏ အမည်ဖြင့်ဖြစ်စေ၊ ဤကုမ္ပဏီ၏ ကိုယ်စားဖြစ်စေ ပေါင်နှံခြင်းကို သင့်လျော်သည်ဟု ယူဆပါက ဆောင်ရွက်ခွင့်ပြုရန်။ အဆိုပါ ပေါင်နှံခြင်းဆိုရာ၌ ရောင်းချနိုင်သည့် အာဏာနှင့် အခြားသော သဘောတူညီထားသည့် တရားဝင်သော တူညီချက်များနှင့် ဥပဒေပြဋ္ဌာန်းချက်များပါ ပါဝင်သည်။

(၁၆) ဤကုမ္ပဏီကခန့်အပ်ထားသောမည်သည့်အရာရှိသို့မဟုတ်ပုဂ္ဂိုလ်ကိုမဆိုအတိအကျဆောင်ရွက်ခဲ့သည့်လုပ်ငန်း သို့မဟုတ် ဆောင်ရွက်မှုတစ်ခုအတွက် ရရှိသောအမြတ်ငွေမှ ကော်မရှင်ပေးခြင်း သို့မဟုတ် ကုမ္ပဏီ၏ အထွေထွေ အမြတ်အစွန်းမှ ခွဲဝေပေးခြင်းများပြုလုပ်ရန်နှင့် အဆိုပါကော်မရှင်များ အမြတ်များခွဲဝေပေးခြင်း စသည်တို့ကို ဤကုမ္ပဏီ၏ လုပ်ငန်းကုန်ကျစရိတ် တစ်စိတ်တစ်ဒေသအဖြစ် သတ်မှတ်ရန်။

(၁၇) ဤကုမ္ပဏီ၏ လုပ်ငန်းများ၊ အရာရှိများ ဝန်ထမ်းများနှင့် အစုရှင်များအတွက် ထုတ်ပြန်ထားသော စည်းမျဉ်းများ၊ စည်းကမ်းချက်များ၊ စည်းကမ်းဥပဒေများကို အခါအားလျော်စွာ သတ်မှတ်ခြင်း၊ ပြင်ဆင်ခြင်း၊ ဖြည့်စွက်ခြင်းများ ဆောင်ရွက်ရန်။

(၁၈) ဤကုမ္ပဏီ၏ လုပ်ငန်းအတွက် ဤကုမ္ပဏီ၏ အမည်ဖြင့်ဖြစ်စေ၊ ဤကုမ္ပဏီ၏ ကိုယ်စားဖြစ်စေ လိုအပ်သည်ဟု ယူဆလျှင် ညှိနှိုင်းဆွေးနွေးခြင်းနှင့် ကန်ထရိုက်စာချုပ် ချုပ်ဆိုခြင်းများကို ပြုလုပ်ရန်၊ ဖျက်သိမ်းရန်နှင့် ပြင်ဆင်ရန်အပြင် အဆိုပါ ဆောင်ရွက်ချက် စာချုပ်များနှင့် ကိစ္စရပ်များကိုလည်းကောင်း ၎င်းတို့နှင့် စပ်လျဉ်းသော ကိစ္စရပ်များကို လည်းကောင်း လုပ်ကိုင်ဆောင်ရွက်ရန်။

(၁၉) ဒါရိုက်တာများက သင့်လျော်လျောက်ပတ်သည်ဟု ယူဆပါက ကုမ္ပဏီ၏ စီးပွားရေးလုပ်ငန်းတွင် အကျိုးရှိ စေရန်အတွက် မည်သည့်ပြည်တွင်းပြည်ပ ပုဂ္ဂိုလ်၊ စီးပွားရေး အဖွဲ့အစည်း၊ ကုမ္ပဏီ သို့မဟုတ် ဘဏ် သို့မဟုတ် ငွေကြေးအဖွဲ့အစည်းထံမှ မဆို ငွေချေးယူရန်။

အထွေထွေအစည်းဝေးကြီးများ

၁၅။ ကုမ္ပဏီကိုဥပဒေအရ ဖွဲ့စည်းတည်ထောင်ပြီးသည့်နေ့မှ တစ်ဆယ့်ရှစ်လအတွင်း အထွေထွေသင်းလုံးကျွတ် အစည်းအဝေးကြီး ကိုကျင်းပရမည်။ ထို့နောက် ဒါရိုက်တာအဖွဲ့က သတ်မှတ်ပေးသည့် အချိန်နှင့် နေရာများတွင် ပြက္ခဒိန်နှစ်တစ်နှစ်လျှင် အနည်းဆုံးတစ်ကြိမ် (နောက်ဆုံးကျင်းပသည့် အထွေထွေအစည်းဝေးကြီးနှင့်တစ်ဆယ့်ငါးလထက်မပိုသည့် အချိန်၌)ကျင်းပရမည်။ သင်းလုံးကျွတ် အစည်းအဝေးစတင်၍ လုပ်ငန်းအတွက် ဆွေးနွေးချိန်တွင် အစည်းအဝေးအထမြောက်ရန် သတ်မှတ်သည့်အစုရှင်အရေအတွက် မတတ်ရောက်သော မည်သည့်သင်းလုံးကျွတ် အစည်းအဝေးတွင်မဆို လုပ်ငန်းနှင့် ပတ်သက်၍ ဆုံးဖြတ်ဆောင်ရွက်ခြင်းမပြုရ။ ဤတွင်အခြားနည်း သတ်မှတ်ပြဌာန်းခြင်းမရှိလျှင် ထုတ်ဝေထားသည့် မ,တည် ရင်းနှီးငွေ အစုရှယ်ယာများ၏ ငါးဆယ်ရာခိုင်နှုန်းထက်မနည်း ပိုင်ဆိုင်ကြသည့် (နှစ်ဦးထက်မနည်းသော) အစုရှင်များ ကိုယ်တိုင်တတ်ရောက်လျှင် လုပ်ငန်းကိစ္စအားလုံး ဆောင်ရွက်ရန်အတွက် အစည်းအဝေးအထမြောက်သည့်ဦးရေ ဖြစ်သည်။ အကယ်၍ ကုမ္ပဏီတွင် အစုရှင်အရေအတွက် နှစ်ဦးတည်းသာရှိသည့် ကိစ္စတွင်မူ ထိုနှစ်ဦးတည်းသည်ပင်လျှင် အစည်းအဝေး အထမြောက်ရန် သတ်မှတ်သည့် အရေတွက်ဖြစ် စေရမည်။

အမြတ်ဝေစုများ

၁၆။ သင်းလုံးကျွတ်အစည်းအဝေးတွင် ဤကုမ္ပဏီ၏ အစုရှင်များအားခွဲဝေပေးမည့် အမြတ်ဝေစုကို ကြေညာရမည်။ သို့ရာတွင် အမြတ်ဝေစုသည် ဒါရိုက်တာများက ထောက်ခံသော ငွေပမာဏထက် မကျော်လွန်စေရ။ သက်ဆိုင်ရာနှစ်၏ အမြတ်ပမာဏ သို့မဟုတ် အခြားမခွဲဝေရသေးသည့် အမြတ်ပမာဏမှအပ အမြတ်ဝေစုကို ခွဲဝေမပေးရ။

ရုံးဝန်ထမ်းများ

၁၇။ ကုမ္ပဏီသည် လုပ်ငန်းရုံးတစ်ခုကို ဖွင့်လှစ်၍ ဆောင်ရွက်မည်ဖြစ်ပြီး အရည်အချင်း ပြည့်မီသူပုဂ္ဂိုလ်တစ်ဦးအား အထွေထွေမန်နေဂျာအဖြစ် ခန့်အပ်ရန်နှင့် အခြားအရည်အချင်း ပြည့်မီသူများအား ရုံးဝန်ထမ်းများအဖြစ် ခန့်အပ်မည်ဖြစ်သည်။ လစာ၊ ခရီးသွားလာစရိတ်နှင့် အခြားအသုံးစရိတ်များကဲ့သို့သော ဉာဏ်ပူဇော်ခများနှင့် အခကြေးငွေ များကို ဒါရိုက်တာအဖွဲ့က သတ်မှတ်မည်ဖြစ်ပြီး ၎င်းသတ်မှတ်ချက်များကို သင်းလုံးကျွတ် အစည်းအဝေးက အတည်ပြုရမည်။ အထွေထွေမန်နေဂျာသည် လုပ်ငန်းရုံး၏ ထိရောက်စွာလုပ်ငန်း လည်ပတ်မှုအားလုံးအတွက် တာဝန်ရှိစေရမည်ဖြစ်ပြီး မန်နေးဂျင်း ဒါရိုက်တာအားတာဝန်ခံ၍ ဆောင်ရွက်ရမည်။

ငွေစာရင်းများ

၁၈။ ဒါရိုက်တာများသည် သင့်လျော်သည့် ငွေစာရင်းစာအုပ်များကို အောက်ဖော်ပြပါ သတ်မှတ်ချက်များနှင့်အညီ ထားသိထိန်းသိမ်း ဆောင်ရွက်ရမည်။

(၁) ကုမ္ပဏီ၏ ရငွေ၊ သုံးငွေများ၏ ပမာဏနှင့် ၎င်းရငွေ၊ သုံးငွေများဖြစ်ပေါ်ခြင်းနှင့် စပ်လျဉ်းသည့် အကြောင်း ကိစ္စများ။

(၂) ကုမ္ပဏီ၏ ကုန်ပစ္စည်းများ ရောင်းချခြင်းနှင့် ဝယ်ယူခြင်းများ။

(၃) ဤကုမ္ပဏီ၏ ရရန်ပိုင်ခွင့်နှင့် ပေးရန်တာဝန်များ။

၁၉။ ငွေစာရင်းစာအုပ်အားလုံးကို ဤကုမ္ပဏီ၏ မှတ်ပုံတင်ထားသော လုပ်ငန်းရုံး သို့မဟုတ် ဒါရိုက်တာများကသင့်လျော်သည်ဟုထင်မြင်ယူဆသော အခြားနေရာတွင် သိမ်းဆည်းထားရမည်ဖြစ်ပြီး၊ ရုံးချိန်အတွင်း၌ ဒါရိုက်တာများက စစ်ဆေးနိုင်ရန် ပြသထားရမည်။

စာရင်းစစ်

၂၀။ စာရင်းစစ်များကို ခန့်အပ်ထားရမည်။ ၎င်းစာရင်းစစ်များ၏ တာဝန်သည် မြန်မာနိုင်ငံ ကုမ္ပဏီများ အက်ဥပဒေ သို့မဟုတ် အခါအားလျော်စွာ ပြင်ဆင်သတ်မှတ်သည့် စည်းမျဉ်း စည်းကမ်းများနှင့် လိုက်လျောညီထွေ ဖြစ်ရမည်။

နို့တစ်စာ

၂၁။ ဤကုမ္ပဏီသည် မည်သည့်အစုရှင်ထံသို့မဆို နို့တစ်စာကို လက်ရောက်ပေးအပ်ခြင်း သို့မဟုတ် နို့တစ်စာပါသော စာကို စာတိုက်ခ ကြိုတင်ပေးထား၍ ၎င်းအစုရှင်ထံ မှတ်ပုံတင်လိပ်စာအတိုင်း စာတိုက်မှတစ်ဆင့် လိပ်မူပေးပို့ခြင်းအားဖြင့် ပေးပို့နိုင်သည်။

တံဆိပ်

၂၂။ ဒါရိုက်တာများသည် တံဆိပ်ကို လုံခြုံစွာထိန်းသိမ်းထားရန်အတွက် စီမံဆောင်ရွက်ရမည်။ ထိုတံဆိပ်ကို ဒါရိုက်တာများက ကြိုတင်ပေးအပ်ထားသည့် ခွင့်ပြုချက်ဖြင့်မှတစ်ပါး၊ ထို့အပြင် အနည်းဆုံး ဒါရိုက်တာတစ်ဦး ရှေ့မှောက်တွင်မှ တစ်ပါး မည်သည့်အခါမျှ မသုံးရ။ တံဆိပ်ရိုက်နှိပ်ထားသည့် စာရွက်စာတမ်းတိုင်းတွင် ထိုဒါရိုက်တာက လက်မှတ်ရေးထိုးရမည်။

လျော်ကြေး

၂၃။ မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေ ပုဒ်မ ၈၆ (ဂ) တွင် ဖော်ပြပါရှိသည့် ပြဋ္ဌာန်းချက်များ၊ လက်ရှိတရားဝင်တည်ဆဲ ဥပဒေပြဋ္ဌာန်းချက်များနှင့် မဆန့်ကျင်စေဘဲ ကုမ္ပဏီ၏ ဒါရိုက်တာ၊ စာရင်းစစ်၊ အတွင်းရေးမှူး သို့မဟုတ် အခြားအရာရှိ တစ်ဦးဦးမှာ မိမိ၏ တာဝန် ဝတ္တရားများကို ဆောင်ရွက်ရာ၌ဖြစ်စေ၊ ထိုတာဝန် ဝတ္တရားများနှင့် စပ်လျဉ်း၍ဖြစ်စေ ကျခံခဲ့ရသည့်စရိတ်များ၊ တောင်းခံငွေများ၊ ဆုံးရှုံးငွေများ၊ ကုန်ကျငွေများနှင့် ကြွေးမြီတာဝန်များအတွက် ကုမ္ပဏီထံမှ လျော်ကြေး ရထိုက်ခွင့်ရှိစေရမည်။

ဖျက်သိမ်းခြင်း

၂၄။ ကုမ္ပဏီ၏ အထွေထွေအစည်းအဝေး ဆုံးဖြတ်ချက်ဖြင့် ကုမ္ပဏီအား ဖျက်သိမ်းနိုင်သည်။ ယင်းသို့ ဖျက်သိမ်းရာတွင် မြန်မာနိုင်ငံကုမ္ပဏီများ အက်ဥပဒေများနှင့် ယင်းဥပဒေများအား အခါအားလျော်စွာ ပြင်ဆင်ပြောင်းလဲထားသည့် တရားဥပဒေများတွင် ပါဝင်သည့် စည်းမျဉ်းများအတိုင်း လိုက်နာပြုလုပ်ရမည်။

❖ ❖ ❖ ❖ ❖ ❖ ❖

အောက်တွင်အမည်၊ နိုင်ငံသား၊ နေရပ်နှင့် အကြောင်းအရာစုံလင်စွာပါသော ဇယားတွင် လက်မှတ်ရေးထိုးသူ ကျွန်ုပ်တို့ ကိုယ်စီကိုယ်ငှသည် ဤသင်းဖွဲ့စည်းမျဉ်းအရ ကုမ္ပဏီတစ်ခုဖွဲ့စည်းရန် လိုလားသည့်အလျောက် ကျွန်ုပ်တို့၏ အမည်အသီးသီးနှင့် ယှဉ်တွဲ၍ပြထားသော အစုရှယ်ယာများကို ကုမ္ပဏီ၏ မတည်ရင်းနှီးငွေတွင် ထည့်ဝင်ကြရန် သဘောတူပါသည်။

စဉ်	အစုထည့်ဝင်သူများ၏အမည်၊ နေရပ်လိပ်စာနှင့်အလုပ်အကိုင်	နိုင်ငံသားနှင့် အမျိုးသား မှတ်ပုံတင်အမှတ်	ဝယ်ယူသော အစုရှယ်ယာ ဦးရေ	ထိုးမြဲ လက်မှတ်
1.	Parkway Healthcare Indo-China Pte. Ltd. 111 Somerset Road, #15-01, Tripleone Somerest, Singapore (238164) <u>Represented By</u> Liaw Yit Ming 6 Keng Chin Road, #05-05 Cyan, Singapore 258709	Incorporated in Singapore (Registration No. 200723244M) Singapore PP No. 32825840	78,000	
2.	Macondray Holdings Pte. Ltd. 78 Shenton Way #28-01 Singapore 079120 <u>Represented By</u> Mr. Ng How Kiat Charlie 25 Moonstone Lane #19-03 Singapore 328465	Incorporated in Singapore (Registration No. 201317874R) Singapore PP No. E3133254L	15,750	
3.	AMMK Medicare Company Limited 33 Pyay Road, 6 1/2Miles, Hlaing Township, Yangon. <u>Represented By</u> U Aung Moe Kyaw No. 18, Aung Mingalar St, Aung Theikdi Road, (3) Ward, Mayangone Township,Yangon.	Incorporated in Myanmar (Registration No. 1397/2015-2016 [YGN]) Myanmar Nation Scrutiny Card No.12/MAYAKA (N) 106397	32,250	
4.	Global Star Company Limited N0. (2), Ba Yint Naung Road, Ywar Mha Gwe (2) Ward, Hlaing Township, Yangon. <u>Represented By</u> U Thurane Aung @ Christopher Aung 105, University Avenue Road, (10) Ward, Kamayut Township, Yangon.	Incorporated in Myanmar (Registration No.1507(2008-2009) Myanmar Nation Scrutiny Card No. 12/KAMAYA (N) 050839	24,000	

ရန်ကုန်။ နေ့စွဲ၊ ၂၀၁၆ ခုနှစ်၊ လ၊ ရက်။

အထက်ပါ လက်မှတ်ရှင်များသည် ကျွန်ုပ်တို့၏ ရှေ့မှောက်တွင်
လက်မှတ် ရေးထိုးကြပါသည်။

THE MYANMAR COMPANIES ACT

PRIVATE COMPANY LIMITED BY SHARES

Memorandum Of Association

OF

ANDAMAN ALLIANCE HEALTHCARE LIMITED

❖❖❖❖❖❖❖

I. The name of the Company is "**ANDAMAN ALLIANCE HEALTHCARE LIMITED**".

II. The registered office of the Company will be situated in the Union of Myanmar.

III. The objects for which the Company is established are as on the next page.

IV. The liability of the members is limited.

V. The authorised capital of the Company is US$ **150,000,000**/- (**United States DollarOne Hundred and Fifty Million** Only) divided into (**150,000,000**) shares of US$ **1**/- (United States Dollar OneOnly)each, with power in General Meeting either to increase, reduce or alter such capital from time to time in accordance with the regulations of the Company and the legislative provisions for the time being in force in this behalf.

(6) To carry on the following services either solely on its own or in joint-venture, with any foreign or local partners-

(a) Private Hospital Services

(7) To borrow money for the benefit of the Company's business from any person, firm, company, bank or financial organization in the manner that the Company thinks fit.

PROVISO:- *Provide that the Company shall not exercise any of the above objects whether in the Union of Myanmar or elsewhere, save in so far as it may be entitled so as to do in accordance with the Laws, Orders and Notifications in force from time to time and then only subject to such permission and or approval as may be prescribed by the Laws, Orders and Notifications of the Union of Myanmar for the time being in force.*

အောက်တွင်အမည်၊ နိုင်ငံသား၊ နေရပ်နှင့် အကြောင်းအရာစုံလင်စွာပါသော ဇယားတွင် လက်မှတ်ရေးထိုးသူ ကျွန်ုပ်တို့ ကိုယ်စီကိုယ်ငှသည် ဤသင်းဖွဲ့မှတ်တမ်းအရ ကုမ္ပဏီတစ်ခုဖွဲ့စည်းရန် လိုလားသည့်အလျောက် ကျွန်ုပ်တို့၏ အမည်အသီးသီးနှင့် ယှဉ်တွဲ၍ပြထားသော အစုရှယ်ယာများကို ကုမ္ပဏီ၏ မတည်ရင်းနှီးငွေတွင် ထည့်ဝင်ကြရန် သဘောတူပါသည်။

စဉ်	အစုထည့်ဝင်သူများ၏အမည်၊ နေရပ်လိပ်စာနှင့်အလုပ်အကိုင်	နိုင်ငံသားနှင့် အမျိုးသား မှတ်ပုံတင်အမှတ်	ဝယ်ယူသော အစုရှယ်ယာ ဦးရေ	ထိုးမြဲ လက်မှတ်
1.	Parkway Healthcare Indo-China Pte. Ltd. 111 Somerset Road, #15-01, Tripleone Somerest, Singapore (238164) <u>Represented By</u> Liaw Yit Ming 6 Keng Chin Road, #05-05 Cyan, Singapore 258709	Incorporated in Singapore (Registration No. 200723244M) Singapore PP No. 32825840	78,000	
2.	Macondray Holdings Pte. Ltd. 78 Shenton Way #28-01 Singapore 079120 <u>Represented By</u> Mr. Ng How Kiat Charlie 25 Moonstone Lane #19-03 Singapore 328465	Incorporated in Singapore (Registration No. 201317874R) Singapore PP No. E3133254L	15,750	
3.	AMMK Medicare Company Limited 33 Pyay Road, 6 1/2Miles, Hlaing Township, Yangon. <u>Represented By</u> U Aung Moe Kyaw No. 18, Aung Mingalar St, Aung Theikdi Road, (3) Ward, Mayangone Township,Yangon.	Incorporated in Myanmar (Registration No. 1397/2015-2016 [YGN]) Myanmar Nation Scrutiny Card No.12/MAYAKA (N) 106397	32,250	
4.	Global Star Company Limited N0. (2), Ba Yint Naung Road, Ywar Mha Gwe (2) Ward, Hlaing Township, Yangon. <u>Represented By</u> U Thurane Aung @ Christopher Aung 105, University Avenue Road, (10) Ward, Kamayut Township, Yangon.	Incorporated in Myanmar (Registration No.1507(2008-2009) Myanmar Nation Scrutiny Card No. 12/KAMAYA (N) 050839	24,000	

ရန်ကုန်။ နေ့စွဲ၊ ၂၀၁၆ ခုနှစ်၊ လ၊ ရက်။

အထက်ပါ လက်မှတ်ရှင်များသည် ကျွန်ုပ်တို့၏ ရှေ့မှောက်တွင်
လက်မှတ် ရေးထိုးကြပါသည်။

THE MYANMAR COMPANIES ACT

PRIVATE COMPANY LIMITED BY SHARES

Articles of Association

OF

ANDAMAN ALLIANCE HEALTHCARE LIMITED

❖❖❖❖❖❖❖❖

1. The regulation contained in Table 'A' in the First Schedule to the Myanmar Companies Act shall apply to the Company save in so far as such regulation which are inconsistent with the following Articles. The compulsory regulations stipulated in Section 17 (2) of the Myanmar Companies Act shall always be deemed to apply to the Company.

PRIVATE COMPANY

2. The Company is to be a Private Company and accordingly following provisions shall have effect:-

(a) The number of members of the Company, exclusive of persons who are in the employment the Company, shall be limited to fifty.

(b) Any invitation to the public to subscribe for any share or debenture stock of the Company is hereby prohibited.

CAPITAL AND SHARES

3. The authorized capital of the Company is US$ 150,000,000(United States DollarOne Hundredand Fifty Million Only) divided into (150,000,000) shares of US$ 1 (United States Dollar One Only) each, with power in General Meeting either to increase, reduce or alter such capital from time to time in accordance with the regulations of the Company and the legislative provisions for the time being in force in this behalf.

4. Subject to the provisions of the Myanmar Companies Act the shares shall be under the control of the Directors, who may allot or otherwise dispose of the same to such persons and on such terms and conditions as they may determine.

5. The certificate of title to share shall be issued under the Seal of the Company, and signed by the General Manager or some other persons nominated by the Board of Directors. If the share certificate is defaced, lost or destroyed, it may be renewed on payment of such fee, if any, and on such terms, if any, as to evidence and indemnity as the Directors may think fit. The legal representative of a deceased member shall be recognised by the Directors.

6. The Directors may, from time to time make call upon the members in respect of any money unpaid on their shares, and each member shall be liable to pay the amount of every call so made upon him to the persons, and at the times and places appointed by the Directors. A call may be made payable by instalments or may be revoked or postponed as the Directors may determine.

DIRECTORS

7. Unless otherwise determined by a General Meeting the number of Directors shall not be less than (2) and not more than (10).

The First Directors shall be:-

(1) Mr Tan See Leng
(2) Ms Tan Hui Ann Sherry
(3) Mr Lai Kok Peng
(4) Mr LiawYit Ming
(5) Mr Ng How Kiat Charlie
(6) U Aung Moe Kyaw
(7) U Thurane Aung @ Christopher Aung

8. The Directors may from time to time appoint one of their body to the office of the Managing Director for such term and at such remuneration as they think fit and he shall have all the powers delegated to him by the Board of Directors from time to time.

9. The qualification of a Director shall be the holding of at least (-) shares in the Company in his or her own name and it shall be his duty to comply with the provision of Section (85) of the Myanmar Companies Act.

10. The Board of Directors may in their absolute and uncontrolled discretion refuse to register any proposed transfer of shares without assigning any reason.

PROCEEDINGS OF DIRECTORS

11. The Director may meet together for the despatch of business, adjourn and otherwise regulate their meeting as they think fit and determine the quorum necessary for the transaction of business. Unless otherwise determined, two shall form a quorum. When any matter is put to a vote and if there shall be an equality of votes, the Chairman shall have a second or casting vote.

12. Any Director may at any time summon a meeting of Directors.

13. A resolution in writing signed by all the Directors shall be as effective for all purposes as a resolution passed out at meeting of the Directors, duly called, held and constitued.

POWERS AND DUTIES OF DIRECTORS

14. Without prejudice to the general power conferred by Regulation 71 of the Table "A" of the Myanmar Companies Act, it is hereby expressly declared that the Directors shall have the following powers, that is to say power: -

(1) To purchase or otherwise acquire for the Company any property, rights or privileges which the Company is authorized to acquire at such price, and generally on such terms and conditions as they think fit; also to sell, lease, abandon or otherwise deal with any property, rights or privileges to which the Company may be entitled, on such terms and conditions as they may think fit.

(2) To raise, borrow or secure the payment of such sum or sums in such manner and upon such terms and conditions in all respects as they think fit and in particular by the issue of debentures or debenture stocks of the Company charged upon all or any part of the property of the Company (both present and future) including its uncalled capital for the time being.

(3) At their discretion, to pay for any rights acquired or services rendered to the Company, either wholly or partially in cash or in shares, bonds, debentures or other securities of the Company and any such shares may be issued either as fully paid up or with such amount credited as paid up thereon as may be agreed upon; and any such bonds, debentures or other securities may be either specifically charged upon all or any part of the property of the Company and its uncalled capital or not so charged.

(4) To secure the fulfilment of any contract or engagement entered into by the Company by mortgage or charge upon all or any of the property of the Company and its uncalled capital for the time being or by granting calls on shares or in such manner as they may think fit.

(5) To appoint at their discretion, remove or suspend such Managers, Secretaries, Officers, Clerks, Agents and Servants for permanent, temporary or special services as they may from time to time think fit and to determine their duties and powers and fix their salaries or emoluments and to require security in such instances in such amount as they think fit and to depute any officers of the Company to do all or any of these things on their behalf.

(6) To appoint a Director as Managing Director, General Manager, Secretary or Departmental Manager in conjunction with his Directorship of the Company.

(7) To accept from any member on such terms and conditions as shall be agreed on the surrender of his shares or any part thereof.

(8) To appoint any person or persons to accept and hold in trust for the Company any property belonging to the Company or in which it is interested or for any other purposes and to execute and do all such deeds and things as may be requisite in relation to any such trust.

(9) To institute, conduct, defend of abandon any legal proceedings by or against the Company or its officers or otherwise concerning the affairs of the Company and also to compound and allow time for payment or satisfaction of any debts due to or of any claims and demands by or against the Company.

(10) To refer claims and demands by or against the Company to arbitration and to observe and perform the awards.

(11) To make and give receipts, releases and other discharges for money payable to the Company and for the claims and demands of the Company.

(12) To act on behalf of the Company in all matters relating to bankruptcy and insolvency.

(13) To determine who shall be entitled to sign bills of exchange, cheques, promissory notes, receipts, endorsements, releases, contracts and documents for or on behalf of the Company.

(14) To invest, place on deposit and otherwise deal with any of the moneys of the Company not immediately required for the purpose thereof, upon securities or without securities and in such manners as the Directors may think fit, and from time to time vary or realize such investments.

(15) To execute in the name and on behalf of the Company in favour of any Director or other person who may incur or be about to incur any personal liability for the benefit of the Company, such mortgages of the Company's property (present and future)as they think fit and any such mortgage may contain a power of sale and such other powers, covenants and provisions as shall be agreed on.

(16) To give any officer or other person employed by the Company a commission on the profits of any particular business or transaction or a share in the general profit of the Company and such commission or share of profit shall be treated as part of the working expenses of the Company.

(17) From time to time, to make, vary and repeal bye-laws for the regulation of the business of the Company, the officers and servants or the members of the Company or any section thereof.

(18) To enter into all such negotiations and contracts and rescind and vary all such contracts and execute and do all such acts, deeds and things in the name and on behalf of the Company as they may consider expedient for or in relation to any of the matter aforesaid or otherwise for the purposes of the Company.

(19) To borrow money for the benefit of the Company's business from any person, firm or company or bank or financial organization of local and abroad in the manner that the Directors shall think fit.

GENERAL MEETINGS

15. A general meeting shall be held within eighteen months from the date of its incorporation and thereafter at least once in every calendar year at such time(not being more than fifteen month after the holding of the last preceding general meeting)and places as may be fixed by the Board of Directors. No business shall be transacted at any general meeting unless a quorum of members is presented at the time when the meeting proceeds to business, save as herein otherwise provided Member holding not less than 50 percent of the issued shares capital(not less than two members) personally present, shall form a quorum for all purposes. And if and when in the case of there are only two number of members in the Company, those two members shall form a quorum.

DIVIDENDS

16. The Company in general meeting may declare a dividend to be paid to the members, but no dividend shall exceed the amount recommended by the Directors. No dividends shall be paid otherwise than out of the profits of the year or any other undistributed profits.

OFFICE STAFF

17. The Company shall maintain an office establishment and appoint a qualified person as General Manager and other qualified persons as office staffs. The remunerations and allowances such as salaries, travelling allowances and other expenditures incidental to the business shall be determined by the Board of Directors, and approved by the general meeting. The General Manager shall be responsible for the efficient operation of the office in every respect and shall be held accountable at all times to the Managing Director.

ACCOUNTS

18. The Directors shall cause to be kept proper books of account with respect to : -
    (1) all sums of money received and expended by the Company and the matters in respect of which the receipts and expenditures take place;
    (2) all sales and purchases of goods by the Company;
    (3) all assets and liabilities of the Company.

19. The books of account shall be kept at the registered office of the Company or at such other place as the Directors shall think fit and shall be opened to inspection by the Directors during office hours.

AUDIT

20. Auditors shall be appointed and their duties regulated in accordance with the provisions of the Mya ımar Companies Act or any statutory modifications thereof for the time being in force.

NOTICE

21. A notice may be given by the Company to any member either personally or sending it by post in a prepaid letter addressed to his registered address.

THE SEAL

22. The Directors shall provide for the safe custody of the Seal, and the Seal shall never be used except by the authority of the Directors previously given, and in the presence of one Director at least, who shall sign every instrument to which the Seal is affixed.

INDEMNITY

23. Subject to the provisions of Section 86 (C) of the Myanmar Companies Act and the existing laws, every Director, Auditor, Secretary or other officers of the Company shall be entitled to be indemnified by the Company against all costs, charges, losses, expenses and liabilities incurred by him in the execution and discharge of the duties or in relation thereto.

WINDING-UP

24. Subject to the provisions contained in the Myanmar Companies Act and the statutory modification thereupon, the Company may be wound up voluntarily by the resolution of General Meeting.

❖ ❖ ❖ ❖

We, the several persons, whose names, nationality, addresses and descriptions are subscribed below, are desirous of being formed into a Company in pursuance of this Articles of Association, and we respectively agree to take the number of shares in the capital of the Company set opposite our respective names.

Sr. No.	Name, Address and Occupation of Subscribers	Nationality & N. R. C. No.	Number of Shares taken	Signatures
1.	Parkway Healthcare Indo-China Pte. Ltd. 111 Somerset Road, #15-01, Tripleone Somerest, Singapore (238164) <u>Represented By</u> Liaw Yit Ming 6 Keng Chin Road, #05-05 Cyan, Singapore 258709	Incorporated in Singapore (Registration No. 200723244M) Singapore PP No. 32825840	78,000	
2.	Macondray Holdings Pte. Ltd. 78 Shenton Way #28-01 Singapore 079120 <u>Represented By</u> Mr. Ng How Kiat Charlie 25 Moonstone Lane #19-03 Singapore 328465	Incorporated in Singapore (Registration No. 201317874R) Singapore PP No. E3133254L	15,750	
3.	AMMK Medicare Company Limited 33 Pyay Road, 6 1/2Miles, Hlaing Township, Yangon. <u>Represented By</u> U Aung Moe Kyaw No. 18, Aung Mingalar St, Aung Theikdi Road, (3) Ward, Mayangone Township,Yangon.	Incorporated in Myanmar (Registration No. 1397/2015-2016 [YGN]) Myanmar Nation Scrutiny Card No.12/MAYAKA (N) 106397	32,250	
4.	Global Star Company Limited N0. (2), Ba Yint Naung Road, Ywar Mha Gwe (2) Ward, Hlaing Township, Yangon. <u>Represented By</u> U Thurane Aung @ Christopher Aung 105, University Avenue Road, (10) Ward, Kamayut Township, Yangon.	Incorporated in Myanmar (Registration No.1507(2008-2009) Myanmar Nation Scrutiny Card No. 12/KAMAYA (N) 050839	24,000	

Yangon Dated the day of , 2016. ,

.

It is hereby certified that the persons mentioned above put their signatures in my presence.

Andaman Alliance Healthcare Limited Annex C-12

Recoupment period

	Pre-Op Y-0	Pre-Op Y-1	Pre-Op Y-2	Pre-Op Y-3	Pre-Op Y-4	Y-1	Y-2	Y-3
Cash inflow						**(1,393,581)**	**1,560,035**	**3,164,546**
Profit						(5,043,453)	(2,223,687)	(1,004,891)
Depreciation						3,649,872	3,783,722	4,169,436
Terminal value								
Cash outflow	(2,838,000)	(10,680,000)	(12,150,000)	(15,590,000)	(28,778,546)	(413,740)	(1,510,120)	(3,031,631)
Land premium	(2,838,000)	(2,580,000)	-	(3,440,000)	-	-	-	-
Facilities expansion from cash flow							-	-
Furniture and Fittings		-	-	-	(1,800,000)	-	-	(2,700,000)
Equipment and IT		-	-	-	(16,865,105)	-	(936,950)	-
Others		-	-	-	(10,000)	-	-	-
Pre-Opening		-	-	-	(2,003,441)	-	-	-
Construction and Renovation		(8,100,000)	(12,150,000)	(12,150,000)	(8,100,000)	-	-	-
Replacement						-	-	-
Change in Net Working Capital						(413,740)	(573,170)	(331,631)
Tax						-	-	-
Net Cash Flow	(2,838,000)	(10,680,000)	(12,150,000)	(15,590,000)	(28,778,546)	(1,807,321)	49,915	132,915
Accumulated Cash Flow	(2,838,000)	(13,518,000)	(25,668,000)	(41,258,000)	(70,036,546)	(71,843,867)	(71,793,952)	(71,661,038)

Recoupment period =
10th year of operation

Andaman Alliance Healthcare Limi Annex C-12

Recoupment period

	Y-4	Y-5	Y-6	Y-7	Y-8	Y-9	Y-10
Cash inflow	**9,941,632**	**12,220,009**	**15,918,564**	**18,184,113**	**19,313,631**	**20,503,871**	**141,402,610**
Profit	4,606,672	5,961,493	9,434,009	11,395,246	14,871,364	15,857,169	16,639,362
Depreciation	5,334,960	6,258,516	6,484,556	6,788,867	4,442,267	4,646,702	5,118,535
Terminal value							119,644,713
Cash outflow	(9,766,682)	(7,031,959)	(4,638,233)	(5,425,868)	(6,245,025)	(6,627,260)	(7,775,343)
Land premium							
Facilities expansion from cash flow	-	-	-	-	-	-	-
Furniture and Fittings	-	-					
Equipment and IT	(7,807,919)	(5,621,702)					
Others							
Pre-Opening							
Construction and Renovation	-						
Replacement	(350,744)	(843,189)	(1,582,281)	(2,130,180)	(2,248,906)	(2,367,994)	(3,302,831)
Change in Net Working Capital	(1,608,020)	(567,068)	(697,449)	(446,877)	(278,277)	(294,974)	(312,672)
Tax	-	-	(2,358,502)	(2,848,811)	(3,717,841)	(3,964,292)	(4,159,841)
Net Cash Flow	174,949	5,188,050	11,280,332	12,758,244	13,068,607	13,876,610	133,627,267
Accumulated Cash Flow	(71,486,089)	(66,298,039)	(55,017,707)	(42,259,463)	(29,190,856)	(15,314,246)	118,313,021

Recoupment period =
10th year of operation



PARKWAY YANGON HOSPITAL

PROPOSAL FOR MULTI TERTIARY HOSPITAL 250 BEDS

Prepared by

CRIADOR CONSULTING PTE. LTD.

SPIRAL ARCHITECTS

Parkway YANGON

21 SEPTEMBER 2015


EPC Transformer Area




Prepared by CRIADOR SPIRAL ARCHITECTS

Parkway YANGON

21 SEPTEMBER 2015

LEVEL RELATION BETWEEN SHWEDAGON PAGODA AND PARKWAY BOGYOKE ROAD






Prepared by

Parkway YANGON

21 SEPTEMBER 2015

PROPOSED HOSPITAL AREA
CONER OF PYAY ROAD & BO GYOKE ROAD

Annex A – Site Boundary





SITE PLAN SURVEY


PLOT AREA

5.00 Acres (20,264.055 m²)

Prepared by

21 SEPTEMBER 2015

HOSPITAL ACCESSES



HOSPITAL ACCESS

SURFACE CAR PARKING	125 nos
BASEMENT CAR PARKING	42 nos
TOTAL CAR PARKING	167 nos

Prepared by

Parkway Yangon Hospital


8TH FLOOR
UTILITY AREA
HOUSEKEEPING AREA
SERVICE AREA
SUITE AREA
TECHNICAL & STAFF AREA
MEDICAL CONFERENCE AREA
DOCTOR & NURSE AREA

7TH FLOOR
UTILITY AREA
HOUSEKEEPING AREA
SERVICE AREA
DOUBLE ROOM
SINGLE ROOM

6TH FLOOR
UTILITY AREA
HOUSEKEEPING AREA
SERVICE AREA
SINGLE ROOM AREA

5TH FLOOR
UTILITY AREA
HOUSEKEEPING AREA
SERVICE AREA
SINGLE ROOM AREA

4TH FLOOR
UTILITY AREA
HOUSEKEEPING AREA
SERVICE AREA
SUITE AREA
DELUXE AREA
PRSSIDENTIAL AREA
DOCTOR & NURSE AREA



3RD FLOOR
UTILITY AREA
HOUSEKEEPING AREA
SERVICE AREA
DOUBLE ROOM

2ND FLOOR
UTILITY AREA
HOUSEKEEPING AREA
SERVICE AREA
SINGLE ROOM AREA


1ST FLOOR
OPERATION THEATRE
STERILIZATION
ICU/HDU
EXECUTIVE HEALTH SCREENING
PHYSIOTHERAPY
HOSPITAL ADMINSTRATION
POST OPERATION
STAFF LOUNGE
SERVICE AREA

GROUND FLOOR
RADIOTHERAPY
ONCOLOGY,HEMODIALYSIS
EMERGENCY,IMAGING
LABORATORY,CONSULTATIONS
PHARMACY STORE,MORTUARY
CAFETERIA,ADMIN ,SERVICE AREA

BASEMENT
LAUNDRY AREA
KITCHEN ,STAFF
WATER TREATMENT
SEWEAGE TREATMENT
TECHNICAL
ELECTRICAL & MECHNICAL
SERVICE AREA(Stair,Lift)
DRIVE WAY & CAR PARKING

Prepared by CRIADOR CONSULTING PTE. LTD. SPIRAL ARCHITECTS

Parkway YANGON
21 SEPTEMBER 2015




SITE LOCATION PLAN

Prepared by

Parkway YANGON

21 SEPTEMBER 2015

BUILDING LAYOUT PLAN



PLOT AREA (LAND AREA)

5.00 Acres (20,264.055 m²) 100%

BUILDING FOOT PRINT AREA

8,023 m² / 86,358 ft² 39.59%

GREEN AND CIRCULATION AREA

12,241.055 m² / 131,761.81 ft² 60.41%

BCR (BUILDING COVERAGE RATIO)

0.396

FAR (FLOOR AREA RATIO)

1.948

BUILDING HEIGHT

45.95 m (150'-9")

Prepared by

Parkway YANGON

21 SEPTEMBER 2015



SITE PLAN

Prepared by CRIADOR CONSULTING PTE. LTD. SPIRAL ARCHITECTS

Parkway YANGON

21 SEPTEMBER 2015



LAUNDRY AREA	461 m² / 4,962 ft²		TECHNICAL	291 m² / 3,132 ft²
KITCHEN	606 m² / 6,523 ft²		ELECTRICAL & MECHANICAL	1352 m² / 14,553 ft²
STAFF	156 m² / 1679 ft²		SERVICE AREA(Stair,Lift)	1006 m² / 10,829 ft²
WATER TREATMENT	107 m² / 1152 ft²		DRIVE WAY & CAR PARKING	2824 m² / 30,397 ft²
SEWAGE TREATMENT	355 m² / 3821 ft²			

BASEMENT FLOOR TOTAL AREA

7158 m² / 77,048 ft²

(Car Parking 42 Nos)

BASEMENT FLOOR PLAN

Prepared by

Parkway YANGON

21 SEPTEMBER 2015

Parkway Yangon Hospital



RADIOTHERAPY	830 m² / 8,934 ft²	
ONCOLOGY	324 m² / 3,488 ft²	
HEMODIALYSIS	311 m² / 3,348 ft²	
EMERGENCY	844 m² / 9,085 ft²	
IMAGING	493 m² / 5,307 ft²	
LABORATORY	593 m² / 6,383 ft²	
CONSULTATIONS	950 m² / 10,226 ft²	
PHARMACY STORE	322 m² / 3,466 ft²	
MORTUARY	320 m² / 3,444 ft²	
CAFETERIA	593 m² / 6,383 ft²	
ADMIN	282 m² / 3,035 ft²	
SERVICE AREA(Stair,Lift)	1,958 m² / 21,075 ft²	

GROUND FLOOR TOTAL AREA

8,023 m² / 86,358 ft²

(Car Parking 125 Nos)

GROUND FLOOR PLAN

Prepared by CRIADOR CONSULTING PTE. LTD. / SPIRAL ARCHITECTS

Parkway YANGON

21 SEPTEMBER 2015

Parkway Yangon Hospital



OPERATION THEATRE	2216 m² / 23,853 ft²	HOSPITAL ADMINSTRATION	920 m² / 9,903 ft²
STERILIZATION	376 m² / 4,047 ft²	POST OPERATION	463 m² / 4,984 ft²
ICU/HDU	403 m² / 4,338 ft²	STAFF LOUNGE	240 m² / 2,583 ft²
EXECUTIVE HEALTH SCREENING	806 m² / 8,676 ft²	SERVICE AREA(Stair,Lift)	1,436 m² / 15,457 ft²
PHYSIOTHERAPY	520 m² / 5,597 ft²		

FIRST FLOOR TOTAL AREA


7380 m² / 79,438 ft²

FIRST FLOOR PLAN

Prepared by CRIADOR CONSULTING PTE. LTD. SPIRAL ARCHITECTS

Parkway YANGON

21 SEPTEMBER 2015



	UTILITY AREA	109 m²/ 1,173 ft²
	HOUSEKEEPING AREA	77 m²/ 829 ft²
	SERVICE AREA	1,190 m²/ 12,809 ft²
	SINGLE ROOM AREA	1,041 m²/ 11,205 ft²(36 Beds)

SECOND FLOOR TOTAL AREA

2418 m² / 26,027 ft²

SECOND FLOOR PLAN

Parkway YANGON

21 SEPTEMBER 2015

Prepared by CRIADOR CONSULTING PTE. LTD. SPIRAL ARCHITECTS



UTILITY AREA	109 m²/ 1,173 ft²
HOUSEKEEPING AREA	77 m²/ 829 ft²
SERVICE AREA	1,190 m²/ 12,809 ft²
DOUBLE ROOM	1,041 m²/ 11,205 ft²(72 Beds)

THIRD FLOOR TOTAL AREA

2418 m²/ 26,027 ft²

THIRD FLOOR PLAN

Prepared by CRIADOR CONSULTING PTE. LTD. SPIRAL ARCHITECTS

Parkway YANGON

21 SEPTEMBER 2015



	UTILITY AREA	109 m²/ 1,173 ft²
	HOUSEKEEPING AREA	77 m²/ 829 ft²
	SERVICE AREA	1,090 m²/ 11,464 ft²
	SUITE AREA	192 m²/ 2,067 ft²(2 Beds)
	DELUXE AREA	368 m²/ 3,961 ft² (5 Beds)
	PRESIDENTIAL AREA	474 m²/ 5102 ft²(1 Beds)
	DOCTOR & NURSE AREA	111 m²/ 1195 ft²

FOURTH FLOOR TOTAL AREA


2418 m²/ 26,027 ft²

FOURTH FLOOR PLAN

Prepared by

Parkway YANGON

21 SEPTEMBER 2015



	UTILITY AREA	109 m²/ 1,173 ft²
	HOUSEKEEPING AREA	77 m²/ 829 ft²
	SERVICE AREA	1,190 m²/ 12,809 ft²
	SINGLE ROOM AREA	1,041 m²/ 11,205 ft² (36 Beds)

FIFTH FLOOR TOTAL AREA


2418 m² / 26,027 ft²

FIFTH FLOOR PLAN

Parkway YANGON

21 SEPTEMBER 2015

Prepared by CRIADOR CONSULTING PTE. LTD. SPIRAL ARCHITECTS



	UTILITY AREA	109 m²/ 1,173 ft²
	HOUSEKEEPING AREA	77 m²/ 829 ft²
	SERVICE AREA	1,190 m²/ 12,809 ft²
	SINGLE ROOM AREA	1,041 m²/ 11,205 ft²(36 Beds)

SIXTH FLOOR TOTAL AREA

2418 m² / 26,027 ft²

SIXTH FLOOR PLAN

Prepared by CRIADOR CONSULTING PTE. LTD. SPIRAL ARCHITECTS

Parkway YANGON

21 SEPTEMBER 2015



UTILITY AREA	109 m²/ 1,173 ft²	
HOUSEKEEPING AREA	77 m²/ 829 ft²	
SERVICE AREA	1,190 m²/ 12,809 ft²	
DOUBLE ROOM	840 m²/ 9,042 ft² (58 Beds)	
SINGLE ROOM	202 m²/ 2,174 ft² (7 Beds)	

SEVENTH FLOOR TOTAL AREA

2418 m² / 26,027 ft²

SEVENTH FLOOR PLAN

Prepared by

Parkway YANGON

21 SEPTEMBER 2015

Parkway Yangon Hospital



	UTILITY AREA	109 m²/ 1,173 ft²
	HOUSEKEEPING AREA	77 m²/ 829 ft²
	SERVICE AREA	1,061 m²/ 11,421 ft²
	SUITE AREA	398 m²/ 4,284 ft²
	TECHNICAL & STAFF AREA	210 m²/ 2,261 ft²
	MEDICAL CONFERENCE AREA	462 m²/ 4973 ft²
	DOCTOR & NURSE AREA	111 m²/ 1195 ft²

EIGHT FLOOR TOTAL AREA


2418 m²/ 26,027 ft²

EIGHT FLOOR PLAN


Prepared by

Parkway YANGON


21 SEPTEMBER 2015



DELUXE ROOM



SINGLE ROOM



DOUBLE ROOM

TYPICAL ROOM PLAN

Prepared by

Parkway YANGON

21 SEPTEMBER 2015



FRONT ELEVATION

Prepared by CRIADOR CONSULTING PTE. LTD. SPIRAL ARCHITECTS

Parkway YANGON

21 SEPTEMBER 2015




SIDE ELEVATION

Prepared by

Parkway YANGON

21 SEPTEMBER 2015



SECTION

Prepared by



Prepared by

Parkway YANGON

21 SEPTEMBER 2015



Prepared by

Parkway YANGON

21 SEPTEMBER 2015


Parkway Hospital
YANGON
OPD



Prepared by

Parkway YANGON

21 SEPTEMBER 2015


























GENERAL INFORMATION

LAND AREA 20264.055 m² / 218120 ft² (5 Acres)

ROAD AREA 8610 m² / 92677 ft²

GREEN AREA 3125 m² / 33637 ft²

TOTAL CAR PARKING

167 CARS

TOTAL BEDS

PHASE -1

BASEMENT FLOOR

GROUND FLOOR

1ST FLOOR

2ND FLOOR @ 36 BEDS

3RD FLOOR @ 72 BEDS

4TH FLOOR @ DELUXE ROOM-5 BEDS,
SUITE - 2 BEDS
PRESIDENTIAL SUITE- 1BED

PHASE-2

5TH FLOOR @ 36 BEDS

6TH FLOOR @ 36 BEDS

7TH FLOOR @ DOUBLE ROOM-58 BEDS
SINGLE ROOM-7 BEDS

8TH FLOOR @ SUITE 7 BEDS

TOTAL BEDS 260

HOSPITAL	AREA (sq.m.)	AREA (sq.ft.)	
PHASE-1			
BASEMENT FLOOR	7,158 m²	77,048 ft²	KITCHEN ,LAUNDRY, WATER TREATMENT ,TECHNICAL ,ELECTRICAL , MECHANICAL , STAFF
GROUND FLOOR	8,023 m²	86,358 ft²	OPD /CONSULTATIONS , IMAGING ,ADMIN - CASHIER , PHARMACY ,CAFETERIA / GIFT SHOPS ,MORTUARY ,EMERGENCY , ONCOLOGY ,RADIOTHERAPY ,HEMODIALYSIS,MEDICAL GASES , BACKUP GENERATION ,LABORATORY
FIRST FLOOR	7,380 m²	79,438 ft²	CARDIAC , ENDOSCOPY , OBSTETRICS & GYNAECOLOGY ,PEDIATRICS , INTERNAL MEDICINE , ORTHOPEDICS , CSSD (CENTRAL STERILIZATION) ,STAFF LOUNGE & CAFETERIA , ADMINSTRATION OFFICE,(BUSINESS;SUPPORT; MATERIALS MANAGEMENT;IT)
SECOND FLOOR	2,418 m²	26,027 ft²	MEDICAL WARDS (36 BEDS) , NURSE STATION
THIRD FLOOR	2,418 m²	26,027 ft²	MEDICAL WARDS (72 BEDS) , NURSE STATION
FOURTH FLOOR	2,418 m²	26,027 ft²	MEDICAL WARDS SUITE (2 BEDS) , DELUXE (5 BEDS) PRESIDENTIAL SUITE (1 ROOM) ,NURSE STATION
PHASE-2			
FIFTH FLOOR	2,418 m²	26,027 ft²	MEDICAL WARDS (36 BEDS) , NURSE STATION
SIXTH FLOOR	2,418 m²	26,027 ft²	MEDICAL WARDS (36 BEDS) , NURSE STATION
SEVENTH FLOOR	2,418 m²	26,027 ft²	MEDICAL WARDS DOUBLE ROOM (58 BEDS) SINGLE ROOM 7 BEDS , NURSE STATION
EIGHTH FLOOR	2,418 m²	26,027 ft²	MEDICAL WARDS SUITE (7 BEDS) , NURSE STATION MEDICAL CONFERENCE,
TOTAL FLOOR AREA	**39,482 m²**	**424,980 ft²**	

Prepared by CRIADOR CONSULTING PTE. LTD. SPIRAL ARCHITECTS

Parkway YANGON

21 SEPTEMBER 2015